compound_id,standard_inchi_key,compound_name,synonym,target_id,target_pref_name,gene_names,wildtype_or_mutant,mutation_info,pubmed_id,standard_type,standard_relation,standard_value,standard_units,activity_comment,ep_action_mode,assay_format,assaytype,assay_subtype,inhibitor_type,detection_tech,assay_cell_line,compound_concentration_value,compound_concentration_value_unit,substrate_type,substrate_relation,substrate_value,substrate_units,assay_description,title,journal,doc_type,annotation_comments,PIC50,Unnamed: 0,CID,smiles,rdkit_smiles
CHEMBL1232461,AAAQFGUYHFJNHI-SFHVURJKSA-N,GSK525762A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24015967.0,IC50,>=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,J. Med. Chem.,PUBLICATION,,4.481486060122112,1,46943432,CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C,CCNC(=O)CC1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21
CHEMBL2158292,AADUJBXZMSDOOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,5,11533340,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C4=CC=[N+](C=C4)[O-])NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)c4cc[n+]([O-])cc4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL1086377,AATCBLYHOUOCTO-UHFFFAOYSA-N,KU-0060648,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23855836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,PUBLICATION,,5.0,18,11964036,CCN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7,CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1
CHEMBL2017279,AAVAYKQPRIQKRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,20,70685377,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4N5CCOCC5)C(=O)N)OC,COc1cc2c(Nc3ccccc3N3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL490153,ABACVOXFUHDKNZ-UHFFFAOYSA-N,A-867744,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19419141.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.,J. Med. Chem.,PUBLICATION,,5.0,22,23642319,CCC(=O)C1=C(N(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)S(=O)(=O)N)C,CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C
CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,27,46884734,CC(C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC,COc1nccnc1C(C)C1=C(CCN(C)C)Cc2cc(F)ccc21
CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,27,46884734,CC(C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC,COc1nccnc1C(C)C1=C(CCN(C)C)Cc2cc(F)ccc21
CHEMBL489094,ABKBSWVRNXDREE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,5.309803919971486,31,15984938,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1
CHEMBL489094,ABKBSWVRNXDREE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.853871964321762,31,15984938,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1
CHEMBL1097358,ABLYXLXBJMBVQN-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,33,135553232,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C,Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1097358,ABLYXLXBJMBVQN-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,33,135553232,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C,Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL523752,ABOWEPDTQXMFNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,38,21717337,CCC1=CC=CC(=C1CNC2=CC=CN3C2=NC(=C3C)C)C,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12
CHEMBL523752,ABOWEPDTQXMFNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,38,21717337,CCC1=CC=CC(=C1CNC2=CC=CN3C2=NC(=C3C)C)C,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12
CHEMBL476568,ABQNMOMAPSGPLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,40,18104758,C1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccccc1
CHEMBL3114722,ABUAEJMNHRQEPP-NGCAANIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,43,76335964,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL3114713,ABUAEJMNHRQEPP-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,44,23658550,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL1215664,ABUNZHUAYBOXCN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,3210.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,5.493494967595128,46,49864181,C1=CC(=CC=C1C2=CC=C(C=C2)O)C(C3=CC=NC=C3)O,Oc1ccc(-c2ccc(C(O)c3ccncc3)cc2)cc1
CHEMBL1951338,ABZRQOXZIBNTTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,47.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.327902142064283,49,57395300,CCN(CC)C(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CCN(CC)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL3601377,ACBKFGPDANWBLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26105194.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,52,71714121,CC1=C(C=CC(=C1)CN(C)C)C(=O)CN2C(=O)C=C(C=N2)OCC3=NC=C(C=C3)OC,COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1
CHEMBL2029678,ACDVIHRBYWUYPZ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,5.823908740944319,55,44473400,CC1=NSC(=C1)N2C=CC3=C(C2=O)N(N=N3)C(C)C4=CC5=CC(=CN=C5C=C4)OCCOC,COCCOc1cnc2ccc(C(C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1
CHEMBL2029678,ACDVIHRBYWUYPZ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,4.6777807052660805,55,44473400,CC1=NSC(=C1)N2C=CC3=C(C2=O)N(N=N3)C(C)C4=CC5=CC(=CN=C5C=C4)OCCOC,COCCOc1cnc2ccc(C(C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1
CHEMBL208155,ACFQJABFUNOOOS-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.236572006437063,57,44410862,CCN(CC)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,CCN(CC)C(C)C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
CHEMBL2018573,ACUYMTWKMROFBQ-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,4.698970004336019,72,45377016,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4N=CC=N4)CC5=CC=C(C=C5)F,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(Cc2ccc(F)cc2)CN1C(=O)Cn1nccn1
CHEMBL559531,ACXQPBJHXILGLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,74,45268206,C1CN(CCC1C2=NC(=NO2)C3=CC=C(C=C3)C(=O)O)C(=O)NC4CC4C5=CC=CC=C5,O=C(O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1
CHEMBL1911822,ACYMETHQFZHOBR-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,75,57403230,CN1CCN(CC1)C(=O)C(COCC2=CC(=NC=C2)Cl)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCc2ccnc(Cl)c2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL3699326,ACZMHYDTZOAQBH-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2420.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.616184634019569,77,89718399,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=C(C=C8)N,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1081693,ACZVADNXZFAFAJ-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,274.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.562249437179612,78,46883402,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CO2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CO4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cnco1)CC(Cc1ccccc1)NC(=O)OCc1ncco1
CHEMBL502,ADEBPBSSDYVVLD-UHFFFAOYSA-N,DONEPEZIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25499431.0,IC50,=,54680.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.262171494104216,82,3152,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2
CHEMBL482233,ADGULOHTKSMBCP-PXAQALGRSA-N,"(8R,8'R,9'S)-5-METHOXYCLUSIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,6.080921907623926,84,11259008,COC1=CC(=CC2=C1OCO2)CC3COC(C3CC4=CC(=C(C(=C4)OC)OC)OC)O,COc1cc(CC2C(Cc3cc(OC)c4c(c3)OCO4)COC2O)cc(OC)c1OC
CHEMBL1669412,ADLLYWYUHVDQBH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,87,53320189,C1CN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,c1ccc2c(c1)CC(CCN1CCC1)=C2Cc1cnccn1
CHEMBL2004290,ADLPKFFMGIJZIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 ��L final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37�� C. incubator. Pooled human liver microsomes (BD Gentest, 50 ��g/mL) were incubated with 5 concentrations of test compound (from 0.1 ��M to 10 ��M), 1 mM NADPH (Sigma), and 2 ��M midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,5.0,88,46223479,CC(C)(CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC=C(C=C4)NC(=O)NC5=CC=C(C=C5)OC)N)O,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1
CHEMBL3112601,ADMREWYBXXZUMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24447850.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,89,69081964,COC1=C(C(=CC=C1)OC)C2CCCC(=O)N2CC3=NC4=CC=CC=C4C=C3,COc1cccc(OC)c1C1CCCC(=O)N1Cc1ccc2ccccc2n1
CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.0,93,9819053,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
CHEMBL1934523,ADRZQEOBUFIYAZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22172695.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,95,24900259,CC1CCCN1CCC2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)CCCOC,COCCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCCC3C)cc2)cc1
CHEMBL3417505,ADTARRIQWGUIIA-BULQSVBWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,4.522878745280337,96,59548712,CC1CCCN1CC(C)COC2=CC=C(C=C2)C3=NNC(=O)C4C3C4,CC(COc1ccc(C2=NNC(=O)C3CC23)cc1)CN1CCCC1C
CHEMBL3673982,ADVBAMJDBQBHCU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320658,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,98,52934484,COC1=C(C=C(C=N1)F)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C#N)F,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1
CHEMBL3673982,ADVBAMJDBQBHCU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320701,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,98,52934484,COC1=C(C=C(C=N1)F)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C#N)F,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1
CHEMBL2022571,ADYPGEBADRLHCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,100,56840671,CC1=C(C(=NN1)C(=O)O)CC2=CC3=CC=CC=C3S2,Cc1[nH]nc(C(=O)O)c1Cc1cc2ccccc2s1
CHEMBL3218856,ADYZVNMLQOHYDE-BAYWULLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.847711655616943,103,89738547,COC1=C(C=CC(=C1)N2CCC(CC2)N3CCOCC3)C4=NC5=NC=C(C(=C5N4)NC6C7CC(C6C(=O)N)C=C7)Cl,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3218856,ADYZVNMLQOHYDE-BAYWULLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,103,89738547,COC1=C(C=CC(=C1)N2CCC(CC2)N3CCOCC3)C4=NC5=NC=C(C(=C5N4)NC6C7CC(C6C(=O)N)C=C7)Cl,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL241064,AEBNQBMNALVGPB-LJQANCHMSA-N,SR-706,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,109,16662086,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=CC=C4)O,O=C(C(O)c1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL1951321,AEEXIWXDMCZBGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,111,57402329,C1=CC(=CC=C1C2=C3C(=NC=C2)N=CN3)NC(=O)NC4=CC=C(C=C4)Br,O=C(Nc1ccc(Br)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL2041182,AEFKPNYWNAAZGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,112,49849120,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC(=C4)C)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL3235265,AEIYXQGHBFFFPX-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630562.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,114,90654338,CC1CCC(CN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C#CC4=CC=CC(=C4)CO,Cc1ccc(-n2nccn2)c(C(=O)N2CC(C#Cc3cccc(CO)c3)CCC2C)c1
CHEMBL570403,AELBOLRAJBHJSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,117,45487551,COC1=C(C=C2CN(CCC2=C1)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC(=C7)C#N)OC,COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc(C#N)c5)cc1)(C4)C3)CC2
CHEMBL231509,AENCTNCRKXVXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,120,135553271,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)N(C)C,Cc1cc(C(=O)N(C)C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL468551,AEOBYHAZFRJFPZ-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,6.638272163982407,122,11421412,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL561788,AEUILRDAXLSTHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,127,45269104,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=C3C(F)(F)F)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3C(F)(F)F)no2)CC1
CHEMBL2010872,AEULIVPVIDOLIN-UHFFFAOYSA-N,CEP-11981,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148921.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.",J. Med. Chem.,PUBLICATION,,4.522878745280337,128,11751922,CC(C)CN1C2=C(C=C(C=C2)NC3=NC=CC=N3)C4=C1C5=C(C6=CN(N=C6CC5)C)C7=C4CNC7=O,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
CHEMBL252817,AFANGSZMNLRLKU-SJLPKXTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,16900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.772113295386326,133,44447000,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NOC(=N4)C,CCC1CCCC(C2(Cc3noc(C)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL412023,AFKWCSONBYVREL-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,144,44433287,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)C(CC(C)C)NC(=O)CNC,CNCC(=O)NC(CC(C)C)c1cc(C)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2057787,AFLLEMMCAWXUGY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.42021640338319,145,59603324,C#CCNC1=NC2=C(O1)C=C(C=C2)C(=O)N(CC#C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C#CCNc1nc2ccc(C(=O)N(CC#C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL269915,AFNDEYWFNPXTKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,4.886056647693163,146,24822428,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=CC=N5,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccccn5)cccc4c3)c2cc1OC
CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,70.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.154901959985743,150,5318,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL3422082,AFPQNJFINOFINI-BTOOTBGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.619788758288394,152,117751256,C1CC1C(C2=CC=CC=C2F)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,O=C(NC(c1ccccc1F)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
CHEMBL3358923,AFQIBZSGVWHLSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.221848749616356,153,60026895,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=C(N2)C=NC(=C3)C)(C(F)(F)F)O,Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1
CHEMBL2059116,AFUJORLTHMNOKI-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,157,59603306,CC(C)CN(CC(C(CC1=CN=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=CS4,CC(C)CN(CC(O)C(Cc1cccnc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1
CHEMBL1643880,AFUWQWYPPZFWCO-LBPRGKRZSA-N,PUMOSETRAG,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,159,154104,C1CN2CCC1C(C2)NC(=O)C3=CNC4=C(C3=O)SC=C4,O=C(NC1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O
CHEMBL2069579,AFWNZGMHIZENTJ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22884988.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,162,69643233,C1=CC=C(C=C1)CC(C(=O)NC2=CC(=CC(=C2)C(=O)O)C3=CC=NC=C3)NCC4=CSC=N4,O=C(O)c1cc(NC(=O)C(Cc2ccccc2)NCc2cscn2)cc(-c2ccncc2)c1
CHEMBL496469,AFXBTOVGCMXHEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3386.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.4703130462270835,163,25033810,C1CC(C2=C(C1)C=C(C=C2)C3=CC(=C(C=C3)O)F)C4=CC=NC=C4.Br,Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F
CHEMBL2440638,AGDUASOAFRXTRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,175,72374727,CC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CC(=CN=C3)F,Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncc(F)c3)c2)n1
CHEMBL3298906,AGELGZUNOBHRLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,177,68235232,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)F,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1
CHEMBL391915,AGENZPFZMBQUPS-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,640.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1938200260161125,178,44433265,CCNC(CC(C)C)C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O,CCNC(CC(C)C)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL25731,AGHKIFOPIORNFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,53810.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.269137007953506,179,11270541,CNC1=NC=CC2=C1C3=C(N2C)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,CNc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
CHEMBL563732,AGJNHDXJGSWJRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,183,45269947,C1CN(CCC1N2C=NC=N2)C(=O)NC3CC3C4=CC=CC=C4,O=C(NC1CC1c1ccccc1)N1CCC(n2cncn2)CC1
CHEMBL2207386,AGKMPGSBLMAGAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23141912.0,IC50,=,35970.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.444059562181489,185,24965679,CN1CCN(CC1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4Br,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2Br)CC1
CHEMBL429420,AGKSAEJJQWDEES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,187,44454670,CC1=CC(=CC(=C1)CC(=O)NC2=CC(=NC(=N2)C3=CC=CC=N3)N4C(=CC(=N4)C)C)C,Cc1cc(C)cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)c1
CHEMBL2069921,AGMZWJCXRAGFQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,190,8902499,C1CN(CCN1CC2=CC=CC=C2)CC3=NC(=NO3)C4=CC=CC=C4,c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1
CHEMBL470049,AGQLGMXLTFMOAP-OEHKQELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.045757490560675,197,10624340,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)OC(=O)C,CC(=O)OC1C(C)OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(O)C1O
CHEMBL514198,AGQQFHRGGSZZEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,198,44578957,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)NC(=O)CNC(=O)C3=CC=C(C=C3)F,COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccc(OC)cc2)cc1
CHEMBL238763,AGVLKBKXJWTFQT-IBGZPJMESA-N,SR-1450,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.346787486224656,203,16662112,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=CC=C4)N,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccccc1
CHEMBL605410,AGYJPEBXFSGBHP-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,207,46226137,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=C(NC6=CC=CC=C65)C#N)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
CHEMBL401418,AGZBTOKWUUPEBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17937987.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,209,44444649,CC1=CC(=CC(=C1)C2=C(C3=C(N2)SC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)CCN6CCN(CC6)CC(CN7CCNCC7)O)C,Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(O)CN3CCNCC3)CC2)c1
CHEMBL1951344,AHEOXHOZNNFHHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,560.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.251811972993799,213,57404047,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C=CNC4=NC=N3,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]ccc34)cc2)c1
CHEMBL3298322,AHHGHXFTQVZBPO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,216,90645311,COC1=C(C=C2C(=C1)C=CN=C2OC3=CC=C(C=C3)F)OC,COc1cc2ccnc(Oc3ccc(F)cc3)c2cc1OC
CHEMBL450610,AHPTUXAIRHFFGA-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,2.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,229,135960730,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OCCOC,COCCOC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCC(O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL240391,AHPZPEPKIIZAJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.777283528852417,230,23647898,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)CO)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)CO)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL2419495,AHQASDPCJPXGHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,5.853871964321762,231,24968874,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=C(C=C(C=C3)F)F)C,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3F)CC2)nc1C
CHEMBL3673971,AHSCWWTXGYZDOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320641,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,234,67202657,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CC(=C(N=C4)OC)F)N=C1,COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F
CHEMBL3673971,AHSCWWTXGYZDOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320685,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,234,67202657,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CC(=C(N=C4)OC)F)N=C1,COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F
CHEMBL3353357,AHXHWEURVLCQAX-MDTIIALHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.522878745280337,239,58486171,CC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,Cc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3353357,AHXHWEURVLCQAX-MDTIIALHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.2076083105017466,239,58486171,CC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,Cc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL258046,AIAKFZWQGGMPFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,241,11519486,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL258046,AIAKFZWQGGMPFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,241,11519486,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL258046,AIAKFZWQGGMPFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,241,11519486,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL273208,AIBJZSMLYKTKIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18313294.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,243,25022704,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2OC3=CC=CC=C3,CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1
CHEMBL551964,AIBSVCNXTNBLRF-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19719241.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,244,44192200,CC1=NC2=C(C=C1)C3=C(C=C2)OCC(O3)CN4CCN(CC4)C5=NC6=C(C=C5)C=C(C=C6)C#N,Cc1ccc2c3c(ccc2n1)OCC(CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3
CHEMBL3137483,AICSYLICMPMSRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,246,76325843,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C(C4=CC=CC=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(C(c3ccccc3)C(F)(F)F)CC2)cc1
CHEMBL1090186,AIGMIQVSRPRWAQ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,250,46884733,CC(C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CN=C3OC,COc1ccc2c(c1)CC(CCN(C)C)=C2C(C)c1nccnc1OC
CHEMBL3326587,AILCSHZLWQQZEZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,257,46191501,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4)F)(CF)CF)C=N1,Cc1cc2c(NC(=O)NC3CC(CF)(CF)Oc4cc(F)ccc43)cccc2cn1
CHEMBL3682505,AIOINVRWUCXVAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,60000.0,NM,291610,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,4.221848749616356,259,53259483,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(F)(F)F)N3N=CN=N3,CC(C)C(c1ccc2cc(OCC(F)(F)F)ccc2c1)n1ncnn1
CHEMBL2448692,AIOKORCUJNJGMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.154901959985743,260,73348117,C1=CC2=C(C=CC(=C2)Br)C=C1OCC(CN3C=CN=C3)O.Cl,OC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1
CHEMBL395942,AJJCOMDYWQVLKY-JTQLQIEISA-N,SR-705,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,273,16662085,CC(C(=O)N1CCC(CC1)NC2=CC3=C(C=C2)NN=C3)O,CC(O)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL2041184,AJOUEHBWWNCZHX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,282,49847378,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC(=NC=C4)C)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1nccc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)n1
CHEMBL3403826,AJQNILVHTMISRW-KYLTZZOSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,284,71288638,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(CC(C)(C)O)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403826,AJQNILVHTMISRW-KYLTZZOSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,284,71288638,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(CC(C)(C)O)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL1258754,AJUFRGDVXUPOOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,290,16679518,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCNC(=O)C4=C3,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCNC2=O)CC1
CHEMBL518591,AKBRLFXEFQHICT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,294,44579181,CN1CCC2=C(CC1)C=C3C(=C2)C=CN3S(=O)(=O)C4=CC(=CC=C4)Cl,CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1
CHEMBL518591,AKBRLFXEFQHICT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,71000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1487416512809245,294,44579181,CN1CCC2=C(CC1)C=C3C(=C2)C=CN3S(=O)(=O)C4=CC(=CC=C4)Cl,CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1
CHEMBL2059114,AKIPCTAHXSDOJW-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,19.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,298,42635527,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(S4)N,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)sc2c1
CHEMBL230308,AKIQDXURYNYZSE-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,299,136118016,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC(CC4=CC=CC=C4)CO)C5=CC=C(C=C5)F,Cc1cc(-c2ccc(F)cc2)cc2[nH]c(-c3c(NC(CO)Cc4ccccc4)cc[nH]c3=O)nc12
CHEMBL2207503,AKJBLKUZXRMECW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23043539.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 by LC-MS-MS analysis,"Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia.",J. Med. Chem.,PUBLICATION,,5.0,301,71454279,CC1=NN(C=C1C2=NC3=NC=C(C(=C3N2)N4CCN(CC4)CC5=CC=C(C=C5)Cl)Cl)C,Cc1nn(C)cc1-c1nc2ncc(Cl)c(N3CCN(Cc4ccc(Cl)cc4)CC3)c2[nH]1
CHEMBL399045,AKKGFQRBBVGLEB-KRXBUXKQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17869105.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,305,25033361,C1CN(CCC1CN2CCC(CC2)C3=CC=C(C=C3)Cl)C(=O)C=CC4=CC(=C(C=C4)Cl)Cl,O=C(C=Cc1ccc(Cl)c(Cl)c1)N1CCC(CN2CCC(c3ccc(Cl)cc3)CC2)CC1
CHEMBL1642413,AKLPJZCEMGVEQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134749.0,IC50,=,4770.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.321481620959886,309,23624297,CN1CCN(CC1)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=C(C=C4)F,CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1
CHEMBL398773,AKVYSQCDHUSFGD-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,322,11649179,CCCC1(CCN(CC1)C(=O)CC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC)O,CCCC1(O)CCN(C(=O)CC2(C3CCCC(CC)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL1258755,AKYDPJMTCVQONP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,325,16679701,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCCNC(=O)C4=C3,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCCNC2=O)CC1
CHEMBL1078353,ALFVRYXSTFHIKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,333,46882875,CC1(CCCN(C1)C(=O)NCCCC2=CN=CC=C2)C3=CC=CC=C3,CC1(c2ccccc2)CCCN(C(=O)NCCCc2cccnc2)C1
CHEMBL452298,ALINQGUROWXGAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,338,44561195,CN(CC(=O)N(C)C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,CN(CC(=O)N(C)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1
CHEMBL2017284,ALRNRROHBGTUFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,346,52934040,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C5=CC=CC=C5OC(F)(F)F)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3OC(F)(F)F)c12
CHEMBL3604137,ALTKPBXHCBSGOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26037322.0,IC50,>,10000.0,NM,Not Active,,,,,,,,,,,,,,Inhibition of human CYP3A4,3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,349,16666555,C1=CC(=NC=C1F)NC(=O)C2=CC=NN2,O=C(Nc1ccc(F)cn1)c1ccn[nH]1
CHEMBL3699321,ALUBYALCOZFVQB-QCDYIZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,351,89718207,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CN=C(C=C8)N9CCOCC9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCOCC7)nc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3403819,ALWXLBHHPZBMRA-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,355,71288697,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)CCOC)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(CCOC)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403819,ALWXLBHHPZBMRA-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,355,71288697,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)CCOC)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(CCOC)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3605277,AMAVJINBCBZRCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26183084.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,358,66608383,C1CN(CC2=C1N=C(O2)COC3=CC(=CC=C3)F)C(=O)C4=CC=C(C=C4)F,O=C(c1ccc(F)cc1)N1CCc2nc(COc3cccc(F)c3)oc2C1
CHEMBL3331484,AMGZVHXDDMROJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.301029995663981,363,118713773,C1CC1N(CC2=CC(=C(C=C2)Cl)Cl)C3CNC3,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl
CHEMBL231610,AMKPHWUXNDGLHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,366,135553267,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC5CCCCC5,Cc1cc(C(=O)NC2CCCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2165175,AMPOIPUWOSOMBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23010262.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of phosphoinositide 3-kinases (PI3K) p110�� isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,374,71460603,CC1=NC=CC(=C1)C2=CC(=O)N=C(N2)NCC3=CC=CC4=CC=CC=C43,Cc1cc(-c2cc(=O)nc(NCc3cccc4ccccc34)[nH]2)ccn1
CHEMBL1682898,AMRRJPLOMQHTQO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,375,18769074,CC1=C(C=CC2=C1C=CC(=C2)C(C3=CN=CN3)(C(C)C)O)C(=O)NC,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1C
CHEMBL403809,AMSKTYLOKZVQRX-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.008773924307505,376,44447296,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)C(CC5=C(C=CC(=C5F)F)F)NC(=O)C6(CC6)C(F)(F)F,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)C(Cc1c(F)ccc(F)c1F)NC(=O)C1(C(F)(F)F)CC1
CHEMBL3409860,AMVUFSYRJVKFEF-YJBOKZPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,383,69081619,COC1CC(N(C1=O)CC2=CC=C(C=C2)OC(F)(F)F)C3=C(C=CC=C3OC)OC,COc1cccc(OC)c1C1CC(OC)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
CHEMBL482126,ANBSWCCVJMJABF-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,4.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.387216143280265,387,135922386,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCOCC6,Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL482126,ANBSWCCVJMJABF-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,387,135922386,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCOCC6,Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as probe,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,4.6777807052660805,390,11292933,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as probe,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,4.6777807052660805,390,11292933,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as probe,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,4.6777807052660805,390,11292933,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
CHEMBL1631540,ANGUXJDGJCHGOG-UHFFFAOYSA-N,GSK163090,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21053897.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist.",J. Med. Chem.,PUBLICATION,,4.173925197299173,390,11292933,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1
CHEMBL1813459,ANOHHYWFJGBLHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21658961.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.",Bioorg. Med. Chem.,PUBLICATION,,5.031517051446065,395,56668365,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)C(C)C.Cl,CCCCN1C(=O)C(C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
CHEMBL1079246,ANRFQNJNXPRQGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,397,46882972,CNC(=O)CCC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,CNC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL1276654,ANTRYADYILUHOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801551.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.",Eur. J. Med. Chem.,PUBLICATION,,5.795880017344075,400,25016311,C1CC2(CCN(CC2)C3=NN=C(C=C3)C4=NN=C(O4)CC5=CN=CC=C5)OC6=C1C(=CC=C6)F,Fc1cccc2c1CCC1(CCN(c3ccc(-c4nnc(Cc5cccnc5)o4)nn3)CC1)O2
CHEMBL403313,ANXLTXNOZIKJSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18308567.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,406,24879232,CN(C)S(=O)(=O)NC(=O)CCCC1=C(NC2=C1C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12
CHEMBL578578,ANYUTTCGGOBCGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,408,45484968,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3N4CCCCC4,CC1(CC(=O)NCc2ccccc2N2CCCCC2)CC2(CCCCC2)OO1
CHEMBL2336418,AOBPSENKFBJNAZ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,412,71569375,CC1=CC(=C(C2=C1NN=C2)Cl)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12
CHEMBL2336418,AOBPSENKFBJNAZ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,412,71569375,CC1=CC(=C(C2=C1NN=C2)Cl)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12
CHEMBL271581,AOEMSQHYYYHFRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.886056647693163,415,4048115,CC1=CC(=CC(=N1)C)C(C)(C)NC(=O)C(C(C)(C)C)Br,Cc1cc(C(C)(C)NC(=O)C(Br)C(C)(C)C)cc(C)n1
CHEMBL1209538,AOKRQCIWMGZDDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598534.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,inhibition of CYP3A4,Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,418,11632375,CC1=NC2=CC(=NN2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4,Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)cc2Cl)c1CN
CHEMBL536754,AOOTYIRLUTVCBQ-PQQSRXGVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,425,23577403,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)C(C5CCCCC5)O.Cl,CCCCN1C(=O)C(C(O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
CHEMBL2419501,AOOWVFPXPVQQGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,4.301029995663981,426,15983546,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=CC=C3)C,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccccc3)C2)nc1C
CHEMBL2381076,AORYYSDWZJZQSQ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,=,64000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1938200260161125,428,71602354,CC1=NC(=C(C=C1)C2=CC=CC=C2)C(=O)N3CC4(CC4)CC3CNC5=NC=C(C=C5)C(F)(F)F,Cc1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)CC2CNc2ccc(C(F)(F)F)cn2)n1
CHEMBL3310994,AOTCSTMPIJCZDF-APPDUMDISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,800.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,430,25132724,CC(C1=NC=NC=C1F)C(CN2C=CN=C2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1ccnc1)c1ccc(F)cc1F
CHEMBL604087,AOTJVGQNGQYEAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,431,25057409,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NC3=CC4=C(CCNC4)C=C3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC
CHEMBL1173087,AOUKQWFJPNRGAH-FGJGXXMFSA-N,"6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20527970.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.522878745280337,433,49799108,COC(CC=C)C12CC1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,C=CCC(OC)C12CNCCC1(c1ccc(Cl)c(Cl)c1)C2
CHEMBL2058906,AOVQXARIZDLJRY-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.657577319177793,435,62706660,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CC=C4)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cccnc3)cc2o1
CHEMBL225412,APBBPNOWHFPBMZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,38000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.42021640338319,438,10049358,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC(=C3)Cl)Cl,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1C(F)(F)F
CHEMBL3622924,APIGRKGHKBCGNE-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26384287.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,446,53232414,CC1=CC(=CC(=C1)NC2=NC=CC(=N2)N3C=C(C(=C3)CN4CCC(C4)O)C)C,Cc1cc(C)cc(Nc2nccc(-n3cc(C)c(CN4CCC(O)C4)c3)n2)c1
CHEMBL3664695,APIRJHBAONBUEP-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.6777807052660805,447,44476892,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C(F)F)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(C(F)F)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1222865,APPCPYUGJBDNJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,452,49865043,CN(C)CCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,CN(C)CCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL1682897,APPKRPXUNINZJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,453,18769065,CC(C)C(C1=CC2=C(C=C1)C(=C(C=C2)C(=O)NC)Cl)(C3=CN=CN3)O,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1Cl
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.522878745280337,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.301029995663981,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.096910013008056,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.6777807052660805,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,82000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.086186147616283,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.0,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.045757490560675,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241912,APQBIBMHRHYQIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.045757490560675,455,11712756,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL470048,APRVHMRKRPHQLM-NDUFOHEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,98300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.007446482167865,456,44559524,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)O,CC(=O)OC1C(O)C(C)OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C1O
CHEMBL2420674,APSAUQSMWXXDST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1759.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.754734160542538,457,71817943,C1=CC(=CN=C1)C2=C(C3=C(C=CC(=C3)O)C=C2)Cl,Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1
CHEMBL208112,APVPAEUTGJXHOF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,54.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.267606240177032,463,23647912,CC(C)C(=O)OCCN1CCCC2=C1C=C(C=C2)OCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCOC(=O)C(C)C)CCC3)cc1
CHEMBL3422237,APXCHRRPLFZFMP-IXBGWNDUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,465,71812189,CC1=NOC(=C1)C2CC3CSC(=NC3(CO2)C4=C(C=C(C=C4)F)F)N,Cc1cc(C2CC3CSC(N)=NC3(c3ccc(F)cc3F)CO2)on1
CHEMBL1257376,AQACZABFCRPMGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,468,16678616,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CC5=CC=C(C=C5)F,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccc(F)cc3)C2=O)CC1
CHEMBL212084,AQFXVMZZFFFSCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16759855.0,IC50,=,254.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5951662833800615,473,44414322,C1C2=C(C=C(C=C2)CN3C=CN=C3)C4=C1C(=NN4)C5=CSC=C5,c1cn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)cn1
CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26565745.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LC-MS analysis,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,PUBLICATION,,5.0,475,4946,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
CHEMBL1269597,AQHMBDAHQGYLIU-XNFHFXFQSA-N,SCY-635,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19933795.0,IC50,=,58500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 30 mins,"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.",Antimicrob. Agents Chemother.,PUBLICATION,,4.23284413391782,476,6479267,CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)SCCN(C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)C(SCCN(C)C)C(=O)N(C)C(CC(C)(C)O)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,477,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,477,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.823908740944319,477,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.0,477,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
CHEMBL595459,AQJWACKPYCXBCF-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,479,25222706,CC1=C2C=C(N=CC2=NN1)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=CNC6=CC=CC=C65)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)[nH]nc2cn1
CHEMBL3393476,AQQRFOITUMWTQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,5.075720713938118,481,59825704,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=CC(=C(C=C6N5)F)F,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)c(F)cc3[nH]2)o1
CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with midazolam (4-OH),Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,485,44346577,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)CC4CC5C6CCC(C6CCC5C7(C4=CC(=O)CC7)C)O,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)CC3CC4C5CCC(O)C5CCC4C4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with midazolam (1'-OH),Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,485,44346577,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)CC4CC5C6CCC(C6CCC5C7(C4=CC(=O)CC7)C)O,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)CC3CC4C5CCC(O)C5CCC4C4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with testosterone,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,485,44346577,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)CC4CC5C6CCC(C6CCC5C7(C4=CC(=O)CC7)C)O,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)CC3CC4C5CCC(O)C5CCC4C4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
CHEMBL332643,AQWHKMMTMUZLNF-YSBVTMKBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 with nifedipine,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3872161432802645,485,44346577,CCOC(=O)CCCN1C(=O)C2=CC3=CC=CC=C3N(C2=NC1=O)CCCCOC(=O)CC4CC5C6CCC(C6CCC5C7(C4=CC(=O)CC7)C)O,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)CC3CC4C5CCC(O)C5CCC4C4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O
CHEMBL402071,AQXGGRVGXYPDQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,486,44454940,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CC3=CC=C(C=C3)OC)C4=CC=CC=N4)C,COc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1
CHEMBL481233,AQZHZTTUVYQMIN-UHFFFAOYSA-N,"2,4,5-TRIMETHOXYPHENYLACETONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,28700.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.542118103266008,488,3083746,CC(=O)CC1=CC(=C(C=C1OC)OC)OC,COc1cc(OC)c(OC)cc1CC(C)=O
CHEMBL2043169,ARCCMXIHDKFBOJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,490,57386783,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC(=CC=C6)C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4cccc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL506338,ARERDXBHAZDIGD-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,492,44587403,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCOCC(=O)O)F,CNC(Cn1c(=O)c(-c2cccc(OCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL479085,ARHIKEBQUQQYQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,495,44579233,CC1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,Cc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1
CHEMBL2036958,ARJKMWXLIHZLQZ-UHFFFAOYSA-N,SCH-900271,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,497,56950369,CC1(CC1)CCCC2=CC(=O)OC3=C2C(=O)NC(=O)N3,CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1
CHEMBL1209625,ARJPLPHVQBNIKZ-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,498,49862601,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)C(C)C3=CC=C(C=C3)Cl,CC(C)CC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL1209625,ARJPLPHVQBNIKZ-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,498,49862601,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)C(C)C3=CC=C(C=C3)Cl,CC(C)CC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL1209626,ARJPLPHVQBNIKZ-FWJOYPJLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,499,49862602,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)C(C)C3=CC=C(C=C3)Cl,CC(C)CC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL562551,ARYUXFNGXHNNDM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,4.522878745280337,509,44191096,COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=N2)Cl,COc1cc(NC(=O)c2ccccn2)ccc1Cl
CHEMBL3400450,ASBKGVWWADMSIU-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,511,59272228,CC(C)N(CC1CNCC1NC(=O)OCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)OCc2ccccc2)C(C)C)ccc1OC
CHEMBL3400450,ASBKGVWWADMSIU-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,14800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.8297382846050425,511,59272228,CC(C)N(CC1CNCC1NC(=O)OCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)OCc2ccccc2)C(C)C)ccc1OC
CHEMBL1916399,ASJOLIPQCOYRPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21852130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,526,44517795,C1CN(C2=C1C=C(C=C2)C3=NOC(=N3)C4=CC(=CC(=C4)C#N)OC(F)(F)F)C(=O)CCC(=O)O,N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)CCN4C(=O)CCC(=O)O)no2)c1
CHEMBL2070161,ASOXHYLKWBYUGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,532,70688848,C1=CC=C(C=C1)N2C=C(C=CC2=O)C3=NC4=C(N3)C=C(C=C4)S(=O)(=O)CC(F)(F)F,O=c1ccc(-c2nc3ccc(S(=O)(=O)CC(F)(F)F)cc3[nH]2)cn1-c1ccccc1
CHEMBL1208963,ASTXNDZZOAPTNR-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.431798275933005,536,24954671,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCO)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NCCO)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL2019022,ASVPNBDOVHTUEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4010.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.396855627379818,537,4674678,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=N3,COc1ccc2nc(SCc3ccccn3)[nH]c2c1
CHEMBL3702714,ASYDBVRDAOJREX-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.97061622231479,541,89718266,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(O)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2437432,ASYPSYLJDLVBFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,543,72375119,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=NC=CC=N5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ncccn5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL1471,ATALOFNDEOCMKK-OITMNORJSA-N,APREPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,46.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.337242168318426,545,6918365,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NC(=O)NN3)C4=CC=C(C=C4)F,CC(OC1OCCN(Cc2nc(=O)[nH][nH]2)C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL504492,ATHBTCOFQCXOFU-DDKZQSMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19447613.0,IC50,>=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,550,44475943,CC1C(C(CC(O1)OC2C3C4C5=NC(=CS5)C(=O)NC(COC(=O)C6=C(CO3)C7=C(COC2=O)C=CC=C7N6O)C8=NC(=CS8)C9=NC(=C(C=C9C1=NC(=CS1)C(=O)NC(C(=O)NC(=C(C)OC)C1=NC(=CS1)C(=O)N4)C(C)O)OC)C1=NC(=CS1)C(=O)NCCCN1CCOCC1)(C)O)N(C)C,COC(C)=C1NC(=O)C(C(C)O)NC(=O)c2csc(n2)-c2cc(OC)c(-c3nc(C(=O)NCCCN4CCOCC4)cs3)nc2-c2csc(n2)C2COC(=O)c3c4c5c(cccc5n3O)COC(=O)C(OC3CC(C)(O)C(N(C)C)C(C)O3)C(OC4)C(NC(=O)c3csc1n3)c1nc(cs1)C(=O)N2
CHEMBL1210646,ATIUDCBCVSICHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594839.0,IC50,=,9620.0,NM,,,,,,,,,,,,,,,Inhibition of human CY3A4,Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.016824927962187,551,46911720,CCC1=C(C=C(C=C1)S(=O)(=O)NC2=CC=CC=C2Br)NC3CCN(CC3)C,CCc1ccc(S(=O)(=O)Nc2ccccc2Br)cc1NC1CCN(C)CC1
CHEMBL151646,ATLLIISCQQKAQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,29300.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.533132379645891,554,11817019,CCCCOC1=CC=C(C=C1)C2=CN=CC=C2,CCCCOc1ccc(-c2cccnc2)cc1
CHEMBL2409007,ATOKVTDUHKZLMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,6.0,557,60207864,CCOCC1=C(C=NN1C2=NC=C(C(=N2)N3CCCCC3)C)C(=O)NCC4=CN=CN4C,CCOCc1c(C(=O)NCc2cncn2C)cnn1-c1ncc(C)c(N2CCCCC2)n1
CHEMBL3702678,ATQBQXJFNKVZEY-YATWDLPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.107905397309519,559,89716377,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8CCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL180592,ATRBKKFCGWCOAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,344.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.46344155742847,561,11582790,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)[N+](=O)[O-])N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc([N+](=O)[O-])cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL3699342,ATRYSYOKKNIJSL-MVRBIKRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2260.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.645891560852599,563,89718275,CCN(CC)CC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(CN(CC)CC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL208158,ATTJXWVUQQZVGI-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2150.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.667561540084395,564,44411036,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N4CCOCC4,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N1CCOCC1
CHEMBL1095678,AUCPKYPLGAVYAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,566,46888853,CCOCCN1C2=CC=CC=C2N=C1C3CCCN(C3)C4CCCCC4,CCOCCn1c(C2CCCN(C3CCCCC3)C2)nc2ccccc21
CHEMBL2436210,AUCPUCVXSILLHO-QDMMYLPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.552841968657781,567,72711721,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)CC5=CN=CC=C5)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)Cc2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3114735,AUEWZJYNVLYDFR-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,569,57773771,CC(C)CN(CCC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)C(=O)C(CCN3CCOCC3)NC(=O)N(C)CC4=CSC(=N4)C(C)C,CC(C)CN(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)C(CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1
CHEMBL3358954,AUIFRJWXYUNPPV-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.096910013008056,571,44543970,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=C(C=C(C=C3)F)C(=O)N)(C(F)(F)F)O,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1
CHEMBL3358950,AUIFRJWXYUNPPV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.585026652029182,572,67053383,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=C(C=C(C=C3)F)C(=O)N)(C(F)(F)F)O,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1
CHEMBL2436616,AUKNZSATOILHNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,575,44816692,C1CN(CCC1N2CC3=CC=CC=C3CC4=CC=CC=C42)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5Cc5ccccc54)CC3)CC2)ccn1
CHEMBL1950743,AUNMHWAGSWQKHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22290075.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,579,24993178,CC1(CC(=NNC1=O)C2=CC=C(C=C2)OC3CCN(CC3)C4CCC4)C,CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O
CHEMBL3115190,AUQCZFYQJFJHES-HEWUYBSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.096910013008056,581,76335992,C1CC1N(CC2=CN=CS2)C(=O)NC(CO)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,O=C(NC(CCC(Cc1ccccc1)NC(=O)C(CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1
CHEMBL3115170,AUQCZFYQJFJHES-JFPMUIDKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,582,59721254,C1CC1N(CC2=CN=CS2)C(=O)NC(CO)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,O=C(NC(CCC(Cc1ccccc1)NC(=O)C(CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1
CHEMBL2347337,AUTURIRJHQDRSI-ZEQRLZLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,590,71579539,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)CO)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(-c3ccc(CO)cc3)cc2)[nH]1)C(C)C
CHEMBL3287188,AUUYAKJPRWOIHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24899257.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,591,73603391,CC1=C(C=NC=C1)C2=CC3=C(C=C2)N(CC3)C(=O)C,CC(=O)N1CCc2cc(-c3cnccc3C)ccc21
CHEMBL438525,AVESOBXGFYHSSH-AQNXPRMDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,598,44442009,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)OC,CCC1CC(OC)CC(COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL249085,AVESOBXGFYHSSH-VAMGGRTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,10100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.995678626217358,599,44442010,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)OC,CCC1CC(OC)CC(COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL563451,AVFYUSOOXDDQAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,602,45272876,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)N(C)C,Cc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1
CHEMBL2043011,AVIDRKWFHQXSDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,5.0,604,49847755,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL3702697,AVNPLQIOVHQFAT-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,608,89718200,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCN(C)C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL397580,AVPONLNZIPJOOI-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.173925197299173,609,44433294,CC(C)CC(C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,CC(C)CC(NC(=O)CCN)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL1950088,AVRCXDPCPXUSED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,610,57403379,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)[nH]nc3nc12
CHEMBL1950088,AVRCXDPCPXUSED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,610,57403379,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)[nH]nc3nc12
CHEMBL407708,AVSVDPPALUYPPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,611,21049437,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NC(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)Nc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
CHEMBL2387507,AVUOMYZMGMHQBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,612,71659756,C1=CC=C(C(=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F)Cl,O=c1[nH]c2cc(-c3ccccc3Cl)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
CHEMBL365985,AVWXVFNJXMOFEK-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,614,44400121,C1=CC=C(C=C1)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,NC(Cn1c(=O)c(-c2ccccc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL1080088,AWDJPCNXSYKBPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,619,46879643,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3CC=C)C)C,C=CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21
CHEMBL1080293,AWJOAMPQOUEKCN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,623,44626928,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CC5CC5(C4)C6=CC=C(C=C6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CC5CC5(c5ccc(C(F)(F)F)cc5)C4)n3C)cccc2n1
CHEMBL3236638,AWJWXXHHLFWIPR-XCXSIRTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,5.769551078621726,624,90655384,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=CC=CC=C5,CC1(Cc2ccccc2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3422243,AWKVMOUMPQXDPO-NPQNXCPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,625,86343366,CC1C2CC(OCC2(N=C(S1)N)C3=C(C=C(C=C3)F)F)C4=CN(N=C4)C,CC1SC(N)=NC2(c3ccc(F)cc3F)COC(c3cnn(C)c3)CC12
CHEMBL195561,AWLCGHPEKZDBDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,626,44403300,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC#N)CCO)C3=C(C=CC(=C3)Cl)O,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
CHEMBL195561,AWLCGHPEKZDBDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,626,44403300,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC#N)CCO)C3=C(C=CC(=C3)Cl)O,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
CHEMBL522964,AWPVHYLYCREWTR-OQHSHRKDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,633,11225445,CC1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CC3)C4=CC=NC=C4,CC1CN(CC2(c3ccncc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
CHEMBL1642258,AWVFHDAVDXQSNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074994.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,640,50942696,CN(C)C(=O)CN1CCC2=CC(=C(C=C2CC1)OC)NC3=NC=C(C(=N3)NC4=C(C=C(C=C4)N5CCOCC5)OC)Cl,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2
CHEMBL3702682,AXCZNYZPBSOAFX-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6960.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.157390760389438,647,89718195,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)C(=O)N8CCN(CC8)S(=O)(=O)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL506877,AXGALHYEZXVPRS-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,135000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,3.869666231504994,648,25156400,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL1095819,AXIFLPLKZRNVDP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,650,46888857,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
CHEMBL1087089,AXIFLPLKZRNVDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,651,46861860,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
CHEMBL271621,AXKQUNLOEFWORV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.920818753952375,655,4261503,CCOC(=O)C(CC1=C(C=C(C=C1)Cl)Cl)C2=CC=NO2,CCOC(=O)C(Cc1ccc(Cl)cc1Cl)c1ccno1
CHEMBL1650645,AXMKFPDKHLZNID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17��-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,6.657577319177793,658,24970356,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C4=CN=CC=C4,Oc1cccc(-c2ccc3c(-c4cccnc4)c(O)ccc3c2)c1
CHEMBL1682889,AXNQQSNSHKSLDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.0,660,17963726,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL3331502,AXOLLJKPTOLJBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,32700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.485452247339714,661,118713799,C1C(CN1)CN(CC2=C(C(=CC=C2)Cl)Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl
CHEMBL2419515,AXOSMMGWCJFHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,662,71727461,CC1=NC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
CHEMBL2419515,AXOSMMGWCJFHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,662,71727461,CC1=NC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
CHEMBL3125527,AXQMSOFCQLTJGV-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,663,68000593,CCC(CS(=O)(=O)C(C)(C)C)N1C(C(CC(C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,CCC(CS(=O)(=O)C(C)(C)C)N1C(=O)C(C)(CC(=O)O)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
CHEMBL100917,AXRLOUATLDLSKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,51000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.292429823902063,664,20763282,CCCCC1=CC=CC=C1N=CNO,CCCCc1ccccc1N=CNO
CHEMBL2440659,AXVLPJHYYFHCHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,22300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.651695136951839,668,50990953,CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)F)OC3=CN=CN=C3,Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1
CHEMBL2040896,AYBBBAJBBDEEQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,672,57387280,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CC=NO6,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccno3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL1258034,AYDQEBMCUGUQLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.221848749616356,675,52940961,CN1C(=NN=C1SCCCN2CCC3CC3(CC2)C4=CC=C(C=C4)C(F)(F)F)C5=CN=NC=C5,Cn1c(SCCCN2CCC3CC3(c3ccc(C(F)(F)F)cc3)CC2)nnc1-c1ccnnc1
CHEMBL3262028,AYDUTYVLGUMPSM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24758746.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia.",J. Med. Chem.,PUBLICATION,,5.0,676,53380288,CC1=C(N2C=CN=C(C2=N1)N3CCOCC3)C4=CN(N=C4)CCOC,COCCn1cc(-c2c(C)nc3c(N4CCOCC4)nccn23)cn1
CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,678,44247806,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,CC(C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,678,44247806,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,CC(C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
CHEMBL2158221,AYFFPEOVSJSGAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,679,11720104,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCNCC3)NC(=O)C4=NC=C(N4)C#N.C(=O)(C(F)(F)F)O,N#Cc1cnc(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)[nH]1
CHEMBL1951055,AYHCJXIBRDMYBV-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22297111.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,681,49857811,CC1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCOCC3,CC1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1
CHEMBL1951055,AYHCJXIBRDMYBV-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,681,49857811,CC1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCOCC3,CC1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1
CHEMBL3287548,AYKQXOKTTGHBAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900870.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam conversion to 1'-hydroxy midazolam preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,683,86302354,C1CNCC2=C1N(C3=C2C=C(C=C3)F)CCCOC4=CC=C(C=C4)Cl,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1
CHEMBL3287548,AYKQXOKTTGHBAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900870.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone conversion to 6-hydroxy testosterone preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,683,86302354,C1CNCC2=C1N(C3=C2C=C(C=C3)F)CCCOC4=CC=C(C=C4)Cl,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1
CHEMBL3114740,AYNKEDQCQUBXKC-PXTZSQHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3872161432802645,685,59721379,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)N(C)C(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)N(C)C(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL230260,AYPFLXLPOWWLSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,686,23628221,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCCOC)C=C2,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)CCC2
CHEMBL3318481,AYRNGMFSOUXWOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,688,118708938,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2C#N)C3=C(C=CC=C3Cl)Cl,N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Cl)CC1=O
CHEMBL2070159,AYWOBRMICRHNEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,693,70693070,CC(C)(C)S(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN(C(=O)C=C3)C4=CC=CC=C4,CC(C)(C)S(=O)(=O)c1ccc2nc(-c3ccc(=O)n(-c4ccccc4)c3)[nH]c2c1
CHEMBL221113,AZBGLEQDAYJKBP-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17315987.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.",J. Med. Chem.,PUBLICATION,,5.060480747381382,698,11302765,CCC1=CC2=C(C(=C1)C(F)(F)F)C(=O)N3C2CNCC3,CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNCC21
CHEMBL2170607,AZBYJNPBRNIJSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.795880017344075,699,44610104,C1CC1C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)c(C(F)(F)F)c1
CHEMBL3702724,AZEAMEKURIDBIX-OZLPACJUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2450.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.610833915635467,700,89718428,CN1CCC2C1CN(C2)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC6CCN(C)C6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL519132,AZFITEALNSCCOH-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,703,135960712,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)OC,COC1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL100899,AZLFXTDKWCBSKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,708,10198034,CCC(C)C1=CC=C(C=C1)N=CNO,CCC(C)c1ccc(N=CNO)cc1
CHEMBL2010836,AZRVSANIIWCDJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22061639.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by HTRF assay,"Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,710,56643412,CN(C1CCN(CC1)CC2=CC=C(C=C2)C(F)(F)F)C(=O)CC3=CC=C(C=C3)N4C=NN=N4,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1
CHEMBL3629740,AZSDCDNUQDIYHT-HSQYWUDLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.522878745280337,711,76283431,C1CC2(CCOC2=O)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=C1OCCC12CCCC1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC21
CHEMBL3629740,AZSDCDNUQDIYHT-HSQYWUDLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.522878745280337,711,76283431,C1CC2(CCOC2=O)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=C1OCCC12CCCC1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC21
CHEMBL1078189,AZUMWAWLOFIGCX-NYOKMZSHSA-N,"6',7'-DIHYDROXYBERGAMOTTIN OCTANAL ACETAL",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,6.886056647693163,713,44478952,CCCCCCCC1OC(C(O1)(C)C)CCC(=CCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4)C,CCCCCCCC1OC(CCC(C)=CCOc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1
CHEMBL2048062,AZZAPLDRNFVCMT-SYNHAJSKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,5.173925197299173,719,57384273,CC(C)(C)CN1C=C(C=N1)CNC2CS(=O)(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,CC(C)(C)Cn1cc(CNC2CS(=O)(=O)CC(Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)C2O)cn1
CHEMBL2069802,BAAOVUUNXIWPLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,724,22520172,C1=CC=C(C=C1)S(=O)(=O)CC2=NN=C(O2)C(=O)NCC3=CC=NC=C3,O=C(NCc1ccncc1)c1nnc(CS(=O)(=O)c2ccccc2)o1
CHEMBL210322,BABAHNGGVSLMEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,727,11539239,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)NC(=O)CC4=CC=CC=C4,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)Cc3ccccc3)CC2)c1
CHEMBL2163839,BAEIXDSVHABCNB-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.107905397309519,730,57522132,CN(C)CCN(C)C(=O)C(CC1=CC=C(C=C1)Br)NC(=O)C2(CC2)C3=C(C=C(C=C3)Cl)Cl,CN(C)CCN(C)C(=O)C(Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
CHEMBL3702788,BAFJWSOKLYQZFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2570.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.590066876668706,731,89718252,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCCN8CCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCCN6CCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3115253,BAHABGBETCGAQD-WNJJXGMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24462667.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,732,59122522,CC(C)(C)OC(=O)N1CCN(CC1)C2C3=C(C=C(C=C3)Cl)C(=CC4=C2N=CC=C4)C(C)(C5=CN=CN5C)O,Cn1cncc1C(C)(O)C1=Cc2cccnc2C(N2CCN(C(=O)OC(C)(C)C)CC2)c2ccc(Cl)cc21
CHEMBL2331677,BALVINFSPVZXGT-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,737,59239348,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=CN4C)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(c2nccn2C)C3)cc1
CHEMBL3358938,BAOUXBDVAPNGRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.301029995663981,741,118723173,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4S(=O)(=O)N,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O
CHEMBL120185,BARFMAOTOPEJFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,743,9826083,CN1CCN(CC1)C2=NC3=C(C=C2)N(C(=N3)C4=CC=C(C=C4)F)C5=NC(=NC=C5)NC6CCCC6,CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1
CHEMBL3104528,BARKMJDWQGKXIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,800.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,6.096910013008056,744,76321105,CC(C)(C)CC(=O)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3,CC(C)(C)CC(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
CHEMBL1651534,BATCTBJIJJEPHM-UHFFFAOYSA-N,PF-04457845,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,745,24771824,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
CHEMBL1651534,BATCTBJIJJEPHM-UHFFFAOYSA-N,PF-04457845,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,745,24771824,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
CHEMBL3353863,BAUZVWBSZFLVIL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556092.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,747,67953283,CC(C)(C)C1=CC(=NO1)NC(=O)C2CCCN2C3=CC=C(C=C3)Cl,CC(C)(C)c1cc(NC(=O)C2CCCN2c2ccc(Cl)cc2)no1
CHEMBL595632,BAXFMLZOUPMNQW-ZHACJKMWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19700331.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,750,10294290,C1=CC=C2C=C(C=CC2=C1)CCOC3=C(C=CC(=C3)CN4C=CC=N4)C=CC(=O)O,O=C(O)C=Cc1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1
CHEMBL3702712,BAZGKZBDGLGUSD-UCFJPLQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.91721462968355,752,89718456,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN8CCN(CC8C7)C=O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C=O)CC6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3137461,BBBIOQXWVKFUKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.698970004336019,753,76329430,CN(C)S(=O)(=O)C1=CC=CC=C1N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,CN(C)S(=O)(=O)c1ccccc1N1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1
CHEMBL1585484,BBEBKAGLYIMBCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,758,2350190,C1COCCN1S(=O)(=O)C2=CC3=C(C=C2)N=C(N3)SCC4=CC(=CC=C4)Cl,O=S(=O)(c1ccc2nc(SCc3cccc(Cl)c3)[nH]c2c1)N1CCOCC1
CHEMBL3125379,BBFGUZXGQBPQCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,761,57411716,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O)C=CC=C2Cl,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O
CHEMBL235640,BBMVDIOZDPPMNA-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,771,44433285,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CNC,CNCC(=O)NC(CC(C)C)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL1669420,BBPIYFSEHZGVJE-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,2820.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.549750891680639,774,53325600,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CS4,CC(C1=C(CCN(C)Cc2nccs2)Cc2ccccc21)c1cnccn1
CHEMBL2017099,BBXHLOWFZRSHFF-GIPWTMENSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,780,46932047,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=C(C=CC=C4Cl)Cl)Br,OC1(c2ccc(F)c(F)c2)CCNCC1c1onc(-c2c(Cl)cccc2Cl)c1Br
CHEMBL3605558,BBYGAEPKKAXIBP-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26291341.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,PUBLICATION,,4.698970004336019,783,24985745,CCN1C2=CC(=NC=C2N=C1C(C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C4CC4,CCn1c(C(C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C3CC3)cc21
CHEMBL638,BCEHBSKCWLPMDN-MGPLVRAMSA-N,VORICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,13000.0,NM,,inhibition,tissue,binding,,,,,,,,,,,,,,,,4.886056647693163,786,71616,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL638,BCEHBSKCWLPMDN-MGPLVRAMSA-N,VORICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,13000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,786,71616,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL638,BCEHBSKCWLPMDN-MGPLVRAMSA-N,VORICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13000.0,NM,273500,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,4.886056647693163,786,71616,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL1951342,BCHDNCPTPUSOHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,79.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.102372908709558,791,57395301,C1CCN(CC1)C(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)N2CCCCC2)c1
CHEMBL1081505,BCTONXHZFGFJIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,797,18414685,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC=C2)N(C(=N3)C)C,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C
CHEMBL1081505,BCTONXHZFGFJIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,797,18414685,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC=C2)N(C(=N3)C)C,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C
CHEMBL1823410,BDAYYWQLRAMGNO-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21824776.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Amine-constrained pyridazinone histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,804,44539764,CN1C(=O)C=CC(=N1)C2=CC=C(C=C2)C(=O)N3CCCC3CN4CCCC4,Cn1nc(-c2ccc(C(=O)N3CCCC3CN3CCCC3)cc2)ccc1=O
CHEMBL499849,BDBGKADVAYPDNK-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,805,44593614,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CNCC(=O)O)N,NC(Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL499849,BDBGKADVAYPDNK-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,805,44593614,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CNCC(=O)O)N,NC(Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL1951609,BDGAXEZYOOOOBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,813,57400459,CC1=NC(=NC2=CC=CC=C12)CN3C(=O)C4=C(C(=C(N4CC=C(C)C)N5CCCNCC5)C#N)N(C3=O)C,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
CHEMBL310586,BDXLTTUQHGMFEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,<,50.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,7.301029995663981,818,44317414,C1CN2C3=CC=CC=C3C4=CC(=CC=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CNC1C2=O)C#N,N#Cc1ccc2cc1Oc1cccc(c1)-c1ccccc1N1CCC(NCc3cncn3C2)C1=O
CHEMBL1684585,BDYLGPUIUMBDQP-CZTZKLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ��3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,4.0,819,44472590,C1CC(NC1CC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)C(C4=CC=CC=C4)O,Nc1nc(CC(=O)Nc2ccc(CC3CCC(C(O)c4ccccc4)N3)cc2)cs1
CHEMBL1684585,BDYLGPUIUMBDQP-CZTZKLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,4.0,819,44472590,C1CC(NC1CC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)C(C4=CC=CC=C4)O,Nc1nc(CC(=O)Nc2ccc(CC3CCC(C(O)c4ccccc4)N3)cc2)cs1
CHEMBL449192,BEKQKLIWZQJREN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,826,44561240,CC1=CC2=C(C=C1C)OCC(=O)N2CC(=O)N(C)C(CN3CCOCC3)C4=CC=C(C=C4)C5=CC=C(C=C5)NC(=O)C,CC(=O)Nc1ccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(C)c(C)cc43)cc2)cc1
CHEMBL251229,BENXORZPKXUGMY-UHFFFAOYSA-O,STEPHARANINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,5.6020599913279625,831,10358881,COC1=C(C=C2C(=C1)CC[N+]3=C2C=C4C=CC(=C(C4=C3)OC)O)O,COc1cc2c(cc1O)-c1cc3ccc(O)c(OC)c3c[n+]1CC2
CHEMBL1923110,BEPZQODHCZLPEN-MVSFAKPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,835,57390807,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC=CC=C5CC(=O)O4,COCCCc1cc(CN(C(=O)C2CNCCC23OC(=O)Cc2ccccc23)C2CC2)cc(OCCOC)c1
CHEMBL283693,BEQXWFPRVYMACF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,837,11455462,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC(=NC4=C3NC5=C4C=C(C=C5)[N+](=O)[O-])CN6CCOCC6,O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1
CHEMBL516125,BESWAUVYRXNIKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,840,44578960,C1=CC=C(C=C1)C(C2=NN=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccnn1
CHEMBL2017276,BETHVCQFAJRUPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,841,70695889,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4C(=O)C5=CC=CC=N5)C(=O)N)OC,COc1cc2c(Nc3ccccc3C(=O)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL2336416,BEZLXEJGNUZTPC-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,844,11377534,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2336416,BEZLXEJGNUZTPC-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,844,11377534,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL565591,BFBTVZNKWXWKNZ-HWKANZROSA-N,DG-041,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19957930.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding.",J. Med. Chem.,PUBLICATION,,5.823908740944319,847,11296282,CC1=CN(C2=C(C=C(C=C12)F)C=CC(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(C=CC(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12
CHEMBL565591,BFBTVZNKWXWKNZ-HWKANZROSA-N,DG-041,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19957930.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using dibenzylfluorescein as substrate,"Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding.",J. Med. Chem.,PUBLICATION,,5.119186407719209,847,11296282,CC1=CN(C2=C(C=C(C=C12)F)C=CC(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(C=CC(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12
CHEMBL415274,BFCVOTGOHBEFMZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,851,9831072,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN(C)C)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,CN(C)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL2013045,BFKPZXXQVYWHKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,859,57345658,CS(=O)(=O)N1CCC(CC1)OC2=CC3=C(C=C2)OC4(CC3)CCN(CC4)C5CCC5,CS(=O)(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
CHEMBL3664715,BFMZBCSQICXEMN-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.318758762624412,860,44476890,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL3137479,BFOXLQWBMPVYPH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.795880017344075,862,76325842,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=CC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cncnc3)CC2)cc1
CHEMBL258251,BFPVIFSFUVSFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,864,44449202,C1CC(C(N(C1)C(=O)CN(CC#N)C2=CC(=C(C=C2)Cl)Cl)CN3CCOCC3)C4=CC=CC=C4,N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1
CHEMBL1668257,BFWQNCCFSCRIGZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,870,53326213,C1CCC(CC1)C(C(=O)NC2=C(C=C(C=C2)C3=NNN=N3)F)N4C5=CC(=C(C=C5N=C4C6=CC=C(C=C6)Cl)F)F,O=C(Nc1ccc(-c2nn[nH]n2)cc1F)C(C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
CHEMBL438683,BFYGPJBAPDERDU-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,872,44433277,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCN,CC(C)CC(NCCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2419505,BGECQVFGWHCTBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,877,56943206,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4)C=NC=C2,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1
CHEMBL2419505,BGECQVFGWHCTBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,877,56943206,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4)C=NC=C2,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1
CHEMBL1079258,BGFWYEFBAHLCNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,879,46882988,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC(=CC=C3)C(F)(F)F,O=C(O)CCC1(c2cccc(C(F)(F)F)c2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL360541,BGKUWZFWNZFRMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,128000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.8927900303521317,884,11263510,C1=CC(=CN=C1)C#CCN,NCC#Cc1cccnc1
CHEMBL360541,BGKUWZFWNZFRMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,365000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.4377071355435254,884,11263510,C1=CC(=CN=C1)C#CCN,NCC#Cc1cccnc1
CHEMBL3394730,BGNOECVQVUFFHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2441251443275085,886,68276577,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
CHEMBL3394730,BGNOECVQVUFFHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,886,68276577,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
CHEMBL1683444,BGUXTVRZPYKBBN-KXBFYZLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,<,0.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,894,53324198,CC(CC(CS(=O)(=O)N1CCC(CC1)OCC2=C(C=C(C=C2)Cl)Cl)N(C=O)O)C3=NC=C(C=N3)F,CC(CC(CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1
CHEMBL3702693,BGZVJJCLWJQDPD-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6820.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.166215625343521,898,89718242,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL469851,BHCRVKVXJRBQJR-YPDHAKIYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,55800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.253365801062421,900,11203112,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)OC(=O)C)O,CC(=O)OC1C(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)OC(C)C(O)C1OC(C)=O
CHEMBL2448723,BHIWKCYRDRDVNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1040.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.982966660701219,904,73355722,CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CN=CC(=C2)C3=NC4=CC=CC=C4S3,CCS(=O)(=O)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
CHEMBL1092812,BHMPPLVSPUZBNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,907,46884154,CC(C1=CN=C(C=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,COc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1
CHEMBL1088949,BHTGEWHBEIZLOP-VQHVLOKHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,916,24959169,CC1=C(C2=CC=CC=C2N1)CCN3CC4=C(C3)C=C(C=C4)C=CC(=O)NO,Cc1[nH]c2ccccc2c1CCN1Cc2ccc(C=CC(=O)NO)cc2C1
CHEMBL10188,BIAVGWDGIJKWRM-FQEVSTJZSA-N,TALNETANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,924,5311424,CCC(C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O,CCC(NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL2436226,BIAWVZMEBADAPM-MJFWUJRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.795880017344075,925,72714057,CC1C(C(=O)N(C2=C(N1C(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)C)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)C1C
CHEMBL226385,BIFWAJIKBGURHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,51000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.292429823902063,928,10070428,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL3114731,BIJHYGNWGXBYFX-LDNVYYCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.468521082957745,932,70993878,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCN(CC3=CC=CC=C3)C(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2089032,BIUDJFOTQAVFMN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22982525.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,5.301029995663981,941,46912953,CC(C)N1C=NC2=C(N=C(N=C21)NCC(CO)O)NCC3=CC=C(C=C3)C4=CC=CC=N4,CC(C)n1cnc2c(NCc3ccc(-c4ccccn4)cc3)nc(NCC(O)CO)nc21
CHEMBL3112852,BIXKKBQECSTCMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,948,49854753,COC1=CC=CC2=C1CCN2C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,COc1cccc2c1CCN2C(=O)Cc1nc(=O)cc(N2CCOCC2)[nH]1
CHEMBL1951600,BJBOAPYAMPEKGS-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,950,57397016,CC1=NC(=NC2=CC=CC=C12)CN3C(=O)C4=C(C(=C(N4CC=C(C)C)N5CCCC(C5)N)C#N)N(C3=O)C,CC(C)=CCn1c(N2CCCC(N)C2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
CHEMBL392463,BJBXILVBLCBQQY-FTJBHMTQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,951,44433800,CC1=C(C=CC(=C1)F)C2CN(CC2C3=NC(=NO3)C(C)(C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)C5CCN(CC5)C(=O)C,CC(=O)N1CCC(C(=O)N2CC(c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL392464,BJBXILVBLCBQQY-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,952,44433802,CC1=C(C=CC(=C1)F)C2CN(CC2C3=NC(=NO3)C(C)(C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)C5CCN(CC5)C(=O)C,CC(=O)N1CCC(C(=O)N2CC(c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL1673059,BJCHGDBASIDUOJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25680029.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.",J. Med. Chem.,PUBLICATION,,5.154901959985743,953,2811640,C1CN(CCC1C(=O)N)C2=C(C=NC=C2Cl)Cl,NC(=O)C1CCN(c2c(Cl)cncc2Cl)CC1
CHEMBL252518,BJDCWCLMFKKGEE-CMDXXVQNSA-N,ARTENIMOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,>,125000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.9030899869919438,954,10221470,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,CC1CCC2C(C)C(O)OC3OC4(C)CCC1C32OO4
CHEMBL252518,BJDCWCLMFKKGEE-CMDXXVQNSA-N,ARTENIMOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,>,125000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.9030899869919438,954,10221470,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,CC1CCC2C(C)C(O)OC3OC4(C)CCC1C32OO4
CHEMBL2158295,BJMQKWRHLJKHOC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.823908740944319,961,11627369,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CC4=CC=CC=N4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccccn4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL3640015,BJMZKSMCWXSRCH-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2780.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.555955204081924,963,89718409,CC(=O)CCNCCCC(=O)NC1=CC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCNCCC(C)=O)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL596072,BJSFTYZWWXFKSH-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,970,46225572,CC1=C2C=C(C=NC2=NN1)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=COC=C6,Cc1[nH]nc2ncc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12
CHEMBL578588,BJXGGWYWXKQKIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,975,45484916,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)N(C)C,CN(C)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1
CHEMBL3622879,BKAQDKUFAULKQY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,976,91885643,CC1=C(N=C(N=C1Cl)C2CC2)NCC3=C(N=C(S3)C)C,Cc1nc(C)c(CNc2nc(C3CC3)nc(Cl)c2C)s1
CHEMBL1837038,BKJSIODGIVFGTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,985,56672570,COC(=O)N1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,COC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
CHEMBL480219,BKNPWPRZETXJRA-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,46000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.337242168318426,988,16041292,CC1CN(CC(N1)C)CC2=CC=C(C=C2)N3C=CN=C3C(=O)N4CCC(CC4)NC5=CC(=CC=C5)F,CC1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CC(C)N1
CHEMBL480219,BKNPWPRZETXJRA-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.236572006437063,988,16041292,CC1CN(CC(N1)C)CC2=CC=C(C=C2)N3C=CN=C3C(=O)N4CCC(CC4)NC5=CC(=CC=C5)F,CC1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CC(C)N1
CHEMBL1096089,BKRADANXACAJKT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,991,135553240,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CC#N,Cc1cc(N2CCN(CC#N)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2170608,BKTAXDHHVZLQOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,993,58269588,COCC(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,COCC(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL218017,BKWXCVZIALOBBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,998,10268204,C1CN(CCC1CNC2=CC=CC=N2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2ccccn2)CC1
CHEMBL319862,BLIJUBJTRKESFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,94000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.026872146400302,1015,20763421,CCCCC1=CC(=C(C=C1)C)N=CNO,CCCCc1ccc(C)c(N=CNO)c1
CHEMBL283255,BLIMNWSQDQYNMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,6.698970004336019,1016,11168500,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=CC=CC(=C54)C(=O)N)CC6=CC=NC=C6,NC(=O)c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1
CHEMBL2397305,BLLVQWSTMVRWIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1487416512809245,1020,71681728,CC1=C(SC(=N1)NC(=O)CN(CC2=CC=CC=C2)C(=O)C3=CC=NC=C3)C4=CN=C(C=C4)N,Cc1nc(NC(=O)CN(Cc2ccccc2)C(=O)c2ccncc2)sc1-c1ccc(N)nc1
CHEMBL3291423,BLNAAWXUNQHVNT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1021,90467014,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)N(C)C)C)C(=O)NCCO)N=C1,Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1
CHEMBL3669004,BLPWIRCAXJRMJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320646,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1023,67199021,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCCC5)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1
CHEMBL3669004,BLPWIRCAXJRMJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320690,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1023,67199021,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCCC5)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1
CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,1028,9838675,CC1CCC2C(C(=O)OC3C24C1CCC(O3)(OO4)C)C,CC1CCC2C(C)C(=O)OC3OC4(C)CCC1C32OO4
CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22679214.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,1028,9838675,CC1CCC2C(C(=O)OC3C24C1CCC(O3)(OO4)C)C,CC1CCC2C(C)C(=O)OC3OC4(C)CCC1C32OO4
CHEMBL2018908,BLUDPRGGEJCLGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,15700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.804100347590766,1029,56953770,CCCCCCCSC1=NC2=C(N1)C=C(C=C2)OC,CCCCCCCSc1nc2ccc(OC)cc2[nH]1
CHEMBL556487,BLVRDPUKIXDEBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,1032,45273380,C1CN(CCC1C2=NC(=NO2)C3=CC=NC=C3)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1
CHEMBL1911826,BLWAXJUYAKUVSK-ZJSXRUAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,1033,57398065,CN(C)C1CCN(C1)C(=O)C(COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN(C)C1CCN(C(=O)C(COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
CHEMBL2336419,BMBUNRAVRJCKBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,1042,58864297,CCC1=CC(=CC2=C(NN=C12)C)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)[nH]nc12
CHEMBL2336419,BMBUNRAVRJCKBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1042,58864297,CCC1=CC(=CC2=C(NN=C12)C)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)[nH]nc12
CHEMBL359116,BMFUKBQBNCLWGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,7520.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,5.123782159408358,1046,11218177,CCCCOC1=CC=C(C=C1)C2=CNC=C2,CCCCOc1ccc(-c2cc[nH]c2)cc1
CHEMBL409494,BMMXYTGQGZIMDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1053,25023856,C1CN(CCC1C2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)CCC(=O)NC4=CC=CC=C4F,Nc1ccccc1NC(=O)c1ccc(C2CCN(CCC(=O)Nc3ccccc3F)CC2)cc1
CHEMBL2436625,BMWUIIPULBWCPO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1057,44622341,COC1=CC2=C(CN(CCC2)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F)C=C1,COc1ccc2c(c1)CCCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2
CHEMBL2425606,BNFJJDOJXXRZDV-NAOLWSJMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,1063,66649788,CC(C)(C)CC1=CC(=NO1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cc(CC(C)(C)C)on3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL3664677,BNQCJDYJTKIIEZ-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,41000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.3872161432802645,1067,59635652,CCN1C(=CC(=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4)C,CCn1c(C)cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
CHEMBL2018911,BNQHARADWSRQDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,16400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.785156151952302,1069,56953896,COC1=CC2=C(C=C1)N=C(N2)SCC3CC3,COc1ccc2nc(SCC3CC3)[nH]c2c1
CHEMBL3311225,BNRLEARACNMGQQ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,36000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,1070,118707102,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)Cl,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)cc2)cn1
CHEMBL2069841,BNVVNCVXADUCNT-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,1075,70686722,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)OC(F)(F)F,NC(CC(=O)N1CCN(C(=O)c2ccc(OC(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL1835487,BOARCKQGDXYXGL-IJLINHMISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21899332.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,P1-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors with Potent Antiviral Activity against Drug-Resistant Viruses.,J. Med. Chem.,PUBLICATION,,6.853871964321762,1080,54765024,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)CC(C(CC2=CC=C(C=C2)C3=CC(=CN=C3)F)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,COC(=O)NC(C(=O)NC(Cc1ccccc1)CC(O)C(Cc1ccc(-c2cncc(F)c2)cc1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C
CHEMBL3237448,BOEVQFOAJBRYBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,5.0,1086,58300060,C1CCC(C1)N2C3=C(C=CN=N3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2nn1
CHEMBL3702683,BOPMTQCKAADDSO-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.186419011431808,1094,89718429,CN1CCN(CC1)C(=O)C2=NC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL478649,BOPSUAHGQHFKGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18614366.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 transfected in Escherichia coli co-expressed with human NADPH reductase,Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1095,24856363,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC=C(C=C3)C(=O)NCC4CC4,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1
CHEMBL478612,BOSPJTDRCVFWMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,5.769551078621726,1098,24949704,CC1=NC2=C(N1C)C=C(C=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C
CHEMBL478612,BOSPJTDRCVFWMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.585026652029182,1098,24949704,CC1=NC2=C(N1C)C=C(C=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C
CHEMBL3664676,BOWQJDHKKOERLG-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,28000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.552841968657781,1099,44625775,CCN1C=C(C=C(C1=O)C)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCn1cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)c1=O
CHEMBL206146,BOXUVZUCCJGJJB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,5.468521082957745,1101,11510084,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCN5CCCC5)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCC5)c(C)c34)ccc2[nH]1
CHEMBL2436325,BOYASMFQZGSUQJ-RQBPZYBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.481486060122113,1102,72711022,CC(C)CC(=O)N1CC(C(=O)N(C2=CC=CC=C21)CCC3=CC=CC=C3)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)CC(C)C)c2ccccc2N(CCc2ccccc2)C1=O
CHEMBL3702681,BPBSAINEGRFZNG-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.991399828238082,1103,89716381,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)N8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3393473,BPCDCTRGBDOCQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,4.920818753952375,1104,59825756,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=C(C=C6)F,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccc(F)cc3[nH]2)o1
CHEMBL2064412,BPJRFZYPRAUEAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,1112,57523324,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=CC=CC(=C4O3)C5=CC=CC=C5,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3cccc(-c4ccccc4)c3o2)n1
CHEMBL3291427,BPOMAKFXYIVWGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1116,90467159,CC1=C(N=CN=C1OC)CN2C=C(C3=C2C=C(C=N3)OC)C(=O)NCCO,COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC)c3C)c2c1
CHEMBL3137441,BPROOBVYFAZDEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2100.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.6777807052660805,1122,76322223,CC1=C(C(=NO1)C)C(=O)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,Cc1noc(C)c1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3669005,BPZSDIOZLNSESC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320652,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1126,52932838,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC=C4)OC)N=C1,COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
CHEMBL3669005,BPZSDIOZLNSESC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320696,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,1126,52932838,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC=C4)OC)N=C1,COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
CHEMBL2179319,BQAVZGJJQFJSMW-UHFFFAOYSA-N,JNJ-42153605,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23072213.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): A Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor.",J. Med. Chem.,PUBLICATION,,4.522878745280337,1128,49765871,C1CC1CC2=NN=C3N2C=CC(=C3C(F)(F)F)N4CCC(CC4)C5=CC=CC=C5,FC(F)(F)c1c(N2CCC(c3ccccc3)CC2)ccn2c(CC3CC3)nnc12
CHEMBL70,BQJCRHHNABKAKU-KBQPJGBKSA-N,MORPHINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,1136,5288826,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,CN1CCC23c4c5ccc(O)c4OC2C(O)C=CC3C1C5
CHEMBL1223157,BQJFEWXRGPPWBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1137,44160248,CS(=O)(=O)C1=CC=C(C=C1)C(C2=NN=NN2CC3=CC=CC=C3)N4CCCN(CC4)C5CCC5,CS(=O)(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1
CHEMBL103313,BQPCBRFOSWMALO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.187086643357144,1141,20763386,CCCCC1=CC=C(C=C1)N=CNO,CCCCc1ccc(N=CNO)cc1
CHEMBL551991,BQUXAJWDRCSKFN-IBGZPJMESA-N,BMS-269223,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19541481.0,IC50,=,18500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.732828271596986,1148,44249821,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC#N)ccc2o1
CHEMBL551991,BQUXAJWDRCSKFN-IBGZPJMESA-N,BMS-269223,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19541481.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BZR as substrate,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1148,44249821,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC#N)ccc2o1
CHEMBL551991,BQUXAJWDRCSKFN-IBGZPJMESA-N,BMS-269223,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19541481.0,IC50,>,200000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human TC5 cells,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.6989700043360187,1148,44249821,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC#N)ccc2o1
CHEMBL1774931,BQVOMOZXISVWCA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,5.853871964321762,1149,46174269,CC1=CC(=CC(=C1C2=NC(=NC3=C2CN(C3)C(=O)NCC(F)(F)F)N)OCCN4C=C(C=N4)F)Cl,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(F)(F)F)C2
CHEMBL2041181,BQVRVXOKDOEPNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1151,57384750,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CN=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL522877,BQZUAHKGFIUDFA-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.251811972993799,1153,44568804,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC6CC6)C,Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(N3CCOCC3C)nncc2c1
CHEMBL3608458,BRNXJJBPGRMYLF-LBVMUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26259804.0,IC50,=,38800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.411168274405792,1164,91666625,C1CN2C=C(C=C2C(=O)N(C1)C(CO)C3=CC=CC=C3)C4=NC(=NC=C4)NC5CC(C(C5)F)O,O=C1c2cc(-c3ccnc(NC4CC(O)C(F)C4)n3)cn2CCCN1C(CO)c1ccccc1
CHEMBL3608458,BRNXJJBPGRMYLF-LBVMUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26259804.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1164,91666625,C1CN2C=C(C=C2C(=O)N(C1)C(CO)C3=CC=CC=C3)C4=NC(=NC=C4)NC5CC(C(C5)F)O,O=C1c2cc(-c3ccnc(NC4CC(O)C(F)C4)n3)cn2CCCN1C(CO)c1ccccc1
CHEMBL2409024,BROODMBBHUGCOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,1166,42171034,CC1=CN=C(N=C1C2=CC=CS2)N3C(=C(C=N3)C(=O)NCC4=CC=NC=C4)COC,COCc1c(C(=O)NCc2ccncc2)cnn1-c1ncc(C)c(-c2cccs2)n1
CHEMBL452423,BRQGGNFXDOXIBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1167,44579189,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=NC=C3,O=C(CNC(=O)c1ccncc1)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL364738,BRRLRVSLZIYEQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,59000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.229147988357856,1170,11602549,CC(C)(C1=CC(=C(C=C1)C2=CC=C(C=C2)C3CCCCC3)F)C(=O)O,CC(C)(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1
CHEMBL3646211,BRTHUECZMVKNMQ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 ��L final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37�� C. incubator. Pooled human liver microsomes (BD Gentest, 50 ��g/mL) were incubated with 5 concentrations of test compound (from 0.1 ��M to 10 ��M), 1 mM NADPH (Sigma), and 2 ��M midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,5.0,1172,46223480,COC1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CC(CO)O)N,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1
CHEMBL1098395,BRXYAENMEBTBTN-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,1174,136086718,CCN1CCN(CC1)C2=CC3=C(C(=C2)C)N=C(N3)C4=C(C=CNC4=O)NCC(C5=CC(=CC=C5)Cl)O,CCN1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL3115186,BSAFIUYYVIIACE-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,1176,59414209,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CN2C=CC=N2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(Cn2cccn2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL400845,BSKMBSPKWWECJR-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,1185,44447289,CC(C)(C)OC(=O)NC(CC1=C(C=CC=C1Cl)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1c(F)cccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,1189,9795276,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
CHEMBL3632723,BSOYRWMMIWLZGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,4.585026652029182,1192,16064891,CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=C(C=CC(=C5)C(F)(F)F)F,Cn1c(Nc2cc(C(F)(F)F)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
CHEMBL1950091,BSQBUOMKYFGDQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.102372908709558,1194,57334262,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=C(N=C4)C)O)Cl,Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3n[nH]c(C)c23)cn1
CHEMBL1950091,BSQBUOMKYFGDQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,1194,57334262,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=C(N=C4)C)O)Cl,Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3n[nH]c(C)c23)cn1
CHEMBL1242081,BSRXZCMRRHEYBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.154901959985743,1196,46900954,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC7CC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1
CHEMBL1242081,BSRXZCMRRHEYBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.154901959985743,1196,46900954,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC7CC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1
CHEMBL249493,BTCOCIJZIJLOOZ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,1206,11526691,CC(C)(CO)N1CCN(CC1)C(=O)CC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,CC(C)(CO)N1CCN(C(=O)CC2(C3CCCC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL249493,BTCOCIJZIJLOOZ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,1206,11526691,CC(C)(CO)N1CCN(CC1)C(=O)CC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,CC(C)(CO)N1CCN(C(=O)CC2(C3CCCC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL1089865,BTFCCPKDGZFGPR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20218619.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,1207,25052767,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC4=C(N(C3=O)C)N(N=C4)C5=C(C=CC=C5F)F,Cc1ccc(C(=O)NC2CC2)cc1-c1cc2cnn(-c3c(F)cccc3F)c2n(C)c1=O
CHEMBL486444,BTGVFQXCQFVKOT-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539454.0,IC50,=,79000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.102372908709558,1211,24991884,CC(C)C1=NC2=C(N1C3=CC=C(C=C3)CC(C(=O)O)NC4=C(C(=O)C45CCCCC5)Br)N=CC=C2,CC(C)c1nc2cccnc2n1-c1ccc(CC(NC2=C(Br)C(=O)C23CCCCC3)C(=O)O)cc1
CHEMBL3264604,BTLRYDPMPQJNBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,1214,12039019,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CN3)O,COc1cc2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2cc1OC
CHEMBL1078337,BTNSKYZYJVZFJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1217,46883034,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CN=CC=C3,O=C(O)CCC1(c2cccnc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL286494,BTXNYTINYBABQR-UHFFFAOYSA-N,HYPERICIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20408551.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).,J. Nat. Prod.,PUBLICATION,,5.060480747381382,1224,5281051,CC1=CC(=C2C3=C4C5=C(C(=CC(=C5C2=O)O)O)C6=C7C4=C8C(=C13)C(=CC(=C8C(=O)C7=C(C=C6O)O)O)C)O,Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65
CHEMBL476763,BUDREMAUSZLRFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1230,44578955,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=CC=C3,O=C(CNC(=O)c1ccccc1)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL3581144,BUGVUVMZGNNHCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.823908740944319,1232,24832008,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)F,COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1
CHEMBL2440625,BUIOHRKCCSCORH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,1234,72376194,C1=CC(=NC(=C1)Cl)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,O=C(Nc1cccc(Cl)n1)c1cc(Cl)cc(Oc2cncnc2)c1
CHEMBL3664710,BUIPWQYAVGFZFQ-CCLHPLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,1236,59635752,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CCCO)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CCCO)(c2ccccc2)OC1=O
CHEMBL225413,BUMBTDCRGILJJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.0,1241,10071498,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C(=CC=C3)Cl)F,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2F)nc1C(F)(F)F
CHEMBL3353340,BUMGKNPRCXMAGM-FVOFJUMPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,1242,58486267,C1C(C12C3=CC=CC=C3NC2=O)C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=NC=C6,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccncc3)n[nH]c2c1
CHEMBL3702745,BUMKXSPCJBNGGV-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,1243,89718444,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCC(=O)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)O)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1095364,BUNJVHAEMQLYJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1244,46888826,CC(C)N1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,COc1ccc(Cn2c(C3CCCN(C(C)C)C3)nc3ccccc32)cc1
CHEMBL2058833,BUPRVECGWBHCQV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22524250.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,J. Med. Chem.,PUBLICATION,,5.221848749616356,1245,49856296,CC1(C2=NC(=C(N2CCN1C(=O)CN)NC3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C,CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
CHEMBL3581693,BURHGPHDEVGCEZ-KJGLQBJMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25879485.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1246,56941241,CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl,CCC(=C(c1ccc(C=CC(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl
CHEMBL267210,BVCMDMYFMGSYTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17201408.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.,J. Med. Chem.,PUBLICATION,,5.154901959985743,1255,16099905,CC1=C(C2=NC(=C(C(=C2C=C1)C(=O)O)O)C3=CC=C(C=C3)Cl)C,Cc1ccc2c(C(=O)O)c(O)c(-c3ccc(Cl)cc3)nc2c1C
CHEMBL3408944,BVEKREGXHABVFX-KQWMEKAXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.267606240177032,1257,58486224,COC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCCCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3408944,BVEKREGXHABVFX-KQWMEKAXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.0,1257,58486224,COC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCCCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL406388,BVGNPHZIUYGPRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,5.698970004336019,1259,24824316,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CN=CC=C5,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cccnc5)cccc4c3)c2cc1OC
CHEMBL3393290,BVGRLIKCJLZVRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,1260,118725448,C1=CC(=CC=C1C(=O)NCC2=CC=NC=C2)OC3=CC=C(C=C3)Cl,O=C(NCc1ccncc1)c1ccc(Oc2ccc(Cl)cc2)cc1
CHEMBL3114730,BVNBEUVSHPWWQG-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,1267,44132271,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCN(CC2=CC=CC=C2)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL3400459,BVOJUQIDIWBGQI-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1268,59272298,CC(C)N(CC1CNCC1NS(=O)(=O)CC2CCOCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NS(=O)(=O)CC2CCOCC2)C(C)C)ccc1OC
CHEMBL1092496,BVRYNXDISKCAFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1272,11681378,CC1=NC=C(C=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1
CHEMBL3394842,BVUZOFDSUCGTDO-IAGOWNOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25577040.0,IC50,=,25400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5951662833800615,1276,46212134,CC1CCC(CN1C(=O)C2=CC=CC=C2N3N=CC=N3)OC4=C5C=CC=C(C5=NC=C4)F,CC1CCC(Oc2ccnc3c(F)cccc23)CN1C(=O)c1ccccc1-n1nccn1
CHEMBL489480,BVWALIIZZWACOM-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.443697499232712,1279,15984939,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=CC(=C4)C#N,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1
CHEMBL489480,BVWALIIZZWACOM-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.236572006437063,1279,15984939,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=CC(=C4)C#N,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1
CHEMBL3664651,BVXDMTPIOHLIBK-IGKIAQTJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,1281,59635712,CCC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CCO)C4=CC=CC=C4,CCC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CCO)(c2ccccc2)OC1=O
CHEMBL462622,BWAXVHRXKFQTBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19260711.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.",J. Med. Chem.,PUBLICATION,,6.0,1283,25218742,C#CC1=C(C=CN=C1N)OC2=C(C=C(C=C2)NC(=O)C3=CC=CN(C3=O)C4=CC=C(C=C4)F)F,C#Cc1c(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)ccnc1N
CHEMBL356066,BWDQBBCUWLSASG-MDZDMXLPSA-N,DACINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,1285,6445533,C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)C=CC(=O)NO,O=C(C=Cc1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO
CHEMBL3422010,BWTVMVHFJRFVFO-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.301029995663981,1295,71533722,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)cs1
CHEMBL3422010,BWTVMVHFJRFVFO-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1295,71533722,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)cs1
CHEMBL179399,BWYNAQVMYILNCY-UHFFFAOYSA-O,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,262000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.5816987086802543,1299,44388606,C[N+]1=CNC=C1C2=CN=CC=C2,C[n+]1c[nH]cc1-c1cccnc1
CHEMBL2048057,BXBKECSXPXOHQB-IBZMOEQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,6.3979400086720375,1305,57388041,CC(C)(C)C1=CC(=NC=C1)CNC2CS(=O)(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,CC(C)(C)c1ccnc(CNC2CS(=O)(=O)CC(Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)C2O)c1
CHEMBL567798,BXHVZWNKTMYVHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.086186147616283,1313,45487546,COC1=CC=CC(=C1)CN2CCN(CC2)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC(=C7)C(=O)OC,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7cccc(OC)c7)CC6)(C5)C3)C4)cc2)c1
CHEMBL2436329,BXIWKBWJRKXQTA-RIAYWLAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.958607314841775,1314,72711028,CC(C)CC(=O)N1CC(C(=O)N(C2=CC=CC=C21)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3109945,BXKNUXDLZJPPBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27055065.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.",J. Med. Chem.,PUBLICATION,,6.0,1317,66547425,CC(C)(C)OC(=O)N1C(=CC2=CN=C(C=C21)NC3=C(C=C(C=C3)C4=CN=CN4C)Cl)C5=CN(N=C5)C,Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1
CHEMBL2165504,BXNGSUWUIWURRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.823908740944319,1322,24937010,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C(C=CC5=C4C=CN5)F)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL252615,BXPDPGQJBGTDAC-GDBMZVCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,11500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.939302159646388,1324,24936070,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N,CCC1CCCC(C2(CC(N)=O)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL590750,BXRPBINJKFNMDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153655.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.,Bioorg. Med. Chem.,PUBLICATION,,4.173925197299173,1327,24178214,CC1=CC2=C(C=C1C)N(C(=N2)NCCCO)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)OC)C(C)(C)C,COc1c(C(C)(C)C)cc(C(=O)Cn2c(NCCCO)nc3cc(C)c(C)cc32)cc1C(C)(C)C
CHEMBL3604734,BXZGSIDSJSGAJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,4.900000142057633,1338,122185975,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C=CC=C3F)C(F)(F)F,Cc1cc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1
CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,5000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.301029995663981,1339,4189,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,5000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.301029995663981,1339,4189,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,6.7447274948966935,1339,4189,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,851.14,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,6.069998998990925,1339,4189,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,100.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.0,1339,4189,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL550242,BYFSZZCFOSXKJG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,1340,44236322,C1CC2=CC=CC=C2CC1NC(=O)N3CCC(CC3)C4=NC(=NO4)C5=CC=CC=N5,O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1
CHEMBL2436629,BYPZYWWDUSSBJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1354,44622417,C1CN(CCC1N2CC3=CC=CC=C3C2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5C4)CC3)CC2)ccn1
CHEMBL179550,BZFNUUDZCGKAST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,750.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1249387366083,1370,44390231,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OCC(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(OCC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL223156,BZGALMKCNIYKHV-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17027263.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1371,44420235,CN1C(=O)NC(=O)C12CC3=C(C2)C=C(C=C3)NC(=O)CN4C5=CC=CC=C5N(C4=O)C6=CC=CC=N6,CN1C(=O)NC(=O)C12Cc1ccc(NC(=O)Cn3c(=O)n(-c4ccccn4)c4ccccc43)cc1C2
CHEMBL2434978,BZKHTWAGPLWPPO-LJAQVGFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,60000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,4.221848749616356,1373,16041411,C1CN(CCC1N2C(CN(C2=O)C3CCOCC3)C4=CC=CC=C4)CC5=CN=C(C=C5)SC6=CC=C(C=C6)C(=O)O,O=C(O)c1ccc(Sc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)CC4c4ccccc4)CC3)cn2)cc1
CHEMBL2017286,BZNFHPBYRCLAHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,12900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.889410289700751,1379,52934039,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=N5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12
CHEMBL2017286,BZNFHPBYRCLAHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,12900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.889410289700751,1379,52934039,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=N5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12
CHEMBL2338477,BZNKJBLTXSCEIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,6.0,1380,58031728,C1=CC2=C(C=CC(=C2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl)N=C1,O=S(=O)(Nc1cc(Cl)c(Oc2ccc3ncccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl
CHEMBL393218,BZQDCQHUEYPQIB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,1384,23647895,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCO)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL257171,BZSFGIPFIXKNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,1387,44449079,CC1=CC2=C(C=C1C)OCC(=O)N2CC(=O)N3CCCC(C3CN4CCCC4)C5=CC=CC=C5,Cc1cc2c(cc1C)N(CC(=O)N1CCCC(c3ccccc3)C1CN1CCCC1)C(=O)CO2
CHEMBL3640764,BZSFZSCNTDEVRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,64710.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.189028600177792,1388,11367332,C1CC(OC1CN)C2=CN=CC=C2,NCC1CCC(c2cccnc2)O1
CHEMBL3087355,BZUSMKVXJJRSBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,1390,72547283,C1=CC(=CC=C1C2=CC=NC=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL3618396,BZVCZJLQADWIEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26299347.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of a small molecule probe that restores e-cadherin expression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1391,122190972,C1=CC=C(C=C1)C2=CC(=NO2)C(=O)NCCCCNC(=O)C3=CC=CNC3=O,O=C(NCCCCNC(=O)c1ccc[nH]c1=O)c1cc(-c2ccccc2)on1
CHEMBL3605296,CACDSTLXMIALPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26183084.0,IC50,>=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1394,66613450,C1CN(CC2=C1N=C(O2)COC3=CC=CC=C3)C(=O)C4=C5C=CC=NC5=NN4,O=C(c1[nH]nc2ncccc12)N1CCc2nc(COc3ccccc3)oc2C1
CHEMBL3582477,CAFMTLCLARMZDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1396,56645568,CC(C)(C1=CN=CC(=C1)C2=NC3=CC(=C(C=C3N2C4CC4)F)F)O,CC(C)(O)c1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1
CHEMBL1077343,CAFSWHHZBLDQKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,1397,135934888,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCC4=C(N(C=N4)C)Cl)N5CCC(CC5)N6CCN(CC6)C(=O)OC,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCc6ncn(C)c6Cl)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL3218859,CAIAMTHZGVFCNA-XKPGHWPRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,1400,90665988,CN1CCN(CC1)CC2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl)OC,COc1cc(CN2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3218859,CAIAMTHZGVFCNA-XKPGHWPRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,1400,90665988,CN1CCN(CC1)CC2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl)OC,COc1cc(CN2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3216551,CAIIYVGKPOHHBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22318159.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,1401,90664848,CN1CCC(=CC1)C2=CNC3=C2C=C(C=C3)N=C(C4=CC=CO4)N.Cl.Cl,CN1CC=C(c2c[nH]c3ccc(N=C(N)c4ccco4)cc23)CC1
CHEMBL2441848,CAJWPLGXCPYHLW-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.017728766960431,1402,15950685,CCN(CC)C(=O)C(C)N1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,CCN(CC)C(=O)C(C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL2204363,CAVNQHZFZKMWIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,5.259637310505756,1413,53238124,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)Cl.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
CHEMBL3125380,CAVORXGEZDVODE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1414,57411488,C1CN(C2=C1C=C(C=C2)F)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21
CHEMBL463246,CAYMSCGTKZIVTN-TYILLQQXSA-N,ALPHA-CONIDENDRIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,6.698970004336019,1416,457194,COC1=C(C=C2C(C3COC(=O)C3CC2=C1)C4=CC(=C(C=C4)O)OC)O,COc1cc(C2c3cc(O)c(OC)cc3CC3C(=O)OCC32)ccc1O
CHEMBL240436,CBDBSQHFOYMVSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17236765.0,IC50,=,251.19,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of novel glycine sulfonamide antagonists for the EP1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,1418,1283333,CCC1=CC=CC=C1N(CC(=O)NCC2=CC=C(C=C2)Cl)S(=O)(=O)C3=CC=C(C=C3)C,CCc1ccccc1N(CC(=O)NCc1ccc(Cl)cc1)S(=O)(=O)c1ccc(C)cc1
CHEMBL2425889,CBELSOBXHKFTDF-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,91930.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.036542739883292,1419,71731477,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)Cl)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3cc(Cl)ccc3n2)c1=O
CHEMBL3127507,CBGMGQVEMRTNGL-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.853871964321762,1420,76072411,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL3127507,CBGMGQVEMRTNGL-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.823908740944319,1420,76072411,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL3127506,CBGMGQVEMRTNGL-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.568636235841013,1421,76321979,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL3127506,CBGMGQVEMRTNGL-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.522878745280337,1421,76321979,CCCN1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL2436219,CBIBCHQFCAJEHI-WUAPDDLWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.494850021680094,1427,72712132,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=CC=CC=C43)C)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL3112864,CBPIBWZOJGKQSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,1433,49854226,CC1CN(C2=CC=CC=C12)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,CC1CN(C(=O)Cc2nc(=O)cc(N3CCOCC3)[nH]2)c2ccccc21
CHEMBL1357034,CBQRSKMWUASQDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27185330.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,1436,16309462,CC1=C(SC2=NC=NC(=C12)N3CCC(CC3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)N)C,Cc1sc2ncnc(N3CCC(C(=O)Nc4ccc(S(N)(=O)=O)cc4)CC3)c2c1C
CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12161148.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,1440,5362440,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O
CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,1440,5362440,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O
CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,1440,5362440,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O
CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,1440,5362440,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O
CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,400.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.3979400086720375,1440,5362440,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O
CHEMBL194838,CBZPNTGBQQEKFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 at 100 uM; activation observed,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.229147988357856,1443,11645773,C1CCC(CC1)C2=CC=C(C=C2)C3=C(C=C(C=C3)C4(CC4)C(=O)O)F,O=C(O)C1(c2ccc(-c3ccc(C4CCCCC4)cc3)c(F)c2)CC1
CHEMBL1642419,CCAKTJSSELVUBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134749.0,IC50,=,4610.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.336299074610352,1446,23652787,CN1CCN(CC1)C2=CN(C3=C2C=C(C=C3)Br)S(=O)(=O)C4=CC=C(C=C4)F,CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccc(Br)cc23)CC1
CHEMBL217716,CCCCPSHFLXQUBH-UHFFFAOYSA-N,ADS-102550,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17107790.0,IC50,=,53000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.275724130399211,1447,10452725,C1OC2=C(O1)C=C(C=C2)CNCCN3C=CC(=N3)C4=CC=C(S4)C(=O)NO,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1
CHEMBL217716,CCCCPSHFLXQUBH-UHFFFAOYSA-N,ADS-102550,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18247554.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Histone deacetylase inhibitors: from bench to clinic.,J. Med. Chem.,PUBLICATION,,6.292429823902063,1447,10452725,C1OC2=C(O1)C=C(C=C2)CNCCN3C=CC(=N3)C4=CC=C(S4)C(=O)NO,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1
CHEMBL390529,CCCCRDFOGIQSFC-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,7.096910013008056,1448,16658101,C1CC(CN(C1)C2=NC3=C(C=C(C=C3Cl)Cl)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2c(Cl)cc(Cl)cc2c1=O
CHEMBL3673972,CCCJZGXGIRJBEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320642,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1449,67201175,CC1=NC=CC(=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F,Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1
CHEMBL3673972,CCCJZGXGIRJBEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320686,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1449,67201175,CC1=NC=CC(=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F,Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1
CHEMBL2059880,CCCSWRIKNOQGJG-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.075720713938118,1450,70694802,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL2059880,CCCSWRIKNOQGJG-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.060480747381382,1450,70694802,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL442078,CCGWWGUXCYXFJW-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,1452,507737,CC1CN(CCN1C(=O)C(=O)C2=CN=C3C2=CC=CN3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1cnc2[nH]cccc1-2
CHEMBL442078,CCGWWGUXCYXFJW-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,1452,507737,CC1CN(CCN1C(=O)C(=O)C2=CN=C3C2=CC=CN3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1cnc2[nH]cccc1-2
CHEMBL433737,CCLDRSRWGWGQAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,1456,11378954,CCCCOC1=CC=C(C=C1)C2=NOC=C2,CCCCOc1ccc(-c2ccon2)cc1
CHEMBL372751,CCTCISPYUXWOGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,84000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.075720713938118,1462,11516139,CC1(CCC(CC1)C2=CC=C(C=C2)C3=C(C=C(C=C3)C4(CC4)C(=O)O)F)C,CC1(C)CCC(c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC1
CHEMBL2448701,CCXZVZZEXQTCSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.698970004336019,1467,73346614,CS(=O)(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,CS(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
CHEMBL271039,CDBUNSHQNIFGRK-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,1470,11260438,CC1=NC(=CO1)C(C(=O)N2CCOCC2)N3C(C(=O)NC(C3=O)C4CC5=CC=CC=C5C4)CC(C)C,Cc1nc(C(C(=O)N2CCOCC2)N2C(=O)C(C3Cc4ccccc4C3)NC(=O)C2CC(C)C)co1
CHEMBL1671969,CDGHAZKBGHJYNI-PXNMLYILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.008773924307505,1472,25008509,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(=O)OC)C(F)(F)F,COC(=O)c1ccc(Oc2ccc(C=C3SC(=O)NC3=O)cc2OC)c(C(F)(F)F)c1
CHEMBL3629745,CDKNJSXTOTWFRF-CKNGDLFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1478,74538704,CP1(=O)OCCC2(CCCC3(C2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,CP1(=O)OCCC2(CCCC3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OCC23)CO1
CHEMBL3629745,CDKNJSXTOTWFRF-CKNGDLFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1478,74538704,CP1(=O)OCCC2(CCCC3(C2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,CP1(=O)OCCC2(CCCC3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OCC23)CO1
CHEMBL1671981,CEHJREUZXNARDW-JAIQZWGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.346787486224656,1494,25009028,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=CC=C(C4=CC=CC=C43)C#N,COc1cc(C=C2SC(=O)NC2=O)ccc1Oc1ccc(C#N)c2ccccc12
CHEMBL1287844,CEIFOMPAGWECHH-GNAFDRTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,1496,52944842,CC1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)Cl)C(=O)N(C(=O)N3CCCO)C)N.Cl,Cn1c(=O)c2c(cc(N3CCCC(C)(N)C3)n2Cc2cc(F)ccc2Cl)n(CCCO)c1=O
CHEMBL1921984,CEJQKSWZQAQWOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,1498,9880846,CC(C)NC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,CC(C)NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL593573,CEKSBBZAKLNEBU-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1499,46226135,CCNC1=C(C=C(C(=N1)C2=COC=C2)C3=NC4=C(NN=C4N=C3)C)OCC(CC5=CC=CC=C5)N,CCNc1nc(-c2ccoc2)c(-c2cnc3n[nH]c(C)c3n2)cc1OCC(N)Cc1ccccc1
CHEMBL3699330,CELMLYCAIZGNJJ-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,1500,89718414,CCCCOC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OCCCC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2163365,CENBBVPSOFGGNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006603.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1502,60202329,C1=C2C=C(C(=NC2=NC(=C1C(=O)N)N)C(F)(F)F)Br,NC(=O)c1cc2cc(Br)c(C(F)(F)F)nc2nc1N
CHEMBL3116158,CEQKVTUACFLLOZ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1505,16744599,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=CS4)C(F)(F)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1
CHEMBL3116158,CEQKVTUACFLLOZ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1505,16744599,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=CS4)C(F)(F)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1
CHEMBL405895,CETJSTBZOJQTPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18374569.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,1509,22448579,C1C(=NC2=C(C=C(C(=C2)O)C3=CC=CC=C3F)NC1=O)C4=CC(=CC=C4)N5C=CN=C5,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2cc(O)c(-c3ccccc3F)cc2N1
CHEMBL478223,CEVYRUFPINJHBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,1513,44579129,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4Cl,O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3
CHEMBL478223,CEVYRUFPINJHBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,1513,44579129,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4Cl,O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3
CHEMBL3645517,CEYMUNJCMDJNBN-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,1515,42607222,CC1=CC(=O)N(N=C1C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4)C,Cc1cc(=O)n(C)nc1-c1ccc(C(C)N2CCC(CC(C)(C)O)(c3ccccc3)OC2=O)cc1
CHEMBL3664682,CEZXLGMJECLVEW-SIBVEZHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,47000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.327902142064283,1516,59635662,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(COC)C4=CC=CC=C4,COCC1(c2ccccc2)CCN(C(C)c2ccc(-c3ccn(C)c(=O)c3)cc2)C(=O)O1
CHEMBL1766178,CFCJVXMNOZCNMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0915149811213505,1519,18668614,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)NC)(C3=CN=CN3)O,CNC(=O)c1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
CHEMBL1760005,CFDMYSOWNDTWLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21414782.0,IC50,>,3162.28,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,1520,52918120,CCCCN(C1=CC=CC(=C1Cl)C2=CC=C(C=C2)OC(F)(F)F)S(=O)(=O)C3=C(C(=C(C=C3)OC(C)C(=O)O)C)C,CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C
CHEMBL3137482,CFIZCTGVWKFBQU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.795880017344075,1522,76329434,CC(C)(CN1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)F,CC(C)(F)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL151280,CFJNAALMLFXEDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,51100.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.291579099865287,1525,11322127,CCCCOC1=CC=C(C=C1)C2=CC=NC=C2,CCCCOc1ccc(-c2ccncc2)cc1
CHEMBL2407953,CFRHKPBZEFZZII-WNAAXNPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1533,136166866,CC1=CC=CC=C1C(CC(=NO)C2=CC(=NC=C2)C)C3=CC=C(C=C3)CC(=O)O,Cc1cc(C(CC(c2ccc(CC(=O)O)cc2)c2ccccc2C)=NO)ccn1
CHEMBL3408945,CFVRISSXNGRSCL-PPDHBDSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.221848749616356,1537,58486278,CN1C2=C(C=C(C=C2)OC)C3(C1=O)CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
CHEMBL3408945,CFVRISSXNGRSCL-PPDHBDSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1537,58486278,CN1C2=C(C=C(C=C2)OC)C3(C1=O)CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
CHEMBL2420684,CFXIOEDBHCGEDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,5046.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.297052753818444,1539,71818093,C1=CC(=CC2=C1C=CC(=C2Cl)C3=CC(=CN=C3)O)O,Oc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1
CHEMBL499584,CFXKXVRFVROHAJ-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,5.6,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.2518119729938,1540,135960726,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)COC,COCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCC(O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL393576,CGANDSYNDFLFKG-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,1544,24180646,CC(C)CC(C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN,CC(C)CC(NCCN)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3608686,CGCSZFVIPKLGCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,1546,122187069,CC1=NSC(=N1)C2=NN=C3N2CCN(C3(C)C)C(=O)C4=CC=C(C=C4)F,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3(C)C)n1
CHEMBL447822,CGEKXOQYPSFQKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,1549,24890344,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CC=N4,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12
CHEMBL447822,CGEKXOQYPSFQKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,1549,24890344,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CC=N4,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12
CHEMBL1209556,CGIWGBIOKQVESP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,1553,49862550,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)C(F)(F)F,CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O
CHEMBL1209556,CGIWGBIOKQVESP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.552841968657781,1553,49862550,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)C(F)(F)F,CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O
CHEMBL1761525,CGKWKTZGGPMTQN-AQZQMVTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1555,25122183,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5CC5C(=O)O)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2CC2C(=O)O)c1
CHEMBL1761525,CGKWKTZGGPMTQN-AQZQMVTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1555,25122183,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5CC5C(=O)O)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2CC2C(=O)O)c1
CHEMBL503624,CGMLBVPTUVDZPK-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.455931955649724,1556,44593613,CCOC(=O)CNCC1=CC=C(C=C1)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)cc1
CHEMBL503624,CGMLBVPTUVDZPK-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.455931955649724,1556,44593613,CCOC(=O)CNCC1=CC=C(C=C1)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)cc1
CHEMBL1761534,CGMNUBKHKAKYOW-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1557,25119356,CCC(CC)(CCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC)C(=O)O,CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O
CHEMBL1761534,CGMNUBKHKAKYOW-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1557,25119356,CCC(CC)(CCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC)C(=O)O,CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O
CHEMBL2181635,CGZHPIHDTXQFRE-CXUHLZMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.173925197299173,1561,71459317,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=NC=C(C=C5)F)C6CCCC6,Cn1c(-c2ccc(F)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL560386,CHCVZZOPCAVWNV-HTAPYJJXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19520574.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1565,44250288,CC1C(OC2=C(C=CC=C2S1(=O)=O)OC)C3=CC=C(C=C3)OCCCN4CCCC4,COc1cccc2c1OC(c1ccc(OCCCN3CCCC3)cc1)C(C)S2(=O)=O
CHEMBL2041172,CHHBYJXILWRZEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1568,57384237,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC7=C(C=C6)C=NN7,COc1cc(N2C(=O)N(c3ccc(-c4ccc5cn[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL3088175,CHHHEJNQMGBWRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,J. Med. Chem.,PUBLICATION,,4.318758762624412,1569,72713536,CC1=CSC(=N1)C(C)(C2=NN=C(S2)NC3=NN(C=N3)CC4=C(C=CC=C4F)F)O,Cc1csc(C(C)(O)c2nnc(Nc3ncn(Cc4c(F)cccc4F)n3)s2)n1
CHEMBL3215861,CHLPUMOYKYJFFH-PFNYCKIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,=,2730.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,5.5638373529592435,1571,90664458,CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO.Cl.Cl,CCCCc1nc2cc(C=CC(=O)NO)ccc2n1CCN(CC)CC
CHEMBL3215861,CHLPUMOYKYJFFH-PFNYCKIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,1571,90664458,CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO.Cl.Cl,CCCCc1nc2cc(C=CC(=O)NO)ccc2n1CCN(CC)CC
CHEMBL2041187,CHORIEKBRNXNSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,5.0,1574,49848258,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CC=N4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ncccn1
CHEMBL2178714,CHTLTXJCMNCJSN-MBSDFSHPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22989333.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation.,J. Med. Chem.,PUBLICATION,,5.221848749616356,1578,71455427,CN1C(=O)C2CN(CC2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=C5)F,CN1C(=O)C2CN(c3ccc(F)cn3)CC2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
CHEMBL3291340,CHVFRXVZTYHSFP-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,1579,16118895,CC1(C2CCC1(C3=C2C(=O)N(N3CC4=CC=CC=C4)C5=CC=CC=C5)C)C,CC12CCC(c3c1n(Cc1ccccc1)n(-c1ccccc1)c3=O)C2(C)C
CHEMBL525049,CHVUDHLIDGFAMH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,1581,25196406,CN(C)CC#CC1=C(C=CN=C1N)OC2=C(C=C(C=C2)NC(=O)NC(=O)CC3=CC=C(C=C3)F)F,CN(C)CC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N
CHEMBL3260740,CHWARCWCRWGSGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,5.180456064458132,1582,72793032,CN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CN=C(C=C3)C(F)(F)F)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,Cn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O
CHEMBL2441846,CIBRWLRGRGMMMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.180456064458132,1588,15950830,CCN(CC)C(=O)CN1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,CCN(CC)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL397584,CICLLDVQTZRNHL-MFMCTBQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,1589,44433299,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN(C)C,CC(C)CC(NC(=O)CCN(C)C)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL78742,CIFGPLIJBYKXOG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.214670164989233,1593,44317321,CC1C2=CC(=C(C=C2)C#N)OC3=CC=CC(=C3)CN4CCC(C4=O)NCC5=CN=CN15,CC1c2ccc(C#N)c(c2)Oc2cccc(c2)CN2CCC(NCc3cncn31)C2=O
CHEMBL2448738,CIFZHDRCJUNMFW-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.096910013008056,1594,73352681,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=NC=C(N=C3)C4=CC=CC=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)cn2)c1
CHEMBL3634101,CIGZUVLALLRNKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26355532.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).,Eur. J. Med. Chem.,PUBLICATION,,5.0,1595,92045057,C1=CC=C2C(=C1)C=CC=C2NC(=O)NC3=C(C=C4C=NC=NC4=C3)OCC5=CC(=CC=C5)Cl,O=C(Nc1cc2ncncc2cc1OCc1cccc(Cl)c1)Nc1cccc2ccccc12
CHEMBL3137477,CIJXDSNTGMSJOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.769551078621726,1597,76329433,CCC(C(C)O)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,CCC(C(C)O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2012228,CIPPBSIONMAVDW-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22401864.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of oxazole-based PDE4 inhibitors with picomolar potency.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,1600,11598626,CC(C1=C(N=C(O1)C2=C3C=CC(=NC3=C(C=C2)OC)C(F)(F)F)C(=O)NCC4=C(C=C(C=C4)F)F)N,COc1ccc(-c2nc(C(=O)NCc3ccc(F)cc3F)c(C(C)N)o2)c2ccc(C(F)(F)F)nc12
CHEMBL3137392,CISLUIONUORHLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,1603,76314941,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL315766,CITYKBCBSLSOSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,1607,23395806,CCN(CC)CCCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,CCN(CC)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL3394724,CIUHVWRNTOWXDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1608,89795553,CC(C)CN1CCC(CC1)S(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
CHEMBL3394724,CIUHVWRNTOWXDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1608,89795553,CC(C)CN1CCC(CC1)S(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
CHEMBL1829777,CJDCHYFYWWTCPZ-CBZJRKILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.522878745280337,1617,53473394,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCC(=O)N)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCC(N)=O)(c2ccc(F)cc2)OC1=O
CHEMBL3672582,CJGMOBVTWWMPMK-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,130.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.886056647693163,1619,57406387,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCCC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CCCC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672582,CJGMOBVTWWMPMK-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,260.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.585026652029182,1619,57406387,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCCC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CCCC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672583,CJGMOBVTWWMPMK-ZAPWPRAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,110.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.958607314841775,1620,57406386,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCCC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CCCC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672583,CJGMOBVTWWMPMK-ZAPWPRAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,250.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.6020599913279625,1620,57406386,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCCC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CCCC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL1086657,CJHXBFSJXDUJHP-UHFFFAOYSA-N,MK-6892,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20184326.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,J. Med. Chem.,PUBLICATION,,4.0,1621,135416394,CC(C)(CC1=NC(=NO1)C2=NC=C(C=C2)O)C(=O)NC3=C(CCCC3)C(=O)O,CC(C)(Cc1nc(-c2ccc(O)cn2)no1)C(=O)NC1=C(C(=O)O)CCCC1
CHEMBL2397307,CJQUPESWNTXRJX-MOPGFXCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.008773924307505,1632,71681889,CC(=O)N1C(CCC1C(=O)NC2=NC=C(S2)C3=CC=C(C=C3)N)C4=CC=CC=C4,CC(=O)N1C(C(=O)Nc2ncc(-c3ccc(N)cc3)s2)CCC1c1ccccc1
CHEMBL1829772,CJSISZXPMQBPSZ-CBZJRKILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.301029995663981,1633,53473321,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCNC(=O)N)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCNC(N)=O)(c2ccc(F)cc2)OC1=O
CHEMBL3699319,CJSPFBXNXWDZGH-CRKOEVGVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,1634,89718185,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C(C)=O)CC7)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1911829,CJULAJSWQHZFAG-JWQCQUIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,1636,57398066,C1CN2CCC1C(C2)NC(=O)C(COCC3=CC=CC=C3)NC(=O)C4=C(N=CC=C4)OC5=C(C=C(C=C5)C(F)(F)F)Cl,O=C(NC(COCc1ccccc1)C(=O)NC1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl
CHEMBL1911830,CJULAJSWQHZFAG-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,1637,57403233,C1CN2CCC1C(C2)NC(=O)C(COCC3=CC=CC=C3)NC(=O)C4=C(N=CC=C4)OC5=C(C=C(C=C5)C(F)(F)F)Cl,O=C(NC(COCc1ccccc1)C(=O)NC1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl
CHEMBL3087669,CJUSJFAZUSWFLY-KXBFYZLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139584.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 4 hrs,"Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,1638,25265089,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(ON=C4C)C)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1c(C)noc1C
CHEMBL179691,CJUWBZDJMYYRDG-QFIPXVFZSA-N,NBI-42902,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,6.154901959985743,1639,11167850,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)CC(C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL2057523,CKAAVBBZRMQHBC-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029182,1645,59603332,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC3CCCCC3)CC(C(CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)O,CCN(C)c1nc2ccc(C(=O)N(CC3CCCCC3)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL256092,CKCKWQLHSQKPAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18462938.0,IC50,>=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,1647,11962967,CC1=CC(=NN1CC2=C(C=CC(=C2)Cl)OCC3=CC=CC=C3)NC(=O)OC(C)C,Cc1cc(NC(=O)OC(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1
CHEMBL178711,CKCZUAVVHJHNJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,>,400000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.3979400086720375,1648,11210706,C1=CC(=CN=C1)C2=CC=C(S2)CNCC3=CC=C(S3)C4=CN=CC=C4,c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1
CHEMBL205092,CKDWXXGKUKOVBA-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.173925197299173,1649,24825269,CC(C)CN1C2=C(C(=C(S2)CC3=CNC4=C3C=CC=N4)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3c[nH]c4ncccc34)sc21
CHEMBL1779003,CKMRXGUDSNAKMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,1656,53248849,COC1=C(C=CC(=C1)F)C2=CN=CC(=C2)CNC3CCCC3,COc1cc(F)ccc1-c1cncc(CNC2CCCC2)c1
CHEMBL3338866,CKTWQGHVNRYNCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26317591.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,J. Med. Chem.,PUBLICATION,,4.552841968657781,1660,44633765,COC1=C(N=C(C=C1)CNC(=O)C2=C(N=CC(=C2)C3=CC(=CN=C3)Cl)C4=CC=CC=N4)OC,COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC
CHEMBL387785,CKVMUGZRWPZHCY-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,4.698970004336019,1663,23626131,CC1=CN(C=N1)CC(=O)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CN5C=CN=N5)F,Cc1cn(CC(=O)c2ccc(-c3ccc(N4CC(Cn5ccnn5)OC4=O)cc3F)cn2)cn1
CHEMBL2441830,CKZFVWOHYQPQSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,6.096910013008056,1667,15950459,CC1=C(C(=C2C(=N1)CN(C2=O)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL2441830,CKZFVWOHYQPQSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.468521082957745,1667,15950459,CC1=C(C(=C2C(=N1)CN(C2=O)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL262321,CLCIJGHLOGXLMK-KBKXWFDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,1668,44433290,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)C(CC(C)C)NC(=O)C(C)N,Cc1ccc(N2CCN(C(=O)C(Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c(C(CC(C)C)NC(=O)C(C)N)c1
CHEMBL1774924,CLFXZSRJZJUGCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,5.958607314841775,1672,53236350,C1C2CC1(C2)NC(=O)N3CC4=C(C3)N=C(N=C4C5=C(C=C(C=C5Cl)Cl)OCCN6C=CC=N6)N,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NC13CC(C1)C3)C2
CHEMBL3116155,CLGKMSSPTGEPGJ-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,1675,16745086,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc3ccc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
CHEMBL3116155,CLGKMSSPTGEPGJ-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1675,16745086,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc3ccc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
CHEMBL399973,CLMFOKCFOQCBFM-MDETZSQFSA-N,FIBLEUCINOSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,1679,44445725,CC12CC=C3C(=O)OC(CC3(C1C4C=CC2(C(=O)O4)OC5C(C(C(C(O5)CO)O)O)O)C)C6=COC=C6,CC12CC(c3ccoc3)OC(=O)C1=CCC1(C)C2C2C=CC1(OC1OC(CO)C(O)C(O)C1O)C(=O)O2
CHEMBL1910114,CLNAIMPDNPYUGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,1681,15950615,CC1=C(C(=C2CN(C(=O)C2=N1)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,COCCN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL3612341,CLPULQHKORXKMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26344593.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.,Bioorg. Med. Chem.,PUBLICATION,,4.698970004336019,1683,122188138,C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CN3C=NC(=N3)[N+](=O)[O-],O=C(Cn1cnc([N+](=O)[O-])n1)Nc1cccc(-c2ccccc2)c1
CHEMBL2448725,CLRJHAXDAVPZGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.0,1684,73349665,C1=CC=C(C=C1)C2=NC=C(C=N2)C(=O)NC3=CC=CC=C3N4C=CN=C4,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)nc1
CHEMBL1910112,CLVFBWMMCGAYBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1693,15950540,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)O)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)O)C2=O
CHEMBL3673947,CLVZDUIYCBVJLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320625,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1695,67201000,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1
CHEMBL3673947,CLVZDUIYCBVJLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320669,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,1695,67201000,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1
CHEMBL3702779,CMJPMPFRFCDLAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2380.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.623423042943488,1704,89718489,CC(C)(C)CNC1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCC(C)(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1209322,CMLALAZUOVTKKV-HKUYNNGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1706,45256914,CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)C3C(CCN3)O,CCCCCCCc1nc(-c2ccc(CNC(=O)C3NCCC3O)cc2)no1
CHEMBL1209322,CMLALAZUOVTKKV-HKUYNNGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1706,45256914,CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)C3C(CCN3)O,CCCCCCCc1nc(-c2ccc(CNC(=O)C3NCCC3O)cc2)no1
CHEMBL1829779,CMLGYKTUOFEFSU-XRHLQHRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.698970004336019,1707,53473396,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCCN)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCCN)(c2ccc(F)cc2)OC1=O
CHEMBL387125,CMLJYPLKIKPWDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,44000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.356547323513813,1708,10184774,CC1=NC(=C(N1CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)CC(C)C)C(=O)N(C)OC)Cl)Cl,CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc2c1c(=O)n(C)c(=O)n2CC(C)C
CHEMBL2041176,CMMVRTXWYOGXHR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1710,57384481,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C#N,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C#N)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL595944,CMPFTOKTVXYPFY-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1714,25190977,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=CNC6=CC=CC=C65)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
CHEMBL3645516,CMRQSUMZGCSHON-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,31000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.508638306165727,1716,42605499,CC1=CC(=NN(C1=O)C)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,Cc1cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn(C)c1=O
CHEMBL2151921,CMRWHXYMZPXJTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1717,49855167,C1COCCN1C2=CC(=O)N=C(N2)CC(=O)NC3=CC(=CC=C3)Cl,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)Nc1cccc(Cl)c1
CHEMBL2058900,CMTFRXHEOAAMBF-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.638272163982407,1720,59603322,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=C(C=C3)F)NC(=O)OCC4=CN=CS4)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccc(F)cc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL397368,CMVZNDZAGPCNJV-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,1721,44433292,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)C(C)(C)N,CC(C)CC(NC(=O)C(C)(C)N)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3702743,CNCXIRXUMVEQSR-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3580.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.446116973356125,1722,89718328,CCOC(=O)CCNC(=O)C1=CN(C2=C(C=CC=C12)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCC(=O)OCC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3350935,CNEBXOWFQASQAR-FTDXYOEWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16033281.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Cytochrome 450 3A4,"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1725,11223701,C1C2CC3CC1CC(C2)(C3)C(C(=O)N4C(CC5C4C5)C#N)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(C3)C1)C2
CHEMBL3604733,CNMKNEFBMQWAQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,5.0,1734,122185974,CC1=C(C(=CC=C1)Cl)CNC2=C3C=CC=C(C3=NC(=C2)C)C(=O)N,Cc1cc(NCc2c(C)cccc2Cl)c2cccc(C(N)=O)c2n1
CHEMBL1097982,CNSKMPGFRZEZNV-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,1739,136086712,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CC(=O)NCCF,Cc1cc(N2CCN(CC(=O)NCCF)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2041169,COBUMZLYZWRZDS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1748,49849231,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=NN7,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(-c4ccn[nH]4)cc3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL246161,COCZJEZLXFFSJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,1751,44440525,C1CNCCC1CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1
CHEMBL246161,COCZJEZLXFFSJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1751,44440525,C1CNCCC1CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1
CHEMBL3115164,COERSDJIGACFAR-JBKHTMJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,1752,59721369,CC(C)C(C(=O)NC(CCC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(CC4=CSC=N4)C5CC5,CC(C)C(NC(=O)N(Cc1cscn1)C1CC1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL226067,COHGAWYVUMIFCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,82000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.086186147616283,1753,10364379,C1CCC(CC1)CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,O=C(NCC1CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL3702790,CONPEJUHYPYMIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6950.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.158015195409886,1758,89718454,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1222719,CORLLIXOPXNVDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,1762,49864938,CC(C)OCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,CC(C)OCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL3358925,COSBNJYEIDBEST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.522878745280337,1764,60026483,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)C4=CC=CC=C4)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F
CHEMBL3104476,COTNVRIGCSTBHG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,1766,76335558,C1CN(CCC1N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1
CHEMBL3104476,COTNVRIGCSTBHG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,1766,76335558,C1CN(CCC1N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1
CHEMBL1170367,CPBGMRFHFZVCLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21388809.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1770,46911060,CCN(C1=C2C(=C(C=C1)OC)N=C(S2)NC(=O)C3=CC=NN3C)C(=O)C,CCN(C(C)=O)c1ccc(OC)c2nc(NC(=O)c3ccnn3C)sc12
CHEMBL2069588,CPBSLAZOCYUNLG-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22884988.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1771,70684556,CC1=NC=CC(=C1)C2=CNC(=O)C(=C2)NC(=O)C(CC3=CC=CC=C3)NCC4=CSC=N4,Cc1cc(-c2c[nH]c(=O)c(NC(=O)C(Cc3ccccc3)NCc3cscn3)c2)ccn1
CHEMBL1950085,CPFAZCJKWPHSEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,1773,57399874,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)[nH]nc3nc12
CHEMBL1950085,CPFAZCJKWPHSEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,1773,57399874,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)[nH]nc3nc12
CHEMBL230626,CPHIGNAWKKTAEQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1774,44425837,C1CN(CCC12C(=O)NC(=O)N2C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=CC(=C5)C#N,N#Cc1cccc(-c2ccc(CN3CCC4(CC3)C(=O)NC(=O)N4c3ccccc3)cc2)c1
CHEMBL521029,CPUAZCHEZPJRLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1782,25074313,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)N4CCOCC4)C,CC(=O)Nc1cc(-c2cncc(N3CCOCC3)c2)nc(-n2nc(C)cc2C)n1
CHEMBL1241824,CQARAGSWXSYCDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,1783,46900776,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N(C)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1
CHEMBL1241824,CQARAGSWXSYCDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,1783,46900776,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N(C)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1
CHEMBL270903,CQAZSXLFKOPBIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.585026652029182,1784,4450789,CS(=O)(=O)C1=CC=C(C=C1)CN2C=C(C=N2)C3=CC=NC=C3,CS(=O)(=O)c1ccc(Cn2cc(-c3ccncc3)cn2)cc1
CHEMBL2448694,CQJBXYSWHIUOHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.698970004336019,1791,73346612,CCOC(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,CCOC(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
CHEMBL1923113,CQJOBYOSYKVBFX-HXOBKFHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,1792,57403067,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1cccc(Cl)c1Cl)C1CC1
CHEMBL2441837,CQMFJBQSRKSKOJ-JTQLQIEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.886056647693163,1794,15950612,CC1=C(C(=C2C(=N1)CN(C2=O)C(C)COC)C3=C(C=C(C=C3)Cl)Cl)CN,COCC(C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL486162,CQMWNSQCEMHNIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,1796,25138090,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCN(CC4)C)C,CC(=O)Nc1cc(-c2cccc(N3CCN(C)CC3)n2)nc(-n2nc(C)cc2C)n1
CHEMBL2448752,CQVOELRYLBGVRX-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,1801,73355730,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=NC(=CN=C3)C4=CC=CC=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2cncc(-c3ccccc3)n2)c1
CHEMBL1094457,CQVTWPREUGIHHR-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,1803,136086711,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CC(=O)NC,CNC(=O)CN1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL2436324,CRHRZPMSHOKHNW-MKSBGGEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.823908740944319,1813,72711020,CC(C)CC(=O)N1CC(C(=O)N(C2=CC=CC=C21)CC3=CC=CC=C3)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)CC(C)C)c2ccccc2N(Cc2ccccc2)C1=O
CHEMBL3702732,CRIDHUXOEBDKJZ-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16180.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.791021482723746,1814,89718354,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCO)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL515644,CRKSLOZUCXTFQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1817,44579237,C1C2=CC=CC=C2C(C3=C(O1)C=CC(=C3)F)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2COc2ccc(F)cc21
CHEMBL1951445,CRKUAQPSVMLAMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,1818,57393565,C1=CC(=CC=C1C2=CC=C(C=C2)O)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccc(O)cc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL241270,CRKXVRDQRQDSOG-IBGZPJMESA-N,SR-710,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,1819,44439731,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC(=CC=C4)Cl)O,O=C(C(O)c1cccc(Cl)c1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL412083,CRPSLFMUGWFWGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1825,25010550,CCNC(=O)C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N,CCNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1
CHEMBL3622437,CRQOWDFBJSYIHC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,1826,66576773,CC1=NN=C2N1C3=C(CC2)C=C(C=C3)C4=CC(=CN=C4)C(=O)OC,COC(=O)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1
CHEMBL3264601,CRZKGBDGHDTLNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.026872146400302,1833,90656804,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CC=C3)O,COc1cc2ccc(C(O)(c3cccnc3)C(C)C)cc2cc1OC
CHEMBL3121798,CSGBHDHHPUNOGD-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,5.0,1837,66734740,CC1=CC2=C(C=C1F)C(=C(N2C3=C(C=CC=N3)F)C4=NC=C(C=C4)S(=O)(=O)NC(C)C(F)(F)F)C#N,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)NC(C)C(F)(F)F)cn1)n2-c1ncccc1F
CHEMBL2436617,CSHNEQFLMBVIPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1838,44816514,C1CN(CCC1N2C3=CC=CC=C3SC4=CC=CC=C42)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4c5ccccc5Sc5ccccc54)CC3)CC2)ccn1
CHEMBL1242623,CSKHOLSVNNTGRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,1840,46899640,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCCC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1
CHEMBL1242623,CSKHOLSVNNTGRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,1840,46899640,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCCC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1
CHEMBL192530,CSOUXLJIXTUXNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,4.619788758288394,1842,3012020,CCN1C2=C(C=CC=N2)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21
CHEMBL192530,CSOUXLJIXTUXNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,1842,3012020,CCN1C2=C(C=CC=N2)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21
CHEMBL1078123,CSWTXNVAULACPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,1849,46883401,CCN(CC(CC1=CC=C(C=C1)OCC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC(CC4=CC=C(C=C4)OCC5=CC=CC=C5)NC(=O)OCC6=NC=CS6,CCN(CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1nccs1
CHEMBL1939560,CTEITUDGLRIHMG-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22130135.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and specific CXCR3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1855,44137674,CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F,CC(c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(C(F)(F)F)c(F)c1
CHEMBL3358939,CTEXWUFIJCMWCX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.698970004336019,1857,118723174,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC(=C4)C(=O)N,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(C(N)=O)c1
CHEMBL36020,CTFXGZSHNLIYDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177477.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P3A4,An aminomethylpyrimidine DPP-IV inhibitor with improved properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1859,11688776,C1=CC=C(C=C1)C2=NC(=C(C(=N2)N)CN)C3=C(C=C(C=C3)Cl)Cl,NCc1c(N)nc(-c2ccccc2)nc1-c1ccc(Cl)cc1Cl
CHEMBL2436621,CTGSDVZVJSPCBE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1861,72375121,CC1=NN=C2N1C3=C(C=CS3)C(=O)N(C2)C4CCN(CC4)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,Cc1nnc2n1-c1sccc1C(=O)N(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2
CHEMBL2177587,CTJRRDKOXVXXEW-HNAOKYFASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,4.853871964321762,1864,46896338,CN1CC(C(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)C=CC(=O)NC4=CC=CC=C4N,CN1CC(C(=O)Nc2ccc(Cl)cc2)C(c2ccc(C=CC(=O)Nc3ccccc3N)cc2)C1
CHEMBL2177588,CTJRRDKOXVXXEW-RNMWKOHKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,4.6777807052660805,1865,59454252,CN1CC(C(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)C=CC(=O)NC4=CC=CC=C4N,CN1CC(C(=O)Nc2ccc(Cl)cc2)C(c2ccc(C=CC(=O)Nc3ccccc3N)cc2)C1
CHEMBL256970,CTPBZYGSXVZQMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18417343.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1870,44449236,CC1=CC(=C(C=N1)CN(C)C)OC2=C(C=C(C=C2)Cl)C,Cc1cc(Oc2ccc(Cl)cc2C)c(CN(C)C)cn1
CHEMBL1909992,CTVCNKIVQXSUSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,1874,15951429,CC1=CC=C(C=C1)N2CC3=C(C(=C(N=C3C2=O)C)CN)C4=C(C=C(C=C4)Cl)Cl,Cc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1
CHEMBL501260,CTXCWPVELDJQRF-GWCFXTLKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.055517327849831,1876,3013843,CC1=C2C(CC3=C(C(=O)OC3C1)C)C(=CC2=O)C,CC1=CC(=O)C2=C(C)CC3OC(=O)C(C)=C3CC12
CHEMBL2018924,CTYYDYWKCWWQAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,2810.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.55129368009492,1877,56954012,COC1=CC2=C(C=C1)N=C(N2)SCC3=NC4=CC=CC=C4C=C3,COc1ccc2nc(SCc3ccc4ccccc4n3)[nH]c2c1
CHEMBL3127522,CTZSMGLKBKOIGG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.698970004336019,1879,76329164,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=C(C=C4)N,Nc1ccc(C2CC2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1
CHEMBL3127522,CTZSMGLKBKOIGG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.455931955649724,1879,76329164,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=C(C=C4)N,Nc1ccc(C2CC2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1
CHEMBL389809,CUENABWMXANJQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2076083105017466,1886,44425810,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CN=CC(=C5)C#N)N(C2=O)CC6=CC=CC=C6F,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cncc(C#N)c5)cc4)CC3)C2=O)c1
CHEMBL2207388,CULSPSVPJXBZMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23141912.0,IC50,=,30500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.515700160653214,1892,24965329,CN1CCN(CC1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1
CHEMBL1222864,CULSXUUODLMOSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1893,46933530,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCN5CCOCC5)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1
CHEMBL1935111,CUMDJLVCVBQTKA-YSSOQSIOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1894,57397654,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)CC3C,CC1CC(=O)NN=C1c1ccc(OCCCN2CCCC2C)cc1
CHEMBL1269673,CUTKYKYSCGXEOF-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,1903,12001872,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCNC)Cl)C5CC5)Cl,CNCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269673,CUTKYKYSCGXEOF-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,1903,12001872,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCNC)Cl)C5CC5)Cl,CNCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL2420688,CUWBTTOKHGCTNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1739.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.759700417997288,1906,71818232,C1=CC=C2C(=C1)C=NC=C2C3=C(C4=C(C=CC(=C4)O)C=C3)Cl,Oc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1
CHEMBL1916700,CUWBXEPNHLJYKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,1907,44159530,CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)OCC3=CC=CC=C3,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccccc1
CHEMBL1909647,CVARTXOKUSBAQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,1908,15950456,CC1=C(C(=C2CNC(=O)C2=N1)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CNC2=O
CHEMBL2377662,CVDJQEZVCYECCM-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,1910,57994936,COC(=S)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCNN(CC3)C(=O)CO)F,COC(=S)NCC1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1
CHEMBL403441,CVFBVSUFNWOPLD-LJQANCHMSA-N,PF-526014,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20471260.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1912,16043230,CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CCOc1ccccc1CC(c1ccccc1)N1CCNCC1
CHEMBL1097078,CVFXBFRIDRAJBH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,923.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,6.034798298974088,1913,46237257,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=C(C=C5)Cl)C)OC,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(Cl)cc1)cc(=O)n2C)c1cncn1C
CHEMBL3628115,CVGSBYQJDYXQRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,4.522878745280337,1914,122193179,CC1=C(OC=C1)C(=O)NC2=CC(=C(C=C2)N3C(=O)C4=C(C3=O)C=NC=C4)Cl,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccncc3C2=O)c(Cl)c1
CHEMBL2041183,CVJHUBCBROARAB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,1915,49849122,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC(=C4)C(F)(F)F)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(C(F)(F)F)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
CHEMBL3335556,CVKXGRRJHJHUFY-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221667.0,IC50,=,15600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by electrospray ionization,,ACS Med. Chem. Lett.,PUBLICATION,,4.806875401645538,1916,72737723,C1COC(CN1CC2=CC=C(C=C2)Cl)CCC3=CC=CC=C3,Clc1ccc(CN2CCOC(CCc3ccccc3)C2)cc1
CHEMBL3358929,CVNFMOXXWTZVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,8.0,1917,11225369,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)N4CCOCC4)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F
CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1926,44250284,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,1926,44250284,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL577694,CVYPJFLZLTYYGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,1931,45484899,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)Cl,CC1(CC(=O)NCc2cccc(Cl)c2)CC2(CCCCC2)OO1
CHEMBL3617986,CVZOIBZVGKOLJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26365710.0,IC50,=,4920.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.308034897232639,1933,122190700,CC1=NN(C(=C1C(=O)NC(CN2C=CN=C2)C(=O)OC(C)C)Cl)C3=CC=CC=C3,Cc1nn(-c2ccccc2)c(Cl)c1C(=O)NC(Cn1ccnc1)C(=O)OC(C)C
CHEMBL3706615,CWAPFPHVCGEYRK-YKTJUOTHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,1936,12108566,CC(C)(C1=NC=C(O1)C2=CC(=CN=C2)OC)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,COc1cncc(-c2cnc(C(C)(C)N3CCN(CC(O)CC(Cc4ccccc4)C(=O)NC4c5ccccc5OCC4O)C(C(=O)NCC(F)(F)F)C3)o2)c1
CHEMBL150146,CWDVFUCLYPBQNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,1939,11345209,CCCCOC1=CC=C(C=C1)C2=NC=CN=C2,CCCCOc1ccc(-c2cnccn2)cc1
CHEMBL1835782,CWDYYODRDVPEOW-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,1940,54753626,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4=C3CCC4)C,CC1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCC3)cc1
CHEMBL3581150,CWFBWCJRVBRKPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,4.823908740944319,1941,24830882,CS(=O)(=O)NC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)N,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1
CHEMBL1940296,CWFNNQMBLVACQD-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1942,57392969,CNC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)C#CC3(CN4CCC3CC4)O,CNC(=O)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
CHEMBL1921980,CWOCSWWXAHRGJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.161150909262744,1948,57397795,CC(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3C)O,CNC(=O)c1ccc2cc(C(C)(O)c3cncn3C)ccc2c1
CHEMBL178780,CWPOROUIZKNJHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,75100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.124360062995832,1949,11207072,C1=CC=C(C=C1)CN2C=C(N=C2)C3=CN=CC=C3,c1ccc(Cn2cnc(-c3cccnc3)c2)cc1
CHEMBL400262,CWRBPYURGIMZCJ-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,1952,44447278,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)C(CC5=CC=CC=C5C(F)(F)F)NC(=O)C6=CC=CC=C6OC(F)(F)F,O=C(NC(Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)c1ccccc1OC(F)(F)F
CHEMBL2448698,CWSHQIYLOHFEFL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.698970004336019,1953,73346613,CCN(CC)S(=O)(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,CCN(CC)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
CHEMBL253655,CWWHQEWKNCFPES-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,1955,44447017,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NOC(=N4)CN5CCOCC5,CCC1CCCC(C2(Cc3noc(CN4CCOCC4)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2436227,CWXNEODDUDWHDU-WKRVVKTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.7447274948966935,1957,72713171,CC(C(=O)NC1C(=O)N(C2=CC=CC=C2OC13CCOCC3)CC4=C(N(C5=CC=CC=C54)C6=CC=CC=C6C#N)C#N)NC,CNC(C)C(=O)NC1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2
CHEMBL390776,CWYRIAXMURYWCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.200659450546418,1958,11153488,COC1=CC=CC2=C1N=C(N(C2=O)CC3=CC=CC=C3C#N)N4CCCC(C4)N,COc1cccc2c(=O)n(Cc3ccccc3C#N)c(N3CCCC(N)C3)nc12
CHEMBL2448734,CWZYIVSBZLEQJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,470.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.327902142064283,1960,73352678,CC(=O)N(CC1=CN=CC=C1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,CC(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F
CHEMBL1782308,CXBHAEGCPVKQMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19447034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of selective PDE4B inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1962,15951076,CCC1=C(N=C(N=C1NC2=C(C=C(C=C2)CC(=O)O)F)C3=CC=C(S3)F)C,CCc1c(C)nc(-c2ccc(F)s2)nc1Nc1ccc(CC(=O)O)cc1F
CHEMBL2018912,CXDABZKLWORATA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,6230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.205511953340831,1963,56953897,COC1=CC2=C(C=C1)N=C(N2)SCC3CCCCC3,COc1ccc2nc(SCC3CCCCC3)[nH]c2c1
CHEMBL3581139,CXDDGXVAUWXVAV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.130768280269024,1964,24829746,CC1=NC=CC(=C1)C2=CSC(=N2)NC(=O)CC3=CC(=CC=C3)OC,COc1cccc(CC(=O)Nc2nc(-c3ccnc(C)c3)cs2)c1
CHEMBL1276948,CXDSZAINFKAKPN-AKRCKQFNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,1965,49836633,C1CC2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)C1
CHEMBL3702751,CXGXIWKKJJULSE-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2540.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.595166283380062,1966,89718276,CN1CCN(CC1)CCCNC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCN(C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2016935,CXHZPUIYOWOMEL-VLIAUNLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,1967,46932044,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=CC(=NO3)C4=C(C=C(C=C4)F)Br,OC1(c2ccc(F)c(F)c2)CCNCC1c1cc(-c2ccc(F)cc2Br)no1
CHEMBL3409853,CXIIMWBTYWXFSS-GJZGRUSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,1968,69081640,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)Cl,COc1cccc(OC)c1C1CC(Cl)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
CHEMBL1078657,CXIKGNQQHDCIPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,1969,46882919,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCCCC(=O)O)C3=CC=CC=C3,O=C(O)CCCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL1208892,CXJOVIBONXRCNI-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.167491087293763,1970,49862053,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)N)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL1208892,CXJOVIBONXRCNI-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,1970,49862053,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)N)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL3645515,CXOMREQXULTUTB-PPHZAIPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15600.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.806875401645538,1977,44625843,CC(C1=CC=C(C=C1)C2=NN(C(=O)C=C2)CC(F)(F)F)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(CC(F)(F)F)n2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL522730,CXPNFWFXVCDMOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,>,6947.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.158202701125645,1980,25033653,C1C=C(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)C4=CN=CC=C4.Cl,Fc1ccc(-c2ccc3c(c2)CC=C3c2cccnc2)cc1
CHEMBL3358924,CXXWEXDTTVWKSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.698970004336019,1989,11774981,CC1=CC2=C(C(=N1)C)NC(=C2)CC(CC(C)(C)C3=C(C=CC(=C3)F)OC)(C(F)(F)F)O,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C)nc(C)c2[nH]1)C(F)(F)F
CHEMBL207100,CXYAINZZOIQMET-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,<,70.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985743,1990,24825268,CC(C)CN1C2=C(C(=C(S2)CC3=CN=CC4=CC=CC=C43)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3cncc4ccccc34)sc21
CHEMBL2441951,CXZGZTKUARYIDS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,1995,57641254,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)NC)C3=C(C=C(C=C3)Cl)Cl)CN,CNC(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL3341983,CYBITNCPJFQMIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26985315.0,IC50,=,77.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis,Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.,ACS Med. Chem. Lett.,PUBLICATION,,7.113509274827518,1997,71559365,C1=CC2=C(C=C1C3=C(C=CC(=C3)Cl)OC4=CC(=C(C=C4F)S(=O)(=O)NC5=NC=NS5)F)C(=NO2)N,Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncns4)cc3F)cc12
CHEMBL3298909,CYCDARWXZPYIBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.0,1999,68234870,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1
CHEMBL374350,CYCGGKILBWERDJ-UHFFFAOYSA-N,CID 2858522,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153655.0,IC50,=,85000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.,Bioorg. Med. Chem.,PUBLICATION,,4.070581074285707,2000,2858523,CC1=CC2=C(C=C1C)N(C(=N2)NCCCO)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C
CHEMBL374350,CYCGGKILBWERDJ-UHFFFAOYSA-N,CID 2858522,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20481485.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.",J. Med. Chem.,PUBLICATION,,5.522878745280337,2000,2858523,CC1=CC2=C(C=C1C)N(C(=N2)NCCCO)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C
CHEMBL486131,CYCJQENBXNRINR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,2001,25138081,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)CN3CCOCC3)C4=CC(=CN=C4)OC)C,COc1cncc(-c2cc(NC(=O)CN3CCOCC3)nc(-n3nc(C)cc3C)n2)c1
CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,2004,16040587,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,2004,16040587,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,5.853871964321762,2004,16040587,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL473921,CYEIOVYZTVJICS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.698970004336019,2004,16040587,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)NC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL3640259,CYEJSPJMRTVXJN-ORAYPTAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.522878745280337,2005,44467507,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=CC=CC=C4)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3ccccc3)C2)nc(C)c1F
CHEMBL2022997,CYKPIMPUPKXTNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,5.259637310505756,2008,57326678,CC1=CC(=CC=C1)C(CCCN)(C2=CC=CC=C2)C3=CC=CC=C3,Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1
CHEMBL2017110,CYMWJUNBUBLPTM-CLOONOSVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,2012,46932234,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)OC)Br,COC1(c2ccc(F)c(F)c2)CCNCC1c1noc(-c2ccccc2CCNC(C)=O)c1Br
CHEMBL2393183,CYPHXCMPISHSDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23668988.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2016,66610926,C1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)NCC3=CN=C(C=C3)N,Nc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1
CHEMBL2086759,CYPOOUITBHWAKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,2017,67163022,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC(=CC=C4)F)C5=NC=CN5,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc[nH]2)C(=O)N3)CC1
CHEMBL3403984,CZAMPUPYSSGHRM-WNCULLNHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,<=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,2023,68447092,CC(C)N(CC1CNCC1OCC2=CC(=CC=C2)OC)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2OCc2cccc(OC)c2)C(C)C)ccc1OC
CHEMBL517503,CZBRRHLYIHWSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.013228265733755,2024,44579133,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CSC=C4,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL517503,CZBRRHLYIHWSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,2024,44579133,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CSC=C4,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL254316,CZFFBEXEKNGXKS-UHFFFAOYSA-N,RALTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763751.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.",J. Med. Chem.,PUBLICATION,,4.301029995663981,2027,54671008,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
CHEMBL2407749,CZFUYZPXZGGWKC-SRQUHQSVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,5.568636235841013,2028,58189810,C1=CC=C2C(=C1)C(=CC3=CC4=C(C=C3)C(=NN4)C=CC5=CC=NC=C5)C(=O)N2,O=C1Nc2ccccc2C1=Cc1ccc2c(C=Cc3ccncc3)n[nH]c2c1
CHEMBL2407749,CZFUYZPXZGGWKC-SRQUHQSVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,2028,58189810,C1=CC=C2C(=C1)C(=CC3=CC4=C(C=C3)C(=NN4)C=CC5=CC=NC=C5)C(=O)N2,O=C1Nc2ccccc2C1=Cc1ccc2c(C=Cc3ccncc3)n[nH]c2c1
CHEMBL496287,CZHBHMYFEKBMAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,1697.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.770318157682325,2029,25033661,C1CC2=C(C1C3=CN=CC=C3)C=CC(=C2)C4=CC=C(C=C4)F.Cl,Fc1ccc(-c2ccc3c(c2)CCC3c2cccnc2)cc1
CHEMBL10441,CZOIKFCTLASDKV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2036,10122657,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2
CHEMBL1078121,CZQXPDBVKLWLQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8696662315049934,2040,46883399,CCN(CC(COCC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(COCC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CCN(CC(COCc1ccccc1)NC(=O)OCc1cncs1)CC(COCc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1643735,CZSPPTVCJPFLSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21195616.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2041,25101821,CC(C)(C)NC(=O)CN1C2=C(C=C(C=C2)C(C)(C)C(=O)NC(C)(C)C)C=C1C3=CC=C(C=C3)OC(F)(F)F,CC(C)(C)NC(=O)Cn1c(-c2ccc(OC(F)(F)F)cc2)cc2cc(C(C)(C)C(=O)NC(C)(C)C)ccc21
CHEMBL2018906,CZSQXDMMIUJHSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.301029995663981,2042,126266,CCSC1=NC2=C(N1)C=C(C=C2)OC,CCSc1nc2ccc(OC)cc2[nH]1
CHEMBL3672580,CZSVRXPBPZIVEN-PYPNIHNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,7.0,2043,57390060,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,CC(C)c1nc(CN(C)C(=O)N2CC(N3CCOCC3)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672580,CZSVRXPBPZIVEN-PYPNIHNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.823908740944319,2043,57390060,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,CC(C)c1nc(CN(C)C(=O)N2CC(N3CCOCC3)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672579,CZSVRXPBPZIVEN-WSQFZFBESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.920818753952375,2044,57406207,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,CC(C)c1nc(CN(C)C(=O)N2CC(N3CCOCC3)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672579,CZSVRXPBPZIVEN-WSQFZFBESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,350.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.455931955649724,2044,57406207,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N6CCOCC6,CC(C)c1nc(CN(C)C(=O)N2CC(N3CCOCC3)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL1770373,CZWQBSKNHUVZLI-UHFFFAOYSA-N,PF-3246799,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21195614.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrimido[4,5-d]azepines as potent and selective 5-HT(2C) receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2050,25070582,C1CNCCC2=NC(=NC=C21)CC3=CC=CC=C3,c1ccc(Cc2ncc3c(n2)CCNCC3)cc1
CHEMBL1092600,CZXWYWSRENNIBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2052,46884668,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)CC3=NC=CN=C3,Cc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1
CHEMBL2043326,DACGAATZKIWONI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,2055,49848896,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC(=C(C=C6)C(=O)O)C,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(C)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL1950082,DACGLYAGZQBCCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1487416512809245,2056,57396433,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C)(C4=CC=NC=C4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C)(O)c3ccncc3)c2c1
CHEMBL1950082,DACGLYAGZQBCCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.847711655616943,2056,57396433,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C)(C4=CC=NC=C4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C)(O)c3ccncc3)c2c1
CHEMBL3408947,DADASRPKWOGKCU-FVTQAUBDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.508638306165727,2057,58486178,CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CC(C)OC(C)C5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3408947,DADASRPKWOGKCU-FVTQAUBDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.337242168318426,2057,58486178,CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CC(C)OC(C)C5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL1079244,DAHUROVPPIYTLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2060,46882970,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC3=NNNN3)C4=CC=CC=C4,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCC2=NNNN2)(c2ccccc2)C1
CHEMBL2064347,DAIOZRXKBOQYHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,2061,57523246,CN1C2=CC=CC(=C2N=C1CC3=NC(=O)C=C(N3)N4CCOCC4)C5=CC=CC=C5,Cn1c(Cc2nc(=O)cc(N3CCOCC3)[nH]2)nc2c(-c3ccccc3)cccc21
CHEMBL3112861,DALZLCXHMHOFAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,2063,49854023,CN1C(=O)C=C(N=C1CC(=O)N2CCC3=CC=CC=C32)N4CCOCC4,Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O
CHEMBL552211,DBIFFPLSGSBZGY-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2093,45270148,CN(C1CCC2=C(C1)C3=C(N2CC(=O)O)N=CC=C3)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(c3cccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL1078442,DBMJZOMNXBSRED-OQLLNIDSSA-N,BERGAMOTTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,2420.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,5.616184634019569,2097,5471349,CC(=CCCC(=CCOC1=C2C=CC(=O)OC2=CC3=C1C=CO3)C)C,CC(C)=CCCC(C)=CCOc1c2ccoc2cc2oc(=O)ccc12
CHEMBL2057791,DBMXSZMLQSZJTB-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,2098,70692667,C1CCN(C1)C2=NC3=C(O2)C=C(C=C3)C(=O)N(CC4CCC(CC4)(F)F)CC(C(CC5=CC=CC=C5)NC(=O)OCC6=CN=CS6)O,O=C(NC(Cc1ccccc1)C(O)CN(CC1CCC(F)(F)CC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
CHEMBL238103,DBPMWRYLTBNCCE-UHFFFAOYSA-N,BMS-488043,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,2100,507806,COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC,COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12
CHEMBL238103,DBPMWRYLTBNCCE-UHFFFAOYSA-N,BMS-488043,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,2100,507806,COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC,COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12
CHEMBL522295,DBWKEBCQXCVXLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18752960.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.,Bioorg. Med. Chem.,PUBLICATION,,4.698970004336019,2110,24882359,C1CC2CC(CC1N2CC3=CC4=C(C=C3)C=C(C=C4)F)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,O=C(NC1CC2CCC(C1)N2Cc1ccc2cc(F)ccc2c1)c1ccccc1-c1ccccc1
CHEMBL320105,DCDHWTNKKCKJLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,76900.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.114073660198569,2116,44341439,CCCCCCOC1=NC=C(C=C1)N2C=CN=C2,CCCCCCOc1ccc(-n2ccnc2)cn1
CHEMBL3629736,DCLAUMXJFMZEKA-UWJYYQICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.958607314841775,2120,118478848,C1CC(C2COC3=C(C=CC(=C3C2(C1)S(=O)(=O)C4=CC=C(C=C4)Cl)F)F)(CO)CO,O=S(=O)(c1ccc(Cl)cc1)C12CCCC(CO)(CO)C1COc1c(F)ccc(F)c12
CHEMBL3629736,DCLAUMXJFMZEKA-UWJYYQICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,11500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.939302159646388,2120,118478848,C1CC(C2COC3=C(C=CC(=C3C2(C1)S(=O)(=O)C4=CC=C(C=C4)Cl)F)F)(CO)CO,O=S(=O)(c1ccc(Cl)cc1)C12CCCC(CO)(CO)C1COc1c(F)ccc(F)c12
CHEMBL271580,DCMHHJQTRGXPBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,6.638272163982407,2121,4450788,C1=CC(=C(C=C1Cl)Cl)CN2C=C(C=N2)C3=CC=NC=C3,Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1
CHEMBL3545241,DCRWIATZWHLIPN-UHFFFAOYSA-N,AC-430,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,10900.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,4.962573502059376,2130,46892373,CC1=CC(=NN1)NC2=NC(=NC3=CC=CC=C32)C(C4=CC=C(C=C4)F)O,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.522878745280337,2132,2769,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
CHEMBL58832,DCXYFEDJOCDNAF-REOHCLBHSA-N,ASPARAGINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,2138,6267,C(C(C(=O)O)N)C(=O)N,NC(=O)CC(N)C(=O)O
CHEMBL58832,DCXYFEDJOCDNAF-REOHCLBHSA-N,ASPARAGINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,2138,6267,C(C(C(=O)O)N)C(=O)N,NC(=O)CC(N)C(=O)O
CHEMBL3628112,DCYOTMCWHBEKAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,4.522878745280337,2139,122193176,CC1=C(OC=C1)C(=O)NC2=CC(=C(C=C2)N3C(=O)C4=C(C3=O)C=C(C=C4)Cl)Cl,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)c(Cl)c1
CHEMBL150278,DDBBWDREHWCNNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,2142,3718258,CCCCOC1=CC=C(C=C1)C2=NNN=N2,CCCCOc1ccc(-c2nn[nH]n2)cc1
CHEMBL3310992,DDDMLZABRFSWRF-MGPLVRAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,8000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,2143,25132380,CC(C1=NC=NC=C1F)C(CN2C=CN=N2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1ccnn1)c1ccc(F)cc1F
CHEMBL476323,DDDZBLNULGDPGA-UHFFFAOYSA-N,MK-0249,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18598020.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.",J. Med. Chem.,PUBLICATION,,4.568636235841013,2146,11697697,CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OCCCN4CCCC4)C(F)(F)F,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1
CHEMBL493001,DDGVRFAFSCAHHH-KQQUZDAGSA-N,GO-Y026,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,13200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.87942606879415,2148,10691533,COC1=CC(=CC(=C1O)OC)C=CC(=O)C=CC2=CC(=C(C(=C2)OC)O)OC,COc1cc(C=CC(=O)C=Cc2cc(OC)c(O)c(OC)c2)cc(OC)c1O
CHEMBL493001,DDGVRFAFSCAHHH-KQQUZDAGSA-N,GO-Y026,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,76032627.69,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,1.1190000000229516,2148,10691533,COC1=CC(=CC(=C1O)OC)C=CC(=O)C=CC2=CC(=C(C(=C2)OC)O)OC,COc1cc(C=CC(=O)C=Cc2cc(OC)c(O)c(OC)c2)cc(OC)c1O
CHEMBL558467,DDHSIUUOIYFUOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,2150,45272875,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL3092468,DDKHTWASHUKHLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,28600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.543633966870957,2153,71506845,C1=CC(=CC=C1C2=NC3=NNC(=C3N=C2)N)NS(=O)(=O)C4=C(C=CC(=C4)Cl)F,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12
CHEMBL3092468,DDKHTWASHUKHLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2153,71506845,C1=CC(=CC=C1C2=NC3=NNC(=C3N=C2)N)NS(=O)(=O)C4=C(C=CC(=C4)Cl)F,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12
CHEMBL429850,DDKRPWSDORFUBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18329269.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,2154,24739481,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)COC4=C(C=C(C=C4)OC)CN(C)C,COc1ccc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)c(CN(C)C)c1
CHEMBL655,DDLIGBOFAVUZHB-UHFFFAOYSA-N,MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,5.0915149811213505,2157,4192,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
CHEMBL655,DDLIGBOFAVUZHB-UHFFFAOYSA-N,MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256005.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,2157,4192,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
CHEMBL1766187,DDQPLMGLQXMKLK-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,2163,53249084,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
CHEMBL1766188,DDQPLMGLQXMKLK-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.173925197299173,2164,54585326,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
CHEMBL1766176,DDQPLMGLQXMKLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.1487416512809245,2165,18668593,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
CHEMBL273503,DDUPDZLICFQTTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,2172,10282620,CCC1=CN(C(=NC1=O)SCC2=CC=C(C=C2)F)CC(=O)N(CCN(CC)CC)CC3=CC=C(C=C3)C4=CC=C(C=C4)Cl,CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(Cl)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O
CHEMBL255858,DDVVRHNNOPQPGB-UHFFFAOYSA-N,GT-1282,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18267361.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,2175,10278617,CC1=C(C(=[N+](C=C1)[O-])C)C(=O)N2CCC(CC2)(C)N3CCC(CC3)N(C4=CC=CC=C4)C5=CN=CC=C5,Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1
CHEMBL242011,DDWGQGZPYDSYEL-LSDHHAIUSA-N,HINOKININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.096910013008056,2176,442879,C1C(C(C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O=C1OCC(Cc2ccc3c(c2)OCO3)C1Cc1ccc2c(c1)OCO2
CHEMBL3664643,DDWYZIPKUZUFSJ-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,25000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.6020599913279625,2179,59635703,CC(C1=CC=C(C=C1)C2=CC(=O)NC=C2)N3CCC(OC3=O)(CC(C)(C)C#N)C4=CC=CC=C4,CC(c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CCC(CC(C)(C)C#N)(c2ccccc2)OC1=O
CHEMBL3137462,DEAFEEMWPWVLTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.154901959985743,2183,76314943,CN(C)S(=O)(=O)C1=CC=CC(=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1
CHEMBL2347415,DEIUHXGBXURZNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,2187,71280416,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=C(C=C4)OC(F)F)CCCN(C)C,CN(C)CCCn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21
CHEMBL526327,DEOLAXKUWDBBIS-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,2191,44576679,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)F,COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL2331688,DEQRJEPSLGPYFN-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.853871964321762,2194,67178880,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=C(C=N4)F)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(c2ncc(F)cn2)C3)cc1
CHEMBL1760338,DEYOMMQLWMIBRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,2201,20906619,COC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC(=NN3)C4=CC=C(C=C4)Cl,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n[nH]2)CC1
CHEMBL2436982,DFBYFJSXUCUKLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,4.522878745280337,2205,46234188,COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CN=C(C=C4)N)N=C2,COc1cc(-c2cnc3[nH]cc(-c4ccc(N)nc4)c3c2)cc(OC)c1OC
CHEMBL1951346,DFFVLCZIIWJVNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,2207,57404048,CC1=CNC2=NC=NC(=C12)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC(C)C,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12
CHEMBL2408045,DFJSJLGUIXFDJP-UHFFFAOYSA-N,SAPITINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,2211,11488320,CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1
CHEMBL1671877,DFLJUOUAVYDDBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,2213,51346919,C1CC1CCCC2=CC(=O)OC3=C2C(=O)NC(=N3)C(F)F,O=c1cc(CCCC2CC2)c2c(=O)[nH]c(C(F)F)nc2o1
CHEMBL1922660,DFQGDHBGRSTTHX-UHFFFAOYSA-N,FIBOFLAPON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,>,50.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,7.301029995663981,2220,44473151,CCOC1=NC=C(C=C1)C2=CC=C(C=C2)CN3C4=C(C=C(C=C4)OCC5=NC=C(C=C5)C)C(=C3CC(C)(C)C(=O)O)SC(C)(C)C,CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1
CHEMBL1215665,DFRORZVGCQQRJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,2450.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,5.610833915635467,2221,46901443,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC=C(C=C3)N,Nc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
CHEMBL526466,DFXJFEAHWLUMQK-DHIUTWEWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.180456064458132,2226,9867098,C1CC2=C3C1N4CCC(C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,N#Cc1ccc2cc1Oc1ccc3c(c1)C(CC3)N1CCC(NCc3cncn3C2)C1=O
CHEMBL526466,DFXJFEAHWLUMQK-DHIUTWEWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,10400.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,4.982966660701219,2226,9867098,C1CC2=C3C1N4CCC(C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,N#Cc1ccc2cc1Oc1ccc3c(c1)C(CC3)N1CCC(NCc3cncn3C2)C1=O
CHEMBL526656,DFXJFEAHWLUMQK-PKTZIBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.552841968657781,2227,10928028,C1CC2=C3C1N4CCC(C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,N#Cc1ccc2cc1Oc1ccc3c(c1)C(CC3)N1CCC(NCc3cncn3C2)C1=O
CHEMBL526656,DFXJFEAHWLUMQK-PKTZIBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,14800.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,4.8297382846050425,2227,10928028,C1CC2=C3C1N4CCC(C4=O)NCC5=CN=CN5CC6=CC(=C(C=C6)C#N)OC(=C3)C=C2,N#Cc1ccc2cc1Oc1ccc3c(c1)C(CC3)N1CCC(NCc3cncn3C2)C1=O
CHEMBL1078452,DFXLYUBDPQCNSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2228,42643591,CC1(CCCN(C1)C(=O)NCCC2=CC3=NC=CN=C3C=C2)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nccnc3c2)C1
CHEMBL2170637,DFXNQXMRQVGHED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,2230,58269670,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC=N3,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccccn3)CC2)c(C(F)(F)F)c1
CHEMBL1909986,DFYJCRFQTFRQQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.136677139879544,2231,15950387,CC1=NC2=CN(C=C2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)CC4=CC=CC=C4,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN
CHEMBL1909986,DFYJCRFQTFRQQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,2231,15950387,CC1=NC2=CN(C=C2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)CC4=CC=CC=C4,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN
CHEMBL557527,DGCSBHYGDCRAOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,>,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,7.301029995663981,2232,16224456,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=CN=C(C=C5)OC)CC(C)(C)C(=O)O,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)cn1
CHEMBL253641,DGEILIRHSDUTDK-XTEPFMGCSA-N,GSK188909,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,2235,15981486,CCNC1=CC(=C(C(=C1)N2CCCCS2(=O)=O)F)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)C(F)(F)F)O,CCNc1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1
CHEMBL253641,DGEILIRHSDUTDK-XTEPFMGCSA-N,GSK188909,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,2235,15981486,CCNC1=CC(=C(C(=C1)N2CCCCS2(=O)=O)F)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)C(F)(F)F)O,CCNc1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1
CHEMBL207881,DGENZVKCTGIDRZ-UHFFFAOYSA-N,GW9508,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17240142.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,2236,11595431,C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC3=CC=C(C=C3)CCC(=O)O,O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1
CHEMBL3145341,DGGLFHJMXJUSDG-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ��-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,7.42021640338319,2239,60182322,CC1=CC=CC=C1C(CC(=O)O)NC(=O)C2=CC(=O)N(N2)C3=CC=CC=C3F,Cc1ccccc1C(CC(=O)O)NC(=O)c1cc(=O)n(-c2ccccc2F)[nH]1
CHEMBL206145,DGPAWMWBQNMPFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,6.154901959985743,2248,11561190,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCC5CCN(CC5)C)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCCC5CCN(C)CC5)c(C)c34)ccc2[nH]1
CHEMBL2170062,DGPGXHRHNRYVDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22784008.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and biological evaluation of the 1-arylpyrazole class of s(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",J. Med. Chem.,PUBLICATION,,5.0,2249,44247568,CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1
CHEMBL2170062,DGPGXHRHNRYVDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22784008.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Synthesis and biological evaluation of the 1-arylpyrazole class of s(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",J. Med. Chem.,PUBLICATION,,5.0,2249,44247568,CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1
CHEMBL2441953,DGSUAHCROANBGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.259637310505756,2254,15950756,CCCN(C)C(=O)CN1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,CCCN(C)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL1615152,DGVNGMXASUNRAO-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,2255,49837869,C1CCC(CC1)C(C(=O)NC2=C(C=C(C=C2)C(=O)O)F)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,O=C(O)c1ccc(NC(=O)C(C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1
CHEMBL1236391,DHDKYDLNUPJXFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21033679.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,2267,49800098,CSC1=NN(C2=C1C=CC(=C2)NC(=O)C3CCNCC3)C4=CC=CC=C4,CSc1nn(-c2ccccc2)c2cc(NC(=O)C3CCNCC3)ccc12
CHEMBL2018481,DHHGEOKAXUKQCM-ZBLYBZFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,=,7146.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,5.145936988133579,2274,56954242,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CC4=CN=CN4)CC5=CC=CC=C5,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1
CHEMBL3422018,DHRKQJQSMYHSPN-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.096910013008056,2279,71549769,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=NS5)C,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1
CHEMBL3422018,DHRKQJQSMYHSPN-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,79000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.102372908709558,2279,71549769,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=NS5)C,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1
CHEMBL564975,DIBROLGRIJOMRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,2287,45269087,C1CN(CCC1N2C=CN=N2)C(=O)NC3CC3C4=CC=CC=C4,O=C(NC1CC1c1ccccc1)N1CCC(n2ccnn2)CC1
CHEMBL1271600,DIGDIWHKKJZMKG-NZSAHSFTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,13.6,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.866461091629782,2289,52946978,CC(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCC(C4)O,CC(C)C1COCC(C2(OC(=O)N3CCC(O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1271651,DIGDIWHKKJZMKG-YTQUADARSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,2290,11576464,CC(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCC(C4)O,CC(C)C1COCC(C2(OC(=O)N3CCC(O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL208787,DIHNBIJLWDSARE-ZRJLEYOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,2292,11488952,CC(C)CC1C(=O)NC(C(=O)N1C(C2=CC3=C(C=C2)OC=C3)C(=O)NC(C)C)C4CC5=CC=CC=C5C4,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)NC(C)C)c1ccc2occc2c1
CHEMBL208787,DIHNBIJLWDSARE-ZRJLEYOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,5.366531544420414,2292,11488952,CC(C)CC1C(=O)NC(C(=O)N1C(C2=CC3=C(C=C2)OC=C3)C(=O)NC(C)C)C4CC5=CC=CC=C5C4,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)NC(C)C)c1ccc2occc2c1
CHEMBL2448741,DIMLXAZFUWCAKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,612.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.213248577854439,2298,73352682,CS(=O)(=O)N(CC1=CN=CC=C1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,CS(=O)(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F
CHEMBL2440637,DIPLMIIVEFADBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,2299,72374726,C1=CC(=NC=C1F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CC(=CN=C3)F,O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncc(F)c2)c1
CHEMBL179398,DIQWXENHCURRML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,23900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.621602099051862,2301,10899427,C1=CC(=CN=C1)C2=CC=C(S2)C=O,O=Cc1ccc(-c2cccnc2)s1
CHEMBL179398,DIQWXENHCURRML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23930.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.621057301386562,2301,10899427,C1=CC(=CN=C1)C2=CC=C(S2)C=O,O=Cc1ccc(-c2cccnc2)s1
CHEMBL3667554,DIUDVHGBTFDFCN-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26317591.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,J. Med. Chem.,PUBLICATION,,5.096910013008056,2304,26719840,COC1=CC=C(C=C1)S(=O)(=O)N2CCCC2C(=O)NC3=CC(=CC=C3)SC,COc1ccc(S(=O)(=O)N2CCCC2C(=O)Nc2cccc(SC)c2)cc1
CHEMBL358214,DIVNKPFJAVQFJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,50900.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.293282217663242,2305,11148936,CCCCOC1=CC=C(C=C1)N2C=CN=C2C,CCCCOc1ccc(-n2ccnc2C)cc1
CHEMBL325829,DIVWCYHNQIMLLP-NKBKYVEPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,2306,10233724,C1CN(C(CN1CC2=CC3=CC=CC=C3O2)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=NC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccncc1)CC(O)CN1CCN(Cc2cc3ccccc3o2)CC1C(=O)NCC(F)(F)F
CHEMBL551517,DIYUAKHOKKCOEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,2310,45271610,C1CN(CCC1C2=NC(=NO2)C3=NC=CC=N3)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ncccn3)no2)CC1
CHEMBL399831,DIYWRNLYKJKHAM-MDOVXXIYSA-N,(-)-CUBEBIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.040958607678906,2311,117443,C1C(C(C(O1)O)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,OC1OCC(Cc2ccc3c(c2)OCO3)C1Cc1ccc2c(c1)OCO2
CHEMBL1093058,DJILKXZJMQURGL-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2316,46830289,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CC=N3,CC(c1c(CCN(C)C)sc2ccccc12)n1cccn1
CHEMBL498434,DJKTUOFJPXSXPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.036212172654444,2317,44583667,CC1=C(C(=CC=C1)C)COC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL498434,DJKTUOFJPXSXPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,2317,44583667,CC1=C(C(=CC=C1)C)COC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL2018486,DJLRGOWWXNREJY-FNZWTVRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,4.698970004336019,2318,45377580,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=NC=N4)CC5=CC=C(C=C5)F,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1
CHEMBL2018485,DJLRGOWWXNREJY-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,=,12605.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,4.899457149987535,2319,46190696,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=NC=N4)CC5=CC=C(C=C5)F,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1
CHEMBL517440,DJNOSUSXPUIIRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,2322,24961687,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=CC=CC=C3Cl,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl
CHEMBL517440,DJNOSUSXPUIIRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,2322,24961687,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=CC=CC=C3Cl,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl
CHEMBL240070,DJWUDIFTUQYCIR-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,2330,44435367,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)CCO,CCC1CCCC(C2(OC(=O)N3CCN(CCO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2158222,DJXBOGHWDLVTJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.769551078621726,2331,11642625,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C4=CC=CC=N4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL387611,DJXOQVPIGHGJIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.455931955649724,2332,135681590,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NCCN5C,Cc1cc(C2=NCCN2C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2107826,DJXRIQMCROIRCZ-XOEOCAAJSA-N,VIBEGRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,4.0,2333,44472635,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O,O=C(Nc1ccc(CC2CCC(C(O)c3ccccc3)N2)cc1)C1CCc2nccc(=O)n21
CHEMBL271240,DKIUFVFEAUCDLY-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.080921907623926,2342,10391684,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,COc1ccc(N2C(=O)C(Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)C2C(=O)O)cc1
CHEMBL271240,DKIUFVFEAUCDLY-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,2342,10391684,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,COc1ccc(N2C(=O)C(Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)C2C(=O)O)cc1
CHEMBL3115185,DKJJHJFCGCQNOZ-MCQSSSDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,2344,59721409,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CC2=CN(C=N2)C)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(Cc2cn(C)cn2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2029988,DKNUPRMJNUQNHR-UHFFFAOYSA-N,CEP-32496,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22168626.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.",J. Med. Chem.,PUBLICATION,,5.0,2349,56846693,CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
CHEMBL3353348,DKVKUPRCFKTRIY-IRIFPNPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,2355,58486384,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=C(C=CC(=C6)OC)NC5=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3353348,DKVKUPRCFKTRIY-IRIFPNPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.1249387366083,2355,58486384,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=C(C=CC(=C6)OC)NC5=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2
CHEMBL2152165,DLEGYAJVPJEXJD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,2364,16739953,C1CCC(C1)NC(=O)NC(CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F,O=C(NC1CCCC1)NC(Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1
CHEMBL2152165,DLEGYAJVPJEXJD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.055517327849831,2364,16739953,C1CCC(C1)NC(=O)NC(CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F,O=C(NC1CCCC1)NC(Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1
CHEMBL222424,DLFIQCGXPLUMEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17352462.0,IC50,=,91900.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cells,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,PUBLICATION,,4.036684488613889,2366,16125372,C1CN(CCC1N2CC(NC2=O)(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC5=CC=CC=C5,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2ccccc2)CC1
CHEMBL445120,DLGSCKSKWYCGOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,2369,20763372,C1=CC=C(C=C1)CC2=CC=C(C=C2)N=CNO,ONC=Nc1ccc(Cc2ccccc2)cc1
CHEMBL3702792,DLHZRUXHGKNJGU-DWQLLFNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2730.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.5638373529592435,2370,89718461,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCNCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCNCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3264608,DLIXONPOBWMUIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,2371,69281314,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC(F)F)(C3=NNN=C3)O,CC(C)C(O)(c1ccc2cc(OC(F)F)ccc2c1)c1cn[nH]n1
CHEMBL3702741,DLKIIRFCOFZXQS-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2890.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.539102157243452,2373,89718441,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(CCNCCO)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(CCO)CCNCCO)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3639635,DLWOOKUVKDJBLM-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,14000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.853871964321762,2383,44476980,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(CC(C)(C)C#N)C4=CC=CC=C4,CC(c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CCC(CC(C)(C)C#N)(c2ccccc2)OC1=O
CHEMBL2312555,DLYCRJBHFXFNNZ-HPBYZVIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23253441.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2384,46214673,CC1=CN(C=N1)C2=C(C=C(C=C2)C=C3CCCN4C3=NOCCC4C5=CC(=C(C(=C5)F)F)F)OC,COc1cc(C=C2CCCN3C2=NOCCC3c2cc(F)c(F)c(F)c2)ccc1-n1cnc(C)c1
CHEMBL1650654,DMEBSJDKEXDYPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,1070.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17��-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,5.97061622231479,2390,25074167,C1=CC(=CC(=C1)N)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1
CHEMBL368448,DMLUZARQJJUBAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,640.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1938200260161125,2394,11750760,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL368448,DMLUZARQJJUBAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1180.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.928117992693875,2394,11750760,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL30052,DMLYJUNKHVPUCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,2395,11293927,CN1C2=C(C(=CC=C2)[N+](=O)[O-])C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,Cn1c2cccc([N+](=O)[O-])c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL3702761,DMNKTIQUDQHBLV-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2390.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.621602099051862,2396,89718280,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCN(CC7)C8CCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(C6CCCC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2087167,DMQYDVBIPXAAJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,2399,67163677,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC(=CC=C4)F)C5=NC=C(N5)C,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc(C)[nH]2)C(=O)N3)CC1
CHEMBL3137445,DMRRQBPJVXEDNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.958607314841775,2400,76336699,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1
CHEMBL3137445,DMRRQBPJVXEDNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,2400,76336699,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1
CHEMBL559506,DMSVLPBDBXCIAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.508638306165727,2402,44190581,CC1=C(C(=NC=C1)CNC(=O)C(C)C)COC2=CC=CC3=C(C=C(N=C32)C)C4=CC=NN4C,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C(C)C)c2n1
CHEMBL1258078,DNJOROZLUNUHBO-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,2424,52944579,CC1CNC(=O)C2=CC3=CC(=C(C=C3N12)Br)OC4CCN(CC4)C(C)C,CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)C(C)CNC4=O)CC1
CHEMBL1276946,DNKYHHFCPXKFIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942471.0,IC50,=,20900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,PUBLICATION,,4.679853713888946,2427,17027464,CC1=C2C(=CC(=O)N1CC3=CC=CC=N3)NN(C2=O)C4=CC=CC=C4Cl,Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1
CHEMBL512126,DNLNFXITFOQXRI-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,5.113509274827518,2428,135875711,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=C(C=C4)OC)Cl)O)C5CCN(CC5)CCOC,COCCN1CCC(c2cc(C)c3nc(-c4c(NCC(O)c5ccc(OC)c(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL1933349,DNTVJEMGHBIUMW-IBGZPJMESA-N,MK-0893,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22708876.0,IC50,=,60000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes assessed as testosterone 6beta-hydroxylation after 48 hrs,"Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-��-alanine (MK-0893) for the treatment of type II diabetes.",J. Med. Chem.,PUBLICATION,,4.221848749616356,2435,11570626,CC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=CC(=N2)C3=CC(=CC(=C3)Cl)Cl)C4=CC5=C(C=C4)C=C(C=C5)OC,COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3C(C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1
CHEMBL3403825,DOAHUBOSPSWMOM-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.107905397309519,2440,71288713,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)CCOC)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(CCOC)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403825,DOAHUBOSPSWMOM-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,2440,71288713,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)CCOC)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(CCOC)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL1210648,DOQWXXFLJCNROA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594839.0,IC50,=,8440.0,NM,,,,,,,,,,,,,,,Inhibition of human CY3A4,Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.073657553374344,2457,46911719,CN1CCC(CC1)NC2=C(C=CC(=C2)S(=O)(=O)NC3=C(C(=CC(=C3)Cl)Cl)OC)OC,COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1NC1CCN(C)CC1
CHEMBL398772,DORVKDBVLHMAPQ-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,2458,44446982,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCN(CC4)C(C)(C)CO,CCC1CCCC(C2(CC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3114716,DOSBKYYTXRWRCG-PXTZSQHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1487416512809245,2459,59721374,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)N(C)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)N(C)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL3104374,DOTQGOWEPGZREI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,2460,76335555,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
CHEMBL3104374,DOTQGOWEPGZREI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,2460,76335555,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
CHEMBL1642412,DOUUUDLTKJRZKD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134749.0,IC50,=,5540.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2564902352715706,2461,23653135,CC(C)C1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)N4CCN(CC4)C,CC(C)c1ccc(S(=O)(=O)n2cc(N3CCN(C)CC3)c3ccccc32)cc1
CHEMBL508435,DOYPVXXUUVHXLK-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,48.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.318758762624412,2463,44576644,C1CC1C(=O)OCC2=CC=C(C=C2)C3=CN(C(=O)N(C3=O)CC(C4=CC=CC=C4)N)CC5=C(C=CC=C5F)C(F)(F)F,NC(Cn1c(=O)c(-c2ccc(COC(=O)C3CC3)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL2064352,DPBSWFWWWKYRFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,2464,49853724,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(O3)C=CC(=C4)F,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3cc(F)ccc3o2)n1
CHEMBL3104472,DPJQHVMKIJQTCX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,2472,76324750,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)Cl,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1
CHEMBL3104472,DPJQHVMKIJQTCX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,2472,76324750,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)Cl,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1
CHEMBL2436334,DPMXDKUIEMIVNP-YMZODZAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.853871964321762,2474,72711478,CC1=CC=C(C=C1)C(=O)N2CC(C(=O)N(C3=CC=CC=C32)CC4=C(C=CC5=C4C=CC(=C5)Br)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccc(C)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL212521,DPOJEFZKFIWUGN-ROUUACIJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16647256.0,IC50,=,3604.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443215217692974,2475,11771234,CCC(C(=O)NC(CC1=CC=C(C=C1)C2=CC=CC=C2)C#N)N,CCC(N)C(=O)NC(C#N)Cc1ccc(-c2ccccc2)cc1
CHEMBL2048855,DPONSKCACOZTGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727639.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2476,70690453,CC1=CSC(=N1)N(C2CC2)C(=O)CSC3=NN=C(C=C3)C4=CC=CC=C4,Cc1csc(N(C(=O)CSc2ccc(-c3ccccc3)nn2)C2CC2)n1
CHEMBL1777979,DPOWGCZOKVGFCN-CLJLJLNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,2477,54587553,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)C2CC(=O)NC3CCCC4=C3C=CC(=C4)CNCC(C)(C)C,Cc1ccc(S(=O)(=O)N2CCNC(=O)C2CC(=O)NC2CCCc3cc(CNCC(C)(C)C)ccc32)cc1
CHEMBL1777979,DPOWGCZOKVGFCN-CLJLJLNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2477,54587553,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)C2CC(=O)NC3CCCC4=C3C=CC(=C4)CNCC(C)(C)C,Cc1ccc(S(=O)(=O)N2CCNC(=O)C2CC(=O)NC2CCCc3cc(CNCC(C)(C)C)ccc32)cc1
CHEMBL568138,DPSHYRRSRHVRRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,2479,45102733,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
CHEMBL568138,DPSHYRRSRHVRRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,2479,45102733,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
CHEMBL377928,DPUNFIBGNOBPIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,4.522878745280337,2481,11608743,C1=CC(=CC=C1C2=NC(=C(O2)N)C(=O)N)C(F)(F)F,NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)oc1N
CHEMBL1928095,DPVYRXNZNFJFRP-STBIYBPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22100140.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Antifungal activities of novel non-azole molecules against S.��cerevisiae and C.��albicans.,Eur. J. Med. Chem.,PUBLICATION,,4.0,2483,9554933,CC1=C(SC(=C1C#N)N=CC2=CC=C(C=C2)C3=CC=CC=C3)C4=CC(=C(C=C4)OC)OC,COc1ccc(-c2sc(N=Cc3ccc(-c4ccccc4)cc3)c(C#N)c2C)cc1OC
CHEMBL1951452,DPZQITNCJMQOKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,2488,57400491,C1=CC(=CC=C1CNC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4)Br,O=C(NCc1ccc(Br)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL1794073,DQBBVXOEACBXDP-UHFFFAOYSA-N,GW770220A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,5.769551078621726,2489,24949545,CC1=NN(C2=C1C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N)C.Cl,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
CHEMBL1794073,DQBBVXOEACBXDP-UHFFFAOYSA-N,GW770220A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.886056647693163,2489,24949545,CC1=NN(C2=C1C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N)C.Cl,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
CHEMBL255394,DQBDGBGYLBNZBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,2490,44454845,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)N(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(N(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL27102,DQBOLYOAFHZWDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,2440.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.61261017366127,2491,11444700,COC1=CC=CC(=C1OC)CNC(=O)C2=C3CCCCN3C4=C2N=CN=C4N5CCN(CC5)CCC6=CC(=C(C=C6)F)F,COc1cccc(CNC(=O)c2c3n(c4c(N5CCN(CCc6ccc(F)c(F)c6)CC5)ncnc24)CCCC3)c1OC
CHEMBL567908,DQDNVYJAOVRUOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,2493,24865175,CC1=NSC(=C1)C2=NN3C(=NN=C3COC4=C5C=CC(=CC5=NC=C4)OC)C=C2,COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
CHEMBL567908,DQDNVYJAOVRUOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,2493,24865175,CC1=NSC(=C1)C2=NN3C(=NN=C3COC4=C5C=CC(=CC5=NC=C4)OC)C=C2,COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
CHEMBL563664,DQHOYVVIVFHEBF-LSJNQWAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2494,45269307,CN(C1CCC2=C(C1)C3C=CC=CC3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCC2=C(C1)C1C=CC=CC1N2CC(=O)O)S(=O)(=O)c1ccc(F)cc1
CHEMBL27007,DQRJVPCIGZXELF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,2503,11201011,CC1=NC=CC2=C1C3=C(N2C)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,Cc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
CHEMBL3353356,DQTLTCIEAKFGBZ-DNGGJULVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,2504,58486191,C1COCCN1CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)F)NC6=O,O=C1Nc2ccc(F)cc2C12CC2c1ccc2c(C=Cc3ccc(CN4CCOCC4)cc3)n[nH]c2c1
CHEMBL1951326,DQTWQNOOTFOMSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,2505,57391852,C1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL1683074,DQWSENNLMPJNRJ-WHLIWEHUSA-N,PF-903,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295478.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,2507,50992246,CC(C)C1(CCC(C1)NC2CCOCC2OC)C(=O)N3CCN(CC3)C4=NC=CC(=C4)C(F)(F)F,COC1COCCC1NC1CCC(C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1
CHEMBL3393474,DQXCRLJTGIDAES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,5.346787486224656,2509,118725519,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC=C6F,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cccc3[nH]2)o1
CHEMBL502182,DQYGXRQUFSRDCH-UQIIZPHYSA-M,ELAGOLIX SODIUM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,56000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.251811972993799,2510,24785956,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+],COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)[O-])c3ccccc3)c2=O)c1F
CHEMBL3417531,DQZAEYUQSKTFAR-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,4.522878745280337,2511,56838673,CC(C)(CN1C=C(C=N1)C2=NC(=NO2)C(C)(C3CC3)C4=CC=C(C=C4)C5=CN=C(N=C5)N)O,CC(C)(O)Cn1cc(-c2nc(C(C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1
CHEMBL2207100,DRHNPWMFAGWFPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23079519.0,IC50,=,5011.87,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.300000202445418,2519,71454248,C1=CN(N=N1)CC2=CC(=C(C=C2NS(=O)(=O)C3=CC=C(S3)Cl)Cl)Cl,O=S(=O)(Nc1cc(Cl)c(Cl)cc1Cn1ccnn1)c1ccc(Cl)s1
CHEMBL505919,DRQNCWQLZYUQOI-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.455931955649724,2526,135960729,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OC,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCC(O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL505919,DRQNCWQLZYUQOI-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,2526,135960729,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OC,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCC(O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL3702738,DRVYXXNUQCITHS-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7870.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.104025267640935,2529,89718436,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(C)C)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL478834,DRWJMJVERMOJBX-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621528.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,2530,24962988,CCOC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)C3CCNC3,CCOC(=O)N(Cc1ccccc1-c1ccccc1)C1CCNC1
CHEMBL3318978,DSIKPABWAOKGSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050169.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A3,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,2543,118709259,C1CC1C2=CC=CN3C2=NN=C3C4(CC4)C5=CC=C(C=C5)Cl,Clc1ccc(C2(c3nnc4c(C5CC5)cccn34)CC2)cc1
CHEMBL2387592,DSKHNDVPASXXTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,2544,71659489,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=C(C=C4)Cl)Cl,O=c1[nH]c2ccc(Cl)cc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL489297,DSMHXHKJIOOKIY-WCRBZPEASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,5.060480747381382,2545,15984242,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C(C)C(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,CC1CN(Cc2ccc(C(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL2181634,DSQHZRQDKSGPJS-CXUHLZMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,10900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,4.962573502059376,2551,71459316,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=NC=C(C=C5)Cl)C6CCCC6,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL1927147,DSRNDKNGQPKUQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22041175.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by mass spectrophotometry,"Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,2555,57399290,C1CN(CC2=C3C(=CC(=O)N2C1)NN(C3=O)C4=CC=CC=C4Cl)CC5=CC=CC=C5.Cl,O=c1c2c3n(c(=O)cc2[nH]n1-c1ccccc1Cl)CCCN(Cc1ccccc1)C3
CHEMBL1215620,DSSRNDXICGBGMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.958607314841775,2557,46914577,CC1=C(C(C(=C(N1)CN2C=CC=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
CHEMBL493937,DTBFDAJNODVUMF-VOTSOKGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19256503.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxy 4-trifluoromethylcoumarin as substrate,Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.,J. Med. Chem.,PUBLICATION,,4.522878745280337,2565,24811794,CN1CCCN(CC1)C2=NC(=CN=C2)C3=CC=CC(=C3)C=CC(=O)O,CN1CCCN(c2cncc(-c3cccc(C=CC(=O)O)c3)n2)CC1
CHEMBL493937,DTBFDAJNODVUMF-VOTSOKGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19256503.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxyquinoline as substrate,Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.,J. Med. Chem.,PUBLICATION,,4.522878745280337,2565,24811794,CN1CCCN(CC1)C2=NC(=CN=C2)C3=CC=CC(=C3)C=CC(=O)O,CN1CCCN(c2cncc(-c3cccc(C=CC(=O)O)c3)n2)CC1
CHEMBL1819089,DTNUQCRCHKWJCE-PKLMIRHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21865048.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.",Bioorg. Med. Chem.,PUBLICATION,,5.795880017344075,2572,56661747,CN1C2=C(C(=O)N(C1=O)C)N(C(=C2)N3CCCC(C3)N)CC4=C(C=CC(=C4)F)C#N.Cl,Cn1c(=O)c2c(cc(N3CCCC(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O
CHEMBL2338343,DTQWCHXPSGNTKM-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23560650.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective s1 receptor ligands.",J. Med. Chem.,PUBLICATION,,5.301029995663981,2574,71655748,CC(C)CCOC1=CC2=C(C=C1)NC(C3C2OCCC3)C4CCOCC4,CC(C)CCOc1ccc2c(c1)C1OCCCC1C(C1CCOCC1)N2
CHEMBL1671972,DTWGKFUSEYNFHI-DHDCSXOGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.721246399047171,2577,51051125,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=CC=CC=C3C(F)(F)F,COc1cc(C=C2SC(=O)NC2=O)ccc1Oc1ccccc1C(F)(F)F
CHEMBL3422091,DUKJABPGWUISRC-BOSRLCDASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.769551078621726,2585,118735389,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL3422091,DUKJABPGWUISRC-BOSRLCDASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.6777807052660805,2585,118735389,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL3422092,DUKJABPGWUISRC-SBZVUBOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.886056647693163,2586,118735390,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL3422092,DUKJABPGWUISRC-SBZVUBOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.853871964321762,2586,118735390,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL1683577,DUTKICDSXNUMBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21324691.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2597,51346908,CC1=C(N=CN1CC2=CC(=CC=C2)C(F)(F)F)C(=O)NC3=NN(C=C3)C,Cc1c(C(=O)Nc2ccn(C)n2)ncn1Cc1cccc(C(F)(F)F)c1
CHEMBL393204,DUUPSEFOQYYDEP-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,2599,44433272,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCNC,CNCCNC(CC(C)C)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2441845,DUYPYSBUOWVEJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,2603,15950616,CC1=C(C(=C2C(=N1)CN(C2=O)CCC(=O)O)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CCC(=O)O)C2
CHEMBL2448697,DVAJHBMDTLCJMY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,250.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.6020599913279625,2605,73357234,CCOC(CN1C=CN=C1)COC2=CC3=C(C=C2)C=C(C=C3)Br.C(=O)O,CCOC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1
CHEMBL499705,DVGGLGXQSFURLP-PYFXTMFGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15568772.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa.",J. Nat. Prod.,PUBLICATION,,6.154901959985743,2614,10175330,C1=CC(=CC=C1C=CC(=O)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O,O=C(C=Cc1ccc(O)cc1)OCC1OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(O)C(O)C1O
CHEMBL266564,DVGGLGXQSFURLP-VWMSDXGPSA-N,TILIROSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15568772.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa.",J. Nat. Prod.,PUBLICATION,,6.154901959985743,2615,5320686,C1=CC(=CC=C1C=CC(=O)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O,O=C(C=Cc1ccc(O)cc1)OCC1OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(O)C(O)C1O
CHEMBL3632722,DVJYMPYLFMEZMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,2619,16064449,CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=CC(=C5)C(F)(F)F,Cn1c(Nc2cccc(C(F)(F)F)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
CHEMBL468092,DVPZNDPOWUEVAP-UKSTWOGXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,5.301029995663981,2622,25141896,CN(CC=CCN)CC1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)N)O)O,CN(CC=CCN)CC1OC(n2cnc3c(N)nc(Cl)nc32)C(O)C1O
CHEMBL3359270,DVWXXJHSHNVODR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25423411.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM).",J. Med. Chem.,PUBLICATION,,5.494850021680094,2624,92239323,CCN1CCCC1CNC(=O)C2=CN(C(=O)C3=C2C4=CC=CC=C4N3C)C5CCCC5,CCN1CCCC1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C
CHEMBL499582,DWAGGUQJLSNEEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,2627,44561237,CC1=CC2=C(C=C1C)N(C(=O)C=N2)CC(=O)N(C)C(CN3CCOCC3)C4=CC=C(C=C4)C5=CC(=CC=C5)C(=O)NC,CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(C)c(C)cc43)cc2)c1
CHEMBL151037,DWBVBONATVNRGC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,93800.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.027797161620936,2628,11195591,CCCCOC1=CC=C(C=C1)C2=CC=NN2C,CCCCOc1ccc(-c2ccnn2C)cc1
CHEMBL3664679,DWCHGEBWHYTIPU-JRPXNJEYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.638272163982407,2629,42605610,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C3CC3)N4CCC(OC4=O)(CC(C)(C)O)C5=CC=CC=C5,CC(c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL3699336,DWHDFUVHGLXNKO-YATWDLPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.600326278518962,2632,89718420,CN1CCN(CC1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(C)CC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL260636,DWHFXDLHZUPSDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18374569.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,2633,22224657,C1C(=NC2=C(C=C(C=C2)C3=CC=CC=C3F)NC1=O)C4=CC(=CC=C4)N5C=CN=C5,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3F)cc2N1
CHEMBL1242533,DWJGZXZILMOEGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.221848749616356,2636,46899639,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1
CHEMBL1242533,DWJGZXZILMOEGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.221848749616356,2636,46899639,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCCC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1
CHEMBL3622898,DWLPNEAIQATTGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,2638,56949451,CC1=C(N=C(N=C1Cl)OCCCC2=NC3=CC=CC=C3C=C2)NCC4=C(N=C(S4)C)C,Cc1nc(C)c(CNc2nc(OCCCc3ccc4ccccc4n3)nc(Cl)c2C)s1
CHEMBL517933,DWMFXLXZBXBWJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.119186407719209,2639,25028373,C1=CC(=C(C(=C1)F)C(=O)N(CCO)CC(CNC(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N)(C(F)(F)F)O)F,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1
CHEMBL205447,DWMQJCAMZAGHHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,2640,11533398,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)NC(=O)C4(CCNCC4)C5=CC=CC=C5,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)CC2)c1
CHEMBL2035053,DWMYQJBUFRLTQG-GORDUTHDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,=,970.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,6.013228265733755,2641,25154436,CC1=CN=C2NC3=CC(=C(C=C3)OCCN4CCCC4)COCC=CCCOC5=NC=CC(=C5)C1=N2,Cc1cnc2nc1-c1ccnc(c1)OCCC=CCOCc1cc(ccc1OCCN1CCCC1)N2
CHEMBL270271,DWRKFAJEBUWTQM-UHFFFAOYSA-N,ETACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,6.6777807052660805,2645,91673,CCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1
CHEMBL3664661,DWXBSPQGQLKLDE-SVEHJYQDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,2651,59635774,CCC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL497031,DXBRVISEKVIIAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,2656,11619260,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N(C(=C3)C(=O)N4CCC(CC4)(F)F)C(C)C,CC(C)N1CCC(Oc2ccc3c(c2)cc(C(=O)N2CCC(F)(F)CC2)n3C(C)C)CC1
CHEMBL3702778,DXCUGDBVIFFNKH-RAGPDMHTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2550.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.5934598195660445,2657,89718240,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCC(CO)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCC(O)CO)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3673952,DXDZIZAESKHCEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320621,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,2662,52934025,CC1=CC2=C(NC=C2CC3=CN=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1
CHEMBL3673952,DXDZIZAESKHCEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320665,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,2662,52934025,CC1=CC2=C(NC=C2CC3=CN=C(C=C3)NCC4=CN=C(C=C4)C(F)(F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1
CHEMBL3421983,DXQQRCJKVWAXDC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.0,2672,53482945,C1CN2C(=NN=C2C3=CC=CC=N3)CN1C(=O)C4=CC=C(C=C4)F,O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2ccccn2)C1
CHEMBL3216313,DXRIKERZCUUBEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,2673,90664721,CN(C)CCN1CCCC2=C1C=CC(=C2)N=C(C3=CC=CS3)N.Cl.Cl,CN(C)CCN1CCCc2cc(N=C(N)c3cccs3)ccc21
CHEMBL2347183,DXYIYKUZINROPB-POYCELQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,6.886056647693163,2675,57415260,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CC=C3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cccnc2)Cc2ccccc2)C(C)C)cs1
CHEMBL178878,DYEAIDZAOQKZJM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,400000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.3979400086720375,2683,13349629,C1=CC(=CN=C1)C2=NC=CC=N2,c1cnc(-c2cccnc2)nc1
CHEMBL3673936,DYGYHFMGUUCRQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320647,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,2685,87307147,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)Cl)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1
CHEMBL3673936,DYGYHFMGUUCRQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320691,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,2685,87307147,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)Cl)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1
CHEMBL3315062,DYJSODVHTVCXIA-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24980053.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,2687,118707979,CC(C)(C1C2=C(C(=CC=C2)F)OC3=C1C=CC(=N3)C4=CC=C(C=C4)C(=O)N5CCOCC5)C(=O)NC6=NN=CS6,CC(C)(C(=O)Nc1nncs1)C1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21
CHEMBL2420425,DYJWAINZWLNTNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23855836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,PUBLICATION,,5.0,2688,11519784,CN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7,CN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1
CHEMBL2041177,DYPIWIAOPDZEOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,2690,57384482,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)N,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(N)=O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL485972,DYRFUYFXUGUOIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,2692,25074004,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N(C)CCOC)C,COCCN(C)c1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)n1
CHEMBL207028,DYRYDYQWWQHRQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,5.455931955649724,2693,2756534,C1=CC=C(C=C1)C2=CC(=C(S2)C(=O)N)N,NC(=O)c1sc(-c2ccccc2)cc1N
CHEMBL495492,DYSGCGRDHIJLBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.251811972993799,2694,44568820,CC1=C(C2=C(C=C1)C(=NO2)NC3CC3)C4=CC5=CN=NC(=C5C=C4)NC(C)C,Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(NC(C)C)nncc2c1
CHEMBL2440639,DYWOKTOZNTWQJV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,2695,72374728,C1=CC(=NC=C1F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CC(=C3)C#N,N#Cc1cncc(Oc2cc(Cl)cc(C(=O)Nc3ccc(F)cn3)c2)c1
CHEMBL3706620,DYYJWDSYFDXNOW-FLOLVYIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,2698,9875352,CC(C)(C1=CC=C(O1)C2=CC=NC=C2)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,CC(C)(c1ccc(-c2ccncc2)o1)N1CCN(CC(O)CC(Cc2ccccc2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL3682506,DZBCCEIMLOAXBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,291611,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,3.6989700043360187,2702,53259484,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)N3N=CN=N3,COc1cc2ccc(C(C(C)C)n3ncnn3)cc2cc1OC
CHEMBL447085,DZCNPAGZPPBTBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2703,44583356,C1CC2(CCN(CC2)C(=O)CCC3=CC=CC=C3)OC4=C1C=C(C=C4)F,O=C(CCc1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1
CHEMBL383077,DZEADOQXGYJGID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,4.769551078621726,2705,11502912,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCS(=O)(=O)C)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCS(C)(=O)=O)c(C)c34)ccc2[nH]1
CHEMBL3394741,DZFCBWGZQNGTQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2706,89793519,CCCN1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
CHEMBL3394741,DZFCBWGZQNGTQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2706,89793519,CCCN1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
CHEMBL571581,DZIUPOCVDSYPSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19703774.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2707,23627212,CC1=C(C=CC2=C1C=CN2)NC3=C(C=NC=C3C#N)C4=CC5=C(O4)C=CC(=C5)CN6CCN(CC6)C,Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12
CHEMBL3218645,DZKYPGWZOFNJJM-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,680.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,6.167491087293763,2708,90665845,CC1=CC=CC=C1C2=NC3=C(C=C(C=C3)C4=CC=C(C=C4)Cl)C(=O)N2CC5CCCN(C5)C(C)C,Cc1ccccc1-c1nc2ccc(-c3ccc(Cl)cc3)cc2c(=O)n1CC1CCCN(C(C)C)C1
CHEMBL346178,DZOJBGLFWINFBF-UMSFTDKQSA-N,OSANETANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,2710,219077,CC(=O)N(C)C1(CCN(CC1)CCCC2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5,CC(=O)N(C)C1(c2ccccc2)CCN(CCCC2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1
CHEMBL1289515,DZPCZIBGZIYEKK-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20961756.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,2711,25054288,C1CN(CC1O)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCC(O)C2)c1
CHEMBL2036273,DZWCPJPFRNJGMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22420844.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,4.0,2718,70686000,CNC1CCCC(C1)C2=CNC3=C2C=C(C=C3)N=C(C4=CC=CS4)N.Cl,CNC1CCCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)C1
CHEMBL3578244,FAALBEAEXAFDGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27117261.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 (unknown origin),Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test.,Bioorg. Med. Chem.,PUBLICATION,,5.0,2721,90469437,CC1=C2C=C(C=CC2=NN1C3CC3)N4C=CC(=CC4=O)OCC5=CSC(=C5)C(F)(F)F,Cc1c2cc(-n3ccc(OCc4csc(C(F)(F)F)c4)cc3=O)ccc2nn1C1CC1
CHEMBL3326569,FADLVMRJQZQOBL-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,6.0,2724,46191622,CC1(CC(C2=C(O1)C=CC(=C2)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)C,CC1(C)CC(NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1
CHEMBL3330442,FAHBXTXHOUMNTM-ZFWWWQNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25179681.0,IC50,=,85120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.",J. Med. Chem.,PUBLICATION,,4.069968385049027,2728,76685067,C1COCC(=O)N1C2=CC3=C(C=C2)N4C(CO3)C(OC4=O)CNC(=O)C5=CC=C(S5)Cl,O=C(NCC1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OCC12)c1ccc(Cl)s1
CHEMBL2043172,FAJZUSKJMKJEFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,2731,57387028,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC(=C(C=C6)C(=O)O)Cl,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(Cl)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL1923120,FAMHFRDBTJMOTD-KCWPFWIISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,2732,57394343,C1CC1N(CC2=CC=CC3=CC=CC=C32)C(=O)C4CNCCC45C6=CC(=C(C=C6CO5)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1cccc2ccccc12)C1CC1
CHEMBL560993,FATGTHLOZSXOBC-UHFFFAOYSA-N,OC000459,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2743,11462174,CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O
CHEMBL2177300,FAWSUKOIROHXAP-NPMXOYFQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,4.6777807052660805,2744,52912222,CC1CC(C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)C(=O)O)NC4=CC=C(C=C4)Cl,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2C(Nc2ccc(Cl)cc2)CC1C
CHEMBL2177300,FAWSUKOIROHXAP-NPMXOYFQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,4.494850021680094,2744,52912222,CC1CC(C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)C(=O)O)NC4=CC=C(C=C4)Cl,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2C(Nc2ccc(Cl)cc2)CC1C
CHEMBL2017103,FAYUIOXPYLILNE-ODXCJYRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,2750,46932237,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=NOC(=C3)C4=C(C=CC=C4Cl)Cl,OC1(c2ccc(F)c(F)c2)CCNCC1c1cc(-c2c(Cl)cccc2Cl)on1
CHEMBL381568,FBIQASFAEYMVBJ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,3790.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.421360790031928,2756,23644726,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3C(CNCC3=O)COC4=CC5=C(CCCN5CCN6CCOC6=O)C=C4,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCN2CCOC2=O)CCC3)cc1
CHEMBL460542,FBLFUQVNJABTNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19208473.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microplate-based direct fluorometric assay,"Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2757,17955460,CN(CCC1C2=CC=CC=C2OC3=CC=CC=C13)CCC(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F,CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2Oc2ccccc21
CHEMBL2064418,FBMOTDKLUMGRFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,2758,49853719,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=CC=CC=C4O3,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3ccccc3o2)n1
CHEMBL2018921,FBPRLONMUCVTOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4910.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.308918507877031,2761,56954010,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)I,COc1ccc2nc(SCc3ccc(I)cc3)[nH]c2c1
CHEMBL3115168,FBSUYYBKHUUTKC-JBKHTMJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,2763,76321520,CC(C)C1=NC(=CS1)CN(C2CC2)C(=O)NC(CO)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C(=O)NC(CO)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C2CC2)cs1
CHEMBL3673946,FBZGWPOPVWFXLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320624,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,2772,52935603,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)OC)F,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1
CHEMBL3673946,FBZGWPOPVWFXLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320668,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,2772,52935603,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)OC)F,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1
CHEMBL1835787,FCAOLWOHALEOJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,2774,56658548,CN1C(=O)C2=C(CCCC2)C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCCC2
CHEMBL3699343,FCBOHKLIJSVJMO-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,2775,89718312,CNC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(NC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2440624,FCGGFIQFAJSREN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,2783,69936689,C1=CC(=NC(=C1)F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,O=C(Nc1cccc(F)n1)c1cc(Cl)cc(Oc2cncnc2)c1
CHEMBL488642,FCGNBJORLIKCKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,2784,44561157,CN(CC(=O)N(C)C(CN1CCCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,CN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1
CHEMBL3137473,FCJZZWNHWMKTJN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,2788,76311345,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=C(C=C(C=C4)C(F)(F)F)C#N,N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3623278,FCKWCFASCOSSIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26313252.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",J. Med. Chem.,PUBLICATION,,5.0,2789,122192382,COC1=CC2=C(C=C1CN3CCOCC3)C(=NC=N2)NC4=C(C(=CC=C4)Cl)F,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1
CHEMBL3261331,FDBYIYFVSAHJLY-UHFFFAOYSA-N,MGL-3196,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24712661.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor �� Agonist in Clinical Trials for the Treatment of Dyslipidemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,2799,15981237,CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl,CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O
CHEMBL1766180,FDFWKYDHOYTJRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.259637310505756,2803,54583409,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)NC)(C3=CN=CN3)O,CNC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
CHEMBL469916,FDHFWHRGVDRJIK-IRXDYDNUSA-N,(-)-DIHYDROCLUSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,6.096910013008056,2804,332806,COC1=CC(=CC(=C1OC)OC)CC(CO)C(CC2=CC3=C(C=C2)OCO3)CO,COc1cc(CC(CO)C(CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC
CHEMBL2425158,FDJZQQFTZNUNEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2806,72190130,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CC=NC=C4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1
CHEMBL1643883,FDKJLUOOFWBTDY-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2807,53317926,CN1C2=CC=CC3=C2C(=N1)CN(C3=O)C4CN5CCC4CC5,Cn1nc2c3c(cccc31)C(=O)N(C1CN3CCC1CC3)C2
CHEMBL455769,FDMBTLJSOVSBHD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.292429823902063,2809,44593615,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)OC)CC4=C(C=CC=C4F)C(F)(F)F,COC(=O)CCCNC(Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL455769,FDMBTLJSOVSBHD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.292429823902063,2809,44593615,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)OC)CC4=C(C=CC=C4F)C(F)(F)F,COC(=O)CCCNC(Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL3216112,FDNWQXLEXJHDHG-JPKZNVRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,2811,53392451,CN1CCCC1CCN2CCCC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,CN1CCCC1CCN1CCCc2cc(N=C(N)c3cccs3)ccc21
CHEMBL3142403,FDNWQXLEXJHDHG-NTEVMMBTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,2812,53387025,CN1CCCC1CCN2CCCC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,CN1CCCC1CCN1CCCc2cc(N=C(N)c3cccs3)ccc21
CHEMBL252838,FDQCFYCBHPKCAN-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,2814,44447294,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)C(CC5=CC=CC=C5Cl)NC(=O)C6(CC6)C(F)(F)F,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)C(Cc1ccccc1Cl)NC(=O)C1(C(F)(F)F)CC1
CHEMBL1830397,FDURBWFXDKGGLQ-PKNBQFBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,=,2280.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,5.642065152999546,2817,16068056,CC(C)(C)CC1=NC2=C(N1CC(C)(C)CN(C)C)C=CC(=C2)C=CC(=O)NO,CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(C=CC(=O)NO)ccc21
CHEMBL1830397,FDURBWFXDKGGLQ-PKNBQFBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,2817,16068056,CC(C)(C)CC1=NC2=C(N1CC(C)(C)CN(C)C)C=CC(=C2)C=CC(=O)NO,CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(C=CC(=O)NO)ccc21
CHEMBL1782306,FDVSPBLZPJMXFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19447034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of selective PDE4B inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2818,15951010,CCC1=C(N=C(N=C1NC2=CC=C(C=C2)CC(=O)O)C3=CC=C(S3)Cl)C,CCc1c(C)nc(-c2ccc(Cl)s2)nc1Nc1ccc(CC(=O)O)cc1
CHEMBL3664659,FDWSADYIJUUILD-YZNIXAGQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.318758762624412,2819,59635792,CCC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCC(c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL3401115,FDZATKOLZHJUHC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,2820,57870160,CC(C)C1CN(CCO1)C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,CC(C)C1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1
CHEMBL1915564,FECLNDAIKILJAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,2825,25107260,COC1=C(C=C(C=C1)Br)C2=CSC(=N2)NC3=CC(=C(C=C3)N4C=CN=C4)OC,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)c(OC)c2)n1
CHEMBL2165511,FEDDPOSFMNPAII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,2827,49834218,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=NC=CC5=C4C=CN5)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4nccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL1951444,FEDMEJWMCJAMHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.958607314841775,2828,57391832,C1=CC(=CC=C1C#N)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,N#Cc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5nc[nH]c45)cc3)cc2)cc1
CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,2836,4595,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1796296,FEOIBPWKGPFSTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21669521.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2840,56670034,C1CN2CCC1C(C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=CC=NC=C5)O,O=C(NCc1ccncc1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
CHEMBL541214,FEPAAIQAIYOLJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17705360.0,IC50,>,500000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.,J. Med. Chem.,PUBLICATION,,3.3010299956639813,2842,11786814,C1CN(CCC1NC2=CC=CC(=C2)C3=C(C(=C(S3)C(=O)O)OCC(=O)O)Br)S(=O)(=O)CC4=CC=CC=C4,O=C(O)COc1c(C(=O)O)sc(-c2cccc(NC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c2)c1Br
CHEMBL502381,FEUFUIYJXCOHJM-UIUQJESISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19441819.0,IC50,<,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.",J. Med. Chem.,PUBLICATION,,6.3979400086720375,2846,44157716,CCOC(=O)C(CC1=CC=C(C=C1)NC(=O)C2=C(C=NC=C2Cl)Cl)NC(=O)C3CC(CN3S(=O)(=O)C4=CC(=CC(=C4)Cl)Cl)NC5CCC5,CCOC(=O)C(Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)C1CC(NC2CCC2)CN1S(=O)(=O)c1cc(Cl)cc(Cl)c1
CHEMBL1951448,FEXVVARRVIVWEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,2848,57395276,C1=CC=C2C(=C1)C=CC=C2C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C5=C6C(=NC=C5)N=CN6,O=C(Nc1ccc(-c2cccc3ccccc23)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL1813314,FEYNATNTSNGKKO-DOMZBBRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.187086643357144,2850,46701089,CN1CC2CCCCC2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1CC2CCCCC2(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1813315,FEYNATNTSNGKKO-SWLSCSKDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,5280.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.277366077466188,2851,46701088,CN1CC2CCCCC2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1CC2CCCCC2(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1241546,FFCUBEJNESQWBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.301029995663981,2855,46900606,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=C(N=N6)C)CO5,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1
CHEMBL1241546,FFCUBEJNESQWBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.301029995663981,2855,46900606,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=C(N=N6)C)CO5,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1
CHEMBL2036215,FFFIIHASYUWNJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,2858,49872872,CCCCC(=O)N(CC1=CC=C(C=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)Cl,CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(Cl)cc(-c2nn[nH]n2)c1
CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,2861,2554,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,2861,2554,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
CHEMBL1911827,FFOYIXXRNGMCDQ-NFBKMPQASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,2870,56928630,CNC1CCN(C1)C(=O)C(COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CNC1CCN(C(=O)C(COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
CHEMBL1911828,FFOYIXXRNGMCDQ-NZQKXSOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,2871,57403232,CNC1CCN(C1)C(=O)C(COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CNC1CCN(C(=O)C(COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
CHEMBL427267,FFQLXAQWHRYUNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17188869.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Thienopyridine urea inhibitors of KDR kinase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6020599913279625,2872,11259499,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN=CC=C5)N,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cccnc5)cnc(N)c34)cc2)c1
CHEMBL458224,FGADYIBOWLXZLA-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19140664.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.,J. Med. Chem.,PUBLICATION,,4.301029995663981,2882,24812771,CC1=CC(=NN1C2=NC(=CC(=N2)N3CCCC3COC)NC(=O)C)C,COCC1CCCN1c1cc(NC(C)=O)nc(-n2nc(C)cc2C)n1
CHEMBL1080472,FGLOYVLTOMTFMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,2889,46879549,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12
CHEMBL1080472,FGLOYVLTOMTFMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.045757490560675,2889,46879549,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12
CHEMBL2324491,FGMUHFCARDYHEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23380375.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2892,71582799,CCCS(=O)(=O)N1CCN(CC1)C2(CCC(CC2)(F)F)CNC(=O)C3=C(C=CC=C3F)F,CCCS(=O)(=O)N1CCN(C2(CNC(=O)c3c(F)cccc3F)CCC(F)(F)CC2)CC1
CHEMBL252209,FGXUMNZSIFNZHG-AOHZBQACSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602099,2900,44446986,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCN5CCCCC5C4,CCC1CCCC(C2(CC(=O)N3CCN4CCCCC4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL181309,FHATZVOKYMKNGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344075,2906,11510548,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)OC)N4C=CN=C4)N(C)C,COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1
CHEMBL181309,FHATZVOKYMKNGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,2906,11510548,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)OC)N4C=CN=C4)N(C)C,COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1
CHEMBL26369,FHHKQICOQJWLCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,9250.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.0338582672609675,2913,11200621,CC1=C2C(=CC=C1)NC3=C2N=CN=C3N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,Cc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12
CHEMBL3188567,FHLVOZBERTUZSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,=,28200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.549750891680639,2921,45202552,CC(C)N1CCC(CC1)OC2=C(C=CC(=C2)C(=O)NC(C)CC3=CC=CC=N3)OC,COc1ccc(C(=O)NC(C)Cc2ccccn2)cc1OC1CCN(C(C)C)CC1
CHEMBL3409869,FHPANOIZEGWXAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,2926,86695644,COC1=C(C(=CC=C1)OC)C2CCC(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54,COc1cccc(OC)c1C1CCC(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL3673944,FHPWLAWTGBVVFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320622,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,2927,52935602,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=CN=C4)F)F)N=C1,COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1
CHEMBL3673944,FHPWLAWTGBVVFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320666,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,2927,52935602,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=CN=C4)F)F)N=C1,COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1
CHEMBL1092766,FHUODQKGUFFZJE-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2931,46884200,CC(C1=C(N=CC=C1)Cl)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccnc1Cl)c1c(CCN(C)C)sc2ccccc12
CHEMBL204476,FHYIMZUERWPLHA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,2938,24825267,CC(C)CN1C2=C(C(=C(S2)CC3=C4C=CC=NC4=CC=C3)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3cccc4ncccc34)sc21
CHEMBL3409872,FIAZRNWKETVBOU-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,2941,89789843,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,COc1cccc(OC)c1C1CC(O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL113275,FIFQJYUSSPRJIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,4460.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.350665141287858,2944,10108128,CN(C)CCCCCCOC1=CC=C(C=C1)N2C=CN=C2,CN(C)CCCCCCOc1ccc(-n2ccnc2)cc1
CHEMBL2436216,FIIIMJJTBBJHIV-FXXKCHFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.318758762624412,2950,72712126,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(OC)ccc3cc(Br)ccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL386369,FIMRNLAKAARHPD-IRXDYDNUSA-N,ABT-279,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17034148.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.",J. Med. Chem.,PUBLICATION,,4.522878745280337,2953,16049769,CC1(CCN(CC1)C2=NC=CC(=C2)C(=O)O)NCC(=O)N3C(CCC3C#N)C#C,C#CC1CCC(C#N)N1C(=O)CNC1(C)CCN(c2cc(C(=O)O)ccn2)CC1
CHEMBL1614766,FIMYFEGKMOCQKT-UHFFFAOYSA-N,RO-4987655,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316218.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,2955,11548630,C1CC(=O)N(OC1)CC2=CC(=C(C(=C2F)F)NC3=C(C=C(C=C3)I)F)C(=O)NOCCO,O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F
CHEMBL330425,FINMPMBYTTVLPJ-QPPBQGQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,4.301029995663981,2956,10224745,CC1=CC(=NC(=N1)OC(C(=O)O)C2(C3=CC=CC=C3N(C(=O)CN2)C)C4=CC=CC=C4)C,Cc1cc(C)nc(OC(C(=O)O)C2(c3ccccc3)NCC(=O)N(C)c3ccccc32)n1
CHEMBL387620,FIPRYNJHSXMAOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,5.0,2959,16719554,C1CCC(CC1)(CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl)O,O=C(NCC1(O)CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL1201131,FIPWRIJSWJWJAI-UHFFFAOYSA-N,PIPERONYL BUTOXIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.522878745280337,2960,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2
CHEMBL1201131,FIPWRIJSWJWJAI-UHFFFAOYSA-N,PIPERONYL BUTOXIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.522878745280337,2960,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2
CHEMBL2425617,FIUDDEQHPBHZBI-CPTQHNDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,2966,72191343,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(C(C)(C)C)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL2425612,FIUDDEQHPBHZBI-XPLIUGCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,2967,51003469,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(C(C)(C)C)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL2419487,FIXSKMNOWATHBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,4.698970004336019,2969,69224555,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)C)C,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)C2)nc1C
CHEMBL2435856,FJAGYOZYOQUDEQ-HKBQPEDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,73000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,4.136677139879544,2974,58835217,CCC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)O)CN3CCC(CC3)N4C(CN(C4=O)C5CCOCC5)C6=CC=CC=C6,CCc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)CC2c2ccccc2)CC1
CHEMBL2425149,FJBJLLWDMQHEBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2975,72189517,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NC(=C4Cl)Cl,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1
CHEMBL3260567,FJCDSQATIJKQKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24786585.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins prior to substrate addition measured after 10 mins by LC/MS/MS analysis,"Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-�� Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent.",J. Med. Chem.,PUBLICATION,,5.0,2977,54766013,CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1
CHEMBL3417504,FJHKZEVPGYADEG-NVPAJSRCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,4.522878745280337,2983,59651989,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C4C3C4,CC1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1
CHEMBL3417585,FJHKZEVPGYADEG-XOKHGSTOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,4.522878745280337,2984,118734875,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C4C3C4,CC1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1
CHEMBL3417586,FJHKZEVPGYADEG-XYPHTWIQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25827402.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,4.522878745280337,2985,118734876,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C4C3C4,CC1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1
CHEMBL219128,FJHLLCXNGZGREC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,2986,44418490,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)C(C)(C)C,CC(C)N1CCN(C(=O)N2CCC(C(C)(C)C)CC2)CC1
CHEMBL1682887,FJJLMFGGWNDUMR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.0,2991,9830290,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC)(C3=CN=CN3)O,COc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL1766193,FJJLMFGGWNDUMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.0,2992,9948129,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC)(C3=CN=CN3)O,COc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL1271880,FJKZYQSIFVSZGU-HNYUPJOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,2.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.638272163982407,2993,11497693,C1CC1CC2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CC6CCC(C5)N6CCO,O=C(OC1(C2COCC(CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO
CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.522878745280337,2994,4174,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,3000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.522878745280337,2994,4174,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,4931.74,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.306999827360513,2994,4174,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,800.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.096910013008056,2994,4174,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
CHEMBL3394719,FJWQSGSAPLRSAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2999,89795796,CC(C)CN1CCC(CC1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
CHEMBL3394719,FJWQSGSAPLRSAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,2999,89795796,CC(C)CN1CCC(CC1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1
CHEMBL3408941,FJXHOUJMCHOYIO-QCPDJZBESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.552841968657781,3001,58486138,C1CN(CCN1)C2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccc(N4CCNCC4)cc3)n[nH]c2c1
CHEMBL2425892,FJXWXOWWURDLGA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,42190.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.374790474618119,3003,71731604,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)OC)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3cc(OC)ccc3n2)c1=O
CHEMBL3134098,FKMUEAUWXYPTIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,4.522878745280337,3011,76322162,CCC1(C(=O)NC2=C(C=C(C=C2Cl)S(=O)(=O)NC3=C(C=C(C=C3)F)F)C(=O)N1)C,CCC1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(F)cc3F)cc(Cl)c2NC1=O
CHEMBL585293,FKNPFDGOZHGKTD-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,3013,25064510,CC(C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,COc1ccc2c(OC(C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL585293,FKNPFDGOZHGKTD-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,3013,25064510,CC(C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,COc1ccc2c(OC(C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL566253,FKNPFDGOZHGKTD-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,3014,25065131,CC(C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,COc1ccc2c(OC(C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL566253,FKNPFDGOZHGKTD-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,3014,25065131,CC(C1=NN=C2N1N=C(C=C2)C3=CC=CC=C3)OC4=C5C=CC(=CC5=NC=C4)OC,COc1ccc2c(OC(C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL2023898,FKRSSPOQAMALKA-CUPIEXAXSA-N,DACLATASVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22704887.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,3017,25154714,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(-c3ccc(-c4cnc(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
CHEMBL2023898,FKRSSPOQAMALKA-CUPIEXAXSA-N,DACLATASVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,3017,25154714,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(-c3ccc(-c4cnc(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
CHEMBL2023898,FKRSSPOQAMALKA-CUPIEXAXSA-N,DACLATASVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25148100.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,J. Med. Chem.,PUBLICATION,,5.142667503568732,3017,25154714,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(-c3ccc(-c4cnc(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
CHEMBL1910107,FKVLYYNFSQERBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,3020,15950386,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)F)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(F)cc1)C2=O
CHEMBL485765,FKWNFEDFTOOVQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,3021,25138087,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCCC4)C,CC(=O)Nc1cc(-c2cccc(N3CCCC3)n2)nc(-n2nc(C)cc2C)n1
CHEMBL2181638,FLBBIJRWUURIRG-SFQUDFHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.154901959985743,3030,71453938,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=NC(=CC=C5)N)C6CCCC6,Cn1c(-c2cccc(N)n2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL523516,FLEVSYIGMCAFBK-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.346787486224656,3034,44568943,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC(C)C)Cl,CC(C)Nc1noc2c(-c3ccc4c(N5CCOCC5C)nncc4c3)c(Cl)ccc12
CHEMBL2417553,FLLIVPRKOUZFTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23869452.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy trifluoromethylcoumarin as substrate,Cushing's Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type.,J. Med. Chem.,PUBLICATION,,5.958607314841775,3039,57330086,CC1=CC(=CN=C1)CC2=CN=C(C=C2)C3=CC=CC=C3,Cc1cncc(Cc2ccc(-c3ccccc3)nc2)c1
CHEMBL407034,FLMOTUCGPJDWCT-KQQUZDAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,40300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.394694953858891,3043,10829689,CC1=CC(=CC(=C1O)C)C=CC(=O)C=CC2=CC(=C(C(=C2)C)O)C,Cc1cc(C=CC(=O)C=Cc2cc(C)c(O)c(C)c2)cc(C)c1O
CHEMBL407034,FLMOTUCGPJDWCT-KQQUZDAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,40271703.43,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,1.3950000000274554,3043,10829689,CC1=CC(=CC(=C1O)C)C=CC(=O)C=CC2=CC(=C(C(=C2)C)O)C,Cc1cc(C=CC(=O)C=Cc2cc(C)c(O)c(C)c2)cc(C)c1O
CHEMBL3237445,FLNHSHVOGZEONH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,5.0,3044,58300068,CC1=NC=CC2=C1N(C3=NC(=NC=C23)NC4=NC=C(C=C4)N5CCNCC5)C6CCCC6,Cc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12
CHEMBL447955,FLNYCRJBCNNHRH-OIYLJQICSA-N,SERLOPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19354254.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.",J. Med. Chem.,PUBLICATION,,4.4089353929735005,3047,23653789,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2CCC3CN(CC3C2C4=CC=C(C=C4)F)C5=CC(=O)CC5,CC(OC1CCC2CN(C3=CC(=O)CC3)CC2C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL3645513,FLPLVVYBPARPKW-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,32700.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.485452247339714,3048,58109730,CCN1C(=O)C=CC(=N1)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCn1nc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O
CHEMBL2064343,FLQGKGPZQLXFCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,3049,49854130,C1CCC(CC1)N2C3=CC=CC=C3N=C2CC4=NC(=O)C=C(N4)N5CCOCC5,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3ccccc3n2C2CCCCC2)n1
CHEMBL1214450,FLTNOXKYIPZZCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,3053,11638500,CC1=C(N=CC=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,Cc1cccnc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2
CHEMBL496942,FLTYDFYSVZBKOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,5.6020599913279625,3054,10224181,CN1C2=C(C=C(C=C2)C#CCC3=CC=CC=C3)C(=O)N(C1=O)CC4=CC=C(C=C4)C(=O)O,Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21
CHEMBL496942,FLTYDFYSVZBKOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,5.6020599913279625,3054,10224181,CN1C2=C(C=C(C=C2)C#CCC3=CC=CC=C3)C(=O)N(C1=O)CC4=CC=C(C=C4)C(=O)O,Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21
CHEMBL231430,FLVVAVLMHCUYGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17084080.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.236572006437063,3057,10173403,CN1CCC2=C(CC1)C=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1
CHEMBL237365,FLYJFSWZKPJYBP-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,650.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.187086643357144,3060,44433271,CC(C)CC(C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N(C)CCN,CC(C)CC(c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1)N(C)CCN
CHEMBL266738,FLYSTSPNPXBSFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,3061,44425803,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CC=NC=C5)N(C2=O)CC6=CC=CC=C6F,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5ccncc5)cc4)CC3)C2=O)c1
CHEMBL550337,FLZIWHXEHDCVMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3062,45272046,CN(CCOC)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,COCCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL218067,FMAJVYNCYIOPMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,5.040958607678906,3063,9858476,C1CN(CCC1CNC2=CN=CC=C2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1
CHEMBL2036211,FMGHQGPKEYNZBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,3069,49873181,CCCCC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,CCCCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
CHEMBL3115074,FMJSLPJYTAKVLJ-CQVJSGDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26091726.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of a potent and selective EP4 receptor antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3074,72695026,CC(C1=CC=C(C=C1)C(=O)O)NC(=O)C2CCCCN2CCOC3=CC=CC=C3.Cl,CC(NC(=O)C1CCCCN1CCOc1ccccc1)c1ccc(C(=O)O)cc1
CHEMBL2165513,FMMAYYQMOFCNPH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,7.0,3076,57506732,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=NC=C4)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4ccnc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL2017113,FMQCDKUHURZNPN-AQDMSIBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,3077,58083336,CC(COC)COCC1=CC=C(C=C1)C2(CCNCC2C3=NOC(=C3Br)C4=CC=CC=C4CCNC(=O)C)O,COCC(C)COCc1ccc(C2(O)CCNCC2c2noc(-c3ccccc3CCNC(C)=O)c2Br)cc1
CHEMBL2069799,FMQXAKIGOZZDAL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,=,14200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.847711655616943,3079,70682487,C1CC1N2C(=NN=C2SCC3=NOC(=N3)C4=CC(=NC=C4)Cl)C5=CC=NC=C5,Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1
CHEMBL3330260,FMRUHQLKCRUMNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,6.0,3080,68230798,CCC1=C(C(=CC=C1)CC)NC(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1
CHEMBL3330260,FMRUHQLKCRUMNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,5.0,3080,68230798,CCC1=C(C(=CC=C1)CC)NC(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1
CHEMBL2059798,FMTJCQSCGILGKH-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,3083,70682193,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC=CC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1cccc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL1087637,FMTLMIDADBADOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,3084,10438856,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3=C(CNCC3)C(=O)N(CC4=C(C(=CC=C4)Cl)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3=C(C(=O)N(Cc4cccc(Cl)c4Cl)C4CC4)CNCC3)cc2)c(Cl)c1
CHEMBL3298273,FMUAFDSEYCJYKD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914612.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).,J. Med. Chem.,PUBLICATION,,4.522878745280337,3085,57405264,C1CNC(=O)C2=C1N=C(C=C2)OCC3=CC(=CC=C3)F,O=C1NCCc2nc(OCc3cccc(F)c3)ccc21
CHEMBL2437199,FMXIIIZGXBOJGX-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044938.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.",Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,3086,73352560,CNC(=O)N1CCN(CCN1)C2=C(C=C(C=C2)N3CC(OC3=O)CNC(=S)OC)F,CNC(=O)N1CCN(c2ccc(N3CC(CNC(=S)OC)OC3=O)cc2F)CCN1
CHEMBL382144,FMXZUNZJIFSWPW-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3087,23647913,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3C(CNCC3=O)COC4=CC5=C(CCCN5CCC(=O)O)C=C4,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCC(=O)O)CCC3)cc1
CHEMBL2181789,FNEMLYLQYCOWSI-LICLKQGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.026872146400302,3090,71461098,CC(C)(C(=O)NC1=CC=C(C=C1)C=CC(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=NC=C(C=C4)Cl)C5CCCC5,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(C=CC(=O)O)cc3)cc21
CHEMBL3104478,FNJIMNLSIQAWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.920818753952375,3096,76324753,CS(=O)(=O)C1=CC=C(C=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
CHEMBL3104478,FNJIMNLSIQAWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.920818753952375,3096,76324753,CS(=O)(=O)C1=CC=C(C=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1
CHEMBL3640290,FNMJFZYRSQTKIH-HXPMCKFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.522878745280337,3099,44467360,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=C(C=C(C=C4)F)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3ccc(F)cc3F)C2)nc(C)c1F
CHEMBL2206994,FNNLUWFZABEVSW-QHGBNFBXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,3100,60172115,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL2206994,FNNLUWFZABEVSW-QHGBNFBXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,3100,60172115,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3689756,FNQBQSDVRFAVIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,233065,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. ",Metalloenzyme inhibitor compounds,,PATENT,,4.638272163982407,3105,69093231,CC(C)C(C1=CC2=CC(=C(C=C2C=N1)OC)OC)(C3=NNN=C3)O,COc1cc2cnc(C(O)(c3cn[nH]n3)C(C)C)cc2cc1OC
CHEMBL1077941,FNQUUONWSOHCPS-JHOUSYSJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985743,3107,46883347,C1=CC=C(C=C1)CC(CN(CC2=CC3=CC=CC=C3N=C2)CC(CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5)NC(=O)OCC6=CN=CS6,O=C(NC(Cc1ccccc1)CN(Cc1cnc2ccccc2c1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL87071,FNUFKVJAONMVTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,3114,23395766,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,Cn1cc(Cc2cn(CC(=O)N(CCN)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
CHEMBL1224590,FNXJLFFFNIDKMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,3115,11450354,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CN=C(N3)C(=O)N)C(F)(F)F,NC(=O)c1ncc(-c2cccc(-c3ccccc3C(F)(F)F)c2)[nH]1
CHEMBL3627895,FOHVKOZKLHOUOO-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3127,121407246,CC1=NN(C=N1)C2=CC(=C(C(=C2)Cl)C(=O)NCC(C3=CC(=CC=C3)F)C4=NC5=C(N4)C=C(C=C5)Cl)Cl,Cc1ncn(-c2cc(Cl)c(C(=O)NCC(c3cccc(F)c3)c3nc4ccc(Cl)cc4[nH]3)c(Cl)c2)n1
CHEMBL227899,FOIIYTALCBINLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,75000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.1249387366083,3128,10045603,C1CC(C1)CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,O=C(NCC1CCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL555347,FOJGGWIJRFOXIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,3129,44236320,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=N3)C(=O)NC4=CC=C(C=C4)C(F)(F)F,O=C(Nc1ccc(C(F)(F)F)cc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
CHEMBL3422006,FONDHAXAYFJYSI-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.173925197299173,3131,67450880,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=CSC(=N4)C5=CC=CC=C5,CC1c2nnc(-c3csc(-c4ccccc4)n3)n2CCN1C(=O)c1ccc(F)cc1
CHEMBL282156,FOTDWYFVTJDSLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,6620.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.1791420105603,3134,11270563,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3NC5=C4C(=CC=C5)[N+](=O)[O-],O=[N+]([O-])c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12
CHEMBL219861,FOUGTHXAKKBTGL-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,46000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.337242168318426,3135,9805776,CC(C)CN1C2=C(C(=C(S2)CC3=CC=NC4=CC=CC=C34)C(=O)N5CC(CO5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC(O)CO3)c(Cc3ccnc4ccccc34)sc21
CHEMBL1269176,FOWDOWQYRZXQDP-UHFFFAOYSA-N,ADAMANTAN-2-OL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11��-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3137,64149,C1C2CC3CC1CC(C2)C3O,OC1C2CC3CC(C2)CC1C3
CHEMBL1947144,FOYKYLQAKICGEN-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22070604.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor �� (PPAR��) modulators.,J. Med. Chem.,PUBLICATION,,4.657577319177793,3140,11591164,CC1(C(=O)NC(=O)O1)C2=CC=CC(=C2)CN3C4=CC=CC=C4N(C3=O)C5=NOC6=C5C=CC(=C6)OC,COc1ccc2c(-n3c(=O)n(Cc4cccc(C5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1
CHEMBL2064413,FPAPMCJELAEURQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,=,19000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.721246399047171,3142,57523325,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(C=CC=C4O3)C5=CC=CS5,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3c(-c4cccs4)cccc3o2)n1
CHEMBL410420,FPDOTOGFAZHEPN-UEVCKROQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,3145,44456424,CC(C)CC1C(=O)NC(C(=O)N1C(C2=CC=C(S2)Br)C(=O)NC(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)NC(C)C)c1ccc(Br)s1
CHEMBL2064419,FPFCFOIMTFHSNY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,3149,49855165,C1COCCN1C2=CC(=O)N=C(N2)CC(=O)NC3=CC=CC=C3,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)Nc1ccccc1
CHEMBL3264607,FPFLLZAGPFEDBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,102000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.9913998282380825,3151,69093249,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C3=CN=CO3)(C4=NNN=C4)O,CC(C)C(O)(c1ccc2cc(-c3cnco3)ccc2c1)c1cn[nH]n1
CHEMBL495118,FPNJQEAHFJNZFI-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.221848749616356,3155,44568929,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC)Cl,CNc1noc2c(-c3ccc4c(N5CCOCC5C)nncc4c3)c(Cl)ccc12
CHEMBL1808640,FPQYARBHMSUIMN-YCRREMRBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3158,24958075,COC1=CC=C(C=C1)S(=O)(=O)N2CC3=C(C2)C=C(C=C3)C=CC(=O)NO,COc1ccc(S(=O)(=O)N2Cc3ccc(C=CC(=O)NO)cc3C2)cc1
CHEMBL2387596,FPXKRKAWESOZII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,3162,71659492,CCCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,CCCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
CHEMBL1209627,FPYFDKXCMNWPRU-HKALDPMFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,3163,49862603,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O
CHEMBL1209627,FPYFDKXCMNWPRU-HKALDPMFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,3163,49862603,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O
CHEMBL3603923,FQAXDSVNYVVQSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26225459.0,IC50,>,15848.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).,J. Med. Chem.,PUBLICATION,,4.800000052738446,3166,86763358,C1=CC(=NC=C1F)C2=CC(=NC=N2)C3=CC(=CC(=C3)C#N)Cl,N#Cc1cc(Cl)cc(-c2cc(-c3ccc(F)cn3)ncn2)c1
CHEMBL361153,FQCXYANVLWAPNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,56900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.244887733604929,3169,595254,C1=CC(=CN=C1)C2=CSC=C2,c1cncc(-c2ccsc2)c1
CHEMBL361153,FQCXYANVLWAPNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,55910.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.252510507741327,3169,595254,C1=CC(=CN=C1)C2=CSC=C2,c1cncc(-c2ccsc2)c1
CHEMBL2041165,FQMDPZWWVSRDFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,3178,70688210,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=COC(=C6)C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4coc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL213390,FQMMZAXRATYRCZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16806913.0,IC50,>,18000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,3180,16007091,C1=CC=C(C=C1)C2=NC=C(C=C2)C(=O)NC3=CC4=C(C=CC=N4)C=C3,O=C(Nc1ccc2cccnc2c1)c1ccc(-c2ccccc2)nc1
CHEMBL2407899,FQWPBCFJZAKNEQ-CBVNATGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,6.096910013008056,3187,58189710,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C=C5C6=CC=CC=C6NC5=O,CN1CCN(c2ccc(C=Cc3n[nH]c4cc(C=C5C(=O)Nc6ccccc65)ccc34)cn2)CC1
CHEMBL399656,FRCSXRRNAXDKOX-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,>,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.050609993355088,3195,25190493,CCNC1=CC(=CC(=C1)C(=O)NC(CC2=CC=CC=C2)C(CNCC3=CN(N=C3)CC)O)N4CCCCS4(=O)=O,CCNc1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1
CHEMBL399656,FRCSXRRNAXDKOX-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,>,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.050609993355088,3195,25190493,CCNC1=CC(=CC(=C1)C(=O)NC(CC2=CC=CC=C2)C(CNCC3=CN(N=C3)CC)O)N4CCCCS4(=O)=O,CCNc1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1
CHEMBL1766174,FRDLFNZPCFFPFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.275724130399211,3196,9883171,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)F)(C3=CN=CN3)O,CC(C)C(O)(c1ccc(-c2ccc(F)cc2)cc1)c1cnc[nH]1
CHEMBL427860,FRHBHVROLQSPMW-BTYSJIOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.036212172654444,3200,23635235,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=CC=C(C=C3)Cl)C(C(C)C)NC(=O)CCN(C)C,Cc1ccc(N2CCN(C(=O)C(C)Cc3ccc(Cl)cc3)CC2)c(C(NC(=O)CCN(C)C)C(C)C)c1
CHEMBL3115176,FRHKZTWSEIPHQR-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,3201,59721245,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCO)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CCO)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL510285,FRLGCDYZXBVROR-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,6.356547323513812,3204,25156944,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)OC)C4=C(C(=CC=C4)OC)F,COC(=O)CCCNC(Cn1c(=O)c(-c2cccc(OC)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL2164048,FROGGFONBYACJB-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22793372.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.",J. Med. Chem.,PUBLICATION,,5.4089353929735005,3206,26873419,CCC(C1=CC=CC=C1)C(=O)NC2=CC=CC=C2N3CCCC3,CCC(C(=O)Nc1ccccc1N1CCCC1)c1ccccc1
CHEMBL2030386,FRRLLRQAGKSVMU-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22542012.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of PIM kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,3209,57899488,C1CN(CC1O)CC2=NC(=O)C3=C(N2)C4=C(O3)C=CC(=C4)Br,O=c1nc(CN2CCC(O)C2)[nH]c2c1oc1ccc(Br)cc12
CHEMBL1288289,FRTRJCUGYXZWQF-GJFSDDNBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.872895201635193,3211,52943757,CC1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)Cl)C(=O)N(C(=O)N3CC(=O)N(C)C)C)N.Cl,CN(C)C(=O)Cn1c(=O)n(C)c(=O)c2c1cc(N1CCCC(C)(N)C1)n2Cc1cc(F)ccc1Cl
CHEMBL1650658,FRZBNIHVXARHST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1070.0,NM,221147,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,5.97061622231479,3216,25069768,CS(=O)(=O)NC1=CC=CC(=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,CS(=O)(=O)Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1
CHEMBL3137389,FRZSLHWYVJOSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,3217,76318570,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1
CHEMBL252632,FSDIGHDJKRVNHH-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.008773924307505,3226,44447262,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2CC(C(F)(F)F)(F)F)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC(F)(F)C(F)(F)F
CHEMBL2425153,FSWRFMXJBKPOTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3244,72189808,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=CO4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1
CHEMBL3702673,FSYNBGHPEGKIGK-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,3247,89718230,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CN=C(C=C8)N,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)nc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL480210,FSYXVLMRBONNFA-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,3248,44570528,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)C(=O)C5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL480210,FSYXVLMRBONNFA-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,3248,44570528,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)C(=O)C5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL2163825,FTCUCNANDOCSHQ-PRCIMEDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.366531544420414,3257,57522248,C1CC2CC(CC1N2C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4(CC4)C5=C(C=C(C=C5)Cl)Cl)N,NC1CC2CCC(C1)N2C(=O)C(Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
CHEMBL2057516,FTKKBBITVQQSEP-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,3267,70684211,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N(C)CCN(C)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CCN(C)C)oc2c1
CHEMBL510298,FTKTXHIRMKWXBE-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,3268,135960728,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)C7CC7,Cc1cc(N2CCC(N3CCN(C(=O)C4CC4)CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2387504,FTNFWJGKFMEIIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,3270,71659753,CC1=CC=CC=C1C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,Cc1ccccc1-c1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3c(F)cccc3Cl)nc12
CHEMBL1818452,FTQFUQZSKDXZNW-ZYMOGRSISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,3275,56659201,CC1=CC=NN1CC23CC2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccnn1CC12CNCCC1(c1ccc(Cl)c(Cl)c1)C2
CHEMBL498251,FTQWKXRWLDQPEE-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,3277,44583664,CC1=C(N2C=C(C=C(C2=N1)NC3C(CC4=CC=CC=C34)O)N5C=NC=N5)C,Cc1nc2c(NC3c4ccccc4CC3O)cc(-n3cncn3)cn2c1C
CHEMBL498251,FTQWKXRWLDQPEE-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,3277,44583664,CC1=C(N2C=C(C=C(C2=N1)NC3C(CC4=CC=CC=C34)O)N5C=NC=N5)C,Cc1nc2c(NC3c4ccccc4CC3O)cc(-n3cncn3)cn2c1C
CHEMBL3104537,FUCHTSBIUIZRIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,5.2839966563652006,3287,76328299,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4C#N,N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3104537,FUCHTSBIUIZRIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5200.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.2839966563652006,3287,76328299,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=CC=C4C#N,N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL1823817,FUCKCIVGBCBZNP-MRXNPFEDSA-N,CE-224535,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21565499.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3288,11547499,COCC(CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O,COCC(O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O
CHEMBL2181899,FUDKQBKYDLVSHY-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.0,3290,71453953,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC=C(C=C4)C#C)NC(=O)COC)O,C#Cc1ccc(CC(NC(=O)COC)C(O)CNC2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)cc1
CHEMBL1242717,FUDKWFQKXWHRLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,3291,11720815,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCOCC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1
CHEMBL1242717,FUDKWFQKXWHRLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,3291,11720815,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N7CCOCC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1
CHEMBL596290,FULBTJANHDAKTA-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,3294,46190876,CC1=C2C(=NN1)N=CC(=N2)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=COC=C6,Cc1[nH]nc2ncc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12
CHEMBL1803004,FUNHEVBLXUQXLG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21608528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,4.301029995663981,3295,15981007,CS(=O)(=O)NC1=CC2=C(C=C1)C=CC3=C(C2=O)C=C(C=N3)C4=CC=CC=C4,CS(=O)(=O)Nc1ccc2ccc3ncc(-c4ccccc4)cc3c(=O)c2c1
CHEMBL1076449,FUPYLBRXZJOVDD-SKCUWOTOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19853442.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New classes of potent and bioavailable human renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,3300,46880059,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3=C(CC4CCC3N4)C5=CC=C(C=C5)CCCOC6=C(C=CC(=C6Cl)F)F,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CC2CCC1N2)N(Cc1cccc(Cl)c1Cl)C1CC1
CHEMBL2387606,FUSNGHKYBLQGJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,3303,71659752,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=NC=C5)Cl,O=c1[nH]c2cc(-c3ccncc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL3702826,FUTQMNXPKCMVCI-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6410.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.193141970481182,3305,89718500,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(N=C7)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc(N(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL477563,FUUMHDABRAONFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.568636235841013,3307,10273854,CC1=NC2=C(N1C)C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C
CHEMBL477563,FUUMHDABRAONFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.346787486224656,3307,10273854,CC1=NC2=C(N1C)C=CC(=C2)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C
CHEMBL2018913,FUVYXGUCJOVMNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,5490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.260427655549908,3310,43388611,COC1=CC2=C(C=C1)N=C(N2)SCCCO,COc1ccc2nc(SCCCO)[nH]c2c1
CHEMBL238762,FUWYDCSEHWKYSH-JTQLQIEISA-N,SR-1448,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3312,16662110,CC(C(=O)N1CCC(CC1)NC2=CC3=C(C=C2)NN=C3)N,CC(N)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL214021,FVFURMJFTAJXRH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17234405.0,IC50,=,23500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.628932137728264,3317,11539096,C1CN(CCC1NC(=O)C2=CC(=O)C3=C(O2)C=C(C=C3)F)CC4=CC5=C(C=C4)OCO5,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1
CHEMBL3137463,FVGJATLYSKGWEO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.221848749616356,3318,76318575,CN(C)S(=O)(=O)C1=CC=CC(=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)c1
CHEMBL2013195,FVHKIGHCUWTXCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22366657.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3320,1394668,C1CCN(CC1)CC2=C(C=CC3=C2N=C(N3)C4=CC=CC=C4)O,Oc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCCC1
CHEMBL254705,FVHUZYZMUXKNEP-QWFCFKBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,11900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.924453038607469,3321,11641059,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCC(C4)O,CCC1CCCC(C2(CC(=O)N3CCC(O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2448735,FVHYOKKAMSUARF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1500.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.823908740944319,3322,73352679,CS(=O)(=O)N(CC1=CN=CN1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1
CHEMBL219483,FVIJIRCHSMDMJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,6.0,3323,16102867,CC(C)CN1C2=C(C(=C(S2)CN3C4=CC=CC=C4N=C3NC)C(=O)N5CCC5)C(=O)N(C1=O)C,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC1)c(=O)n(C)c(=O)n2CC(C)C
CHEMBL517828,FVKXOARNHRLXBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,3325,44579085,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL517828,FVKXOARNHRLXBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,3325,44579085,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL2059122,FVLSAYPPCYXSQP-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,3326,70684268,C1CCN(C1)CCN(CC(C(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)O)C(=O)C4=CC5=C(C=C4)N=C(O5)N6CCCC6,O=C(NC(Cc1ccccc1)C(O)CN(CCN1CCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
CHEMBL249494,FVMSLFYQMWOIFN-OEMFJLHTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,3327,44442017,CC(C)(CO)N1CCN(CC1)C(=O)CC2(CC2)C3CC(CC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5)O,CC(C)(CO)N1CCN(C(=O)CC2(C3CC(O)CC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL1829769,FVYWUKYMYNOWNN-QMTYFTJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.522878745280337,3336,53473234,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CC(=O)N)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CC(N)=O)(c2ccc(F)cc2)OC1=O
CHEMBL3187348,FWNNFDXOWQESMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3342,42210730,CC1=NC(=CS1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C(C)C,COc1ccc(C(=O)NCc2csc(C)n2)cc1OC1CCN(C(C)C)CC1
CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,3346,11331001,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,39810.72,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.399999967876858,3346,11331001,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,3346,11331001,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL509075,FWSQRSDDLDNXGE-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.443697499232712,3346,11331001,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL271941,FXFJPJRHXSPGDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,3353,11540571,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCO)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCO)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL252614,FXFOLNQQHHEMOR-UIIQDGRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,3354,11526667,C1CC(N(C(C1)C2(CC2)CC(=O)N3CC4CCC(C3)N4CCO)S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,O=C(CC1(C2CCCC(C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO
CHEMBL2017268,FXGZSKNYBROIMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,3357,70691697,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4C(C)(C)C)C(=O)N,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2c1
CHEMBL1923107,FXKQOXVNWKMPRT-OFSOJUDTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,3360,57396095,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC=CC=C5C(=O)O4,COCCCc1cc(CN(C(=O)C2CNCCC23OC(=O)c2ccccc23)C2CC2)cc(OCCOC)c1
CHEMBL1910121,FXPZWVGNKACNOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,3367,57403170,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCN(CC3)S(=O)(=O)C)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(S(C)(=O)=O)CC1)C2=O
CHEMBL3114721,FXUQDXOBSPOBSH-ABANCFTRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165727,3369,76321484,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C3C(OC(O3)(C)C)C(CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)C2OC(C)(C)OC2C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL1222718,FYAWQQTZMXAAFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.869666231504994,3376,49864937,CCOCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,CCOCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL1272098,FYBUXXZDXWUPPE-ZQJMJJNQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,3377,52944293,CCC1CN(C(CN1C(=O)OC2(CC2)C3COCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5)C)C(=O)C,CCC1CN(C(C)=O)C(C)CN1C(=O)OC1(C2COCC(CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL2036643,FYNKTKAUIWKPFC-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3386,49857998,CC1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCC(CC3)(F)F,CC1CCCN1CCCOc1ccc(C(=O)CN2CCC(F)(F)CC2)cc1
CHEMBL3702776,FYOUXYBMHVIQDP-JSXFGMRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6750.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.170696227168975,3388,71532139,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1818455,FYXXTOJUMHTXEW-QRWMCTBCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.096910013008056,3395,56669563,CC1=CC(=NN1CC23CC2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,Cc1cc(C)n(CC23CNCCC2(c2ccc(Cl)c(Cl)c2)C3)n1
CHEMBL3702695,FYYNKEATFHKTBH-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.94692155651658,3396,89718296,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702737,FYYWCVHKYFUZEZ-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2010.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.696803942579511,3397,89718467,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCCOC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCCOC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2437420,FYZINNJJPXURBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3398,58863113,COCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC(=NC=C5)N,COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccccc21
CHEMBL2064417,FZBMKSZVGOJNQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,3403,57523353,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(O3)C=CC(=C4C5=CC=CC=C5)F,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)n1
CHEMBL2419485,FZGNWTQJSVKAPD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,5.481486060122113,3406,15983053,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)Cl)C,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(Cl)cc3)C2)nc1C
CHEMBL1079896,FZIDUWWIFBUCIN-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,3407,46883194,C1=CC=C(C=C1)CC(CNCC(CC2=CC=CC=C2)NC(=O)OCC3=NC=CS3)NC(=O)OCC4=CN=CS4,O=C(NC(CNCC(Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
CHEMBL1079897,FZIDUWWIFBUCIN-DNQXCXABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,99.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.00436480540245,3408,46883195,C1=CC=C(C=C1)CC(CNCC(CC2=CC=CC=C2)NC(=O)OCC3=NC=CS3)NC(=O)OCC4=CN=CS4,O=C(NC(CNCC(Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
CHEMBL1079722,FZIDUWWIFBUCIN-ZEQRLZLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,148.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8297382846050425,3409,46883193,C1=CC=C(C=C1)CC(CNCC(CC2=CC=CC=C2)NC(=O)OCC3=NC=CS3)NC(=O)OCC4=CN=CS4,O=C(NC(CNCC(Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
CHEMBL3091529,FZPYWVVOFIWWAQ-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3416,11176034,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=C(C=C3)F)C4=CC=NC=C4,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O
CHEMBL3091547,FZPYWVVOFIWWAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3417,10133485,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=C(C=C3)F)C4=CC=NC=C4,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O
CHEMBL519149,FZSIIVFTLMHKAP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3420,44583237,C1CC2=CC=CC=C2CCC1NC(=O)N3CCC4(CC3)CC(=O)C5=CC=CC=C5O4,O=C1CC2(CCN(C(=O)NC3CCc4ccccc4CC3)CC2)Oc2ccccc21
CHEMBL1086579,FZTUPODAEPTYNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20565112.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 from human liver microsome by LC-MS/MS analysis,"Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.",J. Med. Chem.,PUBLICATION,,5.0,3423,46889932,CC1=CC(=NO1)CN2CCN(CC2)C3=C4C(=NC=C3Br)N=C(N4)N5CCN(CC5)C,Cc1cc(CN2CCN(c3c(Br)cnc4nc(N5CCN(C)CC5)[nH]c34)CC2)no1
CHEMBL1078190,GAAPAEWIPWJVMW-AYBMPSMDSA-N,"6',7'-DIHYDROXYBERGAMOTTIN DECANAL ACETAL",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,6.568636235841013,3428,44478953,CCCCCCCCCC1OC(C(O1)(C)C)CCC(=CCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4)C,CCCCCCCCCC1OC(CCC(C)=CCOc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1
CHEMBL3702691,GAARYPFMGZTUSF-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.094743951251549,3429,56959156,CCN1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2440663,GAENEKJGLXICIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2076083105017466,3431,69936777,C1=CC(=NC=C1F)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncnc2)c1
CHEMBL3604174,GAGGCNZJYKWGJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26037322.0,IC50,=,58100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.235823867609669,3433,16663122,C1=CC(=C(C=C1Cl)Cl)NC(=O)C2=NNN=C2,O=C(Nc1ccc(Cl)cc1Cl)c1cn[nH]n1
CHEMBL1208962,GALNGZPXDPAWDR-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,3434,49862093,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCS(=O)(=O)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NCCS(C)(=O)=O)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL3605557,GAPKQSFTRWQZTL-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26291341.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,PUBLICATION,,4.698970004336019,3436,24985395,CCN1C2=CC(=NC=C2N=C1C(C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C(F)(F)F,CCn1c(C(C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C(F)(F)F)cc21
CHEMBL3633320,GARYHNNCUAMEQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26363868.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,3439,122195192,C1CN(CCN1CC2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=NC(=N3)[N+](=O)[O-],O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(C(F)(F)F)cc2)CC1
CHEMBL1270834,GASOVDDSXLJYME-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,3440,25073049,CCCC#CC1=C(C=CC(=C1)C2(C(=O)N(C(=N2)N)C)C3=CC(=C(C=C3)OC(F)F)C)F,CCCC#Cc1cc(C2(c3ccc(OC(F)F)c(C)c3)N=C(N)N(C)C2=O)ccc1F
CHEMBL1271608,GAWPXOIHRKJZND-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20934334.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,3443,50899467,C1=CC=C(C=C1)C(=O)NC2=NC=C(C=C2)N3C(=CC(=N3)C4=CN=CC=C4)C(F)(F)F,O=C(Nc1ccc(-n2nc(-c3cccnc3)cc2C(F)(F)F)cn1)c1ccccc1
CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.6989700043360187,3444,23645678,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)(CC(C5)(C4)O)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(O)(CC(O)(C3)C1)C2
CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.6989700043360187,3444,23645678,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)(CC(C5)(C4)O)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(O)(CC(O)(C3)C1)C2
CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,3.6989700043360187,3444,23645678,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)(CC(C5)(C4)O)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(O)(CC(O)(C3)C1)C2
CHEMBL3350936,GAWUJFVQGSLSSZ-SZRCHTAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,3.6989700043360187,3444,23645678,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)(CC(C5)(C4)O)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(O)(CC(O)(C3)C1)C2
CHEMBL3288451,GAWXPLJRMGISPF-AAYBCKPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,6.045757490560675,3445,90644648,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3CCO)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2CCO)CC1
CHEMBL3288451,GAWXPLJRMGISPF-AAYBCKPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,13300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,4.876148359032914,3445,90644648,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3CCO)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2CCO)CC1
CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.0,3446,5311497,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2
CHEMBL2151497,GBGNPCMUCLQITD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22975301.0,IC50,=,25000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.6020599913279623,3451,71454747,C1CC(CCC1C(=O)N2CC(C2)C3=NC(=NO3)C4=CC(=CC=C4)Cl)(F)F,O=C(C1CCC(F)(F)CC1)N1CC(c2nc(-c3cccc(Cl)c3)no2)C1
CHEMBL321814,GBGNQOSPNHQALW-CEWIDEQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,3452,10190506,C1CN(C(CN1CC2=CC3=C(O2)C(=CC=C3)Cl)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2cc3cccc(Cl)c3o2)CC1C(=O)NCC(F)(F)F
CHEMBL2070142,GBMMBKZVOXBMPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,3454,70693067,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=CC=C3)C(F)(F)F,CCCS(=O)(=O)c1ccc2nc(-c3cccc(C(F)(F)F)c3)[nH]c2c1
CHEMBL2407900,GBUDRABUNBYJKG-WWAWLHJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,5.0,3460,58189785,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C=C5C6=C(C=CC(=C6)OC)NC5=O,COc1ccc2c(c1)C(=Cc1ccc3c(C=Cc4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
CHEMBL2407900,GBUDRABUNBYJKG-WWAWLHJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,3460,58189785,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C=C5C6=C(C=CC(=C6)OC)NC5=O,COc1ccc2c(c1)C(=Cc1ccc3c(C=Cc4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
CHEMBL2419518,GBWFXYVAVDSWDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3463,71727930,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
CHEMBL2419518,GBWFXYVAVDSWDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3463,71727930,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
CHEMBL240355,GBXSOZDYCSBLQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,3465,6914627,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C)O2
CHEMBL481745,GBZPNPQJVWRRPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19119007.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel imidazole-based histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3467,10134089,CC(C)N1CCC(CC1)COC2=NC=C(N2C)C(=O)C3=CC=C(C=C3)Cl,CC(C)N1CCC(COc2ncc(C(=O)c3ccc(Cl)cc3)n2C)CC1
CHEMBL3394729,GCBARIQAGXVYET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3468,71727801,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
CHEMBL3394729,GCBARIQAGXVYET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3468,71727801,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1
CHEMBL572184,GCBIADPPDPBDLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3469,45484913,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)Br,CC1(CC(=O)NCc2cccc(Br)c2)CC2(CCCCC2)OO1
CHEMBL2170605,GCFQTXXNPYVOLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.886056647693163,3474,58269629,CC(C)(C)C(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL10440,GCGPDMHRIZLRII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,3476,10232552,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)C,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1
CHEMBL1951331,GCLFXARMPHAWHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029182,3482,57395298,C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL150799,GCLVZVSTRWZGFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,3484,11183547,CCCCOC1=CC=CC=C1C2=CC=NO2,CCCCOc1ccccc1-c1ccno1
CHEMBL3127500,GCNBJSNHYPKHIT-LEWJYISDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.7447274948966935,3485,76311092,CS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)c1
CHEMBL3127500,GCNBJSNHYPKHIT-LEWJYISDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.050609993355088,3485,76311092,CS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)c1
CHEMBL2024248,GCNDDOJRCKHYLZ-ZXMXYHOLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.552841968657781,3487,53497561,CNCC(CC1CCCOC1)NC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC,CNCC(CC1CCCOC1)NC(=O)N1CCCC(C(OCCNC(=O)OC)c2cccc(Cl)c2)C1
CHEMBL1911824,GCNGNRXFHCZYCX-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,3488,46869440,CC1(CC1)COCC(C(=O)N2CCN(CC2)C)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCC2(C)CC2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL262968,GCRYIIOKZWQWIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,417.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.379863945026242,3491,44341278,C1=CC(=CN=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3,c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1
CHEMBL218410,GDAGKQMCMNZJDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,3498,44418482,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)C(=O)OC(C)(C)C,CC(C)N1CCN(C(=O)N2CCC(C(=O)OC(C)(C)C)CC2)CC1
CHEMBL329477,GDAGOGOXJLUVGB-OFSOJUDTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,41000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,4.3872161432802645,3499,10166543,CC1=CC(=NC(=N1)OC(C(=O)O)C2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C5=CC=CC=C5)C,Cc1cc(C)nc(OC(C(=O)O)C2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1
CHEMBL1915565,GDEPVUVIBMMPRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,3502,25107259,CC1=CN(C=N1)C2=CC=C(C=C2)NC3=NC(=CS3)C4=C(C=CC(=C4)Br)OC,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)cc2)n1
CHEMBL3645519,GDEYVKYYDNYXSM-WRONEBCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15700.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.804100347590766,3503,42605501,CC(C1=CC=C(C=C1)C2=NN(C(=O)C=C2)C3CC3)N4CCC(OC4=O)(CC(C)(C)O)C5=CC=CC=C5,CC(c1ccc(-c2ccc(=O)n(C3CC3)n2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL3702768,GDHZDZNRIQPUBT-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9650.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.015472686656207,3505,89718346,CN1CCN(CC1)C2=CC=C(C=C2)C(=O)N3CCC(CC3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1209617,GDJANRNMFHNVOW-DCPHZVHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3507,46911228,CC(C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCC3)NC(=O)C4C(CCN4)O,CC(NC(=O)C1NCCC1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1
CHEMBL1209617,GDJANRNMFHNVOW-DCPHZVHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3507,46911228,CC(C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCC3)NC(=O)C4C(CCN4)O,CC(NC(=O)C1NCCC1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1
CHEMBL578928,GDKCAAWSNQLXNX-UHFFFAOYSA-N,GNF-PF-2094,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19914064.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3509,697226,CC1=CC(=NC(=N1)NCC2=CC=CC=C2)NC3CCCCC3,Cc1cc(NC2CCCCC2)nc(NCc2ccccc2)n1
CHEMBL3235253,GDLACGKFMPNRBW-MSOLQXFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630562.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3510,71522361,CC1CCC(CN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C#CC4=NC=C(C=C4)F,Cc1ccc(-n2nccn2)c(C(=O)N2CC(C#Cc3ccc(F)cn3)CCC2C)c1
CHEMBL518287,GDLSKBDRIIJEHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3513,24900235,C1=CC=C(C=C1)C(C2=CC(=CC=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(Cl)c1
CHEMBL1230065,GDTQLZHHDRRBEB-UHFFFAOYSA-N,BMS-582949,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20804198.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38a MAP kinase inhibitor for the treatment of inflammatory diseases.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,3520,10409068,CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C
CHEMBL1091774,GDVOQNXWYQVYJH-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3521,11508317,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCCC4,CC(c1ccccn1)c1c(CCN2CCCC2)sc2ccccc12
CHEMBL1269692,GEBGDXKEDPYHHN-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,3525,12001869,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL1269692,GEBGDXKEDPYHHN-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.102372908709558,3525,12001869,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL3236639,GEDLWRDUBQVNGB-JCUDBWTNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,3526,90655372,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=NC=CC(=C5)C(=O)O,CC1(Cc2cc(C(=O)O)ccn2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL1708,GELRVIPPMNMYGS-RVXRQPKJSA-N,PAROXETINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,24100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.617982957425132,3536,62878,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.Cl,Fc1ccc(C2CCNCC2COc2ccc3c(c2)OCO3)cc1
CHEMBL1672632,GEPUTKWSUKGITG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,3540,53322692,C1CC1C(=O)NC2=CN=C(C(=N2)C3=NC=CO3)C4=C(C=NC=C4)F,O=C(Nc1cnc(-c2ccncc2F)c(-c2ncco2)n1)C1CC1
CHEMBL396186,GEQDEWSMDBTYED-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,3541,44433300,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCCN,CC(C)CC(NC(=O)CCCN)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3330652,GERXWWPNRKXYSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3544,44137226,C1=CC(=C(C=C1I)F)NC2=C(C=CN3C2=CN=C3)C(=O)NOCCO,O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F
CHEMBL3330652,GERXWWPNRKXYSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3544,44137226,C1=CC(=C(C=C1I)F)NC2=C(C=CN3C2=CN=C3)C(=O)NOCCO,O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F
CHEMBL1092377,GETROLYXSDDSDH-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3545,46884152,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)F,CC(c1ncccc1F)c1c(CCN(C)C)sc2ccccc12
CHEMBL1269675,GETZVQZESTVPJG-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,3546,12001956,CCNCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,CCNCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269675,GETZVQZESTVPJG-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,3546,12001956,CCNCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,CCNCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL520828,GEWPHZNCWUIEEN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,5.568636235841013,3553,11641672,CC1=C(C(N=C(N1)C2=CC=C(C=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1
CHEMBL2152252,GEYLKEHPEKRUTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22548342.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate after 15 mins by LC/MS/MS analysis,Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase �� Inhibitors.,J. Med. Chem.,PUBLICATION,,4.698970004336019,3555,56955954,CNC(=O)C1=NC(=CN=C1N)C2=CC(=C(C=C2)Cl)S(=O)(=O)NC3=C(C(=CC=C3)F)F,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N
CHEMBL2152252,GEYLKEHPEKRUTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22548342.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 15 mins by LC/MS/MS analysis,Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase �� Inhibitors.,J. Med. Chem.,PUBLICATION,,4.698970004336019,3555,56955954,CNC(=O)C1=NC(=CN=C1N)C2=CC(=C(C=C2)Cl)S(=O)(=O)NC3=C(C(=CC=C3)F)F,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N
CHEMBL226345,GFFGJBXGBJISGV-UHFFFAOYSA-N,ADENINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,3564,190,C1=NC2=NC=NC(=C2N1)N,Nc1ncnc2nc[nH]c12
CHEMBL226345,GFFGJBXGBJISGV-UHFFFAOYSA-N,ADENINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,3564,190,C1=NC2=NC=NC(=C2N1)N,Nc1ncnc2nc[nH]c12
CHEMBL569185,GFFIHDXPUGXVGG-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19888755.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.,J. Med. Chem.,PUBLICATION,,4.431798275933005,3565,25019282,COC1=CC=C(C=C1)CCN2C(CN(C2=O)NS(=O)(=O)C)C3=CC=C(C=C3)OC,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)CC2c2ccc(OC)cc2)cc1
CHEMBL252240,GFFRRUFVZMBJGA-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0915149811213505,3567,44447291,CC(C)(C)OC(=O)NC(CC1=C(C(=CC=C1)F)C(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1cccc(F)c1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL525001,GFGBAMIIMZDJCH-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,3570,44583665,CC1=C(N2C=C(C3=C(C2=N1)NC(CC3)C4=CC=CC=C4)N5C=CC=CC5=O)C,Cc1nc2c3c(c(-n4ccccc4=O)cn2c1C)CCC(c1ccccc1)N3
CHEMBL1607077,GFGKJXGFRNRWOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,3571,2568387,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=NC=C3,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
CHEMBL1172882,GFIBJCSJSOCGMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,538.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,6.269217724333611,3572,46901446,C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3,Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
CHEMBL1172882,GFIBJCSJSOCGMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,538.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,6.269217724333611,3572,46901446,C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3,Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
CHEMBL3113764,GFIGTNGISUKHQE-BBRMVZONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.060480747381382,3573,69080188,CC1CC(N(C1=O)CC2=CC=C(C=C2)OC(F)(F)F)C3=C(C=CC=C3OC)OC,COc1cccc(OC)c1C1CC(C)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
CHEMBL2407949,GFIMEKUFCRTWGH-DARPEHSRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,3574,136166933,CC1=CC=CC=C1C(CC(=NO)C2=CC=NC=C2)C3=CC=C(C=C3)Br,Cc1ccccc1C(CC(=NO)c1ccncc1)c1ccc(Br)cc1
CHEMBL394438,GFJJIBKQWYQEJL-UHFFFAOYSA-N,SR-1351,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.275724130399211,3578,16662100,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Cl)N,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Cl)cc1
CHEMBL1951336,GFKDVMSTTKOYOX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,3579,57395299,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL3628942,GFKPWKCDJBRXQK-OHMHCFLMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,314.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.503070351926785,3580,122193876,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)C(C)(C(C)C)NCC3=NC4=CC=NN4C=C3,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(C(C)(NCc2ccn3nccc3n2)C(C)C)nn1
CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,49100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.308918507877031,3582,31307,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,CC12C=CC(=O)C=C1CCC1C3CC(O)C(O)(C(=O)CO)C3(C)CC(O)C12F
CHEMBL3291124,GFQOLQIWVXUSEO-HMQJICCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,216.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,6.665546248849069,3587,90644505,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)CO)C,C=CC1(C)CC(OC(=O)CSc2cncc(CO)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291124,GFQOLQIWVXUSEO-HMQJICCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,242.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,6.616184634019569,3587,90644505,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)CO)C,C=CC1(C)CC(OC(=O)CSc2cncc(CO)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL231334,GGAQZJOAVWSKSS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17084080.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,3591,44425701,CCCCC1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(CCN(CC3)C)C=C2,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1
CHEMBL2151935,GGNJJMKBSUZZTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,3598,66553214,CN1C(=O)C=C(N=C1CC(=O)NC2=CC(=C(C=C2)F)Cl)N3CCOCC3,Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O
CHEMBL114555,GGPFRXPJXXCZQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,3601,10154555,CCOC(=O)N1CCN(CC1)CCOC2=CC=C(C=C2)N3C=CN=C3,CCOC(=O)N1CCN(CCOc2ccc(-n3ccnc3)cc2)CC1
CHEMBL396433,GGRHVKPDRUOVCO-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3604,44433279,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCC(=O)O,CC(C)CC(NCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3104536,GHDKWWRARPMTNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,30200.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.519993057042849,3615,76310155,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
CHEMBL3104536,GHDKWWRARPMTNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.0,3615,76310155,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
CHEMBL1209693,GHGFTZSRECGLSO-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,3617,49862650,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)OC,COC(C)(C)CC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL1209693,GHGFTZSRECGLSO-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.275724130399211,3617,49862650,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C)(C)OC,COC(C)(C)CC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL1271601,GHHUJPFVTHAWJJ-LEWJYISDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,13.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.860120913598763,3618,11627465,CC(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCC(CC4)CO,CC(C)C1COCC(C2(OC(=O)N3CCC(CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1951431,GHICRWADWFXKES-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,3619,23634281,CC(=CCN1C2=C(C(=C1N3CCCC(C3)N)C#N)N=CN(C2=O)CC4=CC=NC5=CC=CC=C45)C,CC(C)=CCn1c(N2CCCC(N)C2)c(C#N)c2ncn(Cc3ccnc4ccccc34)c(=O)c21
CHEMBL271622,GHLQJCUCOQSQFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.481486060122112,3622,1480806,COC1=CC=C(C=C1)C2=NOC(=C2)CNS(=O)(=O)C3=CC=CC=C3,COc1ccc(-c2cc(CNS(=O)(=O)c3ccccc3)on2)cc1
CHEMBL229861,GHMFVPOVQMEIHB-CORIIIEPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17552509.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,3623,16732000,CCC1C2C(CCN2C(=O)N1C3=C(C(=C(C=C3)C#N)Cl)C)O,CCC1C2C(O)CCN2C(=O)N1c1ccc(C#N)c(Cl)c1C
CHEMBL1774932,GHMZDEVGWDRXIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,6.221848749616356,3625,46175091,CC(CNC(=O)N1CC2=C(C1)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=C(C=N4)F)N)(F)F,CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)c2C1
CHEMBL1171991,GHOBTHCFQZXIBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,1770.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,5.752026733638194,3626,46854759,CC(=C(C1=CC=C(C=C1)C2=CC(=C(C=C2)N)N)C3=CC=NC=C3)C,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(N)c(N)c2)cc1
CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.075720713938118,3634,9951066,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,3634,9951066,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,3634,9951066,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
CHEMBL497011,GHVIMBCFLRTFHI-UHFFFAOYSA-N,LINAPRAZAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,3634,9951066,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12
CHEMBL1079362,GHVKHDJQMCSVLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3635,46883473,CC1(CCCN(C1)C(=O)NC2=CC=NC=C2)C3=CC=CC=C3,CC1(c2ccccc2)CCCN(C(=O)Nc2ccncc2)C1
CHEMBL3353359,GHVNNCGXWGZXJH-DAGBDIRBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,5.0,3636,58486301,CN1CCN(CC1)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,CN1CCN(Cc2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)Nc5ccccc56)ccc34)cc2)CC1
CHEMBL559060,GHZHZIJXYOTTAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3642,45272889,C1CN(CCC1NCC2CCOCC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
CHEMBL1208801,GIBBMQIFJKTBNZ-WHUIICBVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,3644,49862652,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4CC4,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O
CHEMBL1208801,GIBBMQIFJKTBNZ-WHUIICBVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,3644,49862652,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4CC4,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O
CHEMBL1682895,GICBPQGKGLLFIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.468521082957745,3646,53319749,CCCNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(C3=CN=CN3)(C(C)C)O,CCCNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL558468,GIEBQTVDYXTBCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,3649,45272877,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,COc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1
CHEMBL245412,GIHNTRQPEMKFKO-SKTNYSRSSA-N,ZERUMBONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,21800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.661543506395395,3653,5470187,CC1=CCC(C=CC(=O)C(=CCC1)C)(C)C,CC1=CCC(C)(C)C=CC(=O)C(C)=CCC1
CHEMBL242711,GIJHDGJRTUSBJR-UHFFFAOYSA-N,BERGAPTOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17400460.0,IC50,=,24920.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit.,Bioorg. Med. Chem.,PUBLICATION,,4.603451962012868,3656,5280371,C1=CC(=O)OC2=CC3=C(C=CO3)C(=C21)O,O=c1ccc2c(O)c3ccoc3cc2o1
CHEMBL2338482,GIORSITYZQXFRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,6.443697499232713,3665,71525219,CC(=O)C1=CC(=CN=C1)OC2=C(C=C(C=C2Cl)NS(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)Cl,CC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
CHEMBL3702742,GIPAHZVDJUDHQA-NRMCGMLCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10890.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.962972120244225,3666,89718345,CC(C(=O)OC)NC(=O)C1=CN(C2=C(C=CC=C12)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC(C)C(=O)OC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL14563,GIUZEIJUFOPTMR-UHFFFAOYSA-N,SB-242084,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9357513.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,PUBLICATION,,4.0,3671,3644637,CC1=CC2=C(C=C1Cl)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
CHEMBL14563,GIUZEIJUFOPTMR-UHFFFAOYSA-N,SB-242084,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,4.0,3671,3644637,CC1=CC2=C(C=C1Cl)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
CHEMBL1649656,GIVZDASVXCBGBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.0,3672,24783140,C1CCN(C1)C(=O)C2=CC=C(C=C2)N3C4=C(COCC4)C(=N3)C(F)(F)F,O=C(c1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1)N1CCCC1
CHEMBL3422099,GJGMLBSXNZXSBX-NDIVSWGXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.886056647693163,3682,118735397,C1CC1CC(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(CC1CC1)c1ccccn1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL2178249,GJJWKAPPVNNWLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,6.698970004336019,3685,49857227,C1=CC(=CC(=C1)Cl)C2=C(C=CN=C2)NC(=O)C3=C4N=CC=CN4N=C3,O=C(Nc1ccncc1-c1cccc(Cl)c1)c1cnn2cccnc12
CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.7447274948966935,3692,9799604,CC(C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)C=CC3=CC=C(C=C3)F,CC(NC(=O)C=Cc1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.721246399047171,3692,9799604,CC(C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)C=CC3=CC=C(C=C3)F,CC(NC(=O)C=Cc1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.721246399047171,3692,9799604,CC(C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)C=CC3=CC=C(C=C3)F,CC(NC(=O)C=Cc1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
CHEMBL100379,GJTBBHPPJLHWKQ-ULYATVDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.6777807052660805,3692,9799604,CC(C1=CC(=C(C=C1)F)N2CCOCC2)NC(=O)C=CC3=CC=C(C=C3)F,CC(NC(=O)C=Cc1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1
CHEMBL3628943,GJWDUYBKAOXWIS-JKDDQTOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,263.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.580044251510242,3694,122193877,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)C(C)(C3CCCC3)NCC4=NC5=CC=NN5C=C4,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(C(C)(NCc2ccn3nccc3n2)C2CCCC2)nn1
CHEMBL3358927,GJXAQWRUPWTIBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.221848749616356,3695,69571559,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)N(C)C)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N(C)C)ncc2[nH]1)C(F)(F)F
CHEMBL2103830,GKDRMWXFWHEQQT-UHFFFAOYSA-N,FOSTAMATINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,3700,11671467,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC
CHEMBL1835784,GKEPUTPZCYQUOQ-PBPGXSGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3701,56679101,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4C3CCC4)C,CC1CCCN1CCCOc1ccc(C2=NN(C)C(=O)C3CCCC23)cc1
CHEMBL2431365,GKIDVBFFLSYPRO-RMKNXTFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,4.301029995663981,3704,67070065,CC(C)(C)C1=CC(=CC(=C1OC)C=CC2=CC=C(C=C2)NS(=O)(=O)C)C3=CC(=CNC3=O)F,COc1c(C=Cc2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C
CHEMBL2431365,GKIDVBFFLSYPRO-RMKNXTFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,4.301029995663981,3704,67070065,CC(C)(C)C1=CC(=CC(=C1OC)C=CC2=CC=C(C=C2)NS(=O)(=O)C)C3=CC(=CNC3=O)F,COc1c(C=Cc2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C
CHEMBL3673976,GKKXSXHWFUUCKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320655,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,3708,52933056,CN1C=C(C=C(C1=O)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl)F,Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O
CHEMBL3673976,GKKXSXHWFUUCKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320699,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,3708,52933056,CN1C=C(C=C(C1=O)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl)F,Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O
CHEMBL3673960,GKLDYZQMDUADGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320673,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,3709,52935599,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1
CHEMBL3673960,GKLDYZQMDUADGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320629,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,3709,52935599,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1
CHEMBL1738841,GKQIKYWYJQQLLD-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21441024.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,3716,10008365,CC1C(=O)N(C(=O)N1CC2=CC=NC3=CC=CC=C23)C4=CC=C(C=C4)S(=O)(=O)C(F)(F)F,CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12
CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.045757490560675,3717,5311217,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C
CHEMBL179589,GKRQVVOAAXTIGR-UHFFFAOYSA-N,"5-METHYL-[2,3']BIPYRIDINYL",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,84230.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.074533199308462,3718,15543761,CC1=CN=C(C=C1)C2=CN=CC=C2,Cc1ccc(-c2cccnc2)nc1
CHEMBL2419486,GKUTXOAQZPNFCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,4.698970004336019,3720,15983175,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CC(C2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)F)C,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)C2)nc1C
CHEMBL2334760,GKVOTXQBCIYYJV-INIZCTEOSA-N,6-AZA-THQ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,5.6020599913279625,3722,59239374,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CN(CC3)C4COC4)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CN(C2COC2)CC3)cc1
CHEMBL538357,GLCGPUDWOPXBAY-HLRBRJAUSA-M,CALIFORNIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,4.096910013008056,3727,45266443,C[N+]1(C2CC3=CC4=C(COC4)C=C3C1CC5=CC6=C(C=C25)OCO6)C.[Cl-],C[N+]1(C)C2Cc3cc4c(cc3C1Cc1cc3c(cc12)COC3)OCO4
CHEMBL3702709,GLDNZQYGNSOWKA-HWHSMDOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.823908740944319,3728,89718452,CC(=O)N1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(C)=O)CC6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1649675,GLEVYNXKNNNUSS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,<=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,6.0,3731,24827043,CC(=O)CC1=CC=C(C=C1)N2C3=C(CCCC3)C(=N2)C(F)(F)F,CC(=O)Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1
CHEMBL256072,GLISBSFAODYFPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,3734,136036546,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCC4=C(N(C=N4)C)Cl)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCc4ncn(C)c4Cl)cc[nH]c3=O)nc12
CHEMBL2347405,GLPNWSBFGKTKTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.721246399047171,3740,71279608,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NNC4=C3C=C(C=C4)OC(F)F,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3n[nH]c4ccc(OC(F)F)cc34)nc12
CHEMBL257517,GLSSNBLKKWINSD-JDXGNMNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,3743,11757696,CC1=C(N=C(O1)C2=CC=C(C=C2)OC)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,COc1ccc(-c2nc(CCOc3cccc(CC4C(=O)N(c5ccc(C(C)(C)C)cc5)C4C(=O)O)c3)c(C)o2)cc1
CHEMBL27415,GLTOTRUXBZKBKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,9440.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.025028005701931,3745,11212921,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)Cl,Cn1c2ccnc(Cl)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL397666,GLTRPHMPCVLOJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.096910013008056,3746,135530418,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC4=CC=CC=N4)N5C=CN=C5,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCc4ccccn4)cc[nH]c3=O)nc12
CHEMBL3263996,GLVLHQQZXXQWEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,3747,24753786,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=NC=C3)NS(=O)(=O)NC,CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1
CHEMBL3263996,GLVLHQQZXXQWEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,3747,24753786,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=NC=C3)NS(=O)(=O)NC,CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1
CHEMBL1761520,GLYFGYIXZOBFGF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,3751,24953519,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCN(C)C)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1
CHEMBL1761520,GLYFGYIXZOBFGF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,22700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6439741428068775,3751,24953519,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCN(C)C)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1
CHEMBL267690,GMAUZWFHZJGCSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,3756,44425809,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CC(=CN=C5)OC)N(C2=O)CC6=CC=CC=C6F,COc1cncc(-c2ccc(CN3CCC4(CC3)C(=O)N(c3cccc(OC)c3)C(=O)N4Cc3ccccc3F)cc2)c1
CHEMBL281496,GMAXIWRMMJVMOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,33690.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.47249898901888,3757,11295806,CN1C2=C(C3=C(C=CN=C31)C(=O)N)N=C(N=C2N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)CN6CCOCC6,Cn1c2nccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL324777,GMBQUUCZMIXCEQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177477.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome cytochrome P450 3A4,An aminomethylpyrimidine DPP-IV inhibitor with improved properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3759,10405951,CN(CCOC)C1=NC(=C(C(=N1)N)CN)C2=C(C=C(C=C2)Cl)Cl,COCCN(C)c1nc(N)c(CN)c(-c2ccc(Cl)cc2Cl)n1
CHEMBL251800,GMGMXDBCSMRQME-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,3762,44447022,C1CCN(C1)CC2=NC(=NO2)CC3(CC3)C4CCCC(N4S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,O=S(=O)(c1ccc(Cl)cc1)N1C(C2CC2)CCCC1C1(Cc2noc(CN3CCCC3)n2)CC1
CHEMBL2177737,GMIREKPIMOCOBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,3764,60203901,COC1=C(C=C(C=C1)NC2=C3C(=NC(=N2)C4=CC(=CC=C4)C(=O)NC5=CC=C(C=C5)C(=O)O)SC=N3)OC,COc1ccc(Nc2nc(-c3cccc(C(=O)Nc4ccc(C(=O)O)cc4)c3)nc3scnc23)cc1OC
CHEMBL471067,GMLDZDDTZKXJLU-JKSUJKDBSA-N,(-)-DEOXYPODORHIZONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,6.0,3767,442835,COC1=CC(=CC(=C1OC)OC)CC2C(COC2=O)CC3=CC4=C(C=C3)OCO4,COc1cc(CC2C(=O)OCC2Cc2ccc3c(c2)OCO3)cc(OC)c1OC
CHEMBL2017111,GMLLRQVRERMQBQ-CJAUYULYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,3769,70687502,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)C(=O)N)Br,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2(C(N)=O)c2ccc(F)c(F)c2)c1Br
CHEMBL1078354,GMTQAOXNCHJFPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3775,46882876,CC1(CCCN(C1)C(=O)NCCC2=CC3=C(C=C2)N=CN3)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nc[nH]c3c2)C1
CHEMBL179825,GMYMOUHNOWZKMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,3777,11633939,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)CC(=O)OC)N4C=CN=C4)N(C)C,COC(=O)Cc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
CHEMBL380866,GNLDZONRYOENMG-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.376750709602099,3783,23647911,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3C(CNCC3=O)COC4=CC5=C(CCCN5CCN6CCCC6=O)C=C4,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCN2CCCC2=O)CCC3)cc1
CHEMBL360148,GNOBXZHCXJWOKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,481.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.317854923626168,3785,44390206,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)N)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3cccc(C(N)=O)c3)ccc2c1)n1ccnc1)N(C)C
CHEMBL3393475,GNSDDKAAHUFOKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,6.0,3788,59825774,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=C(C=C6F)F,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cc(F)cc3[nH]2)o1
CHEMBL501315,GNURRCJPQXKFTN-HNRBIFIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,3793,16752689,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(CCC4=CC(=CC=C4)OC)C(=O)NC5CCCCC5,COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3CC(C)NC(C)C3)cc2)C(=O)NC2CCCCC2)c1
CHEMBL501315,GNURRCJPQXKFTN-HNRBIFIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,3793,16752689,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(CCC4=CC(=CC=C4)OC)C(=O)NC5CCCCC5,COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3CC(C)NC(C)C3)cc2)C(=O)NC2CCCCC2)c1
CHEMBL567904,GNYXHJVKEWBHAI-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,3796,44473086,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=CC=C5,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3cccnc3)ccc2o1
CHEMBL2436976,GNZKXRXWADXJOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,4.522878745280337,3797,46234349,COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CN=C(N=C4)N)N=C2,COc1cc(-c2cnc3[nH]cc(-c4cnc(N)nc4)c3c2)cc(OC)c1OC
CHEMBL498652,GOEOPYMHOCPWHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,8757.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.057644650292323,3802,25033730,C1CC2=C(C=CC(=C2)C3=CC=C(C=C3)F)C(C1)(C4=CC=NC=C4)O,OC1(c2ccncc2)CCCc2cc(-c3ccc(F)cc3)ccc21
CHEMBL3331503,GOHLFHFVKPDRNY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.958607314841775,3805,118713801,CC(C)N(CC1CNC1)CC2=CC(=C(C=C2)Cl)Cl.Cl,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1
CHEMBL1836215,GOJFPSNMWCYOTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838322.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using vivid green as substrate,Discovery of a Brain-Penetrant S1P(3)-Sparing Direct Agonist of the S1P(1) and S1P(5) Receptors Efficacious at Low Oral Dose.,J. Med. Chem.,PUBLICATION,,5.075720713938118,3806,53492750,CC1=C(C=CC2=C1CCN(C2)C(CO)CO)C3=NOC(=N3)C4=CC(=C(C=C4)OC(C)C)C#N,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2
CHEMBL1836215,GOJFPSNMWCYOTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838322.0,IC50,=,15300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using vivid red as substrate,Discovery of a Brain-Penetrant S1P(3)-Sparing Direct Agonist of the S1P(1) and S1P(5) Receptors Efficacious at Low Oral Dose.,J. Med. Chem.,PUBLICATION,,4.815308569182402,3806,53492750,CC1=C(C=CC2=C1CCN(C2)C(CO)CO)C3=NOC(=N3)C4=CC(=C(C=C4)OC(C)C)C#N,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2
CHEMBL2023123,GOOZHZPTJHCQEV-VGCGRUFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.1487416512809245,3807,59201574,CNCC(C(C1CCCCC1)O)NC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC,CNCC(NC(=O)N1CCCC(C(OCCNC(=O)OC)c2cccc(Cl)c2)C1)C(O)C1CCCCC1
CHEMBL3581121,GOPDRFODUBCWMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,750.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,6.1249387366083,3808,4803142,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC=NC=C3,COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1
CHEMBL218573,GOSZMIDOMHVHDD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,5.080921907623926,3811,10185917,CC(C)CN1C2=C(C(=C(S2)CC3=CC=CC=C3C(F)(F)F)C(=O)N4CC(CO4)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC(O)CO3)c(Cc3ccccc3C(F)(F)F)sc21
CHEMBL402319,GOZLZTGPYFRJDJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,3817,11584329,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL475684,GPBATYISDDVOGP-KQWNVCNZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,5.102372908709558,3821,44520861,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(C(=CC(=O)NCC4=NN=CC=C4)C5=CC=CC=C53)(F)F)Cl,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)C(=CC(=O)NCc4cccnn4)c4ccccc43)c(Cl)c2)n1
CHEMBL2391518,GPOINCDNNRDNCO-SFQUDFHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23324405.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3837,11509269,C1CC2=CC=CC=C2N(C1)C(=O)C(=CC3=CN(C4=CC=CC=C43)CC(=O)O)C#N,N#CC(=Cc1cn(CC(=O)O)c2ccccc12)C(=O)N1CCCc2ccccc21
CHEMBL1276947,GPWMNUXSJDSCAV-NZICPMOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,3843,49836528,C1CC2(CC1N3CC4CC4(C3)C(=O)O)CC5=CC=CC=C5CC6=CC=CC=C26,O=C(O)C12CC1CN(C1CCC3(Cc4ccccc4Cc4ccccc43)C1)C2
CHEMBL511410,GPXKVULNYYNGDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,5.0,3845,25207521,C1=CC(=CC(=C1)O)C(C(=O)N)NC2=C(C(=O)C2=O)NC3=CC=NC=C3,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1cccc(O)c1
CHEMBL371409,GQCGJUPPZILNPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,3847,11669364,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC(=O)N)CCO)C3=C(C=CC(=C3)Cl)O,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
CHEMBL371409,GQCGJUPPZILNPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3847,11669364,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC(=O)N)CCO)C3=C(C=CC(=C3)Cl)O,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21
CHEMBL3353881,GQCPYMUOLFAADB-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556092.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3848,67953330,CC(C)(C)C1=NOC(=C1)NC(=O)C2CCC(=O)N2C3=CC=C(C=C3)C(F)(F)F,CC(C)(C)c1cc(NC(=O)C2CCC(=O)N2c2ccc(C(F)(F)F)cc2)on1
CHEMBL2441844,GQGRTDFKONOVAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,3852,57641205,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)O)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)O)C2
CHEMBL2170636,GQLSQBMTTDVNKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,3854,58269625,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CN=CC=C3,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3cccnc3)CC2)c(C(F)(F)F)c1
CHEMBL1171008,GQLXQNMFKWOOSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,3856,16124598,C1=CC=C(C(=C1)C(=O)O)OC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,O=C(O)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
CHEMBL552196,GQPZWGHDZGLONB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,3858,45269948,CC1=C(ONC1=O)C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,Cc1c(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)o[nH]c1=O
CHEMBL1076192,GQQOBKGSKQCRQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,3860,46879432,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2C=C(N3C)C,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C
CHEMBL1076192,GQQOBKGSKQCRQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,3860,46879432,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2C=C(N3C)C,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C
CHEMBL1951327,GQSDFZXXEZBDPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,3863,57398846,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL509347,GQUNRVHHNJVPMJ-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,3868,44587404,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCCOCC(=O)O)F,CNC(Cn1c(=O)c(-c2cccc(OCCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL1778506,GQXDJHYRFLVFCI-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3870,54583706,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)C(=O)CC4=CC=C(C=C4)F,CN(C(=O)Cc1ccc(F)cc1)C1CCc2c(CC(=O)O)c3ccccc3n2C1
CHEMBL3116154,GQXQRBDIIIITDT-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,3871,16745241,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5F)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc3c(F)cc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
CHEMBL3116154,GQXQRBDIIIITDT-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,3871,16745241,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=C(N4)C=C(C=C5F)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc3c(F)cc(F)cc3[nH]2)c2ccc(Cl)cn2)c1
CHEMBL528996,GRCPGLCEGKJUFI-ULJHMMPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,4.958607314841775,3873,9959174,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(C(=CC(=O)NCC4=CC=CC=N4)C5=CC=CC=C53)(F)F)Cl,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)C(=CC(=O)NCc4ccccn4)c4ccccc43)c(Cl)c2)n1
CHEMBL237847,GRFNBEZIAWKNCO-UHFFFAOYSA-N,SR-1C8,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,767361.49,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.1149999996388162,3875,7971,C1=CC(=CN=C1)O,Oc1cccnc1
CHEMBL3112778,GRGMVSNJGMXWAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24486134.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) compound preincubated with substrate,Substituted piperidines as HDM2 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,3878,76321301,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
CHEMBL3112778,GRGMVSNJGMXWAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24486134.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) compound co-incubated with substrate,Substituted piperidines as HDM2 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,3878,76321301,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
CHEMBL3288447,GRGMVSNJGMXWAY-YNMZEGNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,6.522878745280337,3879,90681222,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
CHEMBL3288447,GRGMVSNJGMXWAY-YNMZEGNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,5.309803919971486,3879,90681222,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1
CHEMBL1951320,GRHDAFPDCKOVQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165727,3880,57400522,C1=CC(=CC=C1C2=C3C(=NC=C2)N=CN3)NC(=O)NC4=CC=C(C=C4)Cl,O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL364914,GRKSCYLPVRPFEA-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,380.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.42021640338319,3884,44400245,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4S(=O)(=O)C)F,COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL2178247,GRKVHVFMHBOEFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,3885,58063487,CC1=NN(C(=C1)NC(=O)C2=C3N=C(C=CN3N=C2)NC)C4=CC(=CC=C4)Cl,CNc1ccn2ncc(C(=O)Nc3cc(C)nn3-c3cccc(Cl)c3)c2n1
CHEMBL539650,GRQYMCJQVKMJAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,8.853871964321762,3888,16223655,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=NC=CS5)CC(C)(C)C(=O)O,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3nccs3)cc2)c2ccc(OCc3ccccn3)cc12
CHEMBL1077940,GSCQTFZOCSWXSI-SVBPBHIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458132,3897,46883346,C1=CC=C(C=C1)CC(CN(CC2=CN=CN2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,O=C(NC(Cc1ccccc1)CN(Cc1cnc[nH]1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL521982,GSGDLBUOSWGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,4.522878745280337,3900,10338547,C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NC4=NC(=CO4)C(F)(F)F,O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21
CHEMBL521982,GSGDLBUOSWGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27013388.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Re-exploration of the mGlu1 PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,3900,10338547,C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NC4=NC(=CO4)C(F)(F)F,O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21
CHEMBL497418,GSIKNNVDKLEWNH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,3904,24888658,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3)N4C=CC=CC4=O)C,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C
CHEMBL497418,GSIKNNVDKLEWNH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,3904,24888658,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3)N4C=CC=CC4=O)C,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C
CHEMBL1078207,GSIRAOVJCFHRIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,3905,46882521,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=CC=C4)CC5=CC=NN5,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(-c2ccccc2)cc1
CHEMBL1078207,GSIRAOVJCFHRIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,3905,46882521,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=CC=C4)CC5=CC=NN5,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(-c2ccccc2)cc1
CHEMBL2415098,GSJRIJNVASEMGE-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,3906,67607112,CC1=CN(C=N1)C2=C(C=C(C=C2)C3=NN4CCOC(C4=N3)C5=CC=CC=C5C(F)(F)F)OC,COc1cc(-c2nc3n(n2)CCOC3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
CHEMBL2043170,GSKYNYTYBPKISP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,3908,57386784,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=CC=C6C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4ccccc4C(=O)O)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL3114792,GTCKEOBLPDFXJN-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3928,11363702,CCCS(=O)(=O)N1CCC(CC1)(C2=CC=CC=C2)C(C)NC(=O)C3=C(C=C(C=C3)Cl)Cl,CCCS(=O)(=O)N1CCC(c2ccccc2)(C(C)NC(=O)c2ccc(Cl)cc2Cl)CC1
CHEMBL2070163,GTLZLQHDDDIYEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,3935,70684605,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CN(C3=O)C4=CC=CC=C4.Cl,CCCS(=O)(=O)c1ccc2nc(-c3cccn(-c4ccccc4)c3=O)[nH]c2c1
CHEMBL3702752,GTMVVLWZHLESSJ-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.297569463554475,3936,89718277,CN1CCN(CC1)C(=O)CN(C)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC(=O)N5CCN(C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702677,GTOJANLBFNSIOW-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9480.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.023191662661934,3938,89716369,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=CC=C(C=C8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3672581,GTQUHFLNJSGNRA-UWEBUPBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,7.0,3940,57406385,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC(=O)C,CC(=O)NC1CC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
CHEMBL3672581,GTQUHFLNJSGNRA-UWEBUPBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,370.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.431798275933005,3940,57406385,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC(=O)C,CC(=O)NC1CC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
CHEMBL2158301,GTTVVDKDTQATHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,3941,11699804,CC(C)(C(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4)N,CC(C)(N)C(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
CHEMBL2059878,GTTXVOAFXQHQKC-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,3942,24863323,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=NNN=C4C=C3)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2n[nH]nc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2448695,GTWXTKFMPIUMBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.721246399047171,3947,73351196,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC(=C(C=C2)NC(=O)CN(C)C3CCN(CC3)C)Cl.Cl,CCN(c1ccccc1)S(=O)(=O)c1ccc(NC(=O)CN(C)C2CCN(C)CC2)c(Cl)c1
CHEMBL230761,GTXFFNURYUQKEA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,4.823908740944319,3949,17758574,CN1C=C(N=C1)CNC2=CC3=C(C(=CN=C3C(=C2)Br)C#N)NC4=CC(=C(C=C4)F)Cl,Cn1cnc(CNc2cc(Br)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)c1
CHEMBL565843,GTZBFNQZVAGCGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,3951,45487864,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
CHEMBL565843,GTZBFNQZVAGCGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3951,45487864,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
CHEMBL1908842,GUBJNPWVIUFSTR-UHFFFAOYSA-N,JNJ-28312141,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.318758762624412,3953,11676971,CN(C)CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
CHEMBL1257850,GUBYCKMGWYDLAE-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3956,16679616,CC1CN2C3=C(C=C(C=C3)OC4CCN(CC4)C(C)C)C=C2C(=O)N1,CC1Cn2c(cc3cc(OC4CCN(C(C)C)CC4)ccc32)C(=O)N1
CHEMBL1257729,GUBYCKMGWYDLAE-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3957,16679617,CC1CN2C3=C(C=C(C=C3)OC4CCN(CC4)C(C)C)C=C2C(=O)N1,CC1Cn2c(cc3cc(OC4CCN(C(C)C)CC4)ccc32)C(=O)N1
CHEMBL1209555,GUDPVWCEUPKJOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,3958,49862549,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)OC(F)(F)F,CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O
CHEMBL1209555,GUDPVWCEUPKJOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,3958,49862549,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)OC(F)(F)F,CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O
CHEMBL3634013,GUDQJFKBBOAOIC-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26522950.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,3959,70817382,CC(C1=CC=C(C=C1)OC)NC(=O)COC2=NC3=C(C(=C2)C(F)(F)F)C(=NN3C)C4=CC=CC=C4,COc1ccc(C(C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1
CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,6.494850021680094,3965,5405,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL2448714,GUGQLGOBTCENLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,250.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.6020599913279625,3966,73346618,CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=NC4=CC=CC=C4S3,CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
CHEMBL1091782,GUNAZEDORZMWRN-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3974,46884201,CC(C1=CSC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cscn1)c1c(CCN(C)C)sc2ccccc12
CHEMBL3394734,GUOKRDAMSCOAIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3976,71728054,C1=CC(=NC=C1S(=O)(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
CHEMBL3394734,GUOKRDAMSCOAIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,3976,71728054,C1=CC(=NC=C1S(=O)(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
CHEMBL1834657,GUQNHCGYHLSITB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,3981,56669626,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
CHEMBL1834657,GUQNHCGYHLSITB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,3981,56669626,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
CHEMBL3627896,GUQYDHZACNNLCK-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,3982,122192990,CC1=CC(=CC2=C1N=C(N2)C(CNC(=O)C3=C(C=C(C=C3Cl)N4C=NC(=N4)C)Cl)C5=CC(=CC=C5)F)Cl,Cc1ncn(-c2cc(Cl)c(C(=O)NCC(c3cccc(F)c3)c3nc4c(C)cc(Cl)cc4[nH]3)c(Cl)c2)n1
CHEMBL1093937,GURZVIGBGHQFAY-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20206513.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,3984,46883849,CC1=CC(=C(C(=C1)Cl)OCCCC2=CC=C(C=C2)CC(CN)C(=O)N(CC3=CC(=CC(=C3)CCCOC)OCCOC)C4CC4)Cl,COCCCc1cc(CN(C(=O)C(CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1
CHEMBL2059124,GUUNMYDKORYEGX-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,3986,59603317,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NCCN(C)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCN(C)C)oc2c1
CHEMBL2203434,GVFQHBBRWBJGNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,3994,54761157,CCN1CCC(CC1)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C,CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1
CHEMBL2070948,GVFZKOCFOOBUQV-IAGOWNOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,3995,70697225,CC(C)(C#N)C1=CN=C(S1)N2CCN(CC2)C(=O)C3CCCCC3C(=O)NC4(CC4)C#N,CC(C)(C#N)c1cnc(N2CCN(C(=O)C3CCCCC3C(=O)NC3(C#N)CC3)CC2)s1
CHEMBL3310484,GVIKXRIOBFGDFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1487416512809245,3996,118706538,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl
CHEMBL207486,GVLPJHAOLSTQRA-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,3998,44410871,CC(C)N(C)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,CC(C)N(C)C(C)C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
CHEMBL2338480,GVPOBQMDDUCYKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,9.0,4001,71525170,CC1=CC(=CN=C1)OC2=C(C=C(C=C2Cl)NS(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)Cl,Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
CHEMBL1761673,GVPWTNYUPQDJAS-QYSAAILDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4002,54584273,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5CC5C(=O)NS(=O)(=O)C)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2CC2C(=O)NS(C)(=O)=O)c1
CHEMBL1761673,GVPWTNYUPQDJAS-QYSAAILDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4002,54584273,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5CC5C(=O)NS(=O)(=O)C)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2CC2C(=O)NS(C)(=O)=O)c1
CHEMBL1774926,GVSHPPIHCUEEAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,5.721246399047171,4005,53236589,C1C2=C(CN1C(=O)NCC(F)(F)F)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=CC=N4)N,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NCC(F)(F)F)C2
CHEMBL3310486,GVURCJXFYIMVMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,4007,118706540,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
CHEMBL1209628,GVZKXJCNQYYFST-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,4010,49862604,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4(COC4)C,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O
CHEMBL1209628,GVZKXJCNQYYFST-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,4010,49862604,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC4(COC4)C,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O
CHEMBL605162,GWEYXGKHUJIVFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20064717.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirocyclic ureas: orally bioavailable 11beta-HSD1 inhibitors identified by computer-aided drug design.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,4016,46216689,C1CN(CCC12CC(C3=C2C(=CC=C3)Br)CC(=O)O)C(=O)NC4C5CC6CC(C5)CC4C6,O=C(O)CC1CC2(CCN(C(=O)NC3C4CC5CC(C4)CC3C5)CC2)c2c(Br)cccc21
CHEMBL2338484,GWGJULRGKVMITG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,6.221848749616356,4018,12112546,C1=CC(=C(C=C1NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C#N)OC3=CC(=CN=C3)Cl,N#Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1
CHEMBL1649684,GWGLGISJEZMMGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.0,4019,24951943,C1CC(=O)N(C1)CC2=CC=C(C=C2)N3C4=C(CCOC4)C(=N3)C(F)(F)F,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1
CHEMBL3702699,GWPBPJXIAURZGV-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.950781977329818,4026,89718333,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)S(=O)(=O)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(C)(=O)=O)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1209685,GWRUOXQHIKZCTE-ZRCAFCQKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,4035,49862647,CC(C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCCC3)NC(=O)C4C(CCN4)O,CC(NC(=O)C1NCCC1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1
CHEMBL1209685,GWRUOXQHIKZCTE-ZRCAFCQKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,4035,49862647,CC(C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCCC3)NC(=O)C4C(CCN4)O,CC(NC(=O)C1NCCC1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1
CHEMBL453067,GWRZMVNMDPUMHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,4036,44561238,CN(C(CN1CCCC1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N)C(=O)CN(CCOC)C4=CC(=C(C=C4)Cl)Cl,COCCN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccc(C(N)=O)cc2)cc1)c1ccc(Cl)c(Cl)c1
CHEMBL3121096,GWVIOFUJTJGECV-MSOLQXFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24513042.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): Histamine H3 receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4037,76321713,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)C5C4C5,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C2CC12
CHEMBL3121095,GWVIOFUJTJGECV-ZWKOTPCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24513042.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): Histamine H3 receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4038,76328873,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)C5C4C5,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C2CC12
CHEMBL3318482,GWYLMRVMCFHIIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,4039,118708939,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2C#N)C3=C(C=CC=C3Br)Cl,N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Br)CC1=O
CHEMBL3105228,GXBAKXRLQAPKEE-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24164599.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,"Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).",J. Med. Chem.,PUBLICATION,,4.795880017344075,4040,71598521,C1CN(C2(N1C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)C5=CC(=C(C=C5)F)F,O=C(c1ccc(F)c(F)c1)N1CCN2C(=O)c3ccccc3C12c1ccc(Cl)cc1
CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,5.481486060122113,4041,2247,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.97469413473523,4041,2247,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
CHEMBL284676,GXENRQLSQOSEPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,4042,11419244,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)OC,COc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
CHEMBL3422073,GXKIHPXGVQZMIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.823908740944319,4045,86711045,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)OC6CCN(CC6)C=O,O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccn5)C5CC5)cc34)cc2)CC1
CHEMBL2011266,GXKRHWPFLHJAKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148957.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 co-incubated with substrate,Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4047,56593147,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)NS(=O)(=O)C4CC4)CC5=C(C=CC(=C5)F)F,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F
CHEMBL2011266,GXKRHWPFLHJAKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148957.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated prior to substrate addition,Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4047,56593147,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)NS(=O)(=O)C4CC4)CC5=C(C=CC(=C5)F)F,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F
CHEMBL3112857,GXZTVBBVCJUSKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,4052,57389707,C1CN(C2=CC=CC(=C21)C3=CN=CC=C3)C(=O)CC4=NC(=O)C=C(N4)N5CCOCC5,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(-c3cccnc3)cccc21
CHEMBL3604713,GYCQQTSTDOHQQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,4.900000142057633,4055,122185954,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=CC=CC=C3C(F)(F)F,Cc1cc(NCc2ccccc2C(F)(F)F)c2cccc(C(N)=O)c2n1
CHEMBL1095818,GYCWXDHHROKGSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,4056,46888856,CC1=CSC(=N1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCOCC5,Cc1csc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)n1
CHEMBL3422015,GYGRAOHPQAELJF-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,43000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.366531544420414,4059,90417914,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=COC(=N5)C(C)C,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)co1
CHEMBL577316,GYHNFQYONGGRTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,2840.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.546681659952962,4060,45487553,COC1=C(C=C2CN(CCC2=C1)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC8=C7N=CC=C8)OC,COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc6cccnc56)cc1)(C4)C3)CC2
CHEMBL404289,GYNUNSOVAWLPHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,4066,44448913,C1CC(C(N(C1)C(=O)CN2C3=C(C=CC(=C3)Cl)OC2=O)CN4CCOCC4)C5=CC=CC=C5,O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
CHEMBL1823591,GYNUQDKANQWZSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21803580.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,4067,44629236,C1CN(CCN1C2=NC(=NO2)C3=NC4=CC=CC=C4C=C3)C(=O)NC5=CC=CC=C5Cl,O=C(Nc1ccccc1Cl)N1CCN(c2nc(-c3ccc4ccccc4n3)no2)CC1
CHEMBL2062808,GYQHHRDRGBGZKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22594690.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779.",J. Med. Chem.,PUBLICATION,,6.698970004336019,4069,57502386,CS(=O)(=O)C1=CC=C(C=C1)C2=CC=CN3C2=NC(=N3)NC4=CC(=CC=C4)N5CCC(CC5)N6CCOCC6,CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1
CHEMBL3262163,GYVJDAOHVCIKJN-XFULWGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24814197.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,4.0,4071,90643570,COC1=CC=C(C=C1)NC(=O)N2CCNCC2COC3=CN=CC=C3.Cl,COc1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1
CHEMBL577103,GYVVGEZWBYIVER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,3790.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.421360790031928,4072,45487547,COC1=C(C=C2CN(CCC2=C1)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC=C7C(=O)OC)OC,COC(=O)c1ccccc1NC(=O)COc1ccc(C23CC4CC(CC(C(=O)N5CCc6cc(OC)c(OC)cc6C5)(C4)C2)C3)cc1
CHEMBL1077938,GYWHTWFXMMRVDZ-KYJUHHDHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458132,4073,46883344,C1=CC=C(C=C1)CC(CN(CC2=CN=CC=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,O=C(NC(Cc1ccccc1)CN(Cc1cccnc1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL2348853,GYZYQCKKUYZJRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,4076,71279444,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)Cl)C,Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2ccc(Cl)cc21
CHEMBL3702811,GZAPAWDCWTYELQ-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4870.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.3124710387853655,4077,89718265,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CC(C8)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(O)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL566875,GZLYPLRRKZCYLV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,41000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3872161432802645,4082,25064730,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL566875,GZLYPLRRKZCYLV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4082,25064730,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL2041175,GZOBVYAVRWIDTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,4086,57384480,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CC7=C(C=C6)SC=N7,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc4scnc4c3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2704.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.567993312730402,4087,132971,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12
CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19211174.0,IC50,=,2704.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.",Eur. J. Med. Chem.,PUBLICATION,,5.567993312730402,4087,132971,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12
CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,5.568636235841013,4087,132971,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12
CHEMBL254328,GZOSMCIZMLWJML-VJLLXTKPSA-N,ABIRATERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.568636235841013,4087,132971,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12
CHEMBL2407955,GZXVWGBFYAAUGQ-CCFHIKDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4092,136166841,CC1=CC=CC=C1C(CC(=NO)C2=CC(=NC=C2)C)C3=CC=C(C=C3)C4=CC(=CC=C4)C(=O)O,Cc1cc(C(CC(c2ccc(-c3cccc(C(=O)O)c3)cc2)c2ccccc2C)=NO)ccn1
CHEMBL3291422,HAXIOICGNCICAB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,4106,90467013,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCC(F)F)N=C1,COc1ncnc(Cn2cc(C(=O)NCC(F)F)c3ncc(C)cc32)c1C
CHEMBL237147,HAYIRZKTTMIXAL-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.318758762624412,4108,44433267,CC(C)CC(C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCO,CC(C)CC(NCCO)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL1921983,HAYOATKZZXIZAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,4109,21879624,C1CC1NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C4(CCN5C4=CN=C5)O,O=C(NC1CC1)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL9861,HBDKFZNDMVLSHM-UHFFFAOYSA-N,TIMOPRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,309029.54,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.5100000045692954,4111,72171,C1=CC=C2C(=C1)NC(=N2)S(=O)CC3=CC=CC=N3,[O-][S+](Cc1ccccn1)c1nc2ccccc2[nH]1
CHEMBL1945843,HBDLBTSITBUDIR-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22107017.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H3 receptor antagonists with potent cognition enhancing activity.",J. Med. Chem.,PUBLICATION,,4.522878745280337,4112,24996322,CC1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)C4=CC=CC=N4,CC1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1
CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,6.886056647693163,4117,60663,CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C
CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22409598.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks.,J. Med. Chem.,PUBLICATION,,6.522878745280337,4117,60663,CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C
CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,6.327902142064283,4117,60663,CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C
CHEMBL45816,HBNPJJILLOYFJU-VMPREFPWSA-N,MIBEFRADIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,140000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.853871964321762,4117,60663,CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C
CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,5.107905397309519,4118,44593666,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,4.585026652029182,4118,44593666,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes assessed as metabolism of testosterone,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,4118,44593666,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.173925197299173,4118,44593666,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL450668,HBOINTMVWRSZQS-SSEXGKCCSA-N,BMS-694153,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,4118,44593666,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL2059853,HBRMZOPADQKLOP-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4123,24863332,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL179477,HBSOMQPAIFVKGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,77540.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.110474203328809,4124,4730695,C1=CC(=CN=C1)N2C=CN=C2,c1cncc(-n2ccnc2)c1
CHEMBL179477,HBSOMQPAIFVKGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,109000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.962573502059376,4124,4730695,C1=CC(=CN=C1)N2C=CN=C2,c1cncc(-n2ccnc2)c1
CHEMBL1099326,HCBQJHASLYAXLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,5.1249387366083,4135,25174150,C1=CC(=C(C(=C1)OCCCC(=O)O)CCC(=O)O)CCCCCCOC2=CC(=CC(=C2)C3=CC=NC=C3)C4=CC=NC=C4,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccncc3)cc(-c3ccncc3)c2)c1CCC(=O)O
CHEMBL2407897,HCLJFCCORISDCX-NLUXTTPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829549.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents.,J. Med. Chem.,PUBLICATION,,5.0,4142,58189807,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C=C4C5=CC=CC=C5NC4=O,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C=C4C(=O)Nc5ccccc54)ccc23)cc1
CHEMBL2407897,HCLJFCCORISDCX-NLUXTTPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,940.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.026872146400302,4142,58189807,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C=C4C5=CC=CC=C5NC4=O,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C=C4C(=O)Nc5ccccc54)ccc23)cc1
CHEMBL1835918,HCOIQQJHIUTQMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4145,54752774,CC1=NN=C(C=C1)N2CC(C2)COC3=CC=C(C=C3)C4=NOC(=N4)C,Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1
CHEMBL1835918,HCOIQQJHIUTQMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.300000029139089,4145,54752774,CC1=NN=C(C=C1)N2CC(C2)COC3=CC=C(C=C3)C4=NOC(=N4)C,Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1
CHEMBL3341815,HCVDCGIODJNTBK-XXBGQOOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25148100.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,J. Med. Chem.,PUBLICATION,,5.0,4150,118716059,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C#CC#CC3=CC=C(C=C3)C4=CN=C(N4)C5CCCN5C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC.Cl,COC(=O)NC(C(=O)N1CCCC1c1ncc(C#CC#Cc2ccc(-c3cnc(C4CCCN4C(=O)C(NC(=O)OC)C(C)C)[nH]3)cc2)[nH]1)C(C)C
CHEMBL1951323,HDAZCZMFLGRFRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1487416512809245,4157,57391850,C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(F)c1
CHEMBL2425155,HDCHOQUOIZCTAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4158,72189810,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=NN=CN4C,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1
CHEMBL2064340,HDOZVDVCQITIFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,4169,49853927,CCN1C2=CC=CC=C2N=C1CC3=NC(=O)C=C(N3)N4CCOCC4,CCn1c(Cc2nc(=O)cc(N3CCOCC3)[nH]2)nc2ccccc21
CHEMBL3125381,HDZUKCNSPUYSLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4177,57411715,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O)C=CC(=C2)F,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O
CHEMBL2069800,HEACMNRMWPGIPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4178,70695067,C1CC1N2C(=NN=C2SCC3=NN=C(O3)C4=CC(=NC=C4)Cl)C5=CC=NC=C5,Clc1cc(-c2nnc(CSc3nnc(-c4ccncc4)n3C3CC3)o2)ccn1
CHEMBL496102,HEAIZQNMNCHNFD-UHFFFAOYSA-N,AMG-208,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3872161432802645,4179,24864821,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL496102,HEAIZQNMNCHNFD-UHFFFAOYSA-N,AMG-208,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,4179,24864821,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL519300,HEBKCUAEAWNUQL-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.9,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,4180,135960717,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N(C)C,Cc1cc(N2CCC(N(C)C)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1784356,HECFJRXDSZZJLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4181,54581030,CN1CCC(CC1)(CS(=O)(=O)N2CCN(CC2)C3=CC=C(C=C3)F)N(C=O)O,CN1CCC(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)(N(O)C=O)CC1
CHEMBL2387604,HEDJFFINYDHRNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,4182,71659615,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=CO5)Cl,O=c1[nH]c2cc(-c3ccco3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL372416,HEFYJBZEIVFECQ-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,455.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.341988603342887,4184,23586140,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3C(CNCC3=O)COC4=CC5=C(CCCN5CCCO)C=C4,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCCO)CCC3)cc1
CHEMBL1241547,HEHHNIMMUJHLIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,<,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.3979400086720375,4186,46900451,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=C(N=C6CO5)C,Cc1cn2c(n1)COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL205457,HEILLZBUQBOKMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,4187,11541073,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)NC(=O)C4(CCCCC4)C5=CC=C(C=C5)Cl,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccc(Cl)cc4)CCCCC3)CC2)c1
CHEMBL1796063,HELJPBHTIIYJPZ-RPWUZVMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21621998.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,4190,44462719,CC1=C(C=C(C=C1Br)CN(C2CC2)C(=O)C3CNCCC3C4=CC(=O)N(C=C4)C)CCCOC,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C
CHEMBL1796063,HELJPBHTIIYJPZ-RPWUZVMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21621998.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone preincubated for 30 mins,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,4190,44462719,CC1=C(C=C(C=C1Br)CN(C2CC2)C(=O)C3CNCCC3C4=CC(=O)N(C=C4)C)CCCOC,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C
CHEMBL1796063,HELJPBHTIIYJPZ-RPWUZVMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21621998.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,4190,44462719,CC1=C(C=C(C=C1Br)CN(C2CC2)C(=O)C3CNCCC3C4=CC(=O)N(C=C4)C)CCCOC,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C
CHEMBL1951345,HENQQNHTKQZKIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,4192,57397069,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C=CN(C4=NC=N3)C,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4c3ccn4C)cc2)c1
CHEMBL2425145,HEQHRPBZBOEOFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4194,72189207,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=C(N=C4)C,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1
CHEMBL3627897,HERLNGSHQVSJKT-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4195,121399281,CC1=NC2=C(N1)C=C(C=C2)C(CNC(=O)C3=C(C=C(C=C3Cl)N4C=NC(=N4)C)Cl)C5=CC(=CC=C5)F,Cc1ncn(-c2cc(Cl)c(C(=O)NCC(c3cccc(F)c3)c3ccc4nc(C)[nH]c4c3)c(Cl)c2)n1
CHEMBL2171398,HEVPKOFLFHIHOI-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ��-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,7.823908740944319,4199,71455231,CC1=CC=CC=C1C(CC(=O)O)NC(=O)C2=NN(C(=C2)OCC3CC3)C4=CC=CC=C4F,Cc1ccccc1C(CC(=O)O)NC(=O)c1cc(OCC2CC2)n(-c2ccccc2F)n1
CHEMBL2441832,HEZZWSOOCHPSTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,6.045757490560675,4201,15950458,CC1=C(C(=C2C(=N1)CN(C2=O)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccccc1)C2
CHEMBL252210,HFBWMSOJXRBXJD-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,4205,11504172,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCC5(CCN5)CC4,CCC1CCCC(C2(CC(=O)N3CCC4(CCN4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3234579,HFCRZUQHFUTZFW-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.107905397309519,4208,90654568,CCN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC3C(=O)NCCC4=CN=C(C=C4)C#N,CCN1CCN(c2cc(N3CCC3C(=O)NCCc3ccc(C#N)nc3)nc(C(F)(F)F)n2)CC1
CHEMBL3137443,HFDMMKOMGWVDMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4400.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.356547323513812,4210,76318572,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C(=O)C4=CC=C(C=C4)F,O=C(c1ccc(F)cc1)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2397311,HFFDHCIWKMSYST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,4212,71682210,CC1=C(SC(=N1)NC(=O)C2(CCCCC2)C)C3=CN=C(C=C3)N,Cc1nc(NC(=O)C2(C)CCCCC2)sc1-c1ccc(N)nc1
CHEMBL1683000,HFJIPLBZCAJCMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4217,53320163,CC1=CC=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
CHEMBL1683000,HFJIPLBZCAJCMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4217,53320163,CC1=CC=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
CHEMBL402520,HFKOPAUXFQJXCN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.136677139879544,4221,44449107,C1CC(C(N(C1)C(=O)CN2C(=O)COC3=CC(=C(C=C32)Cl)Cl)CN4CCOCC4)C5=CC=CC=C5,O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1
CHEMBL1091791,HFLPUFFCCFMOMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4222,11702578,CC1=CC(=NC=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1ccnc(C(C)c2c(CCN(C)C)sc3ccccc23)c1
CHEMBL2441346,HFOKVVVCWLIUBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,20500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,4.688246138944246,4223,53469061,CC1=CC(=NN1CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C)C,Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
CHEMBL2441346,HFOKVVVCWLIUBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,4.6020599913279625,4223,53469061,CC1=CC(=NN1CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C)C,Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
CHEMBL2057789,HFPGPGDSWIYRPR-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,97.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.013228265733755,4225,70688461,CCNC1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)(C)O,CCNc1nc2ccc(C(=O)N(CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1
CHEMBL1290746,HFTDLOVSQHYBFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21035336.0,IC50,>,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-amino-pyrazoles as potent and selective p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,4227,49838879,CC1=C(C=C(C=C1)C(=O)NC2=NOC=C2)NC(=O)C3=C(N(N=C3)C4=CC=CC=C4F)N,Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N
CHEMBL1222650,HFUSFQGTWBGKDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,4229,49864902,CC(C)CN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL3702799,HGEWYKGKUXXAQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.377785977033705,4237,89718382,CC(C)(C)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL500157,HGHDKUIVPHCCKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,4239,25196404,C1=CC(=CC=C1CC(=O)NC(=O)NC2=CC(=C(C=C2)OC3=C(C(=NC=C3)N)C#CCO)F)F,Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#CCO
CHEMBL1951599,HGHVKBWSAOTJGC-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,4240,57391804,CC(=CCN1C2=C(C(=C1N3CCCC(C3)N)C#N)N(C(=O)N(C2=O)CC4=NC=CC5=CC=CC=C54)C)C,CC(C)=CCn1c(N2CCCC(N)C2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C
CHEMBL1669421,HGLDEVLFUAEPJC-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4840.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.315154638355588,4241,53318873,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CO4,CC(C1=C(CCN(C)Cc2ncco2)Cc2ccccc21)c1cnccn1
CHEMBL1243305,HGLGWLWXYRAXPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,4.769551078621726,4242,46929447,C1CNCCC1C(CSC2=CC=C(C=C2)C(F)(F)F)C3=CN=CN3,FC(F)(F)c1ccc(SCC(c2cnc[nH]2)C2CCNCC2)cc1
CHEMBL1172346,HGOSXKUMUKYUKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20570147.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.060480747381382,4246,24759171,C1CCC(=CC1)C2=C(C=CC(=C2)C3=CC=NC=C3)NC(=O)C4=NC=C(N4)C#N,N#Cc1cnc(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)[nH]1
CHEMBL1210434,HGSCTPUCDDAAQZ-OIDHKYIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20579874.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,4250,10327211,CS(=O)(=O)N(C1=CC=CC=C1)C2=CC(=CC(=C2)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)C(F)(F)F)O)C5CCCC5,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1
CHEMBL1210434,HGSCTPUCDDAAQZ-OIDHKYIRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20579874.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,4250,10327211,CS(=O)(=O)N(C1=CC=CC=C1)C2=CC(=CC(=C2)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)C(F)(F)F)O)C5CCCC5,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1
CHEMBL1668259,HGULPEXUXHAGBL-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,49000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.309803919971486,4252,53324265,C1CCC(CC1)C(C(=O)NC2=C(C=C(C=C2)C(=O)O)C(F)(F)F)N3C4=CC=CC=C4N=C3C5=CC=C(C=C5)Cl,O=C(O)c1ccc(NC(=O)C(C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1
CHEMBL2151616,HGULSDBPQFERGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22975301.0,IC50,=,25000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.6020599913279623,4253,71451192,CC1CCCCC1C(=O)N2CC(C2)C3=NC(=NO3)C4=CC(=CC=C4)F,CC1CCCCC1C(=O)N1CC(c2nc(-c3cccc(F)c3)no2)C1
CHEMBL3331504,HGXZDFUNUJFDRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.0915149811213505,4257,118713803,C1CCC(CC1)N(CC2=CC=C(C=C2)Cl)C3CNC3,Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1
CHEMBL2448744,HGZPMOZVQYACMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13040.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.884722408604099,4258,73349666,C1=CC=C2C(=C1)N=C(S2)C3=CC=C(C=C3)N(CC4=CN=CC=C4)C(=O)CN,NCC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1
CHEMBL3093462,HHJSGMINRSKVLO-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24215891.0,IC50,=,940.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.026872146400302,4266,25205475,CCC(CN1C=C(C2=CC=CC=C21)C)NS(=O)(=O)C3=C(C=C(C=C3Cl)Cl)N,CCC(Cn1cc(C)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl
CHEMBL3353992,HHLPOWRWLBEWKR-PZGXJGMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,5.698970004336019,4268,68161075,CC1CC(C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)CN4CCCCC4)NC5=CC=CC=C5,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2C(Nc2ccccc2)CC1C
CHEMBL3353992,HHLPOWRWLBEWKR-PZGXJGMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25249180.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,PUBLICATION,,5.0,4268,68161075,CC1CC(C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)CN4CCCCC4)NC5=CC=CC=C5,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2C(Nc2ccccc2)CC1C
CHEMBL200267,HHRJZEIOBZQYGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16297617.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,4270,9948238,C1CN(CCC1CC2=CN=CN2)CCCOC3=CC=CC=C3,c1ccc(OCCCN2CCC(Cc3cnc[nH]3)CC2)cc1
CHEMBL3628113,HHRZBUWNLICHOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,4.522878745280337,4271,122193177,CC1=C(OC=C1)C(=O)NC2=CC(=C(C=C2)N3C(=O)C4=C(C3=O)C(=CC=C4)F)Cl,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)c(Cl)c1
CHEMBL2204357,HHVBUSGGPUQAOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,5.060480747381382,4274,53237898,CC1=C(C(=CC=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1cccc(Sc2ccccc2N2CCNCC2)c1C
CHEMBL2048293,HHVPFOZVFPAJBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22633692.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Fused tricyclic indoles as S1P(1) agonists with robust efficacy in animal models of autoimmune disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4276,44138103,C1CN2C3=C(C=C(C=C3)C4=NOC(=N4)C5=CC(=CC(=C5)C#N)OC(F)(F)F)C=C2C1CC(=O)O,N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)cc3n4CCC3CC(=O)O)no2)c1
CHEMBL397667,HHYOQRDAWFAMAJ-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,4280,136118015,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC(CC4=CC=CC=C4)CO)Br,Cc1cc(Br)cc2[nH]c(-c3c(NC(CO)Cc4ccccc4)cc[nH]c3=O)nc12
CHEMBL404622,HHYSIKMUKJWYNN-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,4281,44447285,CC(C)(C)OC(=O)NC(CC1=C(C=CC(=C1)F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1cc(F)ccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL3581140,HIGGJLMBFDDVKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,4.585026652029182,4285,24832012,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)N,COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1
CHEMBL3393477,HIJNIPAQZUMXON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,4.468521082957745,4287,59825775,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC(=C6F)F,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)ccc3[nH]2)o1
CHEMBL1671918,HIPNUROOFUMNSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,4293,883547,CCCC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,CCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
CHEMBL1078264,HIQKQNMARNQIET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4294,46882874,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC4=C(C=C3)NC=C4)C5=CC=CC=C5,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccc4[nH]ccc4c3)cc2)C1
CHEMBL403268,HIQWWDCRULXYDF-SWROZOJRSA-N,GRL-8234,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18180160.0,IC50,=,696.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.157390760389438,4295,24882306,CC(C1=CC=CC=C1)NC(=O)C2=CC(=CC(=C2)N(C)S(=O)(=O)C)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)OC)O,COc1cccc(CNCC(O)C(Cc2ccccc2)NC(=O)c2cc(C(=O)NC(C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1
CHEMBL1079481,HIRZFMOIKMLUHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4296,44626929,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)n1C
CHEMBL3234858,HIVDHOVSADNOOW-KWMCUTETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630411.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4299,71544946,CC(C1=CC=CC=C1)N2C(=O)C(OC2=O)(CC3=CC=CC=C3)C4=NN=C(O4)C5=CC(=CC(=C5)OC)OC,COc1cc(OC)cc(-c2nnc(C3(Cc4ccccc4)OC(=O)N(C(C)c4ccccc4)C3=O)o2)c1
CHEMBL2325503,HIWVLHPKZNBSBE-OUKQBFOZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473363.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Structural Basis and SAR for G007-LK, a Lead Stage 1,2,4-Triazole Based Specific Tankyrase 1/2 Inhibitor.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,4300,67960134,CS(=O)(=O)C1=CN=C(C=C1)C2=NN=C(N2C3=CC=CC=C3Cl)C=CC4=NN=C(O4)C5=CC=C(C=C5)C#N,CS(=O)(=O)c1ccc(-c2nnc(C=Cc3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1
CHEMBL1672621,HIXMVSBRCJHLQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,5.301029995663981,4301,16070337,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CC=C3)C4=CC=NC=C4,O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1
CHEMBL3137468,HIYFVUVAYQAIHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1900.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.721246399047171,4304,76325841,C1CN(CCC1N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3)C(=O)C4=CC=CC=C4,O=C(c1ccccc1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
CHEMBL3407774,HJBSZHIETZPEQW-NQWXTVAOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,5.0,4306,91799687,CNC1=C2C(=NC(=N1)C#CC3=NC=CN=C3)N(C=N2)C4C5CC5(C(C4O)O)C(=O)NC,CNC(=O)C12CC1C(n1cnc3c(NC)nc(C#Cc4cnccn4)nc31)C(O)C2O
CHEMBL3114880,HJDCUVZLLHFFAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,4307,44469819,CC(C)OC(=O)N1CCC(CC1)N2C3=C(C=N2)C(=NC=N3)OC4=CC=C(C=C4)S(=O)(=O)C,CC(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1
CHEMBL2111784,HJEPFPDXSFKWQH-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,4308,10390073,CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(N=C(S3)C4CCN(CC4)C)C5=CC=C(C=C5)F,CC(Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1
CHEMBL271579,HJJVPARKXDDIQD-UHFFFAOYSA-N,BROMUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,6.886056647693163,4313,3444,C1C(COC1(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl)Br,Clc1ccc(C2(Cn3cncn3)CC(Br)CO2)c(Cl)c1
CHEMBL2047188,HJKMXSQUWHPDOS-KRCBVYEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22704887.0,IC50,=,13800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.860120913598763,4315,53251325,CC(C)C(C(=O)N1CCCC1C2=NC(=C(N2)Cl)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=C(NC(=N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)Cl)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1nc(-c2ccc(-c3ccc(-c4nc(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)[nH]c4Cl)cc3)cc2)c(Cl)[nH]1)C(C)C
CHEMBL1669408,HJNGVQMITVXZEN-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4316,53322959,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCF,CC(C1=C(CCN(C)CCF)Cc2ccccc21)c1cnccn1
CHEMBL3628116,HJQXPBKPTGWZCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26426481.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,PUBLICATION,,4.522878745280337,4321,91885483,C1=CC2=C(C(=C1)Cl)C(=O)N(C2=O)C3=C(C=C(C=C3)NC(=O)C4=C(C=CC=N4)Cl)Cl,O=C(Nc1ccc(N2C(=O)c3cccc(Cl)c3C2=O)c(Cl)c1)c1ncccc1Cl
CHEMBL1094525,HJXPDUZXVIVZJB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,4329,46888825,C1CCC(CC1)N2CCCC(C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1
CHEMBL473326,HKDAECHYHSQLRG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4333,2047223,C1CC2=C(C1)NC(=NC2=O)SCC3=CC=C(C=C3)Cl,O=c1nc(SCc2ccc(Cl)cc2)[nH]c2c1CCC2
CHEMBL473326,HKDAECHYHSQLRG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4333,2047223,C1CC2=C(C1)NC(=NC2=O)SCC3=CC=C(C=C3)Cl,O=c1nc(SCc2ccc(Cl)cc2)[nH]c2c1CCC2
CHEMBL398430,HKDPOFYBYXNETQ-NOZRDPDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,4334,44441997,C1CCN(CC1)C2CCN(CC2)C(=O)OCC3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,O=C(OCC1CCCC(C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCC(N2CCCCC2)CC1
CHEMBL490609,HKIDSMNVQATMCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4337,44579273,CN1C2=CC=CC=C2C(C3=CC=CC=C3C1=O)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,CN1C(=O)c2ccccc2C(CNC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc21
CHEMBL3311223,HKIZMJLDZKXRKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,16000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,4339,53497480,C1=CC(=CC=C1C#N)C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F,N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1
CHEMBL3311223,HKIZMJLDZKXRKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,253314,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,4.795880017344075,4339,53497480,C1=CC(=CC=C1C#N)C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F,N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1
CHEMBL178873,HKJCSUNJDASSCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,4340,44390265,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(=O)O)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(=O)O)ccc2c1)n1ccnc1)N(C)C
CHEMBL2058901,HKJYWDQSNKARFG-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.376750709602099,4342,62706821,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)oc2c1
CHEMBL557052,HKMFVKRDAUAEAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,8.0,4343,16223656,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=NC=CC=N5)CC(C)(C)C(=O)O,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3ncccn3)cc2)c2ccc(OCc3ccccn3)cc12
CHEMBL3236361,HKMNSIXDWLMKFA-JVUUKAHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,4344,90655377,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)C(=O)O,CC1(CC(=O)C(=O)O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3581138,HKOLLRSMOQGSSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.698970004336019,4346,60097359,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=NC=NC=C3,COc1cccc(CC(=O)Nc2cc(-c3ccncn3)cs2)c1
CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.045757490560675,4347,7516,C1=CC=C(C=C1)NN,NNc1ccccc1
CHEMBL3394721,HKRNGLFQUVCSOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4350,89795484,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4)C5CCOCC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1
CHEMBL3394721,HKRNGLFQUVCSOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4350,89795484,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4)C5CCOCC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1
CHEMBL2207044,HLADQIZFAZEQAS-PUSSPCMTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,4356,71461437,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CCOC)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CCOC)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL375955,HLCPJLIYGNWTAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,7.0,4361,10454092,C1=CC(=CC(=C1)Cl)NC2=NC=C(C(=N2)C(F)(F)F)C(=O)NCC3=CC=NC=C3,O=C(NCc1ccncc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL465956,HLKTZTOQJFCERL-IKJXHCRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.187086643357144,4371,11155482,CC1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CCC3)C(=O)N,CC1CN(CC2(C(N)=O)CCC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
CHEMBL258502,HLMBXBGDBBCYII-UHFFFAOYSA-N,SK&F-96365,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,45.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,7.346787486224656,4374,104956,COC1=CC=C(C=C1)CCCOC(CN2C=CN=C2)C3=CC=C(C=C3)OC,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1
CHEMBL2181313,HLNMMXYNDBSAPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,5.0,4375,73351350,COC1=C2COCC=CCOCC3=C(C=CC(=C3)NC4=NC=CC(=N4)C(=C2)C=C1)OCCN5CCCC5,COc1ccc2cc1COCC=CCOCc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1
CHEMBL3673966,HLNUKOUNRKYWML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320636,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4376,52936038,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(C=CN=C4)C(F)(F)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1
CHEMBL3673966,HLNUKOUNRKYWML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320680,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4376,52936038,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(C=CN=C4)C(F)(F)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1
CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,61000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.214670164989233,4379,11655728,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,88000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.055517327849832,4379,11655728,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.0,4379,11655728,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,4.0,4379,11655728,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.045757490560675,4379,11655728,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
CHEMBL1241913,HLQJZFFWUXHYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.045757490560675,4379,11655728,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1
CHEMBL563949,HLSYGDSWXJGENX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19592244.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4380,11667741,CC1=C(C2=C(N1S(=O)(=O)C3=CC(=C(C=C3)F)F)N=CC=C2)CC(=O)O,Cc1c(CC(=O)O)c2cccnc2n1S(=O)(=O)c1ccc(F)c(F)c1
CHEMBL1641808,HLWCJDUVRWNSEA-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21185722.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4382,51003549,CN(C1CCC2=C(C3=C(N2C1)N=CC=C3)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3cccnc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL494916,HLWJGXQCGMRQQG-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.920818753952375,4383,44568926,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5N)C,Cc1ccc2c(N)noc2c1-c1ccc2c(N3CCOCC3C)nncc2c1
CHEMBL3400449,HLXHCRZAVCFDIS-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,4384,59272040,CC(C)N(CC1CNCC1NC(=O)OCC2CCCCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC
CHEMBL3400449,HLXHCRZAVCFDIS-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,4384,59272040,CC(C)N(CC1CNCC1NC(=O)OCC2CCCCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC
CHEMBL471757,HLZVKJIKNRQXFG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19231183.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4389,44565796,CC(C)(C)CNC1=C(C(=NC(=N1)C#N)N2CCOCC2)N,CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N
CHEMBL1078122,HMEXQGCRIYZAFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,91.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.040958607678906,4393,46883400,CCN(CC(CC1=CC=C(C=C1)O)NC(=O)OCC2=CN=CS2)CC(CC3=CC=C(C=C3)O)NC(=O)OCC4=NC=CS4,CCN(CC(Cc1ccc(O)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(O)cc1)NC(=O)OCc1nccs1
CHEMBL384536,HMICMRQBKBXVSC-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.823908740944319,4396,10184529,CC(C)CN1C2=C(C(=C(S2)CC3=CNC4=C3C=CC=N4)C(=O)N5CC(CO5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC(O)CO3)c(Cc3c[nH]c4ncccc34)sc21
CHEMBL1648,HMJIYCCIJYRONP-UHFFFAOYSA-N,ISRADIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,4399,3784,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12
CHEMBL3125537,HMKAZNCSHAJLSA-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,4401,68001087,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)O,CC1(CC(=O)O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3125537,HMKAZNCSHAJLSA-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.0962,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,10.016824927962187,4401,68001087,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)O,CC1(CC(=O)O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3702735,HMTKWBHPXLSHBK-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16360.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.786216700664696,4410,89718271,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCOCCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCOCCO)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL576457,HMUIATLYRCNFSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,4411,45484922,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)C(C)(C)C,CC1(CC(=O)NCc2ccc(C(C)(C)C)cc2)CC2(CCCCC2)OO1
CHEMBL3699323,HMVQIFYVRUUARJ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.7966950838615166,4413,89718304,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=CC(=C8)C(=O)N,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(C(N)=O)c6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL17962,HNDVDQJCIGZPNO-YFKPBYRVSA-N,HISTIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,4421,6274,C1=C(NC=N1)CC(C(=O)O)N,NC(Cc1cnc[nH]1)C(=O)O
CHEMBL17962,HNDVDQJCIGZPNO-YFKPBYRVSA-N,HISTIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,4421,6274,C1=C(NC=N1)CC(C(=O)O)N,NC(Cc1cnc[nH]1)C(=O)O
CHEMBL3702765,HNTUEHPJUVJGOY-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.29073003902417,4431,89718485,CC(=O)N1CCC(CC1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(C)=O)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL509440,HOAMIPKTWNMGQI-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.443697499232712,4434,25156399,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCC(=O)O)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL239074,HOBWYNFQYPRIDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,590.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.229147988357856,4435,23647890,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC=C(C=C4)Cl,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2
CHEMBL3114724,HOCVGRINDQNQSX-XIFFEERXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.619788758288394,4436,76310561,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)N(CCCCN(CC2=CC=CC=C2)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)N(CCCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL3664696,HOIIUDAZGJZKGR-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,29000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.5376020021010435,4443,59635811,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C(F)F)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL3344121,HOUNMJYTCWEHQD-WGQHWTFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25300820.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay,"Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5a-androstane-3a,17��-diol derivatives.",Bioorg. Med. Chem.,PUBLICATION,,5.42021640338319,4449,46895367,CC12CCC3C(C1CCC2(C#C)O)CCC4C3(CC(C(C4)O)N5CCN(CC5)C(=O)C6CCCN6C(=O)C7=NC8=CC=CC=C8C=C7)C,C#CC1(O)CCC2C3CCC4CC(O)C(N5CCN(C(=O)C6CCCN6C(=O)c6ccc7ccccc7n6)CC5)CC4(C)C3CCC21C
CHEMBL1092813,HOUUGSUKNBXWNT-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4450,46884155,CC1=C(C=CC=N1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1ncccc1C(C)c1c(CCN(C)C)sc2ccccc12
CHEMBL486757,HOWZJLASEFUNIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18823779.0,IC50,>,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,4454,25110600,CN(CC1=CC2=C(C=C1)N(C(=N2)NC(=O)C3=CC=C(C=C3)C#N)CCCOC)C4CCCCC4,COCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(CN(C)C3CCCCC3)ccc21
CHEMBL256721,HOXGYLKYFIXRJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,4455,44448976,CC1=CC2=C(C=C1C)N(C(=O)C=N2)CC(=O)N3CCCC(C3CN4CCOCC4)C5=CC=CC=C5,Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCOCC3)c2cc1C
CHEMBL1669413,HOXVEGPFZJNLIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4456,53318872,C1CCN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,c1ccc2c(c1)CC(CCN1CCCC1)=C2Cc1cnccn1
CHEMBL2425952,HPCPCLJRBNRLLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23905680.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,7.0,4459,71811261,CCC1=NC2=C(C=CC=C2C(=O)N1CCC3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)NO,CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1
CHEMBL3114739,HPCUDPZRFYSGPP-AEHIRBQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,460.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.337242168318426,4460,76310563,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CC3=CC=CC=C3)CN(CC4=CC=CC=C4)C(=O)OCC5=CN=CS5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1
CHEMBL3114739,HPCUDPZRFYSGPP-AEHIRBQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,4460,76310563,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CC3=CC=CC=C3)CN(CC4=CC=CC=C4)C(=O)OCC5=CN=CS5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1
CHEMBL1210552,HPGPGSLIDVUPKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4462,11996303,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)S(F)(F)(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C
CHEMBL1210552,HPGPGSLIDVUPKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4462,11996303,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)S(F)(F)(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C
CHEMBL2441840,HPJPGGHVDQQGCO-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,4464,57641228,CC1=C(C(=C2C(=N1)CN(C2=O)CC3CCCN3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC1CCCN1)C2
CHEMBL1923122,HPNCTFIRUULSCT-NEEKEDPPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,4467,57401308,COCCCC1=CC=CC2=C1C(=CC=C2)CN(C3CC3)C(=O)C4CNCCC45C6=CC(=C(C=C6CO5)F)F,COCCCc1cccc2cccc(CN(C(=O)C3CNCCC34OCc3cc(F)c(F)cc34)C3CC3)c12
CHEMBL1092651,HPVUAGMZZRSSHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4475,11515387,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3OC,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(F)ccc21
CHEMBL228133,HPWBHQIUIBFTQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17451235.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.,J. Med. Chem.,PUBLICATION,,5.0,4476,16122633,C1CNCCC1(C2=CC=C(C=C2)C3=C4C(=NC=N3)N=CN4)C5=CC=C(C=C5)Cl,Clc1ccc(C2(c3ccc(-c4ncnc5nc[nH]c45)cc3)CCNCC2)cc1
CHEMBL3672586,HQAFPESZZWFRFI-XDUPDYOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,170.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.769551078621726,4480,57406205,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC,CNC1CC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
CHEMBL3672586,HQAFPESZZWFRFI-XDUPDYOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,360.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.443697499232713,4480,57406205,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)NC,CNC1CC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1
CHEMBL3408951,HQCQFKQGMPBYGP-HQXRPOMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.346787486224656,4485,118731287,CC(C1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=C(C=CC(=C6)OC)N(C5=O)C)N7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(C(C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
CHEMBL3408951,HQCQFKQGMPBYGP-HQXRPOMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,4.958607314841775,4485,118731287,CC(C1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=C(C=CC(=C6)OC)N(C5=O)C)N7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(C(C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C
CHEMBL3608740,HQFWWFCJWZXHFM-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.508638306165727,4487,86275207,CC1C2=NN=C(N2CCN1C(=O)C3=CC=CC=C3)C4=NC(=NS4)C,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)C3C)n1
CHEMBL477387,HQMMZOJQYXBMCZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,4497,44579132,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=N4,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL477387,HQMMZOJQYXBMCZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,77000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.113509274827518,4497,44579132,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC=CC=N4,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL1867804,HQPRJYQZDYZZOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,5.275724130399211,4500,16013186,CC1=NN=C(N1C2=CC=C(C=C2)OC)SCC3=NC(=NO3)C4=CC(=C(C=C4)OC)OC,COc1ccc(-n2c(C)nnc2SCc2nc(-c3ccc(OC)c(OC)c3)no2)cc1
CHEMBL2010883,HQXPCHZUQMTZKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22366657.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4506,70685177,C1CCN(C1)CC2=C(C=CC3=C2N=C(N3)C4=CC=CC=C4)F,Fc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCC1
CHEMBL552061,HRCSHGYOQCEMTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,4514,45270788,C1CN(CCC1C2=NC(=NO2)C3=NC=CC4=CC=CC=C43)C(=O)NC5CC5C6=CC=CC=C6,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1
CHEMBL2425605,HRIOTEGBWIQIPA-ZZSUWZICSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,4520,66649612,CC(C)(C)CN1C=C(C=N1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cnn(CC(C)(C)C)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL272980,HRNLUBSXIHFDHP-UHFFFAOYSA-N,MOCETINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2441251443275085,4523,9865515,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1
CHEMBL2387501,HRSOWEMVVPAURP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,5.1249387366083,4529,71659897,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)C(F)(F)F,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3c(Cl)cccc3C(F)(F)F)[nH]c12
CHEMBL178534,HRTKQHILWNVFIX-KPKJPENVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.886056647693163,4531,11264173,C1=CC(=CN=C1)C2=CC=C(S2)C=NO,ON=Cc1ccc(-c2cccnc2)s1
CHEMBL2018916,HRUYBRGMRSNLNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,8860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.052566278112949,4534,702869,CC1=CC=C(C=C1)CSC2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc(SCc3ccc(C)cc3)[nH]c2c1
CHEMBL562926,HRXSTBZYYQOBSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,4535,44236321,C1CC2=CC=CC=C2CCC1NC(=O)N3CCC(CC3)C4=NC(=NO4)C5=CC=CC=N5,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1
CHEMBL257415,HRYXMTQIDOBCMH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.167491087293763,4538,44449004,CC1=CC2=C(C=C1C)N(C(=O)C=N2)CC(=O)N3CCCC(C3CN4CCCC4)C5=CC=CC=C5,Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCCC3)c2cc1C
CHEMBL477611,HSCPAFQDYZFJML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,5.119186407719209,4541,21956341,CC1=C2C=CC(=CC2=NN1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,Cc1[nH]nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
CHEMBL477611,HSCPAFQDYZFJML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.795880017344075,4541,21956341,CC1=C2C=CC(=CC2=NN1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,Cc1[nH]nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12
CHEMBL236731,HSIYJWUPHNPTOY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,4550,24741625,CC(C)CC(C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,CC(C)CC(N)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2059794,HSLRVLOIHHUQLE-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,4554,70690615,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC(=C(C(=C3)Br)O)Br)NC(=O)N4CCC(CC4)N5C6=CC=CC=C6NC5=O,O=C(NC(Cc1cc(Br)c(O)c(Br)c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL1412368,HSNSQMGDNFKEES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21375347.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.",J. Med. Chem.,PUBLICATION,,4.301029995663981,4561,2187415,C1C(=O)N(C(=O)N(C1=O)CCC2=CC=CC=C2)CCC3=CC=CC=C3,O=C1CC(=O)N(CCc2ccccc2)C(=O)N1CCc1ccccc1
CHEMBL2436321,HSRCYVWMJRQEPM-OGZMHEHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.7447274948966935,4564,72714289,CC(C)CC(=O)N1CC(C(=O)N(C2=CC=CC=C21)CC3=CC=CC4=CC=CC=C43)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)CC(C)C)c2ccccc2N(Cc2cccc3ccccc23)C1=O
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,217270.12,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.66299999577514,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,7.0,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,7.0,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,5.0915149811213505,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,5.017728766960431,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.920818753952375,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.721246399047171,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.443697499232712,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.207608310501746,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,80000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.096910013008056,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.0,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,110000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.958607314841775,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,110000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.958607314841775,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,146000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.835647144215563,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,190000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.721246399047171,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,220000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.657577319177794,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,220000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,3.657577319177794,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1836.6,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.735985420019022,4569,39186,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1
CHEMBL193816,HSXYVWHEMSHBBB-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,35.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,4572,11204336,COCCCN1C(=O)CCC2=C1C=C(C=C2)OCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COCCCN1C(=O)CCc2ccc(OCC3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21
CHEMBL3115061,HTGQYRRHOSKREA-NLWFPOLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 10 to 30 mins,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4577,76310598,C1C=CCOC2=CC(=C(C=C2)Cl)C(=O)NC(CC3=CN1C=N3)C(=O)O.Cl,O=C1NC(C(=O)O)Cc2cn(cn2)CC=CCOc2ccc(Cl)c1c2
CHEMBL501329,HTGWEIMTGKBAKN-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.161150909262744,4578,25156946,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCC(=O)O)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL2159210,HTMCBXLLCSRXLQ-GHMZBOCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22698084.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 using midazolam as substrate,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,5.0,4583,56929216,CC1=NC2=CN=C3C(=C2N1C4CCCC(C4)O)C=CN3,Cc1nc2cnc3[nH]ccc3c2n1C1CCCC(O)C1
CHEMBL2159210,HTMCBXLLCSRXLQ-GHMZBOCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22698084.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 using testosterone as substrate,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,5.0,4583,56929216,CC1=NC2=CN=C3C(=C2N1C4CCCC(C4)O)C=CN3,Cc1nc2cnc3[nH]ccc3c2n1C1CCCC(O)C1
CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.045757490560675,4585,2541,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
CHEMBL1939222,HTSQRRQNKJNSLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22191331.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,PUBLICATION,,4.301029995663981,4586,45102767,C1=C(C=C(C=C1Cl)Cl)OCC2=CC(=O)NN2,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1
CHEMBL1939222,HTSQRRQNKJNSLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22191331.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,PUBLICATION,,4.301029995663981,4586,45102767,C1=C(C=C(C=C1Cl)Cl)OCC2=CC(=O)NN2,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1
CHEMBL1092238,HTXMSBSZASVVFP-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4587,46830335,C1CN(CC1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4Cl,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CCN(CCN2CCN(C(=O)c3ccccc3Cl)CC2)C1
CHEMBL3291424,HTYQZSAJLSHXHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,4588,90467156,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC(F)F)C)C(=O)NCCO)N=C1,Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC(F)F)c3C)c2c1
CHEMBL555260,HUDSSSKDWYXKGP-UHFFFAOYSA-N,2-ANILINOPYRIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,430526.61,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.366000000496014,4594,81130,C1=CC=C(C=C1)NC2=CC=CC=N2,c1ccc(Nc2ccccn2)cc1
CHEMBL1223237,HUDWMNWXZIMODJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,4595,44159044,C1CC(C1)N2CCCN(CC2)C(C3=CC4=C(C=C3)OC=C4)C5=NN=NN5CC6=CC=CC=C6,c1ccc(Cn2nnnc2C(c2ccc3occc3c2)N2CCCN(C3CCC3)CC2)cc1
CHEMBL476312,HUGQKIWTNMQGCP-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621528.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,4597,44578266,CS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)C3CCNC3,CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)C1CCNC1
CHEMBL2017112,HUNKRAKTFQRWLG-HAPXSTRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4605,46932704,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)OCC(CO)O)Br,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2(OCC(O)CO)c2ccc(F)c(F)c2)c1Br
CHEMBL1672630,HUPNMGIBODMDOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,6.0,4608,16071897,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CC=NC=C3)C4=C(C=NC=C4)F,O=C(Nc1cnc(-c2ccncc2F)c(-c2ccncc2)n1)C1CC1
CHEMBL1669427,HUPZZDHJGMFMTN-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4609,53326727,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4CCOCC4,CC(C1=C(CCN(C)CC2CCOCC2)Cc2ccccc21)c1cnccn1
CHEMBL3702825,HUUMXLZSQBAKBN-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2090.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.679853713888946,4614,89718476,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC8=CC=CC=C8N=C7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc6ccccc6c5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL489479,HUZVCBYMIXTYBP-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,5.327902142064283,4616,15984318,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C(C)(C)C(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,CC1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL3422242,HVEVDFRWOQHAPJ-CKMNQQOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,4623,86343364,CC1C2CC(OCC2(N=C(S1)N)C3=C(C=C(C=C3)F)F)C4=CC(=NO4)C,Cc1cc(C2CC3C(C)SC(N)=NC3(c3ccc(F)cc3F)CO2)on1
CHEMBL3706711,HVJDCVDGPGBRLJ-KFIZHRIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,4626,122197339,CC(C)C1=NC(=CS1)COC(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CN3CCN(CC3C(=O)NC(C)(C)C)CC4=CC=CC5=C4COC5)O,CC(C)c1nc(COC(=O)NC(C(=O)NC(Cc2ccccc2)C(O)CN2CCN(Cc3cccc4c3COC4)CC2C(=O)NC(C)(C)C)C(C)C)cs1
CHEMBL1939559,HVQPVIBEPUHUPH-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22130135.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and specific CXCR3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4631,56834986,CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F,CC(c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(F)c(C(F)(F)F)c1
CHEMBL1923132,HVSAPLYLNVBLPG-MYVCOICNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,4635,57394345,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)Cl)CCC(=O)N6CCOCC6,COCCCc1cc(CCC(=O)N2CCOCC2)c(Cl)c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1
CHEMBL1682888,HVVULDASPWETLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.853871964321762,4640,22018410,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)C)(C3=CN=CN3)O,CC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL221401,HWCBLDPYKRZMKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17352462.0,IC50,>,100000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cells,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,PUBLICATION,,4.0,4644,16125682,C1CN(CCC1N2CC(NC2=O)(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC5=CC(=CC=C5)F,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(F)c2)CC1
CHEMBL105592,HWLBLFBLGGVDBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497764.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,4656,397855,CN1CCN(CC1)C(=O)C2=CN(C=C2C3=CC=CC4=CC=CC=C43)CC5=CN=CN5CC6=CC7=C(C=C6)OCO7,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1
CHEMBL3629741,HWLVLRSTFUBCSW-CVDCTZTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,4657,76283681,C1CC2(CCS(=O)(=O)CC2)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=S1(=O)CCC2(CCCC3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OCC23)CC1
CHEMBL3629741,HWLVLRSTFUBCSW-CVDCTZTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,4657,76283681,C1CC2(CCS(=O)(=O)CC2)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=S1(=O)CCC2(CCCC3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OCC23)CC1
CHEMBL404451,HWOKKMFQJSXDKU-XRKRLSELSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4658,44453913,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)cc1
CHEMBL404451,HWOKKMFQJSXDKU-XRKRLSELSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4658,44453913,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)cc1
CHEMBL256468,HWOKKMFQJSXDKU-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,4659,10482372,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)cc1
CHEMBL256468,HWOKKMFQJSXDKU-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4659,10482372,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)cc1
CHEMBL3087349,HWRMSAWZMPETAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,4662,72547023,C1=CC(=CC=C1C2=NN=CO2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2nnco2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL2181330,HWXVIOGONBBTBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,5.301029995663981,4668,73354318,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1
CHEMBL254918,HWYCIQPXYXDOBI-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.086186147616283,4669,44447269,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL286272,HXAMYHYXTZMWQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,4672,11408751,CCNC(=O)C1=C2CCCCN2C3=C1N=CN=C3N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,CCNC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
CHEMBL2035183,HXETYVYQZULBML-ONEGZZNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,5.0,4675,16750291,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC=C(S4)C5=NC(=NC=C5)NC(=C3)C=C2,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC1
CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,4683,2082,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
CHEMBL1209623,HXLCTJVFRQYWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,4685,49862599,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CS3,CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O
CHEMBL1209623,HXLCTJVFRQYWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,1160.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.935542010773082,4685,49862599,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CS3,CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O
CHEMBL2420677,HXMFOYHQXLDGBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1009.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.996108833763089,4689,71818086,COC1=C(C2=C(C=CC(=C2Cl)C3=CN=CC=C3)C=C1)F,COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F
CHEMBL2022495,HXNBYYPGRZHDKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503248.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.318758762624412,4690,23624283,COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=C2F)C3=NN=C(O3)NCCCN4CCCCC4,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1
CHEMBL2022495,HXNBYYPGRZHDKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503248.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.119186407719209,4690,23624283,COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=C2F)C3=NN=C(O3)NCCCN4CCCCC4,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1
CHEMBL3358006,HXNOCBIFNWVJLT-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25286150.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by high throughput fluorescence assay,Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists.,J. Med. Chem.,PUBLICATION,,5.0,4691,71722055,CC1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=C(C=C3)CS(=O)(=O)C)F)C4=NC(=NO4)C(F)(F)F,CC1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1
CHEMBL1258308,HXPHDFPROQRYEG-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4695,16122898,CC1CCCN1CCCOC2=CC3=C(C=C2)N4CCNC(=O)C4=C3,CC1CCCN1CCCOc1ccc2c(c1)cc1n2CCNC1=O
CHEMBL2041173,HXQJWMVKPWEYDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,4696,57384238,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC7=C(C=C6)NN=C7,COc1cc(N2C(=O)N(c3ccc(-c4ccc5[nH]ncc5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL205710,HXSAWRBPCYILHG-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,6.0,4698,11495012,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(COC)O)C,COCC(O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C
CHEMBL1770317,HXVAXOYPIPUCRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.300000029139089,4704,49850345,CC(C)C1(C(=O)NC(=O)O1)C2=CC=C(NC2=O)C3=CC4=CC=CC=C4C=C3,CC(C)C1(c2ccc(-c3ccc4ccccc4c3)[nH]c2=O)OC(=O)NC1=O
CHEMBL402303,HXWCQEQIPYCSAM-QPPBQGQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18420409.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,4705,25067046,CN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
CHEMBL254356,HXWCQEQIPYCSAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,4706,44448775,CN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
CHEMBL254356,HXWCQEQIPYCSAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,4706,44448775,CN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
CHEMBL474934,HXXABQAEGBRHAX-BGYRXZFFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,41000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.3872161432802645,4708,15604512,CC1CN(CC(N1)C)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL474934,HXXABQAEGBRHAX-BGYRXZFFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.229147988357856,4708,15604512,CC1CN(CC(N1)C)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC=C(C=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL3408523,HXZWMRQMVOIXHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4710,118730937,CC1=CSC(C2=NOC(=O)N12)(C3=CC=C(C=C3)Br)OCC(F)(F)F,CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21
CHEMBL3408523,HXZWMRQMVOIXHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,4710,118730937,CC1=CSC(C2=NOC(=O)N12)(C3=CC=C(C=C3)Br)OCC(F)(F)F,CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21
CHEMBL192172,HYFHKEYEUYHQDQ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,4713,44400230,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)F)C4=CC=CC=C4Cl)N,NC(Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1
CHEMBL3358953,HYFZBJIDQLQGIG-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.468521082957745,4715,44545482,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=CC=CC=C3C(=O)N)(C(F)(F)F)O,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1
CHEMBL3358949,HYFZBJIDQLQGIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.853871964321762,4716,67053425,CCS(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=CC=CC=C3C(=O)N)(C(F)(F)F)O,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1
CHEMBL3629744,HYGZSKLILPYKMS-LZYVTZSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,4718,76283684,CP1(=O)OCC2(CCCC3(C2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,CP1(=O)OCC2(CCCC3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OCC23)CO1
CHEMBL3629744,HYGZSKLILPYKMS-LZYVTZSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,4718,76283684,CP1(=O)OCC2(CCCC3(C2COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl)CO1,CP1(=O)OCC2(CCCC3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OCC23)CO1
CHEMBL271326,HYHBTUQUIVVEHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.468521082957745,4719,747770,CCOC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N3C=NN=N3,CCOc1ccc(NC(=O)c2ccc(-n3cnnn3)cc2)cc1
CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4720,4485,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,46989.41,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,4.3280000079532766,4720,4485,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256005.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,4720,4485,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,5620.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,5.250263684430939,4720,4485,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
CHEMBL1950086,HYMHPKUKPVAHSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,4722,57403378,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)[nH]nc3nc12
CHEMBL1950086,HYMHPKUKPVAHSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,4722,57403378,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)[nH]nc3nc12
CHEMBL3115177,HYMRCMPXDULDOD-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,4723,59721308,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CCN)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3623127,HYNANJUKEMCYEQ-GVYRHCHYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288692.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4724,122192293,CCS(=O)(=O)NC1CC2(C3C(C1(O2)C)C(=O)N(C3=O)C4=CC(=C(C=C4)C#N)C(F)(F)F)C,CCS(=O)(=O)NC1CC2(C)OC1(C)C1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C12
CHEMBL3408943,HYQVDRMLTQMPMN-ABKNGVQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.0,4728,58486237,C1CN(CC1F)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccc(CN4CCC(F)C4)cc3)n[nH]c2c1
CHEMBL3408943,HYQVDRMLTQMPMN-ABKNGVQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.0,4728,58486237,C1CN(CC1F)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccc(CN4CCC(F)C4)cc3)n[nH]c2c1
CHEMBL3319533,HYRZJDXFIXBPRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25001129.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket.,J. Med. Chem.,PUBLICATION,,4.568636235841013,4729,118709623,CN1C=C(C=N1)C2=C(N=CC(=C2)C(C(F)(F)F)(C(F)(F)F)O)N3CCN(CC3)S(=O)(=O)C4=CN=C(C=C4)N,Cn1cc(-c2cc(C(O)(C(F)(F)F)C(F)(F)F)cnc2N2CCN(S(=O)(=O)c3ccc(N)nc3)CC2)cn1
CHEMBL2437427,HYUUZONCAYJTHP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,4730,58863146,C1CCC(C1)N2C3=C(C=CC(=C3)F)N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(C5CCCC5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL1671916,HYWCKSHSBGMFFR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,5.853871964321762,4732,577307,CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)NC3=NC=CS3,Cc1ccccc1C(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
CHEMBL306226,HYZJCKYKOHLVJF-UHFFFAOYSA-N,BENZIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,4738,5798,C1=CC=C2C(=C1)NC=N2,c1ccc2[nH]cnc2c1
CHEMBL306226,HYZJCKYKOHLVJF-UHFFFAOYSA-N,BENZIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,4738,5798,C1=CC=C2C(=C1)NC=N2,c1ccc2[nH]cnc2c1
CHEMBL2338479,HYZYVEZIXMCICK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,8.0,4739,71525169,C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)NC2=CC(=C(C(=C2)Cl)OC3=CN=CC(=C3)C#N)Cl,N#Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
CHEMBL3357641,HZBHTRUJNPPRNW-KAZCASEASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,5.0,4740,71513157,CN(C)CC=C(C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4)F,CN(C)CC=C(F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1
CHEMBL253528,HZUKSEBFKWBMBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18329269.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,4751,44448056,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)COC4=CC(=NC(=C4)C)C,Cc1cc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(C)n1
CHEMBL3112849,IADWZPWKRCWMPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,4759,66882808,C1CN(C2=C1C(=CC=C2)Cl)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(Cl)cccc21
CHEMBL2387224,IAFNAEGXTKTGHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23867602.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Lead identification of novel and selective TYK2 inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,5.0,4761,49839561,C1CC1C(=O)NC2=NC=CC(=C2)NC(=O)C3=C(C=CC=C3Cl)Cl,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl
CHEMBL2113263,IAFVOFFJCUHEHP-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17274610.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.0,4763,10458842,CCCC1=C(C=CC(=C1)C2=NC3=C(S2)CCCC3)OCCCOC4=CC5=C(C=C4)C(CC5)CC(=O)O,CCCc1cc(-c2nc3c(s2)CCCC3)ccc1OCCCOc1ccc2c(c1)CCC2CC(=O)O
CHEMBL571204,IAGNLKFJNSJHHD-GAJHUEQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19632830.0,IC50,>,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.455931955649724,4764,45487345,CC(C(CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(C)(C)C(=O)NC3=NC=C(C=C3)C(F)(F)F,CC(NC(C)(C)C(=O)Nc1ccc(C(F)(F)F)cn1)C(Cc1ccc(Cl)cc1)c1cccc(C#N)c1
CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,4770,6167,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2
CHEMBL2181898,IANAVLJQRMMYRG-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.522878745280337,4772,71461110,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC=C(C=C4)C5=NC=CS5)NC(=O)COC)O,COCC(=O)NC(Cc1ccc(-c2nccs2)cc1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL1950643,IAUVZRBJEZBOFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22290075.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4775,24993500,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)C=C4,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1
CHEMBL577965,IBABQVTVKGTVDW-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,4781,44473094,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=CC(=C5)C(=O)N,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3cncc(C(N)=O)c3)ccc2o1
CHEMBL579199,IBCNGCWXJWSCOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,4784,45484966,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC(=C3)OC)OC,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1
CHEMBL239099,IBEQZETWFPHMMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,4786,24749961,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
CHEMBL239099,IBEQZETWFPHMMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,4786,24749961,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
CHEMBL1090527,IBILQKIYEWGQDQ-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4791,46884735,CC(C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CS3,CC(C1=C(CCN(C)C)Cc2cc(F)ccc21)c1nccs1
CHEMBL373039,IBJYNRZEQITOHY-VIHJOENHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16203148.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,4793,10284289,CC(C)(C1=NC=C(O1)C2=CC=C(C=C2)Cl)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC5=C(S4)C=CN=C5)C(=O)NC6C(COC7=CC=CC=C67)O)O,CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(CC(O)CC(Cc2cc3cnccc3s2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL248231,IBOXMUIHNFMJTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,4797,44443098,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C=C4)OCC(=O)N5CC6=CC=CC=C6,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(Cc4ccccc4)C(=O)CO5)CC3)cccc2n1
CHEMBL2181895,IBQBCHBBSWVJOQ-HZFUHODCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.0,4799,71457466,CC1=CSC(=N1)C2=CC=CC(=C2)CC(C(CNC3CC4(CCC4)OC5=C3C=C(C=N5)CC(C)(C)C)O)NC(=O)COC,COCC(=O)NC(Cc1cccc(-c2nc(C)cs2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL3664646,IBSYVSTWEQVFDZ-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,4802,59635741,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4F,CC(c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2F)OC1=O
CHEMBL534942,IBUZSMCHAASZTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16750363.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4804,45263405,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3.Cl,Clc1ccccc1CC(c1ccccc1)N1CCNCC1
CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.045757490560675,4812,25025581,CCOCC1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOCC1C2CNCC21c1ccc(Cl)c(Cl)c1
CHEMBL2207099,ICBWFOBAWJKURO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23079519.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4814,15604497,CN1C(=NN=N1)CC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,Cn1nnnc1Cc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
CHEMBL570596,ICDRVGLMFQWTDX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19831396.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.,J. Med. Chem.,PUBLICATION,,6.301029995663981,4816,25192475,CC1=C(C=CC(=C1)C2=CC=C(S2)C3=CC(=CC=C3)O)O,Cc1cc(-c2ccc(-c3cccc(O)c3)s2)ccc1O
CHEMBL239497,ICDYHYNUXPDZEQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,460.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.337242168318426,4817,23647887,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(CC)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2
CHEMBL1222799,ICHWSWUZDRHGDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.97469413473523,4821,49864989,CCOCCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,CCOCCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL1916686,ICMOGANJAUQPKT-LMKMVOKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4826,44205724,CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=C(C=CC(=C3)CC(=O)O)OC)C4=CC=CC=C4,COc1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)OC(c2ccccc2)C1C
CHEMBL1081874,ICNXLCSJEDSWTK-CLJLJLNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,4831,46883334,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1081147,ICNXLCSJEDSWTK-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,4832,46883333,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1080964,ICNXLCSJEDSWTK-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,4833,46883332,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20527970.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.0,4838,24802842,COCC12CC1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COCC12CNCCC1(c1ccc(Cl)c(Cl)c1)C2
CHEMBL3633460,ICYNYWFGIDGBRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26509551.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.",J. Med. Chem.,PUBLICATION,,4.0,4840,71571306,COC1=C(C=C(C=C1)Cl)C2=CC(=O)NC(=S)N2CC(=O)N,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O
CHEMBL3633460,ICYNYWFGIDGBRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26509551.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes,"Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.",J. Med. Chem.,PUBLICATION,,4.0,4840,71571306,COC1=C(C=C(C=C1)Cl)C2=CC(=O)NC(=S)N2CC(=O)N,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O
CHEMBL2042239,IDAMFVNNSWRUTJ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,4843,68011817,CN1C(=O)N(C(=O)C12C3=C(C=CC(=C3)Cl)N(C2=O)CC(=O)O)CC4=C(C=CC(=C4)Cl)F,CN1C(=O)N(Cc2cc(Cl)ccc2F)C(=O)C12C(=O)N(CC(=O)O)c1ccc(Cl)cc12
CHEMBL3673957,IDCXHTGCSOGOJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320614,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4846,52934486,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)OC)F)N=C1,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1
CHEMBL3673957,IDCXHTGCSOGOJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320660,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4846,52934486,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)OC)F)N=C1,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1
CHEMBL2331747,IDMZBDJWQBWWLK-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23206863.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,4857,66553128,CC1=CN(C(=O)NC1=O)C2CCCN(C2)S(=O)(=O)C3=CC(=C(C=C3)O)OC4=CC(=CC=C4)Cl,Cc1cn(C2CCCN(S(=O)(=O)c3ccc(O)c(Oc4cccc(Cl)c4)c3)C2)c(=O)[nH]c1=O
CHEMBL248677,IDOAKQMETXZJBC-NOZRDPDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,4858,44441998,CC(C)C1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4,CC(C)C1CCCC(COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.42021640338319,4866,9864291,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,4866,9864291,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.42021640338319,4866,9864291,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
CHEMBL238146,IDSZXCFCCNVXER-UHFFFAOYSA-N,AR-HO47108,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,4866,9864291,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12
CHEMBL1096182,IDUFEEHNNASCMH-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20423086.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.",J. Med. Chem.,PUBLICATION,,5.481486060122113,4868,24871527,CC1=CC(=NN1)C(=O)NC2CC(OC3=C2C=C(C(=N3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)(C)C,Cc1cc(C(=O)NC2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1
CHEMBL3311228,IDUYJRXRDSPPRC-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,65000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.187086643357144,4869,77050711,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1
CHEMBL1642362,IDVWFRRQOFXIBN-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,4870,50938548,C1CCC(CC1)C(C(=O)NC2CCCCC2)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)Cl,O=C(NC1CCCCC1)C(C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21
CHEMBL3115162,IDZMIOJJLGAUFK-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,4874,59721235,CC1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,Cc1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL2448703,IEAFYLRKILUQOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3280.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.484126156288321,4875,73346615,C1=CC2=C(C=CC(=C2)Br)C=C1C(=O)NCCC3=CN=CN3,O=C(NCCc1cnc[nH]1)c1ccc2cc(Br)ccc2c1
CHEMBL3702684,IEALSSJEWUOVJF-VYQNARHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20390.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.69058277422186,4876,89718435,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)NCC8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCc6ccccc6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3237443,IEPYZPJZYINELK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,5.0,4887,58299836,C1CCC(C1)N2C3=C(C=CN=C3F)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,Fc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12
CHEMBL2018922,IEQJLSGPTIUFRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.301029995663981,4888,672443,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)C(=O)O,COc1ccc2nc(SCc3ccc(C(=O)O)cc3)[nH]c2c1
CHEMBL3581147,IEYJDPAUIUNGSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.301029995663981,4896,24830568,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)Cl,COc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1
CHEMBL1777878,IEYUZLGWSIHESL-WMLDXEAASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4897,54584572,CC#CC(C1C(=O)NC(=O)O1)C2=CC=C(C=C2)OC3=C(C=C(C=C3)C(F)(F)F)OC(F)F,CC#CC(c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1)C1OC(=O)NC1=O
CHEMBL3127501,IFEXCZMSTXWJSK-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,7.187086643357144,4903,76314702,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)OC(F)(F)F)C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)C1CC1c1cccnc1
CHEMBL3127501,IFEXCZMSTXWJSK-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.050609993355088,4903,76314702,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)OC(F)(F)F)C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)C1CC1c1cccnc1
CHEMBL1223235,IFFHPDKLLFCYAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,4905,44159759,C1CC(C1)N2CCCN(CC2)C(C3=CC=C(C=C3)N4C=NC=N4)C5=NN=NN5CC6=CC=CC=C6,c1ccc(Cn2nnnc2C(c2ccc(-n3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1
CHEMBL576094,IFHTTXSATPHTDC-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,4907,44473099,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)NC,CNC(=O)c1ccc(C(=O)NC(=NC2CCCCN(CC(=O)N3CCCC3)C2=O)Nc2ccc3oc(C)cc3c2)cn1
CHEMBL3401121,IFMJXLLSGLDSMX-JTQLQIEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4913,57870042,CC1COCCN1C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,CC1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C
CHEMBL3401118,IFMJXLLSGLDSMX-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,4914,57870067,CC1COCCN1C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,CC1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C
CHEMBL3673970,IFMNZLKDCPETDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320640,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4915,67202442,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4F)OC)F)N=C1,COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1
CHEMBL3673970,IFMNZLKDCPETDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320684,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4915,67202442,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4F)OC)F)N=C1,COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1
CHEMBL1644183,IGCXZPHCSPIQHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21147532.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,4922,9985625,C1=CC(=CC=C1CN2C(=CC(=N2)C3=CC(=CC(=C3)Cl)Cl)C4=CC=C(C=C4)OC(F)(F)F)C(=O)NCCC(=O)O,O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1
CHEMBL2070162,IGDKFGZQZAKEIU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,4924,70695121,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN(C=CC3=O)C4=CC=CC=C4,CCCS(=O)(=O)c1ccc2nc(-c3cn(-c4ccccc4)ccc3=O)[nH]c2c1
CHEMBL401895,IGEDPAQDLDJKOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18329269.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,4926,16654984,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)COC4=CC=CC(=C4)CN(C)C,Cc1cc(C)n(-c2cc(NC(=O)COc3cccc(CN(C)C)c3)nc(-c3ccc(C)o3)n2)n1
CHEMBL3682507,IGKOLFMBNAVTIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,291612,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,3.6989700043360187,4930,53247261,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OC(F)F)N3N=CN=N3,CC(C)C(c1ccc2cc(OC(F)F)ccc2c1)n1ncnn1
CHEMBL2336417,IGMSWNYDGFNYAI-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,4931,11204595,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2336417,IGMSWNYDGFNYAI-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4931,11204595,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL575966,IGRCWJPBLWGNPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19902954.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.,J. Med. Chem.,PUBLICATION,,5.899998417198648,4933,44605616,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N(C)C3=CC=C(C=C3)Cl,Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1
CHEMBL575966,IGRCWJPBLWGNPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20097073.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,4933,44605616,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N(C)C3=CC=C(C=C3)Cl,Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1
CHEMBL210514,IGTBNUVMBDYPQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16722655.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.522878745280337,4935,9872676,CC1=CC2=C(C=C1OC3=CC=C(O3)C(=O)NC4=C(N=C(N=C4OC)NCCCN5CCOCC5)OC)C(CC2)(C)C,COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1
CHEMBL1935441,IGUBZXXWVQQSPY-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,4938,57395287,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1
CHEMBL2069398,IGUGPXBOXUANHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22832311.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,4939,16956771,CC1=CC(=CC=C1)C2=NOC(=N2)C3CC(=O)N(C3)C4=CC=C(C=C4)F,Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1
CHEMBL3263640,IGXJXMLDIIGDNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24685542.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.008773924307505,4942,53356518,CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=NC4=C(C(=N3)NC5=CC=C(C=C5)C(=O)N6CCOCC6)NC=N4,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2[nH]cnc2n1
CHEMBL3263640,IGXJXMLDIIGDNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24685542.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,4942,53356518,CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=NC4=C(C(=N3)NC5=CC=C(C=C5)C(=O)N6CCOCC6)NC=N4,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2[nH]cnc2n1
CHEMBL2170629,IHADGKOGTFHZIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.958607314841775,4944,58269655,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)C#N,N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)cc1
CHEMBL2386081,IHAXLPDVOWLUOS-UHFFFAOYSA-N,SETIPIPRANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,4945,49843471,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2
CHEMBL2414256,IHDMNALHWVSDJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.096910013008056,4947,72205601,CC(C)(C)N1C(=NN=N1)C(C2=CC=C(C=C2)Cl)NCCNC3=C4C=CC(=CC4=NC=C3)Cl,CC(C)(C)n1nnnc1C(NCCNc1ccnc2cc(Cl)ccc12)c1ccc(Cl)cc1
CHEMBL1784351,IHEWXNWFNBGUFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4949,54582076,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCN(CC3)C)N(C=O)O,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C)CC2)CC1
CHEMBL429845,IHOOKNMBJBLZPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,4950,44454684,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)N4CCN(CC4)C)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(N3CCN(C)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL1097426,IHQMLJBDDJVMHI-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,4952,136086709,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCO,Cc1cc(N2CCN(CCO)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3622137,IHSTUTBJVPZZHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288682.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,5.522878745280337,4954,58180596,CCN1C(=CC2=C3C(=C(N=C21)NC4=NC(=C(S4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21
CHEMBL3407554,IHUMWHKQAVMWCV-HXZUPTHJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.102,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,9.991399828238082,4955,86731830,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC(=C(C=C3)Cl)F)C4=CC(=CC=C4)Cl)CC(=O)O,CC1(CC(=O)O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)c(F)c2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3673980,IHUPHYFSKVFFFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320619,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4956,52934260,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)Cl,Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1
CHEMBL3673980,IHUPHYFSKVFFFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320663,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,4956,52934260,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)Cl,Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1
CHEMBL1270738,IHWKYASJAJITBL-MSGZWQTISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20888225.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a vorapaxar analog with increased aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4958,16214871,CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC=CC=N5)C(OC3=O)C,CCOC(=O)NC1CCC2C(C1)CC1C(=O)OC(C)C1C2C=Cc1ccc(-c2ccccn2)cn1
CHEMBL2397314,IIFUCWPNUMIYRT-SSDOTTSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4962,71682214,CC1=C(SC(=N1)NC(=O)C(C)CC(F)(F)F)C2=CN=C(C=C2)N,Cc1nc(NC(=O)C(C)CC(F)(F)F)sc1-c1ccc(N)nc1
CHEMBL2397312,IIFUCWPNUMIYRT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4963,71682211,CC1=C(SC(=N1)NC(=O)C(C)CC(F)(F)F)C2=CN=C(C=C2)N,Cc1nc(NC(=O)C(C)CC(F)(F)F)sc1-c1ccc(N)nc1
CHEMBL2397315,IIFUCWPNUMIYRT-ZETCQYMHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,4964,71682057,CC1=C(SC(=N1)NC(=O)C(C)CC(F)(F)F)C2=CN=C(C=C2)N,Cc1nc(NC(=O)C(C)CC(F)(F)F)sc1-c1ccc(N)nc1
CHEMBL266513,IIFWQQSTZJCTCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,4965,44425811,COC1=C(C=NC=C1)C2=CC=C(C=C2)CN3CCC4(CC3)C(=O)N(C(=O)N4CC5=CC=CC=C5F)C6=CC(=CC=C6)OC,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cnccc5OC)cc4)CC3)C2=O)c1
CHEMBL1784345,IIJIMCYNCLMHHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4968,54586893,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCN(CC3)C(=O)C4CCC4)N(C=O)O,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C(=O)C3CCC3)CC2)CC1
CHEMBL1915566,IILXHJHOJNRNFS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,4971,25107258,CC1=CN(C=N1)C2=C(C=C(C=C2)NC3=NC(=CS3)C4=C(C=CC(=C4)Br)OC)OC,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)c(OC)c2)n1
CHEMBL562822,IIPPFWIHUHXQNA-PKOBYXMFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,4974,44235863,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=N3)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
CHEMBL552382,IIPPFWIHUHXQNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,4975,44232522,C1CN(CCC1C2=NC(=NO2)C3=CC=CC=N3)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1
CHEMBL3702733,IIQWUYYKWLTINN-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3680.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.434152181326482,4976,89718213,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CCCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCCO)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3544960,IIRWNGPLJQXWFJ-KRWDZBQOSA-N,AT-13148,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,inhibition,,,,,,,,,,,,,,,,,,5.0,4977,24905401,C1=CC(=CC=C1C2=CNN=C2)C(CN)(C3=CC=C(C=C3)Cl)O,NCC(O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1
CHEMBL3673934,IITAGIUAJYXYRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320679,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,4981,52936037,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC(=C4)F)OC)N=C1,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
CHEMBL3673934,IITAGIUAJYXYRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320635,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,4981,52936037,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=C(N=CC(=C4)F)OC)N=C1,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1
CHEMBL1669414,IIVFRUJVDGTOEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,4983,53321512,C1C(CN1CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4)F,FC1CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
CHEMBL3086045,IIXUBHOQXODODU-FZCBKRAZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24157366.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,4984,76331595,CC1=CC=CC=C1C2CC(CCC2C(=O)N3CC(C3)(C4=CC=CC=C4)C5=CC=CC=C5)NCC6=CC=C(C=C6)Cl,Cc1ccccc1C1CC(NCc2ccc(Cl)cc2)CCC1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1
CHEMBL253883,IIZFMAZANLMCRM-CAWMZFRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0655015487564325,4985,44447257,CC(C1CC1)N2C(=NC3=C2N=CC=C3)CNC(=O)C(CC4=CC=CC=C4C(F)(F)F)NC(=O)OC(C)(C)C,CC(C1CC1)n1c(CNC(=O)C(Cc2ccccc2C(F)(F)F)NC(=O)OC(C)(C)C)nc2cccnc21
CHEMBL380360,IJDCSVYTXFLAHR-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,4990,23647914,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3C(CNCC3=O)CSC4=CC5=C(C=C4)OCC(=O)N5CC(=O)O,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2CSc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1
CHEMBL203567,IJDQETGUEUJVTB-HNNXBMFYSA-N,RO-3201195,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16509574.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,4991,5327067,C1=CC(=CC(=C1)OCC(CO)O)C(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N,Nc1c(C(=O)c2cccc(OCC(O)CO)c2)cnn1-c1ccc(F)cc1
CHEMBL1669424,IJFPVAYNHAMKAK-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4783.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.320299619128036,4992,53324167,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CC=N4,CC(C1=C(CCN(C)Cc2ccccn2)Cc2ccccc21)c1cnccn1
CHEMBL496624,IJGCNVPTZVEOMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,4993,24889844,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C4=NC=NN4C)C,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12
CHEMBL496624,IJGCNVPTZVEOMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,4993,24889844,CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C4=NC=NN4C)C,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12
CHEMBL487372,IJOJVQBWEGAGTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,5001,25069603,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N)C,CC(=O)Nc1cc(-c2cccc(N)n2)nc(-n2nc(C)cc2C)n1
CHEMBL557885,IJOLYFZBLJPKPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,5002,25165471,COC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
CHEMBL557885,IJOLYFZBLJPKPI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5002,25165471,COC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
CHEMBL255034,IJRBORPEVKCEQD-JMQWOFAPSA-N,MAKISTERONE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,5005,12312690,CC(CC(C(C)(C1CCC2(C1(CCC3C2=CC(=O)C4C3(CC(C(C4)O)O)C)C)O)O)O)C(C)(C)O,CC(CC(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C)C(C)(C)O
CHEMBL3236948,IJTCACUKYBFEGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24512187.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.,J. Med. Chem.,PUBLICATION,,4.0,5007,57505249,CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)C3=CN(C(=O)C4=CC=CC=C43)C(C)C,Cc1c(-c2cn(C(C)C)c(=O)c3ccccc23)c2cc(F)ccc2n1CC(=O)O
CHEMBL1761843,IKCNXAIMXSHWAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11��-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,5010,24896012,CC1COC2=CC=CC=C2N1C(=O)N3CCC(CC3)C4=CN=CN4,CC1COc2ccccc2N1C(=O)N1CCC(c2cnc[nH]2)CC1
CHEMBL226335,IKGXIBQEEMLURG-NVPNHPEKSA-N,RUTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,4.096910013008056,5016,5280805,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,CC1OC(OCC2OC(Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)C(O)C(O)C2O)C(O)C(O)C1O
CHEMBL3137476,IKHACWFDYVNHCT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,5018,76314946,CC(C)(CN1CCC(CC1)N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)O,CC(C)(O)CN1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1
CHEMBL381354,IKJHFSQVBUKKHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,5020,11681610,CCC(=O)NC1CCN(CC1)CC2=CC(=CC=C2)OC3=CC=CC=C3,CCC(=O)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
CHEMBL3401129,IKJQAMMPHAQXBH-HUUCEWRRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,445000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.3516399890190685,5021,57870232,CN1C(=O)C=C(N=C1N2CCOC3C2CCC3)C4=C(C=NC=C4)F,Cn1c(N2CCOC3CCCC32)nc(-c2ccncc2F)cc1=O
CHEMBL579016,IKKXEAGTIWLWTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,5022,45484919,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=NC=C3,CC1(CC(=O)NCc2ccncc2)CC2(CCCCC2)OO1
CHEMBL2436213,IKLDGCFWCBGUCZ-FEINMWSASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.638272163982407,5023,72711927,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5CCOCC5)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)C2CCOCC2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL2381100,IKQMQSFNINGJEH-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,5028,71603188,CC1=NC(=C(S1)C2=CC=CC=C2)C(=O)N3CC4(CC4)CC3CNC5=NC=C(C=C5)C(F)(F)F,Cc1nc(C(=O)N2CC3(CC3)CC2CNc2ccc(C(F)(F)F)cn2)c(-c2ccccc2)s1
CHEMBL2441829,IKUISOBQXBKHEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,6.045757490560675,5031,15950389,CC1=C(C(=C2C(=N1)CN(C2=O)C3=CC=C(C=C3)OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccc(N2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)cc1
CHEMBL3289805,IKURNPPRPBOJIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,4.522878745280337,5032,90644766,C1=CC(=C(C(=C1)Cl)Cl)C(CN2C3=C(C=CC=N3)N=C2N)O,Nc1nc2cccnc2n1CC(O)c1cccc(Cl)c1Cl
CHEMBL1949930,IKXSPLZKOZXPFB-RQBPZYBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22226656.0,IC50,>,5900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,5034,57396812,CC(C)OC1=CC(=CC(=C1)OC)S(=O)(=O)C2=CC3=C(C=C2)C4CCNCC4O3.Cl,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)OC2CNCCC32)c1
CHEMBL2064348,ILFYEJCKTMDWME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,5045,57523247,CN1C(=NC2=CC=CC(=C21)C3=CC=CC=C3)CC4=NC(=O)C=C(N4)N5CCOCC5,Cn1c(Cc2nc(=O)cc(N3CCOCC3)[nH]2)nc2cccc(-c3ccccc3)c21
CHEMBL2437431,ILGIWHFMFHNSOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5046,72375001,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=CC=CC=N5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccccn5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL482102,ILKQWXHVEJRPAL-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,2.6,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.585026652029182,5051,135960716,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC,CNC1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL3702816,ILKXQTQAKMXMSJ-ZUCLMTDXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4600.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.337242168318426,5052,89718465,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC9CCCN9C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7CCCN7C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3218854,ILSYFQQNAQIMBK-BBNYVJOESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,5.275724130399211,5060,90665986,COC1=C(C=CC(=C1)N2CCOCC2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl,COc1cc(N2CCOCC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3218854,ILSYFQQNAQIMBK-BBNYVJOESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,5.267606240177032,5060,90665986,COC1=C(C=CC(=C1)N2CCOCC2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl,COc1cc(N2CCOCC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL2070152,IMBFWYWYCCHQOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,5068,70697154,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3C)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3C)[nH]c2c1
CHEMBL3234578,IMDHTJNGKGZRCP-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,6.096910013008056,5070,90654567,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC3C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(N3CCC3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
CHEMBL3234577,IMDHTJNGKGZRCP-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.522878745280337,5071,90654566,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCC3C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(N3CCC3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
CHEMBL360999,IMFKJIBLFGZFSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,262000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.5816987086802543,5073,11344157,CN1C=C(N=C1)C2=CN=CC=C2,Cn1cnc(-c2cccnc2)c1
CHEMBL360999,IMFKJIBLFGZFSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,261900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.581864501574768,5073,11344157,CN1C=C(N=C1)C2=CN=CC=C2,Cn1cnc(-c2cccnc2)c1
CHEMBL3526984,IMIUKXZVUAUOBR-GFILMBHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,5.251811972993799,5079,12001280,CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(C(C4)O)C(=O)C,CC(=O)N1CCN(C2CCN(C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)CC1O
CHEMBL3526984,IMIUKXZVUAUOBR-GFILMBHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,8220.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,5.0851281824599495,5079,12001280,CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(C(C4)O)C(=O)C,CC(=O)N1CCN(C2CCN(C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)CC1O
CHEMBL1766189,IMIWIUDULMYEKK-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,5080,54586281,CC(C)C(C1=CC=C(C=C1)C2=NC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)n1
CHEMBL1766190,IMIWIUDULMYEKK-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,5081,54586320,CC(C)C(C1=CC=C(C=C1)C2=NC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)n1
CHEMBL1766182,IMIWIUDULMYEKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,5082,18668580,CC(C)C(C1=CC=C(C=C1)C2=NC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)n1
CHEMBL112592,IMJROXJEYNKELD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.200659450546418,5083,44341428,C1=CC=NC(=C1)COC2=CC=C(C=C2)N3C=CN=C3,c1ccc(COc2ccc(-n3ccnc3)cc2)nc1
CHEMBL3310294,IMOQEWXBWXGJOX-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24939756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5087,118706414,C1CC1(C#N)C2=CC(=CC(=C2)C3=CC=NC4=NNC(=C34)C(F)(F)F)CC(CO)O,N#CC1(c2cc(CC(O)CO)cc(-c3ccnc4n[nH]c(C(F)(F)F)c34)c2)CC1
CHEMBL3310295,IMOQEWXBWXGJOX-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24939756.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5088,91754690,C1CC1(C#N)C2=CC(=CC(=C2)C3=CC=NC4=NNC(=C34)C(F)(F)F)CC(CO)O,N#CC1(c2cc(CC(O)CO)cc(-c3ccnc4n[nH]c(C(F)(F)F)c34)c2)CC1
CHEMBL514800,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,APREMILAST,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19256507.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.",J. Med. Chem.,PUBLICATION,,5.0,5090,11561674,CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,CCOc1cc(C(CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
CHEMBL447424,IMUUVHRSPPDBTR-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5097,44587405,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCC(C)(C)CC(=O)O)F,CNC(Cn1c(=O)c(-c2cccc(OCCC(C)(C)CC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL401250,IMYWIXVEAKDSQK-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.080921907623926,5101,23635105,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=CC=C(C=C3)Cl)C(C(C)C)N,Cc1ccc(N2CCN(C(=O)C(C)Cc3ccc(Cl)cc3)CC2)c(C(N)C(C)C)c1
CHEMBL1077929,INGULWRLHYWXJR-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,5110,46883335,CC(C)CN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CC(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1077931,INGULWRLHYWXJR-VSGBNLITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,67.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.173925197299173,5111,46883337,CC(C)CN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CC(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1077930,INGULWRLHYWXJR-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,5112,46883336,CC(C)CN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CC(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL2331699,INKYZVZPRLGVGC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25711516.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",J. Med. Chem.,PUBLICATION,,4.301029995663981,5116,70977969,CC1=NN=C2N1C3=C(CC2)C=C(C=C3F)C4=CC(=CN=C4)F,Cc1nnc2n1-c1c(F)cc(-c3cncc(F)c3)cc1CC2
CHEMBL3645512,INMWFVJXYNMTDV-MYUZEXMDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,5118,44512034,CC(C1=CC=C(C=C1)C2=NN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CCC(CC(C)(C)O)(c2ccc(F)cc2)OC1=O
CHEMBL2206277,INOASWZOZPQAQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,5119,54762055,CC1(CC(CC(N1C)(C)C)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C)C,CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C
CHEMBL3091546,INOJXUNPXDYZIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5120,60001863,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=CC=C3)C4=CC=NC=C4,Cn1c(N2CCOC(c3ccccc3)C2)nc(-c2ccncc2)cc1=O
CHEMBL2425144,INQBVHWEOAKYED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5121,15945881,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NC5=C(N=CN=C54)N,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1
CHEMBL27759,INVTYAOGFAGBOE-UHFFFAOYSA-N,ENTINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.136677139879544,5127,4261,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
CHEMBL3326582,IOEXPPPOEMRUCU-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,5138,46191428,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4F)F)(C)C)C=N1,Cc1cc2c(NC(=O)NC3CC(C)(C)Oc4c3ccc(F)c4F)cccc2cn1
CHEMBL1940315,IOEYWFCDGXVEFG-JVHFYALYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5139,57391205,C1CC(CS(=O)(=O)C1)NC(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)C#CC4(CN5CCC4CC5)O,O=C(NC1CCCS(=O)(=O)C1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
CHEMBL497999,IOSCQMWDOQVSFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18752953.0,IC50,>,29100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.536107011014093,5148,11317045,CS(=O)(=O)C1=CC(=C(C=C1)OCC2CC2)C(=O)N3CCN(CC3)C4=C(C=C(C=C4)C#N)F,CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1
CHEMBL3702701,IOZXECSGCQCHGF-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,5156,89718443,CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCN(C)CC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1923115,IPEIMNMDXCTULH-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,5161,57394340,C1CC1N(CC2=C(C=CC(=C2)Cl)Cl)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1cc(Cl)ccc1Cl)C1CC1
CHEMBL228004,IPGJEBMBCSCKBX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.6020599913279625,5163,16658024,C1CC(CN(C1)C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2cc(Cl)ccc2c1=O
CHEMBL1766179,IPNCNQRVJPVKSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.481486060122113,5169,54585325,CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)S(=O)(=O)NC)(C3=CN=CN3)O,CNS(=O)(=O)c1cccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)c1
CHEMBL2057285,IPVDZHXIOYMFOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,5.0,5172,54576503,CCC1=C(C=CC=C1C2=NSC(=N2)C3=CC(=C(C=C3)CC(C)C)C#N)CCN4CCC(CC4)C(=O)O,CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(CC(C)C)c(C#N)c2)n1
CHEMBL2163826,IPXCMYKDOHLHDR-CRHVVPOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.221848749616356,5174,57522249,C1CC2CC(CC1N2C(=O)C(CC3=CC=C(C=C3)Br)NC(=O)C4(CC4)C5=C(C=C(C=C5)Cl)Cl)N,NC1CC2CCC(C1)N2C(=O)C(Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
CHEMBL393109,IPXPSGDBCIRUBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1060.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.97469413473523,5175,23647905,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOCC)(C)C4=CC(=CC(=C4)F)F,CCOCCCN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21
CHEMBL515252,IQAMTZLKUHMPPE-UHFFFAOYSA-N,"3,8'-BIAPIGENIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20408551.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).,J. Nat. Prod.,PUBLICATION,,7.096910013008056,5178,10414856,C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(OC5=CC(=CC(=C5C4=O)O)O)C6=CC=C(C=C6)O)O,O=c1c(-c2c(O)cc(O)c3c(=O)cc(-c4ccc(O)cc4)oc23)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12
CHEMBL2087169,IQCIFDSCWKQXJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,5179,67161862,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=CC=C4F)C5=NC=C(N5)C,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ncc(C)[nH]2)c2ccccc2F)C(=O)N3)CC1
CHEMBL386515,IQEPRBDBRZZHBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17428043.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.,J. Med. Chem.,PUBLICATION,,4.698970004336019,5180,54678279,CC(C)(C1=NC(=O)C(=C(N1)C(=O)NCC2=CC=C(C=C2)F)O)N(C)C,CN(C)C(C)(C)c1nc(=O)c(O)c(C(=O)NCc2ccc(F)cc2)[nH]1
CHEMBL2431457,IQGTYRBVWNLIFW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,4.301029995663981,5183,44624488,CC(C)(C)C1=C(C(=CC(=C1)C2=CC=CNC2=O)NC(=O)C3=CC=C(C=C3)NS(=O)(=O)C)OC,COc1c(NC(=O)c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
CHEMBL2206059,IQHKHGHDPGFXAV-MISXGVKJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23107482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5184,66557868,CS(=O)(=O)NCC1=NC2=CN=C3C(=C2N1C4CC5CCC4C5)C=CN3,CS(=O)(=O)NCc1nc2cnc3[nH]ccc3c2n1C1CC2CCC1C2
CHEMBL1099330,IQMZIBZJCFEUSM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,5.1249387366083,5186,23501721,C1=CC=C(C=C1)C2=CC(=NC(=C2)OCCCCCCC3=C(C(=CC=C3)OCCCC(=O)O)CCC(=O)O)C4=CC=CC=C4,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)n2)c1CCC(=O)O
CHEMBL495992,IQOLDUIYVMZEKG-VWNXMTODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5189,44583287,C1CN(CCC12CC(=O)C3=C(O2)C=CC(=C3)C4=CC=NC=C4)C(=O)NC5CC5C6=CC=CC=C6,O=C1CC2(CCN(C(=O)NC3CC3c3ccccc3)CC2)Oc2ccc(-c3ccncc3)cc21
CHEMBL230042,IQSICYGTAPFFKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,5193,135681875,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NCC(N5)(C)C,Cc1cc(C2=NCC(C)(C)N2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL431770,IQVRBWUUXZMOPW-PKNBQFBNSA-N,ISTRADEFYLLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,5197,5311037,CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C,CCn1c(=O)c2c(nc(C=Cc3ccc(OC)c(OC)c3)n2C)n(CC)c1=O
CHEMBL1091775,IQWBKNWLBVZZLG-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5198,46884063,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCC4,CC(c1ccccn1)c1c(CCN2CCC2)sc2ccccc12
CHEMBL2425888,IRBQSRFDQHFUPM-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,79360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.100398340853878,5202,71731476,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)Br)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3cc(Br)ccc3n2)c1=O
CHEMBL392609,IRCMQFHWDQBWEZ-UHFFFAOYSA-N,SR-1457,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,5203,16662116,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC(=CC=C4)Cl)N,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1
CHEMBL2448739,IRDKASZLBXOERK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,5205,73355726,CC1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
CHEMBL1774933,IRGGXYIIIARJBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,5.327902142064283,5209,46174270,CC1=CC(=CC(=C1C2=NC(=NC3=C2CN(C3)C(=O)NCC(C)(F)F)N)OCCN4C=C(C=N4)F)Cl,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2
CHEMBL1774933,IRGGXYIIIARJBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,4.522878745280337,5209,46174270,CC1=CC(=CC(=C1C2=NC(=NC3=C2CN(C3)C(=O)NCC(C)(F)F)N)OCCN4C=C(C=N4)F)Cl,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2
CHEMBL1277312,IRGGYSVFJCBILG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,5210,25184832,C1CC2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1
CHEMBL3622434,IRIDOYGIOXFPNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,=,36510.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.437588167050272,5218,89961716,C1CC2=NN=C(N2C3=C1C=C(C=C3)C4=CN=CC=C4)C5=CC=CC=C5,c1ccc(-c2nnc3n2-c2ccc(-c4cccnc4)cc2CC3)cc1
CHEMBL1922662,IRQIBOAVBGKTBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,=,8.5,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,8.070581074285707,5222,56850524,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)O)CC4=CC=C(C=C4)C5=NC=C(C=C5)C,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(C)cn3)cc2)nc1
CHEMBL1872483,IRQYACHFLTWGHT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5224,24817638,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C(C)C,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C(C)C)CC1
CHEMBL2425151,IRSCZNCGMYWXAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5227,72189519,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CSN=N4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1
CHEMBL2431462,IRVBXJQSVGDYQB-DHZHZOJOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,5.958607314841775,5229,44601452,CC(C)(C)C1=CC(=CC(=C1OC)C=CC2=CC=C(C=C2)NS(=O)(=O)C)C3=CC=CNC3=O,COc1c(C=Cc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
CHEMBL3297778,ISIATOZGACZZRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5239,90645309,C1=CC(=CC=C1OC2=NC=CC3=C2C=CN3)F,Fc1ccc(Oc2nccc3[nH]ccc23)cc1
CHEMBL375166,ISIVOJWVBJIOFM-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.0,5240,10226546,CC1=C(C(=NN1)C)CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)CC(C)C)C(=O)N4CC(CO4)O,Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1CC(O)CO1)c(=O)n(C)c(=O)n2CC(C)C
CHEMBL3699338,ISLCCZIUPKFGKN-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,5242,89718225,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=C(C=C8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(OC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3403816,ITAXZEXGQGVKHD-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,5251,71288593,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C(C)C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403816,ITAXZEXGQGVKHD-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,5251,71288593,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C(C)C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3422235,ITDPHYUDGLCWQU-VAHXTSCQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,5255,72547065,C1C2CSC(=NC2(COC1C3=NC=CO3)C4=C(C=C(C=C4)F)F)N,NC1=NC2(c3ccc(F)cc3F)COC(c3ncco3)CC2CS1
CHEMBL2070150,ITFCVHBIFHOZNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,5256,70693068,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)C4=CC=CC=C4)Cl,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccc3Cl)[nH]c2c1
CHEMBL2387595,ITJZUXOTSQYHCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,5262,51000500,CCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,CCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
CHEMBL388012,ITMSPKNBOCNPGW-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,4.698970004336019,5263,23626132,CC1=NC=CN1CC(=O)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CN5C=CN=N5)F,Cc1nccn1CC(=O)c1ccc(-c2ccc(N3CC(Cn4ccnn4)OC3=O)cc2F)cn1
CHEMBL3640255,ITPNKZFHSOFLSJ-APBUJDDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.698970004336019,5267,44467504,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=CC(=C(C=C4F)F)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3cc(F)c(F)cc3F)C2)nc(C)c1F
CHEMBL207411,ITQXAONDFWOMPJ-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,448.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.348721986001856,5270,44410763,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C4CCCCC4,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C1CCCCC1
CHEMBL1209554,ITUKYMGUUJBALP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,5273,49862548,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CC=C3,CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O
CHEMBL1209554,ITUKYMGUUJBALP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,5273,49862548,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=CC=C3,CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O
CHEMBL3087043,ITVVFGALQBNWTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,5276,72547532,CCCC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,CCCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL3623830,ITXORCJLPUUDIY-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,4.301029995663981,5277,89846958,CCC(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
CHEMBL3623831,ITXORCJLPUUDIY-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,4.698970004336019,5278,89846957,CCC(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
CHEMBL3623824,ITXORCJLPUUDIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,4.301029995663981,5279,71811363,CCC(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
CHEMBL151207,ITXWTUUAROJZDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,9170.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,5.037630664329979,5280,11172276,CCCCOC1=CC=C(C=C1)N2C=C(N=C2)C,CCCCOc1ccc(-n2cnc(C)c2)cc1
CHEMBL3699333,ITYPOIOJLXUMJH-KWMOVAKFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,5281,89718217,CC(C)(C)OC(=O)NC1CCC(CC1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NC6CCC(NC(=O)OC(C)(C)C)CC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,5283,4171,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,COCCc1ccc(OCC(O)CNC(C)C)cc1
CHEMBL3699332,IUKGTWNYPLJBGP-GSVOJQHPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.863279432843593,5293,89718400,CC(C)OC1=CC=CC(=C1)NC(=O)C2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC(C)C)c6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1928243,IUQFLLUDDADQCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22061640.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 4-aminomethylphenylacetic acids as ��-secretase modulators via a scaffold design approach.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5304,54768039,CC(C)(C)CC(C1=C(C=C(C=C1)CC(=O)O)C2=CC=C(C=C2)C(F)(F)F)N3CCC(CC3)C(F)(F)F,CC(C)(C)CC(c1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1)N1CCC(C(F)(F)F)CC1
CHEMBL483876,IUTAFCQVIUFADT-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5305,44583234,C1CC2(CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4)OC5=C1C=C(C=C5)F,O=C(NC1CC1c1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1
CHEMBL477145,IUUQWNJIQOXGIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,5307,18440026,CC1=CC(=NNC1=O)CC2=C(C(=C(C=C2)Cl)OC3=CC(=CC(=C3)C#N)F)F,Cc1cc(Cc2ccc(Cl)c(Oc3cc(F)cc(C#N)c3)c2F)n[nH]c1=O
CHEMBL3664681,IUVZNWZLVHMDDR-SIBVEZHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,5309,59635704,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(COC)C4=CC=CC=C4,COCC1(c2ccccc2)CCN(C(C)c2ccc(-c3ccc(=O)n(C)c3)cc2)C(=O)O1
CHEMBL3353099,IVHDOVLHZVPDCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25454273.0,IC50,=,25400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5951662833800615,5323,49872483,CC1=CN(C=N1)C2=C(N=C(C=C2)C3=NN(C(=N3)NC4=C(C=CC(=C4)C(F)(F)F)F)C)OC,COc1nc(-c2nc(Nc3cc(C(F)(F)F)ccc3F)n(C)n2)ccc1-n1cnc(C)c1
CHEMBL207942,IVTCSKRCJOCTBF-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,5328,11719046,CCN(C)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4,CCN(C)C(C)C(c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1
CHEMBL443060,IVTUNYRYCDBVQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,5329,44443132,CCN1C(=O)COC2=C1C(=C(C=C2)CN3CCN(CC3)CCOC4=CC=CC5=C4C=CC(=N5)C)F,CCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)c(F)c21
CHEMBL2348851,IVTZBZBZVFLWIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,5330,44205825,CC(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=CC(=C(C=C3)OC)OC,COc1ccc(-c2cnc3[nH]cc(C(=O)NC(C)CO)c3n2)cc1OC
CHEMBL1222938,IVUVZXDTPUJHFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,5331,49865104,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC=CC=C5)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
CHEMBL1951350,IVWHDODYYCRXLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,5335,57404049,CCN1C2=C(N=CN=C2NC1=O)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC(C)C,CCn1c(=O)[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c21
CHEMBL3137460,IVWIUEUINWDXLX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5300.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.275724130399211,5336,76336701,CC(C)(CN1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)O,CC(C)(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3580669,IVWXFGRLNHCKNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,4.522878745280337,5337,24830571,CS(=O)(=O)NC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)F,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1
CHEMBL468970,IVXGFXACZQBKSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20850301.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,5338,25191022,C1COCCN1C2=CC(=CC(=C2)NC3=NC=CC(=N3)NC4=C(C=CC5=C4OCO5)Cl)N6CCOCC6,Clc1ccc2c(c1Nc1ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n1)OCO2
CHEMBL2048058,IWBWMEKXFWHGKV-YWMUFLPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,5.6777807052660805,5343,57384270,CC(C)(C1=CC=CC(=C1)CNC2CS(=O)(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F)O,CC(C)(O)c1cccc(CNC2CS(=O)(=O)CC(Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)C2O)c1
CHEMBL406917,IWCKJSOBOIUYSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,5.886056647693163,5345,1410239,C1=CC=C(C=C1)CSC2=NN=C(N2C3=CC=C(C=C3)Br)C4=CC=NC=C4,Brc1ccc(-n2c(SCc3ccccc3)nnc2-c2ccncc2)cc1
CHEMBL3673953,IWGLCABRVPLEJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320616,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,5348,52935809,CC(=O)NC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(NC(C)=O)cc23)c(F)n1
CHEMBL1762427,IWGWKANZPRNVTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21354795.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin),"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5349,54586805,CC(C)(C)C1=CC(=NO1)NC(=O)N2CCCN(CC2)C(=O)CN3CCS(=O)(=O)CC3,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)CN3CCS(=O)(=O)CC3)CC2)no1
CHEMBL596515,IWLZOZCKKUEBQR-MDZDMXLPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19700331.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,6.0,5353,10294289,C1=CC=C2C=C(C=CC2=C1)CCOC3=C(C=CC(=C3)CN4C=CN=C4)C=CC(=O)O,O=C(O)C=Cc1ccc(Cn2ccnc2)cc1OCCc1ccc2ccccc2c1
CHEMBL1784347,IWRJDNKXMJBFEA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5357,54583016,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCS(=O)(=O)CC3)N(C=O)O,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCS(=O)(=O)CC2)CC1
CHEMBL3358942,IWTKLSNKJDHVML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5360,58026170,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC=C3C(=O)N,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O
CHEMBL1650443,IWYJYHUNXVAVAA-OAHLLOKOSA-N,TRELAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21186796.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,PUBLICATION,,5.0,5365,15983988,CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O
CHEMBL3604739,IWZDHCYXTXFDQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,5.40000018605658,5366,122185980,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C=CC(=C3Cl)Cl)F,Cc1cc(NCc2c(F)ccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1
CHEMBL3684869,IXDKFUBXESWHSL-JQWIXIFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26985297.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.",ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5370,24963286,CCC(CC1COC(=N1)N)C2=CC=CC=C2,CCC(CC1COC(N)=N1)c1ccccc1
CHEMBL497419,IXGNTQQGMMPWEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602099,5374,44583633,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3OC)N4C=CC=CC4=O)C,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL497419,IXGNTQQGMMPWEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,5374,44583633,CC1=C(N2C=C(C=C(C2=N1)NCC3=CC=CC=C3OC)N4C=CC=CC4=O)C,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL3326584,IXIWLJNULBBLPQ-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,5379,45380848,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4F)C(F)(F)F)(C)C)C=N1,Cc1cc2c(NC(=O)NC3CC(C)(C)Oc4c3ccc(C(F)(F)F)c4F)cccc2cn1
CHEMBL497171,IXKMSVHWGUFUOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18768319.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,5381,25067560,CCCCNC1=NC=CC2=C1C3=CC=CC=C3N2,CCCCNc1nccc2[nH]c3ccccc3c12
CHEMBL486140,IXMNYLMWWGRTJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.769551078621726,5382,25138082,CCC(=O)NC1=NC(=NC(=C1)C2=CC(=CN=C2)OC)N3C(=CC(=N3)C)C,CCC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1
CHEMBL1077963,IXTGDXLZCDARRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5386,46883035,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=N3,O=C(O)CCC1(c2ccccn2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL3087352,IXVQEZZFBBXSMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,5391,72547026,C1=CC(=CC=C1NS(=O)(=O)C2=CC(=CC(=C2)Cl)Cl)N3C=CN=C3,O=S(=O)(Nc1ccc(-n2ccnc2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL1079119,IXZUPBUEKFXTSD-INMULRNOSA-N,"6',7'-DIHYDROXYBERGAMOTTIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19689106.0,IC50,=,1580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,Minor furanocoumarins and coumarins in grapefruit peel oil as inhibitors of human cytochrome P450 3A4.,J. Nat. Prod.,PUBLICATION,,5.801342913045578,5397,12082365,CC(=CCOC1=C2C=CC(=O)OC2=CC3=C1C=CO3)CCC(C(C)(C)O)O,CC(=CCOc1c2ccoc2cc2oc(=O)ccc12)CCC(O)C(C)(C)O
CHEMBL1079119,IXZUPBUEKFXTSD-INMULRNOSA-N,"6',7'-DIHYDROXYBERGAMOTTIN",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22342630.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence assay,"Biotransformations of 6',7'-dihydroxybergamottin and 6',7'-epoxybergamottin by the citrus-pathogenic fungi diminish cytochrome P450 3A4 inhibitory activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0915149811213505,5397,12082365,CC(=CCOC1=C2C=CC(=O)OC2=CC3=C1C=CO3)CCC(C(C)(C)O)O,CC(=CCOc1c2ccoc2cc2oc(=O)ccc12)CCC(O)C(C)(C)O
CHEMBL2047191,IYDMAGVFBIEVMF-KRCBVYEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22704887.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,5405,70694560,CC(C)C(C(=O)N1CCCC1C2=NC(=C(N2)F)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=C(NC(=N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)F)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1nc(-c2ccc(-c3ccc(-c4nc(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)[nH]c4F)cc3)cc2)c(F)[nH]1)C(C)C
CHEMBL1214451,IYPRGGZMVDCNQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,5418,11566489,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=NC=C(C=C3)Cl,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(Cl)cn3)cc2C1
CHEMBL3234863,IYSJAKSFBLSTEX-ACSYHNTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24630411.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,5423,71550657,CC(C1=CC=CC=C1)N2C(=O)C(OC2=O)(CC3=CC=CC=C3)C4=NN=C(O4)C5(CC5)C6=CC=CC=C6,CC(c1ccccc1)N1C(=O)OC(Cc2ccccc2)(c2nnc(C3(c4ccccc4)CC3)o2)C1=O
CHEMBL1214337,IYSOHQIRVSYPNJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,5424,11709762,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=C(N=CC=C3)F,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3F)cc2C1
CHEMBL234412,IYTDSNSLAQHLJL-XIRDDKMYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17418568.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5425,44431744,CCCCC1CN2CCC3=CC(=C(C=C3C2CC1N)OC)OC,CCCCC1CN2CCc3cc(OC)c(OC)cc3C2CC1N
CHEMBL3261479,IYUQYZMILCFRJI-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5427,69937236,C1CN2CCC1C(C2)N3CCN4C=CC5=C4C(=CC=C5)C3=O,O=C1c2cccc3ccn(c23)CCN1C1CN2CCC1CC2
CHEMBL3645518,IYVALPSKVAMDMH-JRPXNJEYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5700.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,5.2441251443275085,5428,42605500,CC(C1=CC=C(C=C1)C2=NN(C(=O)C=C2)CC3CC3)N4CCC(OC4=O)(CC(C)(C)O)C5=CC=CC=C5,CC(c1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL2403888,IYWRCNFZPNEADN-CXODAYGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24555570.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.",J. Med. Chem.,PUBLICATION,,5.698970004336019,5430,46862685,CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=CC5=C4C=CC(=C5)OC)NC(=O)OC(C)(C)C,C=CC1CC1(NC(=O)C1CC(Oc2nccc3cc(OC)ccc23)CN1C(=O)C(NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
CHEMBL1288261,IZHYDDUYSBYFJI-VZYDHVRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,20200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.694648630553377,5441,49836029,CC1=C(C=C(C=C1)F)CN2C(=CC3=C2C(=O)N(C(=O)N3C)C)N4CCCC(C4)(C)N.Cl,Cc1ccc(F)cc1Cn1c(N2CCCC(C)(N)C2)cc2c1c(=O)n(C)c(=O)n2C
CHEMBL3699339,IZKQXLOXCDKRSU-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,5444,89718190,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=C(C=C8)N,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2170638,IZNOPBBLCFPKHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,24500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.610833915635467,5446,58269620,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)C(=O)N,NC(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)cc1
CHEMBL541941,IZQNXPIWJTTZEN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19211174.0,IC50,=,91.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome at 1 uM,"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.",Eur. J. Med. Chem.,PUBLICATION,,7.040958607678906,5448,42642930,CCC(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)Cl)N3C=CN=C3,CCC(c1ccc(-c2ccc(O)c(Cl)c2)cc1)n1ccnc1
CHEMBL3137390,IZRBWBHTBCWWHX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,5449,76322222,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
CHEMBL497309,JAHLIPBSDIJMHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2394.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.620875853929608,5463,25033655,COC1=CC=C(C=C1)C2=CC3=C(C=C2)C(=CC3)C4=CC=NC=C4.Cl,COc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1
CHEMBL3330409,JAHXQCZCZURPTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,6.154901959985743,5465,101903000,CCC1=CC=CC=C1C(C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N)N(C)C,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C
CHEMBL3330409,JAHXQCZCZURPTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,5.5376020021010435,5465,101903000,CCC1=CC=CC=C1C(C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC(=CC=C4)S(=O)(=O)N)N(C)C,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C
CHEMBL1080974,JAJFLSQZGKSQFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5466,46883508,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC=CC=C3C(F)(F)F)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccc3C(F)(F)F)cc2)C1
CHEMBL3310485,JAJZURBQJLCEQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.292429823902063,5467,118706539,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
CHEMBL3298837,JAKPRCPHHDOYBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,5469,68234668,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)OC(F)(F)F,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1
CHEMBL1671964,JATLXGAUZPZTKI-PXNMLYILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.6020599913279625,5476,51051122,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(=O)OC)Cl,COC(=O)c1ccc(Oc2ccc(C=C3SC(=O)NC3=O)cc2OC)c(Cl)c1
CHEMBL464909,JAZXUPQDNGHUCB-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,5482,44570365,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=C(C=C4)F,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)CC(C)N1
CHEMBL464909,JAZXUPQDNGHUCB-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,5482,44570365,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=C(C=C4)F,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)CC(C)N1
CHEMBL2017280,JBGVCJHAJVIUSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,5489,70685378,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4C(=O)N5CCCCC5)C(=O)N)OC,COc1cc2c(Nc3ccccc3C(=O)N3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL2043240,JBKSEOCGJGAYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22749190.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Wake-promoting agents: search for next generation modafinil: part IV.,Eur. J. Med. Chem.,PUBLICATION,,4.494850021680094,5493,11588489,C1=CC=C(C(=C1)CS(=O)CC(=O)N)OC2=CC(=C(C=C2)Cl)Cl,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1
CHEMBL2043240,JBKSEOCGJGAYMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22749190.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Wake-promoting agents: search for next generation modafinil: part IV.,Eur. J. Med. Chem.,PUBLICATION,,4.3979400086720375,5493,11588489,C1=CC=C(C(=C1)CS(=O)CC(=O)N)OC2=CC(=C(C=C2)Cl)Cl,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1
CHEMBL1277677,JBMFBKALKQFKHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942471.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,PUBLICATION,,5.958607314841775,5494,49836293,CN(CC1=C2C(=CC(=O)N1CC3=CC=NC=C3)NN(C2=O)C4=CC=CC=C4Cl)C5=CC=CC=C5,CN(Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccncc1)c1ccccc1
CHEMBL381630,JBMUJPIOBHXTBM-KCMFSSCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16203148.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,5496,15955613,CC(C)(C1=NC=C(O1)C2=CC=C(C=C2)Cl)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC5=C(O4)C=NC=C5)C(=O)NC6C(COC7=CC=CC=C67)O)O,CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(CC(O)CC(Cc2cc3ccncc3o2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL2181776,JBSNALXXNTWUEC-SFQUDFHCSA-N,BILB 1941,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.022276394711152,5499,56949326,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=CC=CC=N5)C6CCCC6,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL2181776,JBSNALXXNTWUEC-SFQUDFHCSA-N,BILB 1941,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25393851.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection.",J. Med. Chem.,PUBLICATION,,4.522878745280337,5499,56949326,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=CC=CC=N5)C6CCCC6,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL2440660,JBUDGQFEYJAIBH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,5501,72375745,CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,Cc1csc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1
CHEMBL3261483,JBVRKZZSTULWTO-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5502,69937162,C1CN2CCC1C(C2)N3CCN4C5=C(C=C(C=C5C3=O)Cl)C=N4,O=C1c2cc(Cl)cc3cnn(c23)CCN1C1CN2CCC1CC2
CHEMBL3330410,JBZRAEUHDPMQSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,5.3979400086720375,5506,101902999,C1CCN(C1)C(C2=CSC=C2)C(=O)NC3=CC4=C(C=C3)NN=C4C5=CC(=CC=C5)S(=O)(=O)N,NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1
CHEMBL3330410,JBZRAEUHDPMQSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25043312.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,PUBLICATION,,6.0,5506,101902999,C1CCN(C1)C(C2=CSC=C2)C(=O)NC3=CC4=C(C=C3)NN=C4C5=CC(=CC=C5)S(=O)(=O)N,NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1
CHEMBL3121811,JCBVSCDADXSWFS-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,5.0,5508,66730677,CC1=CC2=C(C=C1F)C(=C(N2C3=NC=CC=N3)C4=NC=C(C=C4)S(=O)(=O)NC(C)C(F)(F)F)C#N,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)NC(C)C(F)(F)F)cn1)n2-c1ncccn1
CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,5509,3957,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
CHEMBL2420680,JCEKIEMNLATOCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,3581.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.445995678988097,5513,71818089,C1=CC(=CC2=C1C=CC(=C2Cl)C3=CC(=CN=C3)F)O,Oc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1
CHEMBL3260743,JCIBBNGOHWXOKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,3000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,5.522878745280337,5516,60148513,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
CHEMBL3260743,JCIBBNGOHWXOKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,5.040958607678906,5516,60148513,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
CHEMBL3545215,JCINBYQJBYJGDM-UHFFFAOYSA-N,BMS-911543,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288683.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,5.522878745280337,5517,50922691,CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
CHEMBL1951324,JCJHYMTUOKATGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.318758762624412,5519,57391851,C1=CC(=CC(=C1)Cl)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(Cl)c1
CHEMBL1223001,JCMLBHBSAUYDRL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,5522,49865162,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC=C(C=C5)Cl)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccc(Cl)cc3)c3ccccc32)CC1
CHEMBL3291395,JCNNVJAIWLPOMY-JETXTKBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1630.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.787812395596042,5523,75593287,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCC(CC5)O)C,C=CC1(C)CC(OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291395,JCNNVJAIWLPOMY-JETXTKBJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1890.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.723538195826756,5523,75593287,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCC(CC5)O)C,C=CC1(C)CC(OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL1945723,JCOILWGRHHMFON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22196117.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of triazolopyridazinones as potent p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,5525,56951457,CCN1C(=O)C(=CC2=NN=C(N21)C3=C(C=CC=C3Cl)F)C4=C(C=CC(=C4)C(=O)NC5CC5)C,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2nnc(-c3c(F)cccc3Cl)n21
CHEMBL2387593,JCWUZABSZGZYPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,5529,71659490,CC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,Cc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.346787486224656,5532,1367,C1=CC=C2C(=C1)N=NN2N,Nn1nnc2ccccc21
CHEMBL3142317,JCYICIRSTHXKMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,4.0,5534,56593857,C1CN2CCC1C(C2)C3=CNC4=C3C=CC(=C4)N=C(C5=CC=CS5)N.Cl.Cl,NC(=Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1
CHEMBL3142317,JCYICIRSTHXKMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BQ as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,4.0,5534,56593857,C1CN2CCC1C(C2)C3=CNC4=C3C=CC(=C4)N=C(C5=CC=CS5)N.Cl.Cl,NC(=Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1
CHEMBL1951337,JDJSPHQNBFVVDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,5547,57400523,CN(C)C(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CN(C)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL572324,JDKMJELQOXOOJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19883100.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.,J. Med. Chem.,PUBLICATION,,5.356547323513812,5549,16045493,C1=CC(=NC2=NNC(=C21)COC3=CC(=C(C(=C3)F)Cl)OC4=CC(=CC(=C4)C#N)Cl)N,N#Cc1cc(Cl)cc(Oc2cc(OCc3[nH]nc4nc(N)ccc34)cc(F)c2Cl)c1
CHEMBL2441200,JDNUWBKKCJHGHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2D6 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5558,67387021,CC(C)OC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=C(N=C(O3)N4CCCCC4)C(F)(F)F,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1
CHEMBL2441200,JDNUWBKKCJHGHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5558,67387021,CC(C)OC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=C(N=C(O3)N4CCCCC4)C(F)(F)F,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1
CHEMBL2441200,JDNUWBKKCJHGHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5558,67387021,CC(C)OC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=C(N=C(O3)N4CCCCC4)C(F)(F)F,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1
CHEMBL3702775,JDQVENXWSYDAIX-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13030.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.885055584287415,5559,89718484,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2420683,JDZSWHXANGNAGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,6720.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.172630726946175,5566,71818092,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CC(=CN=C3)O,COc1ccc2ccc(-c3cncc(O)c3)c(Cl)c2c1
CHEMBL462513,JECPEAXUEYTRPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18855374.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,PUBLICATION,,5.721246399047171,5568,25093389,C1=CC(=CC(=C1)O)C2=CSC(=C2)C3=CC=C(C=C3)O,Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1
CHEMBL1807440,JEEFQVVXVXIPDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21705217.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064283,5569,56676902,CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)F)N3CCOCC3)NC4=NC=NN5C4=C(C(=C5)C(=O)C6=CC=CC=C6)C,Cc1ccc(NC(=O)c2cc(F)cc(N3CCOCC3)c2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12
CHEMBL1951449,JEFLAXCYXPNMCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,5570,57391833,C1=CC(=CN=C1)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2cccnc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL1923119,JEGFJOUJUPKNPT-IRPSRAIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,5573,57394342,CC1=CC(=CC(=C1C)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)CCCOC,COCCCc1cc(C)c(C)c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1
CHEMBL1222800,JEHMSKUGFGBZMO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5574,46933385,CN(C)CCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,CN(C)CCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL3127163,JELFUQAHMVGHOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24508133.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP1 receptor antagonists for treatment of overactive bladder by core structure replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5575,59179887,C1=CC=C(C=C1)C2=NN(C3=C2C=CC(=C3)C(F)(F)F)C4=NC(=CS4)C(=O)O,O=C(O)c1csc(-n2nc(-c3ccccc3)c3ccc(C(F)(F)F)cc32)n1
CHEMBL453167,JELUMXNSIYVRCU-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5577,44576680,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)CC4=C(C=CC=C4S(=O)(=O)C)F,COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL487553,JENSDTKXNVHSSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,5582,25074316,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCC(CC4)OC)C,COC1CCN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)CC1
CHEMBL398126,JEPDINCGXLHLDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17531480.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5584,11514705,C1CCCC(CC1)C2=C(C=CC(=C2)Cl)OCC(=O)O,O=C(O)COc1ccc(Cl)cc1C1CCCCCC1
CHEMBL3104538,JEQFEWYKPONMMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.3979400086720375,5586,76335565,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CC=C(C=C4)C#N,N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
CHEMBL2087168,JEUQHZZAJFLFGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5594,67162590,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC(=CC(=C4)F)F)C5=NC=C(N5)C,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2ncc(C)[nH]2)C(=O)N3)CC1
CHEMBL3673968,JEYWLGNUKVSWDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320639,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,5604,52936254,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)C)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1
CHEMBL3673968,JEYWLGNUKVSWDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320683,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,5604,52936254,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)C)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1
CHEMBL2018904,JEZZAOQPWKKIKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,26300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.580044251510242,5606,56953768,CCCCCSC1=NC2=C(N1)C=C(C=C2)OC,CCCCCSc1nc2ccc(OC)cc2[nH]1
CHEMBL2165508,JFGXHJQNIFKDJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,6.221848749616356,5610,57506727,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=C(C=C4F)F)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)cc(F)c5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL1829472,JFHYZQNXNHZARY-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782432.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5611,24992519,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C4=NC=CC=N4,CC1CCCN1CCCOc1ccc(-c2ccc(=O)n(-c3ncccn3)n2)cc1
CHEMBL1923126,JFLDDEFROOZARM-HXOBKFHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,5615,57401309,C1CC1N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)C(=O)C3CNCCC34C5=CC(=C(C=C5C(=O)O4)F)F,O=C1OC2(CCNCC2C(=O)N(Cc2cccc(C(F)(F)F)c2Cl)C2CC2)c2cc(F)c(F)cc21
CHEMBL405981,JFLFKVDUANRIPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,5616,23395790,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN4CCCC4)CC5=CC=C(C=C5)C6=CC=C(C=C6)Cl,Cn1cc(Cc2cn(CC(=O)N(CCN3CCCC3)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
CHEMBL2048028,JFOZKMSJYSPYLN-QHCPKHFHSA-N,LIFITEGRAST,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,5620,11965427,CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl,CS(=O)(=O)c1cccc(CC(NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1
CHEMBL2331676,JFXLXTLDGUAURJ-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.075720713938118,5630,59239424,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=NC(=C4)C)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(c2cc(C)ncn2)C3)cc1
CHEMBL1951447,JGCVYORJEGYXGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,48.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.318758762624412,5633,57402295,COC1=CC=CC(=C1)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,COc1cccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5nc[nH]c45)cc3)cc2)c1
CHEMBL1822792,JGEBLDKNWBUGRZ-HXUWFJFHSA-N,MK-2461,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21608528.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,5.1487416512809245,5635,44137946,CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)NS(=O)(=O)N(C)CC5COCCO5)N=C2,CN(CC1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1
CHEMBL1272207,JGLTVCVKQGVHKR-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,5637,52946759,CN1CCC12CCN(CC2)C(=O)OC3(CC3)C4COCC(N4S(=O)(=O)C5=CC=C(C=C5)Cl)CC6CC6,CN1CCC12CCN(C(=O)OC1(C3COCC(CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)CC2
CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.154901959985743,5640,3686,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
CHEMBL1257964,JGXUYJUQTMMZNX-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,5649,16679614,CC1CNC(=O)C2=CC3=C(N12)C=CC(=C3)OC4CCN(CC4)C(C)C,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C(C)CNC2=O)CC1
CHEMBL1257851,JGXUYJUQTMMZNX-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5650,16679612,CC1CNC(=O)C2=CC3=C(N12)C=CC(=C3)OC4CCN(CC4)C(C)C,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C(C)CNC2=O)CC1
CHEMBL1257607,JGXWDNPDGKMFIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5651,16678725,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CCO,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CCO)C2=O)CC1
CHEMBL487438,JHBJKRQQEIQKHE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539454.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5656,24986404,C1CCC2(CC1)C(=C(C2=O)Br)NC(CC3=CC=C(C=C3)N4C5=C(C=CC=N5)N=C4C6(CC6)C(F)(F)F)C(=O)O,O=C(O)C(Cc1ccc(-n2c(C3(C(F)(F)F)CC3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2
CHEMBL1079958,JHGFMOUZDYZILF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,5662,46879597,CCN1C(=C(C2=CC(=NC(=C21)NCC3=C(C=CC=C3C)C)N4C=CC=CC4=O)C)C,CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21
CHEMBL2409691,JHHVLAYNAWPINK-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5664,71814859,CC1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=CC=C(C=C3)OCC4=CC=CC=N4,CC1(CS(=O)(=O)N2CCC(Oc3ccc(OCc4ccccn4)cc3)CC2)NC(=O)NC1=O
CHEMBL3087343,JHIBNQJIDVCRSZ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,5665,72543943,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,Cc1cc(-c2ccc(NC(=O)C(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL3087342,JHIBNQJIDVCRSZ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,5666,42639933,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,Cc1cc(-c2ccc(NC(=O)C(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL359657,JHLIGYPHPBLDDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,58700.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.231361898752385,5668,11206290,C1=CC(=CN=C1)C2=CC=C(S2)CN,NCc1ccc(-c2cccnc2)s1
CHEMBL103651,JHMFRQRLRFFSIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,5669,20763606,CC1=CC=CC=C1N=CNO,Cc1ccccc1N=CNO
CHEMBL2436225,JHUGQHSVPSEAPO-FXXKCHFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.7447274948966935,5673,72714053,CC1C(C(=O)N(C2=C(N1C(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)C1C
CHEMBL264241,JHVAMHSQVVQIOT-MFAJLEFUSA-N,ANIDULAFUNGIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19029327.0,IC50,>,17500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.,Antimicrob. Agents Chemother.,PUBLICATION,,4.756961951313706,5674,166548,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(C)O)NC(=O)C(C(O)C(O)c5ccc(O)cc5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)cc3)cc2)cc1
CHEMBL2064344,JHVHZYMEYYOABD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,5675,49837962,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=CC=CC=C4N3C5=CC=CC=C5,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3ccccc3n2-c2ccccc2)n1
CHEMBL205280,JHXQEUXIBMCBIF-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6439741428068775,5677,44411032,CCCCN(C)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,CCCCN(C)C(C)C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
CHEMBL549930,JHYBPHVVKVPUAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,5678,45272040,CC(CN1C=CN=C1)NC(=O)NC2CCN(CC2)CC3=CN(C=C3)C4=CC=C(C=C4)C(F)(F)F,CC(Cn1ccnc1)NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1
CHEMBL3422245,JIAYOIBUKDISBO-IYPIGGPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,5682,76955651,CC1=NOC(=C1)C2CC3C(SC(=NC3(CO2)C4=C(C=C(C=C4)F)F)N)CF,Cc1cc(C2CC3C(CF)SC(N)=NC3(c3ccc(F)cc3F)CO2)on1
CHEMBL246160,JIEPFEWJSJUYOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,5684,10002960,CN(C)CC1CCC(CC1)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
CHEMBL246160,JIEPFEWJSJUYOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,5684,10002960,CN(C)CC1CCC(CC1)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
CHEMBL2170635,JIIGIBJNCCBNQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,5687,58269689,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=NC=C3,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccncc3)CC2)c(C(F)(F)F)c1
CHEMBL179669,JIOQSJVEVFADJG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,5.221848749616356,5691,23646069,CC1=C(SC=C1)C2=CN=CC=C2,Cc1ccsc1-c1cccnc1
CHEMBL2448709,JIRODWLZHQDZBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,44400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.35261702988538,5692,73349663,CN1CCC(CC1)NCC(COC2=CC3=C(C=C2)C=C(C=C3)Br)O,CN1CCC(NCC(O)COc2ccc3cc(Br)ccc3c2)CC1
CHEMBL392064,JISHTAQRIKFVMS-IBGZPJMESA-N,SR-709,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,5693,16662087,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=CC=C4Cl)O,O=C(C(O)c1ccccc1Cl)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL1078336,JIXUFNPVCLBVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5696,46883033,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=NC=C3,O=C(O)CCC1(c2ccncc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL2059801,JIZRFQIOTHWMPY-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,5699,70696847,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1c[nH]c2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL1221429,JJDRNYKHCUPAGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5702,49865290,CNC(=O)C1=CC=C(C=C1)C(C2=NN=NN2CC3=CC=CC=C3)N4CCCN(CC4)C5CCC5,CNC(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1
CHEMBL3125385,JJEQHQDCYGPKKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,5703,57411134,C1CN(C2=CC=CC=C21)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21
CHEMBL3702739,JJGHCLANFUCWPB-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3640.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.438898616350944,5704,89718439,CCN(CC)CCNC(=O)C1=CN(C2=C(C=CC=C12)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(CC)CC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3680985,JJHAQEOFFYLRAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3800.0,NM,253318,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,5.42021640338319,5706,53493004,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OC(F)(F)F,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1
CHEMBL1682900,JJPKQUVDOTUNRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.173925197299173,5709,9861918,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)NC3)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1cnc[nH]1
CHEMBL1682900,JJPKQUVDOTUNRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.130768280269024,5709,9861918,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)NC3)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1cnc[nH]1
CHEMBL1682900,JJPKQUVDOTUNRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,5709,9861918,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)NC3)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1cnc[nH]1
CHEMBL3331521,JJQZDOKXARNTKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221665.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,5712,71153408,CCCCOC1=CN=CC(=C1)C2=NN=C3N2C4=C(C=CC(=C4)CN5CCOCC5)N=C3C,CCCCOc1cncc(-c2nnc3c(C)nc4ccc(CN5CCOCC5)cc4n23)c1
CHEMBL2397306,JJSJJDRYTQMCBL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5715,71681888,CC1=C(SC(=N1)NC(=O)CN2C(COC2=O)C(C)C)C3=CC=C(C=C3)N,Cc1nc(NC(=O)CN2C(=O)OCC2C(C)C)sc1-c1ccc(N)cc1
CHEMBL2436223,JJTKZZXKJLOOGG-UZIITKLFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.301029995663981,5716,72712569,CC1C(C(=O)N(C2=C(N1C(=O)CS(=O)(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL2397415,JJVAPHYEOZSKJZ-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23632269.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as benzoylresorufin conversion to resorufin metabolites after 45 mins by fluorescence assay,"Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,5717,53472683,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12
CHEMBL2397415,JJVAPHYEOZSKJZ-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23632269.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as 7-benzyloxy-4-trifluoromethylcoumarin conversion to 7-hydroxy-4-trifluoromethylcoumarin after 20 mins by fluorescence assay,"Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,5717,53472683,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12
CHEMBL2030402,JJWLXRKVUJDJKG-VIFPVBQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22560567.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of XL413, a potent and selective CDC7 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5720,57899889,C1CC(NC1)C2=NC(=O)C3=C(N2)C4=C(O3)C=CC(=C4)Cl,O=c1nc(C2CCCN2)[nH]c2c1oc1ccc(Cl)cc12
CHEMBL241241,JJWMJWGVQCRRFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.568636235841013,5721,23647904,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC(F)(F)F)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL2425611,JJZNHUUZTYYRMQ-KYJTYKTMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,5724,72191038,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OCC(F)(F)F,CC(C)(C)c1cccc(CNC2C[S+]([O-])CC(Cc3cc(F)c(N)c(OCC(F)(F)F)c3)C2O)c1
CHEMBL2158289,JJZWAMOLUCACLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.173925197299173,5725,11664409,CN(CCO)CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,CN(CCO)CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
CHEMBL486597,JKCVMTYNARDGET-HOTGVXAUSA-N,DIHYDROCUBEBIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.022276394711152,5726,193042,C1OC2=C(O1)C=C(C=C2)CC(CO)C(CC3=CC4=C(C=C3)OCO4)CO,OCC(Cc1ccc2c(c1)OCO2)C(CO)Cc1ccc2c(c1)OCO2
CHEMBL1173259,JKDQWEZESBYNMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,6.136677139879544,5727,46854605,CC(=C(C1=CC=C(C=C1)C2=CC(=CC=C2)O)C3=CC=NC=C3)C,CC(C)=C(c1ccncc1)c1ccc(-c2cccc(O)c2)cc1
CHEMBL437341,JKIHWNQARLENJW-GGMFNZDASA-N,ABT-341,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17064063.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,PUBLICATION,,4.522878745280337,5732,44417457,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C3=CCC(C(C3)[NH3+])C4=CC(=C(C(=C4)F)F)F.C(=O)(C(F)(F)F)[O-],[NH3+]C1CC(C(=O)N2CCn3c(nnc3C(F)(F)F)C2)=CCC1c1cc(F)c(F)c(F)c1
CHEMBL480965,JKKIQRNCGVRLBH-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,4.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.346787486224656,5734,135960718,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCCC6,Cc1cc(N2CCC(N3CCCC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3627899,JKMOLEWKZMQMRF-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5739,121399082,CC1=C2C(=C(C=C1)F)NC(=NC2=O)C(CNC(=O)C3=C(C=C(C=C3Cl)N4C=NC(=N4)C)Cl)C5=CC(=CC=C5)F,Cc1ncn(-c2cc(Cl)c(C(=O)NCC(c3cccc(F)c3)c3nc(=O)c4c(C)ccc(F)c4[nH]3)c(Cl)c2)n1
CHEMBL1784354,JKTGELXOMXEKJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5744,54582078,CC(C)(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O,CC(C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O
CHEMBL538632,JLCRPHKUMRKGFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,4.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,8.327902142064282,5751,16223851,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=CN=CC=C5)CC(C)(C)C(=O)O,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3cccnc3)cc2)c2ccc(OCc3ccccn3)cc12
CHEMBL2376562,JLEWSFZFGVKGLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23545108.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5756,71300317,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC(=C2)OC3=CC=CC=C3)C(=O)O,Cc1ccc(S(=O)(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1
CHEMBL1288288,JLKSCYCLWCURKZ-GNAFDRTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.026872146400302,5760,52948970,CCN1C2=C(C(=O)N(C1=O)C)N(C(=C2)N3CCCC(C3)(C)N)CC4=C(C=CC(=C4)F)C#N.Cl,CCn1c(=O)n(C)c(=O)c2c1cc(N1CCCC(C)(N)C1)n2Cc1cc(F)ccc1C#N
CHEMBL219162,JLSTVOPSMZBZSR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16950620.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,5771,16049828,COC1=C(C2=CC=CC=C2N=C1C3=CC=CC=C3)C(=O)NN(C4=CC=CC=C4)C(=O)OC,COC(=O)N(NC(=O)c1c(OC)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL3325551,JLXFCNWPMMNUMM-RHSMWYFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25176194.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5777,71558122,C1CNCC(C1C2=CC=C(C=C2)Cl)COC3=CC(=C(C=C3F)S(=O)(=O)NC4=NC=C(C=N4)F)F,O=S(=O)(Nc1ncc(F)cn1)c1cc(F)c(OCC2CNCCC2c2ccc(Cl)cc2)cc1F
CHEMBL2048063,JMAIWRCWOGUIRQ-VOWSPCBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,6.3979400086720375,5780,57384274,CC(C)(C)CC1=CC(=NO1)CNC2CS(=O)(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,CC(C)(C)Cc1cc(CNC2CS(=O)(=O)CC(Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)C2O)no1
CHEMBL3415629,JMBODOHYRWZQEW-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25734520.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,5781,118733374,CC1(CCN(C1=O)C2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)C(=O)NO,CC1(Nc2ccc(C(=O)NO)cc2)CCN(c2ccc(Cl)cc2)C1=O
CHEMBL526081,JMBWJWVAQBXXJN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,357.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,6.447331783887807,5782,25033659,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)O)O)C(=C1)C4=CC=NC=C4.Br,Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1O
CHEMBL1094552,JMEWMZJZKKQIDU-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.376750709602099,5784,46888799,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC(=CC=C5)Cl,Cc1cc(OCP2(=O)OCCC(c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL1096871,JMEWMZJZKKQIDU-YRVHBCJASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,5785,46888836,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC(=CC=C5)Cl,Cc1cc(OCP2(=O)OCCC(c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.301029995663981,5791,42574,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
CHEMBL2425156,JMQOIKOCLOMDPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5794,71695585,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1
CHEMBL526841,JMWWMMLEAUJIFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,5799,44583632,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=NC=N4)C,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C
CHEMBL526841,JMWWMMLEAUJIFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,5799,44583632,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=NC=N4)C,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C
CHEMBL2386077,JMYRYCOGQOEXOC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,5801,11494768,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC(=CC=C4)Cl,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc(Cl)c1)CC2
CHEMBL3393485,JNCWYNONXJVKGY-ZMBIFBSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,6.301029995663981,5807,118725524,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CN(CC3=O)C(=O)CN)C4=CC=C(O4)SC5=NC6=CC=CC=C6N5.Cl,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CN(C(=O)CN)C1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1
CHEMBL1097425,JNGUPQQSJDYXDB-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,5812,136086708,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)S(=O)(=O)C,Cc1cc(N2CCN(S(C)(=O)=O)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3358933,JNJSRSUVKCYZLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,7.0,5814,60026641,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)F,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(F)c1
CHEMBL605209,JNLXUEPMJIMNHM-JMSVASOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.096910013008056,5815,25025977,CC(C)OCC1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CC(C)OCC1C2CNCC21c1ccc(Cl)c(Cl)c1
CHEMBL3114729,JNRQQUKZSNQOTK-YTTGMZPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,5819,68166270,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)N(CCCN(CC2=CC=CC=C2)C(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)N(CCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL3234574,JNWZPZQICCVLFU-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,6.3979400086720375,5823,90654563,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCCC3C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(N3CCCCC3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
CHEMBL2017288,JNYUGWPUYNNZOZ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,5826,52935183,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=C5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12
CHEMBL2017288,JNYUGWPUYNNZOZ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,5826,52935183,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=C5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12
CHEMBL2017287,JNYUGWPUYNNZOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,5827,52932634,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=C5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12
CHEMBL389408,JOBKFJOPMWJCEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,5833,10343679,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=C(C=C3)Cl)Cl,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)c(Cl)c2)nc1C(F)(F)F
CHEMBL3408946,JOCNOQUWDPPPRY-LYWAIKEGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.301029995663981,5838,58486129,CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,CC1CN(Cc2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)Nc5ccccc56)ccc34)cc2)CC(C)O1
CHEMBL3408946,JOCNOQUWDPPPRY-LYWAIKEGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.292429823902063,5838,58486129,CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,CC1CN(Cc2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)Nc5ccccc56)ccc34)cc2)CC(C)O1
CHEMBL205742,JOFQERPJMGKMMX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,5841,5282545,CC(C)CN1C2=C(C(=C(S2)CC3=CC=NC4=CC=CC=C34)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3ccnc4ccccc34)sc21
CHEMBL205742,JOFQERPJMGKMMX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.795880017344075,5841,5282545,CC(C)CN1C2=C(C(=C(S2)CC3=CC=NC4=CC=CC=C34)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3ccnc4ccccc34)sc21
CHEMBL2387602,JOJCAIVXGLEAHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,5844,71659613,C1=CC=C2C=C(C=CC2=C1)C3=CC4=C(C=C3)C5=C(C(=O)N4)NC(=N5)C6=CC=CC=C6Cl,O=c1[nH]c2cc(-c3ccc4ccccc4c3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL2448727,JOJLHQJMMXWUOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,775.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.110698297493689,5846,73355725,CCN(CC1=CN=CC=C1)C2=CC(=CC(=C2)C3=NC4=CC=CC=C4S3)F,CCN(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
CHEMBL2204360,JOJYHYRCIYAVHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,5.0,5847,66860907,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
CHEMBL2436332,JOONUKBNTJXHQT-GYUFFBBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.920818753952375,5851,72711252,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC(=CC=C5)F)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2cccc(F)c2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3673967,JOPUUWAQIQBQBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320637,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,5852,52936039,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=C(C=CN=C4)C(F)(F)F,FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1
CHEMBL3673967,JOPUUWAQIQBQBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320681,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,5852,52936039,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=C(C=CN=C4)C(F)(F)F,FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1
CHEMBL205142,JOPYKTLQPXTHOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,6.0,5853,11575755,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCN5CCCCC5)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCCC5)c(C)c34)ccc2[nH]1
CHEMBL3091464,JOPYOUMYBIOXDP-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5854,57798480,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC(=CC=C3)OC)C4=NC=NC=C4,COc1cccc(C2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCO2)c1
CHEMBL1911825,JOTGVMDUCWBJHB-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.267606240177032,5856,57403231,CN(C)C1CN(C1)C(=O)C(COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN(C)C1CN(C(=O)C(COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1
CHEMBL3114896,JOYCVKLNKIMEJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,5858,57544434,CC(C)(C)OC(=O)N1CCC(CC1)N2C3=NC=NC(=C3C=N2)NC4=C(C=C(C=C4)S(=O)(=O)C)F,CC(C)(C)OC(=O)N1CCC(n2ncc3c(Nc4ccc(S(C)(=O)=O)cc4F)ncnc32)CC1
CHEMBL1222485,JPGAOJPEVJFAIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.022276394711152,5860,49864794,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4NC3=O)CC5=CC=NC=C5,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL2415097,JPJZDOOCHAXOHX-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,5862,70227534,CC1=CN(C=N1)C2=C(C=C(C=C2)C3=NN4CCCC(C4=N3)C5=CC=CC=C5C(F)(F)F)OC,COc1cc(-c2nc3n(n2)CCCC3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
CHEMBL3702821,JPMVTIGHBDXBLG-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9330.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.0301183562535,5865,89718375,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C#N,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C#N)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL324033,JPSLHUGQAVTRKD-SSNHPIBPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,5872,471500,CC(C)C1=NC(=CS1)COC(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CN3CCN(CC3C(=O)NC(C)(C)C)CC4=CN=CC=C4)O,CC(C)c1nc(COC(=O)NC(C(=O)NC(Cc2ccccc2)C(O)CN2CCN(Cc3cccnc3)CC2C(=O)NC(C)(C)C)C(C)C)cs1
CHEMBL1169660,JPSNCFIAJUMDJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,20417.38,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6899999882307535,5873,49798437,C1=CC=C(C(=C1)C(=O)NCCO)OC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,O=C(NCCO)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
CHEMBL1782521,JPSRNNAKSXAWPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21507633.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5874,53233133,C1CNCCC1CNC2=C3C(=CC(=C2)Br)C=C(O3)C(=O)O,O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1
CHEMBL3127494,JPTLLIYJDQIUGS-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.853871964321762,5875,76325597,C1COCCC1N2C=C(C=N2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)C4CC4C5=CN=CC=C5,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)C1CC1c1cccnc1
CHEMBL3127494,JPTLLIYJDQIUGS-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.7447274948966935,5875,76325597,C1COCCC1N2C=C(C=N2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)C4CC4C5=CN=CC=C5,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)C1CC1c1cccnc1
CHEMBL460996,JPXZSYDJAAJFSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.638272163982407,5881,135875714,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCO,Cc1cc(C2CCN(CCO)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
CHEMBL3120454,JQAPVYUJGNPKDM-OXTACIITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25597006.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,5883,76328829,CC1CC(N(C1)C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=C(S3)C4=CC=C(C=C4)C5=CC=C(C=C5)C6=CN=C(N6)C7CC(CN7C(=O)C(C(C)C)NC(=O)OC)C,COC(=O)NC(C(=O)N1CC(C)CC1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c(C6CC(C)CN6C(=O)C(NC(=O)OC)C(C)C)nc5s4)cc3)cc2)[nH]1)C(C)C
CHEMBL2059906,JQBAIBGWHDJVCY-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22732695.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,5885,62705051,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC6(CC5)C7=CC=CC=C7NC(=O)N6,O=C1Nc2ccccc2C2(CCN(C(=O)NC(Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1
CHEMBL3403987,JQBSHVXVLBXSPW-FREGXXQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,<=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,5886,59272220,CC(C)N(CC1CNCC1OCC2=CC(=CC=C2)N3C=CC=C3)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2OCc2cccc(-n3cccc3)c2)C(C)C)ccc1OC
CHEMBL400846,JQJQHTPYDUTCAK-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,5898,44447293,CC(C)(C)OC(=O)NC(CC1=C(C=CC=C1F)C(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1c(F)cccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL1081703,JQJWBTBQHCLTMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5899,46883510,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC=CC=N3)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccn3)cc2)C1
CHEMBL476557,JQODSYNHBPRORC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5902,24743795,C1=CC(=CC(=C1)F)C(C2=CC(=CC=C2)F)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1cccc(F)c1)c1cccc(F)c1
CHEMBL3422086,JQONSQMAQRQLRF-KBSXYSMTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,930.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.031517051446065,5903,73670208,C1CCC(C1)C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,O=C(NC(c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
CHEMBL3422087,JQONSQMAQRQLRF-NZAOONQGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.443697499232713,5904,117751337,C1CCC(C1)C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,O=C(NC(c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
CHEMBL591578,JQRFWBUMHAMLAJ-VJTSUQJLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.337242168318426,5908,46191161,CNCC(CC1CCCCC1)NC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC,CNCC(CC1CCCCC1)NC(=O)N1CCCC(C(OCCNC(=O)OC)c2cccc(Cl)c2)C1
CHEMBL1951610,JQSFOIUVRSFMQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,5909,57402262,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=CN5C=CC=CC5=N4)C)C,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1cn3ccccc3n1)c(=O)n2C
CHEMBL2415099,JRESZLRLRZIQBU-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5921,49872384,CC1=CN(C=N1)C2=C(N=C(C=C2)C3=NN4CCCC(C4=N3)C5=CC=CC=C5C(F)(F)F)OC,COc1nc(-c2nc3n(n2)CCCC3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
CHEMBL520276,JRGXELISXJQLFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,5925,24960588,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=N3)Cl,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl
CHEMBL219113,JRLRJUXCVXQXRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,5929,9945500,C1CN(CCC1CNC2=NN=CS2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2nncs2)CC1
CHEMBL3702802,JRUHHFVCRKGWKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.401209493236885,5936,89718369,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)N9CCCC9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1909989,JSBRNGDYGFBUPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,5944,15950385,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1
CHEMBL2165505,JSISTYTUHYTCID-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.154901959985743,5950,46239494,C1CN(CC2N1CCOC2)CC3=CC4=C(S3)C(=NC(=N4)C5=C(C=CC6=C5C=CN6)F)N7CCOCC7,Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOCC4C3)cc2n1
CHEMBL2420678,JSKZNFLNBMGDAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.0,5955,71818087,C1=CC(=CN=C1)C2=C(C3=C(C=C2)C=CC(=C3F)O)Cl,Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F
CHEMBL1829770,JSLCIPMQVPVXCO-MRDQGFSESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.522878745280337,5956,53473235,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCN)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCN)(c2ccc(F)cc2)OC1=O
CHEMBL3632720,JSLFPRZIKITLJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,4.468521082957745,5957,16064288,CC(C)(C)C1=CC=C(C=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C(F)(F)F,Cn1c(Nc2ccc(C(C)(C)C)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
CHEMBL3702800,JSTSCVPRCNNUJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6940.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.158640529545145,5963,89718367,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9CC9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1672629,JSTVKVBTXCGTLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,5964,53321372,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CC=C3)C4=C(C=NC=C4F)F,O=C(Nc1cnc(-c2c(F)cncc2F)c(-c2cccnc2)n1)C1CC1
CHEMBL2425150,JSUVAYVYZLLXNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,5966,72189518,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NC=C4C,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1
CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,5969,2099,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,5969,2099,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,5969,2099,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL2181888,JSYZFOJZNAGVKR-OIFRRMEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,6.795880017344075,5972,67270792,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=CC=NC=C5)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2ccncc2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,5977,45268455,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.468521082957745,5977,45268455,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21185722.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.468521082957745,5977,45268455,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL561132,JTCAGRAKUAAYDY-OAHLLOKOSA-N,MK-7246,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.468521082957745,5977,45268455,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL3291337,JTCWAXISFRLVOA-ACJLOTCBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,5979,57941522,CC1(C2CCC1(C3=C2C(=O)N(N3C)C4=CC=CC=C4)C)C,Cn1c2c(c(=O)n1-c1ccccc1)C1CCC2(C)C1(C)C
CHEMBL272336,JTGDXZKJMAMXST-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,5981,10415698,CC1=C(N=C(O1)C2=CC=C(C=C2)Cl)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)c1
CHEMBL252211,JTHCGPJOCAGQDY-UYAOXDASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,5983,44446990,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCNCC4,CCC1CCCC(C2(CC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3358921,JTNNQTQMGYMRGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,7.0,5988,11327284,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=C(C3=C(N2)C=NC=C3)C)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F
CHEMBL3358921,JTNNQTQMGYMRGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.42021640338319,5988,11327284,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=C(C3=C(N2)C=NC=C3)C)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F
CHEMBL2204356,JTQUHGRGBNXQDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,5.214670164989233,5993,53237896,C1CN(CCN1)C2=CC=CC=C2SC3=C(C(=CC=C3)Cl)Cl.Cl,Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl
CHEMBL598336,JUBQGWGPNRKSSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,5.3979400086720375,6001,44819015,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3=CC=NC=C3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC
CHEMBL598336,JUBQGWGPNRKSSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.6777807052660805,6001,44819015,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3=CC=NC=C3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC
CHEMBL1649665,JUCJQZNUMLLICR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,6.154901959985743,6002,24825807,C1CCC(C1)NC(=O)CC2=CC=C(C=C2)N3C4=C(CCCC4)C(=N3)C(F)(F)F,O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)NC1CCCC1
CHEMBL2010880,JUEPWZSXQYFPDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22366657.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6006,70685176,C1CCN(CC1)CC2=C3C(=CC=C2)NC(=N3)C4=CC=CC=C4,c1ccc(-c2nc3c(CN4CCCCC4)cccc3[nH]2)cc1
CHEMBL266158,JUJWROOIHBZHMG-UHFFFAOYSA-N,PYRIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26371436.0,IC50,=,4000000.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.,J. Med. Chem.,PUBLICATION,,2.3979400086720375,6009,1049,C1=CC=NC=C1,c1ccncc1
CHEMBL3702692,JUKYJTSFENURII-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.649751981665837,6010,89718299,CC(C)N1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2387597,JULNGCZCLLQCAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,6011,71659493,CCCCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,CCCCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
CHEMBL526887,JULWIPZNVYARKY-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,6012,44576681,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)F)C4=CC=CC=C4Cl)NCCCC(=O)O,O=C(O)CCCNC(Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1
CHEMBL3234564,JUZFKXCBDWBAPH-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,6027,90654583,CC1=CC(=NC(=N1)N2CCCC(C2)C(=O)NCCC3=CC=C(C=C3)C#N)N4CCN(CC4)C,Cc1cc(N2CCN(C)CC2)nc(N2CCCC(C(=O)NCCc3ccc(C#N)cc3)C2)n1
CHEMBL3640786,JUZUBCBEFKWHQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12980.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.88672530753565,6028,91196339,C1=CC(=CN=C1)C2=CC=C(S2)CN=O,O=NCc1ccc(-c2cccnc2)s1
CHEMBL3407558,JVBGVXAXEZXWTE-MCUOQOIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.0503,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,10.298432014944073,6030,90368833,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)NC5=CC(=C(C=C5)C(=O)O)OC,COc1cc(NC(=O)CC2(C)CC(c3cccc(Cl)c3)C(c3ccc(Cl)cc3)N(C(CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O
CHEMBL2206278,JVCWPUFNLFSKFS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,6033,54760053,CCN1C(CC(CC1(C)C)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C)(C)C,CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C
CHEMBL3112853,JVFSDXQBBQIWBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,6037,57389622,C1CN(C2=CC=CC(=C21)C(F)(F)F)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c1cccc2C(F)(F)F
CHEMBL1779012,JVJRXNFULOSTER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,6044,54582823,COC1=C(C=CC(=C1)F)C2=CN=CC(=C2)CNC(=O)C3=NC=CN=C3,COc1cc(F)ccc1-c1cncc(CNC(=O)c2cnccn2)c1
CHEMBL2347185,JVLQVDCETUHZMB-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,6.552841968657781,6047,57415391,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CN3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cnc[nH]2)Cc2ccccc2)C(C)C)cs1
CHEMBL2181892,JVNKLECJDZSZDR-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.0,6051,67270136,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=NC=CS5)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2nccs2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL2437417,JVNKPOHWBICHOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6052,58863165,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCCC(F)(F)F)CC5=CC(=NC=C5)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5ccccc54)CC3)CC2)ccn1
CHEMBL475927,JVOWBHDCJOSBIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6053,44578956,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)C#N,N#Cc1ccc(C(=O)NCC(=O)NC(c2ccccc2)c2ccc(Cl)cc2)cc1
CHEMBL3335537,JVQBISWUXRKBAJ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221667.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by electrospray ionization,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6055,60149678,C1COC(CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4,c1ccc(CCC2CN(Cc3nc4ccccc4[nH]3)CCO2)cc1
CHEMBL2059121,JVUSBRIMSCDKMU-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,6058,70686415,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CCN3CCCC3)CC(C(CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)O,CCN(C)c1nc2ccc(C(=O)N(CCN3CCCC3)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL226386,JVVHLTXQSFRAFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.187086643357144,6059,10318708,C1CCC(C1)CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC=C3)Cl,O=C(NCC1CCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL1684057,JWGAGXNBADXJOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21310612.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,6066,53323813,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)NC.Cl,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
CHEMBL2059877,JWHJIIANXOMUPH-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,6068,24863334,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NC(=O)C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C1Cc2cc(CC(NC(=O)N3CCC(N4Cc5ccccc5NC4=O)CC3)C(=O)N3CCC(N4CCCCC4)CC3)ccc2N1
CHEMBL2163824,JWJDSNJWYOUETR-IRZJEQJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.376750709602099,6070,57522135,C1CC(CC(C1)NC(=O)C(CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl)N,NC1CCCC(NC(=O)C(Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)C1
CHEMBL1270432,JWLSQAAJQTZDQT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3872161432802645,6071,25070193,CC1=C(C=CC(=C1)C2(C(=O)N(C(=N2)N)C)C3=CC(=C(C=C3)F)C#CC4CC4)OC(F)F,Cc1cc(C2(c3ccc(F)c(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F
CHEMBL1951334,JWSOACJPVMVQGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,98.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.008773924307505,6077,57397068,CNC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL455683,JWWBRTLPEUWQCU-OQECSOMKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18990568.0,IC50,=,20600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using dibenzylfluorescein as substrate,Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.686132779630847,6084,25154827,C1CN(CCC1C2=CNC3=C2C=CC=N3)C(CO)C4CCN(CC4)C(=O)C=CC5=CC(=CC(=C5)F)F,O=C(C=Cc1cc(F)cc(F)c1)N1CCC(C(CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1
CHEMBL455683,JWWBRTLPEUWQCU-OQECSOMKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18990568.0,IC50,=,25200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.598599459218456,6084,25154827,C1CN(CCC1C2=CNC3=C2C=CC=N3)C(CO)C4CCN(CC4)C(=O)C=CC5=CC(=CC(=C5)F)F,O=C(C=Cc1cc(F)cc(F)c1)N1CCC(C(CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1
CHEMBL455683,JWWBRTLPEUWQCU-OQECSOMKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18990568.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,6084,25154827,C1CN(CCC1C2=CNC3=C2C=CC=N3)C(CO)C4CCN(CC4)C(=O)C=CC5=CC(=CC(=C5)F)F,O=C(C=Cc1cc(F)cc(F)c1)N1CCC(C(CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1
CHEMBL1914489,JWYIGNODXSRKGP-UHFFFAOYSA-N,AZD1981,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21944852.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6086,11292191,CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl,CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O
CHEMBL482637,JXGJTODYQBRZDL-RTIVMORXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6095,44583235,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CCCN(CC3)C(=O)NC4CC4C5=CC=CC=C5)CC2,CS(=O)(=O)c1ccc2c(c1)CCC1(CCCN(C(=O)NC3CC3c3ccccc3)CC1)O2
CHEMBL2022996,JXIGVUPYYZGRRZ-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,6099,56964577,CC1=CC(=CC=C1)C(CCC(C(=O)O)N)(C2=CC=CC=C2)C3=CC=CC=C3,Cc1cccc(C(CCC(N)C(=O)O)(c2ccccc2)c2ccccc2)c1
CHEMBL2022995,JXIGVUPYYZGRRZ-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,6100,57325589,CC1=CC(=CC=C1)C(CCC(C(=O)O)N)(C2=CC=CC=C2)C3=CC=CC=C3,Cc1cccc(C(CCC(N)C(=O)O)(c2ccccc2)c2ccccc2)c1
CHEMBL3403824,JXJZEDILUDZDFW-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,6101,71288634,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C7COC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403824,JXJZEDILUDZDFW-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,6101,71288634,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C7COC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.585026652029182,6102,13342,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1
CHEMBL2070155,JXONDSQREGQXDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,6107,70684603,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=NC=CC(=C3)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccn3)[nH]c2c1
CHEMBL1271930,JXQLUDIGMMJLLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933409.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,6109,50899748,CC1=C(C(=CC=C1)N2CCN(CC2)CCNC(=O)C3=NC(=NC(=C3)C)SC)C.Cl,CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)n1
CHEMBL2441841,JXXNQEGNWBPSSV-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.522878745280337,6116,57641216,CC1=C(C(=C2C(=N1)CN(C2=O)CC3CCCN3S(=O)(=O)C4CC4)C5=C(C=C(C=C5)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC1CCCN1S(=O)(=O)C1CC1)C2
CHEMBL3422238,JYDYMWJEZLKIBS-CXMBCZLWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,6121,72547320,CN1C=C(C=N1)C2CC3CSC(=NC3(CO2)C4=C(C=C(C=C4)F)F)N,Cn1cc(C2CC3CSC(N)=NC3(c3ccc(F)cc3F)CO2)cn1
CHEMBL1214336,JYFFQMUEOPGGBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,6122,11580514,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=CC=C3,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3)cc2C1
CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,6124,5754,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO
CHEMBL2334759,JYSGBOOAYHHKRU-PAXLWEDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,5.136677139879544,6126,71605054,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C4CCC(C3)N4C(=O)C)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)C2CCC(C3)N2C(C)=O)cc1
CHEMBL1682894,JYTGSYXSDJJCCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.2441251443275085,6127,22737877,CCNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(C3=CN=CN3)(C(C)C)O,CCNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL3217170,JYUAHTUNBVFGGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21823597.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by luceferin-based assay,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,PUBLICATION,,4.698970004336019,6128,90665194,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1
CHEMBL1829776,JYUZCHJMXCOJJR-MRDQGFSESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.920818753952375,6129,53473393,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCNS(=O)(=O)N)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCNS(N)(=O)=O)(c2ccc(F)cc2)OC1=O
CHEMBL1090089,JYYLVUFNAHSSFE-UHFFFAOYSA-N,PAMAPIMOD,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21375264.0,IC50,>,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38a mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.5376020021010435,6131,16220188,CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC(CCO)CCO,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21
CHEMBL3702716,JZAVQNHDPXFZNV-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3860.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.413412695328245,6134,89718316,CCOC(=O)C1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)OCC)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL377177,JZBAXRLBKQTQQE-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.086186147616283,6135,44410840,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1)N(C)C
CHEMBL111,JZCPYUJPEARBJL-UHFFFAOYSA-N,RIMONABANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,6136,104850,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1
CHEMBL412024,JZDBOFKXYADYQD-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,6137,44433288,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CN(C)C,CC(C)CC(NC(=O)CN(C)C)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3298836,JZEFDHAAEABKGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,6.309803919971486,6139,53469411,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)F,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1
CHEMBL434936,JZIURJIEJBKSKI-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,6142,44400235,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL434936,JZIURJIEJBKSKI-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,6142,44400235,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL434936,JZIURJIEJBKSKI-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,7.0,6142,44400235,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)C(F)(F)F,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL3408940,JZIZUMLXHJPWJH-WQRKFILVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.522878745280337,6143,58486297,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7N(C6=O)C,CN1CCN(c2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1
CHEMBL3408940,JZIZUMLXHJPWJH-WQRKFILVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.5376020021010435,6143,58486297,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7N(C6=O)C,CN1CCN(c2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1
CHEMBL2022739,JZLFWWQOPQHUPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503453.0,IC50,=,64000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1938200260161125,6146,57663655,C1COCCN1CCCCNC2=NN=C(O2)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4F)F,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F
CHEMBL2022739,JZLFWWQOPQHUPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22503453.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,6146,57663655,C1COCCN1CCCCNC2=NN=C(O2)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4F)F,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F
CHEMBL1270335,JZQHTDKITQYMAR-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6149,25127622,CN1C(=O)C(N=C1N)(C2=CC=C(C=C2)OC(F)F)C3=CC(=C(C=C3)F)C#CC4CC4,CN1C(=O)C(c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CC3CC3)c2)N=C1N
CHEMBL2425599,JZTFFTMPOGLVCG-CBZQJITBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,6153,66649674,CC(C1=CC(=CC=C1)C(C)(C)C)NC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NC(C)c3cccc(C(C)(C)C)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL2448706,JZXBDYCABDJUSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.0,6162,73348119,CN(CC(COC1=CC2=C(C=C1)C=C(C=C2)Br)O)C3CCCCC3,CN(CC(O)COc1ccc2cc(Br)ccc2c1)C1CCCCC1
CHEMBL428586,JZXUGHRCBRCPON-ZKMPZPQNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,6163,44446995,C1CCN2CCN(CC2C1)C(=O)CC3(CC3)C4CCCC(N4S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,O=C(CC1(C2CCCC(C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN2CCCCC2C1
CHEMBL2332068,KACIGJBSABVNRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570561.0,IC50,=,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.096910013008056,6164,68563058,CN(C)CCN(CC1=CC(=CC=C1)OC)C(=O)NC2=CC=C(C=C2)C3=CNN=C3,COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1
CHEMBL3358934,KAEZOVLEAHIZGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,7.0,6165,60026802,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=C(C=C4)F,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1
CHEMBL3289803,KAHGRTFKEJELQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,4.522878745280337,6167,90644762,C1=CC(=C(C=C1C(F)(F)F)Cl)C(CN2C3=C(C=CC(=C3)C(F)(F)F)N=C2N)O,Nc1nc2ccc(C(F)(F)F)cc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl
CHEMBL3682508,KAJOKEZYYKICFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,200000.0,NM,291609,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,3.6989700043360187,6170,68295900,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(F)(F)F)O,CC(C)C(O)c1ccc2cc(OCC(F)(F)F)ccc2c1
CHEMBL3125384,KAKATSTZIXKFNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,6171,76332666,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O)C=CC=C2Br,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O
CHEMBL2043325,KAPZNJYOKZDXPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,6176,49848897,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL2437426,KARTZJAENYQGIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6179,10436237,C1CC1CN2C3=C(C=CC(=C3)F)N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CC5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL1091778,KAWDUHFGBOIYCO-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6181,11515125,CC(C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1091777,KAWDUHFGBOIYCO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,6182,11659592,CC(C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1091776,KAWDUHFGBOIYCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6183,11623756,CC(C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12
CHEMBL241896,KAYCKFWCZGZEHA-WEPZFIBGSA-N,GERANYLCOUMARIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17400460.0,IC50,=,42930.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit.,Bioorg. Med. Chem.,PUBLICATION,,4.367239111520561,6185,44429171,CC(C)C=CCC(=CCOC1=CC2=C(C=C1)C=CC(=O)O2)C,CC(=CCOc1ccc2ccc(=O)oc2c1)CC=CC(C)C
CHEMBL1777855,KAYILIDZNSBIOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6186,53248847,CC#CC(CC(=O)O)C1=C(C=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)OC(F)F)F,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1F
CHEMBL1911817,KAZJACRSYJQAEE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.869666231504994,6187,46868944,CN1CCN(CC1)C(=O)C(COCC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL2448743,KBAQNZRYJNJHIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,576.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.239577516576788,6189,73351202,CCN(CC1=CN=CN1)C2=CC(=CC(=C2)C3=NC4=CC=CC=C4S3)F,CCN(Cc1cnc[nH]1)c1cc(F)cc(-c2nc3ccccc3s2)c1
CHEMBL393789,KBBHXCZBVZTXQH-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,720.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.142667503568732,6190,44433278,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCC(=O)N,CC(C)CC(NCC(N)=O)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3358948,KBCDLIHQEVOPOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.221848749616356,6191,44543860,CC1=CC(=C(C=C1)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)S(=O)(=O)C)(C(F)(F)F)O)C(=O)N,Cc1ccc(C(C)(C)CC(O)(Cc2cc3cc(S(C)(=O)=O)ncc3[nH]2)C(F)(F)F)c(C(N)=O)c1
CHEMBL1223034,KBDZMHUBIGWJPD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,6194,49865191,CC(C)(C)C1=NN=C(S1)C2=NN(C(=C2CN3C=NC=N3)C4=CC=C(C=C4)Br)C5=C(C=C(C=C5)Cl)Cl,CC(C)(C)c1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1
CHEMBL1077340,KBLBAKODFLPDCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,6204,135934887,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)N5CCC(CC5)N6CCN(CC6)C(=O)OC,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCn6cc(Cl)cn6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL3354313,KBMWPOLIYQYLRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25455487.0,IC50,=,6710.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) after 3 mins by LC-MS/MS analysis,"Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1732774798310075,6205,118720097,COC1=NC=C(C=C1)C2=NC(=NC3=C2SC=C3)CS(=O)(=O)C4=CC(=CC=C4)Cl,COc1ccc(-c2nc(CS(=O)(=O)c3cccc(Cl)c3)nc3ccsc23)cn1
CHEMBL254912,KBQBORFEXVLABK-ZEQKJWHPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,6209,11599077,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCC(CC4)N5CCCCC5,CCC1CCCC(C2(CC(=O)N3CCC(N4CCCCC4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2181786,KBQRHEVOBYQPPE-QGOAFFKASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.102372908709558,6210,71459328,CC(C)(C(=O)NC1=CC=C(C=C1)C=CC(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=CC=CC=N4)C5CCCC5,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(C=CC(=O)O)cc3)cc21
CHEMBL2023803,KBSBJZXYFDQQMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497760.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6211,67304696,CC1=NN(C=C1NC(=O)CC2=C(C=C(C=C2)OC3=C4C=CC(=CC4=NC=C3)OC)OC)C.OS(=O)(=O)O,COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1
CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.552841968657781,6214,16051921,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.0,6214,16051921,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,4.552841968657781,6214,16051921,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1630,KBTNVJNLEFHBSO-UHFFFAOYSA-N,AMODIAQUINE HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using PPR substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,4.0,6214,16051921,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL495493,KBVAYGZXOAZDKK-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.0,6215,44568821,CCNC1=NOC2=C1C=CC(=C2C3=CC4=CN=NC(=C4C=C3)N5CCOCC5C)C,CCNc1noc2c(-c3ccc4c(N5CCOCC5C)nncc4c3)c(C)ccc12
CHEMBL3115188,KBZPKTMYSVUUNF-JHFJJOSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,6217,56948248,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCNC(=O)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(=O)NCCC(NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL3115182,KBZPKTMYSVUUNF-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,6218,24953255,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCNC(=O)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(=O)NCCC(NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL2347990,KCAVKWMGHFWNGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,6219,71718968,CC(C)(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCC(CO)O,CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12
CHEMBL499026,KCCHSZZXJXIDAP-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,6222,44576645,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)COC(=O)CO)N,NC(Cn1c(=O)c(-c2ccc(COC(=O)CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL2057528,KCNVHXJEALIYQI-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,55.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.259637310505756,6235,59603326,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=CO4,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncoc2c1
CHEMBL3264598,KCNWFHLEERWIML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,6236,90656805,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NC=NN3)O,COc1cc2ccc(C(O)(c3ncn[nH]3)C(C)C)cc2cc1OC
CHEMBL2059786,KCPUZNAAPSFNSG-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,6238,70696845,CC(C)CC(C(=O)N1CCC(CC1)N2CCCCC2)NC(=O)N3CCC(CC3)N4C5=CC=CC=C5NC4=O,CC(C)CC(NC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)C(=O)N1CCC(N2CCCCC2)CC1
CHEMBL1092494,KCSVGYHUQTUHTM-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6240,46884153,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)Cl,CC(c1ncccc1Cl)c1c(CCN(C)C)sc2ccccc12
CHEMBL480966,KCSXXVMVRJMJFA-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,6241,135960719,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)C6CC6,Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL480966,KCSXXVMVRJMJFA-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,6241,135960719,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)C6CC6,Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1642897,KDERKEZKMQCRPQ-DZGCQCFKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,=,17100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.767003889607846,6248,50993865,CNC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1642896,KDERKEZKMQCRPQ-HIFRSBDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,6249,53325581,CNC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1642895,KDERKEZKMQCRPQ-UKRRQHHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,6250,53320778,CNC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1642894,KDERKEZKMQCRPQ-ZFWWWQNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,6251,53322084,CNC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL220660,KDHKDFONLOHKCA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.657577319177793,6252,9967123,C1CN(CCC1CNC2=NC=CN=C2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1
CHEMBL2178223,KDHZEOLHBGWCJL-PAJWBHGYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,5.522878745280337,6253,59454159,CC(C)(CN1CC(C(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)C=CC(=O)NC4=CC=CC=C4N)O,CC(C)(O)CN1CC(C(=O)Nc2ccc(Cl)cc2)C(c2ccc(C=CC(=O)Nc3ccccc3N)cc2)C1
CHEMBL3417530,KDIHNMYGWTUGIV-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,4.522878745280337,6254,56838888,CC(C1CC1)(C2=CC=C(C=C2)C3=CN=C(N=C3)N)C4=NOC(=N4)C5=CN(N=C5)CCN(C)C,CN(C)CCn1cc(-c2nc(C(C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1
CHEMBL3237449,KDIKLUVXDINZHL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,5.0,6255,58300031,CC(CO)N1C2=C(C=CN=C2)C3=CN=C(N=C31)NC4=NC=C(C=C4)N5CCNCC5,CC(CO)n1c2cnccc2c2cnc(Nc3ccc(N4CCNCC4)cn3)nc21
CHEMBL1778639,KDOSMMYSHYZFQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21592791.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6264,53359023,CCS(=O)(=O)C1=CC(=C(C=C1)C2=C(C=CC(=C2)C(F)(F)F)OCC(=O)O)C,CCS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)ccc2OCC(=O)O)c(C)c1
CHEMBL206096,KDRGQJRCUVUELE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16503138.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6266,11235389,C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=C(N=CC=C3)C4=CC(=CC=C4)C(=O)O,O=C(O)c1cccc(-c2ncccc2-c2cc(Cl)ccc2OCc2ccccc2)c1
CHEMBL404401,KDTMLCXQOWKVOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,6267,11612461,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NC)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
CHEMBL567570,KDUIBMLGMZJDAG-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,6268,3008866,CC1CN(CCN1C(=O)C(=O)C2=CNC3=CC=CC=C32)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12
CHEMBL567570,KDUIBMLGMZJDAG-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,6268,3008866,CC1CN(CCN1C(=O)C(=O)C2=CNC3=CC=CC=C32)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12
CHEMBL3393295,KDXXYHDZDWLQGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,6271,118725452,C1=CC=C(C(=C1)C#N)OC2=CC=C(C=C2)C(=O)NCC3=CN=CC=C3,N#Cc1ccccc1Oc1ccc(C(=O)NCc2cccnc2)cc1
CHEMBL1092118,KEDAYBZXXNOGOP-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6274,46884202,CC(C1=CN=CS1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cncs1)c1c(CCN(C)C)sc2ccccc12
CHEMBL425519,KEERDUCTIKTUOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,39100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.407823242604133,6275,11389927,CC1=CSC=C1C2=CN=C(C=C2)F,Cc1cscc1-c1ccc(F)nc1
CHEMBL425519,KEERDUCTIKTUOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,114000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.9430951486635273,6275,11389927,CC1=CSC=C1C2=CN=C(C=C2)F,Cc1cscc1-c1ccc(F)nc1
CHEMBL227670,KEHDIZISMAQBKX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.698970004336019,6276,16658103,COC1=CC2=C(C=C1)N=C(N(C2=O)CC3=CC=CC=C3C#N)N4CCCC(C4)N,COc1ccc2nc(N3CCCC(N)C3)n(Cc3ccccc3C#N)c(=O)c2c1
CHEMBL3291120,KELRBTWVTDHIHS-KGTFJIFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.721246399047171,6278,16656782,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CC=CC(=C4)CO)C,C=CC1(C)CC(OC(=O)CSc2cccc(CO)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291120,KELRBTWVTDHIHS-KGTFJIFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1950.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.709965388637482,6278,16656782,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CC=CC(=C4)CO)C,C=CC1(C)CC(OC(=O)CSc2cccc(CO)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3236358,KENRSCUSWCVFPT-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,5.6020599913279625,6281,90655374,CCC(CS(=O)(=O)C(C)(C)C)N1C(C(CC(C1=O)(C)CC2=NNN=N2)C3=CC(=CC=C3)Cl)C4=CC=C(C=C4)Cl,CCC(CS(=O)(=O)C(C)(C)C)N1C(=O)C(C)(Cc2nn[nH]n2)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
CHEMBL403149,KEPLTYGEHMAOOM-DNVJHFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,6284,44456070,CC1=NC(=CO1)C(C(=O)N2CCC2)N3C(C(=O)NC(C3=O)C4CC5=CC=CC=C5C4)CC(C)C,Cc1nc(C(C(=O)N2CCC2)N2C(=O)C(C3Cc4ccccc4C3)NC(=O)C2CC(C)C)co1
CHEMBL1671936,KEUJAGGJGBWRFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,6286,16122818,CC(C)(C)CC(=O)NC1=C(C=C(C=C1F)C(=O)NC2=NC=CS2)F,CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)Nc2nccs2)cc1F
CHEMBL287400,KFCQYUZRWULLQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,6.6777807052660805,6296,11751643,CC1=CC(=C2C3=C(C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)N(C2=N1)C)C(=O)N,Cc1cc(C(N)=O)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1
CHEMBL3091545,KFEKXXFPCURVGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6298,10308589,CN1C(=O)C=C(N=C1NCC(=O)C2=CC=CC=C2)C3=CC=NC=C3,Cn1c(NCC(=O)c2ccccc2)nc(-c2ccncc2)cc1=O
CHEMBL3422083,KFENBNGSHOHELN-BSYJTBJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,7.221848749616356,6299,117751334,CC(C)C(C1=CC=CC=C1Cl)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)N5C6CCC5COC6,CC(C)C(NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1)c1ccccc1Cl
CHEMBL3264600,KFGRUSFLKJSLMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,6300,90656801,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CO3)O,COc1cc2ccc(C(O)(c3cnco3)C(C)C)cc2cc1OC
CHEMBL2296321,KFNVAIUTZXCDKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of Homo sapiens (human) recombinant CYP3A4 by fluorogenic assay,,Med Chem Res,PUBLICATION,,5.0,6303,25064916,COC1=NC2=C(C=C1)OCC23C4=CC=CC=C4N(C3=O)CC5=CC=C(O5)C(F)(F)F,COc1ccc2c(n1)C1(CO2)C(=O)N(Cc2ccc(C(F)(F)F)o2)c2ccccc21
CHEMBL1921855,KFNXSASJRFOSHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,4.522878745280337,6304,46853681,C1=CC=C2C(=C1)S(=O)(=O)N(S2(=O)=O)C3=CC=C(C=C3)NC(=O)C4=CC=CC=N4,O=C(Nc1ccc(N2S(=O)(=O)c3ccccc3S2(=O)=O)cc1)c1ccccn1
CHEMBL2376577,KFQWZEYUSVKRBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23545108.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6305,71300316,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)OC3=CC=CC=C3)C(=O)O,Cc1ccc(S(=O)(=O)Nc2ccc(Oc3ccccc3)cc2C(=O)O)cc1
CHEMBL594933,KFUFYKHPONJLKZ-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.795880017344075,6310,46225589,CC1=C2C=C(N=CC2=NN1)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=COC=C6,Cc1[nH]nc2cnc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12
CHEMBL242983,KFUYKTYUJHLOPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,195.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,6.709965388637482,6312,16745311,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
CHEMBL242983,KFUYKTYUJHLOPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,2480.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,5.605548319173784,6312,16745311,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
CHEMBL563956,KFVOKCIYVVCZGF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.42021640338319,6313,25019714,CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=C(C=NN5)C,Cc1cc(-c2[nH]ncc2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1
CHEMBL25903,KGDYDDZERXXGQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1230.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.910094888560602,6317,11293906,CN1C2=C(C3=C(C=CN=C31)C(=O)N)N=CN=C2N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,Cn1c2nccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL1214395,KGEABTFMCTZXTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,6319,11522969,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=CC(=C3)C#N,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cncc(C#N)c3)cc2C1
CHEMBL219098,KGGUBHJOEDSZBC-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,5.142667503568732,6322,16102868,CC(C)CN1C2=C(C(=C(S2)OC3=CC=CC4=CC=CC=C43)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Oc3cccc4ccccc34)sc21
CHEMBL474130,KGOGIJXNFVIMTA-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,5.0,6327,15984241,CC1CN(CCN1)CC2=CC=C(C=C2)CCC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,CC1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
CHEMBL474130,KGOGIJXNFVIMTA-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,6327,15984241,CC1CN(CCN1)CC2=CC=C(C=C2)CCC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,CC1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
CHEMBL1082053,KGOQVALOLTXUEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,6329,46883369,CCN(CCNC(=O)OCC1=CN=CS1)CCNC(=O)OCC2=NC=CS2,CCN(CCNC(=O)OCc1cncs1)CCNC(=O)OCc1nccs1
CHEMBL501711,KGSZHKRKHXOAMG-HQKKAZOISA-N,HYPERFORIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20408551.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).,J. Nat. Prod.,PUBLICATION,,5.638272163982407,6334,441298,CC(C)C(=O)C12C(=O)C(=C(C(C1=O)(CC(C2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C,CC(C)=CCCC1(C)C(CC=C(C)C)CC2(CC=C(C)C)C(=O)C1(C(=O)C(C)C)C(=O)C(CC=C(C)C)=C2O
CHEMBL529213,KHBYHUBFGVKELV-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19320488.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.,J. Med. Chem.,PUBLICATION,,5.327902142064283,6340,42626024,C1CN(CCN1C(=O)C2CC2C3=CC=C(C=C3)C(F)(F)F)S(=O)(=O)C4=CC(=CC(=C4)C(F)(F)F)C5=NC=NN5,O=C(C1CC1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3ncn[nH]3)cc(C(F)(F)F)c2)CC1
CHEMBL1290004,KHHBKFYFMHFBOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21055936.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: a new class of Neuropeptide S antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,6341,50925457,C1CCN(CC1)C(=O)C2=CC=CC=C2N3CN4C(=CC=C4C3=O)C5=CC=CC=C5,O=C(c1ccccc1N1Cn2c(ccc2-c2ccccc2)C1=O)N1CCCCC1
CHEMBL3582240,KHPZRFSKOJGJEJ-YYHAPLCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,932.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13��-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,6.030584087646019,6353,122179416,CC1(CCC23CCC4(C5(CCC6C(C(=O)C(=CC6(C5=CC(=O)C4(C2C1)N(C3=O)C7CCCCC7)C)C#N)(C)C)C)C)C,CC1(C)CCC23CCC4(C)C5(C)CCC6C(C)(C)C(=O)C(C#N)=CC6(C)C5=CC(=O)C4(C2C1)N(C1CCCCC1)C3=O
CHEMBL3582240,KHPZRFSKOJGJEJ-YYHAPLCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,2535.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13��-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,5.596022036330646,6353,122179416,CC1(CCC23CCC4(C5(CCC6C(C(=O)C(=CC6(C5=CC(=O)C4(C2C1)N(C3=O)C7CCCCC7)C)C#N)(C)C)C)C)C,CC1(C)CCC23CCC4(C)C5(C)CCC6C(C)(C)C(=O)C(C#N)=CC6(C)C5=CC(=O)C4(C2C1)N(C1CCCCC1)C3=O
CHEMBL479084,KHTDXOMKTZIILK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6358,24900236,CC1=CC(=CC=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,Cc1cccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)c1
CHEMBL2041010,KICDUIMXMCSVGI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,6365,57387282,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(S6)C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)s4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL3702781,KIFTVPULPLLOBV-JFKYFZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.343901797987169,6366,89718453,CCN(CC)CCNC1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(CC)CC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3104485,KIOFMOLFMSYGIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,6371,76331988,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1
CHEMBL3104485,KIOFMOLFMSYGIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,6371,76331988,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1
CHEMBL456001,KIOOMMQUJQSBPZ-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,5.886056647693163,6372,44590570,CC1=C(C=CC=C1Cl)C2=CC(=O)N(C3=C2C=C(C=C3)C(C4=CC=C(C=C4)Cl)(C5=CN=CN5C)N)C,Cc1c(Cl)cccc1-c1cc(=O)n(C)c2ccc(C(N)(c3ccc(Cl)cc3)c3cncn3C)cc12
CHEMBL3665949,KIYBJKHIYOZLEC-CABCVRRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.42021640338319,6377,86766622,CC1=C(N=C(N=C1Cl)OCC2CC2C3=CC=CC=N3)NCC4=CN(N=C4)C,Cc1c(Cl)nc(OCC2CC2c2ccccn2)nc1NCc1cnn(C)c1
CHEMBL3673954,KIYZZSWMJCJKKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320617,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,6380,52935601,CS(=O)(=O)NC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)Cl)F)N=C1,CS(=O)(=O)Nc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1
CHEMBL2437416,KJAMWQZICMXSKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6382,58863232,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4NC3=O)CC5=CC(=NC=C5)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)[nH]c5ccccc54)CC3)CC2)ccn1
CHEMBL565362,KJBIXUOGFIZTTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513812,6383,45484950,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=C(C=C(C=C3)Br)F,CC1(CC(=O)NCc2ccc(Br)cc2F)CC2(CCCCC2)OO1
CHEMBL256988,KJBXOWKVXHJXGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,6384,44449052,C1CC(C(N(C1)C(=O)CN2C3=CC(=C(C=C3N=CC2=O)Cl)Cl)CN4CCOCC4)C5=CC=CC=C5,O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
CHEMBL3114738,KJFJLGNTFRFOMY-CHQNGUEUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,6386,76310562,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL3605542,KJFJNOQRMGDJEA-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26291341.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,PUBLICATION,,6.080921907623926,6387,59177057,CCN1C2=C(C=CC(=C2)C(F)(F)F)N=C1C(C)NS(=O)(=O)C3=CN=CC=C3,CCn1c(C(C)NS(=O)(=O)c2cccnc2)nc2ccc(C(F)(F)F)cc21
CHEMBL411095,KJFSUONZDZKWIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,6389,18548739,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC(=CC=C3)N4C=CN=C4,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-n3ccnc3)c1)=N2
CHEMBL239078,KJGSLJURFWWLOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.721246399047171,6390,23647892,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=C(C=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)ccc1F)O2
CHEMBL1224195,KJKVVLUSAUZZBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709545.0,IC50,=,51000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted biaryl pyrazoles as sodium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.292429823902063,6396,49865953,CC1=CC(=NN1C2=CC=CC(=C2)C3=C(C=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)N,Cc1cc(C(N)=O)nn1-c1cccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)c1
CHEMBL1092126,KJQCJXUDPPZASI-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6401,11500781,CC1=C(N=CC=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1cccnc1C(C)c1c(CCN(C)C)sc2ccccc12
CHEMBL398372,KJXOYJXMFGXDRR-QGZVFWFLSA-N,BMS-317180,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17973363.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180).,J. Med. Chem.,PUBLICATION,,4.0,6407,23649669,CC(C)(C(=O)NC(COCC1=CC=CC=C1)C2=NN=NN2CCOC(=O)NCCCCO)N,CC(C)(N)C(=O)NC(COCc1ccccc1)c1nnnn1CCOC(=O)NCCCCO
CHEMBL1096717,KKACLEOGRMSWFM-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,6411,136086721,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)CCCF,Cc1cc(N2CCN(C(=O)CCCF)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2070158,KKANPYOQEOCPDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,6414,70684604,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN(C(=O)C=C3)C4=CC=CC=C4,CCCS(=O)(=O)c1ccc2nc(-c3ccc(=O)n(-c4ccccc4)c3)[nH]c2c1
CHEMBL236520,KKISTVNQPNAOJB-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,6418,44433295,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,CC(C)CC(NC(=O)CCN)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,77500.0,NM,,,,binding,,,,,,,,,,,,,,,,4.110698297493689,6419,77918,C1=CC=C(C=C1)CN2C=CN=C2,c1ccc(Cn2ccnc2)cc1
CHEMBL239629,KKKLWLSGVSXCDO-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,6420,11851431,C1CC(N(C(C1)C2(CC2)OC(=O)N3CCN(CC3)CCO)S(=O)(=O)C4=CC=C(C=C4)Cl)C5=CC(=CC(=C5)F)F,O=C(OC1(C2CCCC(c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1
CHEMBL239629,KKKLWLSGVSXCDO-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,6420,11851431,C1CC(N(C(C1)C2(CC2)OC(=O)N3CCN(CC3)CCO)S(=O)(=O)C4=CC=C(C=C4)Cl)C5=CC(=CC(=C5)F)F,O=C(OC1(C2CCCC(c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1
CHEMBL1230122,KKKRKRMVJRHDMG-UHFFFAOYSA-N,R-1487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21375264.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38a mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,6421,11406590,CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC4CCOCC4,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21
CHEMBL2018482,KKOSHWJEFBAPQK-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,=,301.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,6.521433504406157,6425,56954243,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CC4=CN=CN4)C5=CC=CC=C5,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(c2ccccc2)CN1C(=O)Cc1cnc[nH]1
CHEMBL1668898,KKQXNJWVSUWKOH-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211969.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by time-dependent inhibition assay,"Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.698970004336019,6427,50901657,CCN(CC1=C(C=CC(=C1)C2=CN=C(C=C2)OCC)C3=C(C=CC(=C3)CC(=O)[O-])OC)C(=O)C4CC4.[Na+],CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1
CHEMBL1668898,KKQXNJWVSUWKOH-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211969.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6427,50901657,CCN(CC1=C(C=CC(=C1)C2=CN=C(C=C2)OCC)C3=C(C=CC(=C3)CC(=O)[O-])OC)C(=O)C4CC4.[Na+],CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1
CHEMBL411885,KKULHWAGAYCAAF-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.086186147616283,6431,11330998,CC(=O)NCCN1CCCC2=C1C=C(C=C2)OCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1
CHEMBL411885,KKULHWAGAYCAAF-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.086186147616283,6431,11330998,CC(=O)NCCN1CCCC2=C1C=C(C=C2)OCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1
CHEMBL1077335,KLAOJPFJEJJZAC-QGOAFFKASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20185309.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6434,6479971,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)NC4(CCCC4)C(=O)NC5=CC=C(C=C5)C=CC(=O)O)N=C2C6=CC=CC=N6,O=C(O)C=Cc1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1
CHEMBL1683443,KLCHUAUMSZUJEX-KXBFYZLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,6436,10116047,CC(CC(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O)C3=NC=C(C=N3)F,CC(CC(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1
CHEMBL3182315,KLEAARUETMFQIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6438,42415086,CCN1C(=C(C(=N1)C)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C(C)C)C,CCn1nc(C)c(CNC(=O)c2ccc(OC)c(OC3CCN(C(C)C)CC3)c2)c1C
CHEMBL1092765,KLFVGKSTNOVPOR-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6441,11695591,CC(C1=C(N=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccnc1F)c1c(CCN(C)C)sc2ccccc12
CHEMBL1086580,KLGQSVMIPOVQAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,4.301029995663981,6442,2726824,C1CSCC2=C1NC(=NC2=O)C3=CC=C(C=C3)C(F)(F)F,O=c1nc(-c2ccc(C(F)(F)F)cc2)[nH]c2c1CSCC2
CHEMBL2381116,KLJVDMAOKMSBQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535330.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate by LC-MS/MS analysis,Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6447,24951610,COC1=CC2=C(CN(C2=O)C3=NC(=CS3)C(=O)NC4=C(C=CN=C4)N5CCNCC5)C=C1,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2
CHEMBL2381116,KLJVDMAOKMSBQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535330.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis,Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6447,24951610,COC1=CC2=C(CN(C2=O)C3=NC(=CS3)C(=O)NC4=C(C=CN=C4)N5CCNCC5)C=C1,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2
CHEMBL510538,KLOIUBZMBUJOJL-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.5376020021010435,6451,25156669,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCCC(=O)O)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL232801,KLSJWNVTNUYHDU-UHFFFAOYSA-N,AMITROLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,6454,1639,C1=NNC(=N1)N,Nc1ncn[nH]1
CHEMBL232801,KLSJWNVTNUYHDU-UHFFFAOYSA-N,AMITROLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,6454,1639,C1=NNC(=N1)N,Nc1ncn[nH]1
CHEMBL3093463,KLTYQAJNDLZNSD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24215891.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,6455,25205477,CCC(CN1C=C(C2=CC=CC=C21)C#N)NS(=O)(=O)C3=C(C=C(C=C3Cl)Cl)N,CCC(Cn1cc(C#N)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl
CHEMBL570402,KLUCUOQHRAOQQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.050609993355088,6456,45487545,COC1=CC=C(C=C1)CN2CCN(CC2)C(=O)C34CC5CC(C3)CC(C5)(C4)C6=CC=C(C=C6)OCC(=O)NC7=CC=CC(=C7)C(=O)OC,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(OC)cc7)CC6)(C5)C3)C4)cc2)c1
CHEMBL3632721,KLUQUTDAFSUQQQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,5.481486060122113,6457,16064892,CC(C)(C)C1=CC(=C(C=C1)F)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C(F)(F)F,Cn1c(Nc2cc(C(C)(C)C)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
CHEMBL2436214,KMHYVPFBZOIGRL-VPRHZQQDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.494850021680094,6467,72711929,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C)NC.Cl,CNC(C)C(=O)NC1CN(C(C)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL1923109,KMLLEVUPKXCGML-VEEOACQBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,6469,57397916,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC=CC=C5C=CO4,COCCCc1cc(CN(C(=O)C2CNCCC23OC=Cc2ccccc23)C2CC2)cc(OCCOC)c1
CHEMBL3287179,KMPBWZLPWZAVKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24899257.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,6472,73603344,CCC(=O)N1CCC2=C1C=CC(=C2)C3=CN=CC4=CC=CC=C43,CCC(=O)N1CCc2cc(-c3cncc4ccccc34)ccc21
CHEMBL495586,KMQZBSVCYFOFTL-WOJBJXKFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6475,44583238,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CCN(CC3)C(=O)NC4CCC(C4)C5=CC=CC=C5)CC2=O,CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)NC3CCC(c4ccccc4)C3)CC1)O2
CHEMBL1808645,KMTIRMHMRODSJK-FNORWQNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6476,24959168,C1C2=C(CN1CCC3=C4C=CC=CN4N=C3)C=C(C=C2)C=CC(=O)NO,O=C(C=Cc1ccc2c(c1)CN(CCc1cnn3ccccc13)C2)NO
CHEMBL3622175,KMUOWVJTLAOVPK-PZJWPPBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288697.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,6478,71116039,COCC1=CN=C(N=C1)N2CCC(CC2)C3CC3COCC4=C(C=C(C=C4)S(=O)(=O)C)F,COCc1cnc(N2CCC(C3CC3COCc3ccc(S(C)(=O)=O)cc3F)CC2)nc1
CHEMBL2425614,KNBBTCRFFYVMIG-CTLVIRCOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6483,72190738,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)O,CC(C)(C)c1cccc(CNC2C[S+]([O-])CC(Cc3cc(O)c(N)c(F)c3)C2O)c1
CHEMBL3393479,KNOIFPSQNXJZDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,7.301029995663981,6489,118725520,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC=C6Cl,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(Cl)cccc3[nH]2)o1
CHEMBL1779699,KNQGJTLFPWWGEW-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21570283.0,IC50,=,1075.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.968591535748375,6490,54583545,COC1=CC=C(C=C1)CN2CCN(CC2=O)C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,COc1ccc(CN2CCN(C(=O)CC(N)Cc3cc(F)c(F)cc3F)CC2=O)cc1
CHEMBL3634015,KNSSBXCHRPNPDS-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26522950.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,6494,70817239,CC1=C(C(=NN1)C)C(C)NC(=O)COC2=NC3=C(C(=C2)C(F)(F)F)C(=NN3C)C4=CC=CC=C4,Cc1n[nH]c(C)c1C(C)NC(=O)COc1cc(C(F)(F)F)c2c(-c3ccccc3)nn(C)c2n1
CHEMBL3087340,KNUCAIOJOAOGJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,6496,72543942,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,Cc1cc(-c2ccc(NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL3702796,KNVFYUIRHGJMNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.218963061378868,6498,89718366,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCO)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3085388,KNWFVJXJIMAUCK-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,44000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.356547323513813,6499,76327922,C1=CN(N=C1)CC(C2=C(C=C(C=C2)F)F)(N3C=NC=N3)O,OC(Cn1cccn1)(c1ccc(F)cc1F)n1cncn1
CHEMBL500422,KNZBNTANJVZDOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,6504,25195745,C1=CC=NC(=C1)C#CC2=C(C=CN=C2N)OC3=C(C=C(C=C3)NC(=O)NC(=O)CC4=CC=C(C=C4)F)F,Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#Cc1ccccn1
CHEMBL2013053,KOAYFGOVRZLWGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6505,57345661,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OC5CCN(CC5)C(=O)C6CC6)CC2,O=C(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
CHEMBL468927,KODBDIFHMBDFOH-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19419866.0,IC50,>,100000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 expressed in human hepatocytes,Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,6507,44219611,CC(C(=O)NCC1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)C3=NN=C(O3)C4=C5C(=CC=C4)N=CS5)N,CC(N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3cccc4ncsc34)o2)c1
CHEMBL2437423,KODNBJZZDKPFDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6509,10030750,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)CCCC(F)(F)F)CC5=CC(=NC=C5)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL1951335,KODZKNALZQZEBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,55.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.259637310505756,6511,57404045,CCNC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CCNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL2163837,KOEVIKUFICKWKV-QKKBWIMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.3979400086720375,6512,57522130,CC1CN(CCN1)C(=O)C(CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CC1CN(C(=O)C(Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1
CHEMBL2163836,KOEVIKUFICKWKV-SZNDQCEHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.346787486224656,6513,46892601,CC1CN(CCN1)C(=O)C(CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CC1CN(C(=O)C(Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1
CHEMBL521889,KOHDMWKBUVOITI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,6515,44583590,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCNC4=O,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12
CHEMBL521889,KOHDMWKBUVOITI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,6515,44583590,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCNC4=O,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12
CHEMBL1223158,KOIKIOIHIGLQAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6516,44158698,CN1CCN(CC1)CC2=CC=C(C=C2)C(C3=NN=NN3CC4=CC=CC=C4)N5CCCN(CC5)C6CCC6,CN1CCN(Cc2ccc(C(c3nnnn3Cc3ccccc3)N3CCCN(C4CCC4)CC3)cc2)CC1
CHEMBL1951329,KOIZCQULZQIWHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.086186147616283,6518,57397067,COC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,COC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL1777958,KOPYHSKMDVXZJU-KAYWLYCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6524,53248885,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)C2CC(=O)NC3CCCC4=C3C=CC(=C4)CN5CCCCC5,Cc1ccc(S(=O)(=O)N2CCNC(=O)C2CC(=O)NC2CCCc3cc(CN4CCCCC4)ccc32)cc1
CHEMBL1777958,KOPYHSKMDVXZJU-KAYWLYCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6524,53248885,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)C2CC(=O)NC3CCCC4=C3C=CC(=C4)CN5CCCCC5,Cc1ccc(S(=O)(=O)N2CCNC(=O)C2CC(=O)NC2CCCc3cc(CN4CCCCC4)ccc32)cc1
CHEMBL1951601,KOTAQXKIRQIPRZ-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,6525,57402260,CC(=CCN1C2=C(C(=C1N3CCCC(C3)N)C#N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5N=C4)C)C,CC(C)=CCn1c(N2CCCC(N)C2)c(C#N)c2c1c(=O)n(Cc1cnc3ccccc3n1)c(=O)n2C
CHEMBL273921,KOTITFQGTVUMBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643910.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4,Identification of a novel series of selective 5-HT7 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,6526,9888494,C1CC2=CC=CC=C2C(=O)N(C1)CCN3CCC(CC3)N4C5=C(C=C(C=C5)F)NC4=O,O=C1c2ccccc2CCCN1CCN1CCC(n2c(=O)[nH]c3cc(F)ccc32)CC1
CHEMBL1172779,KOYRCBKCALKGKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,7580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,5.120330794367947,6530,46901610,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)O,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O
CHEMBL1172779,KOYRCBKCALKGKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,7580.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,5.120330794367947,6530,46901610,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)O,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O
CHEMBL230262,KOZVNMWDJGMEPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,6531,23647910,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCCCC(=O)OC)C=C2,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCC(=O)OC)CCC2
CHEMBL1766181,KPCAQRVDZSQEMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.2839966563652006,6533,54582428,CC(C)C(C1=CC=C(C=C1)C2=CC=CC=N2)(C3=CN=CN3)O,CC(C)C(O)(c1ccc(-c2ccccn2)cc1)c1cnc[nH]1
CHEMBL1950084,KPCVLACNFAKGBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,6534,57403377,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)F)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(F)c3ccncc3)c2c1
CHEMBL1950084,KPCVLACNFAKGBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,6534,57403377,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)F)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(F)c3ccncc3)c2c1
CHEMBL3393482,KPFKBJLOCNHHJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,6.309803919971486,6535,118725521,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(N5)C=CC=C6O,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(O)cccc3[nH]2)o1
CHEMBL2441567,KPLGROMQFNWKJK-QPJJXVBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,6541,71585568,CN(C)CC=CC(=O)N1CCOC2=C1C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,CN(C)CC=CC(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21
CHEMBL3664694,KPLJMMNESSARTG-JRPXNJEYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,44000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.356547323513813,6542,44476891,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C3CC3)N4CCC(OC4=O)(CC(C)(C)O)C5=CC=CC=C5,CC(c1ccc(-c2ccc(=O)n(C3CC3)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1241998,KPSUZBNHNICQLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.096910013008056,6547,46900782,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC(C)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1
CHEMBL1241998,KPSUZBNHNICQLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.096910013008056,6547,46900782,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NC(C)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1
CHEMBL164261,KPVDIIPFHYNTLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,6550,515047,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)Cl,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21
CHEMBL164261,KPVDIIPFHYNTLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0915149811213505,6550,515047,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)Cl,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21
CHEMBL3291398,KPVIXBKIJXZQJX-FCEONZPQSA-N,LEFAMULIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,4430.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.3535962737769305,6551,25185057,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C,C=CC1(C)CC(OC(=O)CSC2CCC(N)CC2O)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291398,KPVIXBKIJXZQJX-FCEONZPQSA-N,LEFAMULIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,4650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.3325470471100465,6551,25185057,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C,C=CC1(C)CC(OC(=O)CSC2CCC(N)CC2O)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL261288,KQAQQTRQYSXKHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18374569.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,6558,9952648,C1C(=NC2=C(C=C(C=C2)C3=CC=CC=C3F)NC1=O)C4=CC(=CC=C4)N5C=CN=N5,O=C1CC(c2cccc(-n3ccnn3)c2)=Nc2ccc(-c3ccccc3F)cc2N1
CHEMBL2448700,KQHQMFLSXREETG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16300.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.787812395596042,6570,73354174,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC(=C(C=C2)Cl)NC(=O)CNC3CCCN(C3)C.C(=O)O,CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)CNC2CCCN(C)C2)c1
CHEMBL221445,KQNYTTDHCMFOME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16950617.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6576,11989776,CC(C)(C)N1CCN(CC1)CC2=C(N=C3C(=C2C(=O)NN(C4=CC=CC=C4)C(=O)OC)C=CC=C3F)C5=CC=CC=C5,COC(=O)N(NC(=O)c1c(CN2CCN(C(C)(C)C)CC2)c(-c2ccccc2)nc2c(F)cccc12)c1ccccc1
CHEMBL29609,KQOXLKOJHVFTRN-UHFFFAOYSA-N,PLECONARIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,=,6309.57,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200000237109354,6579,1684,CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1
CHEMBL29609,KQOXLKOJHVFTRN-UHFFFAOYSA-N,PLECONARIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21907579.0,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.300000029139089,6579,1684,CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1
CHEMBL549749,KQRDVNUCOWRFLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19610616.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.",J. Med. Chem.,PUBLICATION,,5.0,6582,44220300,CCNC(=O)C1=CC2=C(N=C(N=C2S1)N)C3=CC(=C(C=C3Cl)Cl)OCCN(CC)CC,CCNC(=O)c1cc2c(-c3cc(OCCN(CC)CC)c(Cl)cc3Cl)nc(N)nc2s1
CHEMBL3104487,KQYYFXSCJMMDOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,6589,76317380,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1
CHEMBL3104487,KQYYFXSCJMMDOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,6589,76317380,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1
CHEMBL3344501,KQZKQPCMHFSLEK-ZXVPZRJPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25310383.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,6590,90142631,CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)CN2CCN(CC2)CCOC)C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)C(C)C(=O)N(C)C(C(C)CN2CCN(CCOC)CC2)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL3326579,KRCMLCOREROPCP-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,6594,25265637,CCC1(CC(C2=C(O1)C(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC,CCC1(CC)CC(NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1
CHEMBL1552719,KRIKILRRJCIWNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,5.769551078621726,6595,16013152,CC1=CC=C(C=C1)C2=NOC(=N2)CSC3=NN=C(N3C4=CC=C(C=C4)OC)C5=CC=NC=C5,COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1
CHEMBL371430,KRLGQBXIHBDUPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,3560.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.448550002027125,6599,11680597,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CC=C3,COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1
CHEMBL1669423,KRLJKEOQHOYBSK-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1535.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.813891620186794,6600,53322839,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4C,CC(C1=C(CCN(C)Cc2nccn2C)Cc2ccccc21)c1cnccn1
CHEMBL1951598,KRMBZIKXHYHITN-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,6601,57395248,CC(=CCN1C2=C(C(=C1N3CCCC(C3)N)C#N)N(C(=O)N(C2=O)CC(=O)C4=CC(=CC=C4)OC)C)C,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCC(N)C4)n3CC=C(C)C)n(C)c2=O)c1
CHEMBL2178422,KRNAOFGYEFKHPB-ANJVHQHFSA-N,RIMEGEPANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23153230.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence assay,"Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine.",J. Med. Chem.,PUBLICATION,,4.769551078621726,6602,51049968,C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6,NC1c2cccnc2C(OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CCC1c1cccc(F)c1F
CHEMBL2178422,KRNAOFGYEFKHPB-ANJVHQHFSA-N,RIMEGEPANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23153230.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using benzoylresorufin as substrate after 45 mins by fluorescence assay,"Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine.",J. Med. Chem.,PUBLICATION,,4.769551078621726,6602,51049968,C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6,NC1c2cccnc2C(OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CCC1c1cccc(F)c1F
CHEMBL1808643,KRVGKRFOWVTXGV-VQHVLOKHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6610,24959543,C1CCC(CC1)CCN2CC3=C(C2)C=C(C=C3)C=CC(=O)NO,O=C(C=Cc1ccc2c(c1)CN(CCC1CCCCC1)C2)NO
CHEMBL1957148,KSDLXGLGEFBZCB-MDWZMJQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22342630.0,IC50,>,172000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorescence assay,"Biotransformations of 6',7'-dihydroxybergamottin and 6',7'-epoxybergamottin by the citrus-pathogenic fungi diminish cytochrome P450 3A4 inhibitory activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.7644715530924513,6618,57393151,CC(=CCOC1=C(C(=CC2=C1C=CO2)O)CCC(=O)O)CCC(C(C)(C)O)O,CC(=CCOc1c(CCC(=O)O)c(O)cc2occc12)CCC(O)C(C)(C)O
CHEMBL243876,KSHJXDWYTZJUEI-UHFFFAOYSA-N,BMS-433771,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,=,27500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.560667306169737,6620,6478034,C1CC1N2C3=C(C=NC=C3)N(C2=O)CC4=NC5=CC=CC=C5N4CCCCO,O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1
CHEMBL3672587,KSIVSAIIPBDCII-LKMBZGFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.823908740944319,6624,57406206,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N(C)C,CC(C)c1nc(CN(C)C(=O)N2CC(N(C)C)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672587,KSIVSAIIPBDCII-LKMBZGFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,330.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.481486060122113,6624,57406206,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N(C)C,CC(C)c1nc(CN(C)C(=O)N2CC(N(C)C)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2181889,KSQJUIXMCGQLTA-OIFRRMEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,6.3979400086720375,6634,67270914,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=CC=CC=N5)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2ccccn2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL1649682,KSRDECNQNMUKOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.0,6636,24951946,C1CC(=O)N(C1)CC2=C(C=C(C=C2F)N3C4=C(COCC4)C(=N3)C(F)(F)F)F,O=C1CCCN1Cc1c(F)cc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1F
CHEMBL3699082,KSUCBNRQDLUBLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,45000.0,NM,273498,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,4.346787486224656,6638,91669043,C1=CC(=C(C=C1F)F)C(CN2C=NN=C2)(C(C3=CN=C4C=C(C=CC4=N3)Cl)(F)F)O,OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1cnc2cc(Cl)ccc2n1
CHEMBL1172744,KTJHVHZJTXJNIH-QZTJIDSGSA-N,1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX),,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20527970.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.096910013008056,6654,24803184,COCC12CC1(CCNC2)C3=CC4=CC=CC=C4C=C3,COCC12CNCCC1(c1ccc3ccccc3c1)C2
CHEMBL3664711,KTNRIRGXBWOYQO-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,6656,59635648,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CC(C)(C)O)(c2ccc(F)cc2)OC1=O
CHEMBL1951611,KTVXOJMKMNUCCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,6666,57395249,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=C(C5=CC=CC=C5C=N4)C#N)C)C,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1ncc3ccccc3c1C#N)c(=O)n2C
CHEMBL2387505,KTVYEQQSGWOYNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,6667,71659754,CC1=CC(=CC=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,Cc1cccc(-c2ccc3c(c2)[nH]c(=O)c2[nH]c(-c4c(F)cccc4Cl)nc23)c1
CHEMBL1917468,KTXVIHVCQVKSMA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21944855.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H(3) receptor antagonists with robust wake-promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6670,44540072,CC1CCCN1CCC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C4=CC=C(C=C4)F,CC1CCCN1CCc1ccc(-c2ccc(=O)n(-c3ccc(F)cc3)n2)cc1
CHEMBL1910122,KTYRZCOFWKPJRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,6672,57398006,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCN(CC3)C)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(C)CC1)C2=O
CHEMBL2425159,KUBYYBWHXPIUIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6677,72190131,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=NC(=CC(=N4)OC)OC,COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1
CHEMBL448656,KUCPVNZOVVPTBB-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,6678,44587391,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=C(C(=CC=C4)OCCCCC(=O)O)F)N,NC(Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL3699341,KUEBPEWAUJGQRQ-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.663540266151471,6680,89718270,CCCCCCCC(=O)NC1=CC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCCCCC)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1427458,KUELMQAVLKNHFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,6682,4358655,CC1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=NC=C3,Cc1ccc(Oc2ccc(C(=O)NCc3ccncc3)cc2)cc1
CHEMBL2018926,KUIKUTZPAAIPGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,3560.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.448550002027125,6685,56954137,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)OCC4=CC=CC=C4,COc1ccc2nc(SCc3ccc(OCc4ccccc4)cc3)[nH]c2c1
CHEMBL2448740,KUIOELMGPFXPNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.3979400086720375,6686,73346620,CCN(CC1=CN=CN1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,CCN(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1
CHEMBL1818445,KUJKCGJIUCGPED-AAFJCEBUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.221848749616356,6687,56683046,CC1=CSC(=N1)C23CC2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C23CNCCC2(c2ccc(Cl)c(Cl)c2)C3)n1
CHEMBL2057524,KUJLAGMVWGXVMF-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,6688,59603305,C#CCN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,C#CCN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
CHEMBL520238,KUMYJQZMYWIEHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,5.070581074285707,6689,25138074,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC=NC=C3)C,CC(=O)Nc1cc(-c2ccncc2)nc(-n2nc(C)cc2C)n1
CHEMBL508020,KUOHOWIMYSEGDM-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.318758762624412,6691,11456285,CS(=O)(=O)C1=CC=CC(=C1CN2C=C(C(=O)N(C2=O)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=CC=CC=C4Cl)F,CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(CC(NCCCC(=O)O)c2ccccc2)c1=O
CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,4.207608310501746,6699,11465834,CC(C)CC1C(=O)NC(C(=O)N1C(C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N(C)C)c1ccc(F)cc1F
CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16821776.0,IC50,=,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,4.050609993355088,6699,11465834,CC(C)CC1C(=O)NC(C(=O)N1C(C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N(C)C)c1ccc(F)cc1F
CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,5.301029995663981,6699,11465834,CC(C)CC1C(=O)NC(C(=O)N1C(C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N(C)C)c1ccc(F)cc1F
CHEMBL377414,KUYYTTWJIWYFTJ-WXFUMESZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,4.508638306165727,6699,11465834,CC(C)CC1C(=O)NC(C(=O)N1C(C2=C(C=C(C=C2)F)F)C(=O)N(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N(C)C)c1ccc(F)cc1F
CHEMBL3087037,KUZUQSLQWYRGST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,6701,72547286,CC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,Cc1cc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1
CHEMBL1921979,KVDGTWKQXMEUBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,6.0,6703,21879620,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3CCN4C3=CN=C4,CNC(=O)c1ccc2cc(C3CCn4cncc43)ccc2c1
CHEMBL515624,KVICYPUXGNRQCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,6706,25110703,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC=CC=C4)Cl,O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3
CHEMBL515624,KVICYPUXGNRQCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,6706,25110703,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC=CC=C4)Cl,O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3
CHEMBL2425613,KVJZSBQIJYQMHT-STZPNVHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,6709,73349243,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(CO)C(F)(F)F,CC(C)(C)c1cccc(CNC2C[S+]([O-])CC(Cc3cc(F)c(N)c(OC(CO)C(F)(F)F)c3)C2O)c1
CHEMBL1910119,KVNIHXPFEOWXRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,6712,57401419,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCC(CC3)C(=O)N)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCC(C(N)=O)CC1)C2=O
CHEMBL1761531,KVNPGGYBLPCJSE-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6713,25121114,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)C(=O)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1
CHEMBL1761531,KVNPGGYBLPCJSE-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6713,25121114,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)C(=O)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1
CHEMBL1097187,KVNUNQVIQXLHFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,275.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,6.560667306169737,6717,46237408,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=C(C=CC=C5F)F)C)OC,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1c(F)cccc1F)cc(=O)n2C)c1cncn1C
CHEMBL495792,KVNUPZLQKXFWBS-IRLDBZIGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6718,44583349,CN1C(=CC=N1)C2=CC3=C(C=C2)OC4(CCN(CC4)C(=O)NC5CC5C6=CC=CC=C6)CC3=O,Cn1nccc1-c1ccc2c(c1)C(=O)CC1(CCN(C(=O)NC3CC3c3ccccc3)CC1)O2
CHEMBL360033,KVOPMRICDIBARO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15582422.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Cytochrome P450 3A4,Aminothiazole inhibitors of HCV RNA polymerase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6721,5273742,C1CCC(CC1)N(C2=NC=C(S2)C(=O)O)C(=O)C3=CC=C(C=C3)OCC4=CC(=CC=C4)C(F)(F)F,O=C(O)c1cnc(N(C(=O)c2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C2CCCCC2)s1
CHEMBL3581143,KVTIRZWDMYIMRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.080921907623926,6723,24831672,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)OC,COc1cccc(CC(=O)Nc2nc(-c3ccnc(OC)c3)cs2)c1
CHEMBL1813316,KVTPLEPXMVVCIZ-CJNGLKHVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.301029995663981,6724,46701091,CCN1CC2CCCCC2(C1)C3=CC(=C(C=C3)Cl)Cl,CCN1CC2CCCCC2(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1813317,KVTPLEPXMVVCIZ-XJKSGUPXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.301029995663981,6725,46701090,CCN1CC2CCCCC2(C1)C3=CC(=C(C=C3)Cl)Cl,CCN1CC2CCCCC2(c2ccc(Cl)c(Cl)c2)C1
CHEMBL3236360,KVURUXGLNAWILE-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,5.42021640338319,6726,90655376,CCC(CS(=O)(=O)C(C)(C)C)N1C(C(CC(C1=O)(C)CC(=O)NS(=O)(=O)C(F)(F)F)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,CCC(CS(=O)(=O)C(C)(C)C)N1C(=O)C(C)(CC(=O)NS(=O)(=O)C(F)(F)F)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
CHEMBL151038,KWEADCNYIUWGLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,6735,11322201,CCCCOC1=CC=C(C=C1)C2=C(C=NO2)C,CCCCOc1ccc(-c2oncc2C)cc1
CHEMBL2041189,KWJTYPOQTXWLHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,6742,57387542,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cnccn1
CHEMBL2158224,KWLXMAXTGKZBPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.251811972993799,6744,11505187,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CC4=CC=CC=N4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL520036,KWQQYOALARJKSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,6748,25138089,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCCOCC4)C,CC(=O)Nc1cc(-c2cccc(N3CCCOCC3)n2)nc(-n2nc(C)cc2C)n1
CHEMBL2387603,KWSYUYDFIFYONI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,6751,71659614,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=CS5)Cl,O=c1[nH]c2cc(-c3cccs3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL3321850,KWWIBMICKVLCQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,6757,118709777,CN1CCN(C2=CC=CC=C21)C(=O)C3(CC3)C(=O)NC4=C(C=CC(=C4)Cl)Cl,CN1CCN(C(=O)C2(C(=O)Nc3cc(Cl)ccc3Cl)CC2)c2ccccc21
CHEMBL3352882,KXMQLNZZFBQWDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.522878745280337,6768,58026176,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4C(=O)N,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O
CHEMBL1269676,KXNILSUQHBEFOR-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,6771,12001953,CCNCCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,CCNCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269676,KXNILSUQHBEFOR-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,6771,12001953,CCNCCC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,CCNCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1681849,KXOXGMSSGWQNPP-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21277198.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6773,53318560,CC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=C(C=C(C=N4)C(=O)NCC5=CC(=C(C=C5)F)F)Cl,CC1CN(c2ncc(C(=O)NCc3ccc(F)c(F)c3)cc2Cl)CCN1C1CCN(Cc2ccc(Cl)cc2)CC1
CHEMBL3702675,KXQBIJCCZVZCTA-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,6776,89716372,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8CCCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCCC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3401131,KXTWFYBMSDHQDY-HZPDHXFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,418000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.378823718224965,6782,57869963,CN1C(=O)C=C(N=C1N2CCOC3C2CCCC3)C4=C(C=NC=C4)F,Cn1c(N2CCOC3CCCCC32)nc(-c2ccncc2F)cc1=O
CHEMBL1079360,KXYUVZFKXATOCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6785,44555473,CC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL2041185,KXZUNTUEDNVFLH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,6786,57387539,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,COc1nccnc1N1C(=O)N(c2ccc(-c3ccc(C(=O)O)cc3C)cc2)C(=O)C12CCN(Cc1ncccc1C)CC2
CHEMBL3601196,KYGDXANIBQBNCG-BAOJUYLCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6789,73669500,CC1=CC(=CC(=N1)C)NC2=NC=C(C(=C2)NC3CC(C(C3O)O)CO)C4=NC5=CC=CC=C5S4,Cc1cc(Nc2cc(NC3CC(CO)C(O)C3O)c(-c3nc4ccccc4s3)cn2)cc(C)n1
CHEMBL2437422,KYGYDBWEUNNQKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6790,58863217,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)CCN5CCOCC5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL348263,KYILADUMHVWERU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,6793,20763385,CCCCOC1=CC=C(C=C1)N=CNO,CCCCOc1ccc(N=CNO)cc1
CHEMBL1094511,KYIVOBNKSGAKNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,6794,46888787,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=CC=N4,CN1CCCC(c2nc3ccccc3n2Cc2ccccn2)C1
CHEMBL2016938,KYKXDBASGIWWGF-XCLFUZPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,6796,46932049,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=CC=CC=C4Cl)Br,OC1(c2ccc(F)c(F)c2)CCNCC1c1onc(-c2ccccc2Cl)c1Br
CHEMBL3702744,KYMQIUAUXUGDAK-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3460.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.460923901207224,6800,89718274,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCC(=O)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)OC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3260753,KYOICGKIVJTIGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,6802,44160263,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CN=C(N=C4)C)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(C)nc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
CHEMBL3664684,KYQHBGDFXHLCHY-UGDMGKLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,6805,44476983,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(C)(C)O)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccn(CC(C)(C)O)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL2057794,KYWHIBXYSUFTBJ-DQEYMECFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,69.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.161150909262744,6816,70688463,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CN=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3cccnc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL1813476,KZCROLYCBADBTI-DLBZAZTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,2650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.576754126063192,6822,53391717,C1CC2CNCC2(C1)C3=CC4=CC=CC=C4C=C3,c1ccc2cc(C34CCCC3CNC4)ccc2c1
CHEMBL1813477,KZCROLYCBADBTI-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,4.97061622231479,6823,53391718,C1CC2CNCC2(C1)C3=CC4=CC=CC=C4C=C3,c1ccc2cc(C34CCCC3CNC4)ccc2c1
CHEMBL221542,KZJWDPNRJALLNS-VJSFXXLFSA-N,BETA-SITOSTEROL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.0,6828,222284,CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C,CCC(CCC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C
CHEMBL3589557,KZRCYRFDOFTBHY-BTQNPOSSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26101566.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Competitive inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,6836,122180940,C1CC2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F.Cl,O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCCC2C1
CHEMBL521347,KZYAHEIPPAPADQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,6842,11548023,CC1=C(C(N=C(N1)C2=CC(=NC=C2)Cl)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=C(C=C5C(=C4)C=NN5)F,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1
CHEMBL3407785,KZZIQBCUVRUILN-AQPYCOETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,5.154901959985743,6844,118730352,CNC1=C2C(=NC(=N1)C#CC3=CC=C(S3)Br)N(C=N2)C4C5CC5(C(C4O)O)C(=O)NC,CNC(=O)C12CC1C(n1cnc3c(NC)nc(C#Cc4ccc(Br)s4)nc31)C(O)C2O
CHEMBL450061,LADNPCFYVROVIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19231183.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6845,25256832,CC(C)CNC1=C(C(=NC(=N1)C#N)N2CCOCC2)N,CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N
CHEMBL496400,LAFOUUWSNUQMPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.167491087293763,6846,44583561,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCCCC4=O,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12
CHEMBL496400,LAFOUUWSNUQMPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,6846,44583561,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4CCCCC4=O,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12
CHEMBL240571,LAHUDBCXWRATGM-HRFSGMKKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.161150909262744,6847,23635107,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=C(C=C(C=C3)Cl)F)C(C(C)C)NC(=O)CNC,CNCC(=O)NC(c1cc(C)ccc1N1CCN(C(=O)C(C)Cc2ccc(Cl)cc2F)CC1)C(C)C
CHEMBL606467,LAJHRQQVGFRLQL-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.102372908709558,6849,46226095,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=COC=C4)C#N)OCC(CC5=CNC6=CC=CC=C65)N,Cc1[nH]nc2ncc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12
CHEMBL1269672,LANNZQCALHSARO-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,6850,12001784,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCOC)Cl)C5CC5)Cl,COCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL3394722,LAQHWPIUUQIIKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6853,89795501,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(N3)C=CN=C4)C5CCOCC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1
CHEMBL3394722,LAQHWPIUUQIIKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6853,89795501,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)C3=CC4=C(N3)C=CN=C4)C5CCOCC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1
CHEMBL239816,LBKUIYUPKQWTEX-UHFFFAOYSA-N,SR-1459,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,6876,16662118,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)N,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1
CHEMBL456002,LBLKWZCUZFIOQX-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,1350.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,5.8696662315049934,6878,44590571,CC1=CC=CC=C1C2=CC(=O)N(C3=C2C=C(C=C3)C(C4=CC=C(C=C4)Cl)(C5=CN=CN5C)N)C,Cc1ccccc1-c1cc(=O)n(C)c2ccc(C(N)(c3ccc(Cl)cc3)c3cncn3C)cc12
CHEMBL578547,LBMSLUDBQYSBBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,6879,45484900,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)C(=O)OC,COC(=O)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1
CHEMBL434317,LBNCHIKFTCJSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,26800.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.5718652059712115,6880,11322177,CCCCOC1=CC=C(C=C1)C2=C(C=NN2)C,CCCCOc1ccc(-c2[nH]ncc2C)cc1
CHEMBL565383,LBOFATLQBXVRSA-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,6881,44473093,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=C[N+](=CC=C5)[O-],Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc[n+]([O-])c3)ccc2o1
CHEMBL3088176,LBTQISHPRWJOLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,J. Med. Chem.,PUBLICATION,,4.301029995663981,6891,72713752,CC1=CSC(=N1)C(C)(C2=NN=C(S2)NC(=O)CC3=C(C=CC=C3F)F)O,Cc1csc(C(C)(O)c2nnc(NC(=O)Cc3c(F)cccc3F)s2)n1
CHEMBL3291430,LCCDAYCGXSEETO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,6898,90467162,CC1=C(N=CN=C1N(C)C)CN2C=C(C3=C2C=C(C=N3)OC)C(=O)NCCO,COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1
CHEMBL2425148,LCGWKKYPAXXXPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6907,72189516,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=NNC(=S)N4C,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3n[nH]c(=S)n3C)cc2)cc1
CHEMBL1778587,LCPOJFADYAPLKQ-LFIBNONCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550240.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.060480747381382,6916,54586630,CC(C)(C(=O)NC1=CC=C(C=C1)C=CC(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=COC=C4)C5CCCCC5,Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(C=CC(=O)O)cc3)cc21
CHEMBL3137459,LCQMERCOLHHNJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4300.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.366531544420414,6917,76325840,C1CN(CCC1N(C2=CC=C(C=C2)C#N)C3=CN=CC=C3)C4=CC(=C(C=C4)F)F,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(F)c(F)c3)CC2)cc1
CHEMBL539475,LCXRMOKMNODMLL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.102372908709558,6927,45273802,CC1=CC(=NN1CC(C2=CC=CC=C2)NC(=O)NC3CCN(CC3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F)C,Cc1cc(C)n(CC(NC(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccccc2)n1
CHEMBL3632717,LDACHLNBCOVNBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,6931,60098131,CC(C)(C)C1=CC(=CC=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=CN5,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc[nH]4)c3)ccc21
CHEMBL239149,LDDVFORMTQHFKD-GOSISDBHSA-N,SR-897,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,6934,16662093,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=CC=C4)O,O=C(C(O)c1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL1269680,LDHQAYBINPIZLI-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,6940,12001955,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNCCF)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL1269680,LDHQAYBINPIZLI-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,9900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.00436480540245,6940,12001955,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNCCF)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL561696,LDIUIXFIAWISPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,<,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,6941,45267853,CSC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
CHEMBL561696,LDIUIXFIAWISPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6941,45267853,CSC1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
CHEMBL3234567,LDKJFGZHRKASEF-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,6946,90654586,CC1=NC(=CC(=N1)N2CCCC(C2)C(=O)NCCC3=CC=C(C=C3)C#N)N4CCN(CC4)C,Cc1nc(N2CCN(C)CC2)cc(N2CCCC(C(=O)NCCc3ccc(C#N)cc3)C2)n1
CHEMBL1094510,LDKQFEPUPKIHCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,6947,46861858,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4,CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1
CHEMBL3291348,LDMFKWUZUDRFEG-ZMZPIMSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,6948,16116998,CC1(C2CCC1(C3=C2C(=O)N(N3C)C4=C(C=CC(=C4)Cl)Cl)C)C,Cn1c2c(c(=O)n1-c1cc(Cl)ccc1Cl)C1CCC2(C)C1(C)C
CHEMBL3291354,LDOLONWICSGMOO-ZMZPIMSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,6951,16118896,CC1(C2CCC1(C3=C2C(=O)N(N3C)C4=CC=CC=C4Cl)C)C,Cn1c2c(c(=O)n1-c1ccccc1Cl)C1CCC2(C)C1(C)C
CHEMBL1951602,LDQKRHYWUXCKBV-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,6957,57391805,CC(=CCN1C2=C(C(=C1N3CCCC(C3)N)C#N)N(C(=O)N(C2=O)CC4=C(C=CC=N4)C#N)C)C,CC(C)=CCn1c(N2CCCC(N)C2)c(C#N)c2c1c(=O)n(Cc1ncccc1C#N)c(=O)n2C
CHEMBL373751,LDTAHRLHGHFHKP-UHFFFAOYSA-N,GSK-319347A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16997559.0,IC50,<,50118.72,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.300000029139089,6960,11626927,COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C#N)OCC4=CC=CC=C4S(=O)(=O)C)OC,COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC
CHEMBL361812,LDXDSHIEDAPSSA-OAHLLOKOSA-N,RAMATROBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,6966,123879,C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O,O=C(O)CCn1c2c(c3ccccc31)CC(NS(=O)(=O)c1ccc(F)cc1)CC2
CHEMBL2159071,LDZFSHKFVOIAHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Adamantyl carboxamides and acetamides as potent human 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,5.795880017344075,6970,71449606,CC1=CC=C(C=C1)C2(CC2)C(=O)N(C)CC3=CC=CS3,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1
CHEMBL2159071,LDZFSHKFVOIAHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,5.136677139879544,6970,71449606,CC1=CC=C(C=C1)C2(CC2)C(=O)N(C)CC3=CC=CS3,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1
CHEMBL3325537,LDZNFFGWKHAEMM-GDBMZVCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25176194.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,6971,71557789,CN1CCC(C(C1)COC2=CC(=C(C=C2F)S(=O)(=O)NC3=NC=NS3)F)C4=CC=C(C=C4)Cl,CN1CCC(c2ccc(Cl)cc2)C(COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1
CHEMBL180829,LEDOEMLBTIQWQV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,2010.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.696803942579511,6974,11475327,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)NC)N3C=CN=C3)N(C)C,CNC(=O)C(C)(C)COc1ccc2cc(C(C(C)N(C)C)n3ccnc3)ccc2c1
CHEMBL2181777,LEMKJLWZCSZLJU-GZTJUZNOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.236572006437063,6981,71452111,CC1=CN=C(C=C1)C2=C(C3=C(N2C)C=C(C=C3)C(=O)NC4(CCC4)C(=O)NC5=CC=C(C=C5)C=CC(=O)O)C6CCCC6,Cc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(C=CC(=O)O)cc5)CCC4)cc3n2C)nc1
CHEMBL178090,LENAVORGWBTPJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,47100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.326979092871104,6982,11332763,C1=CC(=CN=C1)C2=CC=C(O2)CN,NCc1ccc(-c2cccnc2)o1
CHEMBL1088290,LEPZPTOEMLDSMH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19853442.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New classes of potent and bioavailable human renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,6984,46880060,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3=C(CCNC3)C4=CC=C(C=C4)CCCOC5=C(C=CC(=C5Cl)F)F,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CCNC1)N(Cc1cccc(Cl)c1Cl)C1CC1
CHEMBL1774930,LEXXECNYBXJPMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,6.096910013008056,6992,46175090,C1C2=C(CN1C(=O)NCC(F)(F)F)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=C(C=N4)F)N,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)n1)CN(C(=O)NCC(F)(F)F)C2
CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,430.53,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,6.365996580840961,6994,3198,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,50.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.301029995663981,6994,3198,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL261805,LFQVOSHWRZTZHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17983756.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.468521082957745,7009,11632540,C1CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6,Nc1nccn2c(C3CCC3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12
CHEMBL557210,LFSBNTMFCXGIEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7010,45268653,CN(CCO)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(CCO)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL2436205,LFSWTUZKDFSREL-OBRDHALPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.698970004336019,7012,72711480,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)S(=O)(=O)C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccc(S(C)(=O)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL1949941,LFZMKXMCRKNUCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,7019,57396814,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncn3C)c2c1
CHEMBL1949941,LFZMKXMCRKNUCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,7019,57396814,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncn3C)c2c1
CHEMBL252437,LGAIRKZXPYNIQE-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7021,44447280,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL3318477,LGARZUXXEONOTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7023,118708934,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=C(C=CC=C3C(F)(F)F)C(F)(F)F,O=C1CC(c2c(C(F)(F)F)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl
CHEMBL3087339,LGBXCUAQHIUOHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,7025,72547533,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)C3=CC(=CC(=C3)Cl)Cl,Cc1cc(-c2ccc(NC(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1
CHEMBL348475,LGGHDPFKSSRQNS-UHFFFAOYSA-N,TARIQUIDAR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,4.0,7028,148201,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2
CHEMBL348475,LGGHDPFKSSRQNS-UHFFFAOYSA-N,TARIQUIDAR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,4.0,7028,148201,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2
CHEMBL218375,LGJRRERRFSZFTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17266208.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.",J. Med. Chem.,PUBLICATION,,5.0,7030,16105788,CCOC(=O)N1CCC(CC1)NS(=O)(=O)C2=CC=C(C3=CC=CC=C32)NC(=O)C4=CC=CC=C4C,CCOC(=O)N1CCC(NS(=O)(=O)c2ccc(NC(=O)c3ccccc3C)c3ccccc23)CC1
CHEMBL326796,LGMBHWQZEHFJOS-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,7034,10212348,C1CN(C(CN1CC2=CC=C(O2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=NC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccncc1)CC(O)CN1CCN(Cc2ccc(-c3ccccc3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL1650646,LGNVIXULXLACQS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2050.0,NM,221148,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,5.688246138944246,7036,25069763,COC1=NC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,COc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cn1
CHEMBL3115173,LGNYHLQWWSCHTL-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,7037,59721232,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CC(=O)O)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CC(=O)O)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL389074,LGQVNFUOFPCSSQ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.6020599913279625,7039,16658023,C1CC(CN(C1)C2=NC3=C(C=C(C=C3)Cl)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2ccc(Cl)cc2c1=O
CHEMBL3702731,LGRWYGGRXLUJDO-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.600326278518962,7041,89718463,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCO)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702770,LGWHJDRHSPNXIU-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2610.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.583359492661719,7044,89718282,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CC=C(C=C7)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2024249,LGZMQYLGIALXSF-VHSZZVNMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2910.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.536107011014093,7048,57544848,COCCCCC(C1CCCN(C1)C(=O)NCC(CC2CCCCC2)N)(C3=C(C(=CC=C3)Cl)F)O,COCCCCC(O)(c1cccc(Cl)c1F)C1CCCN(C(=O)NCC(N)CC2CCCCC2)C1
CHEMBL1671982,LHEAAXNLFNVCGK-NDENLUEZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,6.096910013008056,7051,25009027,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=CC=C(C4=CC=CC=C43)C(=O)OC,COC(=O)c1ccc(Oc2ccc(C=C3SC(=O)NC3=O)cc2OC)c2ccccc12
CHEMBL519383,LHFROBFAPLSYRB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.853871964321762,7052,25138080,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)OCCOC)C,COCCOc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
CHEMBL3357637,LHHLPNVJMCVRGH-YVNNLAQVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,5.0,7055,71513822,CCOC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)NC(=O)C(=CCN(C)C)F,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C(F)=CCN(C)C
CHEMBL3702736,LHIDQAMOAPBRHZ-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.5968794788241825,7056,89718323,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CC7(CC7)CO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC5(CO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL191817,LHWQBUMJKGGLOH-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,7070,44399944,COC1=CC=CC(=C1F)C2=CN(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)CC4=C(C=CC=C4F)F,COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(CC(N)c3ccccc3)c2=O)c1F
CHEMBL3702674,LHXHSXDYTBEHRK-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,7071,89716370,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7072,46884732,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)C(C)C3=NC=CN=C3OC,COc1nccnc1C(C)C1=C(CCN(C)C)Cc2cc(C)ccc21
CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7072,46884732,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)C(C)C3=NC=CN=C3OC,COc1nccnc1C(C)C1=C(CCN(C)C)Cc2cc(C)ccc21
CHEMBL2037604,LIEAKONJVOLXFZ-LSDHHAIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22578490.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,7074,57411066,CC1CCCN1CC(C)COC2=CC=C(C=C2)C3=CC(=O)NN=C3,CC(COc1ccc(-c2cn[nH]c(=O)c2)cc1)CN1CCCC1C
CHEMBL3311222,LIFCTIRUKQXXCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,53000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.275724130399211,7075,53497485,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1
CHEMBL465470,LIKKKFAHHSRGPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,=,64000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1938200260161125,7077,25181419,CC(C)(C)C1=CC(=NC=C1C(=O)NCC2CCOCC2)NC3=C(C=C(C=C3)Cl)Cl,CC(C)(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1
CHEMBL3288752,LIKSGJKEDNKMAF-FTWQHDNSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24842618.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.,Bioorg. Med. Chem.,PUBLICATION,,4.958607314841775,7078,53467975,CC1=CC2=NN(C(=O)N2C=C1Cl)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,Cc1cc2nn(Cc3cc(C4OC(CO)C(O)C(O)C4O)ccc3Cl)c(=O)n2cc1Cl
CHEMBL1098726,LILGMDXLRPEBNH-HFZDXXHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20405922.0,IC50,>,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).",J. Med. Chem.,PUBLICATION,,4.455931955649724,7079,11699447,CN1C(=O)N(C(=O)C12CN(CC2C3=CC=C(C=C3)C#N)C4=NC=C(C=C4)C(=O)O)C5=CC(=CC(=C5)Cl)Cl,CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)C12CN(c1ccc(C(=O)O)cn1)CC2c1ccc(C#N)cc1
CHEMBL2331772,LIMFSRUCVSKRHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,5.920818753952375,7080,11249025,C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)NC2=CC(=C(C(=C2)Cl)OC3=CC(=CN=C3)Cl)Cl,O=S(=O)(Nc1cc(Cl)c(Oc2cncc(Cl)c2)c(Cl)c1)c1ccc(Cl)cc1Cl
CHEMBL2386076,LINXGADXFCBIBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7084,11610353,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC(=CC=C4)Cl,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc(Cl)c1)CC2
CHEMBL1938681,LIPNXDIBECKOMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes co-incubated with testosterone,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,7087,53475321,C1CN(CCN1)C2=CC=C(C=C2)N(CC3=CC=CC=N3)C(=O)C4=CC=C(O4)C5=CC=C(C=C5)Cl,O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1
CHEMBL1938681,LIPNXDIBECKOMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 30 mins prior to substrate addition,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,7087,53475321,C1CN(CCN1)C2=CC=C(C=C2)N(CC3=CC=CC=N3)C(=O)C4=CC=C(O4)C5=CC=C(C=C5)Cl,O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1
CHEMBL2017091,LIQNVPVFYAIYPC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,7088,70681152,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4)C(=O)O,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(=O)O)cnc2c1
CHEMBL522689,LIQUKCBVEIEJGE-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,7089,44568942,CCC(C)NC1=C2C=CC(=CC2=CN=N1)C3=C(C=CC4=C3ON=C4NC)C,CCC(C)Nc1nncc2cc(-c3c(C)ccc4c(NC)noc34)ccc12
CHEMBL3115179,LIRHQWJNEWJZFF-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,7091,59721382,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CCN(C)C)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2018923,LISPYUNURYPUOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,1870.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.728158393463501,7092,56954011,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC(=CC=C3)C4=CC=CC=C4,COc1ccc2nc(SCc3cccc(-c4ccccc4)c3)[nH]c2c1
CHEMBL2397186,LIWXQSMSAZJCQT-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7096,71682651,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=NC(=NC=C3)C(C)(C)C,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1
CHEMBL3702812,LIXAEKDRWMNILP-LFCBDPIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.3872161432802645,7097,89718497,CN1CCN(CC1)C2CN(C2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCN(C)CC7)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1081515,LIXMKOKUEJGOKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458132,7098,46883398,CCN(CC(CC1CCCCC1)NC(=O)OCC2=CN=CS2)CC(CC3CCCCC3)NC(=O)OCC4=NC=CS4,CCN(CC(CC1CCCCC1)NC(=O)OCc1cncs1)CC(CC1CCCCC1)NC(=O)OCc1nccs1
CHEMBL196945,LIYLTQQDABRNRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,48000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.318758762624412,7101,9996409,C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O,O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1
CHEMBL2069845,LJDGJZNBWICGDO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,7103,11854299,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC(=CC=C3)C(=O)O,NC(CC(=O)N1CCN(C(=O)c2cccc(C(=O)O)c2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL540359,LJDOMRHCUJTSAI-ZBBHSQCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18680280.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,7104,45259193,CC(C)OC(=O)C1=CC=C(C=C1)NC(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC3CCC[N+](C3)(C)CC4=CC(=CC=C4)O.[I-],CC(C)OC(=O)c1ccc(NC(=O)NC(Cc2ccc(O)cc2)C(=O)NC2CCC[N+](C)(Cc3cccc(O)c3)C2)cc1
CHEMBL3109797,LJGARRQSIYHDHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,7107,67402849,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)F,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1
CHEMBL1223002,LJHSDTNRTCEUNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,7108,49865163,COC1=CC=CC(=C1)CN2C3=CC=CC=C3N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC=NC=C6,COc1cccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)c1
CHEMBL2059799,LJKCPRJTSAUESM-JGCGQSQUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,7109,70692759,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=CC=CC=C4C=C3)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2ccccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL114756,LJMLRDFXBGZNOB-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,7113,10146899,C1CN(C(CN1CC2=CC=C(O2)C3=CC=NC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccccc1)CC(O)CN1CCN(Cc2ccc(-c3ccncc3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL114756,LJMLRDFXBGZNOB-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,7113,10146899,C1CN(C(CN1CC2=CC=C(O2)C3=CC=NC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccccc1)CC(O)CN1CCN(Cc2ccc(-c3ccncc3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL2165498,LJTQAIKAEMCJSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,7120,57506741,CC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCC(CC6)N(C)C,Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(N(C)C)CC3)cc2n1
CHEMBL1921961,LJUABYFUJVRUSJ-FRVJLOGJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,4.522878745280337,7121,54752951,C1C2C=CC1C3C2C(=O)N(C3=O)C4=C(C=C(C=C4)NC(=O)C5=CC=CC=N5)Cl,O=C(Nc1ccc(N2C(=O)C3C4C=CC(C4)C3C2=O)c(Cl)c1)c1ccccn1
CHEMBL594072,LJVDXVHUFXOWBO-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,7122,46226156,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=C(NC6=CC=CC=C65)C(=O)N)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
CHEMBL1079712,LJXHKSLKMJASBE-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,348.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.458420756053419,7124,46883435,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CN2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CN4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cnc[nH]1)CC(Cc1ccccc1)NC(=O)OCc1ncc[nH]1
CHEMBL196875,LKBXWNYXDMSFQU-ONNFQVAWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15837312.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against human Cytochrome P450 3A4,"Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7126,44402523,C1=CC(=CC=C1C=CC(=O)NC2=C(C=C(C=C2)C3=NC4=C(O3)C=CC(=C4)CC(=O)O)F)Br,O=C(O)Cc1ccc2oc(-c3ccc(NC(=O)C=Cc4ccc(Br)cc4)c(F)c3)nc2c1
CHEMBL3261082,LKDWXLBCDHUZRF-HXPMCKFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.522878745280337,7127,44467574,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=C(C=CC(=C4)F)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3cc(F)ccc3F)C2)nc(C)c1F
CHEMBL1272046,LKJNOKVJAZHRAT-OMXLDXBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.698970004336019,7133,11534139,CC1CN(CC(N1CCO)C)C(=O)OC2(CC2)C3COCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5,CC1CN(C(=O)OC2(C3COCC(CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC(C)N1CCO
CHEMBL2441836,LKKWOSVPEMTNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.853871964321762,7135,15950463,CC1=C(C(=C2C(=N1)CN(C2=O)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL2441836,LKKWOSVPEMTNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.638272163982407,7135,15950463,CC1=C(C(=C2C(=N1)CN(C2=O)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL2441836,LKKWOSVPEMTNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.5376020021010435,7135,15950463,CC1=C(C(=C2C(=N1)CN(C2=O)CCOC)C3=C(C=C(C=C3)Cl)Cl)CN,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL3422244,LKLYLZSFUBTUBW-KDQZPGIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,7136,91666686,CC1=COC(=N1)C2CC3C(SC(=NC3(CO2)C4=C(C=C(C=C4)F)F)N)CF,Cc1coc(C2CC3C(CF)SC(N)=NC3(c3ccc(F)cc3F)CO2)n1
CHEMBL461012,LKQMULLPLYLIGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,7140,44569945,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=C3Cl)Cl,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl
CHEMBL502531,LKUSYUYBQDJFNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,7143,44586731,C#CC1=C(C=CN=C1N)OC2=C(C=C(C=C2)NC(=O)NC(=O)CC3=CC=C(C=C3)F)F,C#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N
CHEMBL3601192,LKWUVRWXZPRGNM-BMZZKGLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7145,118453722,CC1=CC(=CC(=N1)C)NC2=NC=C(C(=N2)NC3CC(C(C3O)O)CO)C4=NC5=CC=CC=C5C=C4,Cc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(NC3CC(CO)C(O)C3O)n2)cc(C)n1
CHEMBL312121,LLIPALBHLJKSHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.301029995663981,7155,22966419,CN1CC2=CN=CN2CC3=CC(=C(C=C3)C#N)OC4=CC5=C(C=CC=C5N6CCC1C6=O)C=C4,CN1Cc2cncn2Cc2ccc(C#N)c(c2)Oc2ccc3cccc(c3c2)N2CCC1C2=O
CHEMBL2425152,LLLIYKLRWQOPGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7159,72189807,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C(=NN=N4)C,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1
CHEMBL324461,LLRKKARNQCFJDO-NKBKYVEPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.318758762624412,7168,10233723,C1CN(C(CN1CC2=CC3=CC=CC=C3O2)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2cc3ccccc3o2)CC1C(=O)NCC(F)(F)F
CHEMBL1822515,LLSXHTXXTKDPRH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21859094.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,5.026872146400302,7169,54577892,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NN4C(=CC=C4C5=CC=CC=C5OC)C=N3,COc1ccccc1-c1ccc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nn12
CHEMBL3137450,LLTMFKOMKKKDNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.096910013008056,7170,76314942,COC1=CC=C(C=C1)CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
CHEMBL3137450,LLTMFKOMKKKDNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.823908740944319,7170,76314942,COC1=CC=C(C=C1)CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
CHEMBL1241738,LMIGPJJYYRXPJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,7178,46900459,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=NN=C6CO5)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1
CHEMBL1241738,LMIGPJJYYRXPJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,7178,46900459,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=NN=C6CO5)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1
CHEMBL2419491,LMMAPNCJSSIUOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,5.346787486224656,7181,15983672,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)F)C,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)CC2)nc1C
CHEMBL3264002,LMMJFBMMJUMSJS-UHFFFAOYSA-N,RG-7304,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,7182,16719221,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
CHEMBL3264002,LMMJFBMMJUMSJS-UHFFFAOYSA-N,RG-7304,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,7182,16719221,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
CHEMBL2059900,LMPHOXYGKFAVAU-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22732695.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,7184,70694804,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC6(CC5)C(=O)NC(=N6)C7=CC=CC=C7,O=C(NC(Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC2(CC1)N=C(c1ccccc1)NC2=O
CHEMBL3581141,LMRBHLOXIRMINE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,11400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,4.943095148663527,7186,24829572,CNC1=NC=CC(=C1)C2=CSC(=N2)NC(=O)CC3=CC(=CC=C3)OC,CNc1cc(-c2csc(NC(=O)Cc3cccc(OC)c3)n2)ccn1
CHEMBL1097772,LMTYJQQFAMWXIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,2345.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,5.629857152948898,7188,46237255,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=CC=C5)C)OC,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccccc1)cc(=O)n2C)c1cncn1C
CHEMBL2036214,LNAWXIMKZTUGJB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,7196,49872867,CCCCC(=O)N(CC1=CC=C(C=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
CHEMBL3264609,LNCAMLLVHZJNDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,>=,195000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.709965388637482,7199,69281312,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(F)(F)F)(C3=NNN=C3)O,CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)ccc2c1)c1cn[nH]n1
CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,5.086186147616283,7203,3559,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,33100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.480172006224281,7203,3559,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
CHEMBL3287849,LNFPEBXLWIXQLF-STQMWFEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900876.0,IC50,>,20000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,PUBLICATION,,1.6989700043360187,7206,46938037,C1CNC(CC1C2=CC(=O)NO2)CC3=CC=CC=C3,O=c1cc(C2CCNC(Cc3ccccc3)C2)o[nH]1
CHEMBL1080419,LNFPYTXWNUBAEF-PMACEKPBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,136.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.866461091629782,7207,46883373,CCN(CC(CC(C)C)NC(=O)OCC1=CN=CS1)CC(CC(C)C)NC(=O)OCC2=NC=CS2,CCN(CC(CC(C)C)NC(=O)OCc1cncs1)CC(CC(C)C)NC(=O)OCc1nccs1
CHEMBL519336,LNOMZGGJGBXFOZ-RTWAWAEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7209,44593664,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C(=O)NC4CC4C5=CC=CC=C5,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)NC3CC3c3ccccc3)CC1)O2
CHEMBL2407950,LNPHHOCWZOSXKI-YYDJUVGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7212,136167006,CC1=CC=CC=C1C(CC(=NO)C2=CC(=NC=C2)C)C3=CC=C(C=C3)Br,Cc1cc(C(CC(c2ccc(Br)cc2)c2ccccc2C)=NO)ccn1
CHEMBL3298907,LNTJQFBTDQICKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,7214,68234693,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)Cl,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1
CHEMBL256391,LOBKVXVGQZRYKH-DNVJHFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,7226,44456109,CC1=NC(=CO1)C(C(=O)N(C)CCO)N2C(C(=O)NC(C2=O)C3CC4=CC=CC=C4C3)CC(C)C,Cc1nc(C(C(=O)N(C)CCO)N2C(=O)C(C3Cc4ccccc4C3)NC(=O)C2CC(C)C)co1
CHEMBL3394738,LOBWMLUMWDKDBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7227,89793516,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
CHEMBL3394738,LOBWMLUMWDKDBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7227,89793516,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CN=C(C=C2)CNC(=O)C3=CC4=C(O3)C=NC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1
CHEMBL1766170,LOFFEKCUNLMSQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.6777807052660805,7228,9883170,CC(C)C(C1=CC=CC(=C1)C2=CC=C(C=C2)F)(C3=CN=CN3)O,CC(C)C(O)(c1cccc(-c2ccc(F)cc2)c1)c1cnc[nH]1
CHEMBL3702685,LOFXNVBNYNYEPK-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.6595558851598815,7230,89718411,CC(C)(C)CNC(=O)NC1=NC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCC(C)(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL495727,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,AT-9283,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19143567.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",J. Med. Chem.,PUBLICATION,,5.0,7235,135398495,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,O=C(Nc1cn[nH]c1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
CHEMBL1224524,LOMHDTDKMKKMKY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,<,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,7236,11380674,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CN=CN3)C(F)(F)F,FC(F)(F)c1ccccc1-c1cccc(-c2cnc[nH]2)c1
CHEMBL1294,LOUPRKONTZGTKE-LHHVKLHASA-N,QUINIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,7245,441074,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12
CHEMBL3702757,LOVFQEUYPQWFHE-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.211124884224583,7246,89718451,CCOC(=O)CNNC(=O)C1=CN(C2=C(C=CC=C12)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNCC(=O)OCC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL230309,LOYHRPQPVDZCBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,710.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1487416512809245,7248,135681596,CC1=C2C(=CC=C1)NC(=N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O,Cc1cccc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL404646,LPCDOMMRICKOBC-JDXGNMNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,7254,10257392,CC1=C(N=C(O1)C2=CC(=CC=C2)OC)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,COc1cccc(-c2nc(CCOc3cccc(CC4C(=O)N(c5ccc(C(C)(C)C)cc5)C4C(=O)O)c3)c(C)o2)c1
CHEMBL240568,LPIMZWKKMREGHM-ZBLYBZFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.045757490560675,7258,23635106,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=C(C=C(C=C3)Cl)F)C(C(C)C)NCCNC,CNCCNC(c1cc(C)ccc1N1CCN(C(=O)C(C)Cc2ccc(Cl)cc2F)CC1)C(C)C
CHEMBL460178,LPKACSKZPXNEBK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,4.913640169325252,7260,25180304,COC1CCC2=C(C1)C=CC(=C2)C3=CN=CC=C3,COC1CCc2cc(-c3cccnc3)ccc2C1
CHEMBL471072,LPRPIMHDDACJHT-AWEZNQCLSA-N,(S)-6-GINGEROL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,36400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.438898616350944,7264,44559528,CCCCCC(CC(=O)CCC1=CC(=C(C=C1)OC)O)O,CCCCCC(O)CC(=O)CCc1ccc(OC)c(O)c1
CHEMBL1651525,LPTGBERPUYIOJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,6.096910013008056,7266,24967634,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
CHEMBL1651525,LPTGBERPUYIOJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,5.366531544420414,7266,24967634,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
CHEMBL3315061,LPVOSIGKKGTQCK-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24980053.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,7267,118707978,CC(C)(C1C2=C(C(=CC=C2)F)OC3=C1C=CC(=N3)C4=CC=C(C=C4)C(=O)N5CCOCC5)C(=O)NC(=O)N,CC(C)(C(=O)NC(N)=O)C1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21
CHEMBL464245,LQAJJWMXZBDMAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,7272,44570275,C1=CC(=C(C(=C1)F)C(=O)N(CCF)CC(CNC(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N)(C(F)(F)F)O)F,Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1
CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.795880017344075,7275,202225,CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O
CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.698970004336019,7275,202225,CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O
CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.481486060122112,7275,202225,CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O
CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,61000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.214670164989233,7275,202225,CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O
CHEMBL564085,LQCLVBQBTUVCEQ-QTFUVMRISA-N,TROLEANDOMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,7998.34,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.0970001384638906,7275,202225,CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O
CHEMBL3233058,LQCUMLOMFBTKNQ-NWDGAFQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7276,71626755,CC1=NC(=CC=C1)NC2=CC(=NN=C2C(=O)N)NC3CCCCC3N,Cc1cccc(Nc2cc(NC3CCCCC3N)nnc2C(N)=O)n1
CHEMBL3236363,LQFZONHTRLPWKM-ZJTSJXPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,5.886056647693163,7278,90655379,CCC(CS(=O)(=O)C(C)(C)C)N1C(C(CC(C1=O)(C)CC(=O)N)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,CCC(CS(=O)(=O)C(C)(C)C)N1C(=O)C(C)(CC(N)=O)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
CHEMBL2016937,LQMJDFXYANXGEK-VLIAUNLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,7285,46932046,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=CC(=NO3)C4=C(C=C(C=C4)F)Cl,OC1(c2ccc(F)c(F)c2)CCNCC1c1cc(-c2ccc(F)cc2Cl)no1
CHEMBL258694,LQNDDQQRHZEHDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18395443.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,7286,44449577,CC1=NN=C(O1)C2=CN3C(=C2C(C)C)C(=NC=N3)NC4=CN=C5C(=C4)C=CN5,Cc1nnc(-c2cn3ncnc(Nc4cnc5[nH]ccc5c4)c3c2C(C)C)o1
CHEMBL2023802,LQNNUQKZSZVOBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497760.0,IC50,>,8600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0655015487564325,7287,70691981,CCC1=C(C(=NN1)NC(=O)CC2=C(C=C(C=N2)OC3=C4C=C(C(=CC4=NC=C3)OCC)OC)OC)C,CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC
CHEMBL3092467,LQOIAHRPEWFITJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,18600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.730487055782084,7288,71537836,CC1=C2C(=NN1)N=C(C=N2)C3=CC=C(C=C3)NS(=O)(=O)C4=C(C=CC(=C4)OC)Cl,COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)[nH]nc4n3)cc2)c1
CHEMBL3092467,LQOIAHRPEWFITJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,26800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.5718652059712115,7288,71537836,CC1=C2C(=NN1)N=C(C=N2)C3=CC=C(C=C3)NS(=O)(=O)C4=C(C=CC(=C4)OC)Cl,COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)[nH]nc4n3)cc2)c1
CHEMBL575448,LQVXSNNAFNGRAH-QHCPKHFHSA-N,BMS-754807,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19778024.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-resorufin as substrate,"Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.",J. Med. Chem.,PUBLICATION,,5.154901959985743,7292,24785538,CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F,CC1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1
CHEMBL575448,LQVXSNNAFNGRAH-QHCPKHFHSA-N,BMS-754807,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19778024.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,7292,24785538,CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F,CC1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1
CHEMBL1682903,LQWYAFZMARIARA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.267606240177032,7294,12074103,CC(C)C(C1=CC2=CC3=C(C=C2C=C1)C(=O)N(C3)C)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2cc3c(cc2c1)CN(C)C3=O)c1cnc[nH]1
CHEMBL231350,LQYNONCEAYAGNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17084080.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,7296,44425719,CC(C)NC1=C(C=C2CCN(CCC2=C1)C)NS(=O)(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)Cl,CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2
CHEMBL1898239,LQZSHPITKSPDLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,5.2441251443275085,7299,16013184,CC1=NN=C(N1C2=CC=C(C=C2)OC)SCC3=NC(=NO3)C4=CC=C(C=C4)OC,COc1ccc(-c2noc(CSc3nnc(C)n3-c3ccc(OC)cc3)n2)cc1
CHEMBL496263,LRECNGBVUUBJSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,15190.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,4.818442226137214,7305,25033731,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C(CCC3)(C4=CC=NC=C4)O)F,COc1ccc(-c2ccc3c(c2)CCCC3(O)c2ccncc2)cc1F
CHEMBL2425894,LRJXBQIWFWQGFB-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,54650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.262409833714278,7307,71731605,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=CC(=C3)F)C=C2)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3ccc(F)cc3n2)c1=O
CHEMBL1089270,LRJYGHMKTIYPPQ-OMKJIRLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188553.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydroindolizinone NK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7308,24768572,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2CN3C(C2C4=CC=C(C=C4)F)CC(=CC3=O)C5=CCN(CC5)C(C)(C)C,CC(OC1CN2C(=O)C=C(C3=CCN(C(C)(C)C)CC3)CC2C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL3137471,LRPTWDVRWNQMPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.301029995663981,7314,76333073,CC(C(=O)C)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,CC(=O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2425157,LRUCJVKBTVPLFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7317,72189811,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=C(C=C4)N,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1
CHEMBL3103437,LRYNXQMWCWCCSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24360604.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11��-hydroxysteroid dehydrogenase type 1 (11��-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,7323,73213123,C1C2CC3CC1CC(C2)C3(CC4=NNN=N4)C5=CC=C(C=C5)C6=CC=CC=C6,c1ccc(-c2ccc(C3(Cc4nn[nH]n4)C4CC5CC(C4)CC3C5)cc2)cc1
CHEMBL496387,LRZALAWCYDMOCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,7324,24889168,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=O)C=CC=N4,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12
CHEMBL496387,LRZALAWCYDMOCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.070581074285707,7324,24889168,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=O)C=CC=N4,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12
CHEMBL2203397,LSFSILMVQQMGRP-OPRSCSRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24328103.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Discovery of a non-estrogenic irreversible inhibitor of 17��-hydroxysteroid dehydrogenase type 1 from 3-substituted-16��-(m-carbamoylbenzyl)-estradiol derivatives.,J. Med. Chem.,PUBLICATION,,5.4089353929735005,7331,53494954,CC12CCC3C(C1CC(C2O)CC4=CC(=CC=C4)C(=O)N)CCC5=C3C=CC(=C5)CCBr,CC12CCC3c4ccc(CCBr)cc4CCC3C1CC(Cc1cccc(C(N)=O)c1)C2O
CHEMBL1766191,LSNINMQJLNWRJL-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,7338,54580449,CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CCC(O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1cnc[nH]1
CHEMBL1766192,LSNINMQJLNWRJL-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,7339,54586321,CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CCC(O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1cnc[nH]1
CHEMBL1766184,LSNINMQJLNWRJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,7340,18668538,CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)C)(C3=CN=CN3)O,CCC(O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1cnc[nH]1
CHEMBL482034,LSSNBHGWOAHIQS-LSDHHAIUSA-N,"(8R,8'R)-4-HYDROXYCUBEBINONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.130768280269024,7345,3013841,COC1=CC(=CC(=C1O)OC)CC2COC(=O)C2CC3=CC4=C(C(=C3)OC)OCO4,COc1cc(CC2COC(=O)C2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1O
CHEMBL567089,LSZYMWXOOBDCEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,7352,25064073,COC1=CC2=NC=CC(=C2C=C1)SCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL567089,LSZYMWXOOBDCEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,7352,25064073,COC1=CC2=NC=CC(=C2C=C1)SCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL408444,LTEJRLHKIYCEOX-TZMCWYRMSA-N,BMS-582664,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,6.292429823902063,7356,24824494,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(C)N)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)C(C)N)c(C)c34)ccc2[nH]1
CHEMBL408444,LTEJRLHKIYCEOX-TZMCWYRMSA-N,BMS-582664,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,5.795880017344075,7356,24824494,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(C)N)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)C(C)N)c(C)c34)ccc2[nH]1
CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,7360,2724385,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O
CHEMBL487766,LTWAUSKVHLPSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,7368,25138073,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CN=CC=C3)C,CC(=O)Nc1cc(-c2cccnc2)nc(-n2nc(C)cc2C)n1
CHEMBL2040895,LUCCLRBBVBPHOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7376,57387032,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)N6C=CC=N6,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-n3cccn3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL1269696,LUCJQRCTXXOATA-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,7377,52941838,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)OC)Cl)C5CC5)Cl,COC(=O)NCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269696,LUCJQRCTXXOATA-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,7377,52941838,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)OC)Cl)C5CC5)Cl,COC(=O)NCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1095404,LUCVGGOCKASWHT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,7379,136086724,CCOC(=O)N1CCN(CC1)C2=CC3=C(C(=C2)C)N=C(N3)C4=C(C=CNC4=O)NCC(C5=CC(=CC=C5)Cl)O,CCOC(=O)N1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL1910116,LUDLSGUXLBEWMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,7380,53356519,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)NC)C3=C(C=C(C=C3)Cl)Cl)CN,CNC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL426789,LUDUPPNOCMHNSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1590.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.798602875679548,7382,11235737,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C
CHEMBL426789,LUDUPPNOCMHNSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,3790.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.421360790031928,7382,11235737,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C
CHEMBL2420686,LUGXRTWVGQQQDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,2145.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.668572703479257,7384,71818234,C1=CC(=CC2=C1C=CC(=C2Cl)C3=CN=CN=C3)O,Oc1ccc2ccc(-c3cncnc3)c(Cl)c2c1
CHEMBL1645462,LUJZZYWHBDHDQX-QFIPXVFZSA-N,AC-480,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19821562.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.",J. Med. Chem.,PUBLICATION,,5.795880017344075,7390,10437018,CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F,Cc1c(NC(=O)OCC2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12
CHEMBL1645462,LUJZZYWHBDHDQX-QFIPXVFZSA-N,AC-480,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19821562.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome,"Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.",J. Med. Chem.,PUBLICATION,,4.920818753952375,7390,10437018,CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F,Cc1c(NC(=O)OCC2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12
CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.221848749616356,7392,445154,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1
CHEMBL244239,LUNFWPKHPVTQAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,1620.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,5.790484985457369,7396,16072099,CN(CCC1=CC(=C(C=C1)OC)OC)CCNC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4N=C3,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC
CHEMBL244239,LUNFWPKHPVTQAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,7750.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,5.110698297493689,7396,16072099,CN(CCC1=CC(=C(C=C1)OC)OC)CCNC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4N=C3,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC
CHEMBL1643773,LUSAWDRMCLUELC-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7400,53317957,CN(C1CCC2=C(C3=C(N2C1)C=C(C=C3)F)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccc(F)cc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL552026,LUSFVKKEBIMJTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7401,45270339,C1CCN(C(=O)C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,O=C1CCCCN1C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL578413,LUTXIHFTNWRKIR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19664922.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7403,2941086,CC1=C(C(=NC2=C1SC3=C2C(CC(=O)N3)C4=CC=CC=C4Cl)N)C#N,Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl
CHEMBL3407814,LUVKXYMOSKKHHP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,70000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,4.154901959985743,7405,118730373,C1=CC(=CN=C1)CCCNCCC2=NC(=NC=C2)N3C=CN=C3.Cl,c1cncc(CCCNCCc2ccnc(-n3ccnc3)n2)c1
CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,2999.16,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.523000364762793,7408,10531,CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C,CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)CC2c3cccc4[nH]cc(c34)CC21
CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.301029995663981,7408,10531,CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C,CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)CC2c3cccc4[nH]cc(c34)CC21
CHEMBL2059117,LVCRRGONEHSFIT-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,33.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.481486060122113,7412,70692716,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
CHEMBL3330073,LVDNNHBINPPRBD-IMODNSLOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25164763.0,IC50,=,2250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,5.647817481888637,7413,118712788,C1CC2CC(N(C2C1)C(=O)CC(CC3=CC(=C(C=C3F)F)F)N)C#N,N#CC1CC2CCCC2N1C(=O)CC(N)Cc1cc(F)c(F)cc1F
CHEMBL25905,LVDUAUUVOUUFCK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,36820.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.433916215832004,7414,11443156,CN1C2=C(C3=C1C(=NC(=N3)COC)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)Cl,COCc1nc(N2CCN(CCc3ccc(F)c(F)c3)CC2)c2c(n1)c1c(Cl)nccc1n2C
CHEMBL2017274,LVFMQRNYMLOTHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,7416,70681171,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4C(C)(C)C)C(=O)N)OC,COc1cc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL3330649,LVHMCPRJISQGAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7420,25013308,C1=CC(=C(C=C1I)F)NC2=C(OC3=C2C=NC=C3)C(=O)NOCCO,O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F
CHEMBL3330649,LVHMCPRJISQGAK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7420,25013308,C1=CC(=C(C=C1I)F)NC2=C(OC3=C2C=NC=C3)C(=O)NOCCO,O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F
CHEMBL1077339,LVOHHKIFPDWJJY-NLJOTIRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,7425,136164068,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CC7CC6CO7,Cc1cc(N2CCC(N3CC4CC3CO4)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL474469,LVOHHKIFPDWJJY-ONBPZOJHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.301029995663981,7426,135960723,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CC7CC6CO7,Cc1cc(N2CCC(N3CC4CC3CO4)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2380735,LWCCEQKYCZQPRK-HBFSDRIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23639544.0,IC50,=,9950.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence detection method,Synthesis of proline analogues as potent and selective cathepsin S inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.002176919254275,7436,71624246,CCC(C(=O)C1=NC2=CC=CC=C2O1)NC(=O)C3CC(CN3C(=O)C)S(=O)(=O)C4=CC=CC=C4,CCC(NC(=O)C1CC(S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1
CHEMBL3629738,LWHLEVWRUZVAKD-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,7439,76283430,C1CC2(CCOC2)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=S(=O)(c1ccc(Cl)cc1)C12CCCC3(CCOC3)C1COc1c(F)ccc(F)c12
CHEMBL3629738,LWHLEVWRUZVAKD-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,7439,76283430,C1CC2(CCOC2)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=S(=O)(c1ccc(Cl)cc1)C12CCCC3(CCOC3)C1COc1c(F)ccc(F)c12
CHEMBL3664683,LWLLZFJSQXCRGM-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,7443,59635727,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2F)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2cc(=O)n(C)cc2F)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL2430983,LWMQAANXGYCZIW-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7444,67496729,CN1C(=CC(=N1)C2=CC=NC=C2)NC(=O)C(CC3=CC=CC=C3)NCC(=O)O,Cn1nc(-c2ccncc2)cc1NC(=O)C(Cc1ccccc1)NCC(=O)O
CHEMBL3702748,LWMQTYQSMZDRPA-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11510.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.938924676370208,7445,89718215,CN1CCN(CC1)CCNC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCN(C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2436211,LWORELOKAQNWTQ-GZAZCRCBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.795880017344075,7446,72711723,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=NC=CN=C5)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2cnccn2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL1077325,LWTKJTIPCMXHIH-GBXCKJPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,>,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,7448,136164067,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(C5)NC(=O)OC(C)(C)C,Cc1cc(N2CCC(NC(=O)OC(C)(C)C)C2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2448705,LWTNFEIUOJCFKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.795880017344075,7449,73355719,C1=CC=C(C=C1)C2=CN=C(C=N2)C(=O)NCCC3=CN=CN3,O=C(NCCc1cnc[nH]1)c1cnc(-c2ccccc2)cn1
CHEMBL3125389,LWUXPHDHNVTIOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,7451,57411372,C1CN(C2=C1C(=CC=C2)Cl)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21
CHEMBL2178713,LWVMTILRDSZVMA-CYFREDJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.522878745280337,7452,66557875,CN1C(=O)C2CN(CC2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=C(C=CC=N5)C#N,CN1C(=O)C2CN(c3ncccc3C#N)CC2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
CHEMBL2018920,LWYPYTJNIOQAJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.373659632624958,7453,827839,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)Br,COc1ccc2nc(SCc3ccc(Br)cc3)[nH]c2c1
CHEMBL293391,LXBGSDVWAMZHDD-UHFFFAOYSA-N,2-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1253141.17,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,2.9020000017125205,7454,12749,CC1=NC=CN1,Cc1ncc[nH]1
CHEMBL3702807,LXCBABHDWQHVDN-QCDYIZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6320.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.199282921717615,7455,89718460,CN1CCN(CC1)C2CCN(CC2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCN(C)CC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3601070,LXFJUSIWCMBIBJ-XTUVKROYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7457,117885758,CC(C)OC1=NC=CC(=C1)NC2=NC=C(C(=N2)NC3CC(C(C3O)O)CO)C4=NC5=CC=CC=C5C=C4,CC(C)Oc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(NC3CC(CO)C(O)C3O)n2)ccn1
CHEMBL1837037,LXHAZNJVVVBJIF-UHFFFAOYSA-N,PF-184563,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7458,11237434,CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,CN1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
CHEMBL3112847,LXISESLTVSOLPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,7459,49854228,C1CN(C2=C1C=C(C=C2)F)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2cc(F)ccc21
CHEMBL3087353,LXIVCWUSTWHNJI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,7460,72547282,CC1=NC=CN1C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,Cc1nccn1-c1ccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1
CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,7467,57400502,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C
CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.119186407719209,7467,57400502,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C
CHEMBL2064333,LXQCVNDYORNYIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,7468,49853824,CN1C2=C(C=C(C=C2)F)N=C1CC3=NC(=O)C=C(N3)N4CCOCC4,Cn1c(Cc2nc(=O)cc(N3CCOCC3)[nH]2)nc2cc(F)ccc21
CHEMBL550816,LXXCGDJSCVIHPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,16500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.782516055786093,7473,45270319,C1CN(CCC1NC(=O)NC(CN2CCOCC2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1
CHEMBL407246,LYDVUNMUKWQJAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.698970004336019,7481,1475789,C1=CC=C(C=C1)NC(=O)OCC2=CN(N=N2)C3=CC=C(C=C3)Cl,O=C(Nc1ccccc1)OCc1cn(-c2ccc(Cl)cc2)nn1
CHEMBL274551,LYHMZZTVHAMCGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7482,10189993,CCCC1=CN(C(=NC1=O)SCC2=CC=C(C=C2)F)CC(=O)N(CCN(CC)CC)CC3=CC=C(C=C3)C4=CC=C(C=C4)C(F)(F)F,CCCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O
CHEMBL2170294,LYHNSWOZRDSWLX-MRXNPFEDSA-N,AS1940477,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22905713.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,"Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.",J. Med. Chem.,PUBLICATION,,4.0,7483,136173253,CC1=CC=CC=C1N2C(=O)C=CC(=N2)C3=C4NCC(CN4N=C3C5=CC=C(C=C5)F)CO,Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)nn3c2NCC(CO)C3)ccc1=O
CHEMBL2431463,LYKFFNSXZSUFOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,7.3979400086720375,7487,49784695,CC(C)(C)C1=CC(=CC(=C1OC)C2CC2C3=CC=C(C=C3)NS(=O)(=O)C)C4=CC=CNC4=O,COc1c(C2CC2c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
CHEMBL267865,LYNOGBKNFIHKLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,71000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1487416512809245,7491,2727594,CCCCC1=CC(=C(C=C1)N=CNO)C,CCCCc1ccc(N=CNO)c(C)c1
CHEMBL267865,LYNOGBKNFIHKLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,65400.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.184422251675732,7491,2727594,CCCCC1=CC(=C(C=C1)N=CNO)C,CCCCc1ccc(N=CNO)c(C)c1
CHEMBL266212,LYPHFRXCVAZTEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,3580.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,5.446116973356125,7494,44428924,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
CHEMBL266212,LYPHFRXCVAZTEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17399990.0,IC50,=,20200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,PUBLICATION,,4.694648630553377,7494,44428924,COC1=C(C=C(C=C1)CN2CCN(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC
CHEMBL1214449,LYPZADYPKMLUQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,7495,11566130,CC1=CN=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)nc1
CHEMBL1629855,LYTVXCQQTLUEQR-UHFFFAOYSA-N,RO-4491533,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,7497,11158623,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC(=NC(=C4)C)C,Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)cc(C)n1
CHEMBL116772,LZAICYPRHBGZTR-XREYCITQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.017728766960431,7504,471501,CC(C)C1=NC(=CS1)COC(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CN3CCN(CC3C(=O)NC(C)(C)C)CC4=CC5=C(C=C4)OCO5)O,CC(C)c1nc(COC(=O)NC(C(=O)NC(Cc2ccccc2)C(O)CN2CCN(Cc3ccc4c(c3)OCO4)CC2C(=O)NC(C)(C)C)C(C)C)cs1
CHEMBL249293,LZCMGTZILVEQAQ-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,7509,44442014,CC(C)C1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,CC(C)C1CCCC(C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2043171,LZELSEPAXCUBKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7512,57386785,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)Cl,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4Cl)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL585191,LZGLHOVCHAQTAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7516,45484907,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC4=C(C=C3)OCCO4,CC1(CC(=O)NCc2ccc3c(c2)OCCO3)CC2(CCCCC2)OO1
CHEMBL2397194,LZHWZDRNJFDAFI-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7517,59293763,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=NC(=NC=C3)C4CCC4,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C2CCC2)n1
CHEMBL3115165,LZJOGRNDENREKS-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.096910013008056,7518,59721364,CC(C)C(C(=O)NC(CCC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(C)CC4=CN=CS4,CC(C)C(NC(=O)N(C)Cc1cncs1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL3702713,LZMJCQWNDIGSIP-HWHSMDOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.297569463554475,7523,89718426,CCN1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC)CC6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL485752,LZPFERLGKNQAQE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,7527,25138084,CCOC(=O)NC1=NC(=NC(=C1)C2=CC(=CN=C2)OC)N3C(=CC(=N3)C)C,CCOC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1
CHEMBL3401132,LZPSMMDCTAIZFR-ZIAGYGMSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,545000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.2636034977233574,7529,57869877,CN1C(=O)C=C(N=C1N2CCOC3C2COC3)C4=C(C=NC=C4)F,Cn1c(N2CCOC3COCC32)nc(-c2ccncc2F)cc1=O
CHEMBL1077939,LZXPGRRYRBSCOY-KYJUHHDHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,49.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.309803919971486,7534,46883345,C1=CC=C(C=C1)CC(CN(CC2=CC=NC=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,O=C(NC(Cc1ccccc1)CN(Cc1ccncc1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL3672578,MAACKGCFQFNWKO-PIGLOVQCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.721246399047171,7538,57406032,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N,CC(C)c1nc(CN(C)C(=O)N2CC(N)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672578,MAACKGCFQFNWKO-PIGLOVQCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,310.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.508638306165727,7538,57406032,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)N,CC(C)c1nc(CN(C)C(=O)N2CC(N)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL465941,MAAFRGFJCFJJAS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,7539,44570410,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=CC=C4)Cl,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)CC(C)N1
CHEMBL465941,MAAFRGFJCFJJAS-SZPZYZBQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,7539,44570410,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=CC=C4)Cl,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)CC(C)N1
CHEMBL3702730,MADNMYLUHTVLOZ-ACHIHNKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.5003129173815966,7544,89718324,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)C)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,5.3979400086720375,7545,76321102,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,5.3979400086720375,7545,76321102,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7100.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,5.1487416512809245,7545,76321102,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
CHEMBL3104490,MAEQYLYKCWECPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.721246399047171,7545,76321102,CS(=O)(=O)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
CHEMBL397367,MAHFSCYTEUPDKY-IYKJZBSOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,8600.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0655015487564325,7548,44433291,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)C(C)N,CC(C)CC(NC(=O)C(C)N)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL396434,MAHFSCYTEUPDKY-NBYOPXRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,7549,44433289,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)C(C)N,CC(C)CC(NC(=O)C(C)N)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3706623,MAMJAUDDHCPYJQ-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,7551,10283706,C1CN(C(CN1CC2=CC=C(O2)C3=CN=CC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccccc1)CC(O)CN1CCN(Cc2ccc(-c3cccnc3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL3236364,MANSWCXFKVIKPE-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,5.920818753952375,7552,90354304,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N,CC1(CC(N)=O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3236364,MANSWCXFKVIKPE-HIJQLYNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1.83,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,8.73754891026957,7552,90354304,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N,CC1(CC(N)=O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3137472,MAUKISZQMSQDOJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,7557,76336703,CC(C(C)O)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,CC(O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL1834661,MAYIXESJSMZIQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.920818753952375,7560,23630291,CCN1CCC(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
CHEMBL1834661,MAYIXESJSMZIQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.221848749616356,7560,23630291,CCN1CCC(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
CHEMBL3702680,MBBBZVXOEJXMKY-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4610.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.336299074610352,7561,89716378,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=NC=CN=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6cnccn6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL101296,MBDCLNRSFGFOLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,7563,10130125,CCC1=CC=C(C=C1)N=CNO,CCc1ccc(N=CNO)cc1
CHEMBL1080973,MBEXSEUYYAPDIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7565,42647178,CC1(CCCN(C1)C(=O)NCC2=C(C=C(C=C2)Cl)Cl)C3=CC=CC=C3,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(Cl)cc2Cl)C1
CHEMBL3702758,MBMVBQUBYZAPMZ-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17440.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.758453519403451,7572,89718360,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3092460,MBNNXCKHRKSGSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,=,14500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.838631997765025,7575,71536970,C1=CC(=C(C(=C1)Cl)Cl)S(=O)(=O)NC2=CC=C(C=C2)C3=NC4=NNC(=C4N=C3)N,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12
CHEMBL3092460,MBNNXCKHRKSGSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589934.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7575,71536970,C1=CC(=C(C(=C1)Cl)Cl)S(=O)(=O)NC2=CC=C(C=C2)C3=NC4=NNC(=C4N=C3)N,Nc1[nH]nc2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12
CHEMBL1271822,MBQIBPDSTIZHQM-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.301029995663981,7578,52940664,CC1(CC1)C2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCN(CC4)C(C)(C)CO,CC1(C2COCC(COC(=O)N3CCN(C(C)(C)CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL3702794,MBXAGHYXINTFRA-JFKYFZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5730.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.24184537803261,7586,89718364,CCN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3261481,MBYAMJFNDALRJQ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7587,49843532,C1CN2CCC1C(C2)N3CCN4C5=C(C=CC=C5C3=O)C=N4,O=C1c2cccc3cnn(c23)CCN1C1CN2CCC1CC2
CHEMBL466496,MCBPNFWHHNJTGN-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,5.886056647693163,7590,15295578,CC(C1=CC=CC=C1)NC2=C(C(=O)C2=O)NC3=CC=NC=C3,CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1
CHEMBL408479,MCDBKPBDTVBVTL-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18217703.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,7593,54709839,CN(C)S(=O)(=O)N(C)C1CCCN2C1=NC(=C(C2=O)O)C(=O)NCC3=CC=C(C=C3)F,CN(C)S(=O)(=O)N(C)C1CCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O
CHEMBL2325485,MCDNCMGVHBZICR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23445448.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells.",J. Med. Chem.,PUBLICATION,,5.167491087293763,7594,71718136,CC1=CC(=CC=C1)N2CNC(=O)C23CCN(CC3)CC(C)NC(=O)C4=CC=C(C=C4)Br,Cc1cccc(N2CNC(=O)C23CCN(CC(C)NC(=O)c2ccc(Br)cc2)CC3)c1
CHEMBL1092929,MCEPAFGIBULHLP-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7596,46842383,C1CN(CCC1CCN2CCC(C2)NC(=O)CNC(=O)C3=CC(=CC=C3)C(F)(F)F)C(=O)C4=CC=CC=C4,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1
CHEMBL590810,MCIPSMFHIWYOIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,5.229147988357856,7602,25056112,C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)NC4=CC=C(C=C4)C#N,N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1
CHEMBL590810,MCIPSMFHIWYOIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,7602,25056112,C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)NC4=CC=C(C=C4)C#N,N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1
CHEMBL3664675,MCLUYWYPALEDGG-WRONEBCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.638272163982407,7606,44251346,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)C#N)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CC(C)(C)C#N)(c2ccc(F)cc2)OC1=O
CHEMBL294616,MCMMCRYPQBNCPH-DVKRWUGUSA-N,DPDPE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,7607,44299404,CC1(C(C(=O)NCC(=O)NC(C(=O)NC(C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)C(CC3=CC=C(C=C3)O)N)C,CC1(C)SSC(C)(C)C(NC(=O)C(N)Cc2ccc(O)cc2)C(=O)NCC(=O)NC(Cc2ccccc2)C(=O)NC1C(=O)O
CHEMBL1923729,MCNAJLPLCULBOJ-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22014551.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7610,54764158,CC1CCCN1CCCOC2=CC=C(C=C2)C3=CN(C(=O)C=C3)C,CC1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)c2)cc1
CHEMBL2420687,MCOVGPFVWGBXTJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.0,7613,71818094,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CC4=CC=CC=C43,COc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1
CHEMBL3237442,MCPPMOSBWNMSOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,6.259637310505756,7615,44132585,C1CCC(C1)N2C3=C(C=CN=C3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1
CHEMBL543,MCTWTZJPVLRJOU-UHFFFAOYSA-N,1-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,7616,1390,CN1C=CN=C1,Cn1ccnc1
CHEMBL543,MCTWTZJPVLRJOU-UHFFFAOYSA-N,1-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,7616,1390,CN1C=CN=C1,Cn1ccnc1
CHEMBL543,MCTWTZJPVLRJOU-UHFFFAOYSA-N,1-METHYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,2697739.43,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,2.5690000003935944,7616,1390,CN1C=CN=C1,Cn1ccnc1
CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,7620,57400503,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.107905397309519,7620,57400503,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.022276394711152,7620,57400503,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL497481,MCXOBRFKSNUMRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3643.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.438540828758084,7624,25033657,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)F)F)C(=C1)C4=CC=NC=C4.Cl,Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F
CHEMBL2057515,MDFDAKQXZVXGEL-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,7629,70686347,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NCCCN(C)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCN(C)C)oc2c1
CHEMBL559825,MDGWFKBCHGOIRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.301029995663981,7632,44191040,CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=CC=NN5C,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1
CHEMBL2397303,MDHMYNMBYCVKJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,7633,73348992,C1=CC=C(C=C1)CN(CC(=O)NC2=NC=C(S2)C3=CC=C(C=C3)N)C(=O)C4=CC=NC=C4,Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cc1
CHEMBL2331704,MDISRFPYOOBZRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7635,71716957,CC1=NN=C2N1C3=C(CC2)C=C(C=C3)C4=CC(=CN=C4)C(C)(C)OC,COC(C)(C)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1
CHEMBL1766177,MDJDLHSQYRTGNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.0,7636,18668583,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C)(C3=CN=CN3)O,CC(=O)Nc1ccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)cc1
CHEMBL475928,MDOZGPZABUSJAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7643,44593648,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)Cl,O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL1091790,MDTGYTUAMOVSAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,7645,11638166,CC(C1=CC=NC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccncc1)c1c(CCN(C)C)sc2ccccc12
CHEMBL3427272,MDXDEVDOOLNVAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7647,118737720,C1CC1N2C3=C(C=NC=C3)N(C2=O)CC4=C(N5C=CC(=CC5=N4)Cl)CCC(=O)O,O=C(O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12
CHEMBL1230001,MEAQCLPMSVEOQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25210858.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,PUBLICATION,,4.0,7649,25138295,C1CN(CCC1C2=CC=CC=C2C(F)(F)F)C(=O)NC3=CC=CC=C3C(=O)O,O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1
CHEMBL28168,MECOLUCWZLXWNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,7653,11453657,CC1=CC(=C2C3=C(C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)N(C2=N1)C)C#N,Cc1cc(C#N)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1
CHEMBL3702808,MEEAYSRFSVBIAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23670.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.625801742070918,7656,89718385,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9=CC=C(C=C9)C(F)(F)F,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccc(C(F)(F)F)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1683445,MEGFCBVTRXVKDO-KKSFZXQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,7659,53318910,CC(CC(C)(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O)C3=NC=C(C=N3)F,CC(CC(C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1
CHEMBL1271703,MELKFGZURAGNSX-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.522878745280337,7662,52941879,CC(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCNCC4,CC(C)C1COCC(C2(OC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2347208,MELQHVBGGSKVJQ-YJBOKZPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23590342.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,��-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,7663,71305058,CC1(CC(OC(=N1)N)C(F)(F)F)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F,CC1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)CC(C(F)(F)F)OC(N)=N1
CHEMBL1784368,MESQXIKYNYUZRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,7666,54580054,CC(CS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)F)N(C=O)O,CC(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O
CHEMBL3702817,MEWIHUZHSMPRNO-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.949233688766958,7669,89718498,CN1CCCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCN(C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL449468,MEXADSOJSYPZRE-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,7670,44587393,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N)C4=CC(=CC=C4)OCCCCC(=O)O,Cc1c(-c2cccc(OCCCCC(=O)O)c2)c(=O)n(CC(N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
CHEMBL3702785,MFDVDJXFNUJFNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2320.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.634512015109101,7674,78101269,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL520419,MFFQPYYPGSJIDM-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.397940008672037,7676,135960711,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)O,Cc1cc(N2CCC(O)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1910118,MFMDQBPDMCWAMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,7682,57403169,CCN(CC)C(=O)CN1CC2=C(C(=C(N=C2C1=O)C)CN)C3=C(C=C(C=C3)Cl)Cl,CCN(CC)C(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL480398,MFMYBHHGKONKNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,7683,11430331,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=CC(=CC=C4)Br,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Br)c2)cc1C1CC1
CHEMBL3310285,MGKQPZFQZLLPPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24939756.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,Strategies for the modulation of phase II metabolism in a series of PKCe inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,7705,118706405,CS(=O)(=O)NCCC1=CC(=CC(=C1)C2(CC2)C#N)C3=CC=NC4=NNC(=C34)C(F)(F)F,CS(=O)(=O)NCCc1cc(-c2ccnc3n[nH]c(C(F)(F)F)c23)cc(C2(C#N)CC2)c1
CHEMBL3699327,MGPNHBYVGAWOLH-GTMCEHENSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.764471553092451,7708,89718257,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC(=CC=C8)OCC9=CC=CC=C9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OCc7ccccc7)c6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3639714,MGUFMPBNVRJNSL-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,140.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.853871964321762,7711,57406031,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCN(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)C,CC(C)c1nc(CN(C)C(=O)N2CCN(C)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3639714,MGUFMPBNVRJNSL-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.522878745280337,7711,57406031,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CCN(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)C,CC(C)c1nc(CN(C)C(=O)N2CCN(C)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL476572,MGWSCJCLMDQNGB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,74000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.130768280269024,7714,24949702,CC1=C2C=CC(=CC2=NN1CC3=CC=CC=C3)N(C)C4=NC(=NC=C4)NC5=CC(=CC=C5)S(=O)(=O)N,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1
CHEMBL476572,MGWSCJCLMDQNGB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,79000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.102372908709558,7714,24949702,CC1=C2C=CC(=CC2=NN1CC3=CC=CC=C3)N(C)C4=NC(=NC=C4)NC5=CC(=CC=C5)S(=O)(=O)N,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1
CHEMBL486745,MHSIRMSFRHMBDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,7728,25138076,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=C(C(=CC=C3)OC)F)C,COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1F
CHEMBL2178250,MHVVFDUISIWISF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,7731,70497750,CC1=CC(=C(C=N1)C2=CC(=CC=C2)Cl)NC(=O)C3=C4N=CC=CN4N=C3,Cc1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)cn1
CHEMBL1923116,MHVYWHNMBRDTMC-BWKNWUBXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,7732,50905013,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)C,Cc1cccc(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1C
CHEMBL5,MHWLWQUZZRMNGJ-UHFFFAOYSA-N,NALIDIXIC ACID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,7733,4421,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21
CHEMBL5,MHWLWQUZZRMNGJ-UHFFFAOYSA-N,NALIDIXIC ACID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,7733,4421,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21
CHEMBL518421,MHXCIKYXNYCMHY-AUSJPIAWSA-N,LARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,25600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.591760034688151,7736,332427,COC1=C(C=CC(=C1)CC2COC(C2CO)C3=CC(=C(C=C3)O)OC)O,COc1cc(CC2COC(c3ccc(O)c(OC)c3)C2CO)ccc1O
CHEMBL1762293,MIBQBFVAZRBAFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21354795.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin),"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7741,51351511,CC(C)(C)C1=CC(=NO1)NC(=O)N2CCCN(CC2)C(=O)C3CCOCC3,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)C3CCOCC3)CC2)no1
CHEMBL1631095,MIGUNWYRDMCMDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106456.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,7747,50925404,C1=CC(=CC(=C1)N2C(=CC(=N2)C(=O)N)C(=O)N)C3=C(C=CC(=C3)C(F)(F)F)C(F)(F)F,NC(=O)c1cc(C(N)=O)n(-c2cccc(-c3cc(C(F)(F)F)ccc3C(F)(F)F)c2)n1
CHEMBL2436218,MIHAQLKAZGVBQZ-MJFWUJRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.013228265733755,7748,72712130,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL3702696,MIHDVZBMEYHLOS-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.031517051446065,7749,89718413,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCCCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCCO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702672,MIHIASNXXPUNOB-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.6595558851598815,7750,89716360,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)N8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3125378,MIOMMFIKTOATBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,7756,57411369,C1CN(C2=C1C(=CC=C2)Cl)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21
CHEMBL3702710,MIPWODRTRBZYNE-MJPQJCIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3980.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.400116927926312,7758,89718427,CC(C)CN1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC(C)C)CC6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3259907,MIXIIJCBELCMCZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24944749.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.,ACS Med. Chem. Lett.,PUBLICATION,,4.638272163982407,7768,66561902,CC1=NC2=CC=CC=C2C(=C1C(C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4,Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1C(OC(C)(C)C)C(=O)O
CHEMBL3259907,MIXIIJCBELCMCZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.638272163982407,7768,66561902,CC1=NC2=CC=CC=C2C(=C1C(C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4,Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1C(OC(C)(C)C)C(=O)O
CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,7775,3883,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
CHEMBL473763,MJIOKZJYJYOUKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19208473.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microplate-based direct fluorometric assay,"Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7776,44564950,CN(CCC1C2=CC=CC=C2C3=CC=CC=C13)CCC(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F.Cl,CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2-c2ccccc21
CHEMBL3234573,MJKSBDOYJVJJGS-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.2839966563652006,7781,90654592,CCN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCC(C3)C(=O)NCCC4=CN=C(N=C4)C#N,CCN1CCN(c2cc(N3CCCC(C(=O)NCCc4cnc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1
CHEMBL3357634,MJLGATKKRYTQPD-SOFYXZRVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,5.0,7783,71512060,CN(C)CC=C(C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC)F,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C(F)=CCN(C)C
CHEMBL2407954,MJSLGTDKVDKHMT-CCFHIKDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7792,136167037,CC1=CC=CC=C1C(CC(=NO)C2=CC(=NC=C2)C)C3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O,Cc1cc(C(CC(c2ccc(-c3ccc(C(=O)O)cc3)cc2)c2ccccc2C)=NO)ccn1
CHEMBL3403821,MKBBZNXNYQBPQR-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,7799,71288740,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)CCO)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(CCO)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403821,MKBBZNXNYQBPQR-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,7799,71288740,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)CCO)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(CCO)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL391028,MKCZAMJRNWLDEF-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,7800,44433293,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,CC(C)CC(NC(=O)CCN)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3234571,MKHYOYUIGKEBPI-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.0,7804,90654590,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCC(C3)C(=O)NCCC4=CN=C(C=C4)C#N,CN1CCN(c2cc(N3CCCC(C(=O)NCCc4ccc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1
CHEMBL2448708,MKIGMPSDMNXEHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,7806,73351198,CCN(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=NC4=CC=CC=C4S3,CCN(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
CHEMBL1241642,MKKLXKXAAUILMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,7.0,7807,46900457,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC=C6CO5,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4cncn4-5)CC3)cccc2n1
CHEMBL2436630,MLBBOYBRPZGZGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7820,44622418,C1CN(CCC1N2CC3=C(C2)C=C(C=C3)F)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccc(F)cc5C4)CC3)CC2)ccn1
CHEMBL253023,MLBHRXIETSMRAN-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,7821,44447004,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NOC(=N4)CN(C)C(C)(C)CO,CCC1CCCC(C2(Cc3noc(CN(C)C(C)(C)CO)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1938952,MLDQTQOMWDNTNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7823,54764919,COC1=C(C=NC=C1)C(=O)NC(=O)NC2=CC(=C(C=C2)C3=CC=CC=C3)C(F)(F)F,COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1
CHEMBL2171397,MLFFCILPEDOIHN-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ��-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,7.823908740944319,7827,71449876,CCOC1=CC(=NN1C2=CC=CC=C2F)C(=O)NC(CC(=O)O)C3=CC=CC=C3C,CCOc1cc(C(=O)NC(CC(=O)O)c2ccccc2C)nn1-c1ccccc1F
CHEMBL1081957,MLHRKLZCJRKSHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7828,44627133,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C
CHEMBL1081957,MLHRKLZCJRKSHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7828,44627133,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C
CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,7829,24824705,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,7829,24824705,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,5.698970004336019,7829,24824705,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
CHEMBL494979,MLHUEVZLHPFKKC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,4.5376020021010435,7829,24824705,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C(=C5)F)F)F,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1
CHEMBL2181329,MLIJDZYVRSRDJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,5.552841968657781,7831,73321238,CCN(CC)CCOC1=C2COCC=CCOCC3=CC(=CC=C3)C4=NC(=NC=C4)NC(=C2)C=C1,CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2
CHEMBL378132,MLPHGOPXOJDNLS-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,7834,44410860,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCOCC3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCC3(C(=O)O)CCOCC3)ccc2c1)n1ccnc1)N(C)C
CHEMBL3609325,MLQVQPMTZJBGEY-VGEDNRJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191364.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,7836,122187534,CC(C(=O)NC(C(=O)N1CC2CCCCOC3=CC=C(CC(NC(=O)C(NC(=O)C4CC(CN4C(=O)C(C(C)(C)C)NC(=O)C(C)NC)N5C=C(COC6=CC=C(CC(NC(=O)C(NC(=O)C1C2)CC7=CC8=CC=CC=C8C=C7)NS(=O)(=O)C9CC9)C=C6)N=N5)CC1=CC2=CC=CC=C2C=C1)C(=O)O)C=C3)C(C)(C)C)NC,CNC(C)C(=O)NC(C(=O)N1CC2CCCCOc3ccc(cc3)CC(C(=O)O)NC(=O)C(Cc3ccc4ccccc4c3)NC(=O)C3CC(CN3C(=O)C(NC(=O)C(C)NC)C(C)(C)C)n3cc(nn3)COc3ccc(cc3)CC(NS(=O)(=O)C3CC3)NC(=O)C(Cc3ccc4ccccc4c3)NC(=O)C1C2)C(C)(C)C
CHEMBL2441831,MLRHWBQYYDVLMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.958607314841775,7837,15950753,CC1=C(C(=C2C(=N1)CN(C2=O)C3=NN(C=C3)C)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(c1ccn(C)n1)C2
CHEMBL492591,MMAIBGHDBYQYDI-UHFFFAOYSA-N,"5-CARBOXYFURO[3,2-B]PYRROLE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18455394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,7842,7141881,C1=COC2=C1NC(=C2)C(=O)O,O=C(O)c1cc2occc2[nH]1
CHEMBL3702700,MMEGHIZPLVCKKK-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2820.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.549750891680639,7844,89718310,CCS(=O)(=O)N1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(=O)(=O)CC)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1939876,MMJPVSDTLGFIQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22017539.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins by fluorimetry,Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.,J. Med. Chem.,PUBLICATION,,4.522878745280337,7849,45376872,CCOC(=O)C1=CC2=C(N1)C=CC(=C2)C3=CC(=NN3C)C(=O)NCC4=CC=C(C=C4)C(=O)O,CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1
CHEMBL1209853,MMKVMFVAFDJNGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598534.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,inhibition of CYP3A4,Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,7851,11710700,CC1=NC2=NC(=CN2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4,Cc1nc2nc(-c3ccccc3)cn2c(-c2ccc(Cl)cc2Cl)c1CN
CHEMBL1173335,MMMNQMIQOUFMSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,17650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,4.753255290276159,7852,49799473,CC(=C(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)F)C3=CC=NC=C3)C,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(F)c2)cc1
CHEMBL2336424,MMNFZCWXLBJTKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,7854,10077700,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL2336424,MMNFZCWXLBJTKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,7854,10077700,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,5.221848749616356,7855,11467753,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,4.443697499232712,7855,11467753,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,7855,11467753,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL454791,MMNFZCWXLBJTKN-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,7855,11467753,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL2017101,MMQZUVZXVOBUEW-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.346787486224656,7858,46932139,CC(=O)NCCC1=CC=CC=C1C2=NOC(=C2Br)C3CNCCC3(C4=CC(=C(C=C4)F)F)O,CC(=O)NCCc1ccccc1-c1noc(C2CNCCC2(O)c2ccc(F)c(F)c2)c1Br
CHEMBL599792,MMRPIWYTUYGTFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,5.0915149811213505,7859,25054032,CN(C)CC1=CC=C(C=C1)NC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC(=C(C=C3)OC)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC
CHEMBL599792,MMRPIWYTUYGTFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,7859,25054032,CN(C)CC1=CC=C(C=C1)NC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC(=C(C=C3)OC)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC
CHEMBL2013050,MMTAJJBCVXEVAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7862,57345659,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OC5CCN(CC5)S(=O)(=O)C6CC6)CC2,O=S(=O)(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
CHEMBL3104531,MMWXEYASGQOQGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.769551078621726,7866,76324760,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C(=O)C4=CC=CC=C4C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL241032,MNEZWRIUOPOINT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.173925197299173,7873,23647902,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)OC)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)OC)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL3115187,MNHOXZBSLMSIDR-QYDYLWNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,7876,59721273,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CO)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CO)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3115167,MNHOXZBSLMSIDR-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,7877,59721395,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CO)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CO)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL368883,MNHXJOCWNHZKLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,152000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.8181564120552274,7878,16654686,CC1=NC=CN1C2=CN=CC=C2,Cc1nccn1-c1cccnc1
CHEMBL368883,MNHXJOCWNHZKLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,152000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.8181564120552274,7878,16654686,CC1=NC=CN1C2=CN=CC=C2,Cc1nccn1-c1cccnc1
CHEMBL559168,MNIKGZYFLQZIHV-JUJAXGASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,7883,21064077,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)C(C(C)C)O.Cl,CCCCN1C(=O)C(C(O)C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
CHEMBL1224655,MNJFIVNZRQTGJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7884,11187635,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=NC(=CS3)C(=O)N)OC(F)(F)F,NC(=O)c1csc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)n1
CHEMBL416146,MNJVRJDLRVPLFE-UHFFFAOYSA-N,ETORICOXIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11327589.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 CYP3A4 in human liver microsomes,"In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7885,123619,CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
CHEMBL235955,MNKVGJVJTHPQCA-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,7886,44433282,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCC(=O)O,CC(C)CC(NCCCC(=O)O)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL170159,MNTVJSYTLLQKAC-WTIAOWAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,7890,44380796,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)C(C)CNCCC6=CC=CC7=C6C=CN=C7)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2C(C)CNCCc2cccc3cnccc23)c1
CHEMBL3287925,MODVORZURPOLGV-NDEPHWFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24944749.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.,ACS Med. Chem. Lett.,PUBLICATION,,4.769551078621726,7894,49800475,CC1=C(C(=C(N=C1C2=CC=C(C=C2)C3=C(ON=C3C)C)C)C(C(=O)O)OC(C)(C)C)C4=CC=C(C=C4)Cl,Cc1noc(C)c1-c1ccc(-c2nc(C)c(C(OC(C)(C)C)C(=O)O)c(-c3ccc(Cl)cc3)c2C)cc1
CHEMBL2420682,MOMSGXYFDHLLKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,4196.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.3771645204784795,7904,71818091,COC1=CN=CC(=C1)C2=C(C3=C(C=CC(=C3)O)C=C2)Cl,COc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1
CHEMBL2347323,MOMUFKSOCOPXAG-GJZGRUSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,7905,71580827,CC(C)C(C(=O)N1CCCC1C2=NC(=C(N2)Br)C3=CC=C(C=C3)N=[N+]=[N-])NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1nc(-c2ccc(N=[N+]=[N-])cc2)c(Br)[nH]1)C(C)C
CHEMBL1080803,MONVGMXMCOSOEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,7907,46879598,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4C=CC=CC4=O)C(=C(N3CCO)C)C,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)n(CCO)c12
CHEMBL3702698,MONWIUSEFBOZFB-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.962573502059376,7908,89718300,CC(=O)N1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)=O)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL602483,MOOACFAVSYOZPW-RTWAWAEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20089400.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 muscle isoform in human liver microsomes,"Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,7909,17754437,C1C(N(C2=CC=CC(=C2O1)C3=CC(=CC=C3)OC(F)(F)F)CC(C(F)(F)F)O)C4=CC(=CC=C4)OC(C(F)F)(F)F,OC(CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OCC1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F
CHEMBL602483,MOOACFAVSYOZPW-RTWAWAEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20089400.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 tissue isoform in human liver microsomes,"Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,7909,17754437,C1C(N(C2=CC=CC(=C2O1)C3=CC(=CC=C3)OC(F)(F)F)CC(C(F)(F)F)O)C4=CC(=CC=C4)OC(C(F)F)(F)F,OC(CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OCC1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F
CHEMBL1668108,MOQNWTYYZUVPQT-WBMJQRKESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,99500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.002176919254275,7912,53326249,COC1=C(C=CC(=C1)C2COC3=CC=CC=C3C2O)O,COc1cc(C2COc3ccccc3C2O)ccc1O
CHEMBL3127510,MOQYJMVBPKWDGC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.698970004336019,7913,76071764,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL3127510,MOQYJMVBPKWDGC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.721246399047171,7913,76071764,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL3127509,MOQYJMVBPKWDGC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.522878745280337,7914,73890932,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL3127509,MOQYJMVBPKWDGC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,960.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.017728766960432,7914,73890932,CC(C)N1C=C(C=N1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)C3CC3c3cccnc3)cc2)cn1
CHEMBL514241,MOSUHGCZZUVJGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7915,44578961,C1=CC=C(C=C1)C(C2=NC=CC=N2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ncccn1
CHEMBL3623825,MOUHKVCNIZIARN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7917,89846366,CC(C)C(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,CC(C)C(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
CHEMBL3702798,MOURGQNCSOFJCE-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3670.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.43533393574791,7918,89718494,CC(C)N1CCN(CC1)C2=NC=C(C=N2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5cnc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3699331,MPARRWFWOOSGFT-BNLBYEDMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,7924,89718261,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC(=CC=C7)C(=O)NC8=CC=C(C=C8)N9CCN(CC9)C1=CC=C(C=C1)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccc(N7CCN(c8ccc(OC)cc8)CC7)cc6)c5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3353337,MPFUDUPAOWHBRQ-QPEQYQDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,5.0,7930,118719544,C1=CC=C2C(=C1)C(=CC3=CC4=C(C=C3)C=NN4)C(=O)N2,O=C1Nc2ccccc2C1=Cc1ccc2cn[nH]c2c1
CHEMBL62811,MPGBYGNPFRLHAO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,127000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,3.896196279044043,7931,13728862,C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC=C3,O=C1CCc2cc(-c3cccnc3)ccc2N1
CHEMBL3137455,MPHUQXMZMAGHLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,6.154901959985743,7933,76336700,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=N4)F,Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1
CHEMBL3422017,MPIGZKVWBCATSN-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,55000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.259637310505756,7934,71549767,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=NO5)C,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1
CHEMBL1910110,MPQHCJTZWVZDFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,7941,15950462,CC1=C(C(=C2CN(C(=O)C2=N1)C)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(C)C2=O
CHEMBL3664670,MPRLCRDFWDNLEU-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,7942,59635758,CC1=CC(=CC(=O)N1C)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,Cc1cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(=O)n1C
CHEMBL2436983,MPTRQLXNBJOFSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,=,21800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,4.661543506395395,7943,46213938,C1=CC2=C(C=CN2)C=C1C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)N,Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1
CHEMBL478230,MPYXFPRJIAJIQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,7947,44578959,C1=CC=C(C=C1)C(C2=CC=NC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccncc1
CHEMBL3581149,MPZKHCPHRLXFAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.251811972993799,7948,24830570,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)N,COc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1
CHEMBL2178248,MQGLDOPILNOMIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,7953,70497865,C1=CC(=CC(=C1)Cl)C2=C(C=CC=N2)NC(=O)C3=C4N=CC=CN4N=C3,O=C(Nc1cccnc1-c1cccc(Cl)c1)c1cnn2cccnc12
CHEMBL3234566,MQTKTGBFRROXDQ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.119186407719209,7963,90654585,CC1=C(C(=NC(=N1)N2CCCC(C2)C(=O)NCCC3=CC=C(C=C3)C#N)N4CCN(CC4)C)F,Cc1nc(N2CCCC(C(=O)NCCc3ccc(C#N)cc3)C2)nc(N2CCN(C)CC2)c1F
CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,5.0,7965,447043,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22697905.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,"N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.",J. Med. Chem.,PUBLICATION,,5.0,7965,447043,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
CHEMBL2436220,MQTWTRJTQGLJQD-DDUISNTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,38000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.42021640338319,7966,73352496,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=NOC4=CC=CC=C43)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL254592,MQWJGLSZBHVGLN-VBSSPFTJSA-N,FIBRAURECDYSIDE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,7968,44445723,CC(CC(C(C)(C1CCC2(C1(CCC3C2=CC(=O)C4C3(CC(C(C4)OC5C(C(C(C(O5)CO)O)O)O)O)C)C)O)O)O)C(C)(C)O,CC(CC(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(OC5OC(CO)C(O)C(O)C5O)C(O)CC4(C)C3CCC12C)C(C)(C)O
CHEMBL3608682,MRAPDPPDTOESHB-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,7970,86275449,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NO4)C,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3C)n1
CHEMBL2040897,MRDYEAJRUPFRFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7972,57387281,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=C(N=C(S6)C)C,Cc1nc(C)c(-c2ccc(N3C(=O)N(c4cc(=O)nc[nH]4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)s1
CHEMBL238744,MRGGOQVTDADSFB-GOSISDBHSA-N,SR-889,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,7975,16662090,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC(=CC=C4)Cl)O,O=C(C(O)c1cccc(Cl)c1)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL2041178,MRIBBXXALNMJDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,7978,57384483,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)NC,CNC(=O)c1ccc(-c2ccc(N3C(=O)N(c4cc(OC)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)cc1
CHEMBL2425893,MRWKTDPDQXVRSA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,46180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.335546071418842,7992,71731606,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=CC(=C3)Cl)C=C2)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3ccc(Cl)cc3n2)c1=O
CHEMBL2419494,MRWKTKIMIMOEBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,5.698970004336019,7993,11993787,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)C(C)C)C,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C(C)C)cc3)CC2)nc1C
CHEMBL1097192,MRZTZDFHFHGWFU-YMGMXPECSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,7999,46888866,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CN=CC=C5,Cc1cc(OCP2(=O)OCCC(c3cccnc3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL1669418,MSDXVUCMHKOWGT-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,2751.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.560509409610316,8005,53326726,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CO4,CC(C1=C(CCN(C)Cc2ccco2)Cc2ccccc21)c1cnccn1
CHEMBL2070947,MSHULPIKNRKAQH-QZTJIDSGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,=,630.96,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.199998172182031,8009,70276990,CS(=O)(=O)C1=CC2=C(C=C1)N=C(S2)N3CCN(CC3)C(=O)C4CCCCC4C(=O)NC5(CC5)C#N,CS(=O)(=O)c1ccc2nc(N3CCN(C(=O)C4CCCCC4C(=O)NC4(C#N)CC4)CC3)sc2c1
CHEMBL356594,MSHWCOQQFPXUKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,8010,11379226,CCCCOC1=CC=C(C=C1)C2=NNC(=C2)C,CCCCOc1ccc(-c2cc(C)[nH]n2)cc1
CHEMBL1669406,MSMKOTVNTGCTFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4038.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.393833685392379,8015,53326712,CCCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CCCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
CHEMBL111201,MSOUIIHPMJCUNI-LJAQVGFWSA-N,L-796568,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,5.031517051446065,8016,3038500,C1=CC(=CN=C1)C(CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=NC(=CS4)C5=CC=C(C=C5)C(F)(F)F)O,O=S(=O)(Nc1ccc(CCNCC(O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1
CHEMBL250766,MSOXUNRESBTCBO-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18294849.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989233,8017,44447866,C1CC(N(C1)CCCOC2=CC3=CN=NC(=C3C=C2)NC4=CN(N=C4)CC(=O)NC5=C(C(=CC=C5)F)F)COP(=O)(O)O,O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCCC4COP(=O)(O)O)ccc23)cn1)Nc1cccc(F)c1F
CHEMBL1093607,MSPFRPWEGPBFTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,8019,46884239,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CN=C3,CC(c1c(CCN(C)C)sc2ccccc12)n1ccnc1
CHEMBL1829780,MSQIRKAOYTVRLM-XDBZFTIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,8020,53473397,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCCNC(=O)N)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCCNC(N)=O)(c2ccc(F)cc2)OC1=O
CHEMBL3680984,MSRICOSVBSYAJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5800.0,NM,253317,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,5.236572006437063,8021,53497377,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1
CHEMBL1651533,MSVRZOTYGPKRHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,23500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,4.628932137728264,8022,24967991,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NC=CN=C4,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
CHEMBL1651533,MSVRZOTYGPKRHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,8022,24967991,C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NC=CN=C4,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
CHEMBL1271762,MSWDKLVRBJNSSU-QUCCMNQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,7.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.148741651280925,8023,52946750,CC(C)(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)CO,CC(C)(C)C1COCC(COC(=O)N2CCC(CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1215621,MSXMGTMTOVJLOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.096910013008056,8024,46914578,CC1=C(C(C(=C(N1)CN2C=NC=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
CHEMBL1766169,MSYJBDGOMUPKGB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.920818753952375,8026,9904146,CC(C)C(C1=CC=CC(=C1)C2=CC=CC=C2)(C3=CN=CN3)O,CC(C)C(O)(c1cccc(-c2ccccc2)c1)c1cnc[nH]1
CHEMBL2347994,MTALYIZKNIEGKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,8027,71280067,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)C5CCNCC5,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(C4CCNCC4)c4cc(F)ccc34)nc12
CHEMBL467047,MTDBNJKMVASAKC-LNNUBQDUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,5.301029995663981,8029,44574108,CC1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CN(C)CC=CCN)O)O)N,Cc1nc(N)c2ncn(C3OC(CN(C)CC=CCN)C(O)C3O)c2n1
CHEMBL2041188,MTFKYKNIAONGHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8031,57387541,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CC=N4)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ncccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
CHEMBL2064341,MTHPQWCRVGFTAP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,8032,49853930,C1CC1N2C3=C(C=C(C=C3)F)N=C2CC4=NC(=O)C=C(N4)N5CCOCC5,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3cc(F)ccc3n2C2CC2)n1
CHEMBL1766005,MTHVGGMOKYRPIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21428449.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,PUBLICATION,,5.096910013008056,8033,54581365,CC(C)(C(C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2)N4C=CN=C4)C(=O)OC,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1
CHEMBL1766005,MTHVGGMOKYRPIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838328.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26).",J. Med. Chem.,PUBLICATION,,7.0,8033,54581365,CC(C)(C(C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2)N4C=CN=C4)C(=O)OC,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1
CHEMBL2332097,MTJPSOHLRSAFBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570561.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,8036,68568011,CN(CC1=CC(=CC=C1)OC)C(=O)NC2=CC=C(C=C2)C3=CNN=C3,COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1
CHEMBL2385906,MTLOUGLEHWJVAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23324405.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8038,11695689,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC=CC=C4,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2
CHEMBL2385906,MTLOUGLEHWJVAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8038,11695689,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC=CC=C4,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2
CHEMBL524472,MTSGTWVVCJFRLJ-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,4.3979400086720375,8043,25207352,CC(C1=CC=CC=C1)NC2=C(C(=O)C2=O)NC3=CC=NN3,CC(Nc1c(Nc2ccn[nH]2)c(=O)c1=O)c1ccccc1
CHEMBL454467,MTUYBYGTWUVARZ-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,8046,135960721,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N(CCOC)CCOC,COCCN(CCOC)C1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL2152523,MTYFDEYZRYWPAI-DNQXCXABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19952.62,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,4.70000006855703,8050,21635104,C1CCN(CC1)C(C2=CC=CC=C2)C(C3=CC=CC=C3)N4CCCCC4,c1ccc(C(C(c2ccccc2)N2CCCCC2)N2CCCCC2)cc1
CHEMBL2152522,MTYFDEYZRYWPAI-ZEQRLZLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15848.93,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,4.800000052738446,8051,71449452,C1CCN(CC1)C(C2=CC=CC=C2)C(C3=CC=CC=C3)N4CCCCC4,c1ccc(C(C(c2ccccc2)N2CCCCC2)N2CCCCC2)cc1
CHEMBL1950089,MTYKIQDYUJLUDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,8052,57398224,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)[nH]nc3nc12
CHEMBL1950089,MTYKIQDYUJLUDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.130768280269024,8052,57398224,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)[nH]nc3nc12
CHEMBL1081504,MTYYVNZCZPYFBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.055517327849831,8053,46879428,CC1=C(C(=CC=C1)C)CNC2=NC=NC3=C2NC(=C3C)C,Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12
CHEMBL1081504,MTYYVNZCZPYFBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,8053,46879428,CC1=C(C(=CC=C1)C)CNC2=NC=NC3=C2NC(=C3C)C,Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12
CHEMBL359627,MUCJLTBRRVGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585026652029182,8056,11690073,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C#N)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL359627,MUCJLTBRRVGZER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,8056,11690073,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C#N)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL399772,MUIOMNHOLFGIGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17937987.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,8062,21899433,CC1=CC(=CC(=C1)C2=C(C3=C(N2)SC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)CCN6CCN(CC6)CC(=O)N7CCOCC7)C,Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(=O)N3CCOCC3)CC2)c1
CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8065,6013,CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12
CHEMBL3702822,MUMIOWBMUUBPQQ-NWDJCJOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.0,8066,89718379,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)S(=O)(=O)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(S(C)(=O)=O)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2037608,MURCULVYVOMYIO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22578490.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,8072,59651916,CC1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)COC,COCn1ncc(-c2ccc(OCCCN3CCCC3C)cc2)cc1=O
CHEMBL3286732,MUTPWJCHZIMJSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,8074,24744325,C1CN(CCC12CNC(=O)O2)C3=NC=C(C=C3)C(=O)NC4=C(C=CC(=C4)C5=CC=CS5)N,Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(N2CCC3(CC2)CNC(=O)O3)nc1
CHEMBL312238,MUULRSITXOVVFK-WGAQAMEHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12161148.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165727,8075,493820,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(COC4=CC=CC=C34)O)O)C(C)(C)C5=CC6=C(O5)C=CN=C6,CC(C)(C)NC(=O)C1CN(C(C)(C)c2cc3cnccc3o2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2OCC1O
CHEMBL2346686,MUUWFGCCXBFENT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.721246399047171,8077,71280456,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=C(C=C4)OC(F)F)C,Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21
CHEMBL1171987,MVDKLMQNQSJYHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,1520.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,5.818156412055227,8084,46901444,C1=CC(=CC(=C1)N)C2=CC=C(C=C2)CC3=CC=NC=C3,Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
CHEMBL1171987,MVDKLMQNQSJYHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,1520.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,5.818156412055227,8084,46901444,C1=CC(=CC(=C1)N)C2=CC=C(C=C2)CC3=CC=NC=C3,Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
CHEMBL3358920,MVGWUTBTXDYMND-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516790.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8091,44623998,C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F,O=C(O)CC1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21
CHEMBL3125655,MVIDQQZWMHRXFV-IVAHSZNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23544424.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 7 mins by LC/MS/MS analysis,Hepatitis C replication inhibitors that target the viral NS4B protein.,J. Med. Chem.,PUBLICATION,,4.698970004336019,8093,52917690,C1CC1C2=CC3=C(C(=NN3C(=C2)C(F)(F)F)C(=O)N4CCN(C(=O)C4)C5CC6CC6C5O)Cl,O=C(c1nn2c(C(F)(F)F)cc(C3CC3)cc2c1Cl)N1CCN(C2CC3CC3C2O)C(=O)C1
CHEMBL464907,MVKOXOCIOJFWSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,8095,44570224,CN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=C3F)F,CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F
CHEMBL2158230,MVPRWLBKNHWFPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.42021640338319,8100,11634544,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CCN4CCOCC4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL1761532,MVXIVGJQLGJBTD-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8108,25118294,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC(C)(C)C(=O)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1
CHEMBL1761532,MVXIVGJQLGJBTD-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8108,25118294,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC(C)(C)C(=O)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1
CHEMBL2331785,MWAFLDQEXDZJCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,6.443697499232713,8110,71525043,CCNC(=O)C1=C(C=CC(=C1)NS(=O)(=O)C2=C(C=C(C(=C2)C)Cl)Cl)OC3=CC(=CN=C3)Cl,CCNC(=O)c1cc(NS(=O)(=O)c2cc(C)c(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1
CHEMBL2017277,MWCQWHMNJUFCOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989233,8111,70683271,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4CCCCC4)C(=O)N)OC,COc1cc2c(NC3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL3702723,MWNNUMQFYMZPJW-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2110.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.675717544702307,8117,89718326,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)N8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCOCC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1909725,MWNVVXNYGOUFQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924902.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(2'-Pyridyl)-2-aminothiazoles: Alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,8118,54752621,CN(C)S(=O)(=O)NCCCCCNC1=NC(=CS1)C2=CC=CC=N2,CN(C)S(=O)(=O)NCCCCCNc1nc(-c2ccccn2)cs1
CHEMBL1668112,MWQRAOGWLXTMIC-WZBLMQSHSA-N,(7R)-7-HYDROXYLARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,66500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.1771783546968955,8121,10022393,COC1=C(C=CC(=C1)C2C(C(CO2)C(C3=CC(=C(C=C3)O)OC)O)CO)O,COc1cc(C(O)C2COC(c3ccc(O)c(OC)c3)C2CO)ccc1O
CHEMBL214957,MWULMTACIBZPGN-UHFFFAOYSA-N,GW3430,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,8122,9826520,COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OCCN5CCCC5,COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1
CHEMBL1951325,MWWLVSZLKTULPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,92.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.036212172654444,8125,57404044,C1=CC(=CC(=C1)Br)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(Br)c1
CHEMBL1923111,MWXLYTROOQGXBN-VIZCGCQYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,8127,57390808,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,COCCCc1cc(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)cc(OCCOC)c1
CHEMBL3623290,MXDSJQHFFDGFDK-CYBMUJFWSA-N,AZD3759,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26313252.0,IC50,>,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",J. Med. Chem.,PUBLICATION,,7.301029995663981,8132,78209992,CC1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)CC1C
CHEMBL231924,MXDWNZUMSIYAFL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17524641.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,8133,11222420,C1=CC=C(C(=C1)NC2=NS(=O)(=O)C3=CC(=CC(=C3N2)O)[N+](=O)[O-])Cl,O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2
CHEMBL1290264,MXFUQWVSPVTIIP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.173925197299173,8135,44194849,CN1CCC2=C(C1)C3=C(N2C)C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5,CN1CCc2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc3n2C)C1
CHEMBL444989,MXOCHUKULSSMCN-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,8143,44587392,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=C(C(=CC=C4)OCCCCCC(=O)O)F)N,NC(Cn1c(=O)c(-c2cccc(OCCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL251055,MXTLAHSTUOXGQF-UHFFFAOYSA-O,JATRORRHIZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,5.6777807052660805,8151,72323,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC,COc1cc2c(cc1O)CC[n+]1cc3c(OC)c(OC)ccc3cc1-2
CHEMBL2064335,MXWXREUDDBTARZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,8152,49853720,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(N3)C=C(C=C4)Br,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3ccc(Br)cc3[nH]2)n1
CHEMBL3702725,MYADYUMYQBLDNQ-OZLPACJUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4490.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.347753658996677,8156,89718322,CN1CC2CCN(C2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC6CN(C)CC65)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1916282,MYHHDENZOVCZAX-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21955939.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8159,57394707,CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NN2C3=CC=CC=C3)C)C(=O)NC(C)C(C)(C)C,Cc1ccc(S(=O)(=O)Nc2c(C(=O)NC(C)C(C)(C)C)c(C)nn2-c2ccccc2)cc1
CHEMBL482845,MYJOBXPUJPRQLF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8161,44583236,C1CC2=CC=CC=C2C1NC(=O)N3CCC4(CC3)CC(=O)C5=CC=CC=C5O4,O=C1CC2(CCN(C(=O)NC3CCc4ccccc43)CC2)Oc2ccccc21
CHEMBL207304,MYLJXYCXVOMQPS-NLFFAJNJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,8162,44410814,CC(C)N(C)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4,CC(C)N(C)C(C)C(c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1
CHEMBL1272097,MYNIAARJFHEUIK-UYAOXDASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,8165,11613185,CN1CCN(CC1=O)C(=O)OC2(CC2)C3COCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5,CN1CCN(C(=O)OC2(C3COCC(CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1=O
CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,8171,2764,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,8171,2764,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
CHEMBL1257965,MYTSILBAQHYOET-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8174,46945057,CC1CN2C3=C(C=C(C=C3)OC4CCN(CC4)C(C)C)C=C2C(=O)N1CC5CC5,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CC(C)N(CC3CC3)C2=O)CC1
CHEMBL1951597,MYVRYELIXRBEEQ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,8176,57391803,CN1C2=C(C(=O)N(C1=O)C)N(C(=C2C#N)N3CCCC(C3)N)CC4=CC=CC=C4,Cn1c(=O)c2c(c(C#N)c(N3CCCC(N)C3)n2Cc2ccccc2)n(C)c1=O
CHEMBL240069,MZAPDYQWIGAEQO-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,8178,44435366,C1CC(N(C(C1)C2(CC2)OC(=O)N3CCN(CC3)CCO)S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,O=C(OC1(C2CCCC(C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1
CHEMBL3218855,MZGDIKYASHMRSG-UGCQDJOBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,5.070581074285707,8186,90665987,CN1CCN(CC1)C2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl)OC,COc1cc(N2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3218855,MZGDIKYASHMRSG-UGCQDJOBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.863279432843593,8186,90665987,CN1CCN(CC1)C2=CC(=C(C=C2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl)OC,COc1cc(N2CCN(C)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL2397308,MZTTVVHNFDPGBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,8196,71681890,CC1=NC=C(C=C1)C(=O)N(CC2=CC=CC=C2)CC(=O)NC3=NC=C(S3)C4=CC=C(C=C4)N,Cc1ccc(C(=O)N(CC(=O)Nc2ncc(-c3ccc(N)cc3)s2)Cc2ccccc2)cn1
CHEMBL1222649,MZTTZMXOZUZREU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,8197,49864901,CN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL3326576,MZVVZQZAVDLFTI-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,5.657577319177793,8199,25265057,CC1(CC(C2=C(O1)C=C(C=C2)OC(F)(F)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)C,CC1(C)CC(NC(=O)Nc2cccc3cnccc23)c2ccc(OC(F)(F)F)cc2O1
CHEMBL3702755,NAFGAODZJQDRCU-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2180.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.661543506395395,8201,89718222,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCC7=CC(=NC=C7)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccnc(N(C)C)c5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL558339,NAGKIWFBALBSMD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,8204,45273828,C1CN(CCC1N2C=CC=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(n4cccc4)CC3)nc3ccccc32)cc1
CHEMBL1256004,NAHHNSMHYCLMON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26371436.0,IC50,=,5000000.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.,J. Med. Chem.,PUBLICATION,,2.3010299956639813,8205,854051,C1=CC(=CN=C1)CCN,NCCc1cccnc1
CHEMBL397583,NAHRDBPWFMIDIX-MFMCTBQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,8207,44433298,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)C(CC(C)C)NC(=O)CCNC,CNCCC(=O)NC(CC(C)C)c1cc(C)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL429459,NAJFOBIBNBUZAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,4790.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.319664486585436,8209,23647897,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCCO)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL593375,NANAONFNJKBZQE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,8211,46226080,CC1=C2C=C(C=NC2=NN1)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=CNC6=CC=CC=C65)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2c1
CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8213,11580427,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12
CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8213,11580427,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1090433,NANQRVOKMXDMNL-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8214,11551351,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1090432,NANQRVOKMXDMNL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8215,11580426,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1761533,NASKVDWGYKOGBO-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8217,25121469,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCC(C)(C)C(=O)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1
CHEMBL1761533,NASKVDWGYKOGBO-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8217,25121469,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCC(C)(C)C(=O)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1
CHEMBL271310,NATXHFKXFMNQDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,8218,11584681,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL271310,NATXHFKXFMNQDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,8218,11584681,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL271310,NATXHFKXFMNQDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,8218,11584681,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCN(C)C)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL3640258,NAXGDHGFSCZYGN-OVWNDWIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.698970004336019,8224,44467506,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=C(C=CC=C4F)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3c(F)cccc3F)C2)nc(C)c1F
CHEMBL2435852,NAYZSSQGIKJDGG-PMERELPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,8227,58835024,CC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)O)CN3CCC(CC3)N4C(CN(C4=O)C5CCOCC5)C6=CC=CC=C6,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)CC2c2ccccc2)CC1
CHEMBL496289,NBDGMNQECKEFTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2173.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.662940273679475,8230,25033725,C1CC(C2=C(C1)C=C(C=C2)C3=CC=C(C=C3)F)C4=CC=NC=C4.Cl,Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
CHEMBL1094512,NBMXJNMUHLTYPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,8244,46888788,CC1=CSC(=N1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C,Cc1csc(Cn2c(C3CCCN(C)C3)nc3ccccc32)n1
CHEMBL3640262,NBQUUPYPQVTUSJ-HXPMCKFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.522878745280337,8248,44467575,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=CC=CC=C4F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3ccccc3F)C2)nc(C)c1F
CHEMBL3581137,NBSARUOSCYNPMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,8249,60097693,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=NC=NC=C3,COc1cccc(CC(=O)Nc2nc(-c3ccncn3)cs2)c1
CHEMBL469850,NBVYFPSAUFQMAK-XVCAIJIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,35500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.449771646944906,8252,11310871,CC1=CCC(C=CC(=O)C(=CC(C1)O)C)(C)C,CC1=CCC(C)(C)C=CC(=O)C(C)=CC(O)C1
CHEMBL2058907,NBXKPHVFWKOIHD-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,8253,59603329,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CC=NC=C4)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3ccncc3)cc2o1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6020599913279625,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,7.522878745280337,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497764.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,6.259637310505756,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.795880017344075,8260,392622,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL3311227,NCEHACHJIXJSPD-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,79000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.102372908709558,8261,91886002,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OC(F)(F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1
CHEMBL3125272,NCHSTBMDNNMMEJ-BEFAXECRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24450589.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,J. Med. Chem.,PUBLICATION,,4.301029995663981,8264,72725792,CCC1=NN(C(=C1)C(=O)NC2CC(N(C2)C(=O)C3=COC4=CC=CC=C43)C(=O)NCC)C,CCNC(=O)C1CC(NC(=O)c2cc(CC)nn2C)CN1C(=O)c1coc2ccccc12
CHEMBL408513,NCNRHFGMJRPRSK-MDZDMXLPSA-N,BELINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8268,6918638,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
CHEMBL3087350,NCOYZGPRWXMZKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,8272,72547024,CC1=NOC(=N1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,Cc1noc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)n1
CHEMBL2019023,NCPZEGFWCSOTGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,6.3979400086720375,8273,47144386,CCOC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=N3,CCOc1ccc2nc(SCc3ccccn3)[nH]c2c1
CHEMBL1098148,NCZRGOOBIMCMOT-YMGMXPECSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.075720713938118,8281,46888865,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC=CC=N5,Cc1cc(OCP2(=O)OCCC(c3ccccn3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL1270936,NDAQOTDOXUWRAJ-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,8284,25127299,CC#CC1=C(C=CC(=C1)C2(C(=O)N(C(=N2)N)C)C3=CC=C(C=C3)OC(F)F)F,CC#Cc1cc(C2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)ccc1F
CHEMBL1642906,NDCNHLIWHOBKGK-LRDDRELGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,=,20100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.696803942579511,8285,53320328,CNCC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNCC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1642907,NDCNHLIWHOBKGK-MLGOLLRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,8286,53316823,CNCC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNCC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1642908,NDCNHLIWHOBKGK-WBMJQRKESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,8287,53319480,CNCC1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNCC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL2334758,NDQIDSZBEUKRAW-ZAAXVRCTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,5.301029995663981,8294,71604897,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C4CCC(C3)N4S(=O)(=O)C)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)C2CCC(C3)N2S(C)(=O)=O)cc1
CHEMBL526929,NDRBDNKFYLWQEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18479916.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,8295,25196402,C1=CC(=CC=C1CC(=O)NC(=O)NC2=CC(=C(C=C2)OC3=C(C(=NC=C3)N)C#CCN)F)F,NCC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N
CHEMBL3087036,NDSORUPSARDZBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,8296,72547285,C1=CC(=CC=C1C2=CN=CN=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2cncnc2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL1215732,NDUUGOAGHNLAIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,668.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,6.175223537524454,8298,49864196,C1=CC(=CC(=C1)F)C2=CC=C(C=C2)CC3=CC=NC=C3,Fc1cccc(-c2ccc(Cc3ccncc3)cc2)c1
CHEMBL1079292,NDVUCAXUMZGNKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8299,46882951,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)N)C3=CC=CC=C3,NC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL3127992,NELULMBEPVQNFL-NHCYSSNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24531224.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,5.657577319177793,8307,76325645,C1C(CN(C1C#N)C(=O)C(CC2=CC3=C(C=C2Br)OCO3)N)F,N#CC1CC(F)CN1C(=O)C(N)Cc1cc2c(cc1Br)OCO2
CHEMBL2419490,NEMHKCNXXRQYRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,4.698970004336019,8308,23649325,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=CC=C3)C,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C
CHEMBL2436633,NEPGOHXZJPYLLQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,8309,44602971,C1CN(CCC1N2CC3=CC=CC=C3C4=CC=CC=C4C2)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5-c5ccccc5C4)CC3)CC2)ccn1
CHEMBL3699315,NEQDCWFWVYOBKX-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.912218582190458,8310,89718183,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3699315,NEQDCWFWVYOBKX-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,14700.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.8326826652518236,8310,89718183,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL205245,NEQSVLABUJREKW-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8311,24825272,CC1=NC(=C(N1CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)CC(C)C)C(=O)N4CCC(C4)O)Cl)Cl,Cc1nc(Cl)c(Cl)n1Cc1sc2c(c1C(=O)N1CCC(O)C1)c(=O)n(C)c(=O)n2CC(C)C
CHEMBL3702777,NESCTSGARYERBV-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3450.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.462180904926726,8314,89718371,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N(C)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)CCO)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2347996,NEVNJCLJFXHCCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,8316,71280008,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=C4CCCCN4C=N3,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3ncn4c3CCCC4)nc12
CHEMBL2163830,NEXRPVDFTJNSMM-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.657577319177793,8321,46892972,CN1CCN(CC1)C(=O)C(COCC2=CC=CC=C2)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CN1CCN(C(=O)C(COCc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL2336420,NFKNHAHXAMZIFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.431798275933005,8333,11158071,CC(C)C1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,CC(C)c1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL252837,NFUBWILZNIMKMD-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,8340,44447290,CC(C)(C)OC(=O)NC(CC1=C(C=CC(=C1)F)Cl)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1cc(F)ccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL567169,NFWQSVLWPXHOHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,8341,45484860,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)C(F)(F)F,CC1(CC(=O)NCc2cccc(C(F)(F)F)c2)CC2(CCCCC2)OO1
CHEMBL1077934,NFWXZIIEKXXDMY-CONSDPRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8696662315049934,8342,46883340,C1=CC=C(C=C1)CC(CN(CC2=CC=CC=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,O=C(NC(Cc1ccccc1)CN(Cc1ccccc1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL1077936,NFWXZIIEKXXDMY-FIRIVFDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,8343,46883342,C1=CC=C(C=C1)CC(CN(CC2=CC=CC=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,O=C(NC(Cc1ccccc1)CN(Cc1ccccc1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL1077935,NFWXZIIEKXXDMY-IOWSJCHKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.060480747381382,8344,46883341,C1=CC=C(C=C1)CC(CN(CC2=CC=CC=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4)NC(=O)OCC5=CN=CS5,O=C(NC(Cc1ccccc1)CN(Cc1ccccc1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL3114732,NFZMNPXRMSSCSR-LDNVYYCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,8346,76317768,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCN(CC3=CC=C(C=C3)Cl)C(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCN(Cc2ccc(Cl)cc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL230654,NGCNZPVYWSEEJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,4.795880017344075,8350,17758239,CCCC1=C(NC=N1)CNC2=CC3=C(C(=CN=C3C(=C2)Cl)C#N)NC4=CC(=C(C=C4)F)Cl,CCCc1nc[nH]c1CNc1cc(Cl)c2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1
CHEMBL3216770,NGFJLBUDBMXNIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,8356,90664969,CN(C)CCN1C(=O)CCC2=C1C=CC(=C2)N=C(C3=CC=CS3)N.Cl.Cl,CN(C)CCN1C(=O)CCc2cc(N=C(N)c3cccs3)ccc21
CHEMBL1956397,NGKMIRWLVJBBBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22341942.0,IC50,=,139000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsome,Wake-promoting agents: search for next generation modafinil: part II.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.856985199745905,8361,11855008,C1=CC=C(C(=C1)CS(=O)CC(=O)N)C2=CC=C(C=C2)Cl,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1
CHEMBL1956397,NGKMIRWLVJBBBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22341942.0,IC50,=,159000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsome,Wake-promoting agents: search for next generation modafinil: part II.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.7986028756795487,8361,11855008,C1=CC=C(C(=C1)CS(=O)CC(=O)N)C2=CC=C(C=C2)Cl,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1
CHEMBL2332065,NGOKTEXAUPRBFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570561.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.455931955649724,8372,68560854,COC1=CC=CC(=C1)CN(CCO)C(=O)NC2=CC=C(C=C2)C3=CNN=C3,COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1
CHEMBL2397192,NGSUGGPEIWGUBD-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8375,59293709,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C4(CC4)C#N,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C2(C#N)CC2)c1
CHEMBL1078265,NGZGPRMVYQEQTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8382,42643589,CC1(CCCN(C1)C(=O)NCCC2=CC=C(C=C2)Cl)C3=CC=CC=C3,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc(Cl)cc2)C1
CHEMBL1834662,NHAXYOVOGZMIOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,6.301029995663981,8385,23630305,CN1CCN(CC1)CC2=CC(=CC=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl
CHEMBL1834662,NHAXYOVOGZMIOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,8385,23630305,CN1CCN(CC1)CC2=CC(=CC=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl
CHEMBL3358945,NHDBZQPHSRUJIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.823908740944319,8388,44543858,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC=C3S(=O)(=O)N,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O
CHEMBL3664671,NHDUOZUJFFAZCM-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,8389,59635683,CCN1C=CC(=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCn1ccc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
CHEMBL3321845,NHEYHWKFXOLIOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6020599913279625,8391,53311701,CN1CCN(C2=CC=CC=C21)C(=O)C3=CN=CN=C3OC4=C(C=CC(=C4)Cl)Cl,CN1CCN(C(=O)c2cncnc2Oc2cc(Cl)ccc2Cl)c2ccccc21
CHEMBL2334763,NHJAMHLWORQRFH-XWFZLUIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,5.0,8396,71720046,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CC4CCC3N4C5COC5)C(=N2)N6CCOCC6C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CC2CCC3N2C2COC2)cc1
CHEMBL3597952,NHPQGZOBHSVTAQ-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26317591.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,J. Med. Chem.,PUBLICATION,,4.823908740944319,8400,40924317,CC1=CC(=CC(=C1)NC(=O)C2CCCN2S(=O)(=O)C3=CC=C(C=C3)OC)C,COc1ccc(S(=O)(=O)N2CCCC2C(=O)Nc2cc(C)cc(C)c2)cc1
CHEMBL3355225,NHQZPUJZMXFCFZ-SDNWHVSQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25393851.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection.",J. Med. Chem.,PUBLICATION,,4.522878745280337,8401,11607042,CCOC1=C(C=CC(=C1)NC(=O)C2(CCC2)NC(=O)C3=CC4=C(C=C3)C(=C(N4C)C5=NC=C(C=N5)Cl)C6CCCC6)C=CC(=O)O,CCOc1cc(NC(=O)C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Cl)cn5)n(C)c4c3)CCC2)ccc1C=CC(=O)O
CHEMBL1209694,NHRLPAVZBKIQPV-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,8404,49862651,CC(C)OCC1N2C=NC=C2CN(S1(=O)=O)C(C)C3=CC=C(C=C3)Cl,CC(C)OCC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL1209694,NHRLPAVZBKIQPV-CWQZNGJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,8404,49862651,CC(C)OCC1N2C=NC=C2CN(S1(=O)=O)C(C)C3=CC=C(C=C3)Cl,CC(C)OCC1n2cncc2CN(C(C)c2ccc(Cl)cc2)S1(=O)=O
CHEMBL247428,NHWFUZYIOHEXGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,8407,44443130,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C(=C4)F)OCC(=O)N5C,Cc1ccc2c(OCCN3CCN(Cc4cc(F)c5c(c4)N(C)C(=O)CO5)CC3)cccc2n1
CHEMBL1910286,NHXKTRMFQYHBQT-PXJZQJOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,8408,42641334,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC3(C4=CC=CC=C4)O,COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccccc2)C2CC2)cc(OCCOC)c1
CHEMBL1290150,NIAQGSGCZRZBSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,8411,25205319,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)C5=C(C=C(C=C5)Cl)Cl)C=N2,O=c1cc(-c2ccc(Cl)cc2Cl)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
CHEMBL266647,NICHJJOSEXYBED-AMGIVPHBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994683.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.",J. Med. Chem.,PUBLICATION,,5.0,8414,24180592,CC(C)CC(C1=C(C=CC(=C1)Cl)N2CCN(CC2)C(=O)C(C)CC3=CC=C(C=C3)Cl)NC(=O)CCN(C)C,CC(C)CC(NC(=O)CCN(C)C)c1cc(Cl)ccc1N1CCN(C(=O)C(C)Cc2ccc(Cl)cc2)CC1
CHEMBL26150,NICIICGVYGSKJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,26410.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.578231598793076,8415,11293909,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)N(C)C,CN(C)c1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
CHEMBL391056,NIDQERYOGAPSJL-MNNSJKJDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.1938200260161125,8417,23635108,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=C(C=C(C=C3)Cl)F)C(C(C)C)NC(=O)CCN(C)C,Cc1ccc(N2CCN(C(=O)C(C)Cc3ccc(Cl)cc3F)CC2)c(C(NC(=O)CCN(C)C)C(C)C)c1
CHEMBL1800137,NIFJWDNQUGBNEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21644570.0,IC50,>,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,PUBLICATION,,5.050609993355088,8420,53362097,CC(C)(C(=O)N1CCN2C(=NC(=C2NC3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C1)N,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1
CHEMBL213221,NIKRNNCEAFBTLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16843659.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification of novel pyrazole acid antagonists for the EP1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,8426,11235004,CC1=CC(=NN1CC2=C(C=CC(=C2)Br)OCC3=CC=CC=C3)C(=O)O,Cc1cc(C(=O)O)nn1Cc1cc(Br)ccc1OCc1ccccc1
CHEMBL3234570,NINLJGBDNUJAET-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.958607314841775,8430,90654589,C1CC(CN(C1)C2=NC(=NC(=C2)N3CCN(CC3)C4COC4)C(F)(F)F)C(=O)NCCC5=CC=C(C=C5)C#N,N#Cc1ccc(CCNC(=O)C2CCCN(c3cc(N4CCN(C5COC5)CC4)nc(C(F)(F)F)n3)C2)cc1
CHEMBL1945726,NIPDDLFKIMAGDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22196117.0,IC50,=,11800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of triazolopyridazinones as potent p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.928117992693875,8431,56951458,CCN1C(=O)C(=CC2=NN=C(N21)C3=C(C=CC=C3Cl)F)C4=C(C(=CC(=C4)C(=O)NC5CC5)F)C,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc2nnc(-c3c(F)cccc3Cl)n21
CHEMBL375248,NIQLDGOLJPELPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15566305.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8432,5329333,CNC(=O)N1CCN(CC1)CC2=CC(=NC=C2)NC3=NC=C(S3)C#N,CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2)CC1
CHEMBL1290155,NISSGJHPJFKJDG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,68000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.167491087293763,8435,52942456,C1CNCC2=C1NC3=C2C=CC(=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3
CHEMBL3702787,NIVWMBCQJMTWFL-LFCBDPIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7670.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.115204636051019,8438,89718251,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCCN8CCCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3087041,NIYDALVYCLIMEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,8439,72547530,C=CC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,C=Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL498643,NIYOFXPODJVAGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3291.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.482672117705627,8440,25033729,COC1=CC=C(C=C1)C2=CC3=C(C=C2)C(CC3)(C4=CC=NC=C4)O,COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1
CHEMBL178330,NJFOVAJRFITZIG-GHXNOFRVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,>,400000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.3979400086720375,8446,11355925,C1=CC(=CN=C1)C2=CC=C(O2)C=NO,ON=Cc1ccc(-c2cccnc2)o1
CHEMBL178547,NJFOVAJRFITZIG-KPKJPENVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,>,400000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.3979400086720375,8447,11389855,C1=CC(=CN=C1)C2=CC=C(O2)C=NO,ON=Cc1ccc(-c2cccnc2)o1
CHEMBL252836,NJGHOWOIRIXDKZ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,8448,44447288,CC(C)(C)OC(=O)NC(CC1=C(C=CC(=C1F)F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1c(F)ccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL1794074,NJQSZNSQWNSIHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.795880017344075,8458,24949700,CC1=C2C=CC(=CC2=NN1C)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N.Cl.Cl,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C
CHEMBL1794074,NJQSZNSQWNSIHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,4.508638306165727,8458,24949700,CC1=C2C=CC(=CC2=NN1C)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N.Cl.Cl,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C
CHEMBL1950078,NJVOBGWGMQUPTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,8467,57396432,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=C(C=C4)OC)O)OC,COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
CHEMBL1950078,NJVOBGWGMQUPTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,8467,57396432,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=C(C=C4)OC)O)OC,COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,8471,2733526,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
CHEMBL584261,NKBQZUQMWOWSFW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19683918.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8472,44555352,CC1=C(N(N=C1C2=CN(C=N2)C(C)C)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl,Cc1c(-c2cn(C(C)C)cn2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1
CHEMBL3702786,NKFVGWLSONSSEH-UJGAEZNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.236572006437063,8476,89718490,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN8CCC(CC8)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCC(O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1766171,NKGXIBYLFKGGQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.619788758288394,8477,18668528,CC(C)C(C1=CC=CC(=C1)C2=CC=C(C=C2)Cl)(C3=CN=CN3)O,CC(C)C(O)(c1cccc(-c2ccc(Cl)cc2)c1)c1cnc[nH]1
CHEMBL506169,NKJTYXXPGXIGTL-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,8481,135960725,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)C,CC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCC(O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL3329684,NKKNQMFHKZEGQU-KQWNVCNZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25089810.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate,Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.,Eur. J. Med. Chem.,PUBLICATION,,5.0,8483,71816087,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=C(C=C4)NC(=O)NC(=O)C5=C(C=C(C=C5)OC)F)NC3=O,COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)C3=Cc2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1
CHEMBL3664712,NKQLSIVCYOQHSU-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,8488,59635723,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CCCO)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CCCO)(c2ccc(F)cc2)OC1=O
CHEMBL1631007,NKRSPRREAOOIMI-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20974532.0,IC50,>,38000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.42021640338319,8491,53319905,CC(C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CC3=C(C2)C=C(C=C3)Cl,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(Cl)cc2C1)C(F)(F)F
CHEMBL497747,NKSITFUAIXVDAQ-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040958607678906,8492,44576643,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CN)N,NCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)cc1
CHEMBL1945721,NKSUTIFGDVDLOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22196117.0,IC50,=,25800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of triazolopyridazinones as potent p38a inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.58838029403677,8493,56951456,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=CC4=NN=C(N4N(C3=O)C)C5=C(C=CC=C5Cl)F,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1cc2nnc(-c3c(F)cccc3Cl)n2n(C)c1=O
CHEMBL3104250,NKUDGJUBIVEDTF-FYJGNVAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24237195.0,IC50,=,2610.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.",J. Med. Chem.,PUBLICATION,,5.583359492661719,8498,135743577,CC(=NNC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCOCC2)C3=C(C=CC(=C3)Cl)O,CC(=NNC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1)c1cc(Cl)ccc1O
CHEMBL3091536,NKUNFNVAHJNALA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8499,56589672,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=C(C=C3)F)C4=NC=NC=C4,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O
CHEMBL3091536,NKUNFNVAHJNALA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8499,56589672,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=C(C=C3)F)C4=NC=NC=C4,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O
CHEMBL1257138,NKZJSHCNJFDLTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8505,52941269,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CC5CC5,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CC3CC3)C2=O)CC1
CHEMBL1092169,NLFVFVQFPLEKDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20096577.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,8509,10028888,CC(C)(C(=O)C1=C(C2=CC(=C(N=C2O1)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl)NC(=O)CO)O,CC(C)(O)C(=O)c1oc2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)cc2c1NC(=O)CO
CHEMBL3393472,NLJHGKLCSVZNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,6.769551078621726,8513,118725518,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CNCC3=O)C4=CC=C(O4)SC5=NC6=CC=CC=C6N5.O.Cl,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CNC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1
CHEMBL3401195,NLNMCEXQEHYXBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25683622.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,8517,68290289,C1CN(C(=O)N2C1=NC(=C2)COC3=CC=CC=C3)C4=CC=C(C=C4)F,O=C1N(c2ccc(F)cc2)CCc2nc(COc3ccccc3)cn21
CHEMBL271864,NLNSEABQNGLUMD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,8518,11613524,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)N4CCC(CC4)N)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(N3CCC(N)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL3092198,NLTKWBJFNLWOOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,8525,59447115,CC(C)(C1CCN(CC1)C(=O)C2=C(C=CC(=C2)F)S(=O)(=O)C)S(=O)(=O)C3=CC=CC(=C3)C(F)(F)F,CC(C)(C1CCN(C(=O)c2cc(F)ccc2S(C)(=O)=O)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1
CHEMBL248849,NMADZMIBEVCFDZ-XLCPLWEUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17855089.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,8531,44443532,C1CN(CCC1C(=O)N2CCC(C2)CNS(=O)(=O)C=CC3=CC=C(S3)C4=CC=C(S4)Cl)C5=CC=NC=C5,O=C(C1CCN(c2ccncc2)CC1)N1CCC(CNS(=O)(=O)C=Cc2ccc(-c3ccc(Cl)s3)s2)C1
CHEMBL248849,NMADZMIBEVCFDZ-XLCPLWEUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17855089.0,IC50,=,2330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.632644078973981,8531,44443532,C1CN(CCC1C(=O)N2CCC(C2)CNS(=O)(=O)C=CC3=CC=C(S3)C4=CC=C(S4)Cl)C5=CC=NC=C5,O=C(C1CCN(c2ccncc2)CC1)N1CCC(CNS(=O)(=O)C=Cc2ccc(-c3ccc(Cl)s3)s2)C1
CHEMBL2387590,NMAXYWKTMNUWHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,8532,71659357,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)Cl)Cl,O=c1[nH]c2cc(Cl)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL563055,NMEALLMQARPNTN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,8539,45270330,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)NCC5CCOCC5,COc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
CHEMBL271120,NMEUHELRRBWEPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,5.017728766960431,8543,3296768,CC1=CN=C(N=C1)CNC2=NC(=NC(=C2)C3=CC=CC=C3)C4=CN=CC=C4,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3cccnc3)n2)nc1
CHEMBL3104486,NMIILRZYAIUZRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,8547,76335560,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
CHEMBL3104486,NMIILRZYAIUZRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,8547,76335560,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
CHEMBL3104486,NMIILRZYAIUZRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,8547,76335560,C1CN(CCN1C2=CN=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1
CHEMBL496605,NMKSBEVTNZMDAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,8550,24888487,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL496605,NMKSBEVTNZMDAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.318758762624412,8550,24888487,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL1094348,NMNJWRKGTYNGSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,5.1249387366083,8560,25192471,C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)C4=CC(=CC=C4)F)OCCCCCCC5=C(C(=CC=C5)OCCCC(=O)O)CCC(=O)O,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3cccc(F)c3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O
CHEMBL2419516,NMNMXZAMLXAEMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8561,71727932,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CN=C(C=C4)N)C=NC=C2,Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
CHEMBL2419516,NMNMXZAMLXAEMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8561,71727932,C1C2=C(CN1C(=O)NCC3=CC=C(C=C3)S(=O)(=O)C4=CN=C(C=C4)N)C=NC=C2,Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1
CHEMBL3401117,NMRFTYLCMLGDQK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8563,57869982,CN1C(=O)C=C(N=C1N2CCOC(C2)C3CCC3)C4=C(C=NC=C4)F,Cn1c(N2CCOC(C3CCC3)C2)nc(-c2ccncc2F)cc1=O
CHEMBL1923124,NMRNERYMRSVGHM-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.508638306165727,8564,57394344,C1CC1N(CC2=CC=NC3=CC=CC=C23)C(=O)C4CNCCC45C6=CC(=C(C=C6CO5)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1ccnc2ccccc12)C1CC1
CHEMBL1236924,NMRWDFUZLLQSBN-UHFFFAOYSA-N,INT131,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,8565,10229498,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl,O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl
CHEMBL3261407,NMWIJNGJMPMFQG-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755427.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8569,16666386,CC1=CC(=C(C(=C1)C)S(=O)(=O)NC(C)CNC2=C3C=NN(C3=CC=C2)C4=CC=C(C=C4)F)C,Cc1cc(C)c(S(=O)(=O)NC(C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1
CHEMBL1288260,NMWLWOOLJCZPEH-ZMBIFBSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.991399828238082,8570,52944940,CC1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)Cl)C(=O)N(C(=O)N3C)C)N.Cl,Cn1c(=O)c2c(cc(N3CCCC(C)(N)C3)n2Cc2cc(F)ccc2Cl)n(C)c1=O
CHEMBL1922933,NMYGSMGORGHTCL-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22030028.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,8573,54765285,CCCCCC(CC1=CC=C(C=C1)C(=O)NCCC(=O)O)C(=O)C2=CC3=C(N2C4=CC=CC(=C4)C(F)(F)F)C=CC(=C3)Cl,CCCCCC(Cc1ccc(C(=O)NCCC(=O)O)cc1)C(=O)c1cc2cc(Cl)ccc2n1-c1cccc(C(F)(F)F)c1
CHEMBL1098147,NNBCYIMUIAZCEX-ADSBAMQRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,8580,46888864,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC(=CC=C5)OC,COc1cccc(C2CCOP(=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1
CHEMBL1097507,NNBCYIMUIAZCEX-WWOZWPLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,8581,46888839,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC(=CC=C5)OC,COc1cccc(C2CCOP(=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1
CHEMBL2178804,NNGCTIVKZKXWGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.236572006437063,8584,58063117,CN1C=C(C(=N1)C2=C(C=CC(=C2)Cl)Cl)NC(=O)C3=C4N=C(C=CN4N=C3)N,Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cc(Cl)ccc2Cl)n1
CHEMBL593374,NNIFDNQGXRCFDV-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,8585,46226079,CC1=C2C=C(C=CC2=NN1)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=CNC6=CC=CC=C65)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c[nH]c3ccccc23)cc1-c1ccc2n[nH]c(C)c2c1
CHEMBL3702801,NNTFXIZLDBUGCH-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.763462738511306,8592,89718459,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9CCCC9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2035185,NNXDIGHYPZHXTR-ONEGZZNKSA-N,CT-1578,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,5.0,8596,16750271,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC=C(O4)C5=NC(=NC=C5)NC(=C3)C=C2,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC1
CHEMBL2035185,NNXDIGHYPZHXTR-ONEGZZNKSA-N,CT-1578,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by fluorescence detection assay,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,5.0,8596,16750271,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC=C(O4)C5=NC(=NC=C5)NC(=C3)C=C2,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC1
CHEMBL3112848,NNXWAJVWAVPAPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,8598,49854123,C1CN(C2=C1C(=CC=C2)F)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(F)cccc21
CHEMBL3114714,NODXVDNUTZZZMM-APGVRMINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.552841968657781,8602,59721310,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(=O)C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CC(=O)C(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL521223,NOMOVVSYFDZGOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,8613,25138092,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCC(CC4)O)C,CC(=O)Nc1cc(-c2cccc(N3CCC(O)CC3)n2)nc(-n2nc(C)cc2C)n1
CHEMBL3699340,NOOTYVQYKTUNKR-CXNSMIOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,8614,89718272,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=C(C=C8)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(C)C)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702805,NOQSZIDIAUSSBW-LFCBDPIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3290.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.482804102050026,8617,89718370,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)N9CCC9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2069801,NOTVTROJVYACLT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,=,14600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.835647144215563,8618,5299617,C1=CC=C(C=C1)S(=O)(=O)CC2=NOC(=N2)C(=O)NCC3=CC=NC=C3,O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1
CHEMBL284024,NOYHLVPSJIKFBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,42260.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.374070507283705,8623,10031184,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC(=NC4=C3NC5=C4C=C(C=C5[N+](=O)[O-])[N+](=O)[O-])CN6CCOCC6,O=[N+]([O-])c1cc([N+](=O)[O-])c2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1
CHEMBL2151821,NPAUEGMLUVJJFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,8624,49855166,C1COCCN1C2=CC(=O)N=C(N2)CC(=O)NC3=CC=C(C=C3)F,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)Nc1ccc(F)cc1
CHEMBL2151923,NPBHHSSAUGKQQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,8625,66882551,C1COCCN1C2=CC(=O)N=C(N2)CC(=O)NC3=CC(=CC=C3)Br,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)Nc1cccc(Br)c1
CHEMBL1910123,NPDHHSAKDZBURI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,8630,57390924,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCCC3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCCC1)C2=O
CHEMBL466624,NPGZZLCILZSYOC-KJUCIFOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,5.301029995663981,8632,25141776,CN(CC=CCN)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)F)O,CN(CC=CCN)CC1OC(n2cnc3c(N)ncnc32)C(F)C1O
CHEMBL443705,NPGZZLCILZSYOC-UNCBZGBMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,5.301029995663981,8633,25141777,CN(CC=CCN)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)F)O,CN(CC=CCN)CC1OC(n2cnc3c(N)ncnc32)C(F)C1O
CHEMBL3702754,NPJQSTPHYKZFBF-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2050.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.688246138944246,8639,89718340,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCC7=CN=C(C=C7)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccc(N(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1078892,NPKNHWRWDNDLPC-DYESRHJHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,8641,136164064,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(C5)N,Cc1cc(N2CCC(N)C2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1078991,NPKNHWRWDNDLPC-LAUBAEHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,>,4400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513812,8642,136164065,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(C5)N,Cc1cc(N2CCC(N)C2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL565390,NPLZSLFSOASJNF-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,8644,44473095,CC1=NC=C(C=C1)C(=O)NC(=NC2CCCCN(C2=O)CC(=O)N3CCCC3)NC4=CC5=C(C=C4)OC(=C5)C,Cc1ccc(C(=O)NC(=NC2CCCCN(CC(=O)N3CCCC3)C2=O)Nc2ccc3oc(C)cc3c2)cn1
CHEMBL197140,NPPAGUSXMQPYGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,27000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.568636235841013,8646,11582291,CC1(CC(CC(C1)(C)C)OC2=CC=C(C=C2)C3=C(C=C(C=C3)C4(CC4)C(=O)O)F)C,CC1(C)CC(Oc2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC(C)(C)C1
CHEMBL2178258,NPRMPQSNJGVJOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.173925197299173,8648,58063084,CC1=NC(=C(S1)NC(=O)C2=C3N=C(C=CN3N=C2)N)C4=CC(=CC=C4)Cl,Cc1nc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3ccc(N)nc23)s1
CHEMBL3298908,NPSUKLHLCCMRQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,8650,68234878,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)Cl,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1
CHEMBL498472,NPTCBAGFEZBWJN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3231.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.490663041982356,8651,25034657,C1CC(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)(C4=CC=NC=C4)O,OC1(c2ccncc2)CCc2cc(-c3ccc(F)cc3)ccc21
CHEMBL497480,NPTYKZWLTCILPL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,4199.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.37685412536206,8652,25033734,C1CC2=C(C=CC(=C2)C3=CC=C(C=C3)F)C(=C1)C4=CC=NC=C4.Cl,Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1
CHEMBL2057282,NQEXNUZFXBFSAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,5.0,8662,54576291,CCC1=C(C=CC=C1C2=NSC(=N2)C3=CC(=C(C=C3)OC(C)C)Cl)CCN4CCC(CC4)C(=O)O,CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(OC(C)C)c(Cl)c2)n1
CHEMBL1951612,NQNTUCLHZLYJJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,>=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8669,57402263,CC#CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=NC=CC5=CC=CC=C54)C,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C
CHEMBL364572,NQPPPAJKEZYMMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,6.3,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,8.200659450546418,8670,9827020,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC(=N3)C4=C(C=CC=C4F)F)C5=CC=CC=C5)N=C1N,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc(-c4c(F)cccc4F)[nH]c3-c3ccccc3)cc21
CHEMBL3640762,NQVNWLWVULSZAV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1590.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,5.798602875679548,8675,25817348,C1=CC(=CN=C1)C2=CC=C(S2)N,Nc1ccc(-c2cccnc2)s1
CHEMBL429836,NQXTWVRGKUFRQC-SVFBPWRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,8677,11597977,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCCC4CO,CCC1CCCC(C2(CC(=O)N3CCCC3CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL241271,NQYWUAZXGFMIIN-UHFFFAOYSA-N,SR-715,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,8678,16681732,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)O,O=C(C(O)c1ccc(Br)cc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL3628934,NRDAGRURPLJETJ-QVWGJOIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,8681,24881534,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)C(C)(C(C)C)NCC3=CC4=C(C=C3)N=CS4,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(C(C)(NCc2ccc3ncsc3c2)C(C)C)nn1
CHEMBL499589,NRLWTIIVKXPCSZ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,8687,44576657,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CSCC(=O)O)N,NC(Cn1c(=O)c(-c2ccc(CSCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL1092650,NRNPLYWFPSCQAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8688,46884698,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3OC,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(Cl)ccc21
CHEMBL557117,NROVVWMGTIZNGL-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,8689,45273637,CN(C1CCC2=C(C3=C(N2C1)C=CC=N3)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ncccc3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL1829761,NRQVLVGDMUNLPF-CCLHPLFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.958607314841775,8692,53473137,CC(C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CCC(OC3=O)(CCCO)C4=CC=CC=C4,CC(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CCCO)(c2ccccc2)OC1=O
CHEMBL577338,NRSWHXCLBQLBRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19831396.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.,J. Med. Chem.,PUBLICATION,,6.086186147616283,8693,25192477,C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)O)F,Oc1cccc(-c2ccc(-c3ccc(O)c(F)c3)s2)c1
CHEMBL2397347,NRWYEXCPHKZKIR-NOCBQHASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23932792.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,8696,71680760,CC1CN(CCN1C(=O)C23CC4CC(C2)CC(C4)C3)C5=C(N=CC=C5)C#N,CC1CN(c2cccnc2C#N)CCN1C(=O)C12CC3CC(CC(C3)C1)C2
CHEMBL1671921,NRYURYQHEDZXCQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,8698,3463042,CC(C)CC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,CC(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
CHEMBL509267,NSBUNJVFFBYJER-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,42000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.376750709602099,8700,44587398,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N(C)C)C4=C(C(=CC=C4)OCCCCC(=O)O)F,Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(CC(c2ccccc2)N(C)C)c(=O)n1Cc1c(F)cccc1C(F)(F)F
CHEMBL3127905,NSFZNVJVLSAVRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24428186.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione ��-Secretase Modulators.",J. Med. Chem.,PUBLICATION,,4.522878745280337,8702,68380152,CC1=CN(C=N1)C2=CC=C3C(=O)N(CCN3C2=O)CCOC4=C(C=C(C=C4)F)C(F)(F)F,Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(F)cc2C(F)(F)F)C3=O)cn1
CHEMBL3331506,NSLNAFLIDKTSFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,3640.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.438898616350944,8705,118713805,C1C(CN1)N(CC2=CC=C(C=C2)Cl)C3=CC=CC=C3F,Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1
CHEMBL3639728,NSMOZFXKTHCPTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320632,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,8706,52936034,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
CHEMBL3639728,NSMOZFXKTHCPTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320676,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,8706,52936034,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC(=C4)F)OC)F)N=C1,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
CHEMBL462624,NSOFETGRKBREDS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19260711.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,8709,25218744,C1=CN(C(=O)C(=C1)C(=O)NC2=CC(=C(C=C2)OC3=C(C(=NC=C3)N)Cl)F)C4=CC=C(C=C4)F,Nc1nccc(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)c1Cl
CHEMBL2332055,NSPKBHVNVJWICU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23570514.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8712,71304814,CC(C)(C)C(=O)NCCC1CCN(CC1)C2=NC=NC3=C2SC(=C3)C(=O)N,CC(C)(C)C(=O)NCCC1CCN(c2ncnc3cc(C(N)=O)sc23)CC1
CHEMBL3702728,NSRQJAWPJAFMQG-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5990.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.2225731776106885,8713,89718212,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CC(C7)N8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCOCC6)C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL513868,NTBRVXRWQHXTKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3872161432802645,8722,18440271,C1=CC(=CC(=C1)Cl)OC2=C3C(=CC(=C2)CC4=NNC(=O)C=C4)C=CO3,O=c1ccc(Cc2cc(Oc3cccc(Cl)c3)c3occc3c2)n[nH]1
CHEMBL1287846,NTIFEVGVXWYYHK-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074434.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,8726,10319351,COC1=CC=CC2=C1N(C=C2C(=O)N3CCN4CCCCC4C3)CC5CCCCC5,COc1cccc2c(C(=O)N3CCN4CCCCC4C3)cn(CC3CCCCC3)c12
CHEMBL118258,NTPLIHVIDFWRGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,8733,10005638,CN1CCC(CC1)(C2=CN(C(=N2)C3=CC(=CC=C3)C(F)(F)F)C4=NC(=NC=C4)NC5CCCC5)O,CN1CCC(O)(c2cn(-c3ccnc(NC4CCCC4)n3)c(-c3cccc(C(F)(F)F)c3)n2)CC1
CHEMBL2043324,NTUAWRQDBAVJLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8737,49849007,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)F,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4F)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL375812,NTVBAWSNQRKVKF-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17274610.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.0,8739,16110489,C1CCC2=C(C1)N=C(S2)C3=CC=C(C=C3)OCCCOC4=CC5=C(C=C4)C(CC5)CC(=O)O,O=C(O)CC1CCc2cc(OCCCOc3ccc(-c4nc5c(s4)CCCC5)cc3)ccc21
CHEMBL3407821,NTYRNOKRWWTRNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,6.045757490560675,8742,118730382,CC1=CN=CN1C2=NC=CC(=N2)CCNCCCC3=CC(=CC=C3)F.Cl,Cc1cncn1-c1nccc(CCNCCCc2cccc(F)c2)n1
CHEMBL236732,NUALMFMLNXDIHK-AZGAKELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,8743,44433263,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,CC(C)CC(N)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3702708,NUBFJAZVCPPPLP-HNNLUAMWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6600.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.180456064458132,8744,89718425,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN8CCCC8C7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCCC6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2165509,NUEWJDROHKEDES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,7.0,8746,60165513,CC1=CC2=C(C=CC=C2N1)C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6)C(C)(C)C(=O)N,Cc1cc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc2[nH]1
CHEMBL3401116,NUIXEUAEKRDSJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8750,57869881,CCCCC1CN(CCO1)C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F,CCCCC1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1
CHEMBL3261425,NUUMMLYSKRRLTQ-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755427.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,8761,57690900,CC1=C(C(=NN1C2CCCC2)C)S(=O)(=O)NC(C)CNC3=C4C=NN(C4=CC=C3)C5=CN=C(C=C5)F,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)NC(C)CNc1cccc2c1cnn2-c1ccc(F)nc1
CHEMBL496426,NUUQKRDJXWZEIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,8762,24890348,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CO4,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12
CHEMBL496426,NUUQKRDJXWZEIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,8762,24890348,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CC=CO4,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12
CHEMBL205692,NUWCFGTWEDHTKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,8763,11502217,C1CN(CCC1NC(=O)CC2=CC=CC=C2)CC3=CC(=CC=C3)OC4=CC=CC=C4,O=C(Cc1ccccc1)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
CHEMBL240889,NVABFHSNHQWIJY-IBGZPJMESA-N,SR-1452,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,8766,16662114,C1CN(CCC1NC2=CC3=C(C=C2)NN=C3)C(=O)C(CC4=CC=CC=C4)N,NC(Cc1ccccc1)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
CHEMBL1921982,NVALCPKQWJAPMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,8767,9923132,CCNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,CCNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL2420676,NVDJGCDUAXDWHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,=,1262.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.898940645091884,8768,71817945,C1=CC(=CN=C1)C2=C(C3=C(C=CC(=C3)O)C=C2)F,Oc1ccc2ccc(-c3cccnc3)c(F)c2c1
CHEMBL2425958,NVEBAMFLYZFKKW-CSKARUKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23905680.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,5.187086643357144,8769,71811225,CC1=NC2=C(C=CC(=C2)C=CC(=O)NO)C(=O)N1CCC3=CC=CC=C3,Cc1nc2cc(C=CC(=O)NO)ccc2c(=O)n1CCc1ccccc1
CHEMBL2448693,NVHVFITXPIZHCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.698970004336019,8775,17020121,C1=CC=C(C=C1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4C(=O)N3CC5=CN=CC=C5,O=c1c2ccccc2nc(-c2ccc(-c3ccccc3)cc2)n1Cc1cccnc1
CHEMBL2386079,NVIBILUEGHHNNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8776,11653874,C1CN(CC2=C1N(C3=CC=CC=C23)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc3ccccc13)CC2
CHEMBL253660,NVLCLKSNVBSVHX-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,8780,44447282,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1OC(F)(F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1OC(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL2181896,NVMABPBDYKXNKD-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.522878745280337,8781,71457467,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C#C)NC(=O)COC)O,C#Cc1cccc(CC(NC(=O)COC)C(O)CNC2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1
CHEMBL2436626,NVORSIAIADQRIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,8787,44622342,C1CN(CCC1N2CCNC3=CC=CC=C3C2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCNc5ccccc5C4)CC3)CC2)ccn1
CHEMBL2035186,NVQBQWBWTJVBDD-ONEGZZNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22339472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,PUBLICATION,,5.0,8789,16750304,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CO4)C5=NC(=NC=C5)NC(=C3)C=C2,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC1
CHEMBL2420675,NVRWXGKJXOBEQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.0,8790,71817944,COC1=CC2=C(C=C1)C=CC(=C2F)C3=CN=CC=C3,COc1ccc2ccc(-c3cccnc3)c(F)c2c1
CHEMBL453246,NVTYARUVRYHLSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,8792,24890346,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=N4,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12
CHEMBL453246,NVTYARUVRYHLSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,8792,24890346,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=N4,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12
CHEMBL2058904,NVWBTVGTFCSKEI-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,52.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.2839966563652006,8793,59603310,CC1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,Cc1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL430724,NWGCADAPGOPMCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,17850.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.748361779551788,8807,11304370,CN1C2=C(C=NC=C2)C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,Cn1c2ccncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL3092419,NWLPPUYKURFGOD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,8813,72545105,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC4=NC=NN4C=C3)F,CC(=O)NCC1CN(c2ccc(-c3ccn4ncnc4c3)c(F)c2)C(=O)O1
CHEMBL3112854,NWRXYTMCKVBTKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,8816,57389550,C1CN(C2=C1C(=CC=C2)OC(F)(F)F)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(OC(F)(F)F)cccc21
CHEMBL3114728,NXFTYHPDFHJIBT-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1840.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.735182176990463,8826,76321485,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)N2CCC(CC2)NC(=O)OCC3=CN=CS3,CC(C)c1nc(CN(C)C(=O)NC(C(=O)N2CCC(NC(=O)OCc3cncs3)CC2)C(C)C)cs1
CHEMBL1671922,NXJOSCHYVJGECZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,8832,11771503,CC(C)(C)CC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,CC(C)(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
CHEMBL256195,NXJWRSVRPJAYKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,8833,11620477,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OCC(C)N)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(N)COc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
CHEMBL1209016,NXOJBDCDDRAJDO-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,8837,49862127,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCN6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1209016,NXOJBDCDDRAJDO-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,8837,49862127,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCN6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL2070149,NXOWVMXRWKZXSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.42021640338319,8838,70695119,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3Cl)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3Cl)[nH]c2c1
CHEMBL1087758,NXPLYKRKIFPEOA-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,56.23,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as ratio of IC50 at 0 mins to IC50 at 10 mins using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.250031916490597,8841,9833312,CC1CC1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C,Cc1c(C)n(CC2CC2C)c2c(OCc3ccc(F)cc3)nncc12
CHEMBL1087758,NXPLYKRKIFPEOA-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,8841,9833312,CC1CC1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C,Cc1c(C)n(CC2CC2C)c2c(OCc3ccc(F)cc3)nncc12
CHEMBL1087758,NXPLYKRKIFPEOA-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,8841,9833312,CC1CC1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C,Cc1c(C)n(CC2CC2C)c2c(OCc3ccc(F)cc3)nncc12
CHEMBL1276678,NXWASIVXQMMPLM-ZXMXYHOLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,8843,16126898,CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC,CNC(CNC(=O)N1CCCC(C(OCCNC(=O)OC)c2cccc(Cl)c2)C1)CC1CCCOC1
CHEMBL2041186,NYAAHHZTIZKYSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,8845,57387540,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4C)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3nccnc3C)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
CHEMBL1916224,NYDGEZQQIMDHCY-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21930376.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Development of a highly selective, orally bioavailable and CNS penetrant M(1) agonist derived from the MLPCN probe ML071.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,8846,57391102,CCOC(=O)N1CCC(CC1)N2CCCC(C2)NC(=O)C3=CC=CC=C3C,CCOC(=O)N1CCC(N2CCCC(NC(=O)c3ccccc3C)C2)CC1
CHEMBL3673935,NYJZMHUFDZQMKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320638,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,8849,52936253,COC1=C(C=C(C=N1)F)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1
CHEMBL3673935,NYJZMHUFDZQMKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320682,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,8849,52936253,COC1=C(C=C(C=N1)F)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1
CHEMBL564920,NYOPRXQTXYICBQ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,8853,45272700,CN(C1CCC2=C(C1)N3C=CC=CC3=C2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccccn3c2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL3702813,NYWLSHWADDPCKK-YMJVKMAGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2560.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.59176003468815,8857,89718268,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CC(C8)N9CCC(CC9)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCC(OC)CC7)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1277126,NYWUAMYWDNANQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,8859,49836637,C1CC2(CC1N3CCC(=CC3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1
CHEMBL3353347,NZBZBQUHFXSFOR-VXPCJWDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,5.0,8866,58486197,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=CC=CC=C6NC5=O,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C4CC45C(=O)Nc4ccccc45)ccc23)cc1
CHEMBL3353347,NZBZBQUHFXSFOR-VXPCJWDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.301029995663981,8866,58486197,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=CC=CC=C6NC5=O,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C4CC45C(=O)Nc4ccccc45)ccc23)cc1
CHEMBL3353347,NZBZBQUHFXSFOR-VXPCJWDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.0,8866,58486197,CN(C)CC1=CC=C(C=C1)C=CC2=NNC3=C2C=CC(=C3)C4CC45C6=CC=CC=C6NC5=O,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C4CC45C(=O)Nc4ccccc45)ccc23)cc1
CHEMBL2165500,NZLCSWCXKHCYFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,8883,60165805,CCC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6)S(=O)(=O)C,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1
CHEMBL16596,NZOONKHCNQFYCI-UHFFFAOYSA-N,QUIFLAPON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,5.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,8.236572006437063,8888,60923,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12
CHEMBL16596,NZOONKHCNQFYCI-UHFFFAOYSA-N,QUIFLAPON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19914828.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,8888,60923,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12
CHEMBL270361,NZSRSKNDCCSSGY-KAVGSWPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,64900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.187755303199631,8892,5470829,COC1=C(C=CC(=C1)C=C2CCC(=CC3=CC(=C(C=C3)O)OC)C2=O)O,COc1cc(C=C2CCC(=Cc3ccc(O)c(OC)c3)C2=O)ccc1O
CHEMBL270361,NZSRSKNDCCSSGY-KAVGSWPWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,64863443.35,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,1.188000000032298,8892,5470829,COC1=C(C=CC(=C1)C=C2CCC(=CC3=CC(=C(C=C3)O)OC)C2=O)O,COc1cc(C=C2CCC(=Cc3ccc(O)c(OC)c3)C2=O)ccc1O
CHEMBL253968,NZUICIGFUCOURS-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18294849.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8894,44447872,C1CC(N(C1)CCCOC2=CC3=CN=NC(=C3C=C2)NC4=CN(N=C4)CC(=O)NC5=C(C(=CC=C5)F)F)CO,O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCCC4CO)ccc23)cn1)Nc1cccc(F)c1F
CHEMBL2409710,NZWCKNGEMCPIOP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,8898,59794447,CC1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=CC=C(C=C3)C(F)(F)F,CC1(CS(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)NC(=O)NC1=O
CHEMBL522211,NZZBOICLIUBLLK-MJGOQNOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8901,44583290,C1CC2(CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4)OC5=C1N=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC2(CCc3ncccc3O2)CC1
CHEMBL3422241,OAFBAMRSEZLVDJ-CKMNQQOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,8909,72547070,CC1C2CC(OCC2(N=C(S1)N)C3=C(C=C(C=C3)F)F)C4=NC(=CO4)C,Cc1coc(C2CC3C(C)SC(N)=NC3(c3ccc(F)cc3F)CO2)n1
CHEMBL3408526,OAMJWPLGTPOCHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,8913,118730940,CCOC1(C2=NOC(=O)N2C3=CC=CC=C3S1)C4=CC=C(C=C4)Br,CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O
CHEMBL3408526,OAMJWPLGTPOCHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,8913,118730940,CCOC1(C2=NOC(=O)N2C3=CC=CC=C3S1)C4=CC=C(C=C4)Br,CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O
CHEMBL3582478,OAMLIJKKGZLNHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,8914,56645363,CC(C)(C1=CN=CC(=C1)C2=NC3=C(N2C4CC4)C=C(C=C3)F)O,CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1
CHEMBL1910115,OAPPTAHHCBBEDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,8917,57394441,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(N)=O)C2=O
CHEMBL389608,OAQMOBFXPMYRII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,8918,44425802,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CN=CC=C5)N(C2=O)CC6=CC=CC=C6F,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccnc5)cc4)CC3)C2=O)c1
CHEMBL3357391,OAYGNQGEUIFBFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25499880.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,8923,46852212,CC(C)(C)CC1=NC2=C(N1CCN(C)C)C=CC(=C2)S(=O)(=O)C3CN(C3)CCO,CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CCO)C3)ccc21
CHEMBL1671971,OBBIOCQFTMNSJI-PXNMLYILSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.0,8926,46916268,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C#N)C(F)(F)F,COc1cc(C=C2SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F
CHEMBL387552,OBBPMZQSYHHZLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.886056647693163,8927,11432169,C1CC(CN(C1)C2=NC3=C(C=CC=C3Cl)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2c(Cl)cccc2c1=O
CHEMBL1643512,OBKCQTGBMZHBFE-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,8932,53321979,C1CN(C2=CC=CC=C2C1N)C3=CC(=C(C=C3)Cl)Cl,NC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
CHEMBL579200,OBMNRUUTVNRXAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,8934,45484967,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=C(C(=C3)OC)OC)OC,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1OC
CHEMBL3120505,OBULGMCFXOTNNK-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,5.0,8940,66731056,CCC1=CC2=C(C=C1F)C(=C(N2C3=NC=CC=N3)C4=NC=C(C=C4)S(=O)(=O)NC(C)C(F)(F)F)C#N,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)NC(C)C(F)(F)F)cn1)n2-c1ncccn1
CHEMBL80702,OBXLXUGOZZWQOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,6.221848749616356,8943,1267,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CCNC1C2=O)C#N,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O
CHEMBL80702,OBXLXUGOZZWQOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.221848749616356,8943,1267,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CCNC1C2=O)C#N,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O
CHEMBL3702717,OBYFMRYTDUFAQC-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.303643611266668,8944,89718259,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)C(=O)N(C)CCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)N(C)CCN(C)C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1269683,OBZVMSKEVPNTKM-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,8945,52940639,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCC(=O)NC)Cl)C5CC5)Cl,CNC(=O)CCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269683,OBZVMSKEVPNTKM-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,8945,52940639,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCC(=O)NC)Cl)C5CC5)Cl,CNC(=O)CCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL277535,OCAPBUJLXMYKEJ-UHFFFAOYSA-N,BIFONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,800.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,6.096910013008056,8947,2378,C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1
CHEMBL3128180,OCDCTMROVJZCQS-FBHSLPMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,=,41800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ��3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,4.3788237182249645,8950,76322044,CC1=NC2=C(S1)CCC2C(=O)NC3=CC=C(C=C3)CC4CCC(N4)C(C5=CN=CC=C5)O,Cc1nc2c(s1)CCC2C(=O)Nc1ccc(CC2CCC(C(O)c3cccnc3)N2)cc1
CHEMBL2048061,OCEZDSXYNMWVGV-AZOIQLNYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,5.036212172654444,8954,57384272,C1C(C(C(CS1(=O)=O)NCC2=CC(=CC=C2)OC(F)(F)F)O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,Nc1c(F)cc(CC2CS(=O)(=O)CC(NCc3cccc(OC(F)(F)F)c3)C2O)cc1OC(C(F)(F)F)C(F)(F)F
CHEMBL3325526,OCGIYHGXHMLCPX-UKRRQHHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25176194.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,8957,71557630,C1CNCC(C1C2=CC=C(C=C2)Cl)COC3=CC(=C(C=C3F)S(=O)(=O)NC4=NC=NS4)F,O=S(=O)(Nc1ncns1)c1cc(F)c(OCC2CNCCC2c2ccc(Cl)cc2)cc1F
CHEMBL2059123,OCHINVHFVKJXGW-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,92.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.036212172654444,8960,59603328,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCN(CC5)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCN(C)CC3)oc2c1
CHEMBL3236362,OCIDJOZAAORGQC-RRYSNUMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,6.154901959985743,8961,90655378,CCC(CS(=O)(=O)C(C)(C)C)N1C(C(CC(C1=O)(C)CC(=O)CO)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,CCC(CS(=O)(=O)C(C)(C)C)N1C(=O)C(C)(CC(=O)CO)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
CHEMBL281326,OCIIEYOWWOUETK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,18480.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.733298033115912,8962,11214464,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)NCC6=CC=CC=N6,Cn1c2ccnc(NCc3ccccn3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL600058,OCJFISAERVJZBG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153655.0,IC50,=,97000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.,Bioorg. Med. Chem.,PUBLICATION,,4.013228265733755,8964,24178219,CC1=CC2=C(C=C1C)N(C(=N2)NCCCOC)CC(=O)C3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,COCCCNc1nc2cc(C)c(C)cc2n1CC(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
CHEMBL1214447,OCJKHBCJMIOPJS-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,8965,46900138,CC1=NC=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)cn1
CHEMBL1214397,OCJKHBCJMIOPJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,8966,11688520,CC1=NC=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)cn1
CHEMBL3408192,OCKDTDFLJPUWIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25680029.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.",J. Med. Chem.,PUBLICATION,,5.6777807052660805,8969,91928421,C1CNC(=O)C12CCN(CC2)C3=C(C=NC=C3C4=CC=C(C=C4)N5CCOCC5)Cl,O=C1NCCC12CCN(c1c(Cl)cncc1-c1ccc(N3CCOCC3)cc1)CC2
CHEMBL2425161,OCMTUPKQSOGIPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,8975,72190133,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=C(C=C4)OCC5=CC=CC=C5,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1
CHEMBL482088,OCNLJCSEDBMGNF-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.9,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.045757490560675,8976,135960713,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)OCCOC,COCCOC1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL1214739,OCQPVXWUPNNJIV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,1140.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,5.943095148663527,8979,46901929,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC4=C(C=C3)C=C(C=C4)O,Oc1ccc2cc(-c3ccc(Cc4ccncc4)cc3)ccc2c1
CHEMBL271624,OCSFKRCNTJAHRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.552841968657781,8983,936091,CCN1C(=NN=C1SCC2=CC=C(C=C2)OC)C3=CC=NC=C3,CCn1c(SCc2ccc(OC)cc2)nnc1-c1ccncc1
CHEMBL3702694,OCZUEDNFZLWPEY-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.0400051616715835,8987,89718287,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCOC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCOC)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1485,ODKSFYDXXFIFQN-BYPYZUCNSA-N,ARGININE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,8997,6322,C(CC(C(=O)O)N)CN=C(N)N,NC(N)=NCCCC(N)C(=O)O
CHEMBL1485,ODKSFYDXXFIFQN-BYPYZUCNSA-N,ARGININE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,8997,6322,C(CC(C(=O)O)N)CN=C(N)N,NC(N)=NCCCC(N)C(=O)O
CHEMBL2181897,ODTHBEGKDAPUFY-HZFUHODCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.522878745280337,9007,71450309,CC#CC1=CC=CC(=C1)CC(C(CNC2CC3(CCC3)OC4=C2C=C(C=N4)CC(C)(C)C)O)NC(=O)COC,CC#Cc1cccc(CC(NC(=O)COC)C(O)CNC2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1
CHEMBL476762,ODVRVGNZEWQPJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9010,44578954,C1=CC=C(C=C1)CC(=O)NCC(=O)NC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(Cc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL452808,ODYPAHVIPOBHBB-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602099,9013,44561236,CN(C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
CHEMBL453075,ODYPAHVIPOBHBB-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040958607678906,9014,44561197,CN(C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
CHEMBL453074,ODYPAHVIPOBHBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,9015,44561196,CN(C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
CHEMBL495882,OEBZYYGQPIDGKZ-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,9022,44576642,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CO)N,NC(Cn1c(=O)c(-c2ccc(CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL2018915,OEFRKYNZBGSTRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,>,80.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,7.096910013008056,9025,4384047,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=C3,COc1ccc2nc(SCc3ccccc3)[nH]c2c1
CHEMBL1209015,OENQIJZSDDCZNC-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,9028,49862126,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCN6CCOCC6)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL2331689,OESWUISVDCHYDK-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.481486060122113,9032,59239077,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC(=NC=C4)C)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(c2ccnc(C)n2)C3)cc1
CHEMBL2336411,OEUDGDKDYOXFHU-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,9033,71569533,CC1=CC(=CC2=NNN=C12)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2n[nH]nc12
CHEMBL2336411,OEUDGDKDYOXFHU-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,9033,71569533,CC1=CC(=CC2=NNN=C12)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2n[nH]nc12
CHEMBL2181618,OEYHZQYPYDAJBL-QGOAFFKASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.200659450546418,9037,71450284,CN1C2=C(C=CC(=C2)C(=O)NC3(CCCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=CC=CC=N5)C6CCCC6,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCCC3)cc21
CHEMBL3359272,OEYYOVRNPJSWTO-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25423411.0,IC50,=,10100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM).",J. Med. Chem.,PUBLICATION,,4.995678626217358,9039,101891769,CC(C)N1CCCC1CNC(=O)C2=CN(C(=O)C3=C2C4=CC=CC=C4N3C)C5CCCC5,CC(C)N1CCCC1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C
CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,9044,2094,C1=C2C(=NC=NC2=O)NN1,O=c1ncnc2[nH][nH]cc1-2
CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,9044,2094,C1=C2C(=NC=NC2=O)NN1,O=c1ncnc2[nH][nH]cc1-2
CHEMBL2425602,OFDBSOZDYKJEFG-CAALGAHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,9046,72191661,CC(C)(C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F)O,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(C(C)(C)O)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL179763,OFDVABAUFQJWEZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,64700.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.189095719331299,9047,68487,C1=CC(=CN=C1)C2=CN=CC=C2,c1cncc(-c2cccnc2)c1
CHEMBL522196,OFEDZXBACHVRIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,9048,24864825,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
CHEMBL522196,OFEDZXBACHVRIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9048,24864825,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
CHEMBL391914,OFNOTFBPXMBPPC-AZGAKELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,9056,44433262,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,CC(C)CC(N)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL519761,OFWDHNGVKNRLFY-LHZKXVGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,14400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.841637507904751,9069,11364979,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)OC(=O)C)OC(=O)C,CC(=O)OC1C(C)OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(OC(C)=O)C1OC(C)=O
CHEMBL399512,OGFXBIXJCWAUCH-KPHUOKFYSA-N,ISOLARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.0,9077,160521,COC1=C(C=C2C(C(C(CC2=C1)CO)CO)C3=CC(=C(C=C3)O)OC)O,COc1cc(C2c3cc(O)c(OC)cc3CC(CO)C2CO)ccc1O
CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,9081,4539,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
CHEMBL1784355,OGLLJVIOQHNPQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,9082,54585926,C1CC(C1)(CS(=O)(=O)N2CCN(CC2)C3=CC=C(C=C3)F)N(C=O)O,O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCC1
CHEMBL1669416,OGQADGYHVAQLNE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1405.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.8523236757589014,9089,53317595,C1CN(CC1(F)F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,FC1(F)CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
CHEMBL3087348,OGQIHASBDUUYTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,9090,72547022,C1=COC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2ccco2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL3236365,OGTCBKWJBDPSAX-PAHOUZJPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,6.301029995663981,9092,90655380,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CS(=O)(=O)N,CC1(CS(N)(=O)=O)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL1669409,OGTGPRXXTIEASF-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9093,53317594,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC#N,CC(C1=C(CCN(C)CC#N)Cc2ccccc21)c1cnccn1
CHEMBL395426,OHOPDRRPSWGLIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9115,44440645,C1C(C(CN1C2=NC=NC(=C2)C3=CSC=C3)N)C4=CC(=C(C=C4F)F)F,NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F
CHEMBL1643789,OHOXPFJGCQEEJL-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9116,53317718,C1CC2=C(C3=CC=CC=C3N2CC1N(CC4=CC=C(C=C4)F)S(=O)(=O)C5=CC=C(C=C5)F)CC(=O)O,O=C(O)Cc1c2n(c3ccccc13)CC(N(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(F)cc1)CC2
CHEMBL440964,OIEZHHIBUVJWBU-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.167491087293763,9126,136007966,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC(CC4=CC=CC=C4)CO)C5=CC=C(C=C5)OC,COc1ccc(-c2cc(C)c3nc(-c4c(NC(CO)Cc5ccccc5)cc[nH]c4=O)[nH]c3c2)cc1
CHEMBL3640785,OIFZZHGYNVANQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,400000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.3979400086720375,9127,91097699,C1=CC(=CN=C1)C2=CC=C(O2)CN=O,O=NCc1ccc(-c2cccnc2)o1
CHEMBL519549,OIGKTTFTKCPYQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.795880017344075,9129,25138083,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)OC)C3=CC(=CN=C3)OC)C,COC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1
CHEMBL1171786,OIGUMNDUYFBXEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9131,49798349,C1=CC=C(C(=C1)C(=O)O)OC2=C(C=C(C=C2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,O=C(O)c1ccccc1Oc1ccc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
CHEMBL209350,OIZAFWVARZBXFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,9140,11519336,CCN1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5OC,CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4OC)c3)CC2)(c2ccccc2)CC1
CHEMBL2069844,OJEKLVGMWTUETI-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,9150,11854301,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)C(=O)O,NC(CC(=O)N1CCN(C(=O)c2ccc(C(=O)O)cc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL1778387,OJEQIOOQKHUSKG-CRAIPNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9152,53248845,CC(C1=CC=C(C=C1)F)C(=O)N(C)C2CCC3=C(C4=CC=CC=C4N3C2)CC(=O)O,CC(C(=O)N(C)C1CCc2c(CC(=O)O)c3ccccc3n2C1)c1ccc(F)cc1
CHEMBL3104525,OJFZYAQGMWSUID-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.769551078621726,9154,76313856,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL3104526,OJFZYAQGMWSUID-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.823908740944319,9155,71720882,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.795880017344075,9156,76310149,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1200.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,5.920818753952375,9156,76310149,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7400.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,5.130768280269024,9156,76310149,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL3104376,OJFZYAQGMWSUID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,9156,76310149,C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1
CHEMBL3298910,OJICYBSWSZGRFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.0,9157,68234908,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1
CHEMBL398584,OJPCZEDCYHLAEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.0655015487564325,9163,23647886,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL3326580,OJPHAHBZLDUZLU-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,9164,25263542,CCCC1(CC(C2=C(O1)C(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CCC,CCCC1(CCC)CC(NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1
CHEMBL2418359,OJVHRVLPSCDXSQ-CALCHBBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23932792.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9172,72163837,C1CCC2(C1)CCN(C2)C(=O)N3CC4CN(CC4C3)C5=CC=CC=N5,O=C(N1CC2CN(c3ccccn3)CC2C1)N1CCC2(CCCC2)C1
CHEMBL502908,OKAPKQMESLLPQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18855374.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,PUBLICATION,,5.6777807052660805,9176,21257907,C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC(=CC=C3)O,Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1
CHEMBL205345,OKAUHDJQKYCWBT-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,14.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321762,9177,11422288,COCCCN1C(=O)COC2=C1C=C(C=C2)SCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COCCCN1C(=O)COc2ccc(SCC3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21
CHEMBL2437429,OKCJFCOBXGHPBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9179,10347896,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=CC(=C(C=C5)F)F)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccc(F)c(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL2448699,OKEDBMJLEWWRHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.698970004336019,9180,73349660,C1=CC=C(C=C1)C2=NC=C(C=N2)C(=O)NC3=C(C=CC(=C3)C#N)N4C=CN=C4,N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
CHEMBL3099819,OKFARBMRDHCVLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.769551078621726,9182,72725671,CC1=CC=C(C=C1)C(C2=NN=NN2C(C)(C)C)NCCNC3=C4C=CC(=CC4=NC=C3)Cl,Cc1ccc(C(NCCNc2ccnc3cc(Cl)ccc23)c2nnnn2C(C)(C)C)cc1
CHEMBL453384,OKGGBPZMSDNNFA-UHFFFAOYSA-N,TCMDC-135909,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Activation of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,4.0,9184,9820134,CC(C)(C)NCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)F,CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1F
CHEMBL337301,OKGPFTLYBPQBIX-CQSZACIVSA-N,BMS-377806,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,9186,507771,CC1CN(CCN1C(=O)C(=O)C2=CN=C3C2=C(C=CN3)OC)C(=O)C4=CC=CC=C4,COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3C)c1-2
CHEMBL337301,OKGPFTLYBPQBIX-CQSZACIVSA-N,BMS-377806,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,9186,507771,CC1CN(CCN1C(=O)C(=O)C2=CN=C3C2=C(C=CN3)OC)C(=O)C4=CC=CC=C4,COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3C)c1-2
CHEMBL605360,OKHVXBABEFQOCR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,9187,44819193,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NC3=CC=C(C=C3)CO)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC
CHEMBL3128194,OKIOQHRDFOXEBF-DZCCDHAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,=,86000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ��3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,4.0655015487564325,9188,76336500,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=C3N=C(S4)N)C(C5=CC=CC=C5)O,Nc1nc2c(s1)CCC2C(=O)Nc1ccc(CC2CCC(C(O)c3ccccc3)N2)cc1
CHEMBL321051,OKLABFVDVTVNBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9190,10130685,CCCCCCC1=CC=C(C=C1)N=CNO,CCCCCCc1ccc(N=CNO)cc1
CHEMBL29743,OKLXZLLQLHWOGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,5780.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.2380721615794705,9191,11249529,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=C4C(=CC=C5)[N+](=O)[O-])CC6=CC=NC=C6,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1
CHEMBL2058902,OKOGYZXIHINVRK-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,9192,62706976,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NC5CCN(CC5)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NC3CCN(C)CC3)oc2c1
CHEMBL3288755,OKQVIDODFGYTAX-IFPLKCGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24842618.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.,Bioorg. Med. Chem.,PUBLICATION,,4.958607314841775,9193,53468206,CCN1C(=O)CN(C1=O)C2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,CCN1C(=O)CN(c2ccc(Cc3cc(C4OC(CO)C(O)C(O)C4O)ccc3Cl)cc2)C1=O
CHEMBL2435858,OKRZBWWJVVVKHT-PMERELPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,4.585026652029182,9195,58834953,CC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)N)CN3CCC(CC3)N4C(CN(C4=O)C5CCOCC5)C6=CC=CC=C6,Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)CC2c2ccccc2)CC1
CHEMBL2165317,OKZQWDIOWQYOGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861193.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of hepatic CYP3A4,Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,J. Med. Chem.,PUBLICATION,,4.045757490560675,9197,62707515,CCOC1=C(C=C2CCC(=O)N(C2=C1)C)C3=CN=CC=C3,CCOc1cc2c(cc1-c1cccnc1)CCC(=O)N2C
CHEMBL1917464,OLADFXRHWWGOMN-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21944855.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H(3) receptor antagonists with robust wake-promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9198,44539973,CC1CCCN1CCC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C,CC1CCCN1CCc1ccc(-c2ccc(=O)n(C)n2)cc1
CHEMBL521724,OLCABARHEDJPQC-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,9202,44583648,CC1=C(N2C=C(C=C(C2=N1)NC3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,Cc1nc2c(NC3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
CHEMBL521724,OLCABARHEDJPQC-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,86000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0655015487564325,9202,44583648,CC1=C(N2C=C(C=C(C2=N1)NC3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,Cc1nc2c(NC3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
CHEMBL496402,OLCABARHEDJPQC-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,9203,44583647,CC1=C(N2C=C(C=C(C2=N1)NC3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,Cc1nc2c(NC3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
CHEMBL496402,OLCABARHEDJPQC-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,9203,44583647,CC1=C(N2C=C(C=C(C2=N1)NC3CCC4=CC=CC=C34)N5C=CC=CC5=O)C,Cc1nc2c(NC3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C
CHEMBL1209686,OLDDAHJZTORONS-ONTIZHBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20598880.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP1A2,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,9205,46911229,CCC(C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCCC3)NC(=O)C4C(CCN4)O,CCC(NC(=O)C1NCCC1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1
CHEMBL3393063,OLIKAINVOFFOAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,9209,118725453,C1=CC=C(C(=C1)C#N)OC2=CC=C(C=C2)C(=O)NCC3=NC=NC=C3,N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncn2)cc1
CHEMBL601031,OLJMSYJNZOXIEK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20074949.0,IC50,>=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,9211,46232545,CC(C)N1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)C(=O)O)C(=C2C4=COC=C4)C5CCCCC5,CC(C)N1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1
CHEMBL1327969,OLJPUMGNYIOTFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23867602.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Lead identification of novel and selective TYK2 inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,5.327902142064283,9212,3120536,C1=CC(=C(C(=C1)Cl)C(=O)NC2=CC=NC=C2)Cl,O=C(Nc1ccncc1)c1c(Cl)cccc1Cl
CHEMBL3629743,OLJWGKMQUSBBIA-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.698970004336019,9213,76283682,C1CC2(CCN(C2)S(=O)(=O)C(F)(F)F)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=S(=O)(c1ccc(Cl)cc1)C12CCCC3(CCN(S(=O)(=O)C(F)(F)F)C3)C1COc1c(F)ccc(F)c12
CHEMBL3629743,OLJWGKMQUSBBIA-BWAGFHJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.522878745280337,9213,76283682,C1CC2(CCN(C2)S(=O)(=O)C(F)(F)F)C3COC4=C(C=CC(=C4C3(C1)S(=O)(=O)C5=CC=C(C=C5)Cl)F)F,O=S(=O)(c1ccc(Cl)cc1)C12CCCC3(CCN(S(=O)(=O)C(F)(F)F)C3)C1COc1c(F)ccc(F)c12
CHEMBL213743,OLLCPXMBOYVHAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16759855.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9214,44414347,CN1CCN(CC1)CC2=CC3=C(CC4=C3NN=C4C5=CSC=C5)C=C2,CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1
CHEMBL236521,OLLQZYNQBYGVCQ-IGYGKHONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,9215,24740655,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)C(CC(C)C)NC(=O)CCN(C)C,Cc1ccc(N2CCN(C(=O)C(Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c(C(CC(C)C)NC(=O)CCN(C)C)c1
CHEMBL1668243,OLLRSJLKNAIFCJ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,9216,53319654,C1CCC(CC1)C(C(=O)NC2=C(C=C(C=C2)C(=O)O)Cl)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,O=C(O)c1ccc(NC(=O)C(C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1
CHEMBL496288,OLPCUEGEMPLTMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,1093.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.961379838050298,9220,25033806,C1CC2=C(C1C3=CC=NC=C3)C=CC(=C2)C4=CC=C(C=C4)F.Cl,Fc1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1
CHEMBL3673958,OLQODSJHRJYJIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320627,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,9221,52933794,COC1=C2C(=CNC2=NC=C1)CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F,COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12
CHEMBL3673958,OLQODSJHRJYJIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320671,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,9221,52933794,COC1=C2C(=CNC2=NC=C1)CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F,COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12
CHEMBL2018917,OLVGVEZGCNJPGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,8340.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.078833949362261,9225,56953898,CC(C)C1=CC=C(C=C1)CSC2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc(SCc3ccc(C(C)C)cc3)[nH]c2c1
CHEMBL2165506,OLVSLQHNMMFQPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,6.292429823902063,9227,57506726,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=CC(=C4)F)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(F)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL2041174,OLZGEKRJAPMKEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,9232,57384239,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC7=C(C=C6)N=CN7,COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL455126,OMBSMQLLFJMMRZ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18701276.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Highly functionalized 7-azaindoles as selective PPAR gamma modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9234,44561816,CC1=C(C2=C(N1CC3=CC(=CC=C3)OC(C)C(=O)O)N=CC=C2)C(=O)C4=CC=C(C=C4)OC,COc1ccc(C(=O)c2c(C)n(Cc3cccc(OC(C)C(=O)O)c3)c3ncccc23)cc1
CHEMBL249087,OMDLVUGUASZVGG-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,9238,24779751,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5=CC(=CC(=C5)F)F,CC(C)(CO)N1CCN(C(=O)OC2(C3CCCC(c4cc(F)cc(F)c4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL482089,OMEGCBMNQDIBMF-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,9240,135960714,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)OCCO,Cc1cc(N2CCC(OCCO)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3092417,OMGYQMYQUBRDBB-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,9243,44596160,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC4=NC=CN4C=C3)F,CC(=O)NCC1CN(c2ccc(-c3ccn4ccnc4c3)c(F)c2)C(=O)O1
CHEMBL2181880,OMMVFRZSBCRMQD-LJYZBVLISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.301029995663981,9250,56940718,CC(C(=O)NC(CC1=CC2=C(C=C1)OCO2)C(CNC3CC4(CCC4)OC5=C3C=C(C=N5)CC(C)(C)C)O)OC,COC(C)C(=O)NC(Cc1ccc2c(c1)OCO2)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL499442,OMNLHFZYIBOWOH-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,9252,44587401,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCCNCC(=O)O)F,CNC(Cn1c(=O)c(-c2cccc(OCCCNCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL2385901,OMXKUEXZCQUFSZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,9262,68503758,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)CC4=CC=CC5=CC=CC=C54,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1cccc3ccccc13)CC2
CHEMBL2057522,ONFQJVPTMPUNDQ-XZWHSSHBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029182,9267,59603319,C1CCC(CC1)CN(CC(C(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)O)C(=O)C4=CC5=C(C=C4)N=C(O5)N6CCCC6,O=C(NC(Cc1ccccc1)C(O)CN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
CHEMBL3321846,ONHFEABHFHNJOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585026652029182,9270,91758806,CN1CCN(C2=CC=CC=C21)C(=O)C3=C(NC(=O)N=C3)OC4=C(C=CC(=C4)Cl)Cl,CN1CCN(C(=O)c2cnc(=O)[nH]c2Oc2cc(Cl)ccc2Cl)c2ccccc21
CHEMBL520229,ONJXHXVTYOPVIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.698970004336019,9273,25069914,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CCOCC4)C,CC(=O)Nc1cc(-c2cccc(N3CCOCC3)n2)nc(-n2nc(C)cc2C)n1
CHEMBL3673965,ONKIUNVOKOYXEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320634,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,9274,52936036,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)OC)N=C1,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1
CHEMBL3673965,ONKIUNVOKOYXEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320678,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,9274,52936036,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)OC)N=C1,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1
CHEMBL2375371,ONNNBBBPFLLYHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23545108.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,9277,71602807,C1=CC=C(C=C1)OC2=CC(=C(C=C2)NS(=O)(=O)C3=C(C=C(C=C3)Br)F)C(=O)O,O=C(O)c1cc(Oc2ccccc2)ccc1NS(=O)(=O)c1ccc(Br)cc1F
CHEMBL349638,ONPNRCWCFNPMNG-BKLRJVBYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,9278,44380394,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)C(C)CNCCC6=CC7=C(C=C6)N=C(N7)C)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2C(C)CNCCc2ccc3nc(C)[nH]c3c2)c1
CHEMBL512127,ONRDKYMCESZKKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,9279,44593549,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=CC=CC=C3S(=O)(=O)C,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O
CHEMBL393363,ONRGYKGRPVMXIR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.920818753952375,9280,23647889,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC(=CC=C4)C(F)(F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2
CHEMBL1089866,ONVFZPXWBQZKQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20218619.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.795880017344075,9281,25119991,CCN1C2=C(C=C(C1=O)C3=C(C=CC(=C3)C(=O)NC4CC4)C)C=NN2C5=C(C=C(C=C5)F)F,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2cnn(-c3ccc(F)cc3F)c21
CHEMBL565361,ONWYPTYCJIAWIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.431798275933005,9284,45484949,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC(=CC=C3)OC,COc1cccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)c1
CHEMBL436817,ONXROKMQGCSOMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,5.045757490560675,9286,17759555,C1=CC(=C(C=C1NC2=C3C=C(C=C(C3=NC=C2C#N)Cl)NCC4=CN=CN4)Cl)F,N#Cc1cnc2c(Cl)cc(NCc3cnc[nH]3)cc2c1Nc1ccc(F)c(Cl)c1
CHEMBL2146750,ONYWALXTZFPKAS-XHCCPWGMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,35000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.455931955649724,9289,53493001,CC1CCN(CC1)C(C2=CC=C(C=C2)F)C3=C(C=C(C=C3)C(C)C(=O)O)C4=CC=C(C=C4)C(F)(F)F,CC1CCN(C(c2ccc(F)cc2)c2ccc(C(C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1
CHEMBL2048492,OODHRJXTEITBEQ-JQGGBATGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,36600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.436518914605589,9293,11553111,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OCC)C3CC(C(C(C3O)O)O)CO,CCOc1ccc(Cc2ccc(CC)cc2)cc1C1CC(CO)C(O)C(O)C1O
CHEMBL2048492,OODHRJXTEITBEQ-JQGGBATGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,9293,11553111,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OCC)C3CC(C(C(C3O)O)O)CO,CCOc1ccc(Cc2ccc(CC)cc2)cc1C1CC(CO)C(O)C(O)C1O
CHEMBL219060,OOIJMSVOEKAGEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,9300,9797385,C1CN(CCC1CNC2=CC=NC=C2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2ccncc2)CC1
CHEMBL1077334,OOLQOYHCEMONID-XNTDXEJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20185309.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9302,6479956,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)NC4(CCCC4)C(=O)NC5=CC=C(C=C5)C=CC(=O)O)N=C2C6=COC=C6,O=C(O)C=Cc1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1
CHEMBL2425604,OOOLZCKPVRMIHJ-QKDGCWAWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,9304,72191977,COCC(C(F)(F)F)OC1=C(C(=CC(=C1)CC2CS(=O)CC(C2O)NCC3=CC(=CC=C3)OC(F)(F)F)F)N,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(OC(F)(F)F)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL261592,OOQXPATWSOGSAV-UHFFFAOYSA-N,BMS-645737,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18395443.0,IC50,=,11500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.939302159646388,9307,22273644,CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)C)C(C)C,Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1
CHEMBL495993,OORIVESIQGRNJV-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9308,44583288,C1CN(CCC12CC(=O)C3=C(O2)C=CC=N3)C(=O)NC4CC4C5=CC=CC=C5,O=C1CC2(CCN(C(=O)NC3CC3c3ccccc3)CC2)Oc2cccnc21
CHEMBL460491,OOSUDWRRWZVFEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19053768.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,J. Med. Chem.,PUBLICATION,,5.0,9309,25147749,CC1(CN2C(=CSC2=N1)CSC(=NC3CCCCC3)NC4CCCCC4)C,CC1(C)CN2C(CSC(=NC3CCCCC3)NC3CCCCC3)=CSC2=N1
CHEMBL390642,OOXSSXPKHGFWIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9315,23647908,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCC(=O)OC)C=C2,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)OC)CCC2
CHEMBL193247,OPHKHUCQAYSHKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,4.886056647693163,9318,11366072,CS(=O)(=O)O.CS(=O)(=O)O.C1CCC(C1)S(=O)(=O)N2C3=C(C=CC(=C3)C4=C(NC(=N4)C5=C(C=CC=C5F)F)C6=CC=CC=C6)N=C2N,Nc1nc2ccc(-c3nc(-c4c(F)cccc4F)[nH]c3-c3ccccc3)cc2n1S(=O)(=O)C1CCCC1
CHEMBL230043,OPICGPYWGONRDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,9319,135681832,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NCCCN5,Cc1cc(C2=NCCCN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL216884,OPIYGGWYEOSIPY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17107790.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,9320,11617038,C1=CC=C(C=C1)CNCC2=CN=C(C=C2)C3=CC=C(S3)C(=O)NO,O=C(NO)c1ccc(-c2ccc(CNCc3ccccc3)cn2)s1
CHEMBL487765,OPNAWTWHKNBYIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,43000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.366531544420414,9323,25138072,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC=CC=C3)C,CC(=O)Nc1cc(-c2ccccc2)nc(-n2nc(C)cc2C)n1
CHEMBL3264595,OPPFLHFMEGQSGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,9326,90656803,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CC=NN3)O,COc1cc2ccc(C(O)(c3ccn[nH]3)C(C)C)cc2cc1OC
CHEMBL2448733,OPTBYDHXCQHIPH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,9331,73346619,CCN(CC1=CN=CC=C1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,CCN(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F
CHEMBL1272045,OPVSCKBPGHIATG-UPSGKMMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,3.2,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.494850021680094,9333,11599126,C1CC1CC2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CC6CC5CN6CCO,O=C(OC1(C2COCC(CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CC1CN2CCO
CHEMBL230964,OPZCLJWDQNPUHB-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,6.522878745280337,9339,11705008,C1C(OC(=O)N1C2=CC(=C(C=C2)C3=CN=C(C=C3)C(=O)CN4C=CN=C4)F)CN5C=CN=N5,O=C(Cn1ccnc1)c1ccc(-c2ccc(N3CC(Cn4ccnn4)OC3=O)cc2F)cn1
CHEMBL482101,OQEBLEZRSCIFJK-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.7,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,9345,135960715,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC6(CC5)OCCO6,Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL482101,OQEBLEZRSCIFJK-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,9345,135960715,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC6(CC5)OCCO6,Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1682899,OQFYRLCZKWVBHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.443697499232713,9346,18769059,CC1=CC2=C(C=CC(=C2)C(C3=CN=CN3)(C(C)C)O)C=C1C(=O)NC,CNC(=O)c1cc2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2cc1C
CHEMBL465948,OQGNJLWZKFTRPB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,9347,44570412,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CS(=O)(=O)C4=CC=CC=C4,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)CC(C)N1
CHEMBL465948,OQGNJLWZKFTRPB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,9347,44570412,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CS(=O)(=O)C4=CC=CC=C4,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)CC(C)N1
CHEMBL86932,OQHPRXYGKQHOKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,9349,23395801,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL25105,OQLKNTOKMBVBKV-UHFFFAOYSA-N,HEXAMIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,9351,65130,C1=CC(=CC=C1C(=N)N)OCCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1
CHEMBL25105,OQLKNTOKMBVBKV-UHFFFAOYSA-N,HEXAMIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,9351,65130,C1=CC(=CC=C1C(=N)N)OCCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1
CHEMBL270368,OQLQJPJMZFAIDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.119186407719209,9352,11548497,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OCC4CCNCC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(OCC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL1669415,OQSOOFROGDVPSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,3871.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.412176828681045,9360,53326725,C1C2=CC=CC=C2C(=C1CCN3CC(C3)(F)F)CC4=NC=CN=C4,FC1(F)CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
CHEMBL25948,OQWKEEOHDMUXEO-BQYQJAHWSA-N,SHOGAOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,77700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.1095789811990855,9362,5281794,CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC,CCCCCC=CC(=O)CCc1ccc(O)c(OC)c1
CHEMBL3408955,OQYLKJLEFFUOSP-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.795880017344075,9363,56959991,CC1CN(CC(N1CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O)C)C,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5C(C)CN(C)CC5C)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3408955,OQYLKJLEFFUOSP-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.0,9363,56959991,CC1CN(CC(N1CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O)C)C,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5C(C)CN(C)CC5C)cc4)n[nH]c3c1)C(=O)N2
CHEMBL2448745,OQYZVVJUKASDLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,9364,73352683,CS(=O)(=O)N(CC1=CN=CN1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2ccc(F)cc2)cc1F
CHEMBL2043328,OQZGBAAWFMGASB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,9365,57387030,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)N6CCC6=O,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(N3CCC3=O)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL276140,OQZOXHCRSXYSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9357513.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human Cytochrome P450 3A at 100 uM,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,PUBLICATION,,4.0,9366,443389,CSC1=C(C=C2C(=C1)CCN2C(=O)NC3=CN=CC=C3)C(F)(F)F,CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2
CHEMBL276140,OQZOXHCRSXYSPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,4.0,9366,443389,CSC1=C(C=C2C(=C1)CCN2C(=O)NC3=CN=CC=C3)C(F)(F)F,CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2
CHEMBL2364618,ORDHXXHTBUZRCN-NTEUORMPSA-N,MAVATREP,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25850459.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).,J. Med. Chem.,PUBLICATION,,4.6020599913279625,9371,17751090,CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)C=CC4=CC=C(C=C4)C(F)(F)F)O,CC(C)(O)c1ccccc1-c1ccc2nc(C=Cc3ccc(C(F)(F)F)cc3)[nH]c2c1
CHEMBL3218857,ORFGUEWOGJKLFU-XOSANVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,9372,89726151,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)C4=NC5=NC=C(C(=C5N4)NC6C7CC(C6C(=O)N)C=C7)Cl)OC,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3218857,ORFGUEWOGJKLFU-XOSANVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,9372,89726151,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)C4=NC5=NC=C(C(=C5N4)NC6C7CC(C6C(=O)N)C=C7)Cl)OC,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL1271520,ORJWZBKFHYBQDC-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9377,52943305,C1CN2CCC1C(C2)NC(=O)C3=C4C(=CC=C3)OC(=N4)N5CCOCC5,O=C(NC1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12
CHEMBL3287851,ORLPPUHANSFJCS-VHSXEESVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900876.0,IC50,>,20000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,PUBLICATION,,1.6989700043360187,9378,46938101,CC(C)(C)CC1CC(CCN1)C2=CC(=O)NO2,CC(C)(C)CC1CC(c2cc(=O)[nH]o2)CCN1
CHEMBL247609,ORRRWUZIONHTFN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,9384,44443131,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=C(C5=C(C=C4)OCC(=O)N5C)F,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4F)N(C)C(=O)CO5)CC3)cccc2n1
CHEMBL610795,ORUPHFRKUPILCN-IOASZLSFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,9385,45379947,C1CC1COCC2C3C2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(C23CNCC2C3COCC2CC2)cc1Cl
CHEMBL3699335,ORURZZOCXOQQIN-QCDYIZFSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,9386,89718306,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NN8CCN(CC8)C9=CC=CC=N9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(c7ccccn7)CC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL395573,ORVPEVIDEJOHIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17715908.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.,J. Med. Chem.,PUBLICATION,,4.7447274948966935,9389,17759787,C1=CC=[N+](C(=C1)CNC2=CC3=C(C(=CN=C3C(=C2)Cl)C#N)NC4=CC(=C(C=C4)F)Cl)[O-],N#Cc1cnc2c(Cl)cc(NCc3cccc[n+]3[O-])cc2c1Nc1ccc(F)c(Cl)c1
CHEMBL3325460,ORYICUWIPUTJGI-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,9392,46191427,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4)C(F)(F)F)(C)C)C=N1,Cc1cc2c(NC(=O)NC3CC(C)(C)Oc4cc(C(F)(F)F)ccc43)cccc2cn1
CHEMBL1208958,ORZOCBRCPCCQDN-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,9393,49862090,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1208958,ORZOCBRCPCCQDN-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,9393,49862090,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL446545,OSJROQUTACPGAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18662879.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery of piperidine carboxamide TRPV1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.431798275933005,9408,11719337,C1CN(CCC1C(=O)NC2=CC3=C(C=C2)OC(C(=O)N3)CCO)C4=CC(=C(C(=C4)F)F)F,O=C(Nc1ccc2c(c1)NC(=O)C(CCO)O2)C1CCN(c2cc(F)c(F)c(F)c2)CC1
CHEMBL283438,OSTWYWCXYVRVGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1360.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.866461091629782,9418,10320818,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3NC5=CC=CC(=C54)C(=O)N,NC(=O)c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12
CHEMBL2178251,OSUIVZWZMLHYTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,9419,70497007,CN1C=C(C(=N1)NC(=O)C2=C3N=CC=CN3N=C2)C4=CC(=CC=C4)Cl,Cn1cc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3cccnc23)n1
CHEMBL3298431,OSVVWQSAPRHYFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,9425,90645312,C1=CC(=CC=C1OC2=NC=NC3=C2C=CN3)F,Fc1ccc(Oc2ncnc3[nH]ccc23)cc1
CHEMBL510171,OSZOMNDRPGGELA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,9431,24889676,CC1=C(N2C=C(C=C(C2=N1)NC3CCC4=CC=CC=C34)N5C=NC=N5)C,Cc1nc2c(NC3CCc4ccccc43)cc(-n3cncn3)cn2c1C
CHEMBL510171,OSZOMNDRPGGELA-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,9431,24889676,CC1=C(N2C=C(C=C(C2=N1)NC3CCC4=CC=CC=C34)N5C=NC=N5)C,Cc1nc2c(NC3CCc4ccccc43)cc(-n3cncn3)cn2c1C
CHEMBL1829764,OTARHPTVFRBZQX-XRHLQHRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.522878745280337,9432,53473139,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCCO)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCCO)(c2ccc(F)cc2)OC1=O
CHEMBL2059515,OTAYFQWOFJKZFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,5.0,9434,49848139,CCC1=C(C=CC=C1C2=NOC(=N2)C3=CC(=C(C=C3)OC(C)C)C#N)CCCC(=O)O,CCc1c(CCCC(=O)O)cccc1-c1noc(-c2ccc(OC(C)C)c(C#N)c2)n1
CHEMBL331186,OTDBMSDSGGUFDP-GSFCIGPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.455931955649724,9437,471510,CCC1=NC=C(S1)COC(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CN3CCN(CC3C(=O)NC(C)(C)C)CC4=CC(=C(C=C4)OC)OC)O,CCc1ncc(COC(=O)NC(C(=O)NC(Cc2ccccc2)C(O)CN2CCN(Cc3ccc(OC)c(OC)c3)CC2C(=O)NC(C)(C)C)C(C)C)s1
CHEMBL3699337,OTFUCMLNWGKDEZ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,9440,89718189,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)C8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccccc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3422013,OTGOCKFNIHTQCV-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.0,9442,118735354,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C(F)(F)F,CC1c2nnc(-c3csc(C(F)(F)F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1
CHEMBL1643783,OTGREDPOEXITQK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9443,53325908,CN(C1CCC2=C(C3=C(N2C1)C(=CC=C3)F)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3cccc(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL1081867,OTKZOEOQKWTXMD-GHTZIAJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,9450,11397017,CN1C(=NN=C1SCCCN2CC3CC3(C2)C4=CC=C(C=C4)C(F)(F)F)C5=CN=NC=C5,Cn1c(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1
CHEMBL1684058,OTPNHPXNYRVULV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21310612.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,9452,53326909,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C.Cl,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
CHEMBL230686,OTTCBLPTHPBEEX-UHFFFAOYSA-N,TG-100435,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17113292.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.207608310501746,9454,11562302,CC1=CC(=CC2=C1N=C(N=N2)NC3=CC=C(C=C3)OCCN4CCCC4)C5=C(C=CC=C5Cl)Cl,Cc1cc(-c2c(Cl)cccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
CHEMBL2409564,OTWNXWHEBKCAMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810496.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9455,71812623,C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)NC(=O)C5=C(OC(=N5)C6=CC=CC=C6)C(F)(F)F,O=C(O)CC1CCC(c2ccc(-c3nc4ccc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)cc4[nH]3)cc2)CC1
CHEMBL3291345,OUANOAMFFAKLPS-XIKOKIGWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,22600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.645891560852599,9460,57941404,CC1(C2CCC1(C3=C2C(=O)N(N3C)C4=CC=CC=C4C(F)(F)F)C)C,Cn1c2c(c(=O)n1-c1ccccc1C(F)(F)F)C1CCC2(C)C1(C)C
CHEMBL2436945,OUAYPLUHINPFJL-MWLCHTKSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24042009.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9461,72700776,CCC1=NC2=C(C=CNC2=O)C(=N1)NC3CCCC3C#N,CCc1nc(NC2CCCC2C#N)c2cc[nH]c(=O)c2n1
CHEMBL179529,OUEHWWLIEPNPDR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,5.200659450546418,9465,44388719,CNC1=CC=C(S1)C2=CN=CC=C2,CNc1ccc(-c2cccnc2)s1
CHEMBL1272072,OUENCNZMGZDHGX-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9466,24178536,C1CC1C2=NC3=C(C=CC=C3O2)C(=O)NC4CN5CCC4CC5,O=C(NC1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12
CHEMBL1950087,OUEWVUKWTPRXNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,9468,57391166,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)[nH]nc3nc12
CHEMBL1950087,OUEWVUKWTPRXNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.913640169325252,9468,57391166,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)Cl,Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)[nH]nc3nc12
CHEMBL1951322,OUJNTZAPROXXHI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,9471,57402330,C1=CC=C(C(=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4)Cl,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1ccccc1Cl
CHEMBL2036757,OULRKKBJQGZFKL-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22608963.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,9476,57656715,C1CC(CN(C1)C2CC2)CN3CCN(CC3)C(=O)NC4=CC(=C(C=C4)Cl)Cl,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(CC2CCCN(C3CC3)C2)CC1
CHEMBL1761849,OULYTLMMUGPJHL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11��-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9478,54580341,CN1C=C(C=N1)C2CCN(CC2)C(=O)N3CCCC4=CC=CC=C43,Cn1cc(C2CCN(C(=O)N3CCCc4ccccc43)CC2)cn1
CHEMBL311561,OUQYWOOMZNKZCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.214670164989233,9480,44317319,C1CN2CC3=C(C=CC(=C3)OC4=C(C=CC(=C4)CN5C=NC=C5CNC1C2=O)C#N)Br,N#Cc1ccc2cc1Oc1ccc(Br)c(c1)CN1CCC(NCc3cncn3C2)C1=O
CHEMBL1784346,OUTUIYKUSHWASL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9482,54586894,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCC(CC3)(F)F)N(C=O)O,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCC(F)(F)CC2)CC1
CHEMBL2018918,OUXJOASRGMYGSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,12300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.910094888560602,9488,780263,CC(C)(C)C1=CC=C(C=C1)CSC2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc(SCc3ccc(C(C)(C)C)cc3)[nH]c2c1
CHEMBL3640016,OUYYYTDFXFTOMC-AIQPRDSRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.130768280269024,9491,89718356,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CC=C(C=C7)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(CCO)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL682,OVCDSSHSILBFBN-UHFFFAOYSA-N,AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,9495,2165,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1935601,OVDCCBDDPCBOAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153937.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel brain penetrant benzofuropiperidine 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9497,53327611,C1CC2(COC1)C3=C(CCN2)C4=C(O3)C=C(C=C4)S(=O)(=O)C5=CC=CC(=C5)F,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3
CHEMBL3358931,OVDGYTOZNODCOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.698970004336019,9498,58026153,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=C(C=CC(=C3)F)OC,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F
CHEMBL1760428,OVHGVXGIHHVKIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21414782.0,IC50,>,3162.28,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,9505,52918121,CCCCN(C1=CC=CC(=C1Cl)C2=CC=C(C=C2)C(F)(F)F)S(=O)(=O)C3=C(C(=C(C=C3)OC(C)C(=O)O)C)C,CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C
CHEMBL150653,OVHOEGWGUASELU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,9506,11322128,CCCCOC1=CC=C(C=C1)C2=CC=CC=N2,CCCCOc1ccc(-c2ccccn2)cc1
CHEMBL2070141,OVLFWNCKGOPFPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,9512,70684601,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=C(C=C3)C4=CC=CC=C4,CCCS(=O)(=O)c1ccc2nc(-c3ccc(-c4ccccc4)cc3)[nH]c2c1
CHEMBL1209842,OVNJVYZXVSMONK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,9513,49862783,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1209842,OVNJVYZXVSMONK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,9513,49862783,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1223259,OVNVZWSCIAIPJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,9514,46898063,CC(C)(C)C1=NN=C(S1)C2=NN(C(=C2CN3C=NC=N3)C4=CC=C(C=C4)Br)C5=CC=CC=C5Cl,CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1
CHEMBL1092767,OVTUKEYYZWXZMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9519,11623845,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=NC=CS3,CC(c1nccs1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1765101,OVYVQHHATBRNQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.698970004336019,9523,9949067,CC(C)C(C1=CC=CC(=C1)C2=CC=C(C=C2)OC)(C3=CN=CN3)O,COc1ccc(-c2cccc(C(O)(c3cnc[nH]3)C(C)C)c2)cc1
CHEMBL3121804,OWCPJSPQYMOCLB-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,5.0,9527,66735487,CCC1=CC2=C(C=C1F)C(=C(N2C3=NC=C(C=N3)F)C4=NC=C(C=C4)S(=O)(=O)NC(C)C(F)(F)F)C#N,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)NC(C)C(F)(F)F)cn1)n2-c1ncc(F)cn1
CHEMBL1437764,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CLIMBAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,100.0,NM,,,,binding,,,,,,,,,,,,,,,,7.0,9531,37907,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1
CHEMBL1437764,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CLIMBAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,100.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,7.0,9531,37907,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1
CHEMBL1437764,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CLIMBAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,47500.0,NM,,,,binding,,,,,,,,,,,,,,,,4.323306390375134,9531,37907,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1
CHEMBL3291127,OWLSZODKAZOOLP-PLQLVBBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,44.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,7.35261702988538,9537,90644506,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)N)C,C=CC1(C)CC(OC(=O)CSc2cncc(N)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291127,OWLSZODKAZOOLP-PLQLVBBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,6.8696662315049934,9537,90644506,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)N)C,C=CC1(C)CC(OC(=O)CSc2cncc(N)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL1092663,OWMBYQVIMDTSAW-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9538,46884699,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)C(C)C3=NC=CN=C3,Cc1ccc2c(c1)CC(CCN(C)C)=C2C(C)c1cnccn1
CHEMBL1208959,OWRZQDDNDUUITK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,9543,49862091,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL1208959,OWRZQDDNDUUITK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,9543,49862091,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL3114723,OWSUPSVMUSHQHC-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23746300.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,,,,,,4.823908740944319,9544,71571541,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NCCCCNC(=O)OCC2=CN=CS2,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL3114723,OWSUPSVMUSHQHC-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.060480747381382,9544,71571541,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NCCCCNC(=O)OCC2=CN=CS2,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL2181891,OWSUWCSVFOZIGR-HZFUHODCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.301029995663981,9545,71459342,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=NC=CN5C)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2nccn2C)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL2017269,OWUQUQCSBQATFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,9547,57339435,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4C(C)(C)C)C(=O)O,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1
CHEMBL2017269,OWUQUQCSBQATFQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,9547,57339435,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4C(C)(C)C)C(=O)O,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1
CHEMBL3109801,OWWOVESWHWBLEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,9550,72792633,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCF)N=C1,COc1ncnc(Cn2cc(C(=O)NCCF)c3ncc(C)cc32)c1C
CHEMBL205862,OWYKGJWNYSCISK-NLFFAJNJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,1010.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.995678626217358,9552,44411109,CCN(CC)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCC3)C(=O)O)N4C=CN=C4,CCN(CC)C(C)C(c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1
CHEMBL1765107,OWYXGQALIALHJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21413798.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.,J. Med. Chem.,PUBLICATION,,5.698970004336019,9553,52937251,C1=CC=C(C=C1)NC(=O)C2=NC(=CN=C2N)C3=CN=CC=C3,Nc1ncc(-c2cccnc2)nc1C(=O)Nc1ccccc1
CHEMBL2059516,OXGQQGFOOMMLIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22500954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).",J. Med. Chem.,PUBLICATION,,5.0,9559,49848656,CCC1=C(C=CC=C1C2=NN=C(S2)C3=CC(=C(C=C3)OC(C)C)C#N)CCCC(=O)O,CCc1c(CCCC(=O)O)cccc1-c1nnc(-c2ccc(OC(C)C)c(C#N)c2)s1
CHEMBL218583,OXHYIGFIYVMDLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17201408.0,IC50,=,55000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.,J. Med. Chem.,PUBLICATION,,4.259637310505756,9561,16099923,C1=CC=C(C=C1)C2=CC=CC3=C(C(=C(N=C32)C4=CC=C(C=C4)Cl)O)C(=O)O,O=C(O)c1c(O)c(-c2ccc(Cl)cc2)nc2c(-c3ccccc3)cccc12
CHEMBL3358952,OXLAICHJWSSTJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.698970004336019,9566,118723178,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC4=C3S(=O)(=O)CC4,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1cccc2c1S(=O)(=O)CC2
CHEMBL3358946,OXRSLCFSOLYHEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.522878745280337,9569,44543969,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=C(C=C(C=C3)F)C(=O)N,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1C(N)=O
CHEMBL2448711,OXXAKVXIIVFFEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.853871964321762,9576,73351199,C1CC1C(=O)N(CC2=CN=CC=C2)C3=CC=CC(=C3)C4=NC5=CC=CC=C5S4,O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
CHEMBL476360,OYAZNQWKGGEAGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9579,24897002,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CSC=C3,O=C(CNC(=O)c1ccsc1)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL1766173,OYDIXDAQFNMWOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.309803919971486,9581,12043371,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)OC)(C3=CN=CN3)O,COc1ccc(-c2ccc(C(O)(c3cnc[nH]3)C(C)C)cc2)cc1
CHEMBL456379,OYFRXCWZMBHNHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18855374.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,PUBLICATION,,6.096910013008056,9583,25093374,C1=CC(=CC(=C1)O)C2=CN=C(S2)C3=CC(=CC=C3)O,Oc1cccc(-c2cnc(-c3cccc(O)c3)s2)c1
CHEMBL227954,OYNURZXTLNNKAP-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,5.698970004336019,9592,23647311,C1CC(CN(C1)C2=NC3=CC=CC=C3C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2ccccc2c1=O
CHEMBL3128178,OYURTPRHVJSKRC-DZCCDHAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ��3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,4.0,9597,76322043,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=C3N=CS4)C(C5=CN=CC=C5)O,O=C(Nc1ccc(CC2CCC(C(O)c3cccnc3)N2)cc1)C1CCc2scnc21
CHEMBL3128178,OYURTPRHVJSKRC-DZCCDHAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,4.0,9597,76322043,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=C3N=CS4)C(C5=CN=CC=C5)O,O=C(Nc1ccc(CC2CCC(C(O)c3cccnc3)N2)cc1)C1CCc2scnc21
CHEMBL601821,OYZYVBKQMLQLPM-UHFFFAOYSA-N,GNF-PF-5069,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21644570.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,PUBLICATION,,5.0,9599,45488686,C1CN2C(=NC(=C2NC3=CC4=C(C=C3)OCO4)C5=CC=CC=C5)CN1C(=O)CN,NCC(=O)N1CCn2c(nc(-c3ccccc3)c2Nc2ccc3c(c2)OCO3)C1
CHEMBL2448719,OZACJYWNJRCVMB-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.698970004336019,9600,73354178,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CC=C(S3)C4=CC=CC=N4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccn3)s2)c1
CHEMBL2436208,OZBOMLNKMBJQDW-QDMMYLPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.991399828238082,9601,72711718,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=CC=CC=C43)OC)C(=O)C5=CC=C(C=C5)N)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccc(N)cc2)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O
CHEMBL3609819,OZBPEBNJOSXIBE-SKYBXZRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1'-hydroxylation by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,9602,46203897,CC(C)C(=O)OC1(CC2CCCC1C3=CC=CC=C23)CCN(C)CCCC4=NC5=C(N4)C=CC=C5OC,COc1cccc2[nH]c(CCCN(C)CCC3(OC(=O)C(C)C)CC4CCCC3c3ccccc34)nc12
CHEMBL3609819,OZBPEBNJOSXIBE-SKYBXZRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,9602,46203897,CC(C)C(=O)OC1(CC2CCCC1C3=CC=CC=C23)CCN(C)CCCC4=NC5=C(N4)C=CC=C5OC,COc1cccc2[nH]c(CCCN(C)CCC3(OC(=O)C(C)C)CC4CCCC3c3ccccc34)nc12
CHEMBL3609819,OZBPEBNJOSXIBE-SKYBXZRDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26231163.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.468521082957745,9602,46203897,CC(C)C(=O)OC1(CC2CCCC1C3=CC=CC=C23)CCN(C)CCCC4=NC5=C(N4)C=CC=C5OC,COc1cccc2[nH]c(CCCN(C)CCC3(OC(=O)C(C)C)CC4CCCC3c3ccccc34)nc12
CHEMBL1916704,OZCSUWJJBCTGGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9604,44159411,CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)OC,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OC
CHEMBL2017097,OZFKVMALEJNYGS-ODXCJYRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,9607,46932048,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=C(C(=CC=C4)Cl)Cl)Br,OC1(c2ccc(F)c(F)c2)CCNCC1c1onc(-c2cccc(Cl)c2Cl)c1Br
CHEMBL1615153,OZGKPOZAIWDSQB-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,9610,49837870,C1CCC(CC1)C(C(=O)NC2=CC=C(C=C2)C(=O)O)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,O=C(O)c1ccc(NC(=O)C(C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1
CHEMBL3125375,OZIKWNBSDOTXBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,9613,57411836,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC(=C2)F,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
CHEMBL3702820,OZOANGRWDJQHKF-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3850.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.414539270491499,9615,89718499,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)OC)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2048060,OZOLBCYZUXLXMZ-WVBUVRCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,6.154901959985743,9616,44624240,CC1(C2=C(CO1)C=CC(=C2)CNC3CS(=O)(=O)CC(C3O)CC4=CC(=C(C(=C4)F)N)OC(C(F)(F)F)C(F)(F)F)C,CC1(C)OCc2ccc(CNC3CS(=O)(=O)CC(Cc4cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c4)C3O)cc21
CHEMBL1921985,OZPFIJIOIVJZMN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,9618,10335364,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL1921976,OZPFIJIOIVJZMN-SFHVURJKSA-N,ORTERONEL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,9619,9796590,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL1921976,OZPFIJIOIVJZMN-SFHVURJKSA-N,ORTERONEL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human B-lymphoblastoid cell microsomal CYP3A4 assessed as testosterone 6beta-hydroxylation preincubated for 5 mins with substrate,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,9619,9796590,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL1921977,OZPFIJIOIVJZMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,9620,9883029,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O,CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,2999.16,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.523000364762793,9627,31101,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]c(Br)c(c56)CC4N(C)C3)(C(C)C)C(=O)N12
CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.698970004336019,9627,31101,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]c(Br)c(c56)CC4N(C)C3)(C(C)C)C(=O)N12
CHEMBL1910126,OZVWHEGOMPUFMZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,9629,57403171,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)NCC3=CN=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)NCc1cccnc1)C2=O
CHEMBL362489,OZXGHWIQASWJQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1835.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7363639314118915,9630,11406760,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)N)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C(N)=O)ccc2c1)n1ccnc1)N(C)C
CHEMBL2064331,OZYPJCFRMNJWPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,9631,49853718,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(N3)C=C(C=C4)F,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3ccc(F)cc3[nH]2)n1
CHEMBL292759,OZYPUQNRUYTZDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9925723.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM),"5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.",J. Med. Chem.,PUBLICATION,,5.221848749616356,9632,6918647,CN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)Br)OC,COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1
CHEMBL218468,OZYYOJGDGOAPBJ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.301029995663981,9633,16102853,CC(C)CN1C2=C(C(=C(S2)CC3=C4C=C(C=CC4=NC=C3)F)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3ccnc4ccc(F)cc34)sc21
CHEMBL245585,PAEWYHLNDGOPKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9635,44440659,C1C(C(CN1C2=NC=NC(=C2)C3=CC(=CC=C3)C(=O)O)N)C4=CC(=C(C=C4F)F)F,NC1CN(c2cc(-c3cccc(C(=O)O)c3)ncn2)CC1c1cc(F)c(F)cc1F
CHEMBL1949693,PARCWEQRCVIVGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,9645,57391609,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=C(C=NC5=CC=CC=C54)C#N)C)C,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C
CHEMBL1825096,PARUULGUCQEWNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9646,53308640,CS(=O)(=O)NC1=NC=C(C=C1)NC2=NC=C3C=NN(C3=N2)C4CCCCCC4,CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1
CHEMBL1825096,PARUULGUCQEWNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9646,53308640,CS(=O)(=O)NC1=NC=C(C=C1)NC2=NC=C3C=NN(C3=N2)C4CCCCCC4,CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1
CHEMBL2086758,PAUHYDQXWBOZBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,9649,67161103,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=CC=C4)C5=NC=CN5,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2ncc[nH]2)C(=O)N3)CC1
CHEMBL2147070,PAVGMVFHWIYGKG-PKLMIRHRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22938786.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,9652,71461809,CN1C2=C(C=CC(=C2)C(=O)O)C3=C(C1=O)N(C(=N3)N4CCCC(C4)N)CC5=C(C=CC(=C5)F)Cl.Cl,Cn1c(=O)c2c(nc(N3CCCC(N)C3)n2Cc2cc(F)ccc2Cl)c2ccc(C(=O)O)cc21
CHEMBL2387588,PAWQBUAAGSRLHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,9654,71659895,C1=CC(=C(C(=C1)Cl)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=C(C=C5)Cl)F,O=c1[nH]c2cc(-c3ccc(Cl)cc3)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
CHEMBL1224194,PBADEQPCYAGBIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709545.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted biaryl pyrazoles as sodium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9658,46933697,CC1=CC(=NN1C2=CC=CC(=C2)C3=C(C=C(C=C3)C(F)(F)F)C(F)(F)F)C(=O)N,Cc1cc(C(N)=O)nn1-c1cccc(-c2ccc(C(F)(F)F)cc2C(F)(F)F)c1
CHEMBL1911820,PBCZOAJIAODBER-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,9662,57392788,CC1=NC=C(O1)COCC(C(=O)N2CCN(CC2)C)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,Cc1ncc(COCC(NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C(=O)N2CCN(C)CC2)o1
CHEMBL208528,PBIBEWTURATALQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16495056.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.102372908709558,9669,11641076,CCCC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,CCCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL2059790,PBOUVYGTCAXBDO-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,9679,70688552,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC=C(C=C3)O)NC(=O)N4CCC(CC4)N5C6=CC=CC=C6NC5=O,O=C(NC(Cc1ccc(O)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL3125390,PBQDTIVOGGGFGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,9680,57411254,C1CN(C2=C1C(=CC=C2)Br)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21
CHEMBL2048485,PCAUEUWLOMHNGF-VLQCVTHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,9684,11646163,COC1=CC=C(C=C1)CC2=CC(=CC=C2)C3CC(C(C(C3O)O)O)CO,COc1ccc(Cc2cccc(C3CC(CO)C(O)C(O)C3O)c2)cc1
CHEMBL2048485,PCAUEUWLOMHNGF-VLQCVTHLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,9684,11646163,COC1=CC=C(C=C1)CC2=CC(=CC=C2)C3CC(C(C(C3O)O)O)CO,COc1ccc(Cc2cccc(C3CC(CO)C(O)C(O)C3O)c2)cc1
CHEMBL462360,PCBPNOBJASOPBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,9686,25154864,CC1(CC2(CCCCC2)OO1)CC(=O)NCCNC3=C4C=CC(=CC4=NC=C3)Cl,CC1(CC(=O)NCCNc2ccnc3cc(Cl)ccc23)CC2(CCCCC2)OO1
CHEMBL474484,PCCGUZVUPBIHJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19231183.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9687,25256833,CC(C)CNC1=C(C(=NC(=N1)C#N)N2CCNCC2)N,CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N
CHEMBL563791,PCLLBFUYVTXKME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.872895201635193,9694,45267739,C1CN(CCC1NC(=O)NC(C2=CC=CC=C2)C3=NC=CN3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1
CHEMBL502560,PCMOPVSFMUOUFR-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.050609993355088,9696,9843867,C1CN2CC3=CC(=CC=C3)OC4=C(C=CC(=C4)CN5C=NC=C5CNC1C2=O)C#N,N#Cc1ccc2cc1Oc1cccc(c1)CN1CCC(NCc3cncn3C2)C1=O
CHEMBL2048199,PCMUEDIHLGLRQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,9697,69316129,CCCCNC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1
CHEMBL2048199,PCMUEDIHLGLRQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,9697,69316129,CCCCNC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1
CHEMBL451916,PCOIOMHQQCRCRU-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,9699,21036878,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NC)C4=C(C(=CC=C4)OCCCCC(=O)O)F,CNC(Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL494947,PCWGGOVOEWHPMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19246199.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9703,9901086,C1CN(CCN1)C2=CN=CC(=N2)OCC3=CC(=CC=C3)Cl,Clc1cccc(COc2cncc(N3CCNCC3)n2)c1
CHEMBL3692706,PDBQDSXSCZPLNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27017115.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9709,57331668,CC1=C(C=CC2=C1COC2=O)CCN3CCN(CC3)C(=O)CC4=CN=C(C=C4)N5C=NN=N5,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O
CHEMBL1829759,PDBVUENMKQBWQZ-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.853871964321762,9710,53473135,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCCO)C4=CC=CC=C4,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCCO)(c2ccccc2)OC1=O
CHEMBL1258079,PDDXKTLXEAXUKO-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9711,52948255,CC1CN(C(=O)C2=CC3=CC(=C(C=C3N12)Br)OC4CCN(CC4)C(C)C)CC5CC5,CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)C(C)CN(CC2CC2)C4=O)CC1
CHEMBL103163,PDFBPLZTOXIMKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9712,10313487,CC(C)(C)C1=CC=C(C=C1)N=CNO,CC(C)(C)c1ccc(N=CNO)cc1
CHEMBL2001019,PDMUGYOXRHVNMO-UHFFFAOYSA-N,PF-04217903,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22924734.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,4.522878745280337,9719,17754438,C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=C1,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1
CHEMBL235882,PDQQOEIEIIKGPR-PKTZIBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,9723,44433799,CC1=C(C=CC(=C1)F)C2CN(CC2C(=O)N(C)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C4=NC=C(N=C4)C,Cc1cnc(C(=O)N2CC(C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)cn1
CHEMBL2441952,PECDPZCIECMGCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.886056647693163,9731,15950755,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N(C)C)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2
CHEMBL2441952,PECDPZCIECMGCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.443697499232712,9731,15950755,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N(C)C)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2
CHEMBL502824,PECISPDQTYCDOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,9070.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,5.042392712939905,9732,25034348,CC(=O)C1=CN=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)OC,COc1ccc2cc(-c3cncc(C(C)=O)c3)ccc2c1
CHEMBL1270661,PEFPYUBFXFOFOB-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.130768280269024,9736,12001701,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)C,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1
CHEMBL1270661,PEFPYUBFXFOFOB-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,9736,12001701,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)C,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1
CHEMBL1270661,PEFPYUBFXFOFOB-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,9736,12001701,CC1=C(C(=CC=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)C,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1
CHEMBL1077937,PEKRVEUKQJQVHP-IOWSJCHKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,9738,46883343,COC1=CC=CC(=C1)CN(CC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC(CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5,COc1cccc(CN(CC(Cc2ccccc2)NC(=O)OCc2cncs2)CC(Cc2ccccc2)NC(=O)OCc2nccs2)c1
CHEMBL3260742,PEMIFSRCWZWBKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,4.7447274948966935,9741,72793034,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CN=C(C=C3)C(F)(F)F)C4=CC=NC=C4)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O
CHEMBL467633,PEUFWNJXEBOKMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,9745,24809711,CCN(CC(CNC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)F)N)(C(F)(F)F)O)C(=O)C3=C(C=CC=C3F)F,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F
CHEMBL270978,PEVWUDKTVWGCGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,9746,24824447,CC1=NOC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=C5C=C(C(=CC5=NC=C4)OC)OC,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cc(C)no5)cccc4c3)c2cc1OC
CHEMBL113227,PFAUOLMRDJNYLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,344.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.46344155742847,9753,44341260,C1=CC(=CC=C1N2C=CN=C2)OCCCC3=CC=NC=C3,c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1
CHEMBL2057525,PFEFYYZIBALVTE-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,9755,59603325,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)(C)O,CCN(C)c1nc2ccc(C(=O)N(CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1
CHEMBL3672577,PFESJDCERSQSIQ-ROJLCIKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.721246399047171,9756,57406029,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCN(CC2)C)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)NC(CCC(Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1
CHEMBL3672577,PFESJDCERSQSIQ-ROJLCIKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,340.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.468521082957745,9756,57406029,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCN(CC2)C)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)NC(CCC(Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1
CHEMBL2419524,PFMSCDXGGGWGEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9762,71817351,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5COC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1
CHEMBL2419524,PFMSCDXGGGWGEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9762,71817351,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5COC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1
CHEMBL2058905,PFOCQARJLIDBDQ-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.619788758288394,9764,59603337,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)C5=CC=CC=C5,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccccc3)oc2c1
CHEMBL234940,PFODPHDNBFSMOX-UHFFFAOYSA-N,GW848687,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19036582.0,IC50,=,89000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.050609993355088,9765,10238338,C1CC(=C(C1)C2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)F)C4=NC(=CC=C4)C(=O)O,O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1
CHEMBL214335,PFTJCYRHNKTTTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20471260.0,IC50,=,194000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.712198270069774,9772,44414722,COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,COc1ccccc1CC(c1ccccc1)N1CCNCC1
CHEMBL418382,PFTRTEKHKPGIAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,20030.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.698319050706424,9773,11226516,CN1C2=C(C3=C1C(=NC(=N3)CN4CCOCC4)N5CCN(CC5)CCC6=CC(=C(C=C6)F)F)C(=NC=C2)Cl,Cn1c2ccnc(Cl)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL557263,PFTYUXPUTSSSAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,9774,11635187,C1CN(CCC1NC(=O)NC(CN2C=CN=C2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1
CHEMBL1951575,PFWVGKROPKKEDW-UHFFFAOYSA-N,VIDUPIPRANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22930276.0,IC50,>=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,9778,42641863,CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl,CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1
CHEMBL1951575,PFWVGKROPKKEDW-UHFFFAOYSA-N,VIDUPIPRANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22930276.0,IC50,>=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,9778,42641863,CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl,CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1
CHEMBL476775,PFYPNHSILULSMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9781,44579232,CC1=CC=CC=C1C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,Cc1ccccc1C(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1
CHEMBL3408529,PFZOBHSCNYUKMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,9783,118730943,C1=CC=C2C(=C1)N3C(=NOC3=O)C(S2)(C4=CC=C(C=C4)Br)OCC(F)(F)F,O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1
CHEMBL3408529,PFZOBHSCNYUKMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,9783,118730943,C1=CC=C2C(=C1)N3C(=NOC3=O)C(S2)(C4=CC=C(C=C4)Br)OCC(F)(F)F,O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1
CHEMBL207293,PGBMWNVGYFSLII-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16503138.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,9784,10046844,C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=CN=CN3C4=CC=CC(=C4)C(=O)O,O=C(O)c1cccc(-n2cncc2-c2cc(Cl)ccc2OCc2ccccc2)c1
CHEMBL252616,PGCKAECGLQMGNP-SJLPKXTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9785,44446998,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC(=NO4)C,CCC1CCCC(C2(Cc3nc(C)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL559101,PGDZKICIZRFRTP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,9787,45273373,C1CN(CCC1N2C=CC=N2)C(=O)NC3CC3C4=CC=CC=C4,O=C(NC1CC1c1ccccc1)N1CCC(n2cccn2)CC1
CHEMBL3409588,PGGLRAWFUJMQBN-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25603482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.",J. Med. Chem.,PUBLICATION,,5.0,9791,71727133,C1COCCC1NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)C(CO)C4=CC(=C(C=C4)Cl)F,O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1C(CO)c1ccc(Cl)c(F)c1
CHEMBL481839,PGINMPJZCWDQNT-GJZGRUSLSA-N,ESCHOLTZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,4.872895201635193,9794,12304178,CN1C2CC3=CC4=C(C=C3C1CC5=CC6=C(C=C25)OCO6)OCO4,CN1C2Cc3cc4c(cc3C1Cc1cc3c(cc12)OCO3)OCO4
CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.522878745280337,9796,6918276,CCC(C)C(COC(CC1=CC=CC=C1)C(=O)NC(CCS(=O)(=O)C)C(=O)OC(C)C)NCC(CS)N,CCC(C)C(COC(Cc1ccccc1)C(=O)NC(CCS(C)(=O)=O)C(=O)OC(C)C)NCC(N)CS
CHEMBL3645534,PGQZLXAQNFHWTD-AFMDSPMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,9799,73427552,CC(C1=CC=C(C=C1)C2=NN(C(=O)C=C2)C)N3CCC(OC3=O)(CCCO)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CCC(CCCO)(c2ccccc2)OC1=O
CHEMBL256989,PHGQFDGZFPQJNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,9814,44449053,C1CCN(C1)CC2C(CCCN2C(=O)CN3C4=CC(=C(C=C4N=CC3=O)Cl)Cl)C5=CC=CC=C5,O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1
CHEMBL227089,PHJKYNSEJIZCAD-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.301029995663981,9818,16658105,COC1=C(C=C2C(=C1)C(=O)N(C(=N2)N3CCCC(C3)N)CC4=CC=CC=C4C#N)OC,COc1cc2nc(N3CCCC(N)C3)n(Cc3ccccc3C#N)c(=O)c2cc1OC
CHEMBL1808644,PHMSOOBTXSCMBO-SOFGYWHQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9821,24958816,C1C2=C(CN1CCC3=CNC4=CC=CC=C43)C=C(C=C2)C=CC(=O)NO,O=C(C=Cc1ccc2c(c1)CN(CCc1c[nH]c3ccccc13)C2)NO
CHEMBL3127906,PHNBVYLTLRRMHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24428186.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione ��-Secretase Modulators.",J. Med. Chem.,PUBLICATION,,4.522878745280337,9822,68380260,CC1=CN(C=N1)C2=CC=C3C(=O)N(CCN3C2=O)CCOC4=C(C=C(C=C4)Cl)C(F)(F)F,Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(Cl)cc2C(F)(F)F)C3=O)cn1
CHEMBL2041193,PHOCCMVBRLGOKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,9823,49847377,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC=C4)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
CHEMBL272693,PHUIVAKJVUJLDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,7.0,9827,24822429,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=NC=C5,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccncc5)cccc4c3)c2cc1OC
CHEMBL3291346,PHUJLIRGKVQXJQ-OSPHWJPCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989233,9828,16118899,CC1(C2CCC1(C3=C2C(=O)N(N3CC4=CC=CC=C4)C5=C(C=C(C=C5)F)F)C)C,CC12CCC(c3c1n(Cc1ccccc1)n(-c1ccc(F)cc1F)c3=O)C2(C)C
CHEMBL3358928,PHUOGFXDMSBGIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.522878745280337,9829,11201812,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)OC(C)C)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(OC(C)C)ncc2[nH]1)C(F)(F)F
CHEMBL595154,PHVWYDDIUNHCKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20004097.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,9832,16042459,C1CN(CCC1OC2=CC=CC=C2C(F)(F)F)C3=NN=C(C=C3)N4C=CN=C4,FC(F)(F)c1ccccc1OC1CCN(c2ccc(-n3ccnc3)nn2)CC1
CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,32700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.485452247339714,9833,5472,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,Clc1ccccc1CN1CCc2sccc2C1
CHEMBL2437430,PHYADSPDZPCYNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9836,10099429,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=CC(=CC(=C5)F)F)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cc(F)cc(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL1835772,PIBBQKCYYNVLJZ-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9839,56662000,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4=C3SC=C4)C(C)C,CC1CCCN1CCCOc1ccc(-c2nn(C(C)C)c(=O)c3ccsc23)cc1
CHEMBL1923127,PIBCEYLKROLZIT-SJHOIFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,9840,56837192,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)Cl)CCCN6CCOCC6,COCCCc1cc(CCCN2CCOCC2)c(Cl)c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1
CHEMBL2170606,PIFFTSRNYNUHHY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,6.3979400086720375,9843,58269598,CC(C)C(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,CC(C)C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL1090175,PIHREWZGYZJCNQ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9846,46884731,CC(C1=NC=CN=C1)C2=C(CC3=C2C=CC(=C3)OC)CCN(C)C,COc1ccc2c(c1)CC(CCN(C)C)=C2C(C)c1cnccn1
CHEMBL1821837,PIHRJUVRNRHPAG-LJQANCHMSA-N,GSK1997132B,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798739.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DEF substrate,Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR�� partial agonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.346787486224656,9847,44132009,CCC(C1=CC=CC=C1)NC(=O)C2=CC3=C(C=C2)N(C=N3)CC4=C(C=C(C=N4)F)F,CCC(NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1
CHEMBL1821837,PIHRJUVRNRHPAG-LJQANCHMSA-N,GSK1997132B,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798739.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR�� partial agonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9847,44132009,CCC(C1=CC=CC=C1)NC(=O)C2=CC3=C(C=C2)N(C=N3)CC4=C(C=C(C=N4)F)F,CCC(NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1
CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19647430.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using felodipine as a substrate,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9851,11392888,CC(C)CN(C1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)C1CCNC1
CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19647430.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as a substrate,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9851,11392888,CC(C)CN(C1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)C1CCNC1
CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19647430.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as a substrate,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9851,11392888,CC(C)CN(C1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)C1CCNC1
CHEMBL3702676,PILJPIHRKFJABP-CXNSMIOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10500.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.978810700930062,9854,89716371,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NCCC8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCCc6ccccc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL536743,PIMBSDCVZVPYEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17118654.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,9855,10280944,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)CC5CCCCC5.Cl,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
CHEMBL536743,PIMBSDCVZVPYEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,9855,10280944,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)CC5CCCCC5.Cl,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
CHEMBL3702759,PIPXSGQNTFVPRN-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4780.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.320572103387881,9860,89718362,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCCCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3116160,PIRBVHZKYOUJCV-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,9861,16744748,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=C(S4)Br)C(F)(F)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1
CHEMBL3116160,PIRBVHZKYOUJCV-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,9861,16744748,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC(=C(S4)Br)C(F)(F)F,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1
CHEMBL566242,PITVIIACVFAXRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040958607678906,9863,45487862,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
CHEMBL566242,PITVIIACVFAXRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9863,45487862,COC1=CC2=NC=CC(=C2N=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC(=C(C=C5)F)F,COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1
CHEMBL3234575,PIWZTMSNVDVOEQ-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.657577319177793,9865,90654564,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCC3C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(N3CCCC3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
CHEMBL3234576,PIWZTMSNVDVOEQ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,6.154901959985743,9866,90654565,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCC3C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(N3CCCC3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1
CHEMBL480296,PIYHDSUVUSVLGU-HSQXHLSASA-N,(-)-CUBEBININ,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.823908740944319,9867,44575401,COC1=CC(=CC(=C1OC)OC)CC2COC(C2CC3=CC(=C(C(=C3)OC)OC)OC)O,COc1cc(CC2COC(O)C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC
CHEMBL3104529,PJARPEFKLCVCAE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1900.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.721246399047171,9868,76313857,CC(C)(C)C(=O)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,CC(C)(C)C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2385904,PJEVQOJEJXZQAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,9869,11539410,CCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)N3CCC4=C(C3)C5=CC=CC=C5N4CC(=O)O,CCc1ccc(-c2ccc(C(=O)N3CCc4c(c5ccccc5n4CC(=O)O)C3)cc2)cc1
CHEMBL534958,PJJQGSLLJOVYBM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,9874,24749608,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.Cl,N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1
CHEMBL585182,PJNOYUGDEFSKQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19842661.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.",J. Med. Chem.,PUBLICATION,,4.698970004336019,9878,24963233,CN(C)CC1=NC(=O)C2=C(N1)C3=C(S2)C=CC(=C3)C4=CC=C(C=C4)O,CN(C)Cc1nc(=O)c2sc3ccc(-c4ccc(O)cc4)cc3c2[nH]1
CHEMBL2170754,PJRMJIREEYPPSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22277094.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17��-HSD1.,J. Med. Chem.,PUBLICATION,,4.267606240177032,9884,56847605,CC1=C(C=C(C=C1)C(=O)C2=NC3=C(S2)C=C(C=C3)O)O,Cc1ccc(C(=O)c2nc3ccc(O)cc3s2)cc1O
CHEMBL565195,PKOKKGWFSDPGGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,9902,25165474,CS(=O)(=O)C1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
CHEMBL565195,PKOKKGWFSDPGGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481450.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with compound,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9902,25165474,CS(=O)(=O)C1=CC=C(C=C1)NC2=NC3=C(N2CC4=CC=CC=C4C(F)(F)F)C=CC(=C3)C(=O)N,CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1
CHEMBL1090528,PKONXOYDGGORHO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9903,46884736,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)C(C)C3=NC=CS3,Cc1ccc2c(c1)CC(CCN(C)C)=C2C(C)c1nccs1
CHEMBL1079245,PKPQLLBQJIRCMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9905,46882971,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)NC3=NNNN3)C4=CC=CC=C4,O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)NC1=NNNN1
CHEMBL2448718,PKRLJALWWJCHMA-MTDXEUNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.522878745280337,9906,73355720,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CC=C(C=C3)C4=CC=CC=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)cc2)c1
CHEMBL3664686,PKVHOLANSOCZKZ-QNBVUBCUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,9912,44476984,CC(CN1C=CC(=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4)CO,CC(CO)Cn1ccc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
CHEMBL289228,PLHJCIYEEKOWNM-HHHXNRCGSA-N,TIPIFARNIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,5.769551078621726,9931,159324,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,Cn1cncc1C(N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
CHEMBL289228,PLHJCIYEEKOWNM-HHHXNRCGSA-N,TIPIFARNIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,4060.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,5.391473966422806,9931,159324,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,Cn1cncc1C(N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
CHEMBL1078755,PLHSBHYVGMRRQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9932,42644084,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC#N)C3=CC=CC=C3,N#CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL296580,PLITYYGQMDTHMM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,>,3750.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.425968732272281,9934,683949,C1=CC=C2C(=C1)NC(=N2)SCC3=CC=CC=N3,c1ccc(CSc2nc3ccccc3[nH]2)nc1
CHEMBL586213,PLPFIMGOJTYGRW-UHFFFAOYSA-N,TCMDC-139046,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate incubated for 30 mins prior to substrate addition measured up to 10 mins by fluorimetry,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,9935,44533150,COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)OC(F)(F)F)C(F)(F)F,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(OC(F)(F)F)cc(-c3cccnc3)c1)CC2
CHEMBL3664662,PLRIPZFMRUQNKJ-SVEHJYQDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,9936,59635745,CCC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCC(c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1910120,PLSOUKNNDKPEQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,9938,57390923,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCN(CC3)C(=O)C)C4=C(C=C(C=C4)Cl)Cl)CN,CC(=O)N1CCN(C(=O)CN2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)CC1
CHEMBL2018484,PLUJPPMSHJDKIV-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,4.698970004336019,9940,45378010,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=NC=N4)CC5=CC=CC=C5,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(Cc2ccccc2)CN1C(=O)Cn1cncn1
CHEMBL429736,PLVGDGRBPMVYPB-FDUHJNRSSA-N,RETOSIBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9942,11340891,CCC(C)C1C(=O)NC(C(=O)N1C(C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,CCC(C)C1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N1CCOCC1)c1coc(C)n1
CHEMBL401858,PLVGDGRBPMVYPB-JUJUEEDWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9943,44456034,CCC(C)C1C(=O)NC(C(=O)N1C(C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,CCC(C)C1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N1CCOCC1)c1coc(C)n1
CHEMBL3400443,PLWCLTNJVOKTLA-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9944,59272265,CC(C)N(CC1CNCC1NC(=O)CC2CCOCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)CC2CCOCC2)C(C)C)ccc1OC
CHEMBL377286,PLXKSCLQIJZCDI-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,9945,44410807,CCC(CC)(COC1=CC2=C(C=C1)C=C(C=C2)C(C(C)N(C)C)N3C=CN=C3)C(=O)O,CCC(CC)(COc1ccc2cc(C(C(C)N(C)C)n3ccnc3)ccc2c1)C(=O)O
CHEMBL401910,PLXQKDCMQVUJJI-DNVJHFABSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,9946,44456229,CC1=NC(=CO1)C(C(=O)NC(C)C)N2C(C(=O)NC(C2=O)C3CC4=CC=CC=C4C3)CC(C)C,Cc1nc(C(C(=O)NC(C)C)N2C(=O)C(C3Cc4ccccc4C3)NC(=O)C2CC(C)C)co1
CHEMBL3409857,PLXRFUMPYLQAFR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,9947,69083435,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)(F)F,COc1cccc(OC)c1C1CC(F)(F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,9949,5284373,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,5.187086643357144,9949,5284373,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19933795.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 30 mins,"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.",Antimicrob. Agents Chemother.,PUBLICATION,,5.180456064458132,9949,5284373,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,1450.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,5.838631997765025,9949,5284373,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,2060.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,5.686132779630847,9949,5284373,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
CHEMBL3422085,PMDUMOUXISSZED-BTOOTBGFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.853871964321762,9952,117751339,C1CC1C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6COC7,O=C(NC(c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
CHEMBL1671967,PMEAQKGKOGFUOS-CHHVJCJISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.42021640338319,9953,25009031,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(F)(F)F)Br,COc1cc(C=C2SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Br
CHEMBL507614,PMHDSACGRKBACK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18455394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9955,4961254,C1=CSC2=C1NC(=C2)C(=O)O,O=C(O)c1cc2sccc2[nH]1
CHEMBL2425607,PMIMNVFAGLMWQP-NNWAQCLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,9956,72191978,CC(C)(C)C1=CC(=NC=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cc(C(C)(C)C)ccn3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL2381071,PMJFHEYTYKKNJY-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.102372908709558,9959,71603190,CC1=CC(=NC(=N1)NCC2CC3(CC3)CN2C(=O)C4=C(SC(=N4)C)C5=CC=CC=C5)C,Cc1cc(C)nc(NCC2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1
CHEMBL478870,PMMKHGYQMNVMIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,9963,44579180,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC(=CC=C4)Cl)Cl,O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3
CHEMBL478870,PMMKHGYQMNVMIC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,9963,44579180,C1CNCCC2=CC3=C(C=C21)C(=CN3S(=O)(=O)C4=CC(=CC=C4)Cl)Cl,O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3
CHEMBL2036635,PMRJMYCLQDPGBL-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9970,49855513,CC1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCN(CC3)C(=O)C4=CC=CC=C4,CC1CCCN1CCCOc1ccc(C(=O)CN2CCN(C(=O)c3ccccc3)CC2)cc1
CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,9971,4104,CN1C=CN=C1S,Cn1ccnc1S
CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,9971,4104,CN1C=CN=C1S,Cn1ccnc1S
CHEMBL464234,PMSFEOUVENKQAA-AMVBQIFNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19014886.0,IC50,=,13600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 green,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.866461091629782,9972,25265835,CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O,CC1CN(S(=O)(=O)CC23CCC(CC2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F
CHEMBL464234,PMSFEOUVENKQAA-AMVBQIFNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19014886.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 red,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,9972,25265835,CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O,CC1CN(S(=O)(=O)CC23CCC(CC2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F
CHEMBL550652,PMWSGFIJYUECNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,9976,45270771,CN1C=NN=C1C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,Cn1cnnc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1
CHEMBL2023124,PNDYJPUJHZPECK-NHTMILBNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,9984,46861797,CNCC(CC1CCOCC1)NC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC,CNCC(CC1CCOCC1)NC(=O)N1CCCC(C(OCCNC(=O)OC)c2cccc(Cl)c2)C1
CHEMBL2436327,PNJRQMGMROTWQX-OWEKSZQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.886056647693163,9989,72713609,CC1=C(C2=CC=CC=C2C=C1)CN3C4=CC=CC=C4N(CC(C3=O)NC(=O)C(C)NC)C(=O)CC(C)C.Cl,CNC(C)C(=O)NC1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(C)ccc3ccccc23)C1=O
CHEMBL270655,PNLGKAIYTKSYNF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,9991,44454671,CCOC1=C(C=C(C=C1)CC(=O)NC2=CC(=NC(=N2)C3=CC=CC=N3)N4C(=CC(=N4)C)C)OC,CCOc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1OC
CHEMBL2017105,PNONWZINZRBQGI-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,9993,46932141,CC(=O)NCCC1=CC=CC=C1C2=CC(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)O,CC(=O)NCCc1ccccc1-c1cc(C2CNCCC2(O)c2ccc(F)c(F)c2)no1
CHEMBL248407,PNQPSLZAXAGIOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,9995,44443101,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C=C4)OCC(=O)N5CCC6=CC=CC=C6,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(CCc4ccccc4)C(=O)CO5)CC3)cccc2n1
CHEMBL372846,PNSGYWXRFOWVFA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,58000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.236572006437063,9997,9976141,C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)C4=CC=C(C=C4)O)F)F)C(=O)O,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(O)cc4)c(F)c3)c(F)c2)CC1
CHEMBL1669407,PNSJAJNXVSKCBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,9998,53321494,CN(CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3)CCF,CN(CCF)CCC1=C(Cc2cnccn2)c2ccccc2C1
CHEMBL3311221,PNUGCHCVDNISAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,72000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.142667503568732,10001,71475689,C1=CC(=C(C=C1F)F)C(CN2C=NN=N2)(C(C3=NC=C(C=C3)OCC(F)(F)F)(F)F)O,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(OCC(F)(F)F)cn1
CHEMBL3393294,PNXHUKPFSGHNBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,10006,118725451,C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3C#N,N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccccc2)cc1
CHEMBL2048846,POKKSIROKFEGGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727639.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10012,25067404,CC1=CSC(=N1)N(C)C(=O)CSC2=NN=C(C=C2)C3=CC=CC=C3,Cc1csc(N(C)C(=O)CSc2ccc(-c3ccccc3)nn2)n1
CHEMBL3289813,POQVSNVXDFTBIQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,=,20300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,4.692503962086787,10016,90644769,CC(C(F)(F)F)OC1=NC2=C(C=C1)N=C(N2CC(C3=C(C=C(C=C3)C(F)(F)F)Cl)O)N,CC(Oc1ccc2nc(N)n(CC(O)c3ccc(C(F)(F)F)cc3Cl)c2n1)C(F)(F)F
CHEMBL3673948,POUGJCUMNASOCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320626,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,10018,52933545,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F)N=C1,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1
CHEMBL3673948,POUGJCUMNASOCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320670,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,10018,52933545,COC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC=C(C=C4)Cl)F)N=C1,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1
CHEMBL590850,POVKMUXXHHNJIG-CECLQJIQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19945870.0,IC50,=,12300.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.910094888560602,10021,6479949,CC(C(=O)NC1=CC=C(C=C1)C=CC(=O)O)NC(=O)C2=CC3=C(C=C2)N(C(=N3)C4=COC=C4)C5CCCCC5,CC(NC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)C(=O)Nc1ccc(C=CC(=O)O)cc1
CHEMBL3702715,POYVJUSYLIGQCQ-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.481486060122113,10023,89718430,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(OC)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,10025,28417,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5,C#CC1(O)CCC2C3CCC4=Cc5oncc5CC4(C)C3CCC21C
CHEMBL1762429,POZVWZHXRTXSAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21354795.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin),"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10028,54584868,CC(C)(C)C1=CC(=NO1)NC(=O)N2CCCN(CC2)C(=O)N3CCS(=O)(=O)CC3,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)N3CCS(=O)(=O)CC3)CC2)no1
CHEMBL1643881,PPGYKWQFGNLYIY-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10033,50942419,C1CN2CCC1C(C2)N3CC4=C5C(=NN4)C=CC=C5C3=O,O=C1c2cccc3n[nH]c(c23)CN1C1CN2CCC1CC2
CHEMBL264961,PPIFUYCFGJGTGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10034,25023859,CNC(=O)C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N,CNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1
CHEMBL399731,PPILOQQTEQXAMT-HSWSLHEESA-N,FIBRAURINOSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,10035,44445724,CC12CC=C3C(=O)OC(CC3(C1C4C5C(C2(C(=O)O4)OC6C(C(C(C(O6)CO)O)O)O)O5)C)C7=COC=C7,CC12CC(c3ccoc3)OC(=O)C1=CCC1(C)C2C2OC(=O)C1(OC1OC(CO)C(O)C(O)C1O)C1OC21
CHEMBL480295,PPKABVGOUVBEEX-HSQXHLSASA-N,ETHOXYCLUSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,6.356547323513812,10038,44575400,CCOC1=CC(=CC2=C1OCO2)CC3COC(C3CC4=CC(=C(C(=C4)OC)OC)OC)O,CCOc1cc(CC2COC(O)C2Cc2cc(OC)c(OC)c(OC)c2)cc2c1OCO2
CHEMBL2059126,PPKRNTJCUJJRGN-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,10039,59603307,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(C)c1nc2ccc(C(=O)N(C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL3109356,PPPOUAQYRUUFNJ-GHTZIAJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,10042,66781377,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4OC5CCNCC5F)C=C3,COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5F)c4n3)cnc2c1
CHEMBL3109338,PPPOUAQYRUUFNJ-RXVVDRJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,10043,25098429,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4OC5CCNCC5F)C=C3,COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5F)c4n3)cnc2c1
CHEMBL3109337,PPPOUAQYRUUFNJ-WIYYLYMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,10044,59176329,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4OC5CCNCC5F)C=C3,COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5F)c4n3)cnc2c1
CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,10045,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,10045,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
CHEMBL3608680,PPSNFPASKFYPMN-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.045757490560675,10048,117604931,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3C)n1
CHEMBL551058,PPZAIZWNHZKGPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,10052,45270778,CS(=O)(=O)C1=CC=C(C=C1)C2=NOC(=N2)C3CCN(CC3)C(=O)NC4CC4C5=CC=CC=C5,CS(=O)(=O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1
CHEMBL223079,PPZQHODYVASSTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17352462.0,IC50,>,100000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cells,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,PUBLICATION,,4.0,10054,16125681,C1CN(CCC1N2CC(NC2=O)(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC5=CC(=CC=C5)Cl,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(Cl)c2)CC1
CHEMBL1504335,PQAOSMFYTVFYMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,10056,3959338,C1CN(CCN1CC2=CC=CC=C2)CC3=NN=C(O3)C4=CC=CC=C4,c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1
CHEMBL2069846,PQBMPUQYJGLDHI-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,10058,70684570,CN1CCN(CC1)C2=CC=C(C=C2)C(=O)N3CCN(CC3)C(=O)CC(CC4=CC(=C(C=C4F)F)F)N,CN1CCN(c2ccc(C(=O)N3CCN(C(=O)CC(N)Cc4cc(F)c(F)cc4F)CC3)cc2)CC1
CHEMBL2436328,PQJFVYVHOIOJEX-OGZMHEHASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.823908740944319,10068,72711026,CC(C)CC(=O)N1CC(C(=O)N(C2=CC=CC=C21)CC3=C(C=CC4=CC=CC=C43)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O
CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20384344.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in insect cell microsome after 30 mins by fluorescence assay,Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.,J. Med. Chem.,PUBLICATION,,6.327902142064283,10074,46222048,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2,CC(C)(C)c1ccc(SCCc2cnc[nH]2)cc1
CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.327902142064283,10074,46222048,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2,CC(C)(C)c1ccc(SCCc2cnc[nH]2)cc1
CHEMBL1808424,PQQHOBXFKJXQAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21724392.0,IC50,=,14700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.8326826652518236,10076,11187925,CN1CC(=C(C1)Cl)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4,CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)C1
CHEMBL495084,PQVHRPXGPBDRRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.7447274948966935,10080,44568803,CC1=C(C2=C(C=C1)C(=NO2)NC3CC3)C4=CC5=CN=NC(=C5C=C4)C6=CC=CC=C6C,Cc1ccccc1-c1nncc2cc(-c3c(C)ccc4c(NC5CC5)noc34)ccc12
CHEMBL1761518,PRAXUIQVVJSJMP-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,10089,24953169,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC#N)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1
CHEMBL1761518,PRAXUIQVVJSJMP-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,19600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.707743928643524,10089,24953169,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC#N)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1
CHEMBL3702809,PREDGFPQLQFLSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,10095,89718298,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)C9=CC=CC=C9OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccccc7OC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3581132,PRIKHRTWFXDNDC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,6.318758762624412,10096,60097605,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC=NC=C3,COc1cccc(CC(=O)Nc2cc(-c3ccncc3)cs2)c1
CHEMBL1950080,PRIVQPMFDOJWFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,10097,57392932,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=CC=C4)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C#N)c3ccccc3)c2c1
CHEMBL1950080,PRIVQPMFDOJWFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,10097,57392932,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=CC=C4)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(C#N)c3ccccc3)c2c1
CHEMBL127589,PRPIEBUSWYMLSB-KRXYOAFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,10104,10123174,C1CN(C(CN1CC2=CN(C=C2)C3=CC=C(C=C3)Cl)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2ccn(-c3ccc(Cl)cc3)c2)CC1C(=O)NCC(F)(F)F
CHEMBL498662,PRQQBVJPRNDIGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,159.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,6.798602875679548,10105,25033732,C1C=C(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)C4=CC=NC=C4.Cl,Fc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1
CHEMBL1923118,PRVWMJVSFWNIFV-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,10109,57394341,C1CC1N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1cccc(C(F)(F)F)c1Cl)C1CC1
CHEMBL2441340,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,GSK2656157,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,19700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,4.705533773838407,10110,53469059,CC1=NC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
CHEMBL2441340,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,GSK2656157,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,4.6020599913279625,10110,53469059,CC1=NC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
CHEMBL2441340,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,GSK2656157,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,,25000.0,NM,,inhibition,tissue,functional,,,,,0.01-30,UM,,=,0.1-0.5,MG-ML,,,ACS MED. CHEM. LETT.,PUBLICATION,,4.6020599913279625,10110,53469059,CC1=NC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3F)C4=CN(C5=NC=NC(=C45)N)C,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1
CHEMBL26599,PRXCGBDDTBLDKY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,45800.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.33913452199613,10111,10455921,C1CCN2C(=C(C3=C2C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)N)C1,NC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
CHEMBL2181894,PRYJXFKQLNPQBU-UNCTUWKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.0,10112,67270717,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=CSC=N5)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2cscn2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL1784350,PSAIRTKPKUWNNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10116,54582075,CC1=C(C(=NO1)C)CCC2CCN(CC2)S(=O)(=O)CC3(CCOC(C3)(C)C)N(C=O)O,Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCOC(C)(C)C2)CC1
CHEMBL550068,PSCSTQNZPOWDJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,2490.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.603800652904264,10118,45271134,C1CN(CCC1NC(=O)N2CCN3C=CC=C3C2C4=CC=CC=C4)CC5=CN(C=C5)C6=CC=C(C=C6)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCn2cccc2C1c1ccccc1
CHEMBL468671,PSHCEXAQPYCQDU-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.958607314841775,10124,135875709,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5CCN(CC5)CCOC,COCCN1CCC(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL2448748,PSJMEQMCCNLCBN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.3979400086720375,10127,73346621,CCN(CC1=CN=CN1)C2=C(C=C(C=C2)C3=CC=C(C=C3)F)F,CCN(Cc1cnc[nH]1)c1ccc(-c2ccc(F)cc2)cc1F
CHEMBL559945,PSQYTAPXSHCGMF-BQYQJAHWSA-N,BETA-IONONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,10136,638014,CC1=C(C(CCC1)(C)C)C=CC(=O)C,CC(=O)C=CC1=C(C)CCCC1(C)C
CHEMBL559945,PSQYTAPXSHCGMF-BQYQJAHWSA-N,BETA-IONONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,10136,638014,CC1=C(C(CCC1)(C)C)C=CC(=O)C,CC(=O)C=CC1=C(C)CCCC1(C)C
CHEMBL3673979,PSQZATYJDUBZGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320657,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,10137,52933790,C1=CC(=NC=C1CNC2=C(C=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl)F)C(F)(F)F,Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1
CHEMBL358216,PSSBWTPALOUROH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,58100.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.235823867609669,10141,11148656,CCCCOC1=CC=C(C=C1)C2=CN=CO2,CCCCOc1ccc(-c2cnco2)cc1
CHEMBL3702797,PSSSYLPWYZVQRS-UJGAEZNTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.213248577854439,10142,89718288,CC(C)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2158231,PSWOVPWZYVUKKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.214670164989233,10144,11612700,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C4=CN=CC=C4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL1801364,PTCZOYHYJOCZIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20634071.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyflourescein as a substrate,Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,10147,56662910,CC1=C(N(C(=N1)C2=C(C=C(C=C2)F)F)C)CC(=O)NCC3=C(C=C(C=C3)F)Cl.Cl,Cc1nc(-c2ccc(F)cc2F)n(C)c1CC(=O)NCc1ccc(F)cc1Cl
CHEMBL523565,PTFJFPDNCOEVNS-DVKDBIPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10149,44583289,C1CN(CCC12CC(C3=C(O2)C=CC=N3)O)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC2(CC1)CC(O)c1ncccc1O2
CHEMBL2322875,PTHJVFQTMJMDKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23374868.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Competitive inhibition of CYP3A4 (unknown origin),1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10152,21070989,CC1=C(C(=NN1CC(=O)N2CCN(CC2)C3=CC(=C(C=C3)Cl)OC)C(F)(F)F)Cl,COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl
CHEMBL2178718,PTLJUNIICOHEHE-JTSKRJEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22989333.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated with substrate,Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation.,J. Med. Chem.,PUBLICATION,,5.721246399047171,10158,71457203,CN1C(=O)C2CN(CC2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=N5)F,CN1C(=O)C2CN(c3ncc(F)cn3)CC2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
CHEMBL2178718,PTLJUNIICOHEHE-JTSKRJEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22989333.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 coincubated with substrate,Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation.,J. Med. Chem.,PUBLICATION,,4.522878745280337,10158,71457203,CN1C(=O)C2CN(CC2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=N5)F,CN1C(=O)C2CN(c3ncc(F)cn3)CC2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
CHEMBL2178718,PTLJUNIICOHEHE-JTSKRJEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,5.920818753952375,10158,71457203,CN1C(=O)C2CN(CC2(N=C1N)C3=CC(=CS3)C4=CC=CC(=C4)C#N)C5=NC=C(C=N5)F,CN1C(=O)C2CN(c3ncc(F)cn3)CC2(c2cc(-c3cccc(C#N)c3)cs2)N=C1N
CHEMBL1668909,PTMZDVIBDZFFRW-JCMHNJIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211972.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,10160,53324483,CCOC(=O)C1=C(C2=C(S1)C=NC=C2)NC3=CC4=C(C=C3)C(=NO)CC4,CCOC(=O)c1sc2cnccc2c1Nc1ccc2c(c1)CCC2=NO
CHEMBL2397313,PTNNLDBOIACISQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,10161,71682212,CC1=C(SC(=N1)NC(=O)CC2=NC(=C(O2)C)C3=CC=CC=C3)C4=CN=C(C=C4)N,Cc1nc(NC(=O)Cc2nc(-c3ccccc3)c(C)o2)sc1-c1ccc(N)nc1
CHEMBL2436624,PTPOPPWALKSUMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10162,44622340,COC1=CC2=C(CCCN(C2)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F)C=C1,COc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CCC2
CHEMBL3114737,PUCUZOUCEHETGM-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,10166,76328656,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)N2CCN(CC2)C(=O)OCC3=CN=CS3,CC(C)c1nc(CN(C)C(=O)NC(C(=O)N2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1
CHEMBL368347,PUETUDUXMCLALY-HOTGVXAUSA-N,(+)-SECOISOLARICIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,47300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.325138859262188,10167,65373,COC1=C(C=CC(=C1)CC(CO)C(CC2=CC(=C(C=C2)O)OC)CO)O,COc1cc(CC(CO)C(CO)Cc2ccc(O)c(OC)c2)ccc1O
CHEMBL1830424,PUFPSZILMLJFEU-ZRDIBKRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,6.481486060122113,10168,15983982,CCCCCCC1=NC2=C(N1CCN(C)C)C=CC(=C2)C=CC(=O)NO,CCCCCCc1nc2cc(C=CC(=O)NO)ccc2n1CCN(C)C
CHEMBL1830424,PUFPSZILMLJFEU-ZRDIBKRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634430.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorescence assay,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,10168,15983982,CCCCCCC1=NC2=C(N1CCN(C)C)C=CC(=C2)C=CC(=O)NO,CCCCCCc1nc2cc(C=CC(=O)NO)ccc2n1CCN(C)C
CHEMBL355905,PUHRPYOPXGWCTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14584934.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC,"Identification of a potent and selective 5-HT(6) antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin-4-ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,10170,10286610,CSC1=C(C(=N)N2C=CC=CC2=N1)S(=O)(=O)C3=CC=CC=C3,CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1
CHEMBL355905,PUHRPYOPXGWCTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14584934.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BzRes,"Identification of a potent and selective 5-HT(6) antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin-4-ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,10170,10286610,CSC1=C(C(=N)N2C=CC=CC2=N1)S(=O)(=O)C3=CC=CC=C3,CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1
CHEMBL1241736,PUOXMWOHHZDZBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.301029995663981,10175,46900612,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)C,CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL1241736,PUOXMWOHHZDZBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.301029995663981,10175,46900612,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)C,CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2
CHEMBL2010601,PURKAOJPTOLRMP-UHFFFAOYSA-N,IVACAFTOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25441013.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator.",J. Med. Chem.,PUBLICATION,,4.698970004336019,10176,16220172,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O
CHEMBL562894,PUYPQZLPNDWKQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10179,45271166,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC,COc1ccc(Cn2c(N3CCC(n4cc(C)cn4)CC3)nc3ccccc32)cc1
CHEMBL206884,PVEQEQGWTRAWFX-IERDGZPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,10183,44410808,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CC3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCC3(C(=O)O)CC3)ccc2c1)n1ccnc1)N(C)C
CHEMBL2338474,PVGMGRKQQQTCKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,5.638272163982407,10184,71525222,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)C(F)(F)F)Cl)Cl,O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(C(F)(F)F)cc1Cl
CHEMBL260259,PVISFTMIHRDVDS-ROUUACIJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18387300.0,IC50,>,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,10189,25009937,COC1=C(C=CC(=C1)Cl)OC(C2CNCCO2)C3=CC=CC=C3,COc1cc(Cl)ccc1OC(c1ccccc1)C1CNCCO1
CHEMBL94454,PVLJETXTTWAYEW-UHFFFAOYSA-N,MIZOLASTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10190,65906,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL2437421,PVPHPEBVXPEONF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10193,58863171,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCN5CCOCC5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5ccccc54)CC3)CC2)ccn1
CHEMBL2163822,PVRCCDCVZYOJAG-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.886056647693163,10194,57522133,C1CN(CCC1O)C(=O)C(CC2=CC=C(C=C2)Br)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,O=C(C(Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCC(O)CC1
CHEMBL577470,PVSATFACFVIGLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10196,45484881,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)C(=O)O,CC1(CC(=O)NCc2ccc(C(=O)O)cc2)CC2(CCCCC2)OO1
CHEMBL3577955,PWDBREUBRYUEGC-BTJKTKAUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25893048.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,10204,122178129,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)CN3CCOCC3.C(=CC(=O)O)C(=O)O,CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1
CHEMBL3699344,PWOQCDXDGLGZLQ-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,10210,89718319,CCN(CC)C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(CC)CC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2064336,PWPZIVZLHIOULY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,10212,49853929,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(N3)C=C(C=C4)Cl,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3ccc(Cl)cc3[nH]2)n1
CHEMBL1270630,PWZLUGHNDYWEDU-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,10222,25072736,CC1=C(C=CC(=C1)C2(C(=O)N(C(=N2)N)C)C3=CC=CC(=C3)C#CC4CC4)OC(F)F,Cc1cc(C2(c3cccc(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F
CHEMBL454515,PXCKFKLPESDHTQ-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,10225,135960733,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)N7CCN(CC7)C,Cc1cc(N2CCC(N3CCN(C(=O)N4CCN(C)CC4)CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL113018,PXFGMZGVHWPLCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,5670.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.246416941107094,10231,44341256,C1COCCN1CCOC2=CC=C(C=C2)N3C=CN=C3,c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1
CHEMBL519680,PXFUWAWMHRRZOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,6.455931955649724,10232,11697546,CC1=C(C(N=C(N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)C(=O)NC4=CC5=C(C=C4)NN=C5,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1
CHEMBL3137391,PXISBMZXCKNRIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.7447274948966935,10235,76318571,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CN=C4,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
CHEMBL3409855,PXNXLOMDHVIHNB-GJZGRUSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10243,69082236,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)F,COc1cccc(OC)c1C1CC(F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
CHEMBL496286,PXOBFFWELDGRSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2114.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.674895017028592,10244,25033804,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)O)F)C(=C1)C4=CC=NC=C4.Br,Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F
CHEMBL557461,PXUAIMJAHKAYPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19524437.0,IC50,>,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,10249,11610910,CC1CCN(CC1)C(=O)C2=CC3=C(C=C2)C=C(C=C3)OCCCN4CCCCC4,CC1CCN(C(=O)c2ccc3cc(OCCCN4CCCCC4)ccc3c2)CC1
CHEMBL1935100,PXYUUQSMMYUYSP-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,10251,24994127,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)CC3,CC1CCCN1CCCOc1ccc(C2=NNC(=O)CC2)cc1
CHEMBL2387594,PXZRQATTWSLRPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,10252,71659491,CCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,CCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
CHEMBL3632718,PYBNNACSMHESLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,5.1487416512809245,10255,16064748,CC(C)(C)C1=CC(=CC=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C6=CC=CC=C6,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(-c5ccccc5)[nH]4)c3)ccc21
CHEMBL3673937,PYDGBRKMKPMMFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320648,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10256,67201460,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=C(C=C4)OC)OC)F)N=C1,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1
CHEMBL3673937,PYDGBRKMKPMMFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320692,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10256,67201460,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=C(C=C4)OC)OC)F)N=C1,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1
CHEMBL1822525,PYEVUJXYLLDVLP-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21859094.0,IC50,>,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.920818753952375,10260,53465297,CC(CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NN4C(=CC=C4C5=CC=CC=C5N(C)S(=O)(=O)C)C=N3)OC)O,COc1cc(N2CCN(CC(C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1
CHEMBL514794,PYFRREJCFXFNRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,10262,5289110,CC1=C(C=CC(=C1)CNC(=O)C2=CC(=NC=N2)C(=O)NCC3=CC(=C(C=C3)F)C)F,Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F
CHEMBL514794,PYFRREJCFXFNRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,10262,5289110,CC1=C(C=CC(=C1)CNC(=O)C2=CC(=NC=N2)C(=O)NCC3=CC(=C(C=C3)F)C)F,Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F
CHEMBL3137394,PYHNKTKVQRGVDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.823908740944319,10263,76325837,C1CN(CCN1CC2=CC=CC=C2C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(Cc2ccccc2C(F)(F)F)CC1
CHEMBL47529,PYKJFEPAUKAXNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,10268,108137,CC1=C(N2C=CC=C(C2=N1)OCC3=CC=CC=C3)CC#N,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N
CHEMBL47529,PYKJFEPAUKAXNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,10268,108137,CC1=C(N2C=CC=C(C2=N1)OCC3=CC=CC=C3)CC#N,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N
CHEMBL427548,PYLGXNLJVJXKBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,38000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.42021640338319,10270,11523521,C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)C4=CC=C(C=C4)F)F)F)C(=O)O,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(F)cc4)c(F)c3)c(F)c2)CC1
CHEMBL398472,PYRTUYSUPAFERK-HIKGYAAUSA-N,FIBRAURETIN A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,10274,24762429,CC12CC(OC(=O)C1C(CC3(C2C4C5C(C3(C(=O)O4)O)O5)C)O)C6=COC=C6,CC12CC(c3ccoc3)OC(=O)C1C(O)CC1(C)C2C2OC(=O)C1(O)C1OC21
CHEMBL522228,PYVRRGZFIYKCIN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,632.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,6.199282921717615,10276,25033727,C1CC(C2=C(C1)C=C(C=C2)C3=CC(=C(C=C3)O)O)C4=CC=NC=C4.Br,Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1O
CHEMBL3617983,PYZSBQQHZCMXFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26365710.0,IC50,=,1170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.931814138253839,10281,122190697,CC1=NN(C(=C1C(=O)NC(CN2C=CN=C2)C(=O)OC)Cl)C3=CC=CC=C3,COC(=O)C(Cn1ccnc1)NC(=O)c1c(C)nn(-c2ccccc2)c1Cl
CHEMBL2069838,PZADYECUTZNBBF-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,10282,70697123,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=CC=C3,NC(CC(=O)N1CCN(C(=O)c2ccccc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL1760794,PZAIZRLLCHXVBJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21334894.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenyl triazoles as selective inhibitors of 11��-Hydroxysteroid Dehydrogenase Type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10284,54584119,CN1C(=NN=C1C2(CCC2)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)C5=NC=CN=C5,Cn1c(-c2ccc(-c3cnccn3)cc2)nnc1C1(c2ccc(Cl)cc2)CCC1
CHEMBL257767,PZHLUEBYOAPSNB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,10292,44449228,C1CCN(C1)CC2C(CCCN2C(=O)CN(CC#N)C3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4,N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
CHEMBL487572,PZIMFNJQILPVJP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,10295,25138086,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N(C)C)C,CC(=O)Nc1cc(-c2cccc(N(C)C)n2)nc(-n2nc(C)cc2C)n1
CHEMBL2425600,PZJIORSTWTVMPM-UZRFBLNJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,10296,66649578,CC(C)(C)C1=CC(=C(C=C1)F)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cc(C(C)(C)C)ccc3F)C2O)cc(F)c1N)C(F)(F)F
CHEMBL237364,PZLVUHVHOCIJNX-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,10299,44433269,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN,CC(C)CC(NCCN)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL268764,PZUQQORPORVJNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,10305,44266800,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C(=CC(=O)N=C3SCC4=CC=C(C=C4)F)C,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(C)cc(=O)nc1SCc1ccc(F)cc1
CHEMBL2177582,PZYNOSYZPXJRNG-NAHVQIJJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,5.3979400086720375,10311,59454220,CN1CC(C(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)C=CC(=O)NC4=CC=CC=C4N)F,CN1CC(C(=O)Nc2ccc(Cl)cc2)C(c2ccc(C=CC(=O)Nc3ccccc3N)cc2F)C1
CHEMBL1852688,QADPYRIHXKWUSV-UHFFFAOYSA-N,INFIGRATINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,21936542.0,IC50,>,10000.0,NM,,inhibition,biochemical,functional,enzyme_activity,,fluoresecence,,,,7-BENZYLOXY-4-(TRIFLUOROMETHYL)-COUMARIN,,,,INHIBITION OF HUMAN CYP3A4 IN PRESENCE OF NADPH,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,10320,53235510,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
CHEMBL1852688,QADPYRIHXKWUSV-UHFFFAOYSA-N,INFIGRATINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,21936542.0,IC50,>,10000.0,NM,,inhibition,biochemical,functional,enzyme_activity,,fluoresecence,,,,DIBENZYLFLUORESCEIN,,,,INHIBITION OF HUMAN CYP3A4 IN PRESENCE OF NADPH,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,10320,53235510,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
CHEMBL2441342,QAEKSWBVYBVLNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,5.130768280269024,10321,53469060,CN1C=C(C2=C(N=CN=C21)N)C3=C(C4=C(C=C3)N(CC4)C(=O)CC5=NC(=CC=C5)C(F)(F)F)F,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21
CHEMBL2441342,QAEKSWBVYBVLNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,9090.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,5.041436116778033,10321,53469060,CN1C=C(C2=C(N=CN=C21)N)C3=C(C4=C(C=C3)N(CC4)C(=O)CC5=NC(=CC=C5)C(F)(F)F)F,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21
CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,6.259637310505756,10322,64143,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C
CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.698970004336019,10322,64143,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C
CHEMBL1761536,QAIDCNOXZMESAW-JMUKJWEXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10325,54587173,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC(C)(C(=O)O)OC)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(OC)C(=O)O)c1
CHEMBL1761536,QAIDCNOXZMESAW-JMUKJWEXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10325,54587173,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC(C)(C(=O)O)OC)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(OC)C(=O)O)c1
CHEMBL3289811,QAKLYMPRDNHSCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,5.619788758288394,10331,90644770,C1COCC1OC2=NC3=C(C=C2)N=C(N3CC(C4=C(C=C(C=C4)C(F)(F)F)Cl)O)N,Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl
CHEMBL228792,QANMHLXAZMSUEX-UHFFFAOYSA-N,KINETIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,10336,3830,C1=COC(=C1)CNC2=NC=NC3=C2NC=N3,c1coc(CNc2ncnc3nc[nH]c23)c1
CHEMBL228792,QANMHLXAZMSUEX-UHFFFAOYSA-N,KINETIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,10336,3830,C1=COC(=C1)CNC2=NC=NC3=C2NC=N3,c1coc(CNc2ncnc3nc[nH]c23)c1
CHEMBL236519,QASNNAVCCMXYPS-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,10344,44433270,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN,CC(C)CC(NCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3409859,QAUTYBBMQXPFIE-LSDHHAIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,10346,69082854,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC=C(C=C3)OC(F)(F)F)O,COc1cccc(OC)c1C1CC(O)C(=O)N1Cc1ccc(OC(F)(F)F)cc1
CHEMBL84894,QBBSJLRQRYQJOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,<,500.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,10356,21936345,CN(C)C(=O)CN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN=C(N=C5)OC,COc1ncc(Cc2cn(CC(=O)N(CC(=O)N(C)C)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
CHEMBL2385886,QBCRLDPMQHPGIM-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23718281.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 mins prior to NADPH addition measured after 8 mins by LC/MS/MS analysis,"Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu3 Selective and CNS Penetrant Negative Allosteric Modulator (NAM).",J. Med. Chem.,PUBLICATION,,4.522878745280337,10357,60204017,COC1=CC=C(C=C1)C#CC2=CC(=C(C=C2)C(=O)N3CCCC(C3)O)F,COc1ccc(C#Cc2ccc(C(=O)N3CCCC(O)C3)c(F)c2)cc1
CHEMBL2436331,QBGRYKLTKRKXQV-GYUFFBBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.823908740944319,10364,72711250,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)F)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccc(F)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL2165315,QBIRRYYRDPYJNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861193.0,IC50,=,90000.0,NM,,,,,,,,,,,,,,,Inhibition of hepatic CYP3A4,Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,J. Med. Chem.,PUBLICATION,,4.045757490560675,10369,66559847,CN1C(=O)CCC2=CC(=C(C=C21)OC)C3=CN=CC=C3,COc1cc2c(cc1-c1cccnc1)CCC(=O)N2C
CHEMBL399590,QBLLJHIEFPUVNM-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,10372,11546950,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CCCCC4,CCC1CCCC(C2(CC(=O)N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3322590,QBOWGZQRUNUQGL-ZDLGFXPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25036791.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate,Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor.,Eur. J. Med. Chem.,PUBLICATION,,5.0,10377,71763463,C1=CC=C(C(=C1)C2=CNC=C(C2=O)C(=O)NC3=CC4=C(C=C3)C(=CC5=CC=CN5)C(=O)N4)F,O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2C1=Cc1ccc[nH]1
CHEMBL276856,QBOWMQHTHPHCEL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,10378,23395785,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCO)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,Cn1cc(Cc2cn(CC(=O)N(CCO)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
CHEMBL3114718,QBOYRTIWRZBXKC-HFASVGIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,10379,59721239,CCCC(CCC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)NC(=O)C(C(C)C)NC(=O)N(C)CC3=CSC(=N3)C(C)C,CCCC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)NC(=O)C(NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C
CHEMBL2419525,QBTMLSOSPORBBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10383,71817500,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5CCOCC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1
CHEMBL2419525,QBTMLSOSPORBBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899614.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10383,71817500,C1CN(CCC1S(=O)(=O)C2=CC=C(C=C2)CNC(=O)N3CC4=C(C3)C=NC=C4)C5CCOCC5,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1
CHEMBL150999,QBXIGUJIZJQJQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,44300.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.3535962737769305,10391,11195292,CCCCOC1=CC=C(C=C1)C2=NC=CN2,CCCCOc1ccc(-c2ncc[nH]2)cc1
CHEMBL28629,QBYAEFPHWWOQHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,20800.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.681936665037238,10392,11454703,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=NC=C2)N6CCOCC6,Cn1c2ccnc(N3CCOCC3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL1289283,QBYYFLZCKXHEJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10394,24857598,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
CHEMBL1289283,QBYYFLZCKXHEJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20961756.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10394,24857598,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
CHEMBL409493,QBZHGWVJIIGZNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10395,25023858,C1CC1NC(=O)C2=CC=C(C=C2)CN3CCC(CC3)C4=CC=C(C=C4)C(=O)NC5=CC=CC=C5N,Nc1ccccc1NC(=O)c1ccc(C2CCN(Cc3ccc(C(=O)NC4CC4)cc3)CC2)cc1
CHEMBL1080046,QCDCMDPVHPUROA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,10397,46882458,CCCCC1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(CCN(CC3)CC4=CC=NN4)C=C2,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2ccn[nH]2)CC3)cc1
CHEMBL1080046,QCDCMDPVHPUROA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,10397,46882458,CCCCC1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(CCN(CC3)CC4=CC=NN4)C=C2,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2ccn[nH]2)CC3)cc1
CHEMBL2387589,QCEDWPSURNZKTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,10399,71659356,C1=CC=C2C(=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,O=c1[nH]c2ccccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL2425891,QCTNBSORTFEAEF-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,46240.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.334982174587528,10413,71731479,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)C)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3cc(C)ccc3n2)c1=O
CHEMBL3114736,QCYOPAQQXNLZEV-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,10415,76317769,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NCCNC(=O)OCC2=CN=CS2,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NCCNC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL568242,QDHOZPCLAACLAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602099,10424,45484874,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3OC(F)(F)F,CC1(CC(=O)NCc2ccccc2OC(F)(F)F)CC2(CCCCC2)OO1
CHEMBL1829773,QDIAPKPZNBARDD-XDBZFTIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,6.0,10425,53473322,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCNC(=O)NC)C4=CC=C(C=C4)F,CNC(=O)NCCC1(c2ccc(F)cc2)CCN(C(C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1
CHEMBL1097032,QDKVMCOVHGDSAE-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,10428,136086723,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)OC,COC(=O)N1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL3358932,QDMKBJCCHCGTOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,7.0,10431,60026377,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1
CHEMBL2144409,QDMXVKKPYBGIAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25415535.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Inhibitors of c-Jun N-terminal kinases: an update.,J. Med. Chem.,PUBLICATION,,4.301029995663981,10432,57519510,CC1=NC=C(C=C1)C2=NN(C=N2)C3=CC=C(C=C3)NC4=NC=CC(=N4)C5=CC(=CC=C5)N6CCOCC6,Cc1ccc(-c2ncn(-c3ccc(Nc4nccc(-c5cccc(N6CCOCC6)c5)n4)cc3)n2)cn1
CHEMBL1761524,QDNROJXIPJKYJU-CEBSZYIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,10433,25122184,CCOC(=O)C1CC1COC2=CC(=CC(=C2)CN(C3CC3)C(=O)C4CNCCC4C5=CC=C(C=C5)OCCOC6=C(C=C(C=C6Cl)C)Cl)CCCOC,CCOC(=O)C1CC1COc1cc(CCCOC)cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1761524,QDNROJXIPJKYJU-CEBSZYIUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,19300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.714442690992226,10433,25122184,CCOC(=O)C1CC1COC2=CC(=CC(=C2)CN(C3CC3)C(=O)C4CNCCC4C5=CC=C(C=C5)OCCOC6=C(C=C(C=C6Cl)C)Cl)CCCOC,CCOC(=O)C1CC1COc1cc(CCCOC)cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL2441834,QDXBXMYNKPMRPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.113509274827518,10444,57641271,CC1=C(C(=C2C(=N1)CN(C2=O)CC3=NC=CO3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ncco1)C2
CHEMBL2387500,QEECLILKOYZESR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,10446,71659896,CC1=C(C(=CC=C1)Cl)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CC=CC=C5,Cc1cccc(Cl)c1-c1nc2c([nH]1)c(=O)[nH]c1cc(-c3ccccc3)ccc12
CHEMBL1079437,QEHHTVFVEDPISA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,10449,46879553,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC(=O)N4)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12
CHEMBL1079437,QEHHTVFVEDPISA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,10449,46879553,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC(=O)N4)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12
CHEMBL2385096,QEKANLQOSSFFGI-MXWKQRLJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,5.0,10451,71230234,CC(C1=NC2=CN=C3C(=C2N1C4CCC(C4)NCC(F)(F)F)C=CN3)O,CC(O)c1nc2cnc3[nH]ccc3c2n1C1CCC(NCC(F)(F)F)C1
CHEMBL2385096,QEKANLQOSSFFGI-MXWKQRLJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,5.0,10451,71230234,CC(C1=NC2=CN=C3C(=C2N1C4CCC(C4)NCC(F)(F)F)C=CN3)O,CC(O)c1nc2cnc3[nH]ccc3c2n1C1CCC(NCC(F)(F)F)C1
CHEMBL555563,QEKKZTBXSULKCC-IBGZPJMESA-N,VER-156084,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22209458.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10452,44243144,C1CCN(CC1)C(=O)N2CC(C2)OC(C3=CC=C(C=C3)Cl)C4=C(N=CC=C4)Cl,O=C(N1CCCCC1)N1CC(OC(c2ccc(Cl)cc2)c2cccnc2Cl)C1
CHEMBL1270215,QEMGBPOATYALAI-OBYDGYHJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20864344.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and optimization of adamantyl carbamate inhibitors of 11��-HSD1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10455,52944645,CC(C)(C)OC(=O)NC1CCN(C1)C(=O)OC2C3CC4CC(C3)CC2C4,CC(C)(C)OC(=O)NC1CCN(C(=O)OC2C3CC4CC(C3)CC2C4)C1
CHEMBL17350,QEMSVZNTSXPFJA-HNAYVOBHSA-N,TRAXOPRODIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,10457,219101,CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O,CC(C(O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL239495,QENBZBQERGRPHC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,10458,23647884,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(CC)CC,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(CC)O2
CHEMBL2021600,QENXTKAMWKICNF-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20491477.0,IC50,>,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.",J. Med. Chem.,PUBLICATION,,4.619788758288394,10459,44184875,CC(C(C)(C)C)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F,CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C
CHEMBL2442495,QEOBCNBMVHTMBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252546.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10460,46220498,CC1=C(N(N=C1C2=CC=CC=C2)C3=NC(=CS3)C(=O)O)C4=CC=CC=C4,Cc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1
CHEMBL406832,QERIBPHEBTWPBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,10466,5201490,CC1=CN=C(N=C1)CNC2=NC(=NC(=C2)C3=CC=CC=C3)C4=CC=CC=N4,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccccn3)n2)nc1
CHEMBL222460,QESHSZWKJULSAR-UHFFFAOYSA-N,BMS-223131,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0915149811213505,10467,9951995,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO
CHEMBL222460,QESHSZWKJULSAR-UHFFFAOYSA-N,BMS-223131,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzylether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,10467,9951995,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO
CHEMBL1935416,QEWJHGKQGHFKCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153342.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10474,57404027,CS(=O)(=O)CCCOC1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C4CCC4,CS(=O)(=O)CCCOc1ccc2c(c1)CCC1(CCN(C3CCC3)CC1)O2
CHEMBL1222798,QEXOFWNDNHZFRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,10475,49864988,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCOC5=CC=CC=C5)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCOc3ccccc3)c3ccccc32)CC1
CHEMBL114297,QEYKJWXDJGDHTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,10477,44341461,CN(C)CCCOC1=CC=C(C=C1)N2C=CN=C2,CN(C)CCCOc1ccc(-n2ccnc2)cc1
CHEMBL3669002,QEZRYOVBHVLYKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320644,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10480,52934020,CC1=NC(=CC=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)C,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1
CHEMBL3669002,QEZRYOVBHVLYKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320688,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10480,52934020,CC1=NC(=CC=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)C,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1
CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.698970004336019,10485,5284616,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
CHEMBL3112858,QFOFHWPQHOESHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.508638306165727,10489,57389627,C1CN(C2=CC=CC(=C21)C3=CC=NC=C3)C(=O)CC4=NC(=O)C=C(N4)N5CCOCC5,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(-c3ccncc3)cccc21
CHEMBL494948,QFPUYOAZKKYGQE-CHWSQXEVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19246199.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,10492,44573547,CC1CNCCN1C2=NC=C(C(=N2)OC(C)CC3=CC(=CC=C3)F)F,CC(Cc1cccc(F)c1)Oc1nc(N2CCNCC2C)ncc1F
CHEMBL2387587,QFQMKJXIFPLCNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,10493,71659894,C1=CC(=CC(=C1)Cl)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,O=c1[nH]c2cc(-c3cccc(Cl)c3)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
CHEMBL2048486,QFTZJLCYYMSCKG-TWGBQZSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,10497,11559484,CCC1=CC=C(C=C1)CC2=CC(=CC=C2)C3CC(C(C(C3O)O)O)CO,CCc1ccc(Cc2cccc(C3CC(CO)C(O)C(O)C3O)c2)cc1
CHEMBL2048486,QFTZJLCYYMSCKG-TWGBQZSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,10497,11559484,CCC1=CC=C(C=C1)CC2=CC(=CC=C2)C3CC(C(C(C3O)O)O)CO,CCc1ccc(Cc2cccc(C3CC(CO)C(O)C(O)C3O)c2)cc1
CHEMBL3115175,QFYWEWHEOQPTQQ-XMOVUWPTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,10502,59721398,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CN(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CN(C)C)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL147587,QGFYFOHMBDMGBZ-UHFFFAOYSA-N,ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.0,10509,2166,CCN(CC)CC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
CHEMBL147587,QGFYFOHMBDMGBZ-UHFFFAOYSA-N,ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Activation of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,4.0,10509,2166,CCN(CC)CC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16033281.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Cytochrome P450 3A4,"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,PUBLICATION,,4.0,10511,11243969,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,10511,11243969,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,10511,11243969,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,10511,11243969,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
CHEMBL385517,QGJUIPDUBHWZPV-SGTAVMJGSA-N,SAXAGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22496391.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,10511,11243969,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
CHEMBL380957,QGLWIDUCGVENCV-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,5.0,10512,11661821,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCN5CCC(C5)O)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCCN5CCC(O)C5)c(C)c34)ccc2[nH]1
CHEMBL2170633,QGOFFPIIAILOFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,10515,58269562,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,CS(=O)(=O)c1cccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)c1
CHEMBL3407575,QGOICCMBEDDFCI-NXQGQTBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,0.33,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Homogenous Time-Resolved Fluorescence Assay (HTRF). The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",Benzoic acid derivative MDM2 inhibitor for the treatment of cancer,,PATENT,,9.481486060122112,10516,77108133,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC(=C(C=C3)Cl)F)C4=CC(=CC=C4)Cl)CC(=O)NC5=CC(=C(C=C5)C(=O)O)OC,COc1cc(NC(=O)CC2(C)CC(c3cccc(Cl)c3)C(c3ccc(Cl)c(F)c3)N(C(CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O
CHEMBL3358935,QGPHIACZTUTSAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.698970004336019,10517,60026787,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=C(C=CC(=C4)F)OC,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F
CHEMBL3417525,QGPXEIMWTKWHMH-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,4.522878745280337,10519,66764813,CC(C1CC1)(C2=CC=C(C=C2)C3=CN=C(N=C3)N)C4=NOC(=N4)C5=CN(N=C5)CC(=O)N(C)C,CN(C)C(=O)Cn1cc(-c2nc(C(C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1
CHEMBL469431,QGPZJURATJCKHO-KNRSITRYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.229147988357856,10520,14861225,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)O)O,CC(=O)OC1C(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)OC(C)C(O)C1O
CHEMBL3673962,QGQODCDKRMKJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320630,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10521,52935813,COC1=C(C=CC=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=CC=N4)F,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1
CHEMBL3673962,QGQODCDKRMKJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320674,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,10521,52935813,COC1=C(C=CC=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=CC=N4)F,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1
CHEMBL196478,QGSYCKKZFPLTMQ-UBFVSLLYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,10524,6918854,CC(C)CC1C(=O)NC(C(=O)N1C(C2=C(C=C(C=C2)F)F)C(=O)NC(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)NC(C)C)c1ccc(F)cc1F
CHEMBL2425154,QGUGSIVNZPWVQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10526,72189809,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NN=N4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1
CHEMBL2413849,QGUMEWLTIYRZFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23845281.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using nifedipine as substrate,"Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: A novel, potent and selective type 5 17��-hydroxysteroid dehydrogenase inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,4.0,10527,25210756,CC1=CC2=C(C=C1)NC(=C2)C(=O)N3CCC(CC3)CC(C)(C)O,Cc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1
CHEMBL3326581,QGYOUMYRQKOXET-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,10533,46191502,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4)F)(C)C)C=N1,Cc1cc2c(NC(=O)NC3CC(C)(C)Oc4cc(F)ccc43)cccc2cn1
CHEMBL3702703,QHRIPYHARJRXIH-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8170.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.087777943467584,10546,89718336,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CC8CCNCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCNCC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1188,QHSMEGADRFZVNE-UHFFFAOYSA-N,ALPHA-HYDROXY-MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,2700.0,NM,,inhibition,tissue,binding,,,,,,,,,,,,,,,,5.568636235841013,10547,107917,C1C2=CN=C(N2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4F)CO,OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
CHEMBL1188,QHSMEGADRFZVNE-UHFFFAOYSA-N,ALPHA-HYDROXY-MIDAZOLAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10547,107917,C1C2=CN=C(N2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4F)CO,OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
CHEMBL3702702,QHSQTDUGXXBHGV-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,10548,89718318,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CC8CCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCCC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2338475,QHTHSQXFWCRPEY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,10549,71525223,CC(=O)C1=C(C=CC(=C1)NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)OC3=CC4=CC=CC=C4N=C3,CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cnc2ccccc2c1
CHEMBL1089793,QIBDSCJTWMYQTC-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10553,46830336,C1CN(CC1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=C(C=CC(=C4)F)F,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CCN(CCN2CCN(C(=O)c3cc(F)ccc3F)CC2)C1
CHEMBL205993,QIDWKMNIWOOQON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,10555,11541506,CC(C)(C(=O)O)N1CCC(C1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)C1
CHEMBL1098711,QIEKBURWQYYQLT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,10556,136086719,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)C,CC(=O)N1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL2425890,QIHMOUKJDLOSDC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,58280.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.234480456902047,10560,71731478,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=C2)C=C(C=C3)F)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3cc(F)ccc3n2)c1=O
CHEMBL476567,QIIVIPMIUSRDGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10563,44579191,CC(=O)NCC(=O)NC(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,CC(=O)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL2181775,QIKHXKPKHSBWTR-GIJQJNRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.080921907623926,10564,71462837,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=CC=C(C=C5)Cl)C6CCCC6,Cn1c(-c2ccc(Cl)cc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL410503,QIMASXGTWQEFGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,5.113509274827518,10567,3114841,CS(=O)(=O)OCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1
CHEMBL565983,QIMHTADQASRTKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,10568,45484892,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)OC(F)(F)F,CC1(CC(=O)NCc2ccc(OC(F)(F)F)cc2)CC2(CCCCC2)OO1
CHEMBL3664673,QIMKZFAYADXKFW-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,28000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.552841968657781,10570,59635755,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC(F)(F)F)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(CC(F)(F)F)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1668249,QIOGTBSZDDTWRV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10573,52918135,C1CCC(CC1)C(C(=O)NC2=C(C=C(C=C2)OC3(CC3)C(=O)O)F)N4C5=CC(=C(C=C5N=C4C6=CC=C(C=C6)Cl)F)F,O=C(Nc1ccc(OC2(C(=O)O)CC2)cc1F)C(C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
CHEMBL584554,QIPWTYSOANVUKJ-WZONZLPQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19783143.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10575,45482789,CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5,CCN(CC)C(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C(=O)Nc2ccccc2)C1
CHEMBL54976,QIVBCDIJIAJPQS-VIFPVBQESA-N,TRYPTOPHAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,10581,6305,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N,NC(Cc1c[nH]c2ccccc12)C(=O)O
CHEMBL54976,QIVBCDIJIAJPQS-VIFPVBQESA-N,TRYPTOPHAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,10581,6305,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N,NC(Cc1c[nH]c2ccccc12)C(=O)O
CHEMBL396432,QIYPSKLPQCIXMB-XDFJSJKPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,10587,44433275,CCN(CC)CCNC(CC(C)C)C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O,CCN(CC)CCNC(CC(C)C)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2069804,QIZIZVBSJUAZHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,10588,863679,C1CCC(CC1)C2=NN=C(O2)C3=CC=NC=C3,c1cc(-c2nnc(C3CCCCC3)o2)ccn1
CHEMBL402805,QJEQMNOHVFVNGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,770.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.113509274827518,10591,44448772,CN(CC(=O)N1CCCC(C1CN2CCOCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1
CHEMBL209864,QJFALSJVPBJZRP-GMKZXUHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,10594,11511019,CC1=CC=C(O1)C(C(=O)NC(C)C)N2C(C(=O)NC(C2=O)C3CC4=CC=CC=C4C3)CC(C)C,Cc1ccc(C(C(=O)NC(C)C)N2C(=O)C(C3Cc4ccccc4C3)NC(=O)C2CC(C)C)o1
CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,6.920818753952375,10600,445643,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC
CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22205779.0,IC50,=,620.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method,Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.,Drug Metab. Dispos.,PUBLICATION,,6.2076083105017466,10600,445643,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC
CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.0,10600,445643,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC
CHEMBL3422007,QJNHNXFWOFSZPP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.346787486224656,10603,71549913,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CC=CC(=N5)C,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1
CHEMBL297784,QJQORSLQNXDVGE-UHFFFAOYSA-N,SB-206553,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9357513.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,PUBLICATION,,4.0,10606,5163,CN1C=CC2=CC3=C(CCN3C(=O)NC4=CN=CC=C4)C=C21,Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1
CHEMBL3310995,QJSIDAFXZGMWSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,136000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.8664610916297826,10607,71143790,C1=CC=NC(=C1)C(C(CN2C=NN=N2)(C3=C(C=C(C=C3)F)F)O)(F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccccn1
CHEMBL1214452,QJVMDGUSBHUPRY-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,10610,46900139,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=NC=C(C=C3)F,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)cn3)cc2C1
CHEMBL1214448,QJVMDGUSBHUPRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,10611,11573549,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=NC=C(C=C3)F,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)cn3)cc2C1
CHEMBL112532,QJWFZZZHWWOBNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,348.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,6.458420756053419,10613,11321889,CCCCOC1=CC=C(C=C1)N2C=CN=C2,CCCCOc1ccc(-n2ccnc2)cc1
CHEMBL112532,QJWFZZZHWWOBNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,348.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.458420756053419,10613,11321889,CCCCOC1=CC=C(C=C1)N2C=CN=C2,CCCCOc1ccc(-n2ccnc2)cc1
CHEMBL228814,QJZRFPJCWMNVAV-HHHXNRCGSA-N,ISPINESIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22248262.0,IC50,=,4100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,5.3872161432802645,10615,6851740,CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C,Cc1ccc(C(=O)N(CCCN)C(c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1
CHEMBL2448724,QKAQPMIIFZVJKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.698970004336019,10617,73355723,C1=CC=C(C=C1)C2=NC=C(S2)C(=O)NC3=CC=CC=C3N4C=CN=C4,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1
CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,6095.37,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.214999926783721,10621,5450,C1CCC(CC1)N=C(N2CCC(CC2)C3=CN=CN3)S,SC(=NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
CHEMBL2058903,QKFSCFHGGPCBMY-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,44.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.356547323513813,10623,59603334,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CC5=C(C=C4)OCO5)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3ccc4c(c3)OCO4)cc2o1
CHEMBL501119,QKIQAUSGMKJYFS-CWFCOSEVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,98200.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.00788851221305,10627,11299991,CC1=CC(C23C1CC4=C(C(=O)OC4CC2(O3)C)C)O,CC1=CC(O)C23OC2(C)CC2OC(=O)C(C)=C2CC13
CHEMBL2436978,QKKIWEILHCXECO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,=,16200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,4.790484985457369,10628,54764565,CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(NC=C4C5=CC6=C(C=C5)NC=C6)N=C3,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1
CHEMBL479628,QKRGRWXDVSZBQO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,10634,44570256,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=C(C=CC(=C4)Cl)Cl,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2Cl)cc1C1CC1
CHEMBL1669426,QLDMAQDSTHZTSU-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10638,53318874,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN=C4,CC(C1=C(CCN(C)Cc2cnccn2)Cc2ccccc21)c1cnccn1
CHEMBL1269858,QLFGDTPACJHLRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20850301.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10639,49831162,CN(C1=NC(=NC=C1)NC2=CC(=CC(=C2)N3CCOCC3)N4CCOCC4)C5=CC=CC6=C5C=NN6,CN(c1ccnc(Nc2cc(N3CCOCC3)cc(N3CCOCC3)c2)n1)c1cccc2[nH]ncc12
CHEMBL478035,QLHPJXQAKQNIOE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10642,44579235,C1=CC=C2C(=C1)C(C3=C(S2)C=CC(=C3)Cl)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2Sc2ccc(Cl)cc21
CHEMBL1669410,QLIYPKVJEXOVDM-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10643,53326724,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC#N,CC(C1=C(CCN(C)CCC#N)Cc2ccccc21)c1cnccn1
CHEMBL3288450,QLKVYUYEIZLSOY-QAJMXTGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,5.1249387366083,10646,90644647,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3CC(CO)O)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2CC(O)CO)CC1
CHEMBL3288450,QLKVYUYEIZLSOY-QAJMXTGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10646,90644647,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3CC(CO)O)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2CC(O)CO)CC1
CHEMBL220360,QLYKJCMUNUWAGO-GAJHUEQPSA-N,TARANABANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,10649,11226090,CC(C(CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F,CC(NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)C(Cc1ccc(Cl)cc1)c1cccc(C#N)c1
CHEMBL2170610,QMHRLXNEGYTSRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,10659,51031001,CC(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,CC(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.657577319177793,10660,9949648,CC(C1=CC(=CC=C1)N2CCOCC2)NC(=O)C=CC3=CC=CC=C3,CC(NC(=O)C=Cc1ccccc1)c1cccc(N2CCOCC2)c1
CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin],Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.568636235841013,10660,9949648,CC(C1=CC(=CC=C1)N2CCOCC2)NC(=O)C=CC3=CC=CC=C3,CC(NC(=O)C=Cc1ccccc1)c1cccc(N2CCOCC2)c1
CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.481486060122112,10660,9949648,CC(C1=CC(=CC=C1)N2CCOCC2)NC(=O)C=CC3=CC=CC=C3,CC(NC(=O)C=Cc1ccccc1)c1cccc(N2CCOCC2)c1
CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.207608310501746,10660,9949648,CC(C1=CC(=CC=C1)N2CCOCC2)NC(=O)C=CC3=CC=CC=C3,CC(NC(=O)C=Cc1ccccc1)c1cccc(N2CCOCC2)c1
CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with Benzoylresorufin,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.119186407719209,10660,9949648,CC(C1=CC(=CC=C1)N2CCOCC2)NC(=O)C=CC3=CC=CC=C3,CC(NC(=O)C=Cc1ccccc1)c1cccc(N2CCOCC2)c1
CHEMBL317935,QMIMHUDEVKGOTQ-DVQDXYAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,96000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,4.017728766960431,10660,9949648,CC(C1=CC(=CC=C1)N2CCOCC2)NC(=O)C=CC3=CC=CC=C3,CC(NC(=O)C=Cc1ccccc1)c1cccc(N2CCOCC2)c1
CHEMBL2177818,QMMOUPNLBRDPCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,10666,58344912,C1=CC=C(C=C1)NC(=O)CC2=CC=C(C=C2)N3C4=C(C=CC=N4)N=C3C5=C(N=CC=C5)N,Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1
CHEMBL3702688,QMNHISFQHZSZCX-JUKUECOXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3420.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.465973893943865,10668,89718330,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(O7)C(=O)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N(C)C)o5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2165507,QMOQTGNDEOUYLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.920818753952375,10669,24937637,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CNC5=CC(=C4)C#N)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(C#N)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL520413,QMSZYSVYDVBLRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.2441251443275085,10675,11247557,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=CC(=CC=C4)OC(F)(F)F,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(OC(F)(F)F)c2)cc1C1CC1
CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,10678,45487870,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10678,45487870,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,4.585026652029182,10678,45487870,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
CHEMBL566685,QMWKLCXWSJTEFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,4.301029995663981,10678,45487870,CC1=NSC(=C1)C2=NN3C(=NN=C3CNC4=C5C(=NC=C4)C=C(C=N5)OC)C=C2,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1
CHEMBL404229,QNAWNEAEBOQURR-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,10684,44447295,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)C(CC5=C(C=CC=C5F)F)NC(=O)C6(CC6)C(F)(F)F,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)C(Cc1c(F)cccc1F)NC(=O)C1(C(F)(F)F)CC1
CHEMBL189164,QNIZBEIHYCQTEQ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344075,10691,21018389,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=CC=C4Cl)N,NC(Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL1668022,QNNBMSGFNQRUEH-OCPPCWRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10693,23577461,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O.Cl,CCCCN1C(=O)C(C(O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
CHEMBL1668019,QNNBMSGFNQRUEH-PQQSRXGVSA-N,APLAVIROC HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10694,6918686,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O.Cl,CCCCN1C(=O)C(C(O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
CHEMBL1668021,QNNBMSGFNQRUEH-QBYKQQEBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10695,11947757,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O.Cl,CCCCN1C(=O)C(C(O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
CHEMBL1668020,QNNBMSGFNQRUEH-XZVFQGBBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10696,53324597,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O.Cl,CCCCN1C(=O)C(C(O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
CHEMBL3393469,QNOOVTZVMOOSAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,6.721246399047171,10697,59825673,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=CC=CC=C6N5,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1
CHEMBL448743,QNSOPUXDEXJMIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,<,200000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,3.6989700043360187,10702,18407230,C1CC(=O)C2=C1C=C(C=C2)C3=CN=CC=C3,O=C1CCc2cc(-c3cccnc3)ccc21
CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,5.154901959985743,10707,76321101,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6600.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,5.180456064458132,10707,76321101,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,5.154901959985743,10707,76321101,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
CHEMBL3104488,QODANUKDEHILIF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,10707,76321101,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
CHEMBL1909988,QOGSEZRHWWWULE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,10708,15951427,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccccc1)C2=O
CHEMBL567487,QOJWZANXROFNQS-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,10718,44473096,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)Cl,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(Cl)nc3)ccc2o1
CHEMBL391963,QOPIOMWNHRCPAA-RPBOFIJWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,10721,44433789,CC(=O)N1CCC(CC1)C(=O)N2CC(C(C2)C(=O)N(C)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=CC=CC=C4,CC(=O)N1CCC(C(=O)N2CC(C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccccc3)C2)CC1
CHEMBL2178252,QOQWGXFCUOWNQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,10722,66850717,CN1C=C(C(=N1)C2=CC(=CC=C2)Cl)NC(=O)C3=C4N=CC=CN4N=C3,Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)n1
CHEMBL1669425,QORUSIWOKHYRCP-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1281.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.892450870255313,10723,51039226,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=NC=C4,CC(C1=C(CCN(C)Cc2ccncc2)Cc2ccccc21)c1cnccn1
CHEMBL1951914,QOSMEMHKXNNIGG-SSEXGKCCSA-N,AZD5672,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22266038.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,10725,11614352,CCN(C1CCN(CC1)CCC(C2CCN(CC2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CCC(c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1
CHEMBL461422,QOTMLIIRYJJNCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,10726,135875713,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)C,Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
CHEMBL3702793,QOWBPCJXESFQOP-VBXQXZIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7600.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.119186407719209,10730,89718293,CN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3403817,QOZFSPYDMIHYGH-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.267606240177032,10733,71288752,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C7CCC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403817,QOZFSPYDMIHYGH-HNLCVBAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,10733,71288752,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C7CCC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL2017098,QPHJBQDZTCDVEK-ZHRRBRCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,10739,46932136,CC1=C(C(=CC=C1)C2=NOC(=C2Br)C3CNCCC3(C4=CC(=C(C=C4)F)F)O)C,Cc1cccc(-c2noc(C3CNCCC3(O)c3ccc(F)c(F)c3)c2Br)c1C
CHEMBL3318997,QPIAIQHJZYBDGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050172.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.026872146400302,10740,86279146,CC1=CC2=C(C=C1C#N)N=C(N2)C3CCN(CC3)CCN4C(=O)C=CC5=C4C=C(C=N5)OC,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1
CHEMBL2420310,QPJUVRIRYLMERM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23855836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,PUBLICATION,,5.0,10741,25172265,C1CN(CCN1CCO)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7,O=C(CN1CCN(CCO)CC1)Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)c2sc3ccccc3c12
CHEMBL1254079,QPLQDYDXYCUKKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,7.0,10743,11661172,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=C(N2)C=NC=C3)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F
CHEMBL227464,QPRAFCFDOZPSSH-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.301029995663981,10748,16658022,C1CC(CN(C1)C2=NC3=C(C(=CC=C3)F)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2cccc(F)c2c1=O
CHEMBL2158225,QPSVRPUGGFUWCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,10749,11497455,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CCO)NC(=O)C4=NC=C(N4)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCO)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL390002,QQDQTWDEUJPACU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,10760,135681833,CC1CN=C(N1)C2=CC3=C(C(=C2)C)N=C(N3)C4=C(C=CNC4=O)NCC(C5=CC(=CC=C5)Cl)O,Cc1cc(C2=NCC(C)N2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2181893,QQEJGTCLITVFBA-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.522878745280337,10762,71461109,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=CN=CS5)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2cncs2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL3673964,QQYBNPCNVNQSRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320633,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10781,52936035,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
CHEMBL3673964,QQYBNPCNVNQSRK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320677,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10781,52936035,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)OC)F)N=C1,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
CHEMBL3358963,QRAMNBZTYLSISP-MGPLVRAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,51000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.292429823902063,10782,118723182,CC(C1=NC=NC=C1F)C(CN2C=NN=C2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1cnnc1)c1ccc(F)cc1F
CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,90.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.045757490560675,10794,5353853,C1=CC(=C(C=C1Cl)Cl)CON=C(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL2407951,QRJKRUIJMCAZBY-DARPEHSRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10795,58043414,CC1=CC=CC=C1C(CC(=NO)C2=CN(C(=O)C=C2)C)C3=CC=C(C=C3)Br,Cc1ccccc1C(CC(=NO)c1ccc(=O)n(C)c1)c1ccc(Br)cc1
CHEMBL1271489,QRWIMPDPKYXNEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933413.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DEF substrate by CYPEX bactosome P450 inhibition assay,"2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,10804,3213696,CC1=CC(=CC(=C1)NC(=O)CSC2=NN=C(N2CC3=CC=CO3)C4=C(OC=C4)C)C,Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1
CHEMBL1271489,QRWIMPDPKYXNEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933413.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by CYPEX bactosome P450 inhibition assay,"2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10804,3213696,CC1=CC(=CC(=C1)NC(=O)CSC2=NN=C(N2CC3=CC=CO3)C4=C(OC=C4)C)C,Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1
CHEMBL1257487,QRYUISZNMDTTDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,10809,16678620,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)CC5=CC=NC=C5,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccncc3)C2=O)CC1
CHEMBL1672633,QRZYIOBBNKOVAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10810,53318745,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CO3)C4=C(C=NC=C4)F,O=C(Nc1cnc(-c2ccncc2F)c(-c2cnco2)n1)C1CC1
CHEMBL2170642,QSBOEASQKPQRPF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,10813,58269513,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC=C3,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccccc3)CC2)c(C(F)(F)F)c1
CHEMBL2419492,QSJSWBPRIPCKFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,4.769551078621726,10819,69224988,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)OC)C,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(OC)cc3)CC2)nc1C
CHEMBL3672585,QSJUJJFEVZDXSW-FIRIVFDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.823908740944319,10820,91937391,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCNCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)NC(CCC(Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1
CHEMBL3672585,QSJUJJFEVZDXSW-FIRIVFDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,340.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.468521082957745,10820,91937391,CC(C)C1=NC(=CS1)CN(C)C(=O)NC2(CCNCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC2(C(=O)NC(CCC(Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1
CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4322.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.364315237452778,10822,4011,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
CHEMBL1761522,QSMZHNDKHVVMTF-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,10823,54587171,CCNC(=O)NCCCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC,CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1761522,QSMZHNDKHVVMTF-XDSPJLLDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,10823,54587171,CCNC(=O)NCCCOC1=CC(=CC(=C1)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl)CCCOC,CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL496806,QSPSYONCWQHOSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,10826,24889346,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CNC(=O)NC4=O,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12
CHEMBL496806,QSPSYONCWQHOSB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,10826,24889346,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C4=CNC(=O)NC4=O,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12
CHEMBL1090479,QTBWCSQGBMPECM-UHFFFAOYSA-N,GSK-1070916,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20420387.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate,"Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.",J. Med. Chem.,PUBLICATION,,4.823908740944319,10831,46885626,CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC=CC(=C5)CN(C)C,CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1
CHEMBL1910117,QTCAWQMHWREMFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,10832,57392724,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N(C)C)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N(C)C)C2=O
CHEMBL564547,QTDLNCWVZXZPRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,10834,45271599,CC1=NOC(=N1)C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,Cc1noc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)n1
CHEMBL3326909,QTDRSEIGXUBECZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,10835,46191565,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC=C4F)(CF)CF)C=N1,Cc1cc2c(NC(=O)NC3CC(CF)(CF)Oc4c(F)cccc43)cccc2cn1
CHEMBL445162,QTFCKBFCXDAZIU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20850301.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,10836,25011729,CS(=O)(=O)C1=CC=CC(=C1)NC2=NC=CC(=N2)NC3=C(C=CC4=C3OCO4)Cl,CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1
CHEMBL1916708,QTGFRLQHUVFSMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,10837,44159772,CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)OCC3=CC=C(C=C3)Cl,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccc(Cl)cc1
CHEMBL486950,QTJDEJXKPAATAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,740.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,6.130768280269024,10839,25138075,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CC=C3)OC)C,COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
CHEMBL238945,QTKVIRZNRGRMSC-OAHLLOKOSA-N,SR-895,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10843,16662092,CC(C)C(C(=O)N1CCN(CC1)C2=CC3=C(C=C2)NN=C3)O,CC(C)C(O)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL3326586,QTLBTSMPTYIABU-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.823908740944319,10844,25263541,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=C(C=C4)F)(CF)CF)C=N1,Cc1cc2c(NC(=O)NC3CC(CF)(CF)Oc4ccc(F)cc43)cccc2cn1
CHEMBL2347159,QTLWLBUJOKPYEQ-IRXDYDNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,10846,71580631,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)N=[N+]=[N-])NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C
CHEMBL3604701,QTUZZGDVIHVSHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,5.0,10854,91827500,CC1=C(C(=CC=C1)C)CNC2=C3C=CC=C(C3=NC(=C2)C)C(=O)N,Cc1cc(NCc2c(C)cccc2C)c2cccc(C(N)=O)c2n1
CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,7.568636235841013,10855,11757854,CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CC(c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,68.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,7.167491087293763,10855,11757854,CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CC(c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,650.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,6.187086643357144,10855,11757854,CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CC(c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
CHEMBL1939697,QTVDULQPUXPKEL-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,5.6777807052660805,10855,11757854,CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CC(c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1
CHEMBL377512,QUBCQRMRMDXUHX-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,18.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.7447274948966935,10858,23644725,CC(=O)N(C)CCN1CCCC2=C1C=C(C=C2)OCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CCN(C)C(C)=O)CCC3)cc1
CHEMBL1091356,QUBPQLLMMSZSGD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223663.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10860,46866604,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5C6CCC5COC6)C7CCOCC7,CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1
CHEMBL1910113,QUDCMYBYHAHRMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,10861,15950542,CC1=C(C(=C2CN(C(=O)C2=N1)CCO)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CCO)C2=O
CHEMBL559565,QUNIRDORWCGMDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.6020599913279625,10869,44190263,CC1=C(C(=NC=C1)CNC(=O)C2CCCCC2)COC3=CC=CC4=C(C=C(N=C43)C)C5=CC=NN5C,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C3CCCCC3)c2n1
CHEMBL2170615,QUNSHWVUJWWFTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.619788758288394,10870,58269523,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)S(=O)(=O)N,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccc(S(N)(=O)=O)cc3)CC2)c(C(F)(F)F)c1
CHEMBL2017108,QUOFNJSDYRDJLR-WSXYJJAVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10872,58083331,CC(C1=C(ON=C1C2CNCCC2(C3=CC(=C(C=C3)F)F)O)C4=CC=CC=C4CCNC(=O)C)O,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2(O)c2ccc(F)c(F)c2)c1C(C)O
CHEMBL1080244,QURAXYQDHTYNMN-KBPBESRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,10875,46883370,CCN(CC(C)NC(=O)OCC1=CN=CS1)CC(C)NC(=O)OCC2=NC=CS2,CCN(CC(C)NC(=O)OCc1cncs1)CC(C)NC(=O)OCc1nccs1
CHEMBL1080417,QURAXYQDHTYNMN-UONOGXRCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,1790.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.747146969020107,10876,46883371,CCN(CC(C)NC(=O)OCC1=CN=CS1)CC(C)NC(=O)OCC2=NC=CS2,CCN(CC(C)NC(=O)OCc1cncs1)CC(C)NC(=O)OCc1nccs1
CHEMBL1080418,QURAXYQDHTYNMN-ZIAGYGMSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.876148359032914,10877,46883372,CCN(CC(C)NC(=O)OCC1=CN=CS1)CC(C)NC(=O)OCC2=NC=CS2,CCN(CC(C)NC(=O)OCc1cncs1)CC(C)NC(=O)OCc1nccs1
CHEMBL3114726,QUSGSABPASEHDF-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,10878,76335965,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCN(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCN(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL381717,QUUUOVGZDVVVGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16297617.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10880,9835305,CN(C)CCCOC1=CC=C(C=C1)CN2CCCCC2,CN(C)CCCOc1ccc(CN2CCCCC2)cc1
CHEMBL3114715,QUZLDZPTAVNVTK-RVXMEZTNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,10885,59721363,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C=CC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(C=CC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL3091531,QVCOEHDVYXQCHW-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24176395.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,"2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10891,57877765,CN1C(=O)C=C(N=C1N2CCOC(C2)C3=CC=C(C=C3)F)C4=C(C=NC=C4)F,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2F)cc1=O
CHEMBL2062809,QVEWCURGCSBRER-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22594690.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779.",J. Med. Chem.,PUBLICATION,,4.619788758288394,10895,57502388,CN1CCC(CC1)C2=CC(=CC=C2)NC3=NN4C=CC=C(C4=N3)C5=CC=C(C=C5)S(=O)(=O)C,CN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1
CHEMBL393941,QVNUOJRVQDGJQW-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,10904,44435394,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,CC(C)(CO)N1CCN(C(=O)OC2(C3CCCC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL393941,QVNUOJRVQDGJQW-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,10904,44435394,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,CC(C)(CO)N1CCN(C(=O)OC2(C3CCCC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL1835783,QVUQXLNBQGFHKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10910,54753627,CN1C(=O)C2=C(CCC2)C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCC2
CHEMBL391964,QVYOBGVPVVZIAA-FTJBHMTQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,10915,44433797,CC1=C(C=CC(=C1)F)C2CN(CC2C(=O)N(C)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C4CCN(CC4)C(=O)C,CC(=O)N1CCC(C(=O)N2CC(C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,10917,4601,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,5.823908740944319,10919,441243,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(O)C(Cc1ccccc1)NC(=O)C(CC(N)=O)NC(=O)c1ccc2ccccc2n1
CHEMBL2425147,QWBIFVYQZVMANV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10920,72189515,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=NN=C4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1
CHEMBL252001,QWBIJZNHHTVJRM-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,10921,44447024,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC(=NO4)CN(C)C(C)(C)CO,CCC1CCCC(C2(Cc3nc(CN(C)C(C)(C)CO)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2017089,QWDANQMCVSOTGM-UHFFFAOYSA-N,GW694481,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,10926,70689554,CC1=C(C(=NO1)C)C2=CC3=NC=C(C(=C3C=C2)NC4=CC=CC=C4)C(=O)N,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(N)=O)cnc2c1
CHEMBL2437425,QWEGNKRBUGIZBY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10927,72375000,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)CC(F)(F)F)CC5=CC(=NC=C5)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL515387,QWEWGXUTRTXFRF-KBPBESRZSA-N,GOSOGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19275964.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10928,11516136,C1CN(CC1(F)F)C(=O)C2CC(CN2)N3CCN(CC3)C4=NC=CC=N4,O=C(C1CC(N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1
CHEMBL3702740,QWFNQVFYLFOPLC-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,17890.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.747389659432627,10929,89718471,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN(C)C)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1837040,QWHITGKBRLEYSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,10931,10345610,CC(=O)N1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,CC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
CHEMBL1080717,QWOUZMOGMXMQHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,10935,46880206,CC1=C(C(=CC=C1)C)CNC2=NC=CN3C2=CC(=C3C)C,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12
CHEMBL1080717,QWOUZMOGMXMQHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,10935,46880206,CC1=C(C(=CC=C1)C)CNC2=NC=CN3C2=CC(=C3C)C,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12
CHEMBL568438,QWQVLGPEHGKMST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,10937,45484918,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=N3,CC1(CC(=O)NCc2ccccn2)CC2(CCCCC2)OO1
CHEMBL1795039,QWWBEGGBLMBTSG-LCDQZUQSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,51900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.284832642151542,10941,56679632,C1=CC(=CN=C1)C2=CC=C(O2)C=NO.C1=CC(=CN=C1)C2=CC=C(O2)C=NO,ON=Cc1ccc(-c2cccnc2)o1
CHEMBL1215623,QWWNXNFWXOZGLJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,10942,46914582,CC1=C(C(C(=C(N1)CN2C=NN=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
CHEMBL1215622,QWWNXNFWXOZGLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.920818753952375,10943,46914579,CC1=C(C(C(=C(N1)CN2C=NN=N2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
CHEMBL3695718,QXEIYUPKPSVTRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10950,56952795,CC1=C(SC(=N1)C)CNC2=CC(=NC3=CC=NN32)C4CC4,Cc1nc(C)c(CNc2cc(C3CC3)nc3ccnn23)s1
CHEMBL1289614,QXIJKQBZACKAMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,<,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,10955,52948857,CN1CCN(CC1)CCCN(C2CCC3(C2C3)C4=CC=C(C=C4)C#N)C(=O)NC5=CC(=C(C=C5)F)C(F)(F)F,CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)C2CCC3(c4ccc(C#N)cc4)CC23)CC1
CHEMBL3702782,QXKIAKSRFIMLSF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4050.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.392544976785332,10958,89718455,CC(C)N(CCNC1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C)C(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C(C)C)C(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1951347,QXOYUYUTBFDIFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,10962,57393590,CCC1=CNC2=NC=NC(=C12)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC(C)C,CCc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12
CHEMBL3218858,QXOZRBMOILEYGU-QMKUDKLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,10963,89738540,COC1=C(C=CC(=C1)CN2CCOCC2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl,COc1cc(CN2CCOCC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3218858,QXOZRBMOILEYGU-QMKUDKLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,,MedChemComm,PUBLICATION,,4.522878745280337,10963,89738540,COC1=C(C=CC(=C1)CN2CCOCC2)C3=NC4=NC=C(C(=C4N3)NC5C6CC(C5C(=O)N)C=C6)Cl,COc1cc(CN2CCOCC2)ccc1-c1nc2ncc(Cl)c(NC3C4C=CC(C4)C3C(N)=O)c2[nH]1
CHEMBL3673981,QXPPFGDYXVBPPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320620,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10964,52934259,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)F,Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
CHEMBL3673981,QXPPFGDYXVBPPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320664,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,10964,52934259,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)F,Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
CHEMBL1214399,QXQSUBKWSHMXDP-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,10965,46398805,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=C(C=C3)F,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)nc3)cc2C1
CHEMBL1214338,QXQSUBKWSHMXDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,10966,11544537,CC(C)S(=O)(=O)NC1CC2=C(C1)C=C(C=C2)C3=CN=C(C=C3)F,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)nc3)cc2C1
CHEMBL391615,QXYXAFHTANBIQX-SXOMAYOGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,49000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.309803919971486,10974,44433798,CC1=C(C=CC(=C1)F)C2CN(CC2C(=O)N(C)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C4CCN(CC4)C(=O)C,CC(=O)N1CCC(C(=O)N2CC(C(=O)N(C)C(C)(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL1287901,QYFPABITTUFHKR-ZMBIFBSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21074430.0,IC50,=,11900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.924453038607469,10978,50925422,CC1=C(C=C(C=C1)F)CN2C(=CC3=C2C(=O)N(C=N3)C)N4CCCC(C4)(C)N.Cl,Cc1ccc(F)cc1Cn1c(N2CCCC(C)(N)C2)cc2ncn(C)c(=O)c21
CHEMBL230204,QYHQSWFHKDOPJR-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,10979,136117992,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC(CC4=CC=CC=C4)CO)N5C=CN=C5,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NC(CO)Cc4ccccc4)cc[nH]c3=O)nc12
CHEMBL2070139,QYIHIOVAOFXKMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,10981,70695117,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC=C3C4=CC=CC=C4,CCCS(=O)(=O)c1ccc2nc(-c3ccccc3-c3ccccc3)[nH]c2c1
CHEMBL392525,QYKHWEFPFAGNEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17933533.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,10985,16202152,CN(C)C1=CC=C(C=C1)C2=NC3=NC=C(C(=C3N2)N4CCN(CC4)CC(=O)NC5=NC=CS5)Cl,CN(C)c1ccc(-c2nc3ncc(Cl)c(N4CCN(CC(=O)Nc5nccs5)CC4)c3[nH]2)cc1
CHEMBL561379,QYMLHNYPNZUQCL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,10987,45269096,C1CN(CCC1C2=NN=CO2)C(=O)NC3CC3C4=CC=CC=C4,O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1
CHEMBL375508,QYOZNVCKISSENR-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.6020599913279625,10991,16658104,COC1=C(C=C2C(=C1)C(=O)N(C(=N2)N3CCCC(C3)N)CC4=CC=CC=C4C#N)F,COc1cc2c(=O)n(Cc3ccccc3C#N)c(N3CCCC(N)C3)nc2cc1F
CHEMBL1077932,QYQNOMZLEZZSFR-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,52.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.2839966563652006,10995,46883338,C1CC1CN(CC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC(CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5,O=C(NC(Cc1ccccc1)CN(CC1CC1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL1778524,QYRBBRRASAPCLC-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,10996,53248760,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)C(=O)C4(CCC4)C5=CC=C(C=C5)F,CN(C(=O)C1(c2ccc(F)cc2)CCC1)C1CCc2c(CC(=O)O)c3ccccc3n2C1
CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.0,10997,54676228,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
CHEMBL1760809,QYSSEJDAEHAKCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21334894.0,IC50,=,36000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenyl triazoles as selective inhibitors of 11��-Hydroxysteroid Dehydrogenase Type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.443697499232712,10998,54580144,CN1C(=NN=C1C2(CC(C2)F)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)C5=NC=CN=C5)Cl,Cn1c(-c2ccc(-c3cnccn3)cc2Cl)nnc1C1(c2ccc(Cl)cc2)CC(F)C1
CHEMBL3112856,QYWBMAVBPPCNAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.958607314841775,11004,57389706,C1CN(C2=CC=CC(=C21)C3=CC=CC=N3)C(=O)CC4=NC(=O)C=C(N4)N5CCOCC5,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(-c3ccccn3)cccc21
CHEMBL524992,QYZZTCYPDDNZDI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11006,44583353,C1CC2(CCN(CC2)C(=O)C3=CC=C(C=C3)C(F)(F)F)OC4=CC=CC=C41,O=C(c1ccc(C(F)(F)F)cc1)N1CCC2(CCc3ccccc3O2)CC1
CHEMBL1272016,QZEXFNKCPOFGAE-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20889341.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11015,16727124,COC1=CC=CC=C1C2=NC3=C(C=CC=C3O2)C(=O)NC4CN5CCC4CC5,COc1ccccc1-c1nc2c(C(=O)NC3CN4CCC3CC4)cccc2o1
CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,46300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.334419008982047,11022,135398737,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
CHEMBL3612810,QZUKGDYPSXQBSQ-VXKWHMMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191360.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11024,59568656,CC1=C(C=CC2=C1COC2=O)C(CN3CCN(CC3)CC(C4=NC=C(C(=C4)OC)C#N)O)O,COc1cc(C(O)CN2CCN(CC(O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N
CHEMBL2069839,RABCMFOALSUEDW-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,11030,69576646,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)F,NC(CC(=O)N1CCN(C(=O)c2ccc(F)cc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL240185,RAGNKICHAZGMOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,11033,24748805,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
CHEMBL240185,RAGNKICHAZGMOB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,11033,24748805,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
CHEMBL1397,RAGOYPUPXAKGKH-XAKZXMRKSA-N,POSACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,6.455931955649724,11034,468595,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,CCC(C(C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
CHEMBL1397,RAGOYPUPXAKGKH-XAKZXMRKSA-N,POSACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,7.086186147616283,11034,468595,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,CCC(C(C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
CHEMBL1397,RAGOYPUPXAKGKH-XAKZXMRKSA-N,POSACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,50.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,11034,468595,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,CCC(C(C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
CHEMBL3673973,RALYGEAWFFXYBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320653,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,11041,52933793,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
CHEMBL3673973,RALYGEAWFFXYBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320697,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,11041,52933793,CC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
CHEMBL2069806,RAWYQCOIQXDLOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,11053,22431956,C1CCC(CC1)NC(=O)C2=NN=C(O2)CS(=O)(=O)C3=CC=CC=C3,O=C(NC1CCCCC1)c1nnc(CS(=O)(=O)c2ccccc2)o1
CHEMBL345544,RAXPHFURDFRYJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,11054,11458616,CCCCOC1=CC=C(C=C1)N2C=NC=N2,CCCCOc1ccc(-n2cncn2)cc1
CHEMBL540,RAXXELZNTBOGNW-UHFFFAOYSA-N,IMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,11055,795,C1=CN=CN1,c1c[nH]cn1
CHEMBL540,RAXXELZNTBOGNW-UHFFFAOYSA-N,IMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,11055,795,C1=CN=CN1,c1c[nH]cn1
CHEMBL2048490,RAYPQIFWKYQIKX-HTKBXHQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,11057,11596174,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OC)C3CC(C(C(C3O)O)O)CO,CCc1ccc(Cc2ccc(OC)c(C3CC(CO)C(O)C(O)C3O)c2)cc1
CHEMBL2048490,RAYPQIFWKYQIKX-HTKBXHQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,11057,11596174,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2)OC)C3CC(C(C(C3O)O)O)CO,CCc1ccc(Cc2ccc(OC)c(C3CC(CO)C(O)C(O)C3O)c2)cc1
CHEMBL2337981,RAZOFRCGTLUGNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23200256.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11059,71517197,CC(C)(C)NC(=O)NCCN1CCC(CC1)(CNC(=O)C2=CC(=CC(=C2)Cl)Cl)CO,CC(C)(C)NC(=O)NCCN1CCC(CO)(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1
CHEMBL2177819,RBDDOEXDQAPTRT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,11063,58344916,C1=CC=C(C=C1)C(=O)NCC2=CC=C(C=C2)N3C4=C(C=CC=N4)N=C3C5=C(N=CC=C5)N,Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1
CHEMBL2334082,RBDSYHYBFFEKPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23317570.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11064,56840376,C1CN(CCC1COC2=CC=CC(=C2)C(=O)O)C3=NC=C(C=C3)NC(=O)C4=CC(=CC=C4)OC5=CC=CC=C5,O=C(O)c1cccc(OCC2CCN(c3ccc(NC(=O)c4cccc(Oc5ccccc5)c4)cn3)CC2)c1
CHEMBL3215864,RBEWBQVBFXYCLE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21823597.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by luceferin-based assay,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,PUBLICATION,,4.698970004336019,11065,54579002,CC1=C(C(=CC=C1)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C)C4=CC5=C(C=C4)OCCO5)C)C.Cl.Cl,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C
CHEMBL3408942,RBHLIUIZXOCECI-WCJYFFLOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.638272163982407,11069,58486258,CN1C2=CC=CC=C2C3(C1=O)CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN(C)C,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C4CC45C(=O)N(C)c4ccccc45)ccc23)cc1
CHEMBL3408942,RBHLIUIZXOCECI-WCJYFFLOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.0,11069,58486258,CN1C2=CC=CC=C2C3(C1=O)CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN(C)C,CN(C)Cc1ccc(C=Cc2n[nH]c3cc(C4CC45C(=O)N(C)c4ccccc45)ccc23)cc1
CHEMBL3264599,RBHSEBMDGMNLDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,770.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.113509274827518,11070,71291709,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CN=CS3)O,COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC
CHEMBL435316,RBKBGIONDAWNLO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,11072,9923385,C1CN(CCC1CNC2=NC=CC=N2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2ncccn2)CC1
CHEMBL361364,RBKCNBISIDBWKZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,79200.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.101274818410507,11073,11480732,CCN1C=C(N=C1)C2=CN=CC=C2,CCn1cnc(-c2cccnc2)c1
CHEMBL2441835,RBLWOLKKTLUERQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.327902142064283,11077,57641262,CC1=CC(=NO1)CN2CC3=NC(=C(C(=C3C2=O)C4=C(C=C(C=C4)Cl)Cl)CN)C,Cc1cc(CN2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)no1
CHEMBL218628,RBMGZPYCDQPSLS-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17228867.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,PUBLICATION,,4.657577319177793,11078,10142377,CC(C)CN1C2=C(C(=C(S2)CN3C4=CC=CC=C4N=C3NC)C(=O)N5CC(CO5)O)C(=O)N(C1=O)C,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC(O)CO1)c(=O)n(C)c(=O)n2CC(C)C
CHEMBL3353354,RBNRSVPXZPBXCD-LUCHDKOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,11079,58486169,C1COCCN1CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccc(CN4CCOCC4)cc3)n[nH]c2c1
CHEMBL3353354,RBNRSVPXZPBXCD-LUCHDKOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.568636235841013,11079,58486169,C1COCCN1CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccc(CN4CCOCC4)cc3)n[nH]c2c1
CHEMBL3353354,RBNRSVPXZPBXCD-LUCHDKOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.200659450546418,11079,58486169,C1COCCN1CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3ccc(CN4CCOCC4)cc3)n[nH]c2c1
CHEMBL3664707,RBRPBISFBWYXBR-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,33000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.481486060122112,11081,59635782,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CCF)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccn(CCF)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL3264603,RBYAUFGMTNJMOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,11085,57330959,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NC=NC=C3)O,COc1cc2ccc(C(O)(c3ccncn3)C(C)C)cc2cc1OC
CHEMBL2059127,RCDVRXHRLWGUQK-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,11089,70696806,C1CCN(C1)C2=NC3=C(O2)C=C(C=C3)C(=O)N(CCN4CCOCC4)CC(C(CC5=CC=CC=C5)NC(=O)OCC6=CN=CS6)O,O=C(NC(Cc1ccccc1)C(O)CN(CCN1CCOCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1
CHEMBL1813484,RCJIOMDJRBCHJE-RISCZKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,11092,46701017,CN1CC2CCCC2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1CC2CCCC2(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1813478,RCJIOMDJRBCHJE-SMDDNHRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,12700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,4.896196279044043,11093,46701016,CN1CC2CCCC2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1CC2CCCC2(c2ccc(Cl)c(Cl)c2)C1
CHEMBL27257,RCMQDUQWTWKKOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,2530.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.5968794788241825,11097,11247947,COC(=O)C1=CC2=C(C=C1)NC3=C2N=CN=C3N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,COC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1
CHEMBL476954,RCMVHXAYSDWNBI-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18625557.0,IC50,=,17900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.747146969020107,11098,11659664,CC(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)C2CCNC2,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)C1CCNC1
CHEMBL2336415,RCQSJUJRWTWZNW-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,11101,11388586,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)I)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2336415,RCQSJUJRWTWZNW-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,11101,11388586,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)I)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL596073,RCRPFFUFPBVPHF-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,11102,46225573,CC1=C2C(=NN1)C=CC(=N2)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=COC=C6,Cc1[nH]nc2ccc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12
CHEMBL2441955,RCUCVXSPMYHBOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.086186147616283,11106,15950832,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N3CCCCC3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCCC1)C2
CHEMBL326849,RCVJADBDODGTDD-RMERSUQASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064283,11109,44340870,C1CN(C(CN1CC2=CC3C=CSC3S2)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=NC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccncc1)CC(O)CN1CCN(CC2=CC3C=CSC3S2)CC1C(=O)NCC(F)(F)F
CHEMBL419409,RCXVRYYLBZGIFP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177483.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,11112,10295633,CC(C)(C#CC1=CC(=C(C=C1)OC)C(=O)C2=CC=C(C=C2)NC3=C(C=C(C=C3)F)F)N,COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1
CHEMBL2387598,RCYUPGBXIPSPFZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,11114,71659494,CCCCCCC1=CC2=C(C=C1)C3=C(C(=O)N2)NC(=N3)C4=CC=CC=C4Cl,CCCCCCc1ccc2c(c1)[nH]c(=O)c1[nH]c(-c3ccccc3Cl)nc12
CHEMBL3702746,RCZWSYNLXPXMAE-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8500.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.070581074285707,11115,89718348,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCN7CCOCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCOCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1269671,RDCUZWVELSAOBC-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,11120,12001783,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCCOC)Cl)C5CC5)Cl,COCCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269671,RDCUZWVELSAOBC-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0915149811213505,11120,12001783,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCCOC)Cl)C5CC5)Cl,COCCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL2036209,RDDJIRJLHGHBFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11121,49872677,CCC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC(=C2)C3=NNN=N3,CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cccc(-c2nn[nH]n2)c1
CHEMBL3581142,RDGXFPSQNSIWHF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.455931955649724,11124,24831841,CN(C)C1=NC=CC(=C1)C2=CSC(=N2)NC(=O)CC3=CC(=CC=C3)OC,COc1cccc(CC(=O)Nc2nc(-c3ccnc(N(C)C)c3)cs2)c1
CHEMBL2159075,RDHPRHXSDFSWKG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,5.0,11128,57577004,CN(CC1=CC=CS1)C(=O)C23CC4CC(C2)CC(C4)C3,CN(Cc1cccs1)C(=O)C12CC3CC(CC(C3)C1)C2
CHEMBL407944,RDIYHPCEDLSJLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,11130,11591353,CCCNC1=NN=C(O1)C2=CN3C(=C2C(C)C)C(=NC=N3)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
CHEMBL2019025,RDJRSUIPIPBMAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.97061622231479,11131,56954138,C1=CC=NC(=C1)CSC2=NC3=C(N2)C=C(C=C3)OC(F)F,FC(F)Oc1ccc2nc(SCc3ccccn3)[nH]c2c1
CHEMBL26678,RDMBCGVGRBUTKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,6.585026652029182,11134,11775287,CN1C2=CC=CC(=C2C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)N,Cn1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL1093747,RDPYDEGIIXRWPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20189807.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11137,135546072,CCCC(=O)NC1=NNC2=CC(=C(C=C21)Br)C3=CC=C(C=C3)O,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12
CHEMBL2041179,RDZUCMBSXVPKNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,11146,57384749,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)N(C)C,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)N(C)C)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL2436330,RDZYMACFEJTPOY-QDMMYLPHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.920818753952375,11147,72711248,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=CC=C5)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccccc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3632724,RECKFDASWBRPIB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,5.468521082957745,11150,16064893,CC1=CN=C(N1)C2=NC=CC(=C2)OC3=CC4=C(C=C3)N(C(=N4)NC5=C(C=CC(=C5)C(F)(F)F)F)C,Cc1cnc(-c2cc(Oc3ccc4c(c3)nc(Nc3cc(C(F)(F)F)ccc3F)n4C)ccn2)[nH]1
CHEMBL1079361,RECUJGQMLDHPOK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11151,42646450,CC1(CCCN(C1)C(=O)NC2=NOC3=CC=CC=C32)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)Nc2noc3ccccc23)C1
CHEMBL2059115,REFJKRWNHNILNV-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.638272163982407,11154,42635699,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=CS4,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1
CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,2110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,5.675717544702307,11155,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
CHEMBL3702706,REGJPCAIWDVDNX-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2480.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.605548319173784,11156,89718315,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCN(CC7)C8=CC=CC=N8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(c6ccccn6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3407778,REGVNYFRZZOKQV-NQWXTVAOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,5.0,11157,118730345,CNC1=C2C(=NC(=N1)C#CC3=CC=CO3)N(C=N2)C4C5CC5(C(C4O)O)C(=O)NC,CNC(=O)C12CC1C(n1cnc3c(NC)nc(C#Cc4ccco4)nc31)C(O)C2O
CHEMBL235421,REJCISYQMOGOHG-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,11159,44433284,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CN,CC(C)CC(NC(=O)CN)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL371145,REKGBSFMGZYROU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,5.275724130399211,11160,11364404,CC(C)CN1CCC(CC1)C2=NC(=C(N2)C3=CC=CC=C3)C4=CC5=C(C=C4)N=C(N5S(=O)(=O)C(C)C)N,CC(C)CN1CCC(c2nc(-c3ccc4nc(N)n(S(=O)(=O)C(C)C)c4c3)c(-c3ccccc3)[nH]2)CC1
CHEMBL3298760,RELPPOJGGXOECP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24835202.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,11161,90645310,C1=CC(=C(C=C1F)F)OC2=NC=CC3=C2C=CN3,Fc1ccc(Oc2nccc3[nH]ccc23)c(F)c1
CHEMBL3582243,REMZATIPDXZDEV-CXFHPJBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,2740.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13��-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,5.562249437179612,11163,122179419,CC(=O)C12CCC(CC1C3C(=O)C=C4C(C3(CC2)C)(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C,CC(=O)C12CCC(C)(C)CC1C1C(=O)C=C3C4(C)C=C(C#N)C(=O)C(C)(C)C4CCC3(C)C1(C)CC2
CHEMBL3582243,REMZATIPDXZDEV-CXFHPJBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25992974.0,IC50,=,4780.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis,"Synthesis and Biological Evaluation of Novel Olean-28,13��-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,PUBLICATION,,5.320572103387881,11163,122179419,CC(=O)C12CCC(CC1C3C(=O)C=C4C(C3(CC2)C)(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C,CC(=O)C12CCC(C)(C)CC1C1C(=O)C=C3C4(C)C=C(C#N)C(=O)C(C)(C)C4CCC3(C)C1(C)CC2
CHEMBL2436221,RENIROBQFCXXQO-DZOOXPAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.301029995663981,11164,72712343,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=NN(C4=CC=CC=C43)C)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2nn(C)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL1829475,REOJELNRUGHANJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11165,56683709,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3C,Cc1cc(=O)[nH]nc1-c1ccc(OCCCN2CCCC2C)cc1
CHEMBL3582336,RETOYYSEVCBIRN-JIPXPUAJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005524.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11171,122179477,CCN1C=C(C=N1)C2(C3=C(CC(N2)C4=NC=C(N4)C5=NC=C(C=C5)F)C6=CC=CC=C6N3)C7=NN(C(=O)O7)C,CCn1cc(C2(c3nn(C)c(=O)o3)NC(c3ncc(-c4ccc(F)cn4)[nH]3)Cc3c2[nH]c2ccccc32)cn1
CHEMBL2170631,REUPOOSGSYNYCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,11172,58269685,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC=C3C#N,N#Cc1ccccc1C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL2057527,RFCMNSUTICBGFR-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.568636235841013,11180,70684212,CC(C)(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,CC(C)(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
CHEMBL3393478,RFCYJLIYROYRBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,4.638272163982407,11181,59825681,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(C(=C(C=C6N5)F)F)F,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)c(F)cc3[nH]2)o1
CHEMBL479071,RFDAXGBKSBMVFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11182,24899995,C1=CC=C(C=C1)C(C2=CC(=CC=C2)C(F)(F)F)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(C(F)(F)F)c1
CHEMBL409442,RFENYOLLCXWBKT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18395443.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,11184,44449479,CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)NC)C(C)C,CNc1nnc(-c2cn3ncnc(Nc4cnc5[nH]c(C)cc5c4)c3c2C(C)C)o1
CHEMBL1081870,RFFMAFBDIYXZRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,11185,46879430,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2N=C(N3C)C,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C
CHEMBL1081870,RFFMAFBDIYXZRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,11185,46879430,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2N=C(N3C)C,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C
CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,8000.0,NM,,inhibition,tissue,binding,,,,,,,,,,,,,,,,5.096910013008056,11187,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,11187,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,11187,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,25003.45,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,4.602000062824431,11187,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,273499,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,5.096910013008056,11187,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
CHEMBL429734,RFKDHOWUSOAINF-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,11189,10076802,CC1=C(N=C(O1)C2=CC(=CC=C2)Cl)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)c1
CHEMBL2401834,RFKWZWJQRQCLJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773865.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CP3A4 (unknown origin),"Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,11191,57812483,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C3C(=CN=C2N)C(=CO3)C4=CN(N=C4)C5CCNCC5,CC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl
CHEMBL1934426,RFWSNJBXMGANOQ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22094028.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11201,56949966,CC1=NN(C(=C1C(=O)NC(C)C(C)(C)C)NS(=O)(=O)C2=CC=C(C=C2)C3CC3)C4CCOCC4,Cc1nn(C2CCOCC2)c(NS(=O)(=O)c2ccc(C3CC3)cc2)c1C(=O)NC(C)C(C)(C)C
CHEMBL3330650,RFWVETIZUQEJEF-UHFFFAOYSA-N,RG-7420,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11202,42642654,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO,O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F
CHEMBL3330650,RFWVETIZUQEJEF-UHFFFAOYSA-N,RG-7420,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11202,42642654,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO,O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F
CHEMBL2205775,RFXXESOWGZZTJX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727372.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.",Bioorg. Med. Chem.,PUBLICATION,,6.698970004336019,11205,71463058,CC(C)(C(C1=CC=C(C=C1)NC2=CC=CC=C2)N3C=NC=N3)C(=O)OC,COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1
CHEMBL2062804,RFZKSQIFOZZIAQ-UHFFFAOYSA-N,CEP-33779,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22594690.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779.",J. Med. Chem.,PUBLICATION,,4.958607314841775,11206,57336812,CN1CCN(CC1)C2=CC=CC(=C2)NC3=NN4C=CC=C(C4=N3)C5=CC=C(C=C5)S(=O)(=O)C,CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1
CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,13900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.856985199745905,11209,4748,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
CHEMBL590078,RGCZEETYNQZRTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20022752.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,11210,11615459,CC1=C2C(=CC=C1)N3CCNCC3NC2=O,Cc1cccc2c1C(=O)NC1CNCCN21
CHEMBL162383,RGDXKPQBVYZPLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,11211,515051,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)F,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21
CHEMBL162383,RGDXKPQBVYZPLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11211,515051,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C1N=C(C=C4C)F,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21
CHEMBL2347989,RGIPZCBZGRZGDB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,11215,71279423,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCCS(=O)(=O)C,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12
CHEMBL2331680,RGJOJUGRHPQXGF-INIZCTEOSA-N,RG-7603,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11216,59239165,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4COC4)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(C2COC2)C3)cc1
CHEMBL1829775,RGMQKUNJMKQDMC-XRHLQHRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.045757490560675,11220,53473324,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCNS(=O)(=O)C)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O
CHEMBL2058910,RGTBBKSFLZZHLT-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,31.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.508638306165727,11227,42609861,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL2058665,RGTBBKSFLZZHLT-UIOOFZCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.657577319177793,11228,59603311,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL270869,RHBYGIDSEIHDRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,11234,11512193,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCC(C)(C)CN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCC(C)(C)CN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL495793,RHJMBQWXWMOCDA-IRLDBZIGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11242,44583350,CN1C(=CC=N1)NC2=CC3=C(C=C2)OC4(CCN(CC4)C(=O)NC5CC5C6=CC=CC=C6)CC3=O,Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)NC3CC3c3ccccc3)CC1)O2
CHEMBL3664689,RHLRKYZMELKWGC-WRGVRERRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,11245,45107658,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C3CC3)N4CCC(OC4=O)(CC(C)(C)O)C5=CC=CC=C5F,CC(c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2F)OC1=O
CHEMBL1761869,RHSTYEXBNNRSAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23478147.0,IC50,<,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of SAR184841, a potent and long-lasting inhibitor of 11��-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,11248,52918012,COC1=CC=C(C=C1)C2=CN=C(N=C2)N3CCN(C4=CC=CC=C43)C(=O)N5CCC(C5)C6=CNN=C6,COc1ccc(-c2cnc(N3CCN(C(=O)N4CCC(c5cn[nH]c5)C4)c4ccccc43)nc2)cc1
CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,4.481486060122112,11254,54726191,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,4.267606240177032,11254,54726191,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,=,65000.0,NM,,,,,,,,,,,,,,,Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,4.187086643357144,11254,54726191,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
CHEMBL1229211,RHWKPHLQXYSBKR-BMIGLBTASA-N,DOLUTEGRAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23132334.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,4.0,11254,54726191,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
CHEMBL2336422,RHWMJBIOLRHWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,11255,10394458,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Cl)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2336422,RHWMJBIOLRHWNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,11255,10394458,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C(=C3)Cl)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL314768,RIDDCLHNDOXTES-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11261,10055750,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN4CCCCC4)CC5=CC=C(C=C5)C6=CC=C(C=C6)C(F)(F)F,Cn1cc(Cc2cn(CC(=O)N(CCN3CCCCC3)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
CHEMBL2436212,RIFATYMCUSPMBX-RIAYWLAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.721246399047171,11262,72711925,CC1=CC=C(O1)C(=O)N2CC(C(=O)N(C3=CC=CC=C32)CC4=C(C=CC5=C4C=CC(=C5)Br)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccc(C)o2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL1079290,RIFYAWGYIHDAHH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11264,46882949,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCO)C3=CC=CC=C3,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCO)(c2ccccc2)C1
CHEMBL1270934,RIIMHERUTFJZHJ-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,11269,52942848,CC#CC1=CC(=CC=C1)C2(C(=O)N(C(=N2)N)C)C3=CC=C(C=C3)OC(F)F,CC#Cc1cccc(C2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)c1
CHEMBL3301607,RIJLVEAXPNLDTC-UHFFFAOYSA-N,FILGOTINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369270.0,IC50,>,70000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.,J. Med. Chem.,PUBLICATION,,4.154901959985743,11270,49831257,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
CHEMBL2163835,RIJSQWHSYPOPOZ-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.698970004336019,11271,57522019,C1CC1(C2=C(C=C(C=C2)Cl)Cl)C(=O)NC(CC3=C(C=C(C=C3)Cl)Cl)C(=O)N4CCNCC4,O=C(C(Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCNCC1
CHEMBL1911821,RIMDJKXHMLJROO-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,11274,46869760,CN1CCN(CC1)C(=O)C(COCC2=CC=NC=C2)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCc2ccncc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL327919,RIOXQFHNBCKOKP-UHFFFAOYSA-N,BENOMYL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,11281,28780,CCCCNC(=O)N1C2=CC=CC=C2N=C1NC(=O)OC,CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21
CHEMBL327919,RIOXQFHNBCKOKP-UHFFFAOYSA-N,BENOMYL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,11281,28780,CCCCNC(=O)N1C2=CC=CC=C2N=C1NC(=O)OC,CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21
CHEMBL2397317,RITGMCAEZVMEQO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11283,4904109,CC1=NC2=C(C(=NN2C(=C1)NCCN3CCOCC3)C)C4=CC(=C(C=C4)OC)OC,COc1ccc(-c2c(C)nn3c(NCCN4CCOCC4)cc(C)nc23)cc1OC
CHEMBL1738805,RIVRSBWWXQQZLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21438541.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,PUBLICATION,,5.481486060122113,11287,25003030,CC(CNC(=O)N1CC2=C(C1)N=C(N=C2C3=C(C=C(C=C3Cl)Cl)OCCN4C=CC=N4)N)(F)F,CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)c2C1
CHEMBL2170750,RIYCHKQKHFIRTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22277094.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17��-HSD1.,J. Med. Chem.,PUBLICATION,,4.267606240177032,11288,56929249,C1=CC(=C(C=C1C(=O)C2=NC3=C(S2)C=C(C=C3)O)O)F,O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1
CHEMBL2418364,RIYSYRWQPZAUDK-CAZKFNJPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23932792.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2076083105017466,11289,72163432,C1C2CC3CC1CC(C2)(C3)C(=O)N4CC5CN(CC5C4)C6=CC=CC=N6,O=C(N1CC2CN(c3ccccn3)CC2C1)C12CC3CC(CC(C3)C1)C2
CHEMBL1092652,RJAXVZUSTIFVGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11291,11688223,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccc(Cl)cc2C1
CHEMBL309061,RJCJVIFSIXKSAH-UHFFFAOYSA-N,ERMANIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,21800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.661543506395395,11292,5352001,COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2OC)cc1
CHEMBL3137442,RJDGBMFJYVXZDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2900.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.5376020021010435,11294,76311341,CC1=C(SC=N1)C(=O)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,Cc1ncsc1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL1223003,RJIDHAYRLDHKFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,11298,49865164,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC=NC=C6,COc1ccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)cc1
CHEMBL3326589,RJKMYWXQAHKXOZ-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,11303,118711722,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4)C5CC5)(CF)CF)C=N1,Cc1cc2c(NC(=O)NC3CC(CF)(CF)Oc4cc(C5CC5)ccc43)cccc2cn1
CHEMBL2204359,RJOWFEDJGNNCDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,5.356547323513812,11309,53237902,C1CN(CCN1)C2=CC=CC=C2SC3=C(C=C(C=C3)Cl)Cl.Cl,Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
CHEMBL478402,RJSWFGJQETZYIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,5.4089353929735005,11311,24949548,CN1C=C2C=CC(=CC2=N1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1
CHEMBL478402,RJSWFGJQETZYIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18620382.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,PUBLICATION,,5.327902142064283,11311,24949548,CN1C=C2C=CC(=CC2=N1)N(C)C3=NC(=NC=C3)NC4=CC(=CC=C4)S(=O)(=O)N,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1
CHEMBL2331648,RJTJMAVCPOTSLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11312,71540073,CCNC1=NC2=C(CN(CC2)C(=O)CCC3=CC=C(C=C3)OC(F)(F)F)C(=N1)C(=O)N,CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(OC(F)(F)F)cc1)CC2
CHEMBL3353338,RJUIETDWZAGQNR-GUYCJALGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,5.0,11314,58486367,C1C(C12C3=CC=CC=C3NC2=O)C4=CC5=C(C=C4)C=NN5,O=C1Nc2ccccc2C12CC2c1ccc2cn[nH]c2c1
CHEMBL504522,RJWYZBZWLAFKBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,11319,44578045,C1=CC(=CC(=C1)Cl)CC2=C3C(=CC(=C2)CC4=NNC(=O)C=C4)C=CO3,O=c1ccc(Cc2cc(Cc3cccc(Cl)c3)c3occc3c2)n[nH]1
CHEMBL230367,RJXJBPIINHJDPV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17482464.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,11320,23628222,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(CCCN3CCNC(=O)C)C=C2,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)CCC2
CHEMBL260200,RKDSFEZOQXKQOR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18378449.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11326,25023857,CN(C)C(=O)C1=CC=C(C=C1)CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N,CN(C)C(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1
CHEMBL3326578,RKEWSEJJSIVUTE-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,11327,25265635,CCC1(CC(C2=C(O1)C=CC(=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC,CCC1(CC)CC(NC(=O)Nc2cccc3cnc(C)cc23)c2cc(F)ccc2O1
CHEMBL333306,RKFAZBXYICVSKP-AATRIKPKSA-N,TRANS-ASARONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,92300.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.034798298974088,11328,636822,CC=CC1=CC(=C(C=C1OC)OC)OC,CC=Cc1cc(OC)c(OC)cc1OC
CHEMBL2448689,RKHFQOOMHRJYJM-OGLMXYFKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.3979400086720375,11329,73352676,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(C=C3)C4=CC=CC=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)nc2)c1
CHEMBL1242345,RKTWFMDUKBINRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,11341,46899637,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NCC7CC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1
CHEMBL1242345,RKTWFMDUKBINRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.0,11341,46899637,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C(=O)NCC7CC7,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1
CHEMBL3359523,RLGFHVZCVPTTLP-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516794.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.",ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11350,53362086,CC(C)OC1=C(C=C(C=C1)COC2=CC3=C(C=C2)N4CCC(C4=C3Cl)CC(=O)O)C(F)(F)F,CC(C)Oc1ccc(COc2ccc3c(c2)c(Cl)c2n3CCC2CC(=O)O)cc1C(F)(F)F
CHEMBL3104473,RLKGUNQJMYDNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.795880017344075,11355,76335557,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CN=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1
CHEMBL3104473,RLKGUNQJMYDNRM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.795880017344075,11355,76335557,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=CN=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1
CHEMBL3608688,RLKUYZTZCXMODG-MRVPVSSYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,11356,86272102,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C(F)(F)F,CC1c2nnc(-c3nc(C(F)(F)F)ns3)n2CCN1C(=O)c1ccc(F)cc1
CHEMBL2448696,RLLQZNKWXMDKBR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5830.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.2343314452409855,11357,73348118,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC(=C(C=C2)Cl)NC(=O)C3=CC4=C(CNCC4)C=C3,CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)c2ccc3c(c2)CCNC3)c1
CHEMBL274189,RLQYRXCUPVKSAW-UHFFFAOYSA-M,PALMATINE CHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,6.045757490560675,11361,73442,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC.[Cl-],COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2
CHEMBL252200,RLRBZKLERUDUCY-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,11362,44447027,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC(=NO4)CN5CCCC5,CCC1CCCC(C2(Cc3nc(CN4CCCC4)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL465925,RLWXMWFCYVZNBY-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,11371,11993730,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL465925,RLWXMWFCYVZNBY-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,11371,11993730,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=C(N=CC=C3)C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL596809,RMFDASBXQBLDIL-OUJBWJOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.221848749616356,11378,45379828,COCC1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,COCC1C2CNCC21c1ccc(Cl)c(Cl)c1
CHEMBL3353355,RMGQWXVHWUUVLJ-DSUKGUNVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,11380,56962121,COC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3353355,RMGQWXVHWUUVLJ-DSUKGUNVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.619788758288394,11380,56962121,COC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL3353355,RMGQWXVHWUUVLJ-DSUKGUNVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.1938200260161125,11380,56962121,COC1=CC2=C(C=C1)NC(=O)C23CC3C4=CC5=C(C=C4)C(=NN5)C=CC6=CC=C(C=C6)CN7CCOCC7,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2
CHEMBL1017,RMMXLENWKUUMAY-UHFFFAOYSA-N,TELMISARTAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,11390,65999,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
CHEMBL1093802,RMNQHMQKUFGTQZ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11391,46885213,C1CN(CC1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4F,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CCN(CCN2CCN(C(=O)c3ccccc3F)CC2)C1
CHEMBL1940308,RMPYEISUTHEMLW-NDEPHWFRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11395,57394711,CN1CCC(CC1)NC(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)C#CC4(CN5CCC4CC5)O,CN1CCC(NC(=O)c2ccc(Oc3ccc(C#CC4(O)CN5CCC4CC5)cc3)cc2)CC1
CHEMBL2057792,RMSUKSHEEMXBPN-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,11397,70688462,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N(C)CC#C,C#CCN(C)c1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.698970004336019,11398,3675,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
CHEMBL1290041,RMUWRXSDAOJENI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20951036.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,11399,25205318,C1CCN(C1)CCN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)C5=CC=C(C=C5)C(F)(F)F)C=N2,O=c1cc(-c2ccc(C(F)(F)F)cc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
CHEMBL169620,RMVSZBRIILAXIH-WUXOVTSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,11400,44380538,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)C(C)CNCCC6=CC7=NSN=C7C=C6)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2C(C)CNCCc2ccc3nsnc3c2)c1
CHEMBL542139,RMXZRJYGJMSDQK-UHFFFAOYSA-N,SB-271046A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9925723.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM),"5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,11403,6918455,CC1=C(SC2=C1C=C(C=C2)Cl)S(=O)(=O)NC3=CC(=C(C=C3)OC)N4CCNCC4.Cl,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1
CHEMBL3422014,RMYVKGFVSAOUKW-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.455931955649724,11404,118735355,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C(C)C,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)cs1
CHEMBL1766759,RNMJNHVCCXRKJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21413798.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.,J. Med. Chem.,PUBLICATION,,4.0,11415,46834296,C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N,Nc1ncc(-c2ccccc2)nc1C(=O)Nc1ccccc1
CHEMBL240566,RNPYGOUJOKJBQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,11421,23647883,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)CC,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(CC)O2
CHEMBL461198,RNSWXWFQTKBNOT-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.853871964321762,11423,135875708,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5CCN(CC5)C,Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL470996,RNXCYTSKNUJZDX-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,6.259637310505756,11427,44590271,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=CC6=CC=CC=C65)C)N,Cn1cncc1C(N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc3ccccc13)cc(=O)n2C
CHEMBL475926,ROCIAHLXAQYEAV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11433,24899993,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL2441843,ROEPADSSTIFTHQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.1938200260161125,11437,15950544,CCOC(=O)N1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,CCOC(=O)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL2436622,ROIWDPBJIDVJNS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11439,44622339,C1CN(CCC1N2CCC3=CC=CC=C3CC2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5CC4)CC3)CC2)ccn1
CHEMBL3330060,ROKKOEGCWJIYBM-AXFHLTTASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25164763.0,IC50,=,56490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,4.248028425263673,11441,118712775,C1C(CN(C1C#N)C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)F,N#CC1CC(F)CN1C(=O)CC(N)Cc1cc(F)c(F)cc1F
CHEMBL549534,ROMRTXMEQJYJJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19552431.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assay,Novel small molecule bradykinin B2 receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.522878745280337,11443,45272156,CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=C(SC=N5)Cl,Cc1cc(-c2ncsc2Cl)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1
CHEMBL467114,ROPHIKMBWGQPQO-UHFFFAOYSA-M,GSK269984A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19332369.0,IC50,>=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,11444,11495633,C1=CC(=NC(=C1)C(=O)[O-])CC2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)Cl)F.[Na+],O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2F)n1
CHEMBL2041192,ROQKQYJTPICBKQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,11445,49849002,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=NC=C4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ccncn1
CHEMBL3114905,ROTBIIANJMNEBW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,11447,53257683,CC(C)(C)OC(=O)N1CCC(CC1)N2C3=C(C=N2)C(=NC=N3)OC4=CC=C(C=C4)S(=O)(=O)C,CC(C)(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1
CHEMBL1078232,RPEDWPSRPWEPAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11454,46882986,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)N3CCOCC3)C4=CC=CC=C4,O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)N1CCOCC1
CHEMBL1829781,RPFNAAPDFSAIEH-ADXZGYQBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,6.221848749616356,11459,53473483,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCCNC(=O)NC)C4=CC=C(C=C4)F,CNC(=O)NCCCC1(c2ccc(F)cc2)CCN(C(C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1
CHEMBL2420679,RPIYHUIWRDPDMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.0,11463,71818088,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CC(=CN=C3)F,COc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1
CHEMBL87355,RPMBWDUTWZVOBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,11465,23395807,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCCN(C)C)CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl,CN(C)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL2151925,RPNYSADTAYSTDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,11467,66882625,CC1=C(C=CC(=C1)NC(=O)CC2=NC(=O)C=C(N2)N3CCOCC3)F,Cc1cc(NC(=O)Cc2nc(=O)cc(N3CCOCC3)[nH]2)ccc1F
CHEMBL2448704,RPOKISRPDRUXOJ-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.7447274948966935,11468,73346616,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
CHEMBL3664718,RPXPOAJHLVZLCE-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,11477,59635784,CC(C)N1C=C(C=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(C(C)C)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL2315243,RPXSHXJWFUDNDF-FYGBZDAYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294255.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry,Development of new cyclic plasmin inhibitors with excellent potency and selectivity.,J. Med. Chem.,PUBLICATION,,5.0,11478,71716137,C1CN2CCN(CCC(=O)NC3=CC=C(CC(NC(=O)C(CC4=CC=C(C=C4)NC1=O)NS(=O)(=O)CC5=CC=CC=C5)C(=O)NCC6=CC=C(C=C6)C(=N)N)C=C3)CC2.C(=O)(C(F)(F)F)O,N=C(N)c1ccc(CNC(=O)C2Cc3ccc(cc3)NC(=O)CCN3CCN(CCC(=O)Nc4ccc(cc4)CC(NS(=O)(=O)Cc4ccccc4)C(=O)N2)CC3)cc1
CHEMBL562317,RQDDHVVAAJVVKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19630403.0,IC50,=,450000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,3.3467874862246565,11480,44141871,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)CC5=CC=NC=C5,c1ccc2nc(COc3ccc(-c4[nH]ncc4Cc4ccncc4)cc3)ccc2c1
CHEMBL562869,RQDRWTLKQRNDSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,11481,45271593,CN1C=C(N=N1)C2CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4,Cn1cc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)nn1
CHEMBL568456,RQERHAIDHUSWSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11482,45484931,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)S(=O)(=O)N,CC1(CC(=O)NCc2ccc(S(N)(=O)=O)cc2)CC2(CCCCC2)OO1
CHEMBL3640275,RQQNLWISWSTQLK-RLBGWGEZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.522878745280337,11490,44467711,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=C(C(=C(C=C4F)F)F)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3c(F)cc(F)c(F)c3F)C2)nc(C)c1F
CHEMBL2171396,RQQTYVIPHKLYFS-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22861813.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel ��-amino acid derivatives as inhibitors of cathepsin A.,J. Med. Chem.,PUBLICATION,,7.585026652029182,11491,53308743,CC1=CC=CC=C1C(CC(=O)O)NC(=O)C2=NN(C(=C2)OC)C3=CC=CC=C3F,COc1cc(C(=O)NC(CC(=O)O)c2ccccc2C)nn1-c1ccccc1F
CHEMBL3702771,RQTZYFHLPCPBEQ-KNPJQLEMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.665546248849069,11493,89718238,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL391070,RQVOZSFAHBOBFK-AABGKKOBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17418568.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11496,44431775,CC1=CC(=CC=C1)C2CN3CCC4=CC(=C(C=C4C3CC2N)OC)OC,COc1cc2c(cc1OC)C1CC(N)C(c3cccc(C)c3)CN1CC2
CHEMBL445734,RQXGWBAZTYRGOW-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,11497,44143257,CCNC1=CC(=C(C(=C1)N2CCCC2=O)F)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)C(F)(F)F)O,CCNc1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1
CHEMBL445734,RQXGWBAZTYRGOW-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19428244.0,IC50,=,75000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1249387366083,11497,44143257,CCNC1=CC(=C(C(=C1)N2CCCC2=O)F)C(=O)NC(CC3=CC=CC=C3)C(CNCC4=CC(=CC=C4)C(F)(F)F)O,CCNc1cc(C(=O)NC(Cc2ccccc2)C(O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1
CHEMBL1951451,RQYBGHZNFDAJIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.552841968657781,11498,57391834,C1=CC(=CC=C1CNC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4)F,O=C(NCc1ccc(F)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL1834345,RQYRFYXSSOVCAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21866910.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,"N'-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT(6)R) Antagonists with Unique Structural Features.",J. Med. Chem.,PUBLICATION,,5.0,11501,25056080,CCN=C(NS(=O)(=O)C1=CC(=CC=C1)Cl)N2CC(C=N2)(C)C,CCN=C(NS(=O)(=O)c1cccc(Cl)c1)N1CC(C)(C)C=N1
CHEMBL179704,RRFCTHIOMKUJRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,80900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.092051478387727,11507,11378800,CC1=CSC=C1C2=CN=CC=C2,Cc1cscc1-c1cccnc1
CHEMBL179704,RRFCTHIOMKUJRQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.6020599913279625,11507,11378800,CC1=CSC=C1C2=CN=CC=C2,Cc1cscc1-c1cccnc1
CHEMBL1682891,RRHVEQWMOKQMRJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.853871964321762,11510,22664964,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)OC)(C3=CN=CN3)O,COC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL14276,RRJLJKRFFRZRAF-UHFFFAOYSA-N,SB-228357,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,5.045757490560675,11513,443390,COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)F)C(F)(F)F,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2
CHEMBL2019024,RRLQDVNNRUSNKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,3610.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.442492798094342,11516,3012527,CC1=CC2=C(C=C1)N=C(N2)SCC3=CC=CC=N3,Cc1ccc2nc(SCc3ccccn3)[nH]c2c1
CHEMBL239772,RRMIJFINKILIRL-GOSISDBHSA-N,SR-887,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,11517,16662089,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=CC=C4Cl)O,O=C(C(O)c1ccccc1Cl)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL3109340,RROPCZKHYUPTGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11518,25097876,COCCOC1=CC2=NC=C(N2C=C1)C3=NC4=C(C=CC=C4OC5CCNCC5)C=C3,COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5)c4n3)cnc2c1
CHEMBL3394201,RRQQEAJYJXDKQC-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25699143.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11521,67406727,CC1=CC(=NC=N1)C2=CC3=C(C=C2)C(CC3)N4CC5(C4)CCN(CC5)C(=O)CC6=C(C=C(C=C6)OC)C(=O)N,COc1ccc(CC(=O)N2CCC3(CC2)CN(C2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1
CHEMBL367357,RSDPLFJFCIEHAP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,2032.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.692076296388119,11530,11441615,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)N(C)C)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C(=O)N(C)C)ccc2c1)n1ccnc1)N(C)C
CHEMBL495601,RSJUYPGFGAQOLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11538,44583357,C1CC2=CC=CC=C2CC1NC(=O)N3CCC4(CC3)CC(=O)C5=CC=CC=C5O4,O=C1CC2(CCN(C(=O)NC3CCc4ccccc4C3)CC2)Oc2ccccc21
CHEMBL3628939,RSSMYFQRFUEXTN-JKDDQTOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,11544,122193872,CC(C1CCCC1)(C2=CN(N=N2)C(CCS(=O)(=O)C)C(=O)COC3=C(C(=CC(=C3F)F)F)F)NCC4=CC5=C(C=C4)N=CS5,CC(NCc1ccc2ncsc2c1)(c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1)C1CCCC1
CHEMBL244403,RSUMDJRTAFBISX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17630726.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.",J. Med. Chem.,PUBLICATION,,3.6989700043360187,11545,9799417,CCCCCOC1=CC=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43,CCCCCOc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12
CHEMBL410242,RSVOVHDOLNWYER-RYZVYYIHSA-N,16BETA-(M-CARBAMOYLBENZYL)ESTRADIOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24328103.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Discovery of a non-estrogenic irreversible inhibitor of 17��-hydroxysteroid dehydrogenase type 1 from 3-substituted-16��-(m-carbamoylbenzyl)-estradiol derivatives.,J. Med. Chem.,PUBLICATION,,5.823908740944319,11548,44456599,CC12CCC3C(C1CC(C2O)CC4=CC(=CC=C4)C(=O)N)CCC5=C3C=CC(=C5)O,CC12CCC3c4ccc(O)cc4CCC3C1CC(Cc1cccc(C(N)=O)c1)C2O
CHEMBL2316385,RSYSXDBUOKOFIE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,>,20000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,11553,71720426,CS(=O)CC1=CC=C(C2=CC=CC=C12)C(=O)NC3=NC=CN=C3C(=O)NCC4CCC4,C[S+]([O-])Cc1ccc(C(=O)Nc2nccnc2C(=O)NCC2CCC2)c2ccccc12
CHEMBL3260754,RSYWEFIQLHVGST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,5.154901959985743,11555,72793323,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=C(C=NC=C4)F)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3F)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
CHEMBL517646,RSZNJMNZSVCMKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,11558,11154357,C1CC1C2=CC(=NC=C2C(=O)NCC3CCOCC3)NC4=C(C=C(C=C4)Cl)Cl,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)cc1C1CC1
CHEMBL3706621,RTAOSKPTWQTCBX-GIWSTSDLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11560,10283896,CC(C)(C1=NC=C(O1)C2=CC=CC=N2)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,CC(C)(c1ncc(-c2ccccn2)o1)N1CCN(CC(O)CC(Cc2ccccc2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL150681,RTCYVSYLJFBKLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,11562,10353296,CCCCOC1=CC=C(C=C1)C2=CC=NO2,CCCCOc1ccc(-c2ccno2)cc1
CHEMBL1209674,RTDGHNXXZKSIDE-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,11563,49862643,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC=NC=C5)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccncc4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL2316382,RTEBTDAJVQZWBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,8800.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,5.055517327849831,11566,71544706,COC1=NC(=C(C=C1)NC(=O)C2=CC=C(C3=CC=CC=C32)CS(=O)C)C(=O)NCC4CCOCC4,COc1ccc(NC(=O)c2ccc(C[S+](C)[O-])c3ccccc23)c(C(=O)NCC2CCOCC2)n1
CHEMBL2022570,RTGBSTJGKOHKPO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11568,56840672,CC1=C(C(=NN1)C(=O)O)CC2=CC(=CC=C2)C3=CC=C(C=C3)F,Cc1[nH]nc(C(=O)O)c1Cc1cccc(-c2ccc(F)cc2)c1
CHEMBL3673945,RTGVPSAXYOKKJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320623,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,11571,52935811,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)OC)F)N=C1,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1
CHEMBL3673945,RTGVPSAXYOKKJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320667,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,11571,52935811,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CN=C(C=C4)OC)F)N=C1,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1
CHEMBL117,RTIXKCRFFJGDFG-UHFFFAOYSA-N,CHRYSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20832301.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11575,5281607,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12
CHEMBL513372,RTKZIRJGSBHFAV-BKHUMSDISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,42600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.370590400897281,11579,11357143,CC1=CC(CC2(C(O2)CC(C=CC1=O)(C)C)C)O,CC1=CC(O)CC2(C)OC2CC(C)(C)C=CC1=O
CHEMBL503727,RTKZIRJGSBHFAV-VLROITNISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,62500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.204119982655925,11580,11218910,CC1=CC(CC2(C(O2)CC(C=CC1=O)(C)C)C)O,CC1=CC(O)CC2(C)OC2CC(C)(C)C=CC1=O
CHEMBL1682902,RTMHSNZDMYWGTC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,11581,12074102,CC(C)C(C1=CC2=CC3=C(C=C2C=C1)C(=O)NC3)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2cc3c(cc2c1)CNC3=O)c1cnc[nH]1
CHEMBL2403549,RTNOWHVTNCEMDM-GHTZIAJQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11584,59401886,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1cc(F)ccc1C
CHEMBL2403548,RTNOWHVTNCEMDM-NQIIRXRSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11585,59401793,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1cc(F)ccc1C
CHEMBL2403550,RTNOWHVTNCEMDM-RXVVDRJESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11586,67401728,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1cc(F)ccc1C
CHEMBL2403551,RTNOWHVTNCEMDM-WIYYLYMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23769643.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11587,59401765,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1cc(F)ccc1C
CHEMBL2013051,RTNZBEUCZIJXRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11588,58199027,CC(=O)N1CCC(CC1)OC2=CC3=C(C=C2)OC4(CC3)CCN(CC4)C5CCC5,CC(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
CHEMBL240867,RTOURUVDFOKSFN-UHFFFAOYSA-N,SR-1362,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3872161432802645,11589,16662108,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)N,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1
CHEMBL497829,RTSHWIRSEUIDML-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11592,44583355,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C(=O)CC4=C(C=C(C=C4)Cl)Cl,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)Cc3ccc(Cl)cc3Cl)CC1)O2
CHEMBL2448707,RTSPQNYEIWFBCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,4.698970004336019,11594,73349662,CC(C)N(C)CC(COC1=CC2=C(C=C1)C=C(C=C2)Br)O,CC(C)N(C)CC(O)COc1ccc2cc(Br)ccc2c1
CHEMBL2165666,RTUFGGWXEZHNNA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.040958607678906,11595,57506734,CN(C)C1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C(C=CC5=C4C=CN5)F)N6CCOCC6,CN(C)C1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL3104489,RTVDDYYSYFIYFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,11596,76324755,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1
CHEMBL3104489,RTVDDYYSYFIYFB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS1246 was identified (see also related datasets CHEMBL2448688 and CHEMBL3137440),,DATASET,,4.698970004336019,11596,76324755,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)C(=O)C(C3=CC=C(C=C3)C#N)C4=CN=CC=C4,N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1
CHEMBL1271652,RTYAFVHSTJOJEK-ZHAWHOEGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,6.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.193820026016112,11598,52947930,CC(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CC5CNCC5C4,CC(C)C1COCC(C2(OC(=O)N3CC4CNCC4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1208961,RTYHQIZCRYJKBV-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,11601,24812745,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCN(C)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL1208961,RTYHQIZCRYJKBV-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,11601,24812745,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NCCN(C)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL2165501,RUHKZUQCHSCKRS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,11613,59606002,CCC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCC(CC6)C(C)(C)O,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(C(C)(C)O)CC3)cc2n1
CHEMBL2336413,RUIONSFUCOPZLD-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11615,11445240,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2336413,RUIONSFUCOPZLD-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,11615,11445240,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3Cl)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL557032,RUMNCJSUPKAMTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,11619,45272511,C1CN(CCC1C2=NC(=NO2)C3=NC=CN=C3)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1
CHEMBL2048059,RUMOYGYSWPCFLL-WVBUVRCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,6.096910013008056,11620,57384271,CC(C)(CO)C1=CC=CC(=C1)CNC2CS(=O)(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,CC(C)(CO)c1cccc(CNC2CS(=O)(=O)CC(Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)C2O)c1
CHEMBL601030,RUNGOSGEIDQARZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20074949.0,IC50,>=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,11621,46232544,CCN1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)C(=O)O)C(=C2C4=COC=C4)C5CCCCC5,CCN1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1
CHEMBL3287854,RUNJHXCAYKNYJM-KBPBESRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900876.0,IC50,>,20000000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,PUBLICATION,,1.6989700043360187,11622,46938097,C1CNC(CC1C2=CC(=O)NO2)CCC3=CC=CC=C3,O=c1cc(C2CCNC(CCc3ccccc3)C2)o[nH]1
CHEMBL2170639,RUPPNUAUXUYUMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.522878745280337,11625,58269518,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CNC(=O)C=C3,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccc(=O)[nH]c3)CC2)c(C(F)(F)F)c1
CHEMBL599791,RUVNTEGYLMYXCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,5.769551078621726,11636,25057933,CN1CCC2=C(C1)C=C(C=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)C4=CC(=C(C=C4)OC)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC
CHEMBL599791,RUVNTEGYLMYXCF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,11636,25057933,CN1CCC2=C(C1)C=C(C=C2)NC(=O)C3=CC=CC(=C3)CNC(=O)C4=CC(=C(C=C4)OC)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC
CHEMBL2151922,RUVSRIAGPJOKFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,11637,66882469,COC1=CC=CC(=C1)NC(=O)CC2=NC(=O)C=C(N2)N3CCOCC3,COc1cccc(NC(=O)Cc2nc(=O)cc(N3CCOCC3)[nH]2)c1
CHEMBL3407784,RVLAHZAHALVQKF-AQPYCOETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25422861.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,In vivo phenotypic screening for treating chronic neuropathic pain: modification of c2-arylethynyl group of conformationally constrained a3 adenosine receptor agonists.,J. Med. Chem.,PUBLICATION,,5.0,11648,118730351,CNC1=C2C(=NC(=N1)C#CC3=CC=C(S3)Cl)N(C=N2)C4C5CC5(C(C4O)O)C(=O)NC,CNC(=O)C12CC1C(n1cnc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)C(O)C2O
CHEMBL10501,RVLMCLGUQRGIEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11649,10122289,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C4=C(CCCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2
CHEMBL3408957,RVUPIRNDZZGAJU-KTYYFCFMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.795880017344075,11656,56959836,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,CC(C)N1CCC(Oc2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)Nc5ccccc56)ccc34)cc2)CC1
CHEMBL3408957,RVUPIRNDZZGAJU-KTYYFCFMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.0,11656,56959836,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=CC=CC=C7NC6=O,CC(C)N1CCC(Oc2ccc(C=Cc3n[nH]c4cc(C5CC56C(=O)Nc5ccccc56)ccc34)cc2)CC1
CHEMBL3633943,RVWOJJBVBVIEID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26475522.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11658,122195692,CC(=O)N1CCCN2C1=CC(=N2)COC3=CC=CC=C3,CC(=O)N1CCCn2nc(COc3ccccc3)cc21
CHEMBL3104479,RVXOAGNZYPWFFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,5.200659450546418,11659,76328292,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3104479,RVXOAGNZYPWFFX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6300.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.200659450546418,11659,76328292,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL1682999,RVYDMYJAWLDQQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,11660,53317572,CC1=C(C(=CC=C1)C)C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
CHEMBL1682999,RVYDMYJAWLDQQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21295471.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,11660,53317572,CC1=C(C(=CC=C1)C)C2=NC3=C(N2)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5C=C4,Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1
CHEMBL151974,RWCVRTQNDKYRGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,11664,11264664,CCCCOC1=CC=C(C=C1)C2=NC=NC=C2,CCCCOc1ccc(-c2ccncn2)cc1
CHEMBL2377663,RWLTWYHWMURBOO-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,11672,46850145,COC(=S)NCC1CN(C(=O)O1)C2=CC(=C(C(=C2)F)N3CCNN(CC3)C(=O)CO)F,COC(=S)NCC1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1
CHEMBL2331678,RWSCHRBISRWGQQ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11678,44815590,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C(C)C)C(=N2)N4CCOCC4C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(C(C)C)C3)cc1
CHEMBL2163833,RWTBFMYLCXHAKG-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,760.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.119186407719209,11679,46892977,CN1CCN(CC1)C(=O)C(CC2=CC=C(C=C2)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CN1CCN(C(=O)C(Cc2ccc(Cl)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL2087461,RWZBARRAYNKEQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,11682,44603271,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=C2SN=C3)C(=O)NOCCO,O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F
CHEMBL2087461,RWZBARRAYNKEQD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25193232.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,11682,44603271,C1=CC(=C(C=C1I)F)NC2=C(C=CC3=C2SN=C3)C(=O)NOCCO,O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F
CHEMBL2057788,RXCTZJFVSOGEKG-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,37.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.431798275933005,11685,70696754,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O)CC(C)(C)C,CCN(C)c1nc2ccc(C(=O)N(CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)C)cc2o1
CHEMBL3093461,RXEIQMFFHIVGLD-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24215891.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2441251443275085,11688,25206116,CCC(CN1C=CC2=CC=CC=C21)NS(=O)(=O)C3=C(C=C(C=C3Cl)Cl)N,CCC(Cn1ccc2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl
CHEMBL1208835,RXHOSXWWMGMFAO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,11695,49862010,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL1922663,RXIYTLYKWJVLSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,=,5.5,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,8.259637310505756,11697,56850525,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)O)CC4=CC=C(C=C4)C5=NC=C(C=C5)F,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(F)cn3)cc2)nc1
CHEMBL523374,RXQPWAXTLUQACC-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,11705,25181502,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC)C,CNc1noc2c(-c3ccc4c(N5CCOCC5C)nncc4c3)c(C)ccc12
CHEMBL493496,RXQPWAXTLUQACC-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,11706,44568944,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC)C,CNc1noc2c(-c3ccc4c(N5CCOCC5C)nncc4c3)c(C)ccc12
CHEMBL3617655,RXRVCJFGSOVYLG-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26335039.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by cocktail assay,Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.,J. Med. Chem.,PUBLICATION,,4.522878745280337,11709,122190433,CC1CN(C(=O)C2=CC(=NN12)COC3=NC=C(C=C3)Cl)C4=C(N=CC=C4)F,CC1CN(c2cccnc2F)C(=O)c2cc(COc3ccc(Cl)cn3)nn21
CHEMBL3114719,RXURCMJQURPYAA-JTAQYXEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,11714,59721267,CCC(CCC(CC)NC(=O)OCC1=CN=CS1)NC(=O)C(C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C,CCC(CCC(CC)NC(=O)C(NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
CHEMBL3115189,RXXJTASWFDWOMQ-QYDYLWNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,11719,76314238,CC(C)C(C(=O)NC(CCC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(C)CC4=CSC=N4,CC(C)C(NC(=O)N(C)Cc1cscn1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL3115163,RXXJTASWFDWOMQ-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,11720,59721361,CC(C)C(C(=O)NC(CCC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC3=CC=CC=C3)NC(=O)N(C)CC4=CSC=N4,CC(C)C(NC(=O)N(C)Cc1cscn1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL392760,RYBOXBBYCVOYNO-UHFFFAOYSA-N,WAY-181187,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17948978.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.",J. Med. Chem.,PUBLICATION,,4.481486060122112,11727,10150497,C1=CC=C2C(=C1)C(=CN2S(=O)(=O)C3=C(N=C4N3C=CS4)Cl)CCN,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12
CHEMBL25867,RYGJKZCQNUAGKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,12580.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.90031935889075,11730,11774980,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3NC5=C4C=C(C=C5)[N+](=O)[O-],O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1
CHEMBL179621,RYGQGRAICBWYPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,39080.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.408045444953265,11731,11148236,CC1=C(SC=C1)C2=CN=C(C=C2)F,Cc1ccsc1-c1ccc(F)nc1
CHEMBL3104532,RYGYILSFRDCTJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,11732,76324761,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC=CC=C4C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3ccccc3C(F)(F)F)CC2)cc1
CHEMBL1643513,RYIJMRFACOYPNH-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,11733,53325463,CNC1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
CHEMBL1643511,RYIJMRFACOYPNH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,11734,50941460,CNC1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,11740,54454,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
CHEMBL1649667,RYUIVLRQMHWMSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.221848749616356,11747,24827142,C1CCC2=C(C1)C(=NN2C3=CC=C(C=C3)C4(CC4)C(=O)N5CCCC5)C(F)(F)F,O=C(N1CCCC1)C1(c2ccc(-n3nc(C(F)(F)F)c4c3CCCC4)cc2)CC1
CHEMBL1672611,RZDRIXVHILKLLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,11750,16072021,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CC=CO3)C4=CC=NC=C4,O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1
CHEMBL498373,RZFRGTCAMDRPMQ-BGPOSVGRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,38300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.416801226031377,11753,2407524,COC1=CC(=CC(=C1O)OC)C=C2CCC(=CC3=CC(=C(C(=C3)OC)O)OC)C2=O,COc1cc(C=C2CCC(=Cc3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O
CHEMBL498373,RZFRGTCAMDRPMQ-BGPOSVGRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,38282474.33,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,1.4170000000190845,11753,2407524,COC1=CC(=CC(=C1O)OC)C=C2CCC(=CC3=CC(=C(C(=C3)OC)O)OC)C2=O,COc1cc(C=C2CCC(=Cc3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O
CHEMBL263664,RZIDZIGAXXNODG-UHFFFAOYSA-N,CCT128930,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18345609.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.",J. Med. Chem.,PUBLICATION,,4.301029995663981,11755,17751819,C1CN(CCC1(CC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
CHEMBL263664,RZIDZIGAXXNODG-UHFFFAOYSA-N,CCT128930,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20151677.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomal preparation,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,PUBLICATION,,5.0,11755,17751819,C1CN(CCC1(CC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
CHEMBL489095,RZKDEGZIFSJVNA-IBGZPJMESA-N,CAMICINAL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.585026652029182,11758,15984937,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
CHEMBL489095,RZKDEGZIFSJVNA-IBGZPJMESA-N,CAMICINAL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.161150909262744,11758,15984937,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
CHEMBL523933,RZKDEGZIFSJVNA-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.5376020021010435,11759,15984134,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
CHEMBL523933,RZKDEGZIFSJVNA-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,4.161150909262744,11759,15984134,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1
CHEMBL536086,RZNQLFINCJHZDT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11762,45263621,C1C(C(CN1C2=NC=NC(=C2)C3=CSC=C3)N)C4=CC(=C(C=C4F)F)F.Cl,NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F
CHEMBL2017107,RZUAZHYCHPHTPG-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,11772,46932235,CC(=O)C1=C(ON=C1C2CNCCC2(C3=CC(=C(C=C3)F)F)O)C4=CC=CC=C4CCNC(=O)C,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2(O)c2ccc(F)c(F)c2)c1C(C)=O
CHEMBL10604,RZYAVBJCTLMHKS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,11778,9939495,CCC1=CN(C(=NC1=O)SCC2=CC=C(C=C2)F)CC(=O)N(CCN(CC)CC)CC3=CC=C(C=C3)C4=CC=C(C=C4)C(F)(F)F,CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O
CHEMBL557329,SABBBCPABFDZNM-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,20600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.686132779630847,11784,11533195,C1CN(CCC1NC(=O)NC(CO)C2=CC=CC=C2)CC3=CN(C=C3)C4=CC=C(C=C4)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CO)c1ccccc1
CHEMBL1214394,SAJCBJSFCCCGCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.0,11794,11515728,CC1=NC(=C(C=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2)C,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)c(C)n1
CHEMBL121405,SAMLUEXYGUANPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177482.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,11797,44346053,C1CCC(CC1)NC2=NC=CC(=C2)C3=C(N=C(O3)C4(CCNCC4)O)C5=CC=C(C=C5)F,OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1
CHEMBL193647,SAUCOGITCIJPAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,11806,11655677,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC3=NNN=N3)CCO)C4=C(C=CC(=C4)Cl)O,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1
CHEMBL193647,SAUCOGITCIJPAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16061379.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11806,11655677,C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2CC3=NNN=N3)CCO)C4=C(C=CC(=C4)Cl)O,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1
CHEMBL2151926,SBBKINLPXCJMBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,11816,66881994,C1COCCN1C2=CC(=O)N=C(N2)CC(=O)NC3=CC(=C(C=C3)F)Cl,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)Nc1ccc(F)c(Cl)c1
CHEMBL3115191,SBBZCSSPXOWAMS-RRURFNPQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,11817,59721419,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(Cc2cnc[nH]2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3115184,SBBZCSSPXOWAMS-RWSVXVLSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,11818,59721362,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(Cc2cnc[nH]2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3260745,SBLRGVQPPNSJQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,11824,72793099,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=CC=C(C=C4)C#N)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccc(C#N)cc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
CHEMBL89750,SBMHFUHIBLNLAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.508638306165727,11825,23395723,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CC4=CC=C(C=C4)C5=CC=C(C=C5)C(F)(F)F)CC(=O)O,Cn1cc(Cc2cn(CC(=O)N(CC(=O)O)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1
CHEMBL2316379,SBMZVMAQHHRTLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,610.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,6.214670164989233,11826,58973420,C1COCCC1CNC(=O)C2=C(C=CC=N2)NC(=O)C3=CC=C(C4=CC=CC=C43)CN5C=CN=N5,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12
CHEMBL2409707,SBVAXUGOISPYPX-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11836,11641563,CC1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=CC=C(C=C3)OC(C(F)F)(F)F,CC1(CS(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)C(F)F)cc3)CC2)NC(=O)NC1=O
CHEMBL3699316,SCCIUWBTSOHVEK-VYQNARHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,11841,89713689,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=CN=C(C=C8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)nc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3259928,SCEGQLOWLADTKA-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,11843,46850264,CN1CCCC(C1)(C2=CC=CC=C2)NC(=O)C3=C(C=C(C=C3SC)C(F)(F)F)OC,COc1cc(C(F)(F)F)cc(SC)c1C(=O)NC1(c2ccccc2)CCCN(C)C1
CHEMBL2058663,SCFKYKHATMFMTK-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,37.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.431798275933005,11844,59603321,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)C(C)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(C(C)C)oc2c1
CHEMBL2325697,SCGCBAAYLFTIJU-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23394205.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,5.0,11846,46244454,CC1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=O)(=O)C)C4=C5C=CNC5=CC=C4,CC1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1
CHEMBL562285,SCNLJQQVOVIBKB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,3220.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.492144128304169,11850,45267735,C1CN(CCC1NC(=O)NC(CC2=NC=CN=C2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1
CHEMBL1077781,SCQHVECWBAHHHV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11854,46882918,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CC(=O)O)C3=CC=CC=C3,O=C(O)CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL3414926,SCRRRLBPWUHHER-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,4.301029995663981,11855,118732962,CC1=NOC(=C1)C2=CN3C(=NN=C3C(C)C4=CC5=CC(=CN=C5C=C4)OCCOC)C(=C2)F,COCCOc1cnc2ccc(C(C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1
CHEMBL3414926,SCRRRLBPWUHHER-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26812066.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.",J. Med. Chem.,PUBLICATION,,4.301029995663981,11855,118732962,CC1=NOC(=C1)C2=CN3C(=NN=C3C(C)C4=CC5=CC(=CN=C5C=C4)OCCOC)C(=C2)F,COCCOc1cnc2ccc(C(C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1
CHEMBL3632719,SCUGTCMSRMQNNQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,11857,16064750,CC(C)(C)C1=CC(=CC=C1)NC2=NC3=C(N2C)C=CC(=C3)OC4=CC(=NC=C4)C5=NC=C(N5)C(F)(F)F,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
CHEMBL1651532,SCXPFFTVFSPORD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng testosterone substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,5.522878745280337,11861,24967990,CC1=NC=C(C=C1)NC(=O)N2CCC(=CC3=CC(=CC=C3)OC4=NC=C(C=C4)C(F)(F)F)CC2,Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1
CHEMBL1651532,SCXPFFTVFSPORD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21666860.0,IC50,=,11800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 uisng midazolam substrate,"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.",ACS Med. Chem. Lett.,PUBLICATION,,4.928117992693875,11861,24967990,CC1=NC=C(C=C1)NC(=O)N2CCC(=CC3=CC(=CC=C3)OC4=NC=C(C=C4)C(F)(F)F)CC2,Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1
CHEMBL212689,SCXSQUUTGCWHFU-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16631366.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of P450 3A4,Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11862,16007088,CCN(C1CCN(CC1)CCC(C2=CC=C(C=C2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CCC(c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1
CHEMBL246322,SDCAYDSIXAYUNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11866,44440662,C1COCCN1S(=O)(=O)C2=CC=CC(=C2)C3=CC(=NC=N3)N4CC(C(C4)N)C5=CC(=C(C=C5F)F)F,NC1CN(c2cc(-c3cccc(S(=O)(=O)N4CCOCC4)c3)ncn2)CC1c1cc(F)c(F)cc1F
CHEMBL551347,SDEZSIUXMXPOCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11867,45272070,C1CN(CCC1N2C=CC=N2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(n4cccn4)CC3)nc3ccccc32)cc1
CHEMBL377085,SDMLKCQDZJOSDN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,4.522878745280337,11873,613528,CC1=CC(=NC2=C1C(=C(S2)C(=O)N)N)C,Cc1cc(C)c2c(N)c(C(N)=O)sc2n1
CHEMBL1829782,SDPGWJVXVCTHJY-HMILPKGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.154901959985743,11875,53473484,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCCNS(=O)(=O)C)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O
CHEMBL1778481,SDPOAFSISKXZLC-XMHGGMMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550240.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,11876,53386426,CC(C)(C(=O)NC1=CC=C(C=C1)C=CC(=O)O)NC(=O)C2=CC3=C(C=C2)C(=C(N3C)C4=CC=CC=N4)C5CCCCC5,Cn1c(-c2ccccn2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(C=CC(=O)O)cc3)cc21
CHEMBL96347,SDXSGUVLSFVWRF-BHYZAODMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,4.853871964321762,11879,10347783,CC1=CC(=CC(=C1)OC(C(=O)O)C2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C5=CC=CC=C5)C,Cc1cc(C)cc(OC(C(=O)O)C2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1
CHEMBL495787,SECCFJLAASGLAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,11884,24888820,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL495787,SECCFJLAASGLAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,11884,24888820,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL2409667,SEFFUKHXSNXXNA-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,11885,10278742,C1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)S(=O)(=O)CC(CCCC3=NC=CC=N3)N(C=O)O,O=CN(O)C(CCCc1ncccn1)CS(=O)(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1
CHEMBL2017102,SEGYVZKSGPIGLE-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,11890,56963091,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)O)Br,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2(O)c2ccc(F)c(F)c2)c1Br
CHEMBL2018914,SEPBORGDHRCCDG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.301029995663981,11895,20115797,COC1=CC2=C(C=C1)N=C(N2)SCCCC(=O)O,COc1ccc2nc(SCCCC(=O)O)[nH]c2c1
CHEMBL1271544,SEUYCXXZPFOTNT-RRIIRSAJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.301029995663981,11901,52948180,CC(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CC5CCC(C4)N5,CC(C)C1COCC(C2(OC(=O)N3CC4CCC(C3)N4)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL447591,SEXSHORPOJSDHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,1913.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,5.718285029972704,11904,24827305,COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)OC,COc1cncc(-c2ccc3cc(OC)ccc3c2)c1
CHEMBL578579,SEXWHEGZWUEBDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,11905,45484969,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)N4CCOCC4,CC1(CC(=O)NCc2ccc(N3CCOCC3)cc2)CC2(CCCCC2)OO1
CHEMBL1371684,SEZPRMPVJMVCBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,11909,2072958,CC1=CC=C(C=C1)CSC2=NC(=O)C3=C(N2)CCC3,Cc1ccc(CSc2nc(=O)c3c([nH]2)CCC3)cc1
CHEMBL1371684,SEZPRMPVJMVCBV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,11909,2072958,CC1=CC=C(C=C1)CSC2=NC(=O)C3=C(N2)CCC3,Cc1ccc(CSc2nc(=O)c3c([nH]2)CCC3)cc1
CHEMBL1080975,SFAHBRRRIPXYTB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11910,46883509,CC1(CCCN(C1)C(=O)NCC2=CC=C(C=C2)C3=CC(=CC=C3)Cl)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3cccc(Cl)c3)cc2)C1
CHEMBL1760206,SFBJQTXZKXTYKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,11912,51351504,CN1C(=CC(=N1)C(=O)N2CCN(CC2)C3=CC=CC=C3OC)C4=CC=C(C=C4)Cl,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n(C)n2)CC1
CHEMBL1173260,SFFLHOMUFWFHRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,896.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,6.047691990337875,11916,46901611,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)F,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F
CHEMBL1173260,SFFLHOMUFWFHRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20684610.0,IC50,=,896.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,J. Med. Chem.,PUBLICATION,,6.047691990337875,11916,46901611,C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)F,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F
CHEMBL399283,SFICTTTWDKGKCQ-BAGYTPMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,11918,44447036,C1CC(N(C(C1)C2(CC2)CC3=NC(=NO3)CN4CCC(C4)O)S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,O=S(=O)(c1ccc(Cl)cc1)N1C(C2CC2)CCCC1C1(Cc2nc(CN3CCC(O)C3)no2)CC1
CHEMBL2043437,SFNSLLSYNZWZQG-VQIMIIECSA-N,GLASDEGIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11923,25166913,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1
CHEMBL2347410,SFPNGRVNEZGBGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,11926,71279494,CN1C2=C(C=CC(=C2)F)C(=N1)C3=CN=C4C(=N3)C(=CN4)C(=O)NC5CC(COC5)N,Cn1nc(-c2cnc3[nH]cc(C(=O)NC4COCC(N)C4)c3n2)c2ccc(F)cc21
CHEMBL10769,SFPOPEFEUFHEAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5376020021010435,11927,10122452,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)Cl,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cl)c(=O)nc1SCc1ccc(F)cc1
CHEMBL2382415,SFQBQYYGWHSCJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23628336.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,11928,73353420,C1CC2CN(CC1N2C(=O)OCC(F)(F)F)C3=NC=C(C=N3)OCC4=C(C=NC=C4)C#N,N#Cc1cnccc1COc1cnc(N2CC3CCC(C2)N3C(=O)OCC(F)(F)F)nc1
CHEMBL567911,SFQQUBOFNDDLMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19743867.0,IC50,=,48000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",J. Med. Chem.,PUBLICATION,,4.318758762624412,11930,11689242,CC1=CNC2=C1C(=CN=C2NC3=CC(=CC=C3)Cl)C(=O)N4CCOCC4,Cc1c[nH]c2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c12
CHEMBL500394,SGBOBLSELUHWRG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,3540.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,5.450996737974212,11938,24754344,COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC4=CC=CC=C43,COc1ccc2cc(-c3cncc4ccccc34)ccc2c1
CHEMBL405565,SGDGSDPRWPCTHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,5.886056647693163,11943,3811929,CS(=O)(=O)CC1=CC(=NC(=N1)C2=CC=NC=C2)N3CCCC3,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccncc2)n1
CHEMBL2043004,SGDWPIDXMHBDQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.161150909262744,11944,57386522,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CC=CC=C6,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL3115181,SGJYFRAVXMHBRK-PSUXHBTPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,11947,76310603,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCCCN)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CCCCN)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2178221,SGKCFBSHEIOVRA-XPYDGVJRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061376.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,PUBLICATION,,5.698970004336019,11948,71455398,C1C(C(CN1CCO)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)C=CC(=O)NC4=CC=CC=C4N,Nc1ccccc1NC(=O)C=Cc1ccc(C2CN(CCO)CC2C(=O)Nc2ccc(Cl)cc2)cc1
CHEMBL2059803,SGQSLILVTRDLTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,11952,10483685,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NC=C4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,5.327902142064283,11957,2520,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,76032.63,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,4.11899998682835,11957,2520,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,17600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.7544873321858505,11957,2520,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.920818753952375,11957,2520,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
CHEMBL3702784,SHLJOEBOAVNKSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.5968794788241825,11971,89718488,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN8CCCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1080076,SHOBDCUSXYTMQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,11973,46883474,CC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(-c3ccccc3)cc2)C1
CHEMBL1835153,SHSWWKAPCSHSHG-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21942426.0,IC50,>,75000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders.",J. Med. Chem.,PUBLICATION,,4.1249387366083,11982,42622934,C1CC1C(C(F)(F)F)NC2=NC=C(C3=C2C4=C(N3)C=C(C=C4)C5=CN=C(N=C5)N)C(=O)N,NC(=O)c1cnc(NC(C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12
CHEMBL2165502,SHTICQDOCLQFOS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,11985,57506744,CCC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6(C)C)C7COC7,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4COC4)CC3(C)C)cc2n1
CHEMBL2403816,SHTNULLAAVPXRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773153.0,IC50,=,14800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,J. Med. Chem.,PUBLICATION,,4.8297382846050425,11986,60202316,CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=CC=C(C=C2)NC3=NC=NC4=CC=CC=C43)C5=CC=CC(=C5)N,CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4ccccc34)cc2)n(-c2cccc(N)c2)n1
CHEMBL2113177,SHUVSCHNMZHWMV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16302826.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4 isoform,"Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.",J. Med. Chem.,PUBLICATION,,6.508638306165727,11988,10188844,C1COCCN1CCNC2=CC=C(C=C2)S(=O)(=O)N(CC(=O)NNC3=C4C=CC=CC4=NC3=O)C5=CC=C(C=C5)Cl,O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1)NNC1=c2ccccc2=NC1=O
CHEMBL1081779,SIDLHXXVIBTSJZ-UHFFFAOYSA-N,7-BENZYLOXYQUINOLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,11996,3035604,C1=CC=C(C=C1)COC2=CC3=C(C=CC=N3)C=C2,c1ccc(COc2ccc3cccnc3c2)cc1
CHEMBL1081779,SIDLHXXVIBTSJZ-UHFFFAOYSA-N,7-BENZYLOXYQUINOLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,11996,3035604,C1=CC=C(C=C1)COC2=CC3=C(C=CC=N3)C=C2,c1ccc(COc2ccc3cccnc3c2)cc1
CHEMBL47955,SIMWTRCFFSTNMG-AWEZNQCLSA-N,EPEREZOLID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,12004,73214,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)C(=O)CO)F,CC(=O)NCC1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1
CHEMBL1929238,SIUIQMQVKUUQQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22014550.0,IC50,=,550.0,NM,,inhibition,biochemical,functional,enzyme_activity,non_competitive_inhibitor,radiometry,,30,UM,ATP, =,1,UM,Inhibition of CYP3A4,Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).,Bioorg. Med. Chem. Lett.,PUBLICATION,HOTSPOT FILTRATION ASSAY,6.259637310505756,12011,53384644,CC(C)(C)C1=CC(=C(S1)NC(=O)NC2=C(C(=CC=C2)Cl)Cl)C(=O)N3CCC(=O)N(CC3)CCN(C)C,CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O
CHEMBL2403820,SIXVDPYFTBZLMQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773153.0,IC50,=,1950.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,J. Med. Chem.,PUBLICATION,,5.709965388637482,12016,60202315,CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=CC=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)NC(=O)CCN5CCN(CC5)C)C6=CC=CC(=C6)N,CN1CCN(CCC(=O)Nc2ccc3ncnc(Nc4ccc(NC(=O)Nc5cc(C(C)(C)C)nn5-c5cccc(N)c5)cc4)c3c2)CC1
CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,5.0,12017,53469448,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,,ACS MED. CHEM. LETT.,PUBLICATION,,4.886056647693163,12017,53469448,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,,10000.0,NM,,inhibition,tissue,functional,,,,,0.01-30,UM,,=,0.1-0.5,MG-ML,,,ACS MED. CHEM. LETT.,PUBLICATION,,5.0,12017,53469448,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
CHEMBL2171124,SIXVRXARNAVBTC-UHFFFAOYSA-N,GSK2606414,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900593.0,IC50,,13000.0,NM,,inhibition,tissue,functional,,,,,0.01-30,UM,,=,0.1-0.5,MG-ML,,,ACS MED. CHEM. LETT.,PUBLICATION,,4.886056647693163,12017,53469448,CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21
CHEMBL1760205,SIYPEYKSXSWWFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,12018,51351496,CN1C(=CC(=N1)C2=CC=C(C=C2)Cl)C(=O)N3CCN(CC3)C4=CC=CC=C4OC,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)nn2C)CC1
CHEMBL1257706,SJBVKVDGVANGJA-DOACRVLCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20729082.0,IC50,=,22680.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.644356949779131,12021,46947062,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2CN3C(C2C4=CC=C(C=C4)F)C5CC(CC5C3=O)(C)O,CC(OC1CN2C(=O)C3CC(C)(O)CC3C2C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL3702687,SJDMIRPKIHYUCM-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2920.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.534617148551582,12023,89718197,CN1CCC(CC1)NC(=O)NC2=NC=C(C=C2)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCN(C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL270996,SJDOZKJTMVUAKV-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,6.795880017344075,12025,24824080,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)CN)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)CN)c(C)c34)ccc2[nH]1
CHEMBL270996,SJDOZKJTMVUAKV-GFCCVEGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,6.508638306165727,12025,24824080,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)CN)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)CN)c(C)c34)ccc2[nH]1
CHEMBL270515,SJFBTAPEPRWNKH-CCKFTAQKSA-N,DELANZOMIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18247547.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,5.455931955649724,12026,24800541,B(C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O,CC(C)CC(NC(=O)C(NC(=O)c1cccc(-c2ccccc2)n1)C(C)O)B(O)O
CHEMBL552402,SJIHFYQHTFWHTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,12030,45269950,C1CN(CCC1C2=NC3=CC=CC=C3O2)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1
CHEMBL3313969,SJOFEHGUJFUHSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25711516.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",J. Med. Chem.,PUBLICATION,,4.301029995663981,12032,66575743,CC1=C(C=NC=C1)C2=CC3=C(C(=C2)F)N4C(=NN=C4CC3)C,Cc1ccncc1-c1cc(F)c2c(c1)CCc1nnc(C)n1-2
CHEMBL263179,SJOJFTCKJRUNRE-MBEDZMRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,12033,471430,CC(C)C1=NC(=CS1)COC(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CN3CCN(CC3C(=O)NC(C)(C)C)CC4=CN=CS4)O,CC(C)c1nc(COC(=O)NC(C(=O)NC(Cc2ccccc2)C(O)CN2CCN(Cc3cncs3)CC2C(=O)NC(C)(C)C)C(C)C)cs1
CHEMBL1269687,SJSGQQBOEMCRGY-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,12036,12001871,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)C)Cl)C5CC5)Cl,CC(=O)NCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269687,SJSGQQBOEMCRGY-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.075720713938118,12036,12001871,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC(=O)C)Cl)C5CC5)Cl,CC(=O)NCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL2387599,SJSIOPWZUMWNBI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,12037,71659612,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=CC=CC=C5Cl,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL206545,SJTJWXRSXLQPEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,6.0,12039,11604763,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCCCNS(=O)(=O)C)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCNS(C)(=O)=O)c(C)c34)ccc2[nH]1
CHEMBL207831,SJXXIFKOMSEXRL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16495056.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,12048,11612187,C=CCC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,C=CCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL3260744,SKEJACPDEDIHNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12057,72793098,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=C(N=C(C=C3)C(F)(F)F)C)C4=C(C=NC=C4)C)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3C)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O
CHEMBL1241641,SKGSBVPKDPLIEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,<,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.3979400086720375,12061,46900455,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=C(N=C6CO5)C(F)(F)F,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C(F)(F)F)cn4-5)CC3)cccc2n1
CHEMBL2448737,SKHSDXFQRUQZAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.0,12063,73348121,CC1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(N=C3)C4=CC=CC=C4,Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1
CHEMBL1277935,SKOALCKWENTDHG-TUXUZCGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,12071,49836295,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)CC4=CC=CC=C4CC5=CC=CC=C35,O=C(O)C1=CCCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)C1
CHEMBL2017290,SKRNOPQLHIMWNG-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,12072,70664065,CCC(C1=CC=CC=C1)N2C3=C(C=NC4=CC(=C(C=C43)OC)C5=C(ON=C5C)C)NC2=O,CCC(c1ccccc1)n1c(=O)[nH]c2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21
CHEMBL1093469,SLAGVDVFVOTFNB-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20223662.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by P450-Glo method,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12080,46885027,C1CN(CC1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)CCN3CCN(CC3)C(=O)C4=CC=CC=C4,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CCN(CCN2CCN(C(=O)c3ccccc3)CC2)C1
CHEMBL231383,SLBLVSSPDCNCSA-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,4.97061622231479,12083,23626924,CC1=CN=C(N1CC(=O)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CN5C=CN=N5)F)C,Cc1cnc(C)n1CC(=O)c1ccc(-c2ccc(N3CC(Cn4ccnn4)OC3=O)cc2F)cn1
CHEMBL1209553,SLIFTHAOQMHZDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,12089,49862547,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)Cl,CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O
CHEMBL1209553,SLIFTHAOQMHZDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.060480747381382,12089,49862547,CC(C)CC1N2C=NC=C2CN(S1(=O)=O)CC3=CC=C(C=C3)Cl,CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O
CHEMBL1777976,SLOODFDSRINSMM-JWQCQUIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12092,54585540,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)C2CC(=O)NC3CCCC4=C3C=CC(=C4)CNC(C)(C)C,Cc1ccc(S(=O)(=O)N2CCNC(=O)C2CC(=O)NC2CCCc3cc(CNC(C)(C)C)ccc32)cc1
CHEMBL1777976,SLOODFDSRINSMM-JWQCQUIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514825.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12092,54585540,CC1=CC=C(C=C1)S(=O)(=O)N2CCNC(=O)C2CC(=O)NC3CCCC4=C3C=CC(=C4)CNC(C)(C)C,Cc1ccc(S(=O)(=O)N2CCNC(=O)C2CC(=O)NC2CCCc3cc(CNC(C)(C)C)ccc32)cc1
CHEMBL270666,SLPRBNYHIRCQPB-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,12094,44454303,CC(C)(C(=O)NC(COCC1=CC=CC=C1)C2=NN=NN2C(CC#N)COC3=CC=CC=C3O)N,CC(C)(N)C(=O)NC(COCc1ccccc1)c1nnnn1C(CC#N)COc1ccccc1O
CHEMBL270666,SLPRBNYHIRCQPB-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,9800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.008773924307505,12094,44454303,CC(C)(C(=O)NC(COCC1=CC=CC=C1)C2=NN=NN2C(CC#N)COC3=CC=CC=C3O)N,CC(C)(N)C(=O)NC(COCc1ccccc1)c1nnnn1C(CC#N)COc1ccccc1O
CHEMBL1829763,SLSMHOGJKAPYQU-QLXKLKPCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.920818753952375,12097,53361128,CC(C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)N3CCC(OC3=O)(CCO)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2F)cc1)N1CCC(CCO)(c2ccc(F)cc2)OC1=O
CHEMBL490672,SLVAPEZTBDBAPI-GDLZYMKVSA-N,FILIBUVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19209845.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.",J. Med. Chem.,PUBLICATION,,4.522878745280337,12100,54708673,CCC1=CC(=CC(=N1)CC)CCC2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5,CCc1cc(CCC2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1
CHEMBL3403986,SLZAUJBJBWFYSU-BHDXBOSCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,<=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,12105,59272254,CC(C)N(CC1CNCC1OCC2=CC(=CC=C2)C3=CC=CC=C3)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2OCc2cccc(-c3ccccc3)c2)C(C)C)ccc1OC
CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,12107,941361,C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1
CHEMBL1829433,SMFXSYMLJDHGIE-UHFFFAOYSA-N,AZD-4877,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21899292.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent.",J. Med. Chem.,PUBLICATION,,5.0,12112,10368812,CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C(=NS3)C)C(=O)N2CC4=CC=CC=C4)C(C)C,Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1
CHEMBL399507,SMIMGTZNUUPWTH-ACIOBRDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,19500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.709965388637482,12113,24896257,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)C3CC(CC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5)O,CC(C)(CO)N1CCN(C(=O)OC2(C3CC(O)CC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL399507,SMIMGTZNUUPWTH-ACIOBRDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,19500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.709965388637482,12113,24896257,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)C3CC(CC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5)O,CC(C)(CO)N1CCN(C(=O)OC2(C3CC(O)CC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL570639,SMLNDPGQWMLXAK-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,87000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.060480747381382,12118,44473097,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)O,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)O)nc3)ccc2o1
CHEMBL3702753,SMMMLQJKBCIERQ-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2480.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.605548319173784,12119,89718219,CC1=NC=CN1CCN(C)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCn5ccnc5C)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1099323,SMNCEXHPBATBIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,5.1249387366083,12120,25192021,C1=CC=C(C=C1)C2=CC(=CC(=C2)OCCCCCCC3=C(C(=CC=C3)OCCCC(=O)O)CCC(=O)O)C4=CC=CC=C4,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)c2)c1CCC(=O)O
CHEMBL568012,SMSTUWNNYWFKMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,2030.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.692503962086787,12125,45487544,COC(=O)C1=CC(=CC=C1)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)(C4)C(=O)N6CCN(CC6)CC7=CC=C(C=C7)C(F)(F)F,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(C(F)(F)F)cc7)CC6)(C5)C3)C4)cc2)c1
CHEMBL2407717,SMTXKVURUPJKNQ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829483.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using vivid green as substrate,"Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N-(2-Aminophenyl)benzamide Binding Unit.",J. Med. Chem.,PUBLICATION,,4.795880017344075,12126,71766689,C1C(N=C(S1)NCC2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)C4=CC=CC=C4,Nc1ccccc1NC(=O)c1ccc(CNC2=NC(c3ccccc3)CS2)cc1
CHEMBL2407717,SMTXKVURUPJKNQ-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23829483.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using vivid red as substrate,"Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N-(2-Aminophenyl)benzamide Binding Unit.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,12126,71766689,C1C(N=C(S1)NCC2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)C4=CC=CC=C4,Nc1ccccc1NC(=O)c1ccc(CNC2=NC(c3ccccc3)CS2)cc1
CHEMBL3114717,SMWGYCRIYRMWHW-HFASVGIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23746300.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,,,,,,5.552841968657781,12127,59721405,CCCC(CCC(CC1=CC=CC=C1)NC(=O)C(C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C)NC(=O)OCC3=CN=CS3,CCCC(CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
CHEMBL3114717,SMWGYCRIYRMWHW-HFASVGIHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,12127,59721405,CCCC(CCC(CC1=CC=CC=C1)NC(=O)C(C(C)C)NC(=O)N(C)CC2=CSC(=N2)C(C)C)NC(=O)OCC3=CN=CS3,CCCC(CCC(Cc1ccccc1)NC(=O)C(NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
CHEMBL1642913,SNDGNPRZZZPUAX-BLLLJJGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,12129,16656803,C1C(CC2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)CCN,NCCC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL1642912,SNDGNPRZZZPUAX-WBMJQRKESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,12130,24857759,C1C(CC2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)CCN,NCCC1Cc2ccccc2C(c2ccc(Cl)c(Cl)c2)C1
CHEMBL227676,SNDYOAGMAZLRJN-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.6020599913279625,12131,16658102,C1CC(CN(C1)C2=NC3=C(C=C(C=C3)Br)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2ccc(Br)cc2c1=O
CHEMBL564845,SNFXVJPZRORJQP-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,12132,45268456,CN(C1CCC2=C(N3C=CC=CC3=C2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(c3ccccn3c2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL440464,SNICXCGAKADSCV-UHFFFAOYSA-N,(+/-)NICOTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,142400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.8464900106991626,12135,942,CN1CCCC1C2=CN=CC=C2,CN1CCCC1c1cccnc1
CHEMBL3318998,SNLIVOYLVZGJOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050172.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,12138,86279147,CC1=CC2=C(C=C1C#N)N=C(N2)N3CCN(CC3)CCN4C(=O)C=CC5=C4C=C(C=N5)OC,COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1
CHEMBL2386162,SNNRWIBSGBMYRF-ZFWWWQNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,12140,59536635,CC1=C(C=CC(=N1)OC)OC(CC(C)C)C2CCNC2,COc1ccc(OC(CC(C)C)C2CCNC2)c(C)n1
CHEMBL597211,SNNUMARRAFQOGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20151677.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomal preparation,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,PUBLICATION,,5.0,12141,24993163,CC(C)(C)C1=CC=C(C=C1)CC2(CCN(CC2)C3=NC=NC4=C3C=CN4)N,CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1
CHEMBL178474,SNSYASMKLBWRLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,12146,11495962,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)OC)N4C=CN=C4)N(C)C,COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
CHEMBL178474,SNSYASMKLBWRLR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,12146,11495962,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)C(=O)OC)N4C=CN=C4)N(C)C,COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
CHEMBL2181629,SNWJTLNFUDCRNX-XNTDXEJSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.366531544420414,12149,71455673,CN1C2=C(C=CC(=C2)C(=O)NC3(CCCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=CC=NC=C5)C6CCCC6,Cn1c(-c2ccncc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCCC3)cc21
CHEMBL1668114,SNZZAHRDXCGWEM-CKFHNAJUSA-N,TAXIRESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,85600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.0675262353228465,12151,10088963,COC1=C(C=CC(=C1)CC2COC(C2CO)C3=CC(=C(C=C3)O)O)O,COc1cc(CC2COC(c3ccc(O)c(O)c3)C2CO)ccc1O
CHEMBL479701,SOCNBZCAGNYAED-OKFXBHNASA-N,(-)-CLUSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,830.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,6.080921907623926,12154,44575398,COC1=CC(=CC(=C1OC)OC)CC2C(COC2O)CC3=CC4=C(C=C3)OCO4,COc1cc(CC2C(Cc3ccc4c(c3)OCO4)COC2O)cc(OC)c1OC
CHEMBL1910124,SOFQOASLSXGZBR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,12157,57399665,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)N3CCOCC3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCOCC1)C2=O
CHEMBL3112865,SONKMXSQGHFTFK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12163,66882291,CC1(CN(C2=CC=CC=C21)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4)C,CC1(C)CN(C(=O)Cc2nc(=O)cc(N3CCOCC3)[nH]2)c2ccccc21
CHEMBL3114727,SOOCSEFIXRGIQQ-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1260.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.8996294548824375,12165,76325091,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NCCCNC(=O)OCC2=CN=CS2,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NCCCNC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL240528,SOSLMHZOJATCCP-AEIZVZFYSA-N,AFZELIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.0,12169,5316673,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)O,CC1OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(O)C(O)C1O
CHEMBL448253,SOUIZGJPJARRHY-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12171,44587394,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N)C4=CC(=CC=C4)OCCCC(=O)O,Cc1c(-c2cccc(OCCCC(=O)O)c2)c(=O)n(CC(N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
CHEMBL467079,SOUYYRXENUITFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19364658.0,IC50,=,8600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,PUBLICATION,,5.0655015487564325,12172,25206064,C1=CC=C(C=C1)C(C(=O)N)NC2=C(C(=O)C2=O)NC3=CC=NC=C3,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1
CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,12180,9812710,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C.CC1CCC2(CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)OC1C(C)C,CCC(C)C1OC2(CCC1C)CC1CC(CC=C(C)C(OC3CC(OC)C(OC4CC(OC)C(O)C(C)O4)C(C)O3)C(C)C=CC=C3COC4C(O)C(C)=CC(C(=O)O1)C34O)O2
CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,12180,9812710,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C.CC1CCC2(CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)OC1C(C)C,CCC(C)C1OC2(CCC1C)CC1CC(CC=C(C)C(OC3CC(OC)C(OC4CC(OC)C(O)C(C)O4)C(C)O3)C(C)C=CC=C3COC4C(O)C(C)=CC(C(=O)O1)C34O)O2
CHEMBL2040894,SPCSFCKHCIOCTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,12181,57387031,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=NOC(=N6)COC,COCc1nc(-c2ccc(N3C(=O)N(c4cc(=O)nc[nH]4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)no1
CHEMBL1796293,SPHCZZBTYLIKMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,12186,56673550,C1=CC=C(C(=C1)C#N)OC2=CC=C(C=C2)C(=O)NCC3=CC=NC=C3,N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncc2)cc1
CHEMBL3702711,SPNMGKKKLSOOCQ-SAGRBAIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.657577319177793,12190,89718255,CC(C)(C)OC(=O)N1CCN2CCN(CC2C1)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(=O)OC(C)(C)C)CC6C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702727,SPRRJSDCKXRUNI-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,12192,89718353,CN1CCN(CC1)C2CN(C2)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCN(C)CC6)C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL10271,SPSIJFFRJLVTRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,12193,10305573,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)Br,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Br)c(=O)nc1SCc1ccc(F)cc1
CHEMBL1949939,SPTLTOMHDUZGDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,12195,57402038,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccnc(F)c3)c2c1
CHEMBL1949939,SPTLTOMHDUZGDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602099,12195,57402038,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC(=NC=C4)F)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccnc(F)c3)c2c1
CHEMBL231147,SPUNALFSCHUGOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12196,44425801,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)N5C=CC=C5)N(C2=O)CC6=CC=CC=C6F,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5cccc5)cc4)CC3)C2=O)c1
CHEMBL477204,SPVRNTZJWSWACV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18809327.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12197,44578988,CC1=C(C=CC(=N1)C2=CC=C(C=C2)F)C(=O)NC3=CC4=C(C=CC=N4)C=C3,Cc1nc(-c2ccc(F)cc2)ccc1C(=O)Nc1ccc2cccnc2c1
CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.522878745280337,12199,444034,CC(C)C1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,CC(C)C1(NC(=O)C2CC3c4cccc5[nH]cc(c45)CC3N(C)C2)OC2(O)C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O
CHEMBL2158227,SPZDCHRXPBSIHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,12203,11511361,CS(=O)(=O)CCN1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
CHEMBL2441847,SQBQWLJQRMPESE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.080921907623926,12205,15950684,CCN(CC)C(=O)CCN1CC2=NC(=C(C(=C2C1=O)C3=C(C=C(C=C3)Cl)Cl)CN)C,CCN(CC)C(=O)CCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O
CHEMBL87792,SQCCCUOOWHMPBF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12206,23395772,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CCN(C)C)CC4=CC=C(C=C4)C5=CC=C(C=C5)C(F)(F)F,CN(C)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL3326577,SQDHZRJWYDAANI-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,5.552841968657781,12208,25264907,CCC1(CC(C2=C(O1)C=CC(=C2)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)CC,CCC1(CC)CC(NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1
CHEMBL1669411,SQGLQUFJVYRVPS-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12212,53321511,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC(F)(F)F,CC(C1=C(CCN(C)CCC(F)(F)F)Cc2ccccc21)c1cnccn1
CHEMBL2313764,SQIBVAVXYSKQBW-FZFRBNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23182090.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,12214,71530223,COC1COCCC1NC2CC3CCCC3(C2)C(=O)N4CCC5=C(C4)C=C(C=N5)C(F)(F)F,COC1COCCC1NC1CC2CCCC2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1
CHEMBL1079140,SQMRZYILEJFWLA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12216,46882969,CN(C)CCC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,CN(C)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL3586436,SQOCEMCKYDVLMM-IYBDPMFKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26087021.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,"Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.",J. Med. Chem.,PUBLICATION,,5.0,12218,86278359,CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C,Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1
CHEMBL3702823,SQSHFUZAFRGGRD-JSXFGMRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,12224,89718302,CCOC(=O)NC(=S)NC1=NC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)OCC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702766,SQSKPCJVGCVCQY-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6870.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.16304326294045,12225,89718281,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7CCN(CC7)C(=O)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)CCO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL605833,SREGRCFSXVBPIJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19700331.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,12235,10157813,C1=CC=C2C=C(C=CC2=C1)CCOC3=C(C=CC(=C3)CN4C=CC=N4)CCC(=O)O,O=C(O)CCc1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1
CHEMBL2347991,SRGSOSLNVCMQMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,12237,71279543,CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCC(CO)O,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12
CHEMBL1929387,SRIIFFBJIKZICS-RSAXXLAASA-N,ANAGLIPTIN HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22019046.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.0,12240,54764334,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N.Cl,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N)cn2n1
CHEMBL1091069,SROGIGROUAOOFN-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12247,46884120,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)OC,COc1cccnc1C(C)c1c(CCN(C)C)sc2ccccc12
CHEMBL1098560,SRPFDFNVILUDAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,5.1249387366083,12248,25192022,C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)OCCCCCCC4=C(C(=CC=C4)OCCCC(=O)O)CCC(=O)O)C5=CSC=C5,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccsc3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O
CHEMBL2105423,SRRHGTUDJFMQIV-UHFFFAOYSA-N,SABIPORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,5.154901959985743,12249,9868115,C1CN(CCN1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CN3,NC(N)=NC(=O)c1ccc(N2CCN(C(=O)c3ccc[nH]3)CC2)c(C(F)(F)F)c1
CHEMBL567582,SSCCINNDXPYQQI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12260,45484917,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC4=C(C=C3)OC=CCO4,CC1(CC(=O)NCc2ccc3c(c2)OCC=CO3)CC2(CCCCC2)OO1
CHEMBL240364,SSCJBDJJWLFQLZ-ZBLYBZFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.0,12261,23635237,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=CC=C(C=C3)Cl)C(C(C)C)NC(=O)CCN,Cc1ccc(N2CCN(C(=O)C(C)Cc3ccc(Cl)cc3)CC2)c(C(NC(=O)CCN)C(C)C)c1
CHEMBL3422012,SSHIUOSPXKCYNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.522878745280337,12267,71549359,CC1=NC(=CS1)C2=NN=C3N2CCN(C3)C(=O)C4=CC=C(C=C4)C5=CC=CS5,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1
CHEMBL594755,SSMMEOSYEUOMIT-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,12269,25221040,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=CC=CC=C5)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2ccccc2)cc1-c1cnc2n[nH]c(C)c2n1
CHEMBL3355474,SSPHMGCXSJLCMP-ZIAGYGMSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589928.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,12274,118720885,CC1COCCN1C2=C3C(=CC(=N2)C4=CN=CC5=C4C=CN5)N(C=N3)C(C)S(=O)(=O)C,CC1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2C(C)S(C)(=O)=O
CHEMBL503705,SSTWFLYMZFXJLL-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,69000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.161150909262744,12280,25156942,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N(C)CCCC(=O)O)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(c3ccccc3)N(C)CCCC(=O)O)c2=O)c1F
CHEMBL2041191,SSVPMKGPRCBPJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,12283,57387775,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4)C5=CN=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1
CHEMBL257150,STALPJWOKWGXGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,12287,44448947,C1CCN(C1)CC2C(CCCN2C(=O)CN3C4=C(C=CC(=C4)Cl)OC3=O)C5=CC=CC=C5,O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1
CHEMBL1808631,STCUWCYDLVMFEY-GQCTYLIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,12289,56683440,C1C2=C(CN1S(=O)(=O)C3=CC=CS3)C=C(C=C2)C=CC(=O)NO,O=C(C=Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)C2)NO
CHEMBL2272118,STEPQTYSZVCJPV-UHFFFAOYSA-N,METAZACHLOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,12290,49384,CC1=C(C(=CC=C1)C)N(CN2C=CC=N2)C(=O)CCl,Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl
CHEMBL2272118,STEPQTYSZVCJPV-UHFFFAOYSA-N,METAZACHLOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,12290,49384,CC1=C(C(=CC=C1)C)N(CN2C=CC=N2)C(=O)CCl,Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl
CHEMBL1172847,STFAHYUUOLTNDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,464.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,6.333482019445119,12291,46854608,CC(=C(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)O)C3=CC=NC=C3)C,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(O)c2)cc1
CHEMBL569862,STFVOGWUKNAWOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19831396.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatic CYP3A4,New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.,J. Med. Chem.,PUBLICATION,,5.823908740944319,12292,25192621,CC1=C(C=CC(=C1)C2=CSC(=C2)C3=CC(=CC=C3)O)O,Cc1cc(-c2csc(-c3cccc(O)c3)c2)ccc1O
CHEMBL193306,STINDBVFOPRZHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15943473.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against human cytochrome P450 3A4,"Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.",J. Med. Chem.,PUBLICATION,,5.292429823902063,12294,10388612,CC1=CN=C(O1)C2=CN3C(=C2C(C)C)C(=NC=N3)NC4=C(C=C(C(=C4)C(=O)NOC)F)F,CONC(=O)c1cc(Nc2ncnn3cc(-c4ncc(C)o4)c(C(C)C)c23)c(F)cc1F
CHEMBL560579,STJLVHWMYQXCPB-UHFFFAOYSA-N,PROPICONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,1039.92,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.983000069254019,12296,43234,CCCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,CCCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1
CHEMBL2436627,STNAHDQLZLCSLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12297,44622416,C1CN(CCC1N2CCC3=CC=CC=C3C2)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5C4)CC3)CC2)ccn1
CHEMBL2396661,STUWGJZDJHPWGZ-LBPRGKRZSA-N,ALPELISIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12302,56649450,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1
CHEMBL1910292,STXFMRGIISYYJC-IRPSRAIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,12304,42641453,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC3(C4=CC(=C(C=C4)F)F)O,COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1
CHEMBL1910294,STXFMRGIISYYJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21641209.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,12305,57392011,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC3(C4=CC(=C(C=C4)F)F)O,COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1
CHEMBL2070146,STZWTQUFIPPPOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,12306,70695118,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3F)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3F)[nH]c2c1
CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,77983.01,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,4.108000005860498,12308,4594,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
CHEMBL2387502,SUERHDHTNGFCPM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,12311,71659898,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)[N+](=O)[O-],O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3c(Cl)cccc3[N+](=O)[O-])[nH]c12
CHEMBL1272152,SUGZFIXSMJJZIS-FYYLOGMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,12312,11628240,CC(C)(CO)N1CCN(CC1)C(=O)OC2(CC2)C3COCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)CC5CC5,CC(C)(CO)N1CCN(C(=O)OC2(C3COCC(CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1
CHEMBL559061,SULKMHQPINMVTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12320,45272890,CN(C)CCN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(C)CCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
CHEMBL2018903,SUMJDTVJSTZJFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.301029995663981,12321,40680501,CCCCSC1=NC2=C(N1)C=C(C=C2)OC,CCCCSc1nc2ccc(OC)cc2[nH]1
CHEMBL3313972,SUODWKMMJQIJQB-GZOQVGHDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24422519.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.,J. Med. Chem.,PUBLICATION,,7.167491087293763,12325,46911333,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C4=CC=CC=C4)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(O)c2ccccc2)S1(=O)=O
CHEMBL1209696,SUODWKMMJQIJQB-XABNSEFBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,<,68.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,12326,49862654,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C4=CC=CC=C4)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(O)c2ccccc2)S1(=O)=O
CHEMBL1209696,SUODWKMMJQIJQB-XABNSEFBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,1920.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.716698771296451,12326,49862654,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C4=CC=CC=C4)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(O)c2ccccc2)S1(=O)=O
CHEMBL1209695,SUODWKMMJQIJQB-XDJLXXALSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,12327,49862653,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C4=CC=CC=C4)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(O)c2ccccc2)S1(=O)=O
CHEMBL1209695,SUODWKMMJQIJQB-XDJLXXALSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20615692.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,12327,49862653,CC(C1=CC=C(C=C1)Cl)N2CC3=CN=CN3C(S2(=O)=O)CC(C4=CC=CC=C4)O,CC(c1ccc(Cl)cc1)N1Cc2cncn2C(CC(O)c2ccccc2)S1(=O)=O
CHEMBL390526,SUQCZNPRHQYYQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.0,12329,10341839,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=CC(=CC(=C3)F)F,O=C(NCC1CCOCC1)c1cnc(Nc2cc(F)cc(F)c2)nc1C(F)(F)F
CHEMBL495786,SUVHLBHXIPQGAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,12334,24890525,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC(=O)C=C4,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12
CHEMBL495786,SUVHLBHXIPQGAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,12334,24890525,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=CC(=O)C=C4,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12
CHEMBL227356,SUVWKEOODLERME-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,6.102372908709558,12335,23647314,C1CC(CN(C1)C2=NC3=CC(=C(C=C3C(=O)N2CC4=CC=CC=C4C#N)F)N5CCOCC5)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2cc(N3CCOCC3)c(F)cc2c1=O
CHEMBL568444,SUYWBFYEHQMEKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12336,45484923,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)[N+](=O)[O-],CC1(CC(=O)NCc2ccc([N+](=O)[O-])cc2)CC2(CCCCC2)OO1
CHEMBL1223236,SVBRTHGICYDAAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20667729.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,12338,44159640,C1CC(C1)N2CCCN(CC2)C(C3=CC=C(C=C3)CN4C=NC=N4)C5=NN=NN5CC6=CC=CC=C6,c1ccc(Cn2nnnc2C(c2ccc(Cn3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1
CHEMBL460997,SVKIVWVOFVHFNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,19500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.709965388637482,12345,135875715,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCOC,COCCN1CCC(c2cc(C)c3nc(-c4c(NCCn5cc(Cl)cn5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL1766175,SVOSCUAPCVQCPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.119186407719209,12348,12043374,CC(C)C(C1=CC=C(C=C1)C2=CC=C(C=C2)Cl)(C3=CN=CN3)O,CC(C)C(O)(c1ccc(-c2ccc(Cl)cc2)cc1)c1cnc[nH]1
CHEMBL1269697,SVSUEWKNQNMUNQ-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,12351,24742640,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=NC(=C4)CCCOC)Cl)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c(Cl)cn1
CHEMBL2448712,SVVUFNZMTNZJNC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,4500.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.346787486224656,12353,73348120,C1=CC=C(C=C1)C2=NC=C(S2)C(=O)NC3=C(C=CC(=C3)C#N)N4C=CN=C4,N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
CHEMBL3702726,SVVWQNVWSAFJNO-LQJZCPKCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.73754891026957,12354,89718321,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CC(C7)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(O)C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1909987,SVXNNKHVIMXUBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.468521082957745,12356,15950384,CC1=C(C(=C2CN(CC2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2
CHEMBL1909987,SVXNNKHVIMXUBX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,770.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.113509274827518,12356,15950384,CC1=C(C(=C2CN(CC2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2
CHEMBL438699,SVZZYOGCUPHRBU-ZDTVFLJBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,12357,44446991,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CC5CCC(C4)N5C,CCC1CCCC(C2(CC(=O)N3CC4CCC(C3)N4C)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19616432.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.913640169325252,12358,44517677,C1CC(C1)CN(C2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)C1CCNC1
CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19616432.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using felodipine as substrate,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,12358,44517677,C1CC(C1)CN(C2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)C1CCNC1
CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19616432.0,IC50,=,31200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.505845405981558,12358,44517677,C1CC(C1)CN(C2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)C1CCNC1
CHEMBL197202,SWCLDFSCLHXNAM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134939.0,IC50,=,74000.0,NM,,,cell_based,,,,,,,,,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,PUBLICATION,,4.130768280269024,12359,11602469,CC(C1=CC(=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)O)F)C(=O)O,CC(C(=O)O)c1ccc(-c2ccc(-c3ccc(O)cc3)cc2)c(F)c1
CHEMBL465289,SWCSHYFRURDRBU-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,12360,44570453,CCN(CCC1=CC=CC=C1)C(=O)C2=CC=CC=C2C3=CC=C(C=C3)CN4CC(NC(C4)C)C,CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2CC(C)NC(C)C2)cc1
CHEMBL465289,SWCSHYFRURDRBU-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,12360,44570453,CCN(CCC1=CC=CC=C1)C(=O)C2=CC=CC=C2C3=CC=C(C=C3)CN4CC(NC(C4)C)C,CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2CC(C)NC(C)C2)cc1
CHEMBL1935447,SWDWBOARDFBZAD-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,12361,57400505,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL1935448,SWDWBOARDFBZAD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,15800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.801342913045577,12362,57402230,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL496189,SWEAYHBSAXRXDZ-MOPGFXCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12363,44593665,C1CN(CCC12CC(=O)C3=CC=CC=C3O2)C(=O)NC4CC4C5=CC=CC=C5,O=C1CC2(CCN(C(=O)NC3CC3c3ccccc3)CC2)Oc2ccccc21
CHEMBL3142316,SWEQJWJHTNSSDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,=,74800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,4.126098402135539,12365,56593712,CN1CCC(=CC1)C2=CNC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,CN1CC=C(c2c[nH]c3cc(N=C(N)c4cccs4)ccc23)CC1
CHEMBL3142316,SWEQJWJHTNSSDL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21923116.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BQ as substrate,"Discovery of N-(3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a Selective Inhibitor of Human Neuronal Nitric Oxide Synthase (nNOS) for the Treatment of Pain.",J. Med. Chem.,PUBLICATION,,4.0,12365,56593712,CN1CCC(=CC1)C2=CNC3=C2C=CC(=C3)N=C(C4=CC=CS4)N.Cl.Cl,CN1CC=C(c2c[nH]c3cc(N=C(N)c4cccs4)ccc23)CC1
CHEMBL1935446,SWFSQSZMVIJILA-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,15600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.806875401645538,12367,57397056,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.97469413473523,12368,57400504,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,=,16700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.777283528852417,12368,57400504,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
CHEMBL276081,SWPBTKCAQDJKSO-KRXYOAFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.096910013008056,12375,10212550,C1CN(C(CN1CC2=CN(C=C2)C3=CC(=CC=C3)Cl)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2ccn(-c3cccc(Cl)c3)c2)CC1C(=O)NCC(F)(F)F
CHEMBL2158302,SWPGDCRPXQMSIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.1938200260161125,12376,11576269,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)NCCO)NC(=O)C4=NC=C(N4)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL1813114,SWQLTIWVDZKVMH-SWYRRKHMSA-N,MK-5710,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21737263.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,12377,53361076,CC12CN(CCN1C(=O)N(C2=O)C3CC3C4=CC=CC=C4)C(=O)NC5=CC=NN5C6=CC=CC=C6,CC12CN(C(=O)Nc3ccnn3-c3ccccc3)CCN1C(=O)N(C1CC1c1ccccc1)C2=O
CHEMBL442086,SWSPTEWZUSYXHL-FQEVSTJZSA-N,SR-902,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12382,16662094,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C4CC5=CC=CC=C5CN4,O=C(C1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL3427277,SWWRPROUTDGFFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,12386,118737725,CCS(=O)(=O)CCC1=C(N=C2N1C=CC(=C2)Cl)CN3C4=C(C=CN=C4)N(C3=O)C5CC5,CCS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12
CHEMBL3353342,SXAOLYUXAFWLCI-UXFRTJKQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,6.0,12389,58486164,C1C(C12C3=CC=CC=C3NC2=O)C4=CC5=C(C=C4)C(=NN5)C=CC6=CN=CC=C6,O=C1Nc2ccccc2C12CC2c1ccc2c(C=Cc3cccnc3)n[nH]c2c1
CHEMBL1270362,SXBWNENFIQGMLK-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20833041.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of NADPH,Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,12392,49831178,CC(=O)NC(CC1=CC(=CC(=C1)F)F)C(CNC2(CC2)C3=CC(=CC=C3)C(C)(C)C(F)F)O,CC(=O)NC(Cc1cc(F)cc(F)c1)C(O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1
CHEMBL1270362,SXBWNENFIQGMLK-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20833041.0,IC50,=,46.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.337242168318426,12392,49831178,CC(=O)NC(CC1=CC(=CC(=C1)F)F)C(CNC2(CC2)C3=CC(=CC=C3)C(C)(C)C(F)F)O,CC(=O)NC(Cc1cc(F)cc(F)c1)C(O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1
CHEMBL1270362,SXBWNENFIQGMLK-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20833041.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by competitive inhibition assay,Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,12392,49831178,CC(=O)NC(CC1=CC(=CC(=C1)F)F)C(CNC2(CC2)C3=CC(=CC=C3)C(C)(C)C(F)F)O,CC(=O)NC(Cc1cc(F)cc(F)c1)C(O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1
CHEMBL394993,SXIQBPDOSGYNFP-UHFFFAOYSA-N,SR-890,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12395,16662091,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Cl)O,O=C(C(O)c1ccc(Cl)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL3673959,SXMVDOWLRVXGBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320628,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,12399,52935812,COC1=NC=C(C=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
CHEMBL3673959,SXMVDOWLRVXGBP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320672,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,12399,52935812,COC1=NC=C(C=C1)CNC2=NC=C(C=N2)CC3=CNC4=C3C=C(C=N4)Cl,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
CHEMBL240954,SXOZSDJHGMAEGZ-IGKKHSBFSA-N,SL-0101,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,20600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.686132779630847,12402,10459196,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)OC(=O)C,CC(=O)OC1C(C)OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(O)C1OC(C)=O
CHEMBL1951339,SXQGGECXWPMBCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,12403,57400524,CC(C)N(C(C)C)C(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CC(C)N(C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1)C(C)C
CHEMBL498026,SXRFIFLANPJWQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.42021640338319,12405,44583631,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
CHEMBL498026,SXRFIFLANPJWQC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,12405,44583631,CC1=CC=CC=C1CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
CHEMBL2425160,SXSHRCRPTWSWQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12407,72190132,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)C4=CN=C(C=C4)OC,COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1
CHEMBL2163827,SXVPPLOMCQSJMY-CRHVVPOVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.619788758288394,12408,57522250,C1CC2CC(CC1N2C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4(CC4)C5=CC=C(C=C5)OC(F)(F)F)N,NC1CC2CCC(C1)N2C(=O)C(Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1
CHEMBL1910125,SXXTUZFVBVFYTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 up to 40 uM,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,12412,57396206,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)NC3=CC=NN3C)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)Nc1ccnn1C)C2=O
CHEMBL583867,SXYMVJZFEUONDV-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,12414,507783,CC1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=CN=C3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12
CHEMBL583867,SXYMVJZFEUONDV-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,12414,507783,CC1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=CN=C3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12
CHEMBL509903,SXZFQYPWEANJGQ-SKCUWOTOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20731374.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Direct renin inhibitors as a new therapy for hypertension.,J. Med. Chem.,PUBLICATION,,5.0,12416,16086657,C1CC1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3=C(CC4CNCC3N4)C5=CC=C(C=C5)CCCOC6=C(C=CC(=C6Cl)F)F,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CC2CNCC1N2)N(Cc1cccc(Cl)c1Cl)C1CC1
CHEMBL478037,SYBPXZBWAAAJAX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,12420,44579234,C1=CC=C(C=C1)C(C2=NC=CS2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1nccs1
CHEMBL499307,SYBXHLIANYBTCO-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.173925197299173,12421,44576655,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)COC(=O)CN)N,NCC(=O)OCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(N)c3ccccc3)c2=O)cc1
CHEMBL3236654,SYEJHQQRLZNDAL-GXAGMUTGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,6.096910013008056,12423,90655385,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=NC=C(S5)C(=O)CO,CC1(Cc2ncc(C(=O)CO)s2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL153741,SYEUUCQERNUTBQ-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.102372908709558,12424,44367781,CC1=NC2=C(S1)C=CC(=C2)OCC(CN3CCN(CC3)CC(=O)NC4=CC=C(C=C4)C5=CC=CC=C5)O,Cc1nc2cc(OCC(O)CN3CCN(CC(=O)Nc4ccc(-c5ccccc5)cc4)CC3)ccc2s1
CHEMBL255509,SYNTYRNKHJSTLL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,12427,44449106,C1CCN(C1)CC2C(CCCN2C(=O)CN3C(=O)COC4=CC(=C(C=C43)Cl)Cl)C5=CC=CC=C5,O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1
CHEMBL3673940,SYSOKYYRVIKDBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320651,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,12432,67203040,CC1=CN=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C)F,Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1
CHEMBL3673940,SYSOKYYRVIKDBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320695,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,12432,67203040,CC1=CN=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C)F,Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1
CHEMBL484029,SYVLRDXITUYNAK-USACIQFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15568772.0,IC50,=,120000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa.",J. Nat. Prod.,PUBLICATION,,3.9208187539523753,12434,11485574,CC(C)CC(=O)C1=C(C=C(C=C1OC2C(C(C(C(O2)CO)O)O)O)O)O,CC(C)CC(=O)c1c(O)cc(O)cc1OC1OC(CO)C(O)C(O)C1O
CHEMBL3608741,SZEYAOKHLPDWFZ-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,12439,86274732,CC1=NSC(=N1)C2=NN=C3N2CCN(C3CCO)C(=O)C4=CC=C(C=C4)F,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3CCO)n1
CHEMBL1951454,SZKGHXMOYDKXPX-IRXDYDNUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264487.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis,A ��-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,12443,57393566,CCCOC1=C(C(=C(S1)C(=O)N2C3CCC2CC(C3)C4=C(C=CC(=C4)CN)F)C)Br,CCCOc1sc(C(=O)N2C3CCC2CC(c2cc(CN)ccc2F)C3)c(C)c1Br
CHEMBL1214396,SZKJWXCCFDRJTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20614889.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 10 mins,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,PUBLICATION,,5.045757490560675,12444,11638499,CC1=C(C=NC=C1)C2=CC3=C(CC(C3)NS(=O)(=O)C(C)C)C=C2,Cc1ccncc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2
CHEMBL1669405,SZKXEXNSYILRKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12446,53320177,CCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
CHEMBL1950090,SZMWOWPIZBQHLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,12449,57396434,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)Cl,Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)[nH]nc3nc12
CHEMBL1950090,SZMWOWPIZBQHLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,12449,57396434,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CN4C)O)Cl,Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)[nH]nc3nc12
CHEMBL1076245,SZPJAZAOTADHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,12451,46879551,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCCC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12
CHEMBL1076245,SZPJAZAOTADHKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,12451,46879551,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCCC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12
CHEMBL3702783,SZPKRLIHOZBLQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5350.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.2716462179787715,12452,89718368,CCN(CC)CCN(CCN(CC)CC)C1=NC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(CCN(CC)CC)CCN(CC)CC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL152968,SZRMSHBRXJWBFG-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,12453,44367711,CC1=NC2=C(S1)C=CC(=C2)OCC(CN3CCN(CC3)CC(=O)NC4=CC=CC(=C4)C5=CC=CC=C5)O,Cc1nc2cc(OCC(O)CN3CCN(CC(=O)Nc4cccc(-c5ccccc5)c4)CC3)ccc2s1
CHEMBL2415095,SZSKTZXFLXPROO-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23890837.0,IC50,=,6940.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design and synthesis of bicyclic heterocycles as potent ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.158640529545145,12456,49872381,CC1=C(C=CC(=C1)F)C2CCCN3C2=NC(=N3)C4=CC(=C(C=C4)N5C=C(N=C5)C)OC,COc1cc(-c2nc3n(n2)CCCC3c2ccc(F)cc2C)ccc1-n1cnc(C)c1
CHEMBL2413881,SZTUUDCVQNNFRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23896611.0,IC50,=,6.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis,"Tetrazole-based deoxyamodiaquines: Synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",Bioorg. Med. Chem.,PUBLICATION,,8.221848749616356,12458,71770158,CCN(CC)C(C1=CC(=CC=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)C4=NN=NN4C(C)(C)C,CCN(CC)C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)c1nnnn1C(C)(C)C
CHEMBL2178254,TTWJUJRTJUODCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,12462,58063225,CN1C=C(C(=N1)C2=CC(=CC=C2)Cl)NC(=O)C3=C4N=C(C=CN4N=C3)N,Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cccc(Cl)c2)n1
CHEMBL2163828,TUDINUHHPSENND-VYTWWXLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.5376020021010435,12469,57522251,C1CC2CC(CC1N2C(=O)C(CC3=CC=C(C=C3)Br)NC(=O)C4(CC4)C5=CC=C(C=C5)OC(F)(F)F)N,NC1CC2CCC(C1)N2C(=O)C(Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1
CHEMBL379834,TUFFUEHRXNGQLP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,12471,11706579,COC1=CC=CC=C1OC2=CC=CC(=C2)CN3CCC(CC3)(C(=O)O)NC(=O)C4(CCNCC4)C5=CC=CC=C5,COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)(C(=O)O)CC2)c1
CHEMBL3291118,TUGLCXDNPZXHHN-ZMRSBPIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.903089986991944,12472,90644508,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CC=CC=N4)C,C=CC1(C)CC(OC(=O)CSc2ccccn2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291118,TUGLCXDNPZXHHN-ZMRSBPIZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.866461091629782,12472,90644508,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CC=CC=N4)C,C=CC1(C)CC(OC(=O)CSc2ccccn2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL2181621,TUHQBDDCFFEKIR-LICLKQGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,10700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,4.97061622231479,12473,71452107,CN1C2=C(C=CC(=C2)C(=O)NC3(CCCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=NC=C(C=C5)Cl)C6CCCC6,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCCC3)cc21
CHEMBL246970,TUJUZVJICDSNLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,12476,16727123,C1CC(CCC1CN)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
CHEMBL246970,TUJUZVJICDSNLY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,12476,16727123,C1CC(CCC1CN)CNC2=NC(=NC=C2[N+](=O)[O-])NCC3=CC=CC=C3Cl,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1
CHEMBL2057514,TUMOCTIPKNLFSX-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.075720713938118,12478,70688456,CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
CHEMBL410414,TUOSYWCFRFNJBS-BHVANESWSA-N,DIRLOTAPIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276061.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12480,9917862,CN1C2=C(C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)C=C1C(=O)NC(C5=CC=CC=C5)C(=O)N(C)CC6=CC=CC=C6,CN(Cc1ccccc1)C(=O)C(NC(=O)c1cc2cc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)ccc2n1C)c1ccccc1
CHEMBL476302,TUOXXRMLFZBSTB-UHFFFAOYSA-N,GSK8062,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621523.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome using atrovastatin substrate,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,12481,16214849,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1
CHEMBL476302,TUOXXRMLFZBSTB-UHFFFAOYSA-N,GSK8062,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621523.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome using midazolam substrate,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,12481,16214849,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1
CHEMBL476302,TUOXXRMLFZBSTB-UHFFFAOYSA-N,GSK8062,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621523.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsome using nifedipine substrate,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.055517327849831,12481,16214849,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1
CHEMBL403998,TUQYNUMCKKHFKS-SIRJMXRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,12483,11526524,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC(=O)N4CC5CCC(C4)N5CCO,CCC1CCCC(C2(CC(=O)N3CC4CCC(C3)N4CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL205808,TVFMBJYYWFCDRX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,12490,792361,CCOC(=O)C1CCN(CC1)CC2=CC(=CC=C2)OC3=CC=CC=C3,CCOC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
CHEMBL2448730,TVJSHFZBWQHJFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,12497,73354180,C1=CC=C2C(=C1)N=C(S2)C3=CC(=CC(=C3)F)N(CC4=CN=CC=C4)C(=O)CN.Cl,NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
CHEMBL2448730,TVJSHFZBWQHJFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1010.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.995678626217358,12497,73354180,C1=CC=C2C(=C1)N=C(S2)C3=CC(=CC(=C3)F)N(CC4=CN=CC=C4)C(=O)CN.Cl,NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
CHEMBL558663,TVKCCIBAUDHHBL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12498,45272878,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC,COc1ccc(Cn2c(N3CCC(N(C)CC4CCOCC4)CC3)nc3ccccc32)cc1
CHEMBL1269686,TVMDRXNOEWPGJS-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,12500,52944247,CCNC(=O)CC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269686,TVMDRXNOEWPGJS-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,7100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1487416512809245,12500,52944247,CCNC(=O)CC1=CC(=C(C=C1)Cl)CN(C2CC2)C(=O)C3CNCCC3C4=CC=C(C=C4)OCCOC5=C(C=C(C=C5Cl)C)Cl,CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1078715,TVNCLEMLTQVHDY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12503,46883032,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=C(C=C3)C(F)(F)F,O=C(O)CCC1(c2ccc(C(F)(F)F)cc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL2418954,TVUPSIBSWDXJGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23820386.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,12511,59251679,CC(=O)NC1=CN2C=C(C=CC2=N1)C3=CC(=C(N=C3)N)C(F)(F)F,CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1
CHEMBL149750,TVVGACWXAKCONN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,70600.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.151195298948196,12514,10198293,CCCCOC1=CC=C(C=C1)C2=CC=NN2,CCCCOc1ccc(-c2ccn[nH]2)cc1
CHEMBL456390,TVVPAZUMRVMIFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,<,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,4.301029995663981,12515,25147692,C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC4=CC=CC=C43,O=C1CCc2cc(-c3cncc4ccccc34)ccc2N1
CHEMBL3125394,TVZPBIBWLNLUKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,12517,57411837,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC=C2Cl,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
CHEMBL2070160,TWDJYRDXTHJMHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,12519,70693071,C1=CC=C(C=C1)N2C=C(C=CC2=O)C3=NC4=C(N3)C=C(C=C4)S(=O)(=O)C(F)(F)F,O=c1ccc(-c2nc3ccc(S(=O)(=O)C(F)(F)F)cc3[nH]2)cn1-c1ccccc1
CHEMBL3137475,TWGGJXLRMIHURH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,12522,76336704,CN1C(=CC(=N1)C2CC2)N3CCC(CC3)N(C4=CC=C(C=C4)C(F)(F)F)C5=CN=CC=C5,Cn1nc(C2CC2)cc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2070140,TWKAGABGOWTMNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,12525,66575661,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3)C4=CC=CC=C4,CCCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3)[nH]c2c1
CHEMBL486130,TWPKWYDANODGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,12529,25138079,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)O)C,CC(=O)Nc1cc(-c2cncc(O)c2)nc(-n2nc(C)cc2C)n1
CHEMBL3422102,TWPZRFZCHZSVKG-XQOXSZQVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.481486060122113,12530,118735400,C1CCC(C1)C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CC(CC6COC7)O,O=C(NC(c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5COCC4CC(O)C5)cc3)c2c1
CHEMBL556849,TWQRVSJZLRCHNE-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12531,45272704,CN(C1CCC2=C(C1)C3=NC=CN=C3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(c3nccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL225411,TWQYWUXBZHPIIV-UHFFFAOYSA-N,GW842166X,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.0,12532,10253143,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F
CHEMBL3706613,TWZWSIXDZUIEIJ-BEILRLPOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,12539,10305883,CC(C)(C1=NC=C(O1)C2=CN=CC=C2)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,CC(C)(c1ncc(-c2cccnc2)o1)N1CCN(CC(O)CC(Cc2ccccc2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL191053,TXAXHAIICLKOKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,5.356547323513812,12540,11203237,CCC1=NC(=C(N1)C2=CC=C(C=C2)F)C3=CC4=C(C=C3)N=C(N4S(=O)(=O)C(C)C)N.CS(=O)(=O)O,CCc1nc(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)c(-c2ccc(F)cc2)[nH]1
CHEMBL2069843,TXDCCDZUBCMPHL-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,12543,70682492,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)S(=O)(=O)N,NC(CC(=O)N1CCN(C(=O)c2ccc(S(N)(=O)=O)cc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL497828,TXDIMDCQMFKIQP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12544,44583354,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C(=O)C4=CC=C(C=C4)C(F)(F)F,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)c3ccc(C(F)(F)F)cc3)CC1)O2
CHEMBL380492,TXEFMFGXKKPZEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,12545,11685733,CC(C)(C(=O)O)N1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1
CHEMBL2177736,TXGKRVFSSHPBAJ-JKSUJKDBSA-N,PRT-2607,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,12547,44462758,C1CCC(C(C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N,NC(=O)c1cnc(NC2CCCCC2N)nc1Nc1cccc(-n2nccn2)c1
CHEMBL3664668,TXIQSUUSOLWWTP-WRONEBCDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,48000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.318758762624412,12548,59635742,CCN1C=C(C=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=C(C=C4)F,CCn1cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccc(F)cc4)OC3=O)cc2)ccc1=O
CHEMBL3664717,TXNPQZGSVXLGGP-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,12555,44476893,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL2437424,TXRQOKKFUWBRKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12560,58863082,CC(C)CN1C2=C(C=CC(=C2)F)N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC(=NC=C5)N,CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccc(F)cc21
CHEMBL2387312,TXYHNJMNQMYNTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23591110.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,12570,25263865,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)NC4=CC(=CC(=C4)Cl)Cl)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)Nc1cc(Cl)cc(Cl)c1
CHEMBL2163832,TYAVMDLBFYORIC-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1030.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.987162775294828,12571,57522018,CN1CCN(CC1)C(=O)C(CC2=C(C=C(C=C2)Cl)Cl)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CN1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL1951608,TYCXZEWCOHIARO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12573,57400458,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=NC=CC5=CC=CC=C54)C)C,CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C
CHEMBL1761521,TYDNACGHSINKSF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,12575,54581286,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCNS(=O)(=O)C)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1
CHEMBL1761521,TYDNACGHSINKSF-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,27600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.559090917934783,12575,54581286,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCCNS(=O)(=O)C)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1
CHEMBL1829766,TYERBRGKZKGLIN-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.154901959985743,12576,53473231,CC(C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CCC(OC3=O)(CCCO)C4=CC(=CC=C4)F,CC(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CCCO)(c2cccc(F)c2)OC1=O
CHEMBL485612,TYHGSJHFMYWTNJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,5.275724130399211,12577,25093241,CC1=C(C(N=C(N1)C2=CC(=NC=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=C(C=C5C(=C4)C=NN5)F,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1
CHEMBL3702767,TYIDCPRIOTUDSB-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6150.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.211124884224583,12578,89718358,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7CCN(CC7)C(=O)C8=CC=C(C=C8)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3403815,TYIUULJYLSZQJM-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,12579,71288616,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403815,TYIUULJYLSZQJM-VPNNIMDCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,12579,71288616,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL2205045,TYKBKDLIAKRVRZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.795880017344075,12582,21864917,CC1=CC=C(C=C1)SC2=CC=CC=C2N3CCNCC3.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1
CHEMBL3114720,TYLOVNGZCFIJOG-WFXMLNOXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23746300.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,12584,59721372,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(C)CCC(C)NC(=O)OCC2=CN=CS2,CC(CCC(C)NC(=O)C(NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
CHEMBL3114720,TYLOVNGZCFIJOG-WFXMLNOXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,510.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.292429823902063,12584,59721372,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(C)CCC(C)NC(=O)OCC2=CN=CS2,CC(CCC(C)NC(=O)C(NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1
CHEMBL1951330,TYMZTIRSSWUYPG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,12585,57393588,COC1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,COc1ccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)cc1
CHEMBL1682892,TYNRBNIVUWDJAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.431798275933005,12586,18769127,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)N)(C3=CN=CN3)O,CC(C)C(O)(c1ccc2cc(C(N)=O)ccc2c1)c1cnc[nH]1
CHEMBL3358930,TYOOOSONZFYFLZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.698970004336019,12588,118723171,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)C(=O)N)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(N)=O)ncc2[nH]1)C(F)(F)F
CHEMBL1208966,TYQDNFSUWCTPOC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,12589,49862095,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)NC6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1208966,TYQDNFSUWCTPOC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,12589,49862095,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=NC(=NC=C5)NC6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL2180528,TYQNFWIJWOXJPV-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23075267.0,IC50,>,40000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect cells using fluorogeinc substrate,Discovery and Lead Optimization of a Novel Series of CC Chemokine Receptor 1 (CCR1)-Selective Piperidine Antagonists via Parallel Synthesis.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12590,24758044,CC(C)C(C(=O)N1CCC(CC1)C2=CC=C(C=C2)Cl)NC(=O)C3=CC=CC=C3,CC(C)C(NC(=O)c1ccccc1)C(=O)N1CCC(c2ccc(Cl)cc2)CC1
CHEMBL2018905,TYVFYXGXKSBOIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,27100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.567030709125595,12593,2650025,CCCSC1=NC2=C(N1)C=C(C=C2)OC,CCCSc1nc2ccc(OC)cc2[nH]1
CHEMBL3627894,TYWWABBJXVGGPH-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25978966.0,IC50,=,33260.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4780777551165,12595,122192989,CC1=NN(C=N1)C2=CC(=C(C(=C2)Cl)C(=O)NCC(C3=CC(=CC=C3)F)C4=NC5=CC(=C(C=C5N4)Cl)OC)Cl,COc1cc2nc(C(CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl
CHEMBL126,TYZROVQLWOKYKF-ZDUSSCGKSA-N,LINEZOLID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23584544.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,12600,441401,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
CHEMBL126,TYZROVQLWOKYKF-ZDUSSCGKSA-N,LINEZOLID,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,12600,441401,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
CHEMBL556927,TZAVEMGJPFYKKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513812,12601,45273801,C1CN(CCC1NC(=O)NC(CN2C=CC=N2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cccn1)c1ccccc1
CHEMBL3115174,TZHVWGUJONDDOT-WUNLWTINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,12606,59721343,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CC(=O)N)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CC(N)=O)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL466555,TZNQLVLILPGVRT-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,7.075720713938118,12610,25034109,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL466555,TZNQLVLILPGVRT-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,6.060480747381382,12610,25034109,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL400261,TZRWXVQERJBYNA-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,12614,44447277,C1CC1(C2=CC=CC=C2)N3C(=NC4=C3N=CC=C4)CNC(=O)C(CC5=CC=CC=C5C(F)(F)F)NC(=O)C6(CC6)C(F)(F)F,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)C(Cc1ccccc1C(F)(F)F)NC(=O)C1(C(F)(F)F)CC1
CHEMBL2170632,TZUIJGLTRUKCJZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.823908740944319,12616,58269563,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,CS(=O)(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)cc1
CHEMBL2436620,UADYGGCZODNWRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12628,72375120,CC1=NN=C2N1C3=C(CN(C2)C4CCN(CC4)C(=O)C5(CCN(CC5)CC6=CC(=NC=C6)N)F)C=CS3,Cc1nnc2n1-c1sccc1CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2
CHEMBL3422236,UAFMDFJKXYVYRS-IXBGWNDUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,12630,72547066,CC1=COC(=N1)C2CC3CSC(=NC3(CO2)C4=C(C=C(C=C4)F)F)N,Cc1coc(C2CC3CSC(N)=NC3(c3ccc(F)cc3F)CO2)n1
CHEMBL2381074,UAGIOQUVPZGBMF-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23535328.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,12632,71603193,CC1=NC(=C(C=C1)C2=NC=CC=N2)C(=O)N3CC4(CC4)CC3CNC5=NC=C(C=C5)C(F)(F)F,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)CC2CNc2ccc(C(F)(F)F)cn2)n1
CHEMBL1951453,UAGMQELKQICEOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264487.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis,A ��-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,12634,57395278,CCCOC1=C(C(=C(S1)C(=O)N2CCC(CC2)C3=CC=CC(=C3)CN)C)Br,CCCOc1sc(C(=O)N2CCC(c3cccc(CN)c3)CC2)c(C)c1Br
CHEMBL2036212,UAHVGQVTFGOJQH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,12636,49872772,CCCCC(=O)N(CC1=CC(=CC=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,CCCCC(=O)N(Cc1cccc(OC(F)(F)F)c1)c1cc(F)cc(-c2nn[nH]n2)c1
CHEMBL1682890,UARNBGAVALRVSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.0,12645,22018425,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)NC(=O)NC)(C3=CN=CN3)O,CNC(=O)Nc1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL3112867,UAXHPOBBKRWJGA-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12652,49854425,CC1CC2=CC=CC=C2N1C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,CC1Cc2ccccc2N1C(=O)Cc1nc(=O)cc(N2CCOCC2)[nH]1
CHEMBL3112866,UAXHPOBBKRWJGA-ZDUSSCGKSA-N,SAR-260301,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12653,49854424,CC1CC2=CC=CC=C2N1C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,CC1Cc2ccccc2N1C(=O)Cc1nc(=O)cc(N2CCOCC2)[nH]1
CHEMBL239496,UAXNNGUDPWZOKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.943095148663527,12655,16043268,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL3358947,UAYXTLWPZTYJEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.823908740944319,12656,44544321,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=C(C=C(C=C3)Cl)C(=O)N,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(Cl)cc1C(N)=O
CHEMBL583442,UBCWZOKKGDETJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12663,45484873,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)OC(F)F,CC1(CC(=O)NCc2ccc(OC(F)F)cc2)CC2(CCCCC2)OO1
CHEMBL2316386,UBFBCNIBTXDRJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,5500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,5.259637310505756,12665,71545856,CS(=O)CC1=CC=C(C2=CC=CC=C12)C(=O)NC3=C(N=C(C=C3)OCCOCCO)C(=O)NCC4CCC4,C[S+]([O-])Cc1ccc(C(=O)Nc2ccc(OCCOCCO)nc2C(=O)NCC2CCC2)c2ccccc12
CHEMBL1951596,UBKXEHHBQTWHJR-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12670,57391802,CN1C2=C(C(=O)N(C1=O)CC3=NC=CC4=CC=CC=C43)N(C(=C2C#N)N5CCCC(C5)N)CC6=CC=CC=C6,Cn1c(=O)n(Cc2nccc3ccccc23)c(=O)c2c1c(C#N)c(N1CCCC(N)C1)n2Cc1ccccc1
CHEMBL2431460,UBNVHIMTEMQRJP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,4.301029995663981,12672,59156709,CC(C)(C)C1=CC(=CC(=C1OC)CCN2CCC(CC2)NS(=O)(=O)C)C3=CC=CNC3=O,COc1c(CCN2CCC(NS(C)(=O)=O)CC2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
CHEMBL3260755,UBRBDDDFBPVEQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,5.468521082957745,12674,72793324,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CC=C(C=C3)C#N)C4=CN(N=C4)C)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnn(C)c3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O
CHEMBL3291394,UCALKYGDSCLCAF-POJKVFINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1080.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.966576244513051,12683,90644507,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCCC(C5)O)C,C=CC1(C)CC(OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3291394,UCALKYGDSCLCAF-POJKVFINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874438.0,IC50,=,1240.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,PUBLICATION,,5.906578314837765,12683,90644507,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4=CN=CC(=C4)NC(=O)CN5CCCC(C5)O)C,C=CC1(C)CC(OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O
CHEMBL3702819,UCAOZUWAXDBCRB-VYXSRHMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2630.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.580044251510242,12684,89718386,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CC8=C(C=C7)OCCO8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc6c(c5)OCCO6)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL521860,UCBHJGKWEAXEKC-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,12686,44568928,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC(=O)C)C,CC(=O)Nc1noc2c(-c3ccc4c(N5CCOCC5C)nncc4c3)c(C)ccc12
CHEMBL189942,UCDZIPQDLFQWSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,12690,3012027,CCN1C2=C(C=CC(=N2)F)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21
CHEMBL189942,UCDZIPQDLFQWSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16107158.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,12690,3012027,CCN1C2=C(C=CC(=N2)F)N(C(=O)C3=C1N=CC(=C3)CCOC4=C(C=C(C=C4)C(=O)O)C)C,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21
CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1521.1,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.8178422336652185,12692,60700,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
CHEMBL481575,UCGDJSGANNJRLB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,12694,44570492,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=C(C=C5)Cl,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)CC(C)N1
CHEMBL481575,UCGDJSGANNJRLB-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,12694,44570492,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=C(C=C5)Cl,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)CC(C)N1
CHEMBL1950351,UCMNIYFDRVBMFV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22284817.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,��-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,12701,24894028,CCS(=O)(=O)N1C2=C(CN(CC2)C3CCOCC3)C4=C1C=CC(=C4)C(=O)N5CCC(CC5)C,CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2
CHEMBL2070137,UCTMDJGIDNKBDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,12705,56649677,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=C3)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)c3)[nH]c2c1
CHEMBL1090209,UCUHPRBZQBMMNA-MVBJNABHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12707,46866390,C1CC2(C(CC1NS(=O)(=O)C(F)(F)F)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,O=S(=O)(NC1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1)C(F)(F)F
CHEMBL1090209,UCUHPRBZQBMMNA-MVBJNABHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,5.455931955649724,12707,46866390,C1CC2(C(CC1NS(=O)(=O)C(F)(F)F)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,O=S(=O)(NC1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1)C(F)(F)F
CHEMBL1090209,UCUHPRBZQBMMNA-MVBJNABHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,5.017728766960431,12707,46866390,C1CC2(C(CC1NS(=O)(=O)C(F)(F)F)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,O=S(=O)(NC1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1)C(F)(F)F
CHEMBL1682904,UCYQUZAJMGMKEU-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,12710,50994740,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)N(C3)C)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1cnc[nH]1
CHEMBL1682905,UCYQUZAJMGMKEU-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,12711,53323744,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)N(C3)C)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1cnc[nH]1
CHEMBL1682901,UCYQUZAJMGMKEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,12712,12074093,CC(C)C(C1=CC2=C(C=C1)C3=C(C=C2)C(=O)N(C3)C)(C4=CN=CN4)O,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1cnc[nH]1
CHEMBL2043168,UDDLGZQDALRQID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,12715,49848895,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL401122,UDIQMHOHOCRKGM-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,12720,44442007,C1CC(N(C(C1)C2CC2)S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCN(CC4)CCO,O=C(OCC1CCCC(C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCN(CCO)CC1
CHEMBL399719,UDXAWWYJIGJLRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17629698.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,12730,44443093,CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC5=C(C=C4)OCC(=O)N5C,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(C)C(=O)CO5)CC3)cccc2n1
CHEMBL3702704,UDYNSGNOZYBHLA-YATWDLPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.257274868695301,12731,89718415,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCN8CCCCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCCCC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2170618,UEDSNYYBBFEFCG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,5.522878745280337,12734,58269663,CN1C=NC=C1C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,Cn1cncc1C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL3137467,UEFAKJDYSQUQOO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1500.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.823908740944319,12735,76318576,C1CC1C(=O)N2CCC(CC2)N(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,O=C(C1CC1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
CHEMBL1643514,UEPBVWIBDNMJPA-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21095126.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,12738,53325966,CN(C)C1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)C1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
CHEMBL241663,UERMDDSMFCIPGD-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.769551078621726,12743,23647907,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCC(F)(F)F)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL3314850,UEUUWJVQGWZIJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24969015.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in pooled human liver microsomes in presence of NADPH,Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12747,118707826,C1=CN=C(C=C1Cl)C(=O)NC2=CN=CC(=N2)OC3=CN=CN=C3,O=C(Nc1cncc(Oc2cncnc2)n1)c1cc(Cl)ccn1
CHEMBL3702791,UEWPLDOHKHENQG-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2210.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.655607726314889,12748,89718254,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(OC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL446054,UFAYJVYELGRGFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12752,25110702,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC(=CC=C4)Cl,O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL446054,UFAYJVYELGRGFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,12752,25110702,C1CNCCC2=C1C=C3C=CN(C3=C2)S(=O)(=O)C4=CC(=CC=C4)Cl,O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3
CHEMBL3303792,UFFYJUZFFYYLGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12758,70678458,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OCCN3CCCCC3,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OCCN1CCCCC1
CHEMBL2069316,UFIJMRPHGQWUEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2441251443275085,12759,70688847,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=C(C=C3)C)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3ccc(C)c(-c4ccccc4)c3)[nH]c2c1
CHEMBL2158288,UFIPENMOPMVCOL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.292429823902063,12760,11592380,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CNCCO)NC(=O)C4=NC=C(N4)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)CNCCO)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL2086687,UFJZVFBUUIBTHV-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23628336.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12761,51030984,CC1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C(=O)OCC(F)(F)F,CC1CN(C(=O)OCC(F)(F)F)CCN1c1ncc(OCc2ccncc2C#N)cn1
CHEMBL1210423,UFKVTMVFNCOIKU-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20566292.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.055517327849831,12763,46843035,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)[O-])CC4=CC=C(C=C4)C5=NC=C(C=N5)OC.[Na+],COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1
CHEMBL2437330,UFLCSYKVIUPYKK-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044938.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis,"Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.",Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,12765,73354069,COC(=S)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCNN(CC3)C(=O)C(F)F)F,COC(=S)NCC1CN(c2ccc(N3CCNN(C(=O)C(F)F)CC3)c(F)c2)C(=O)O1
CHEMBL2425146,UFUDJJBHRBMKDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23973211.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12773,72189514,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C=C3)N4C=CN=C4,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1
CHEMBL498220,UFWOHRJEMMPVKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,12775,24888656,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=CC=CC4=O)C,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C
CHEMBL498220,UFWOHRJEMMPVKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,12775,24888656,CC1=C(N2C=C(C=C(C2=N1)NCC3=C(C=C(C=C3)F)Cl)N4C=CC=CC4=O)C,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C
CHEMBL3673943,UFYPFASIUYPWBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320618,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,12778,52935810,C1=CC(=NC(=C1CC2=CNC3=C2C=C(C=N3)Cl)F)NCC4=CC(=CN=C4)F,Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1
CHEMBL3673943,UFYPFASIUYPWBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320662,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,12778,52935810,C1=CC(=NC(=C1CC2=CNC3=C2C=C(C=N3)Cl)F)NCC4=CC(=CN=C4)F,Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1
CHEMBL2435853,UFZMURFKAOEOKB-PMERELPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24090135.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,PUBLICATION,,4.0,12781,58834906,CC1=C(C=CC(=N1)OC2=CC=C(C=C2)C(=O)O)CN3CCC(CC3)N4C(CN(C4=O)C5CCOCC5)C6=CC(=CC=C6)Cl,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)CC2c2cccc(Cl)c2)CC1
CHEMBL2057517,UFZSWPKCQNDLNT-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,41.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3872161432802645,12782,59603333,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NC,CNc1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL1969102,UGEJLCNSVIVALC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 ��L final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37�� C. incubator. Pooled human liver microsomes (BD Gentest, 50 ��g/mL) were incubated with 5 concentrations of test compound (from 0.1 ��M to 10 ��M), 1 mM NADPH (Sigma), and 2 ��M midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,6.522878745280337,12784,18451073,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CNN=C5)N,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1
CHEMBL1969102,UGEJLCNSVIVALC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,760.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 ��L final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37�� C. incubator. Pooled human liver microsomes (BD Gentest, 50 ��g/mL) were incubated with 5 concentrations of test compound (from 0.1 ��M to 10 ��M), 1 mM NADPH (Sigma), and 2 ��M midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,6.119186407719209,12784,18451073,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CNN=C5)N,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1
CHEMBL389433,UGFHIPBXIWJXNA-UHFFFAOYSA-N,LIAROZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,<,100.0,NM,,,,binding,,,,,,,,,,,,,,,,7.0,12785,60652,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1
CHEMBL389433,UGFHIPBXIWJXNA-UHFFFAOYSA-N,LIAROZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,<,100.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,7.0,12785,60652,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1
CHEMBL389433,UGFHIPBXIWJXNA-UHFFFAOYSA-N,LIAROZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26365710.0,IC50,=,690.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.161150909262744,12785,60652,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1
CHEMBL115876,UGLPVHLKYTWQRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,=,252.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.598599459218456,12788,44341234,C1=CC=NC(=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3,c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1
CHEMBL3326570,UGNRNJDBLIKGQC-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,660.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,6.180456064458132,12789,25264621,CC1(CC(C2=C(O1)C=C(C=C2)F)NC(=O)NC3=CC=CC4=C3C=CN=C4)C,CC1(C)CC(NC(=O)Nc2cccc3cnccc23)c2ccc(F)cc2O1
CHEMBL238866,UGOGQLRJKMMHMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,920.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.036212172654444,12791,23647888,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)C4=CC(=C(C=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2
CHEMBL2397316,UGTHQAXCCBBNQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,12795,71682213,CC1=C(SC(=N1)NC(=O)C(C)(C)CC(F)(F)F)C2=CN=C(C=C2)N,Cc1nc(NC(=O)C(C)(C)CC(F)(F)F)sc1-c1ccc(N)nc1
CHEMBL2059802,UGVTUQAEJUZTMQ-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,12797,70690616,CN1C=C(C2=CC=CC=C21)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,Cn1cc(CC(NC(=O)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c2ccccc21
CHEMBL2448722,UGXFQEUACCBNIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1520.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.818156412055227,12798,1227034,CC(=O)N(CC1=CN=CC=C1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1
CHEMBL2448722,UGXFQEUACCBNIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2900.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.5376020021010435,12798,1227034,CC(=O)N(CC1=CN=CC=C1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1
CHEMBL1098125,UGXRUMNFAKOITP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,12799,46888789,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4CCCO4,CN1CCCC(c2nc3ccccc3n2CC2CCCO2)C1
CHEMBL1951607,UHCGBYNFQULPRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12801,57398779,CC(=CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC(=O)C4=CC(=CC=C4)OC)C)C,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCNCC4)n3CC=C(C)C)n(C)c2=O)c1
CHEMBL487554,UHHRYINUVNKFTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.958607314841775,12807,25138091,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=NC(=CC=C3)N4CC(C4)OC)C,COC1CN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)C1
CHEMBL231510,UHIYZXSEOHGEBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12808,135553269,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC5CC5,Cc1cc(C(=O)NC2CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1911819,UHJLPAVCVVEQGP-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,12809,46869239,CN1CCN(CC1)C(=O)C(COCC2=CC=C(C=C2)F)NC(=O)C3=C(N=CC=C3)OC4=C(C=C(C=C4)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCc2ccc(F)cc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL550868,UHMQYWPLWZKMOS-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12812,45270987,CN(C1CCC2=C(C1)C3=C(N2CC(=O)O)C=NC=C3)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(c3ccncc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL2057790,UHNGMTOQQDUDOW-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,31.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.508638306165727,12814,70690521,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)NCCCN5C=CN=C5,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCn3ccnc3)oc2c1
CHEMBL3608684,UHNVQJPBRBMNNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,12815,81689815,CC1=NSC(=N1)C2=NN=C3N2CCN(C3)C(=O)C4=CC=C(C=C4)F,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1
CHEMBL205807,UHNVWCCKBJDIGZ-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,12816,5282549,CC(C)CN1C2=C(C(=C(S2)CC3=CNC4=CC=CC=C43)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CCC(O)C3)c(Cc3c[nH]c4ccccc34)sc21
CHEMBL1092649,UHPLDFSEISHDBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12818,11702114,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccc(F)cc2C1
CHEMBL1649683,UHTWSBHKNUALPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.0,12824,24951942,C1CCN(C1)C(=O)C2=CC=C(C=C2)N3C4=C(CCOC4)C(=N3)C(F)(F)F,O=C(c1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1)N1CCCC1
CHEMBL2426677,UHUCZYJVWVZKAH-AREMUKBSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25699143.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,12825,58438475,COC1=CC=C(C=C1)CC(=O)N2CCC3(CC2)CN(C3)C4CCC5=C4C=CC(=C5)C6=NC=CC=N6,COc1ccc(CC(=O)N2CCC3(CC2)CN(C2CCc4cc(-c5ncccn5)ccc42)C3)cc1
CHEMBL38958,UHYGTCSPRAOTBE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,11.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,7.939302159646388,12828,9828630,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)Cl)CC(C)(C)C(=O)O,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccccn3)cc12
CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,1780.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,5.749579997691106,12831,4497,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
CHEMBL1224197,UIASTQRXRWRHSW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20709552.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,12833,11740023,C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CSC(=N3)C(=O)N)OC(F)(F)F,NC(=O)c1nc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)cs1
CHEMBL1813472,UIBIRCANCAKLIN-RISCZKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,12800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,4.892790030352131,12835,46701087,C1CCC2(CNCC2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CCCCC2CNC3)cc1Cl
CHEMBL1813471,UIBIRCANCAKLIN-SMDDNHRTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,8390.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.0762380391713,12836,46701086,C1CCC2(CNCC2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CCCCC2CNC3)cc1Cl
CHEMBL2058908,UICZFGBRBAVNHU-IZZNHLLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3872161432802645,12838,62706819,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CCN(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(C)c1nc2ccc(C(=O)N(CCN(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL258394,UIDGLYUNOUKLBM-GEBJFKNCSA-N,NARCISSIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,4.096910013008056,12839,5481663,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)O)O)O)O)O)O,COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)ccc1O
CHEMBL1008,UIEATEWHFDRYRU-UHFFFAOYSA-N,BEPRIDIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,12842,2351,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
CHEMBL1008,UIEATEWHFDRYRU-UHFFFAOYSA-N,BEPRIDIL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,23600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.627087997029894,12842,2351,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
CHEMBL3601190,UIGJXMQBTZRJST-MJKPMQHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,12847,117885766,C1CC1OC2=NC=CC(=C2)NC3=NC=C(C(=N3)NC4CC(C(C4O)O)CO)C5=NC6=CC=CC=C6C=C5,OCC1CC(Nc2nc(Nc3ccnc(OC4CC4)c3)ncc2-c2ccc3ccccc3n2)C(O)C1O
CHEMBL480016,UIILMPGHICZFBB-LRDNONRASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19014886.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 red,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,12850,44570180,CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O,CC1CN(S(=O)(=O)CC23CCC(CC2=O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F
CHEMBL236939,UINUKESLPATVPH-AHKZPQOWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,12856,24740535,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)C(CC(C)C)N,Cc1ccc(N2CCN(C(=O)C(Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c(C(N)CC(C)C)c1
CHEMBL1097357,UIUYQDFIVJOTTH-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12864,136164062,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCNCC5,Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1097357,UIUYQDFIVJOTTH-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,12864,136164062,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCNCC5,Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1955989,UJDYXOAGLLGCSW-JLHYYAGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22330635.0,IC50,=,3500.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,12868,49765039,C1CCC(CC1)C=CC2=NC3=C(N2)C=C(C=C3)C4=CC=CC=C4C(F)(F)F,FC(F)(F)c1ccccc1-c1ccc2nc(C=CC3CCCCC3)[nH]c2c1
CHEMBL1955989,UJDYXOAGLLGCSW-JLHYYAGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22330635.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,12868,49765039,C1CCC(CC1)C=CC2=NC3=C(N2)C=C(C=C3)C4=CC=CC=C4C(F)(F)F,FC(F)(F)c1ccccc1-c1ccc2nc(C=CC3CCCCC3)[nH]c2c1
CHEMBL179005,UJFDLQZAPFUWOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,114000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.9430951486635273,12869,11389737,C1=CC(=NC=C1C2=CSC=C2)F,Fc1ccc(-c2ccsc2)cn1
CHEMBL179005,UJFDLQZAPFUWOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,114000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,3.9430951486635273,12869,11389737,C1=CC(=NC=C1C2=CSC=C2)F,Fc1ccc(-c2ccsc2)cn1
CHEMBL1089501,UJIBXDMNCMEJAY-UHFFFAOYSA-N,BMS-687453,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20218621.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12872,16725047,CC1=C(N=C(O1)C2=CC=C(C=C2)Cl)COC3=CC=CC(=C3)CN(CC(=O)O)C(=O)OC,COC(=O)N(CC(=O)O)Cc1cccc(OCc2nc(-c3ccc(Cl)cc3)oc2C)c1
CHEMBL221959,UJLAWZDWDVHWOW-YPMHNXCESA-N,TOFACITINIB,PFE-PKIS 25,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21105711.0,IC50,>,52000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Discovery of CP-690,550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.",J. Med. Chem.,PUBLICATION,,4.2839966563652006,12874,9926791,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12
CHEMBL3288448,UJONHAQOJCHCJU-BRMBYNPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,<,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,6.522878745280337,12875,90681223,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3CC=C)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,C=CCC1N(C(=O)c2cnccc2C(F)(F)F)CCCC1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1
CHEMBL3288448,UJONHAQOJCHCJU-BRMBYNPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24900882.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,12875,90681223,COCCOC1=CC=CC=C1N2CCN(CC2)C(=O)C3(CCCN(C3CC=C)C(=O)C4=C(C=CN=C4)C(F)(F)F)OC5=CC=C(C=C5)C(F)(F)F.Cl,C=CCC1N(C(=O)c2cnccc2C(F)(F)F)CCCC1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1
CHEMBL2017281,UJPOOIUOVCPCTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,12877,70681173,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC5=C4N=CC=C5)C(=O)N)OC,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL2017281,UJPOOIUOVCPCTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,12877,70681173,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC5=C4N=CC=C5)C(=O)N)OC,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL2016639,UJQWCBANYGKWRO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22260203.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,PUBLICATION,,4.301029995663981,12878,2088634,C1=CC=C(C=C1)C2=NOC(=N2)CSC3=NN=C(N3C4=CC=CC=C4)C5=CC=C(C=C5)F,Fc1ccc(-c2nnc(SCc3nc(-c4ccccc4)no3)n2-c2ccccc2)cc1
CHEMBL3702769,UJSWDPBCBIORIG-LRHLLKFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2970.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.527243550682788,12883,89718235,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)F,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(F)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3112592,UJUIPZRMKOMRCU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,12886,49854640,C1CN(C2=C1C=C(C=C2)Cl)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2cc(Cl)ccc21
CHEMBL2448715,UJWMCTCIJSSLTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,790.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.102372908709558,12888,73351200,CCN(CC1=CN=CC=C1)C2=CN=CC(=C2)C3=NC4=CC=CC=C4S3,CCN(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,500.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.301029995663981,12889,73453,CC(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)C1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]cc(c56)CC4N(C)C3)(C(C)C)C(=O)N12
CHEMBL2425895,UKAKHNHDUXRYCO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,14080.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.851397345193907,12891,72707537,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C(=C2)Cl)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2cc(Cl)c3ccccc3n2)c1=O
CHEMBL3234569,UKDXGNZPPKPUKO-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,7.0,12895,90654588,C1CC(CN(C1)C2=NC(=NC(=C2)N3CCNCC3)C(F)(F)F)C(=O)NCCC4=CC=C(C=C4)C#N,N#Cc1ccc(CCNC(=O)C2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cc1
CHEMBL256712,UKGCAEYEQULSSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,12897,11517292,CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4,CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1
CHEMBL1081514,UKPPSZQPJMMBGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,88.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.055517327849832,12905,46883397,CCN(CC(CC(=O)OC)NC(=O)OCC1=CN=CS1)CC(CC(=O)OC)NC(=O)OCC2=NC=CS2,CCN(CC(CC(=O)OC)NC(=O)OCc1cncs1)CC(CC(=O)OC)NC(=O)OCc1nccs1
CHEMBL2059125,UKVVUPPPZVSRBB-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.638272163982407,12910,70696805,CN(C)CCN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,CN(C)CCN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
CHEMBL3297762,UKZRGBUTBINTPD-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139169.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.",Bioorg. Med. Chem.,PUBLICATION,,5.0,12911,71547862,CN1CCN(CC1)CC(C2CCCCC2)NC(=O)CC3CNC(=O)C4=CC(=CN34)C5=CC(=CC=C5)Cl,CN1CCN(CC(NC(=O)CC2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1
CHEMBL230205,ULETZFIZUULMSQ-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,12916,136118017,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC(CC4=CC=CC=C4)CO)C5=CC=CC=C5,Cc1cc(-c2ccccc2)cc2[nH]c(-c3c(NC(CO)Cc4ccccc4)cc[nH]c3=O)nc12
CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.481486060122112,12920,12560,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,132129.56,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.8790000112367293,12920,12560,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,6.721246399047171,12920,12560,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19191554.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,PUBLICATION,,5.721246399047171,12920,12560,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
CHEMBL513491,ULMVHDYUXBTTIU-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19332369.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using DEF substrate,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.455931955649724,12924,11697613,C1=CC(=NC(=C1)C(=O)[O-])CC2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)Cl.[Na+],O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1
CHEMBL513491,ULMVHDYUXBTTIU-UHFFFAOYSA-M,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19332369.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using PPR substrate,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,12924,11697613,C1=CC(=NC(=C1)C(=O)[O-])CC2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)Cl.[Na+],O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1
CHEMBL1923108,ULNHETKFDOYNPV-VEEOACQBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,6400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,12926,57401306,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC=CC=C5CCO4,COCCCc1cc(CN(C(=O)C2CNCCC23OCCc2ccccc23)C2CC2)cc(OCCOC)c1
CHEMBL2017273,ULNHSRPVGJEURD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,12927,70681170,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4F)C(=O)N)OC,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL2017273,ULNHSRPVGJEURD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,12927,70681170,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4F)C(=O)N)OC,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL168563,ULSCNHRBLXYHIC-WUXOVTSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,12930,10008768,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)C(C)CNCCC6=CC7=NNN=C7C=C6)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2C(C)CNCCc2ccc3n[nH]nc3c2)c1
CHEMBL398387,ULSULMMOPVCYQW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,12931,23647885,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC4(CC4)C(=O)N3CCNC(=O)C,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C1(CC1)O2
CHEMBL1923983,ULTCRVJUAZCGPP-UHFFFAOYSA-N,BMS-066,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22018461.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,12933,24825710,CNC1=C2C(=C3C=C(NC3=N1)C4=CC=CC(=N4)CNC(=O)COC)N(C=N2)C,CNc1nc2[nH]c(-c3cccc(CNC(=O)COC)n3)cc2c2c1ncn2C
CHEMBL252404,ULUAOKMJKCFHDN-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,12934,44447030,CC(C)(CO)N(C)CC1=NOC(=N1)CC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,CN(Cc1noc(CC2(C3CCCC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)n1)C(C)(C)CO
CHEMBL604085,ULXYUIOTBNWJFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,12937,25057667,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCNCC3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC
CHEMBL604085,ULXYUIOTBNWJFH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,12937,25057667,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCNCC3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC
CHEMBL1079436,UMIBNFDCUFYJCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,12947,46879552,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12
CHEMBL1079436,UMIBNFDCUFYJCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,12947,46879552,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12
CHEMBL3264596,UMTRREIEFFNJMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,12954,90656802,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=CNN=C3)O,COc1cc2ccc(C(O)(c3cn[nH]c3)C(C)C)cc2cc1OC
CHEMBL1271821,UMWLKNMSOMCHSO-VWNXMTODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,1.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,12957,52946720,CC1(CC1)C2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCC(CC4)N5CCCCC5,CC1(C2COCC(COC(=O)N3CCC(N4CCCCC4)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL2151927,UNDRYPNXYPXVPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,12962,66882548,COC1=C(C=CC(=C1)NC(=O)CC2=NC(=O)C=C(N2)N3CCOCC3)F,COc1cc(NC(=O)Cc2nc(=O)cc(N3CCOCC3)[nH]2)ccc1F
CHEMBL2163831,UNDSHGMDHIMJOM-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1360.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.866461091629782,12963,46892975,CN1CCN(CC1)C(=O)C(CC2=CC=CC=C2)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CN1CCN(C(=O)C(Cc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL567374,UNGALHHMDYBABX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,12965,45484861,CC1(CC2(CCCCC2)OO1)CC(=O)NCCC3=CC(=CC=C3)NC(=O)OC(C)(C)C,CC(C)(C)OC(=O)Nc1cccc(CCNC(=O)CC2(C)CC3(CCCCC3)OO2)c1
CHEMBL2086690,UNGZTVLHLKAKQE-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22545772.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by high-throughput fluorescence assay,Use of small-molecule crystal structures to address solubility in a novel series of g protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.,J. Med. Chem.,PUBLICATION,,4.522878745280337,12967,51030711,CC1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C4=NOC(=N4)C(C)C,CC(C)c1nc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)C(C)C2)no1
CHEMBL3236637,UNKIPWCTGDLSKY-MMYUMUNASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,6.154901959985743,12971,90655383,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=CC=CC=N5,CC1(Cc2ccccn2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL246530,UNKYYGBTNCKVGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17276063.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,12973,44440665,CS(=O)(=O)C1=CC=CC(=C1)C2=NC(=NC=N2)N3CC(C(C3)N)C4=CC(=C(C=C4F)F)F,CS(=O)(=O)c1cccc(-c2ncnc(N3CC(N)C(c4cc(F)c(F)cc4F)C3)n2)c1
CHEMBL3664719,UNNIETXFEWYLRH-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,5.221848749616356,12976,73427554,CC(C1=CC=C(C=C1)C2=CNC(=O)C=C2)N3CCC(OC3=O)(CC(C)(C)C#C)C4=CC=CC=C4,C#CC(C)(C)CC1(c2ccccc2)CCN(C(C)c2ccc(-c3ccc(=O)[nH]c3)cc2)C(=O)O1
CHEMBL1243335,UNQMLUWBMWGIRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.568636235841013,12980,46929551,CC(C)(C)C1=CC=C(C=C1)SCC(C2=CC=CC=N2)C3=CN=CN3,CC(C)(C)c1ccc(SCC(c2ccccn2)c2cnc[nH]2)cc1
CHEMBL3125383,UNRKTJKQLXZCJK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,12981,57410062,C1CN(C2=C1C(=CC=C2)Br)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)O,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21
CHEMBL1683571,UOCHFMVPMIYRHJ-QWRGUYRKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21324688.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,12993,25189891,C1CC(CN(C1=O)C2CN(CC2N)C3=NC=NC(=N3)N4CCC(C4)(F)F)(F)F,NC1CN(c2ncnc(N3CCC(F)(F)C3)n2)CC1N1CC(F)(F)CCC1=O
CHEMBL399568,UONIUQQOOBARAF-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,2430.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.614393726401688,13002,44447264,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2CC4CC4)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC1CC1
CHEMBL3702718,UOSYPEJGZRITSC-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7650.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.116338564846382,13006,89718320,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)NC(=O)CCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)CCO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2338481,UOVZAVLNUTTZBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,7.522878745280337,13008,71525218,C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)NC2=CC(=C(C(=C2)Cl)OC3=CN=CC(=C3)C(=O)N)Cl,NC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1
CHEMBL3597017,UOWQGZGDOQIXHE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26544629.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.,Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,13010,76284760,CC(C)CC1=CC(=C(C(=O)N1)C2=CC=CC=C2)O,CC(C)Cc1cc(O)c(-c2ccccc2)c(=O)[nH]1
CHEMBL3359927,UPBRYBJZTWHUQK-RISCZKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25453808.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,13017,68291752,CC1(CCCC1NC2=C(C=NN3C2=CC=C3)C(=O)N)F,CC1(F)CCCC1Nc1c(C(N)=O)cnn2cccc12
CHEMBL3422072,UPBYKYBKDRDENP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,5.823908740944319,13018,86711021,C1CC1C(C2=CC=CC=C2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)OC6CCN(CC6)C=O,O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1
CHEMBL3394868,UPGJLYYUAKKKAD-JVGMIBGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25577041.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13022,53389570,CC1CC(N(C1)C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=C(C=C3)C4=CC=C(C=C4)C5=CC=C(C=C5)C6=CN=C(N6)C7CC(CN7C(=O)C(C(C)C)NC(=O)OC)C,COC(=O)NC(C(=O)N1CC(C)CC1c1ncc(-c2ccc(-c3ccc(-c4ccc5nc(C6CC(C)CN6C(=O)C(NC(=O)OC)C(C)C)[nH]c5c4)cc3)cc2)[nH]1)C(C)C
CHEMBL271876,UPJVOWNSAUCCBH-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,13026,25022640,CC(C)(C(=O)NC(COCC1=CC=CC=C1)C2=NN=NN2C(CC#N)COC3=CC=CC=N3)N,CC(C)(N)C(=O)NC(COCc1ccccc1)c1nnnn1C(CC#N)COc1ccccn1
CHEMBL271876,UPJVOWNSAUCCBH-RTBURBONSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18282707.0,IC50,=,59000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.229147988357856,13026,25022640,CC(C)(C(=O)NC(COCC1=CC=CC=C1)C2=NN=NN2C(CC#N)COC3=CC=CC=N3)N,CC(C)(N)C(=O)NC(COCc1ccccc1)c1nnnn1C(CC#N)COc1ccccn1
CHEMBL1222884,UPMYXXWLKPRNBD-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673718.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome preincubated for 30 mins,"Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,13032,46945859,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)CC(CN)C(=O)N(CC3=C(C=CC(=C3)CCCOC)Cl)C4CC4)Cl,COCCCc1ccc(Cl)c(CN(C(=O)C(CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1222884,UPMYXXWLKPRNBD-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673718.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,13032,46945859,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)CC(CN)C(=O)N(CC3=C(C=CC(=C3)CCCOC)Cl)C4CC4)Cl,COCCCc1ccc(Cl)c(CN(C(=O)C(CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL29631,UPNGEDJHCUNSGY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,8100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.0915149811213505,13033,11443942,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=C4C(=CC=C5)[N+](=O)[O-])CC6=CN=CC=C6,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1cccnc1
CHEMBL2016936,UPRILTGQBKRVGC-ODXCJYRJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,13038,46932045,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=CC(=NO3)C4=C(C=CC=C4Cl)Cl,OC1(c2ccc(F)c(F)c2)CCNCC1c1cc(-c2c(Cl)cccc2Cl)no1
CHEMBL1271935,UPTFCSZWKUUGCL-HNYUPJOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,13040,52943092,CC(=O)N1C2CCC1CN(C2)C(=O)OC3(CC3)C4COCC(N4S(=O)(=O)C5=CC=C(C=C5)Cl)CC6CC6,CC(=O)N1C2CCC1CN(C(=O)OC1(C3COCC(CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2
CHEMBL207987,UPWLRKVVLBSIPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,4.522878745280337,13044,11708263,C1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N,NC(=O)c1nc(-c2ccccc2)oc1N
CHEMBL1778388,UPZGABGQGJFIDG-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21515053.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,13046,54580721,CN(C1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)C(=O)C4(CCCC4)C5=CC=C(C=C5)F,CN(C(=O)C1(c2ccc(F)cc2)CCCC1)C1CCc2c(CC(=O)O)c3ccccc3n2C1
CHEMBL1761674,UQAYVLAYSNHNRH-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13047,25119716,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC6=NNN=N6)C7CC7)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1
CHEMBL1761674,UQAYVLAYSNHNRH-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13047,25119716,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC6=NNN=N6)C7CC7)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1
CHEMBL2070153,UQCBLTGPBKOQCM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,13050,70693069,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)C4=CC=CC=C4)C,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccc3C)[nH]c2c1
CHEMBL1835706,UQECZBVIJKOGTA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13051,56665357,CN1C(=O)C2=CC=CC=C2C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2ccccc2c1=O
CHEMBL2397304,UQGXIBZKHFGPLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726345.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,13055,71681727,C1=CC=C(C=C1)CN(CC(=O)NC2=NC=C(S2)C3=CN=C(C=C3)N)C(=O)C4=CC=NC=C4,Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cn1
CHEMBL2436980,UQHKXSZPEUNUDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,4.522878745280337,13057,46236221,COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CC5=C(C=C4)NC=C5)N=C2,COc1cc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cc(OC)c1OC
CHEMBL239085,UQHQDWYHACOCCN-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.275724130399211,13058,23647894,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC=CC=C4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccccc1)O2
CHEMBL391463,UQHQDWYHACOCCN-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,13059,23647893,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC=CC=C4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccccc1)O2
CHEMBL391463,UQHQDWYHACOCCN-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20731374.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Direct renin inhibitors as a new therapy for hypertension.,J. Med. Chem.,PUBLICATION,,4.522878745280337,13059,23647893,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C4=CC=CC=C4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccccc1)O2
CHEMBL218834,UQKFKOGOHFMDDR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,13060,16049887,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)C(=O)N3CC4CCC(C3)CC4,CC(C)N1CCN(C(=O)N2CCC(C(=O)N3CC4CCC(CC4)C3)CC2)CC1
CHEMBL236902,UQKHQHYWAJFGDY-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17761416.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13061,16066811,CC1CN(CCN1C(=O)OCC2=CC=CC=C2)C3=NC=C(C=C3)C(=O)NC4=CC=CC=C4N,CC1CN(c2ccc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)OCc1ccccc1
CHEMBL1094165,UQNVJOYCOQUVLD-XMMPIXPASA-N,BMS-577098,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,13065,135448904,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCOC,COCCN1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL3422000,UQPULIPFKDYVSO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.0,13066,67453320,CC1=NC(=CC=C1)C2=NN=C3N2CCN(C3)C(=O)C4=CC=C(C=C4)F,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1
CHEMBL3622939,UQRBPKDDLLIVLG-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26384287.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13067,122192148,CC1=CC(=CC(=C1OCCO)C)NC2=NC=CC(=N2)N3C=C(C(=C3)CN4CCC(C4)O)C,Cc1cn(-c2ccnc(Nc3cc(C)c(OCCO)c(C)c3)n2)cc1CN1CCC(O)C1
CHEMBL2057786,UQSOMQDTFBVVRY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,39.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.4089353929735005,13069,59603336,CCC1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCc1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL2425886,UQXZWOAEVRHHOF-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,=,97900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.009217308196862,13076,71731356,CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C=C2)N4CCCC(C4)N,CC#CCn1c(N2CCCC(N)C2)cc(=O)n(Cc2ccc3ccccc3n2)c1=O
CHEMBL3092421,URBPETAAWZXGNX-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.823908740944319,13078,58239274,C1C(OC(=O)N1C2=CC(=C(C=C2)C3=CC4=NC=CN4C=C3)F)CN5C=CN=N5,O=C1OC(Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)c(F)c1
CHEMBL1671917,URDDZDCIBYBQCB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21210664.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,13081,4652320,CCCCC(=O)NC1=CC=C(C=C1)C(=O)NC2=NC=CS2,CCCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,13082,5743,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
CHEMBL3114894,URGKJLUZLWQADG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,13090,57965013,CS(=O)(=O)C1=CC=C(C=C1)OC2=NC=NC3=C2C=NN3C4CCN(CC4)CC5=CC=C(C=C5)C(F)(F)F,CS(=O)(=O)c1ccc(Oc2ncnc3c2cnn3C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1
CHEMBL2397199,URGNTPNJBQTGQN-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13091,59293676,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=NC(=NC=C3)C4(CC4)C,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C2(C)CC2)n1
CHEMBL2448713,URGZQOIBTDTZPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.0,13093,73354176,CN(C)S(=O)(=O)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,CN(C)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
CHEMBL1649681,URIDIEFPWLZYEF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.096910013008056,13094,24951587,C1CC(=O)N(C1)CC2=CC=C(C=C2)N3C4=C(COCC4)C(=N3)C(F)(F)F,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1
CHEMBL471195,URJAQUYCRCFSSV-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,6.060480747381382,13095,44590272,CC1=C(C=CC=C1Cl)C2=CC(=O)N(C3=C2C=C(C=C3)C(C4=CC=C(C=C4)Cl)(C5=CN=CN5C)OC)C,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1cccc(Cl)c1C)cc(=O)n2C)c1cncn1C
CHEMBL2436217,URLHXBBEIISVEY-FXXKCHFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.769551078621726,13101,72712128,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=C(C=CC4=C3C=CC=C4Br)OC)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(OC)ccc3c(Br)cccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL396431,URXRYNAIWUJHTJ-MFMCTBQISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,32000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,13109,44433274,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCN(C)C,CC(C)CC(NCCN(C)C)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL394864,URZMJARQWGKHCG-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,5.167491087293763,13112,23626128,C1C(OC(=O)N1C2=CC(=C(C=C2)C3=CN=CC=C3)F)CN4C=CN=N4,O=C1OC(Cn2ccnn2)CN1c1ccc(-c2cccnc2)c(F)c1
CHEMBL2158287,USCISWISWCWWPX-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.086186147616283,13114,16718491,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C(CO)O)NC(=O)C4=NC=C(N4)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)C(O)CO)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL2437428,USFZHGOWALHXMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13118,58863126,C1CCC(CC1)CN2C3=C(C=CC(=C3)F)N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CCCCC5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL403525,USHUMFPTMMCHJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,13119,44454697,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CC3=CC(=CC(=C3)OC)OC)C4=CC=CC=N4)C,COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc(OC)c1
CHEMBL3664667,USNQWJSXGPOIQH-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,13124,59635796,CC1=CC(=CN(C1=O)C)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,Cc1cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn(C)c1=O
CHEMBL1671965,USOPBKQVIILZGG-CHHVJCJISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21218783.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of diaryl ether-based ligands for estrogen-related receptor a as potential antidiabetic agents.,J. Med. Chem.,PUBLICATION,,5.0,13126,25008854,COC1=C(C=CC(=C1)C=C2C(=O)NC(=O)S2)OC3=C(C=C(C=C3)C(F)(F)F)Cl,COc1cc(C=C2SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Cl
CHEMBL53821,USPFJPDEADLGIG-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.301029995663981,13127,9932679,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CNC1C2=O)C#N,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCc3cncn3C2)C1=O
CHEMBL53821,USPFJPDEADLGIG-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,5.096910013008056,13127,9932679,C1CN2C3=CC=CC4=C3C=C(C=C4)OC5=C(C=CC(=C5)CN6C=NC=C6CNC1C2=O)C#N,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCc3cncn3C2)C1=O
CHEMBL513510,USSLQUIVSMCVBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18625554.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,13129,44577683,CC1=C(C(=C(C=C1)CC2=NNC(=O)N2C)F)OC3=CC(=CC(=C3)C#N)Cl,Cc1ccc(Cc2n[nH]c(=O)n2C)c(F)c1Oc1cc(Cl)cc(C#N)c1
CHEMBL1957816,USTBGZUJKCBYAR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22325948.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Identification of fused bicyclic heterocycles as potent and selective 5-HT(2A) receptor antagonists for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13131,42606928,C1CN(CCN1CCC2=C(C=C(C=C2)F)F)C(=O)C3=CC=CN4C3=NC=C4,O=C(c1cccn2ccnc12)N1CCN(CCc2ccc(F)cc2F)CC1
CHEMBL476116,USUPIRYFHGUVOR-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18621528.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,13134,11529874,CC(C)C(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)C3CCNC3,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)C1CCNC1
CHEMBL1951343,UTAKVGKVXLTUNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.537602002101044,13138,57391853,C1COCCN1C(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)N2CCOCC2)c1
CHEMBL3601186,UTAVZGFTYULZRM-OJWCNPDFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13139,73670174,CC1=NC=CC(=C1)NC2=NC=C(C(=N2)NC3CC(C(C3O)O)CO)C4=NC(=CS4)C5=CC=CC=C5,Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(NC3CC(CO)C(O)C3O)n2)ccn1
CHEMBL1080603,UTFRBPAGKUDDNY-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,741.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.130181792020672,13141,46883436,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CC=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=CC=CS4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cccs1)CC(Cc1ccccc1)NC(=O)OCc1cccs1
CHEMBL236184,UTPYURSIXIVBEJ-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,13149,24180452,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,CCC1CCCC(C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL236184,UTPYURSIXIVBEJ-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,13149,24180452,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,CCC1CCCC(C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL236184,UTPYURSIXIVBEJ-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19694467.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,J. Med. Chem.,PUBLICATION,,5.698970004336019,13149,24180452,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,CCC1CCCC(C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1761844,UTSIHHDNMUZNMG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11��-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,13150,24895969,C1CC2=CC=CC=C2N(C1)C(=O)N3CCC(CC3)C4=CN=CN4,O=C(N1CCC(c2cnc[nH]2)CC1)N1CCCc2ccccc21
CHEMBL2018331,UTTKPRISWKRTNJ-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22429469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active ��-secretase modulators.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13152,57404500,CC1=CN(C=N1)C2=C(N=C(C=C2)C(=O)NC3COC4=C3C(=C(C=C4)Cl)F)OC,COc1nc(C(=O)NC2COc3ccc(Cl)c(F)c32)ccc1-n1cnc(C)c1
CHEMBL10532,UTZKWISWBRTAEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,13156,10233112,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)C,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1
CHEMBL3673974,UUANLLGTKSTXOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320654,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,13158,67199221,COC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
CHEMBL3673974,UUANLLGTKSTXOT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320698,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,13158,67199221,COC1=CC2=C(NC=C2CC3=CC(=C(N=C3)NCC4=CN=C(C=C4)C(F)(F)F)F)N=C1,COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1
CHEMBL1092259,UUEDQZRCAVWNIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13160,46884670,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccc(Cl)cc2C1
CHEMBL1077780,UUJAMNFWDAPMSE-MFCMXAAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13163,46882917,CC1(CCCN(C1)C(=O)NC2CC2C3=CC=CC=C3)C4=CC=CC=C4,CC1(c2ccccc2)CCCN(C(=O)NC2CC2c2ccccc2)C1
CHEMBL1650652,UUOAAGDQRNIMNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17��-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,7.3979400086720375,13167,25069448,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C4=CC(=CC=C4)O,Oc1cccc(-c2ccc3c(-c4cccc(O)c4)c(O)ccc3c2)c1
CHEMBL3309278,UUTCNLFZEMSWPT-BJOHPYRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,46000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.337242168318426,13171,118706953,CC(C1=NC=NC=C1F)C(CN2N=CN=N2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1ncnn1)c1ccc(F)cc1F
CHEMBL3702773,UUTYIEWFDWBJML-BAEGBANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7620.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.1180450286604,13172,89718486,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCOC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCOC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL520915,UUUXPUGZNDRYSV-GCKMJXCFSA-N,ALPHA-METHYLCUBEBIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.113509274827518,13173,44575384,COC1C(C(CO1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,COC1OCC(Cc2ccc3c(c2)OCO3)C1Cc1ccc2c(c1)OCO2
CHEMBL450829,UUZQHDNTPXKEID-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,74000.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.130768280269024,13180,15172937,CC(=O)C(=O)C1=CC(=C(C=C1OC)OC)OC,COc1cc(OC)c(C(=O)C(C)=O)cc1OC
CHEMBL1987518,UVCJGUGAGLDPAA-UHFFFAOYSA-N,ENSULIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,13185,33919,C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)S(=O)(=O)O,O=S(=O)(O)c1ccc2nc(-c3ccccc3)[nH]c2c1
CHEMBL1987518,UVCJGUGAGLDPAA-UHFFFAOYSA-N,ENSULIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,13185,33919,C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)S(=O)(=O)O,O=S(=O)(O)c1ccc2nc(-c3ccccc3)[nH]c2c1
CHEMBL3422095,UVHDAKLRGJSVKQ-MOMDTQCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,940.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.026872146400302,13186,118735393,C1CCC(C1)C(C2=NC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ncccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL2441838,UVLAIQGSAPXWHH-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.853871964321762,13189,15950680,CC1=C(C(=C2C(=N1)CN(C2=O)CC3CCCO3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC1CCCO1)C2
CHEMBL2441839,UVLAIQGSAPXWHH-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.823908740944319,13190,15950681,CC1=C(C(=C2C(=N1)CN(C2=O)CC3CCCO3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC1CCCO1)C2
CHEMBL3398175,UVPQQVIBGBMPDZ-YKSBVNFPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655723.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,13193,86288905,COC1=CC=CC=C1C2=CC=C3N2N=C(N=C3)NC4=C(C=C(C=C4)C5CCN(CC5O)CCO)OC,COc1cc(C2CCN(CCO)CC2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1
CHEMBL392642,UVZVWLFSZNPMBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BFC substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,13197,44440493,CSC1=CC=CC=C1CNC2=NC=C(C(=N2)NCC3CCC(CC3)CN)[N+](=O)[O-],CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1
CHEMBL392642,UVZVWLFSZNPMBS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17055721.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of BQ substrate,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13197,44440493,CSC1=CC=CC=C1CNC2=NC=C(C(=N2)NCC3CCC(CC3)CN)[N+](=O)[O-],CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1
CHEMBL3702804,UWFLXEHFFLOHAJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,13204,89718458,CC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3261486,UWHBCOHEASCLEA-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13207,69937257,C1CN2CCC1C(C2)N3CCN4C5=C(C3=O)C=CC=C5NC4=O,O=C1c2cccc3[nH]c(=O)n(c23)CCN1C1CN2CCC1CC2
CHEMBL2037511,UWHCWRQFNKUYCG-QUZACWSFSA-N,EPELSIBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,4.0,13208,11634973,CCC(C)C1C(=O)NC(C(=O)N1C(C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,CCC(C)C1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N1CCOCC1)c1ccc(C)nc1C
CHEMBL2037511,UWHCWRQFNKUYCG-QUZACWSFSA-N,EPELSIBAN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239250.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein as substrate,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,PUBLICATION,,4.0,13208,11634973,CCC(C)C1C(=O)NC(C(=O)N1C(C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4,CCC(C)C1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)N1CCOCC1)c1ccc(C)nc1C
CHEMBL3115821,UWIHILLUGAWUQF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24354316.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Substituted 2-phenylimidazopyridines: a new class of drug leads for human african trypanosomiasis.,J. Med. Chem.,PUBLICATION,,5.823908740944319,13212,72710598,C1CCN(C1)C(=O)NC2=CC(=C(C=C2)F)C3=NC4=C(N3)C=C(C=N4)C5=CC=CC=C5,O=C(Nc1ccc(F)c(-c2nc3ncc(-c4ccccc4)cc3[nH]2)c1)N1CCCC1
CHEMBL2059852,UWQDLKXMRMJIJF-HKBQPEDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,7300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,13221,70690617,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,13222,24863333,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18665579.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,13222,24863333,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,13222,24863333,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL454751,UWQDLKXMRMJIJF-WJOKGBTCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13222,24863333,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL1923114,UWRLQDKZLAIUGI-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,13224,57401307,C1CC1N(CC2=C(C=C(C=C2)Cl)Cl)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1ccc(Cl)cc1Cl)C1CC1
CHEMBL537424,UXAMBBJHHKLTIB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,=,19700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.705533773838407,13231,10301330,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=CC=C4)CC(C)C.Cl,CCCCN1C(=O)C(CC(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2
CHEMBL2441833,UXBUGZAYDAHAQU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,5.102372908709558,13235,15950750,CC1=C(C(=C2C(=N1)CN(C2=O)CC3=NN(C=C3)C)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccn(C)n1)C2
CHEMBL465451,UXDNAIXKDXHQMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19019676.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,13236,25028375,C1=CC(=C(C(=C1)Cl)C(=O)N(CCO)CC(CNC(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N)(C(F)(F)F)O)Cl,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(Cl)cccc2Cl)C(F)(F)F)cnn1-c1ccc(F)cc1
CHEMBL225464,UXFAKWBTPNUZRY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,68000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.167491087293763,13239,10410589,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=CC(=C3)Cl)F,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2F)nc1C(F)(F)F
CHEMBL1831092,UXFHVEVFSFZCGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838328.0,IC50,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26).",J. Med. Chem.,PUBLICATION,,6.481486060122113,13240,44547033,CC(C)(C(C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2)N4C=NC=N4)C(=O)OC,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1
CHEMBL1098712,UXGODHMBZZMTNL-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,13241,136086720,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)COC,COCC(=O)N1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL3088172,UXRSVTXAGGLLHU-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,J. Med. Chem.,PUBLICATION,,5.721246399047171,13248,46927949,CC1=CSC(=N1)C(C)(C2=NN=C(S2)NC3=NN(C=C3)CC4=C(C=CC=C4F)F)O,Cc1csc(C(C)(O)c2nnc(Nc3ccn(Cc4c(F)cccc4F)n3)s2)n1
CHEMBL512339,UXYYOHOTPOQJPD-OEPOZYLCSA-N,ZERUMBONE EPOXIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,48400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.315154638355588,13251,11368318,CC1=CCCC2(C(O2)CC(C=CC1=O)(C)C)C,CC1=CCCC2(C)OC2CC(C)(C)C=CC1=O
CHEMBL327705,UYBIRMFTNJZIJL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13253,23395792,CN1CCN(CC1)CCCN(CC2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)CN4C=C(C(=O)N=C4SCC5=CC=C(C=C5)F)CC6=CN(N=C6)C,CN1CCN(CCCN(Cc2ccc(-c3ccc(Cl)cc3)cc2)C(=O)Cn2cc(Cc3cnn(C)c3)c(=O)nc2SCc2ccc(F)cc2)CC1
CHEMBL1698322,UYGDCIXFYIWDMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,4.522878745280337,13257,45110765,C1C(C(=O)N(C1=O)C2=C(C=C(C=C2)NC(=O)C3=CC=CC=N3)Cl)C4=CC=CC=C4,O=C(Nc1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1)c1ccccn1
CHEMBL201094,UYJUZNLFJAWNEZ-UHFFFAOYSA-N,FUBERIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,13260,19756,C1=CC=C2C(=C1)NC(=N2)C3=CC=CO3,c1coc(-c2nc3ccccc3[nH]2)c1
CHEMBL201094,UYJUZNLFJAWNEZ-UHFFFAOYSA-N,FUBERIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,13260,19756,C1=CC=C2C(=C1)NC(=N2)C3=CC=CO3,c1coc(-c2nc3ccccc3[nH]2)c1
CHEMBL1923131,UYULRDAPYWFIRZ-SJHOIFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,13268,57396100,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)Cl)CCCN6CCS(=O)(=O)CC6,COCCCc1cc(CCCN2CCS(=O)(=O)CC2)c(Cl)c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1
CHEMBL3408948,UYYCHKFCCDPBMQ-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.0,13271,56959987,CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)N(C6=O)C,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CC(C)OC(C)C5)cc4)n[nH]c3c1)C(=O)N2C
CHEMBL3408948,UYYCHKFCCDPBMQ-AFYCESQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,6.0,13271,56959987,CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)N(C6=O)C,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CC(C)OC(C)C5)cc4)n[nH]c3c1)C(=O)N2C
CHEMBL483401,UYYWLFZGFMIWIW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,5.259637310505756,13274,11656187,CC1=C(C(N=C(N1)C2=CC(=NC=C2)Cl)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1
CHEMBL1928092,UZBOQGXUHIEDSC-LQKURTRISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22100140.0,IC50,=,33200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Antifungal activities of novel non-azole molecules against S.��cerevisiae and C.��albicans.,Eur. J. Med. Chem.,PUBLICATION,,4.478861916295964,13276,9554928,CC1=C(SC(=C1C#N)N=CC2=CC=C(C=C2)N(C)CCC#N)C3=CC(=C(C=C3)OC)OC,COc1ccc(-c2sc(N=Cc3ccc(N(C)CCC#N)cc3)c(C#N)c2C)cc1OC
CHEMBL2057521,UZHUXAQEJDDGHJ-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,13282,59603314,CCN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCCC5,CCN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1
CHEMBL1829767,UZLJFYGNQAZWLF-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.096910013008056,13287,53473232,CC(C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CCC(OC3=O)(CCCO)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CCCO)(c2ccc(F)cc2)OC1=O
CHEMBL3092124,UZVPIJMLVISXHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252545.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after compound pre-incubation,Discovery of an irreversible HCV NS5B polymerase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13295,25226377,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)O)CC4=CC5=CC=CC=C5N=C4Cl,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F
CHEMBL3092124,UZVPIJMLVISXHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252545.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes measured after concurrent incubation,Discovery of an irreversible HCV NS5B polymerase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13295,25226377,CC1=CC2=C(C=C1F)N(C(=C2C3=CC=CNC3=O)C(=O)O)CC4=CC5=CC=CC=C5N=C4Cl,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F
CHEMBL1096789,UZWZCPWLKKLXON-HOTGVXAUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.236572006437063,13297,46888798,CCOC(=O)C(C)NP(=O)(COC1=C2C(=C(C(=C1)C)C)CC3=C2N=CS3)NC(C)C(=O)OCC,CCOC(=O)C(C)NP(=O)(COc1cc(C)c(C)c2c1-c1ncsc1C2)NC(C)C(=O)OCC
CHEMBL1090210,VAAPJDSRZCMKSZ-QCPUYCGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13299,46884914,C1CC1S(=O)(=O)NC2CCC3(C(C2)COC4=C(C=CC(=C43)F)F)S(=O)(=O)C5=CC=C(C=C5)Cl,O=S(=O)(NC1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1)C1CC1
CHEMBL161,VAAUVRVFOQPIGI-SPQHTLEESA-N,CEFTRIAXONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,13300,5479530,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CSC12)c1csc(N)n1
CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,835603.02,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.0779999990807125,13303,5328,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
CHEMBL204419,VACZJUIZGZSWET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,13304,11526626,CCN1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1
CHEMBL3702772,VAFLWJDQDRVGLV-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.718966632752273,13305,89718487,CC(C)(C)OC1=CC=C(C=C1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC(C)(C)C)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL402813,VAPFYVRZDCWUAW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.318758762624412,13310,44449136,COCCN(CC(=O)N1CCCC(C1CN2CCOCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1
CHEMBL567292,VARGWBUXBMFVJN-UHFFFAOYSA-N,GSK554418A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19743867.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",J. Med. Chem.,PUBLICATION,,4.619788758288394,13311,11501580,CN1C=CC2=C1C(=CN=C2NC3=CC(=CC=C3)Cl)C(=O)N4CCOCC4,Cn1ccc2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c21
CHEMBL2436215,VASRIQFKJJZKID-ZLLYMXMVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.0,13315,72711931,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)CS(=O)(=O)C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)CS(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3664672,VATASNGCLCGJEL-MMTVBGGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.7447274948966935,13317,49800666,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(F)(F)F)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccn(CC(F)(F)F)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1289053,VAXDISKYVOZCHP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20961756.0,IC50,=,38000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.42021640338319,13319,25057124,C1CN=C(N1)CN2C3=C(C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C=N2,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1
CHEMBL237578,VAYCDIWDIOSEFX-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,13320,44433276,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCN,CC(C)CC(NCCCN)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2436632,VBAGFAWQNDYXGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13322,44622499,CN1C2=C(CCN(CC2)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F)C6=CC=CC=C61,Cn1c2c(c3ccccc31)CCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2
CHEMBL3427276,VBHUDCXGFXRLFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25941547.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13330,118737724,CS(=O)(=O)CCC1=C(N=C2N1C=CC(=C2)Cl)CN3C4=C(C=CN=C4)N(C3=O)C5CC5,CS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12
CHEMBL3087040,VBKISNMTKAPFLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,13332,72547529,CC1=NC=CC(=C1)C2=CC(=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)OC,COc1cc(-c2ccnc(C)c2)ccc1NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL2402572,VBUOSAKACWCALS-IOOJMYGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23808489.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.",J. Med. Chem.,PUBLICATION,,4.823908740944319,13339,25028925,CC1=CC=CC=C1C2C(CCC3C2CN(C3)C4=NC(=O)CO4)OC(CO)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F,Cc1ccccc1C1C(OC(CO)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CCC2CN(C3=NC(=O)CO3)CC21
CHEMBL3354553,VBVSLBXYPFYZIR-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25575658.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13340,70865101,CC(C)(C)C1=CC(=NO1)NC(=O)C2CCCCN2C(=O)N3CCS(=O)(=O)CC3,CC(C)(C)c1cc(NC(=O)C2CCCCN2C(=O)N2CCS(=O)(=O)CC2)no1
CHEMBL585487,VBVWWMHZQQUOKJ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,13341,507791,CC1CN(CCN1C(=O)C(=O)C2=CNC3=C2N=CC=C3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12
CHEMBL585487,VBVWWMHZQQUOKJ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,13341,507791,CC1CN(CCN1C(=O)C(=O)C2=CNC3=C2N=CC=C3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12
CHEMBL240646,VBZRXOXVUUYQOV-GOSISDBHSA-N,SR-1357,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,13346,16662104,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(CC4=CC=CC=C4)N,NC(Cc1ccccc1)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL3608683,VCDLSNHPAIHNNG-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,13351,122187067,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NO4)C(C)C,CC(C)c1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3C)n1
CHEMBL392465,VCENFKCGBAWAEQ-FTJBHMTQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17723300.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,13352,44433803,CC1=C(C=CC(=C1)F)C2CN(CC2C3=NOC(=N3)C(C)(C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)C5CCN(CC5)C(=O)C,CC(=O)N1CCC(C(=O)N2CC(c3noc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL2048183,VCLQAHLNTRBSNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,13354,69315206,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=CC=CC=C3N2CC(=O)O,COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O
CHEMBL2048183,VCLQAHLNTRBSNX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13354,69315206,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=CC=CC=C3N2CC(=O)O,COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O
CHEMBL1277678,VCLTUEPMXZBALZ-FHZUCYEKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,13355,49836410,C1CC2(CC1N3CCC(CC3)(C(=O)O)F)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1(F)CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1
CHEMBL444533,VCNRITFCECGWNQ-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.366531544420414,13358,9940105,C1CN(C(CN1CC2=CC=C(O2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2ccc(-c3ccccc3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL444533,VCNRITFCECGWNQ-WZXFIOQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.366531544420414,13358,9940105,C1CN(C(CN1CC2=CC=C(O2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2ccc(-c3ccccc3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL1097165,VCTMBHZQYKYSTO-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,650.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.187086643357144,13363,46888837,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC=C(C=C5)Cl,Cc1cc(OCP2(=O)OCCC(c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL1097180,VCTMBHZQYKYSTO-YRVHBCJASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,730.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.136677139879544,13364,46888838,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC=C(C=C5)Cl,Cc1cc(OCP2(=O)OCCC(c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL1762808,VCUDJYYRRWZBSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21411321.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as a substrate,"Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,13366,11453673,CC(C)N(CCO)CC1=CSC(=N1)C2=CN(C3=C2C=CC=C3Cl)CC4CCOCC4,CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1
CHEMBL1762808,VCUDJYYRRWZBSA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21411321.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using dibenzylfluorescein as a substrate,"Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,13366,11453673,CC(C)N(CCO)CC1=CSC(=N1)C2=CN(C3=C2C=CC=C3Cl)CC4CCOCC4,CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1
CHEMBL3121694,VCYDWWJWQPVMIA-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,5.0,13369,66735127,CC1=CC2=C(C=C1F)C(=C(N2C3=NC=C(C=N3)F)C4=NC=C(C=C4)S(=O)(=O)NC(C)C(F)(F)F)C#N,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)NC(C)C(F)(F)F)cn1)n2-c1ncc(F)cn1
CHEMBL2178807,VCZAFUUQQIEMKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,13370,58063334,CC1=NN(C(=C1)NC(=O)C2=C3N=C(C=CN3N=C2)N)C4=CC(=CC=C4)Cl,Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2cccc(Cl)c2)n1
CHEMBL400642,VDKRGTBLHFOGSC-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989233,13381,44447287,CC(C)(C)OC(=O)NC(CC1=C(C=CC=C1F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1c(F)cccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL2425603,VDLAKWBRPSVZBP-XPLIUGCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,13382,72191976,CC(C)OC1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(OC(C)C)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL3702762,VDQAOEVDXCKSBE-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.167491087293763,13386,89718229,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NNC7=CC=CC=C7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNc5ccccc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3109802,VDRYGTNDKXIPSK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24874895.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,PUBLICATION,,4.301029995663981,13387,72792692,CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1,COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C
CHEMBL3358937,VDSMZEJGVOMCGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,8.0,13389,58026164,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC=CC=C4S(=O)(=O)C,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O
CHEMBL3702747,VDUNEFAIXQBADT-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2860.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.543633966870957,13391,89718350,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N(C)CCN7CCOCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCOCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1093294,VDXIBLBHDRKGBK-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13396,11695811,CC(C1=C(N=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,COc1ncccc1C(C)c1c(CCN(C)C)sc2ccccc12
CHEMBL2420681,VEDXLNFHAQEVMU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.0,13400,71818090,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CC(=CN=C3)OC,COc1cncc(-c2ccc3ccc(OC)cc3c2Cl)c1
CHEMBL319754,VEMZPXZQLOLLKQ-ILFWFZRHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.154901959985743,13407,11377200,CC1=CC(=NC(=N1)OC(C(=O)O)C2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C5=CC=CC(=C5)C6=CC=CC=C6)C,Cc1cc(C)nc(OC(C(=O)O)C2(c3cccc(-c4ccccc4)c3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1
CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13413,3038525,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
CHEMBL2165499,VEPWTRQLXLDABP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,13415,57506743,CC1=NC2=CC=CC=C2N1C3=NC4=C(C(=N3)N5CCOCC5)SC(=C4)CN6CCN(CC6)C(C)(C)C(=O)N,Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(C)(C)C(N)=O)CC3)cc2n1
CHEMBL1269684,VETZEDDIBGTLQT-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,13425,12001952,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL1269684,VETZEDDIBGTLQT-WDYNHAJCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,13425,12001952,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)CC(F)(F)F)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL3581145,VFDUENSNKFWMNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.443697499232713,13432,17757326,COC1=CC=CC(=C1)CC(=O)NC2=NC(=CS2)C3=CC(=NC=C3)Cl,COc1cccc(CC(=O)Nc2nc(-c3ccnc(Cl)c3)cs2)c1
CHEMBL3115178,VFJGSZLCNCKFER-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,13436,59721348,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCNC)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CNCCC(NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL1921978,VFQVXPOUVYTBQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.494850021680094,13445,57390715,CC1(CN2C=NC=C2C1(C3=CC4=C(C=C3)C=C(C=C4)C(=O)NC)O)C,CNC(=O)c1ccc2cc(C3(O)c4cncn4CC3(C)C)ccc2c1
CHEMBL494630,VGGVRYBMGLIVTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.080921907623926,13459,24864993,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
CHEMBL494630,VGGVRYBMGLIVTI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13459,24864993,COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC(=CC(=C5)F)F,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1
CHEMBL10921,VGIQUSQBXZXBGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13460,10417440,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL10921,VGIQUSQBXZXBGW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13460,10417440,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL1241548,VGJMSZYBBPAAOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,<,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.3979400086720375,13461,46900453,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C(=C(N=C6CO5)C)C,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C)c(C)n4-5)CC3)cccc2n1
CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21093273.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.096910013008056,13463,68617,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21
CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,13600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.866461091629782,13463,68617,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21
CHEMBL550465,VGQBIBJVDNWZRI-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13467,45270983,CN(C1CCC2=C(C1)C3=C(N2CC(=O)O)C=CC=N3)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(c3ncccc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL1243333,VGVKTKUHIJKMHS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,5.187086643357144,13471,46929548,CC(C)(C)C1=CC=C(C=C1)SCC(C2CCNCC2)C3=CN=CN3,CC(C)(C)c1ccc(SCC(c2cnc[nH]2)C2CCNCC2)cc1
CHEMBL1080604,VGWCZAIIXZBYSZ-NSOVKSMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,>,300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,13472,46883438,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CNN=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=CNN=C4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cn[nH]c1)CC(Cc1ccccc1)NC(=O)OCc1cn[nH]c1
CHEMBL377931,VHHPNELKVATLRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,13480,3989497,C1CN(CCC1C(=O)O)CC2=CC(=CC=C2)OC3=CC=CC=C3,O=C(O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
CHEMBL2205054,VHKBDODTXKHVJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.958607314841775,13483,53237892,CC1=C(C=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C
CHEMBL1829485,VHKZHZYOGPESQF-JKSUJKDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782432.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13485,56677285,CC1CCCN1CC(C)COC2=CC=C(C=C2)C3=NN(C(=O)C=C3)C,CC(COc1ccc(-c2ccc(=O)n(C)n2)cc1)CN1CCCC1C
CHEMBL391189,VHOKSFYGSMXMTN-GOSISDBHSA-N,SR-1349,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064283,13488,16662098,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=CC=C4)N,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccccc1
CHEMBL1761523,VHSIEYYFBUUDJV-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,13494,24953170,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1
CHEMBL1761523,VHSIEYYFBUUDJV-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,13494,24953170,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC(C)(C)O)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1
CHEMBL3702824,VHTAZBLWIMFABR-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,13495,89718292,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=S)NC(=O)C8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)c6ccccc6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1835949,VHVPQPYKVGDNFY-ARROIKNCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,8.397940008672037,13499,24867300,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL1835951,VHVPQPYKVGDNFY-DFMJLFEVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,8.397940008672037,13500,14179008,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL454471,VHVPQPYKVGDNFY-DKYCYSLVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,8.397940008672037,13501,9961741,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL1835954,VHVPQPYKVGDNFY-MZPAXQNMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,7.698970004336019,13502,56682298,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL1835953,VHVPQPYKVGDNFY-OPVGUIJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,7.795880017344075,13503,14179010,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL1835952,VHVPQPYKVGDNFY-PGTZCRIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,7.769551078621726,13504,14179009,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL1835950,VHVPQPYKVGDNFY-TUJWMRSMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,8.397940008672037,13505,14179013,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL64391,VHVPQPYKVGDNFY-UHFFFAOYSA-N,ITRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27955926.0,IC50,=,32.6,NM,,inhibition,tissue,,,,,,,,,,,,,,,,,7.486782399932061,13506,3793,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL64391,VHVPQPYKVGDNFY-UHFFFAOYSA-N,ITRAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27014922.0,IC50,=,50.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis,Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.,J. Med. Chem.,PUBLICATION,,7.297569463554475,13506,3793,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL1835955,VHVPQPYKVGDNFY-VKHSVWCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,7.585026652029182,13507,56675666,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,6.154901959985743,13508,55283,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,70.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985743,13508,55283,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.045757490560675,13508,55283,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
CHEMBL195217,VHWBXEUHUQDHDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324762.0,IC50,=,1580.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.",J. Med. Chem.,PUBLICATION,,5.801342913045578,13510,10192730,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O,Oc1cccc(-c2ccc3cc(O)ccc3c2)c1
CHEMBL1957676,VIEBGHIBCUYPNE-VWNXMTODSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,13516,46931619,CC(=O)NCCC1=CC=CC=C1C2=CC(=C(C=C2)C3CNCCC3C4=CC(=C(C=C4)F)F)Cl,CC(=O)NCCc1ccccc1-c1ccc(C2CNCCC2c2ccc(F)c(F)c2)c(Cl)c1
CHEMBL1087493,VILNAIPEYFWQQH-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,13522,46889258,CCOCCN1C2=CC=CC=C2N=C1N3CCC(C3)N(C)C,CCOCCn1c(N2CCC(N(C)C)C2)nc2ccccc21
CHEMBL285343,VIMSJHBPSQABPQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,11790.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.928486194904911,13523,11261262,C1CN(CCN1CCC2=CC(=C(C=C2)F)F)C3=NC=NC4=C3N(C5=C4C(=CC=C5)[N+](=O)[O-])CCC6=CC=CC=C6,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2CCc1ccccc1
CHEMBL3702690,VINDQDYEPNHNKQ-PXLJZGITSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.913640169325252,13524,89718202,CN1CCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL204684,VINGQXPBSLYVAK-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,13525,44411110,CC(C)(COC1=CC2=C(C=C1)C=C(C=C2)C(CN(C)C)N3C=CN=C3)C(=O)O,CN(C)CC(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
CHEMBL221044,VIVBCFKGUVZCLT-LRDJCYRESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17274610.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.0,13530,44420600,CCCC1=C(C=CC(=C1)C2=NC3C(S2)CCCO3)OCCCOC4=CC5=C(C=C4)C(CC5)CC(=O)O,CCCc1cc(C2=NC3OCCCC3S2)ccc1OCCCOc1ccc2c(c1)CCC2CC(=O)O
CHEMBL1095681,VIYHZEAFVCWOMU-YMGMXPECSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,13532,46888867,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=CC=NC=C5,Cc1cc(OCP2(=O)OCCC(c3ccncc3)O2)c2c(c1C)Cc1scnc1-2
CHEMBL401323,VIYNQEBUNVSDPK-GUDVDZBRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13533,44442012,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)O,CCC1CC(O)CC(COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL249086,VIYNQEBUNVSDPK-QRVBRYPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,15600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.806875401645538,13534,44442011,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO)O,CCC1CC(O)CC(COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3645225,VIZKFHFQFJRUES-RUDMXATFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2250.0,NM,221149,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,5.647817481888637,13535,59443466,CNC(=O)C=CC1=CC(=CC(=C1)OC)C2=CC3=C(C=C2)C=C(C=C3)OC,CNC(=O)C=Cc1cc(OC)cc(-c2ccc3cc(OC)ccc3c2)c1
CHEMBL564757,VJCACPMAAVZCPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,13537,45272510,C1CN(CCC1C2=NC(=NO2)C3=CN=CC=C3)C(=O)NC4CC4C5=CC=CC=C5,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1
CHEMBL3706619,VJEYRJGOROCIKW-NKDCNHMZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852968.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,13542,10122981,C1CN(C(CN1CC2=CC=C(O2)C3=CC=CC=N3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1ccccc1)CC(O)CN1CCN(Cc2ccc(-c3ccccn3)o2)CC1C(=O)NCC(F)(F)F
CHEMBL3326588,VJJGAJAUECQWSZ-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,13545,46191567,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4)Cl)(CF)CF)C=N1,Cc1cc2c(NC(=O)NC3CC(CF)(CF)Oc4cc(Cl)ccc43)cccc2cn1
CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,13547,36462,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O
CHEMBL165064,VJJZJBUCDWKPLC-UHFFFAOYSA-N,ISOKAEMPFERIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,36200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.441291429466834,13549,5280862,COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,COc1c(-c2ccc(O)cc2)oc2cc(O)cc(O)c2c1=O
CHEMBL513023,VJOBNGRIBLNUKN-ITZZLVQVSA-N,MEDIORESINOL,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,13700.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.863279432843593,13554,332425,COC1=CC(=CC(=C1O)OC)C2C3COC(C3CO2)C4=CC(=C(C=C4)O)OC,COc1cc(C2OCC3C(c4cc(OC)c(O)c(OC)c4)OCC23)ccc1O
CHEMBL389810,VJVGNLWFBAMJAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13555,44425817,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)C5=CC=CC(=C5)C#N)N(C2=O)CC6=CC=CC=C6F,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccc(C#N)c5)cc4)CC3)C2=O)c1
CHEMBL1834663,VJVZPGBCTGRTJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,7.0,13556,56594867,CN(C)CC1=CC(=CC=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl
CHEMBL1834663,VJVZPGBCTGRTJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,13556,56594867,CN(C)CC1=CC(=CC=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl
CHEMBL3646210,VKBFHTIUXUCYRQ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 ��L final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37�� C. incubator. Pooled human liver microsomes (BD Gentest, 50 ��g/mL) were incubated with 5 concentrations of test compound (from 0.1 ��M to 10 ��M), 1 mM NADPH (Sigma), and 2 ��M midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,5.0,13560,68620328,CC1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CC(C)O)N,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1
CHEMBL2170643,VKFYSQSTERJHNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,5.221848749616356,13563,58269516,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=C(C=C3)F,NC(N)=NC(=O)c1ccc(C2CCN(C(=O)c3ccc(F)cc3)CC2)c(C(F)(F)F)c1
CHEMBL539168,VKGRHANZJPGGQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,3364.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.473144012874125,13564,25033651,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C(CC3)(C4=CC=NC=C4)O)F,COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1F
CHEMBL1215552,VKOYHMBQGJRYAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20672820.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.698970004336019,13576,46914454,CC1=C(C(C(=C(N1)CN2C=CN=C2)C(=O)OC)C3=C(C=C(C=C3)F)Cl)C#N,COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl
CHEMBL1949940,VKSDHNUDPMJHKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513812,13582,57398573,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ncco3)c2c1
CHEMBL1949940,VKSDHNUDPMJHKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.107905397309519,13582,57398573,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=NC=CO4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ncco3)c2c1
CHEMBL1951332,VKUPYUAAOPDZKP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,44.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.356547323513813,13584,57393589,CCOC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,CCOC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4nc[nH]c34)cc2)c1
CHEMBL1269674,VKUUNUNXIVLQGO-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,13585,12001873,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC)Cl)C5CC5)Cl,CNCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269674,VKUUNUNXIVLQGO-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,13585,12001873,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNC)Cl)C5CC5)Cl,CNCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL2041180,VLBBPWTZWIHQLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,13588,49847379,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CN=C(C=C5)C6=CC=C(C=C6)C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL2425615,VLHAYZZEMIYRND-PVRJFLCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13593,73356861,COCC(C(F)(F)F)OC1=C(C(=CC(=C1)CC2CS(=O)CC(C2O)N)F)N,COCC(Oc1cc(CC2C[S+]([O-])CC(N)C2O)cc(F)c1N)C(F)(F)F
CHEMBL2181331,VLNBTEQPYIXIMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,6.431798275933005,13596,73351352,C1CCN(CC1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1
CHEMBL3672576,VLNZCNIBUVLVDW-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.795880017344075,13598,57405866,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CS(=O)(=O)CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672576,VLNZCNIBUVLVDW-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,260.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.585026652029182,13598,57405866,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CS(=O)(=O)CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2420615,VLPQNEWDWXCJON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859074.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.,J. Med. Chem.,PUBLICATION,,6.0,13601,6493950,CCC1=CC=C(C=C1)C2=NN(C3=NC(=O)N(C(=O)C3=N2)C)C,CCc1ccc(-c2nc3c(=O)n(C)c(=O)nc-3n(C)n2)cc1
CHEMBL3403823,VLPSRHJLJIZUBN-HRANHPEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,13602,71288636,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C7CCC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403823,VLPSRHJLJIZUBN-HRANHPEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,13602,71288636,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C9CCC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C7CCC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3112850,VLUJVXBQLNFVKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,13606,49837941,C1CN(C2=C1C(=CC=C2)Br)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(Br)cccc21
CHEMBL1667925,VLZBNNUEXCARSV-JCMHNJIXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21211972.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.080921907623926,13612,53316685,CCOC(=O)C1=C(C2=C(O1)C=NC=C2)NC3=CC4=C(C=C3)C(=NO)CC4,CCOC(=O)c1oc2cnccc2c1Nc1ccc2c(c1)CCC2=NO
CHEMBL2323775,VMJFTOSOFDEKTM-UHFFFAOYSA-N,MK-8033,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23379595.0,IC50,=,11580.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis,"Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met.",J. Med. Chem.,PUBLICATION,,4.936291440608582,13618,45142457,CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)CS(=O)(=O)NCC5=CC=CC=N5)N=C2,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1
CHEMBL347303,VMKNDIQDOBATQU-UHFFFAOYSA-O,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,13619,44366980,CCCCOC1=CC=C(C=C1)C2=CC=[N+](N2)C,CCCCOc1ccc(-c2cc[n+](C)[nH]2)cc1
CHEMBL557262,VMMGFPNGNCDEDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2441251443275085,13620,45272853,C1CN(CCC1NC(=O)NC(CN2C=NC=N2)C3=CC=CC=C3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cncn1)c1ccccc1
CHEMBL259922,VMOVZKURWYNTLN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18359226.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13623,16730109,CC1=C(C=C(C=C1)C(=O)NC2=NOC=C2)NC3=C4C=NN(C4=NC=N3)C5=CC=CC=C5,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1
CHEMBL3633321,VMQJQZZJFVZNTF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26363868.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,Eur. J. Med. Chem.,PUBLICATION,,4.698970004336019,13624,122195193,C1CN(CCN1CC2=CC(=C(C=C2)Cl)Cl)C(=O)CN3C=NC(=N3)[N+](=O)[O-],O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(Cl)c(Cl)c2)CC1
CHEMBL497137,VMTCAWWXUQDLPT-DFEHQXHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,73500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.133712660915805,13625,10692619,CCC1=CC(=CC(=C1O)CC)C=C2CCC(=CC3=CC(=C(C(=C3)CC)O)CC)C2=O,CCc1cc(C=C2CCC(=Cc3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O
CHEMBL497137,VMTCAWWXUQDLPT-DFEHQXHXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,73451386.82,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,1.1339999999746435,13625,10692619,CCC1=CC(=CC(=C1O)CC)C=C2CCC(=CC3=CC(=C(C(=C3)CC)O)CC)C2=O,CCc1cc(C=C2CCC(=Cc3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O
CHEMBL439727,VMVGGLFKABPLBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,31310.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.504316932383085,13626,11376266,CN1C2=CC=CC(=C2C3=C1C(=NC(=N3)CN4CCOCC4)N5CCN(CC5)CCC6=CC(=C(C=C6)F)F)C(=O)N,Cn1c2cccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL120067,VMXIUTUFHIFDKH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15177483.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,13629,44346322,CC1=NC2=C(N1)C=C(C(=C2)OC)C(=O)C3=CC=C(C=C3)NC4=C(C=C(C=C4)F)F,COc1cc2nc(C)[nH]c2cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1
CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,4.301029995663981,13631,5039,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
CHEMBL499007,VMXXQQUNEIDJSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,5.42021640338319,13632,25180500,COC1=CN=CC(=C1)C2=CC3=C(CC(=O)CC3)C=C2,COc1cncc(-c2ccc3c(c2)CCC(=O)C3)c1
CHEMBL1093044,VMZBJCIUNPGQKF-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13633,46884062,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCNC,CNCCc1sc2ccccc2c1C(C)c1ccccn1
CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,300.0,NM,,,,binding,,,,,,,,,,,,,,,,6.522878745280337,13642,2812,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,500000.0,NM,,,,binding,,,,,,,,,,,,,,,,3.3010299956639813,13642,2812,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,7.698970004336019,13642,2812,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,7.301029995663981,13642,2812,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,7.0,13642,2812,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.795880017344075,13642,2812,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL2397187,VNGAUNCZCLFPCA-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13643,46932297,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1
CHEMBL231409,VNHSWSVUHFYHIZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.431798275933005,13647,135553266,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC,CNC(=O)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1
CHEMBL598215,VNJFIBFHISUZRV-ZACQAIPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.3979400086720375,13650,25025779,COCC1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3,COCC1C2CNCC21c1ccc2ccccc2c1
CHEMBL2163823,VNJOULOPKZCEMY-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.096910013008056,13651,57522134,C1CN(CCC1N)C(=O)C(CC2=CC=C(C=C2)Br)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,NC1CCN(C(=O)C(Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL499588,VNZZTXDBRSOFHQ-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,13661,44576656,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)COCC(=O)O)N,NC(Cn1c(=O)c(-c2ccc(COCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL3116156,VOCAUMUELJMEHG-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,13663,16745085,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=CC=CC=C5N4,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1
CHEMBL3116156,VOCAUMUELJMEHG-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13663,16745085,C1=CC=C(C=C1)CC(C2=NC=C(C=C2)Cl)(C3=CC(=CC(=C3)F)OC(C(F)F)(F)F)NC4=NC5=CC=CC=C5N4,Fc1cc(OC(F)(F)C(F)F)cc(C(Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1
CHEMBL231609,VOEZJKBTZPTQLU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,13666,135553268,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=O)NC5CCCC5,Cc1cc(C(=O)NC2CCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL2057776,VORKZGMPBYXFTH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22749871.0,IC50,<,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CPY3A4,Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,13675,62705832,C1C2CN(CC2CN1C3=CC=NC=C3)C(=O)C4CN(C4)S(=O)(=O)C5=CC=CC6=C5C=CN=C6,O=C(C1CN(S(=O)(=O)c2cccc3cnccc23)C1)N1CC2CN(c3ccncc3)CC2C1
CHEMBL1949942,VOUAUMKVLOMARH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,13679,57398574,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CS4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncs3)c2c1
CHEMBL1949942,VOUAUMKVLOMARH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,13679,57398574,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CS4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cncs3)c2c1
CHEMBL1911818,VOUTUZMXSRIFMF-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,13681,57394520,CN1CCN(CC1)C(=O)C(COCC2=CC3=C(C=C2)OCCO3)NC(=O)C4=C(N=CC=C4)OC5=C(C=C(C=C5)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCc2ccc3c(c2)OCCO3)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL1923121,VOVWPJYRKUBSTK-JOMNFKBKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,13687,57399556,COCCCC1=CC2=CC=CC=C2C(=C1)CN(C3CC3)C(=O)C4CNCCC45C6=CC(=C(C=C6CO5)F)F,COCCCc1cc(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c2ccccc2c1
CHEMBL2069805,VOXSTMJILMNHJT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.698970004336019,13689,5300578,C1CCC(CC1)NC(=O)C2=NC(=NO2)CS(=O)(=O)C3=CC=CC=C3,O=C(NC1CCCCC1)c1nc(CS(=O)(=O)c2ccccc2)no1
CHEMBL2017283,VOXWVXCIJOFLCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,13691,70681174,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C5=CC=CC=C5C(C)(C)C)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12
CHEMBL2017283,VOXWVXCIJOFLCE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,13691,70681174,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C5=CC=CC=C5C(C)(C)C)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12
CHEMBL502341,VPAUFXIBDRBNIX-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006286.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.",J. Med. Chem.,PUBLICATION,,4.958607314841775,13693,25156943,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2Cl)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F,COc1cccc(-c2c(C)n(Cc3c(F)cccc3Cl)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F
CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,13694,24748995,CC1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,CC1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,13694,24748995,CC1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,CC1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18052318.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using diethoxyfluorescein substrate,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.0,13694,24748995,CC1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,CC1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
CHEMBL3702763,VPECJBKJBLKBNM-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5650.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.247951552180561,13698,89756804,CC(C)(C)OC(=O)N1CCC(CC1)NC(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)OC(C)(C)C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2401818,VPGLBWRUBBOYIG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23773865.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CP3A4 (unknown origin),"Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,13700,57812601,C#CCC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C3C(=CN=C2N)C(=CO3)C4=CN(N=C4)C5CCNCC5,C#CCC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl
CHEMBL1208965,VPGSHWKKZVAVBK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,13702,49862094,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN=C(C=C5)NC6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1208965,VPGSHWKKZVAVBK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,13702,49862094,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN=C(C=C5)NC6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL443065,VPGTXENSHDCTLV-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,13703,44447021,CC(C)(CO)N(C)CC1=NC(=NO1)CC2(CC2)C3CCCC(N3S(=O)(=O)C4=CC=C(C=C4)Cl)C5CC5,CN(Cc1nc(CC2(C3CCCC(C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)no1)C(C)(C)CO
CHEMBL1910108,VPGYQTGJKYIUMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.173925197299173,13704,15950388,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)C#N)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(C#N)cc1)C2=O
CHEMBL3702686,VPIPGPIOBMSQSI-HHDOLNPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.1938200260161125,13705,89718196,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)N8CCN(CC8)S(=O)(=O)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702818,VPIPGPIOBMSQSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6400.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.1938200260161125,13706,89718468,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)N8CCN(CC8)S(=O)(=O)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1949938,VPLAJHSHSVVJEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,13710,57400235,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccccn3)c2c1
CHEMBL1949938,VPLAJHSHSVVJEM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.97469413473523,13710,57400235,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=CC=N4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccccn3)c2c1
CHEMBL252636,VPLYLBCWMYERNA-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,13711,44447286,CC(C)(C)OC(=O)NC(CC1=C(C(=CC=C1)F)F)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1cccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL561932,VPYHMFOFGLWNPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19574047.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13719,44517743,CN1C(=O)C=C(C2=C1N(N=C2)C3=CC=C(C=C3)F)NC4=C(C=CC(=C4)C(=O)NC5CC5)Cl,Cn1c(=O)cc(Nc2cc(C(=O)NC3CC3)ccc2Cl)c2cnn(-c3ccc(F)cc3)c21
CHEMBL2431456,VQCSFAUVYAVXEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24069953.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,PUBLICATION,,6.468521082957745,13721,44624151,CC(C)(C)C1=CC(=CC(=C1OC)CCC2=CC=C(C=C2)NS(=O)(=O)C)C3=CC=CNC3=O,COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C
CHEMBL2334764,VQCWJZWGHDLXCC-ZAAXVRCTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,5.301029995663981,13722,71717638,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CC4CCC3N4S(=O)(=O)C)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CC2CCC3N2S(C)(=O)=O)cc1
CHEMBL2170609,VQGJOZLBMBECDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.585026652029182,13723,58269691,CCC(=O)N1CCC(CC1)C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F,CCC(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL3702721,VQOICHPDWXYAPI-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2230.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.651695136951839,13732,89718260,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N(C)C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1271704,VQOLUEFEGFCAIH-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,23.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.623423042943488,13733,52945528,CC(C)(C)C1COCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)C(C)(C)CO,CC(C)(C)C1COCC(COC(=O)N2CCN(C(C)(C)CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2012951,VQQZSOVXMSWVFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,13735,70685308,CC1=NC2=C(N1C3=CC=C(S3)C(=O)NC4CC4)C=CC=C2OC(F)F,Cc1nc2c(OC(F)F)cccc2n1-c1ccc(C(=O)NC2CC2)s1
CHEMBL193055,VQVKHCWYXCFZSE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,31800.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,4.497572880015567,13738,11490692,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc(C(C)(C)C)[nH]c3-c3ccc(F)cc3)cc21
CHEMBL478871,VQWUSTLVSKKFKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.107905397309519,13741,44579182,CN1C=C(C2=C1C=C3CCNCCC3=C2)S(=O)(=O)C4=CC=CC=C4,Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3
CHEMBL478871,VQWUSTLVSKKFKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,13741,44579182,CN1C=C(C2=C1C=C3CCNCCC3=C2)S(=O)(=O)C4=CC=CC=C4,Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3
CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,13749,4449,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,13749,4449,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22409598.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks.,J. Med. Chem.,PUBLICATION,,7.823908740944319,13749,4449,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22409598.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Competitive inhibition of CYP3A4 in human liver microsomes,Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks.,J. Med. Chem.,PUBLICATION,,5.823908740944319,13749,4449,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
CHEMBL3640286,VRRVVCOABSEJKG-UGZDLDLSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.698970004336019,13763,44467853,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=C(C=CC(=C4F)F)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3c(F)ccc(F)c3F)C2)nc(C)c1F
CHEMBL207071,VRUAXQODZDRLMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,5.698970004336019,13770,2782903,C1=CC(=CC=C1C2=CC(=C(S2)C(=O)N)N)F,NC(=O)c1sc(-c2ccc(F)cc2)cc1N
CHEMBL560377,VRWJZGHUCOFGPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19630403.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,5.0,13772,11610553,C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)C5=CC=NC=C5,c1ccc2nc(COc3ccc(-c4[nH]ncc4-c4ccncc4)cc3)ccc2c1
CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.619788758288394,13776,122068,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.0,13776,122068,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using DEF substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,4.619788758288394,13776,122068,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL1235,VRXFDHAGFYWGHT-UHFFFAOYSA-N,DESETHYL AMODIAQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19284751.0,IC50,=,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using PPR substrate,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,PUBLICATION,,4.0,13776,122068,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
CHEMBL518142,VRZJRRFRFQRESG-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,8400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.075720713938118,13777,44570490,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)OC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL518142,VRZJRRFRFQRESG-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,13777,44570490,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)OC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL2347408,VSAIMZAFUWHQMD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,13779,71280143,CC1(CCNCC1)NC(=O)C2=CNC3=NC=C(N=C23)C4=NN(C5=C4C=CC(=C5)F)C,Cn1nc(-c2cnc3[nH]cc(C(=O)NC4(C)CCNCC4)c3n2)c2ccc(F)cc21
CHEMBL3125270,VSEJBALUHIPEBF-PBHICJAKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24450589.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,J. Med. Chem.,PUBLICATION,,4.301029995663981,13780,76314530,CCC1=NN(C(=C1)C(=O)NC2CC(N(C2)C(=O)C3=COC4=CC=CC=C43)C(=O)N)CC,CCc1cc(C(=O)NC2CC(C(N)=O)N(C(=O)c3coc4ccccc34)C2)n(CC)n1
CHEMBL252414,VSGMPHWPOWPCHF-XZOQPEGZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,13781,11526278,C1CC(N(C(C1)C2(CC2)CC(=O)N3CCC4(CCN4)CC3)S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,O=C(CC1(C2CCCC(C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1
CHEMBL3702707,VSHMJRDIOFZVNT-ZPGRZCPFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3630.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.440093374963888,13783,89718308,CN1CCCN(CC1)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCCN(C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1668115,VSJGYMSTWHUFMX-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,54200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,4.266000713461613,13784,11393842,COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)CCCO)CO)O,COc1cc(C2Oc3cc(CCCO)ccc3OC2CO)ccc1O
CHEMBL2386653,VSKQOMHTMYZRLK-ZJUUUORDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,5.0,13786,58394783,CC(C1=NC2=CN=C3C(=C2N1C4CCCOC4)C=CN3)O,CC(O)c1nc2cnc3[nH]ccc3c2n1C1CCCOC1
CHEMBL2386653,VSKQOMHTMYZRLK-ZJUUUORDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23659214.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,PUBLICATION,,5.0,13786,58394783,CC(C1=NC2=CN=C3C(=C2N1C4CCCOC4)C=CN3)O,CC(O)c1nc2cnc3[nH]ccc3c2n1C1CCCOC1
CHEMBL2057520,VSKXCMMQATYJBE-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,79.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.102372908709558,13787,59603320,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CC)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CC)oc2c1
CHEMBL2204445,VSLWUPHHCFQTDB-LJQANCHMSA-N,(R)-VU0463597,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22607673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu(3)) NAM probe (ML289) derived from a closely related mGlu(5) PAM.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13789,56587994,COC1=CC=C(C=C1)C#CC2=CC=C(C=C2)C(=O)N3CCCC(C3)CO,COc1ccc(C#Cc2ccc(C(=O)N3CCCC(CO)C3)cc2)cc1
CHEMBL1650511,VSMFCZZEKTVDHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128593.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,PUBLICATION,,5.0,13790,135883253,C1CCC2(CC1)CC(=NO2)C3=NC4=C(C=C(C=C4N3)C5=CC=CC=C5C(F)(F)F)C(F)(F)F,FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2nc(C3=NOC4(CCCCC4)C3)[nH]c2c1
CHEMBL3338865,VSOUDUXMPUHJEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25248679.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 (unknown origin),Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,13792,46190695,CC1=CC(=CN=C1)C2=NC=C(C(=C2)C(=O)NCC3=NC(=C(C=C3)OC)OC)C4=NC=CS4,COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC
CHEMBL469292,VSPZMUAUSBZZJK-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,5.0,13794,135875712,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=C(C=C4)OC)Cl)O)C5CCN(CC5)CCCF,COc1ccc(C(O)CNc2cc[nH]c(=O)c2-c2nc3c(C)cc(C4CCN(CCCF)CC4)cc3[nH]2)cc1Cl
CHEMBL2448717,VSTCTLPTEFNPSS-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.853871964321762,13795,73354177,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(C=C3)C4=CC=CS4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3cccs3)nc2)c1
CHEMBL151170,VSYIEXFPNPTQGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,883.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,6.054039296422431,13802,11275964,CCCCOC1=CC=C(C=C1)C2=CN=CN2,CCCCOc1ccc(-c2cnc[nH]2)cc1
CHEMBL552567,VSYWLXSRFUTNAH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19739647.0,IC50,=,15.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,PUBLICATION,,7.82102305270683,13804,16223854,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=CC=CC=N3)CC4=CC=C(C=C4)C5=NN=C(C=C5)OC)CC(C)(C)C(=O)O,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nn1
CHEMBL1916288,VTFOIOURAFZEDM-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21955939.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13810,54752118,CC1=NN(C(=C1C(=O)NC(C)C(C)(C)C)NS(=O)(=O)C2=CC=C(C=C2)C#N)C3=CC=C(C=C3)F,Cc1nn(-c2ccc(F)cc2)c(NS(=O)(=O)c2ccc(C#N)cc2)c1C(=O)NC(C)C(C)(C)C
CHEMBL2387503,VTGCIWWYBFGGNJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,13811,56589615,C1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,O=c1[nH]c2cc(-c3ccccc3)ccc2c2nc(-c3c(F)cccc3Cl)[nH]c12
CHEMBL1258035,VTGDLGOSPAKXEA-WMISUKIASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,>,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,13812,49780809,CC1=C(OC=N1)C2=NN=C(N2C)SCCCNC3CCC4(C3C4)C5=CC=C(C=C5)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCNC2CCC3(c4ccc(C(F)(F)F)cc4)CC23)n1C
CHEMBL2181643,VTIJLRPGYFSCQT-NTEUORMPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,10600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,4.97469413473523,13815,71459318,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=NC=CN=C5)C6CCCC6,Cn1c(-c2cnccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL446793,VTMXWIGCCDHWKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18632268.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,13819,18440270,C1=CC(=CC(=C1)Cl)C(=O)C2=C3C(=CC(=C2)CC4=NNC(=O)C=C4)C=CO3,O=C(c1cccc(Cl)c1)c1cc(Cc2ccc(=O)[nH]n2)cc2ccoc12
CHEMBL3087351,VTPLTXZKMKTFBQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,15300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.815308569182402,13824,72547025,C1=CC(=CC=C1C2=CC=NN2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2ccn[nH]2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL1272135,VTQGIZQKCPGUNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20926294.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,13826,52949188,COC1=CC=CC(=C1)NC(=O)NC2=CC=CN(C2=O)CC3=C(C=CC=C3Cl)F,COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1
CHEMBL2448742,VTTSFAQAAYHUOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.0,13827,73355727,CC(=O)N(CC1=CN=CN1)C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3,CC(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1
CHEMBL3422094,VTWYCQYMWJLMTC-AKOVUPKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,230.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.638272163982407,13830,118735392,C1CCC(C1)C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL3422093,VTWYCQYMWJLMTC-WBXFWKJNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.096910013008056,13831,118735391,C1CCC(C1)C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL3422093,VTWYCQYMWJLMTC-WBXFWKJNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,820.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.086186147616283,13831,118735391,C1CCC(C1)C(C2=CC=CC=N2)NC(=O)C3=CC4=C(C=C3)NN=C4C5=CC=C(C=C5)N6C7CCC6CC(C7)O,O=C(NC(c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1
CHEMBL3623823,VTXPPXZJCHEWPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26403853.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,PUBLICATION,,4.301029995663981,13832,71811365,CC(=O)NC1CCCC2=C1C=NC=C2C3=CC=C(C=C3)C#N,CC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21
CHEMBL472757,VUDLFYRSWDHZSU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24461352.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13834,11604449,CCS(=O)(=O)N1CCC(CC1)(CC2CC2)CNC(=O)C3=C(C=C(C=C3)Cl)Cl,CCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(CC2CC2)CC1
CHEMBL1818451,VUEZBOYAXGKAME-ZYMOGRSISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,13835,56669562,CC1=NN(C=C1)CC23CC2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccn(CC23CNCCC2(c2ccc(Cl)c(Cl)c2)C3)n1
CHEMBL454774,VUFHHJKMMITIBF-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.552841968657781,13838,11365653,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N)C4=C(C(=CC=C4)OCCCCC(=O)O)F,Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(CC(N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
CHEMBL2385902,VUKXPPCLOKSGNR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,13842,71733911,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)CC4=CNC5=CC=CC=C54,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1c[nH]c3ccccc13)CC2
CHEMBL479314,VUNCHONBJWJYID-DLBZAZTESA-N,(-)-CUBEBININOLIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,14900.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.826813731587726,13843,13916150,COC1=CC(=CC(=C1OC)OC)CC2COC(=O)C2CC3=CC(=C(C(=C3)OC)OC)OC,COc1cc(CC2COC(=O)C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC
CHEMBL2409676,VUNVHTRIAQAVIJ-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23810497.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Hydantoin based inhibitors of MMP13-Discovery of AZD6605.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13845,73349098,CC1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCN(CC2)C3=NC=C(C=N3)OCC4=CC=C(O4)C(F)(F)F,CC1(CS(=O)(=O)N2CCN(c3ncc(OCc4ccc(C(F)(F)F)o4)cn3)CC2)NC(=O)NC1=O
CHEMBL1094458,VUVAXIBXIAPBBM-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.346787486224656,13850,136086713,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCCF,Cc1cc(N2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3640263,VUVKLOMPJFHDFF-ORAYPTAESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26937601.0,IC50,=,34100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,Structure-Based Design of an Iminoheterocyclic -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A in Nonhuman Primates.,J. Med. Chem.,PUBLICATION,,4.467245621007502,13853,44467576,CC1=C(C(=NC(=N1)N2CC3C(=O)N(C(=NC3(C2)C4=CC=C(C=C4)F)N)C)OC)F,COc1nc(N2CC3C(=O)N(C)C(N)=NC3(c3ccc(F)cc3)C2)nc(C)c1F
CHEMBL2017291,VUVUVNZRUGEAHB-CYBMUJFWSA-N,GSK1210151A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.013228265733755,13854,52912189,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccn3)c12
CHEMBL2017291,VUVUVNZRUGEAHB-CYBMUJFWSA-N,GSK1210151A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.013228265733755,13854,52912189,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccn3)c12
CHEMBL512079,VUXLKOATKUTQHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19341281.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones.,J. Med. Chem.,PUBLICATION,,5.508638306165727,13856,22239024,C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=NC(=NO4)CN,NCc1noc(-c2nn(Cc3ccccc3)c3ccccc23)n1
CHEMBL576093,VUXWOZNVRFWGIQ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,13857,44473098,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(N)=O)nc3)ccc2o1
CHEMBL479575,VVAHJSXAXRVBPR-NZQKXSOJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18583127.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13859,24894058,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(C)C4=C(C=C(C=C4)F)F,CC(=O)N1CCN(c2ccc(OCC3COC(C)(c4ccc(F)cc4F)O3)cc2)CC1
CHEMBL3358926,VVCVRVUPFSJFRH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.301029995663981,13860,60026849,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=CC(=NC=C3N2)N)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N)ncc2[nH]1)C(F)(F)F
CHEMBL1669419,VVGNEGYIOFKVTA-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,1826.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.73849922680172,13865,53322838,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CS4,CC(C1=C(CCN(C)Cc2cccs2)Cc2ccccc21)c1cnccn1
CHEMBL502092,VVICOEQHILEAPE-PHVLTXCSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.1,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.508638306165727,13866,135960722,CC1CN(CC(O1)C)C2CCN(CC2)C3=CC4=C(C(=C3)C)N=C(N4)C5=C(C=CNC5=O)NCC(C6=CC(=CC=C6)Cl)O,Cc1cc(N2CCC(N3CC(C)OC(C)C3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1094164,VVIPLSCLYCWUQT-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,13868,135423375,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCC#N,Cc1cc(N2CCN(CCC#N)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1091792,VVIWSBGDDVESJJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13869,11530223,CC(C1=NC(=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,COc1cccc(C(C)c2c(CCN(C)C)sc3ccccc23)n1
CHEMBL240645,VVJKDHDXWRSOBK-UHFFFAOYSA-N,SR-1353,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,250.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6020599913279625,13870,16662102,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC(=CC=C4)Cl)N,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1
CHEMBL2152613,VVRUXFPJOVUDCV-UHFFFAOYSA-N,2-((3-PHENETHOXYPHENYL)AMINO)BENZAMIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22642300.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,13873,56935695,C1=CC=C(C=C1)CCOC2=CC=CC(=C2)NC3=CC=CC=C3C(=O)N,NC(=O)c1ccccc1Nc1cccc(OCCc2ccccc2)c1
CHEMBL507691,VVSAPIDRRVMKFJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,13875,24863522,CNC(=O)C1=CC=CC(=C1)C2=CC=C(C=C2)C(CN3CCOCC3)N(C)C(=O)CN4C5=CC(=C(C=C5N=CC4=O)Cl)Cl,CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(Cl)c(Cl)cc43)cc2)c1
CHEMBL3126382,VVUGQHSQCFTHGT-CZCBIWLKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24359185.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein as substrate,"Discovery of a rapidly metabolized, long-acting ��(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.",J. Med. Chem.,PUBLICATION,,5.795880017344075,13876,69119876,CC(=O)O.C1CCC(C1)S(=O)(=O)C2=CC=CC(=C2)CCCCOCCCCCCNCC(C3=CC(=C(C=C3)O)CO)O,O=S(=O)(c1cccc(CCCCOCCCCCCNCC(O)c2ccc(O)c(CO)c2)c1)C1CCCC1
CHEMBL3126382,VVUGQHSQCFTHGT-CZCBIWLKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24359185.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7-benzyloxyquinoline as substrate,"Discovery of a rapidly metabolized, long-acting ��(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.",J. Med. Chem.,PUBLICATION,,5.42021640338319,13876,69119876,CC(=O)O.C1CCC(C1)S(=O)(=O)C2=CC=CC(=C2)CCCCOCCCCCCNCC(C3=CC(=C(C=C3)O)CO)O,O=S(=O)(c1cccc(CCCCOCCCCCCNCC(O)c2ccc(O)c(CO)c2)c1)C1CCCC1
CHEMBL3137446,VVUMTHNDTDZGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.97061622231479,13877,76325838,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC(=CC=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1
CHEMBL3137446,VVUMTHNDTDZGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.7447274948966935,13877,76325838,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC(=CC=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1
CHEMBL3137446,VVUMTHNDTDZGCY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.0,13877,76325838,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC(=CC=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1
CHEMBL1208894,VVYUVUVFTYVYIG-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,13879,49862055,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCNCC6)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1208894,VVYUVUVFTYVYIG-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,5900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,13879,49862055,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCNCC6)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL3393291,VWAWBZYBSWVMRW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25255283.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,13881,24517908,C1=CC(=CC=C1C(=O)NCC2=CC=NC=C2)OC3=CC=C(C=C3)F,O=C(NCc1ccncc1)c1ccc(Oc2ccc(F)cc2)cc1
CHEMBL459729,VWELCPLMPPEKOL-UHFFFAOYSA-N,BMS-695735,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.585026652029182,13885,135441202,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCCF,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
CHEMBL2018925,VWGACEKTAOFWMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,2490.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.603800652904264,13886,56954013,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC(=CC=C3)OC4=CC=CC=C4,COc1ccc2nc(SCc3cccc(Oc4ccccc4)c3)[nH]c2c1
CHEMBL1092258,VWGHJDXVTAUEQY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,13887,46884669,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)OC)CC3=NC=CN=C3,COc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1
CHEMBL255460,VWGHPHKDTXAJJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,680.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.167491087293763,13888,44448874,C1CC(C(N(C1)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O)CN4CCOCC4)C5=CC=CC=C5,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
CHEMBL1222969,VWGSYATZAOMKDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20673729.0,IC50,>,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 30 mins,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,13889,49865137,C1CC(C1)(C2=NN=C(S2)C3=NN(C(=C3CN4C=NC=N4)C5=CC=C(C=C5)Cl)C6=C(C=C(C=C6)Cl)Cl)C(F)(F)F,FC(F)(F)C1(c2nnc(-c3nn(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)c3Cn3cncn3)s2)CCC1
CHEMBL3422008,VWHSUJREXZPXOB-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,5.698970004336019,13890,118735353,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=CN=C5)C,Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1
CHEMBL3137474,VWJAPQXRZIFGME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,13892,76314945,C1CN(CCC1N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3)C4=C(C=C(C=C4)C(F)(F)F)C#N,N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
CHEMBL1095031,VWKIIEUSSJXADS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,13894,46888786,CCOCCN1C2=CC=CC=C2N=C1C3CCCN(C3)C,CCOCCn1c(C2CCCN(C)C2)nc2ccccc21
CHEMBL471074,VWQNZPASHLNLEM-WKSZPJAWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,31600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,4.500312917381596,13899,14825858,CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)OC(=O)C)O)OC(=O)C,CC(=O)OC1C(C)OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(OC(C)=O)C1O
CHEMBL561259,VWTOOZUTLQWOPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,13903,45267348,C1CN(CCC1C2=NOC=N2)C(=O)NC3CC3C4=CC=CC=C4,O=C(NC1CC1c1ccccc1)N1CCC(c2ncon2)CC1
CHEMBL2386075,VXAZUHZNPMCSLD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23721423.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis,"Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist.",J. Med. Chem.,PUBLICATION,,4.301029995663981,13913,11631813,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CS4,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccs1)CC2
CHEMBL1944698,VXBAJLGYBMTJCY-NSCUHMNNSA-N,TG-02,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22148278.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,"Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,13914,16739650,CN1CC=CCCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1,CN1CC=CCCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
CHEMBL364925,VXCUSFSWRIJJDA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,5.214670164989233,13916,11753012,CC(C)C1=NC(=C(N1)C2=CC=C(C=C2)F)C3=CC4=C(C=C3)N=C(N4S(=O)(=O)C(C)C)N.CS(=O)(=O)O,CC(C)c1nc(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)c(-c2ccc(F)cc2)[nH]1
CHEMBL2382414,VXEVEBMHWZDNOF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23628336.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,13919,51030985,C1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C(=O)OCC(F)(F)F,N#Cc1cnccc1COc1cnc(N2CCN(C(=O)OCC(F)(F)F)CC2)nc1
CHEMBL282365,VXFHXZLPYZXJKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,19300.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.714442690992226,13920,11177283,CN1C2=C(C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)N=CC=C2,Cn1c2cccnc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL3702722,VXHCTCQAIMFHGE-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8550.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.068033885271827,13923,89718327,CN1CCC(CC1)N2CCN(CC2)C(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C6CCN(C)CC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2018907,VXHDUQXXAHZWMP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,5330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.273272790973428,13924,56953769,CCCCCCSC1=NC2=C(N1)C=C(C=C2)OC,CCCCCCSc1nc2ccc(OC)cc2[nH]1
CHEMBL3234565,VXHHIPNHNBMMJV-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,5.698970004336019,13925,90654584,CN1CCN(CC1)C2=NC(=NC(=C2)C(F)(F)F)N3CCCC(C3)C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(C(F)(F)F)nc(N3CCCC(C(=O)NCCc4ccc(C#N)cc4)C3)n2)CC1
CHEMBL362412,VXPLIKXVYZZBFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,13940,44390161,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OCC(=O)OC)N4C=CN=C4)N(C)C,COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
CHEMBL362412,VXPLIKXVYZZBFD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,13940,44390161,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OCC(=O)OC)N4C=CN=C4)N(C)C,COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1
CHEMBL1951432,VXTXSTJYACXQSO-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,13945,23633277,CC(=CCN1C2=C(C(=C1N3CCCC(C3)N)C#N)N=CN(C2=O)CC4=NC=CC5=CC=CC=C54)C,CC(C)=CCn1c(N2CCCC(N)C2)c(C#N)c2ncn(Cc3nccc4ccccc34)c(=O)c21
CHEMBL3116157,VXVXUOCSXHINSV-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13946,16744597,CC1=C(N=C(S1)NC(CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F)C(F)(F)F,Cc1sc(NC(Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F
CHEMBL3116157,VXVXUOCSXHINSV-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24424134.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13946,16744597,CC1=C(N=C(S1)NC(CC2=CC=CC=C2)(C3=NC=C(C=C3)Cl)C4=CC(=CC(=C4)F)OC(C(F)F)(F)F)C(F)(F)F,Cc1sc(NC(Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F
CHEMBL3128188,VXXIYUBYYXZZOE-FCJDFRRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24437735.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective ��3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,PUBLICATION,,4.0,13947,70792359,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=CC=NN34)C(C5=CN=CC=C5)O,O=C(Nc1ccc(CC2CCC(C(O)c3cccnc3)N2)cc1)C1CCc2ccnn21
CHEMBL3128188,VXXIYUBYYXZZOE-FCJDFRRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26709102.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,4.0,13947,70792359,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=CC=NN34)C(C5=CN=CC=C5)O,O=C(Nc1ccc(CC2CCC(C(O)c3cccnc3)N2)cc1)C1CCc2ccnn21
CHEMBL2151048,VYALMGYTNFNPPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22981333.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K�� inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,13949,66881945,C1COCCN1C2=CC(=O)N=C(N2)CC(=O)NC3=CC(=C(C=C3)F)Br,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)Nc1ccc(F)c(Br)c1
CHEMBL3237560,VYFZIPUVTIMYCJ-NWDGAFQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,4.301029995663981,13953,71626895,CC1=C(C=CC(=N1)NC2=CC(=NN=C2C(=O)N)NC3CCCCC3N)F,Cc1nc(Nc2cc(NC3CCCCC3N)nnc2C(N)=O)ccc1F
CHEMBL3291357,VYKHHRFZDHVGDQ-KUHUBIRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24815509.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of camphor-derived pyrazolones as 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,13956,16118900,CC1(C2CCC1(C3=C2C(=O)N(N3C)CC4=CC=CC=C4C(F)(F)F)C)C,Cn1c2c(c(=O)n1Cc1ccccc1C(F)(F)F)C1CCC2(C)C1(C)C
CHEMBL312137,VYLMFRUDZGQCNT-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12036349.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.,J. Med. Chem.,PUBLICATION,,6.0,13957,9845018,C1CN(C(=O)C1NCC2=CN=CN2CC3=CC=C(C=C3)C#N)CC4=CC(=CC=C4)Cl,N#Cc1ccc(Cn2cncc2CNC2CCN(Cc3cccc(Cl)c3)C2=O)cc1
CHEMBL592709,VYLVEERKOLDJOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,13958,25054307,CN(C)CC1=CC=C(C=C1)NC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC(=C(C=C3)OC)Cl,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl
CHEMBL3422028,VYSGWFCGFKTGQC-WCWDXBQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25751283.0,IC50,=,1880.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay,Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.,J. Med. Chem.,PUBLICATION,,5.72584215073632,13964,73386689,CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN)C3=CC=C(C=C3)O,CCC(=C(c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1
CHEMBL2017285,VYWGWQXJWULHNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.431798275933005,13967,70691699,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=C5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12
CHEMBL2017285,VYWGWQXJWULHNO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22437115.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.431798275933005,13967,70691699,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)CC5=CC=CC=C5)OC,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12
CHEMBL595092,VYXWHVDEWWHDLH-LJAQVGFWSA-N,AM-679,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19914828.0,IC50,=,16700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.777283528852417,13970,44627267,CC(=O)N1C(CC2=CC=CC=C21)COC3=CC4=C(C=C3)N(C(=C4SC(C)(C)C)CC(C)(C)C(=O)O)CC5=CC=C(C=C5)C6=NC=C(C=N6)OC,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCC5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1
CHEMBL3673963,VYZQJQZLBIQWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320631,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,13974,89970411,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=C(C=N4)OC)F)F)N=C1,COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F
CHEMBL3673963,VYZQJQZLBIQWTL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320675,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,13974,89970411,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=C(C=N4)OC)F)F)N=C1,COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F
CHEMBL2448736,VZAGCRQJRXHJNZ-VULFUBBASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.522878745280337,13975,73352680,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=N4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccn3)s2)c1
CHEMBL207638,VZAYORFJMPOFKB-DVECYGJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,13976,44410841,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCCCC3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCC3(C(=O)O)CCCCC3)ccc2c1)n1ccnc1)N(C)C
CHEMBL521271,VZGOJYYBQQYRJE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.301029995663981,13981,135960720,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)OC,COC(=O)NC1CCN(c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1
CHEMBL1208964,VZQLEKQMCOAWNB-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,13988,46911119,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NC6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1208964,VZQLEKQMCOAWNB-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,4700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064283,13988,46911119,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)NC6CCN(CC6)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1271879,VZTDQEWJIVUVPC-FLQRSKGTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,0.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,13990,11713201,C1CC1CC2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CC6CCC(C5)N6,O=C(OC1(C2COCC(CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2
CHEMBL3236635,VZZITKBMNYFVPR-OQZRLNFTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,13998,90655381,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N5CCC(C5)C(=O)O,CC1(CC(=O)N2CCC(C(=O)O)C2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL3236636,VZZITKBMNYFVPR-RHWDBWQKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,13999,90655382,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC(=O)N5CCC(C5)C(=O)O,CC1(CC(=O)N2CCC(C(=O)O)C2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL2436628,WAEWFNQGFKVNEU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14003,44603096,C1CN(CCC1N2CCC3=C(C2)C=C(C=C3)C#N)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,N#Cc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2
CHEMBL98,WAEXFXRVDQXREF-UHFFFAOYSA-N,VORINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17107790.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,14004,5311,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,O=C(CCCCCCC(=O)Nc1ccccc1)NO
CHEMBL98,WAEXFXRVDQXREF-UHFFFAOYSA-N,VORINOSTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14004,5311,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,O=C(CCCCCCC(=O)Nc1ccccc1)NO
CHEMBL1079257,WAFKWVRPHCVAGK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14005,46882987,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=C3C(F)(F)F,O=C(O)CCC1(c2ccccc2C(F)(F)F)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL2170747,WAIPUKHVRXNDDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22277094.0,IC50,=,54000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17��-HSD1.,J. Med. Chem.,PUBLICATION,,4.267606240177032,14008,56929159,C1=CC2=C(C=C1O)SC(=N2)NC(=O)C3=C(C=CC(=C3F)O)F,O=C(Nc1nc2ccc(O)cc2s1)c1c(F)ccc(O)c1F
CHEMBL453169,WAIWXNYKRBBVSH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,21070.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,4.6763354643919,14010,25034431,COC1=CC2=C(C=C1)C=C(C=C2)C3=C(C=CN=C3)N,COc1ccc2cc(-c3cnccc3N)ccc2c1
CHEMBL3087042,WAKFEUQVWCWZCS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,12200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.913640169325252,14014,72547531,CCC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,CCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL240813,WAMCIKGNVJZNAS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,2180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.661543506395395,14018,23647901,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNS(=O)(=O)C)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNS(C)(=O)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL1209017,WAMWLVAINQIUBS-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,14020,49862128,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCCN(C)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL1209017,WAMWLVAINQIUBS-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,14020,49862128,CC(C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)CCCN(C)C)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl
CHEMBL258199,WAPPDJVNPDRYEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18462938.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,14022,11963255,CC1=CC(=NN1CC2=C(C=CC(=C2)Cl)OCC3=CC=CC=C3)NC(=O)OC(C)(C)C,Cc1cc(NC(=O)OC(C)(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1
CHEMBL231306,WASNZPFVELUKFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,<,18.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,7.7447274948966935,14026,135681612,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5C=CN=C5,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL231306,WASNZPFVELUKFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,<,18.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,7.7447274948966935,14026,135681612,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5C=CN=C5,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL231306,WASNZPFVELUKFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,<,46.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.337242168318426,14026,135681612,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5C=CN=C5,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3672573,WAWNWRVGWKZVLT-CFTUFJLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,170.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.769551078621726,14029,57405863,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,CC(C)c1nc(CN(C)C(=O)N2CC(O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672573,WAWNWRVGWKZVLT-CFTUFJLTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,240.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.619788758288394,14029,57405863,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,CC(C)c1nc(CN(C)C(=O)N2CC(O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672572,WAWNWRVGWKZVLT-HYHVOXATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,160.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.795880017344075,14030,57405694,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,CC(C)c1nc(CN(C)C(=O)N2CC(O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672572,WAWNWRVGWKZVLT-HYHVOXATSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,230.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.638272163982407,14030,57405694,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,CC(C)c1nc(CN(C)C(=O)N2CC(O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672574,WAWNWRVGWKZVLT-YUXCJTBFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,120.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.920818753952375,14031,57405864,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,CC(C)c1nc(CN(C)C(=O)N2CC(O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672574,WAWNWRVGWKZVLT-YUXCJTBFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.522878745280337,14031,57405864,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC(CC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)O,CC(C)c1nc(CN(C)C(=O)N2CC(O)CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL1766185,WAXZAJPOBWYNFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.259637310505756,14034,18668607,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)C(C3CC3)(C4=CN=CN4)O,CC(=O)Nc1cccc(-c2ccc(C(O)(c3cnc[nH]3)C3CC3)cc2)c1
CHEMBL3086078,WBARVJREQICCOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24157370.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by NADPH and substrate addition measured after 5 mins by LC/MS/MS analysis,The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,14035,24753412,CC1=C(C(=O)OC2=CC(=C(C=C12)F)OC(=O)N(C)C)CC3=C(C(=CC=C3)NS(=O)(=O)N)F,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12
CHEMBL3086078,WBARVJREQICCOV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24157370.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins post NADPH addition followed by substrate addition measured after 5 mins by LC/MS/MS analysis,The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,14035,24753412,CC1=C(C(=O)OC2=CC(=C(C=C12)F)OC(=O)N(C)C)CC3=C(C(=CC=C3)NS(=O)(=O)N)F,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12
CHEMBL3304438,WBLVOWHFRUAMCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25801932.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14041,70679283,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1
CHEMBL3112855,WBLYYZMOJFRKFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,14042,57389549,C1CN(C2=CC=CC(=C21)C3=CC=CC=C3)C(=O)CC4=NC(=O)C=C(N4)N5CCOCC5,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2c(-c3ccccc3)cccc21
CHEMBL408962,WBQCKUNNRLRPOG-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18217703.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,14045,54716246,CN(C)C(=O)C(=O)N(C)C1CCCCN2C1=NC(=C(C2=O)O)C(=O)NCC3=CC=C(C=C3)F,CN(C)C(=O)C(=O)N(C)C1CCCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O
CHEMBL156339,WCERJEZPIONOJU-LHEXPUQLSA-N,MAGNOSALIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,85400.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,4.068542129310995,14055,10454589,CC1C(C(C1C2=CC(=C(C=C2OC)OC)OC)C3=CC(=C(C=C3OC)OC)OC)C,COc1cc(OC)c(C2C(C)C(C)C2c2cc(OC)c(OC)cc2OC)cc1OC
CHEMBL1923123,WCHSAUILSYDXQD-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,14058,57396097,C1CC1N(CC2=NC=CC3=CC=CC=C32)C(=O)C4CNCCC45C6=CC(=C(C=C6CO5)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1nccc2ccccc12)C1CC1
CHEMBL502778,WCIIYKWDVLHGIY-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.522878745280337,14059,135960727,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)COCCOC,COCCOCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCC(O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
CHEMBL2058909,WCLGDMOUQNNCRI-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321762,14061,62706820,CCN(C)C1=NC2=C(O1)C=C(C=C2)C(=O)N(CCN3CCOCC3)CC(C(CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)O,CCN(C)c1nc2ccc(C(=O)N(CCN3CCOCC3)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL3645215,WCLQUDCFQAVYPS-ACCUITESSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1580.0,NM,221146,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,5.801342913045578,14062,59443470,CCOC(=O)C=CC1=C(C=CC2=C1C=CC(=C2)C3=CC(=CC=C3)OC)OC,CCOC(=O)C=Cc1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12
CHEMBL2158890,WCUGLWYOYKWQOZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,6.823908740944319,14066,57576905,CN(CC1=CC=CS1)C(=O)CC23CC4CC(C2)CC(C4)C3,CN(Cc1cccs1)C(=O)CC12CC3CC(CC(C3)C1)C2
CHEMBL2387605,WCVGPCAQEVCGQB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.619788758288394,14067,71659751,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)C5=CN=CC=C5)Cl,O=c1[nH]c2cc(-c3cccnc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL377300,WCWUXEGQKLTGDX-LLVKDONJSA-N,BRIVANIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,14069,11234052,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)O)c(C)c34)ccc2[nH]1
CHEMBL377300,WCWUXEGQKLTGDX-LLVKDONJSA-N,BRIVANIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,4.7447274948966935,14069,11234052,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)O)c(C)c34)ccc2[nH]1
CHEMBL377300,WCWUXEGQKLTGDX-LLVKDONJSA-N,BRIVANIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,14069,11234052,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)O)c(C)c34)ccc2[nH]1
CHEMBL427202,WCWUXEGQKLTGDX-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570908.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP3A4,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,14070,11703421,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)O)c(C)c34)ccc2[nH]1
CHEMBL495995,WCYAHHRDZBUIGB-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14071,44583352,C1CC2(CCN(CC2)C(=O)NC3CC3C4=CC=CC=C4)OC5=CC=CC=C51,O=C(NC1CC1c1ccccc1)N1CCC2(CCc3ccccc3O2)CC1
CHEMBL478036,WDADGFYGRSIPGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14073,44579236,C1CC2=CC=CC=C2C(C3=CC=CC=C31)CNC(=O)CNC(=O)C4=CC=C(C=C4)F,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2CCc2ccccc21
CHEMBL401352,WDDRUCUWAOFJED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17937987.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,14076,44444647,CC1=CC(=CC(=C1)C2=C(C3=C(N2)SC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)CCN6CCN(CC6)CC(CN7CCN(CC7)C(=O)C)O)C,CC(=O)N1CCN(CC(O)CN2CCN(CCc3c(-c4cc(C)cc(C)c4)[nH]c4sc(C(C)(C)C(=O)N5C6CCC5CC6)cc34)CC2)CC1
CHEMBL26039,WDEYYJCTUQWQCT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.823908740944319,14080,11179994,CCOC(=O)CN1C2=C(C=C(C=C2)[N+](=O)[O-])C3=C1C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,CCOC(=O)Cn1c2ccc([N+](=O)[O-])cc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21
CHEMBL1818543,WDNOUFVJCUYSDQ-ZYMOGRSISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21550808.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.6020599913279625,14089,56659147,CC1=NN(C(=N1)C)CC23CC2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1nc(C)n(CC23CNCCC2(c2ccc(Cl)c(Cl)c2)C3)n1
CHEMBL204021,WDPFJWLDPVQCAJ-UHFFFAOYSA-N,DARAPLADIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,14093,9939609,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2
CHEMBL1099314,WDPFLACZLYWILA-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,14094,136086722,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)C(=O)OC(C)(C)C,Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3409870,WDQKCMWGNYOTEG-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,8800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.055517327849831,14097,89789751,COC1=C(C(=CC=C1)OC)C2CC(C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)F,COc1cccc(OC)c1C1CC(F)C(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL3527048,WDWIMDKOXZZYHH-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22645092.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5,,Drug Metab. Dispos.,PUBLICATION,,6.522878745280337,14101,71315139,CC1=CC=C(C=C1)C2=C(C=NN2C)C3=NN(C4=C3C(=NC=N4)N5CCC(C5)N6CCCCC6)C,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CCC(N6CCCCC6)C5)c34)cnn2C)cc1
CHEMBL3527048,WDWIMDKOXZZYHH-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22645092.0,IC50,=,690.0,NM,,,,,,,,,,,,,,,Reversible inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5,,Drug Metab. Dispos.,PUBLICATION,,6.161150909262744,14101,71315139,CC1=CC=C(C=C1)C2=C(C=NN2C)C3=NN(C4=C3C(=NC=N4)N5CCC(C5)N6CCCCC6)C,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CCC(N6CCCCC6)C5)c34)cnn2C)cc1
CHEMBL2159084,WECXXIXHKMZMPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Adamantyl carboxamides and acetamides as potent human 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.7447274948966935,14108,23583191,CN1C=CC=C1CN(C)C(=O)C23CC4CC(C2)CC(C4)C3,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2
CHEMBL2159084,WECXXIXHKMZMPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23040895.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Adamantyl carboxamides and acetamides as potent human 11��-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.721246399047171,14108,23583191,CN1C=CC=C1CN(C)C(=O)C23CC4CC(C2)CC(C4)C3,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2
CHEMBL2436206,WEHMXUQKHFVNFA-DZGIFAGBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.7447274948966935,14113,72711482,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)C(=O)C)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccc(C(C)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL2069842,WEOYJEAONRLZTP-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14117,70693036,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)C(F)(F)F,NC(CC(=O)N1CCN(C(=O)c2ccc(C(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL2448720,WERADNQQDSSVCI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1120.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.950781977329818,14119,73351201,C1CC1C(=O)N(CC2=CN=CC=C2)C3=CN=CC(=C3)C4=NC5=CC=CC=C5S4,O=C(C1CC1)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
CHEMBL10759,WESWMZAUSGJQRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.657577319177793,14121,10305047,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C(=C(C(=O)N=C3SCC4=CC=C(C=C4)F)C)C,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c(C)c1C
CHEMBL1951614,WFBDTIOQYJHWJC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,>=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14130,57397017,CC#CCN1C2=C(C(=C1N3CCCNCC3)C#N)N(C(=O)N(C2=O)CC4=C(C=NC5=CC=CC=C54)C#N)C,CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C
CHEMBL2177836,WFDHLKUQFQCHKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,14133,56965952,CC(=O)NC1=CC=CC(=C1)C2=NC3=C(C=C2)N=C(N3C4=CC=C(C=C4)CNC(=O)C5=CC(=CC=C5)F)C6=C(N=CC=C6)N,CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1
CHEMBL1079061,WFKBKGKEWUKRGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14141,42646202,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)(CCC(=O)O)C3=CC=C(C=C3)C4=CC=CC=C4,O=C(O)CCC1(c2ccc(-c3ccccc3)cc2)CCCN(C(=O)Nc2ccc(OC(F)(F)F)cc2)C1
CHEMBL3673950,WFKFRFWYVHBMNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320615,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,14142,52935600,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)F)F,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1
CHEMBL3673950,WFKFRFWYVHBMNZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320661,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,14142,52935600,COC1=NC=C(C=C1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)F)F,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1
CHEMBL2158228,WFLCXRISIXFCBZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.0,14143,11524843,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)CC(=O)N)NC(=O)C4=NC=C(N4)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CC(N)=O)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL2165512,WFNROQCVMLIPMS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.494850021680094,14148,49834039,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=CN=CC5=C4C=CN5)N6CCOCC6,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cncc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1
CHEMBL2163829,WFRXEZYSVYRRFE-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.0,14153,46847258,CN1CCN(CC1)C(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C4(CC4)C5=C(C=C(C=C5)Cl)Cl,CN1CCN(C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL283253,WFSCZQNQFUCKDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.0,14155,11488138,CC(C)OC1=NC=CC2=C1C3=C(N2C)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,CC(C)Oc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C
CHEMBL3422074,WGEHOPBYUQXTMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.0,14180,89509786,CN(C)CC(=O)N1CCC(CC1)OC2=CC=C(C=C2)C3=NNC4=C3C=C(C=C4)C(=O)NC(C5CC5)C6=CC=CC=C6,CN(C)CC(=O)N1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1
CHEMBL3403995,WGHJKYWWSVIRLL-JYFHCDHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25754490.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,14181,59271992,CC(C)N(CC1CNCC1OC(=O)NCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2OC(=O)NCc2ccccc2)C(C)C)ccc1OC
CHEMBL2059905,WGJMVERMPFJOTM-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22732695.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14187,21102224,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CSC4=CC=CC=C43)NC(=O)N5CCC6(CC5)C7=CC=CC=C7NC(=O)O6,O=C1Nc2ccccc2C2(CCN(C(=O)NC(Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)O1
CHEMBL1800774,WGKXETUOZHHSRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21644570.0,IC50,>,8900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 3A4,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,PUBLICATION,,5.050609993355088,14188,49856484,CC(C)(C(=O)N1CCN2C(=NC(=C2NC3=CC(=C(C=C3)F)F)C4=CC=C(C=C4)F)C1)N,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)c(F)c2)C1
CHEMBL495331,WGLILLWPZIBWTQ-UHFFFAOYSA-N,L-900525,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763751.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.",J. Med. Chem.,PUBLICATION,,4.301029995663981,14190,54712015,CC(C)(C1=NC(=C(C(=O)N1C)O)C(=O)NCC2=CC=C(C=C2)F)NC(=O)C(=O)N(C)C,CN(C)C(=O)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C
CHEMBL3358941,WGPUIGWWPPLBBA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.698970004336019,14191,118723176,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)S(=O)(=O)N,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(N)(=O)=O)c1
CHEMBL425819,WGPYWDLNUPWWNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,14192,135681730,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C(=NC)N,CN=C(N)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1
CHEMBL1222651,WGQSWRLDQGXUQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14193,49864903,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CCO)CC5=CC=NC=C5,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCO)c3ccccc32)CC1
CHEMBL517438,WGVPSTQRQHGEEP-QRWLVFNGSA-N,R-116010,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21428449.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,PUBLICATION,,4.958607314841775,14195,9870337,CC(C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=CN=C4)N(C)C,CC(C(c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C
CHEMBL517438,WGVPSTQRQHGEEP-QRWLVFNGSA-N,R-116010,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21838328.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26).",J. Med. Chem.,PUBLICATION,,6.455931955649724,14195,9870337,CC(C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=CN=C4)N(C)C,CC(C(c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C
CHEMBL1095040,WGVVIVGNBSSANI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20189807.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14196,22319604,CCCC(=O)NC1=NNC2=CC(=C(C=C21)C3=CC=CC=C3)Cl,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12
CHEMBL1916697,WGXIPXHUOIQNGL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958540.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of a biphenylacetic acid series of prostaglandin D(2) receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14198,56924869,COC1=C(C=C(C=C1)CC(=O)O)C2=C(C=C(C=C2)C(F)(F)F)CN(CC3=CC=CC=C3)C(=O)OC,COC(=O)N(Cc1ccccc1)Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC
CHEMBL2425618,WHGCVYRLVFZOSN-JUZXMZQFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,14206,72191344,CC(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(C(C)C)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL1081687,WHGLFZPJAYDODK-WMZHIEFXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19891474.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,14207,11751828,CC1=C(C=CC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC=C(C=C5)C(F)(F)F,Cc1ncccc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)n1C
CHEMBL495794,WHHQPBQWWSSETM-QUCCMNQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19481932.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14209,44583351,CS(=O)(=O)C1=CC2=C(C=C1)OC3(CCN(CC3)C(=O)NC4CC4C5=CC=CC=C5)CC2=O,CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)NC3CC3c3ccccc3)CC1)O2
CHEMBL1210614,WHOZDXFLKLSAJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14215,11996304,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)S(F)(F)(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C
CHEMBL1210614,WHOZDXFLKLSAJU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20573506.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14215,11996304,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=CC(=CC=C5)S(F)(F)(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C
CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,29200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.534617148551582,14216,2333,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
CHEMBL76,WHTVZRBIWZFKQO-UHFFFAOYSA-N,CHLOROQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,349945.17,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.455999996312085,14218,2719,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12
CHEMBL402279,WICCBBOVLJSUTQ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,14229,11577280,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)OC4CCNC4)NC5=C(C=C(C(=C5)C(=O)NC6CC6)F)F,CC(C)c1c(-c2nnc(OC3CCNC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL230080,WIFGAYBFSSWCPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17350839.0,IC50,=,35.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,14233,44425789,COC1=CC=CC(=C1)N2C(=O)C3(CCN(CC3)CC4=CC=C(C=C4)N5C=CN=C5)N(C2=O)CC6=CC=CC=C6F,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5ccnc5)cc4)CC3)C2=O)c1
CHEMBL1091793,WIKAXVDAJYMGCT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14236,46884119,CC(C1=NC(=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccc(F)n1)c1c(CCN(C)C)sc2ccccc12
CHEMBL2070949,WIKIUJMLESFHCO-HZPDHXFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,>,31622.78,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.499999953328896,14239,70276830,C1CCC(C(C1)C(=O)NC2(CC2)C#N)C(=O)N3CCN(CC3)C4=NC5=C(S4)N=CC=C5,N#CC1(NC(=O)C2CCCCC2C(=O)N2CCN(c3nc4cccnc4s3)CC2)CC1
CHEMBL3664674,WILRFGPGSCIZNX-CHJDUVSTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,43000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.366531544420414,14244,59635676,CC(C)N1C=CC(=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CC(c1ccc(-c2ccn(C(C)C)c(=O)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1949936,WIPFOPZHWMUVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,14250,57403779,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccncc3)c2c1
CHEMBL1949936,WIPFOPZHWMUVDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,14250,57403779,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CC=NC=C4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3ccncc3)c2c1
CHEMBL1078218,WIPOZGZUHPTZTR-ACHIHNKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,14251,46883437,CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CC=C2)CC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CC=C4,CCN(CC(Cc1ccccc1)NC(=O)OCc1cccnc1)CC(Cc1ccccc1)NC(=O)OCc1cccnc1
CHEMBL341089,WIUDTZXSQKGXHD-ZUHKWECKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,14252,10190433,C1CN(C(CN1CC2=CN(C=C2)C3=CC=CC=C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2ccn(-c3ccccc3)c2)CC1C(=O)NCC(F)(F)F
CHEMBL446083,WIUTZMQRXHUOSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,<,200000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,3.6989700043360187,14253,25180109,CN1C(=O)CCC2=C1C=CC(=C2)C3=CN=CC=C3,CN1C(=O)CCc2cc(-c3cccnc3)ccc21
CHEMBL1232887,WIXHEGLMUQGJCC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19772287.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,PUBLICATION,,4.0,14254,21914519,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC4CC4,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1
CHEMBL3311226,WJGQBRYSRQIYNV-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,54000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.267606240177032,14264,118707103,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)C(F)(F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1
CHEMBL3311224,WJGQBRYSRQIYNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,>,60000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.221848749616356,14265,53497481,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)C(F)(F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1
CHEMBL3311224,WJGQBRYSRQIYNV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,60000.0,NM,253315,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,4.221848749616356,14265,53497481,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)C(F)(F)F,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1
CHEMBL2070147,WJKJOKNERLASNI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,14269,70697153,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)C4=CC=CC=C4)F,CCS(=O)(=O)c1ccc2nc(-c3cc(-c4ccccc4)ccc3F)[nH]c2c1
CHEMBL3699328,WJLYZJUAZGDOJF-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6530.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.185086818724926,14271,89718407,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC(=CC=C8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC)c6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1951443,WJTBCUZNVGPRTM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,14274,57398809,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=CC=NC=C3,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccncc3)cc2)c1
CHEMBL1813067,WJUJICMNSMPLLG-PFEQFJNWSA-N,IRDABISANT HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21634396.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.",J. Med. Chem.,PUBLICATION,,4.522878745280337,14275,53363810,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3.Cl,CC1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
CHEMBL3702756,WJUKAGADXSWIEY-ACHIHNKUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2330.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.632644078973981,14276,89718343,CNN(C)C(=O)C1=CN(C2=C(C=CC=C12)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)NC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2048496,WKVPTVMGLXDFTB-OTBWLPETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,25700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.590066876668706,14292,11524511,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)C3CC(C(C(C3O)O)O)CO,CCc1ccc(Cc2cc(C3CC(CO)C(O)C(O)C3O)c(OC)cc2OC)cc1
CHEMBL2048496,WKVPTVMGLXDFTB-OTBWLPETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,40300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.394694953858891,14292,11524511,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)C3CC(C(C(C3O)O)O)CO,CCc1ccc(Cc2cc(C3CC(CO)C(O)C(O)C3O)c(OC)cc2OC)cc1
CHEMBL1631876,WLGXHFREMLNUDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,14298,11406781,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CN=CC=C4,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3cccnc3)c1)=N2
CHEMBL3261482,WLINCFBAKQHMPZ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14299,66898814,C1CN2CCC1C(C2)N3CCN4C5=C(C=C(C=C5C3=O)F)C=N4,O=C1c2cc(F)cc3cnn(c23)CCN1C1CN2CCC1CC2
CHEMBL2334756,WLQPHPRJRBGPBN-XWFZLUIHSA-N,6-AZA-PAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23473235.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR).",J. Med. Chem.,PUBLICATION,,5.0,14307,71604895,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C4CCC(C3)N4C5COC5)C(=N2)N6CCOCC6C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)C2CCC(C3)N2C2COC2)cc1
CHEMBL3264602,WLSFHVCGANYCRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,14308,90656800,CC(C)C(C1=CC=NC=C1)(C2=CC3=CC(=C(C=C3C=C2)OC)OC)O,COc1cc2ccc(C(O)(c3ccncc3)C(C)C)cc2cc1OC
CHEMBL1094852,WLXTZKAROJEVMI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,14310,46888828,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCOCC5,COc1ccc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)cc1
CHEMBL1834658,WMASPOZRAFIGIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.958607314841775,14312,56594864,CN1CCN(CC1)C2=CC=CC(=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl
CHEMBL1834658,WMASPOZRAFIGIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,14312,56594864,CN1CCN(CC1)C2=CC=CC(=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl
CHEMBL360072,WMGCLEIKLXKKON-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,357.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.447331783887807,14317,44390142,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)N(C)C)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3cccc(C(=O)N(C)C)c3)ccc2c1)n1ccnc1)N(C)C
CHEMBL3664665,WMGGVACWNSZZQE-RPLLCQBOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,5.096910013008056,14318,59635810,CCC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(CC)C4=CC=CC=C4,CCC(c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CCC(CC)(c2ccccc2)OC1=O
CHEMBL2315239,WMLLWXCYJMFXSU-LTJSBYPUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294255.0,IC50,>,22000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry,Development of new cyclic plasmin inhibitors with excellent potency and selectivity.,J. Med. Chem.,PUBLICATION,,4.657577319177793,14324,71720404,C1CN2CCN1CC(=O)NC3=CC=C(CC(C(=O)NC(CC4=CC=C(C=C4)NC(=O)C2)C(=O)NCC5=CC=C(C=C5)C(=N)N)NS(=O)(=O)CC6=CC=CC=C6)C=C3.C(=O)(C(F)(F)F)O,N=C(N)c1ccc(CNC(=O)C2Cc3ccc(cc3)NC(=O)CN3CCN(CC3)CC(=O)Nc3ccc(cc3)CC(NS(=O)(=O)Cc3ccccc3)C(=O)N2)cc1
CHEMBL252438,WMLNCGYLJNOXEB-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,14325,44447283,CC(C)(C)OC(=O)NC(CC1=CC(=CC=C1)Cl)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1cccc(Cl)c1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL3403820,WMMVSZKVXZQWAL-UZIYNMEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,14327,71288754,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(CC(C)(C)O)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403820,WMMVSZKVXZQWAL-UZIYNMEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,14327,71288754,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)CC(C)(C)O)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(CC(C)(C)O)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL192848,WMNVYPIDBPUURP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,5.795880017344075,14328,11326501,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC=N3)C4=CC=CC=C4)N=C1N,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc[nH]c3-c3ccccc3)cc21
CHEMBL3400440,WMOLSILQHXYKNV-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14331,59272204,CC(C)N(CC1CNCC1NC(=O)C2CCOCC2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)C2CCOCC2)C(C)C)ccc1OC
CHEMBL79236,WMTSGCIMPPZQLI-LZVMDTAVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12161148.0,IC50,,30.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,14338,493830,CC(C)(C1=CC2=C(O1)C=CN=C2)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,CC(C)(c1cc2cnccc2o1)N1CCN(CC(O)CC(Cc2ccccc2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL495290,WMURFNLBNNBFQO-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.376750709602099,14339,44568819,CC1CN(CCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4ON=C5NC6CC6)C)C(=O)C,CC(=O)N1CCN(c2nncc3cc(-c4c(C)ccc5c(NC6CC6)noc45)ccc23)C(C)C1
CHEMBL1800911,WMXJYEDCJIDCNY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21696951.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Indolin-2-one p38a inhibitors I: design, profiling and crystallographic binding mode.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14345,44251218,CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC4=C(C=C3)C5(CCCC5)C(=O)N4,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)NC(=O)C21CCCC1
CHEMBL1094349,WMYNTTGGSSIVHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20380377.0,IC50,>,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 fluorescence method,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,PUBLICATION,,5.1249387366083,14347,25192468,C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)OCCCCCCC4=C(C(=CC=C4)OCCCC(=O)O)CCC(=O)O)C5=CC=CC=C5F,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccc4c(c3)OCO4)cc(-c3ccccc3F)c2)c1CCC(=O)O
CHEMBL3436346,WNJHNFPCLVLFKX-LREBCSMRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,5.0,14355,71494647,CC1=NN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C.C(C(C(=O)O)O)(C(=O)O)O,COc1ccc(S(=O)(=O)n2nc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1
CHEMBL3115172,WNKJULKGXFIBJE-XRRFYDIFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,14358,67522993,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(COCC2=CC=CC=C2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(COCc2ccccc2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL207345,WNMJTTIGNYLSJY-VGSWGCGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,14360,44410881,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3(CCC3)C(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCC3(C(=O)O)CCC3)ccc2c1)n1ccnc1)N(C)C
CHEMBL249243,WNOWXHZXFDFPBC-IWQLRFKPSA-N,EPI-FIBRAURETINOSIDE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,14362,24762503,CC12CC(OC(=O)C1(CC3C4(C2CC=CC4(C(=O)O3)OC5C(C(C(C(O5)CO)O)O)O)C)O)C6=COC=C6,CC12CC(c3ccoc3)OC(=O)C1(O)CC1OC(=O)C3(OC4OC(CO)C(O)C(O)C4O)C=CCC2C13C
CHEMBL400494,WNOWXHZXFDFPBC-WEYSNVRMSA-N,FIBRAURETINOSIDE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,14363,24762502,CC12CC(OC(=O)C1(CC3C4(C2CC=CC4(C(=O)O3)OC5C(C(C(C(O5)CO)O)O)O)C)O)C6=COC=C6,CC12CC(c3ccoc3)OC(=O)C1(O)CC1OC(=O)C3(OC4OC(CO)C(O)C(O)C4O)C=CCC2C13C
CHEMBL2418946,WNYMKNYCLRXAIM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23820386.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,14371,59251838,CC(=O)NC1=NC2=C(S1)C=C(C=C2)C3=CN=C(C=C3)N,CC(=O)Nc1nc2ccc(-c3ccc(N)nc3)cc2s1
CHEMBL3318469,WOBNNXBIQRYYDO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,14373,91668260,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=C(C=CC=C3Cl)Cl,O=C1CC(c2c(Cl)cccc2Cl)CC(O)=C1Sc1ccccc1Cl
CHEMBL398160,WOCKQPIYHQRKEQ-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17722903.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,PUBLICATION,,4.698970004336019,14376,23626439,C1C(OC(=O)N1C2=CC(=C(C=C2)C3=CN=C(C=C3)CO)F)CN4C=CN=N4,O=C1OC(Cn2ccnn2)CN1c1ccc(-c2ccc(CO)nc2)c(F)c1
CHEMBL1079256,WODRVGVVTPASNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14378,42646199,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=C3,O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL1079256,WODRVGVVTPASNM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,14378,42646199,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCC(=O)O)C3=CC=CC=C3,O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL2041170,WOFLYJYTODVGLV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,14379,49849233,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CC=C(C=C6)N7CCOCC7,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(N4CCOCC4)cc3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL3104477,WOGNYOHGZLVUOP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.698970004336019,14383,76324752,CS(=O)(=O)C1=CC=C(C=C1)N2CCC(CC2)N(C3=CC=C(C=C3)Cl)C4=CN=CC=C4,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1
CHEMBL218547,WOIDDZSLDVWACJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,5.0,14384,10131619,C1CN(CCC1CNC2=NC=CS2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2nccs2)CC1
CHEMBL3686863,WOJKYHBOHSQZDW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27020304.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14387,72695136,CC1=C(N=C(C=C1)N2CCC(CC2)O)C(=O)NC3=C(C=C(C=C3C)C(=O)O)C,Cc1ccc(N2CCC(O)CC2)nc1C(=O)Nc1c(C)cc(C(=O)O)cc1C
CHEMBL1951328,WOLVVZYIMHOLRF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,61.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.214670164989233,14391,57393587,C1=CC(=CC(=C1)[N+](=O)[O-])NC(=O)NC2=CC=C(C=C2)C3=C4C(=NC=C3)N=CN4,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc([N+](=O)[O-])c1
CHEMBL453587,WOLXSMOIVRMEIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,14392,44561239,CN(C(CN1CCCC1)C2=CC=C(C=C2)C3=CC(=CC=C3)C(=O)N)C(=O)CN(CC#N)C4=CC(=C(C=C4)Cl)Cl,CN(C(=O)CN(CC#N)c1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1
CHEMBL2064346,WOQUVNKDDWFSGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,14394,57523210,C1COCCN1C2=CC(=O)N=C(N2)CC3=NC4=C(C=CC=C4N3)C5=CC=CC=C5,O=c1cc(N2CCOCC2)[nH]c(Cc2nc3c(-c4ccccc4)cccc3[nH]2)n1
CHEMBL400431,WPAPODFGOZXFLG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,14399,6914629,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCOC)(C)C,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(C)O2
CHEMBL1096103,WPASHFXVTJYQPC-LBEKAKSKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,14400,46888898,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=C(N=CC=C5)C,Cc1cc(OCP2(=O)OCCC(c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2
CHEMBL1096105,WPASHFXVTJYQPC-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,14401,46861803,CC1=CC(=C2C(=C1C)CC3=C2N=CS3)OCP4(=O)OCCC(O4)C5=C(N=CC=C5)C,Cc1cc(OCP2(=O)OCCC(c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2
CHEMBL541483,WPBLHQJDLOPHGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19524437.0,IC50,>,41000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3872161432802645,14404,44249906,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)C=C(C=C3)C(=O)N4CCOCC4,CC(C)N1CCC(Oc2ccc3cc(C(=O)N4CCOCC4)ccc3c2)CC1
CHEMBL3237564,WPELTQURDISYSR-GXTWGEPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,4.301029995663981,14409,71626971,C1CCC(C(C1)N)NC2=NN=C(C(=C2)NC3=NC4=C(CCC4)C=C3)C(=O)N,NC(=O)c1nnc(NC2CCCCC2N)cc1Nc1ccc2c(n1)CCC2
CHEMBL1980297,WPHKIQPVPYJNAX-UHFFFAOYSA-N,ILORASERTIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22465635.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14413,46207586,C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
CHEMBL1980297,WPHKIQPVPYJNAX-UHFFFAOYSA-N,ILORASERTIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibtion Assay. Assays (200 ��L final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37�� C. incubator. Pooled human liver microsomes (BD Gentest, 50 ��g/mL) were incubated with 5 concentrations of test compound (from 0.1 ��M to 10 ��M), 1 mM NADPH (Sigma), and 2 ��M midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.","Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile",,PATENT,,5.0,14413,46207586,C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
CHEMBL3358922,WPHQTOKGVMHYCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.698970004336019,14414,60026481,CC1=C(C=C(C=C1)F)C(C)(C)CC(CC2=CC3=C(N2)C=NC=C3C)(C(F)(F)F)O,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cncc2[nH]1)C(F)(F)F
CHEMBL442398,WPQGTFWRUQZWSD-XREYCITQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,9934466.0,IC50,=,120000.0,NM,,,,,,,,,,,,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.9208187539523753,14422,471507,CC1=NC(=CS1)COC(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)C(CN3CCN(CC3C(=O)NC(C)(C)C)CC4=CC(=C(C=C4)OC)OC)O,COc1ccc(CN2CCN(CC(O)C(Cc3ccccc3)NC(=O)C(NC(=O)OCc3csc(C)n3)C(C)C)C(C(=O)NC(C)(C)C)C2)cc1OC
CHEMBL3582481,WPQXLUHKXSHBCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,=,8235.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.084336396494227,14423,56645571,CC1=C(C=NC=C1C2=NC3=CC(=C(C=C3N2C4CC4)F)F)F,Cc1c(F)cncc1-c1nc2cc(F)c(F)cc2n1C1CC1
CHEMBL3401541,WPSURGXSNWIBBJ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,4400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513812,14426,59272004,CC(C)N(CC1CNCC1NS(=O)(=O)CC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC
CHEMBL3401541,WPSURGXSNWIBBJ-BJKOFHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14426,59272004,CC(C)N(CC1CNCC1NS(=O)(=O)CC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC
CHEMBL2017104,WPTSXGNZZOZOLL-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,45000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.346787486224656,14428,58083358,CC(=O)NCCC1=C(C=CC(=C1)F)C2=C(C(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)O)Br,CC(=O)NCCc1cc(F)ccc1-c1onc(C2CNCCC2(O)c2ccc(F)c(F)c2)c1Br
CHEMBL3409875,WPUHSUHTXPVKAB-MUMRKEEXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,46000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.337242168318426,14431,118731957,COC1=C(C(=CC=C1)F)C2CC(C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,COc1cccc(F)c1C1CC(O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL3409876,WPUHSUHTXPVKAB-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14432,89789762,COC1=C(C(=CC=C1)F)C2CC(C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,COc1cccc(F)c1C1CC(O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL3409876,WPUHSUHTXPVKAB-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14432,89789762,COC1=C(C(=CC=C1)F)C2CC(C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)O,COc1cccc(F)c1C1CC(O)C(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL1170725,WPZKKCHLDQPKDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,19498.45,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.709999910852971,14436,49798461,CC1=C(C=CC=N1)OC2=C(C=C(C=N2)Cl)NS(=O)(=O)C3=CC(=C(C=C3)Cl)Cl,Cc1ncccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1
CHEMBL2181522,WQBAZXIQANTUOY-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,900.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.045757490560675,14438,59239114,CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=CC=N4)C(=N2)N5CCOCC5C,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(c2ncccn2)C3)cc1
CHEMBL3260741,WQCVKQKJPUHDNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,5.167491087293763,14441,72793033,CC1=C(C=CC(=N1)C(F)(F)F)CN2C(=O)C(=C(C3=NN(C(=O)N32)C)C4=CC=C(C=C4)Cl)C5=CC=NC=C5,Cc1nc(C(F)(F)F)ccc1Cn1c(=O)c(-c2ccncc2)c(-c2ccc(Cl)cc2)c2nn(C)c(=O)n21
CHEMBL1271246,WQGSTVFPWRFZTI-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,14444,25127621,CN1C(=O)C(N=C1N)(C2=CC=C(C=C2)OC(F)F)C3=CC=CC(=C3)C#CC4CC4,CN1C(=O)C(c2ccc(OC(F)F)cc2)(c2cccc(C#CC3CC3)c2)N=C1N
CHEMBL481659,WQKGOLGYPXZSSX-QFIPXVFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18539454.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.207608310501746,14446,24988956,C1CCC2(CC1)C(=C(C2=O)Br)NC(CC3=CC=C(C=C3)N4C5=C(C=CC=N5)N=C4C6=CN=CC=C6)C(=O)O,O=C(O)C(Cc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2
CHEMBL3702705,WQKONMWIFWSSSD-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6090.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.215382707367125,14447,89718201,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCN(CC7)CCN8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCOCC6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2181765,WQNYJRIRCUZJJO-NTEUORMPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.036212172654444,14449,71461095,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=COC=C5)C6CCCC6,Cn1c(-c2ccoc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(C=CC(=O)O)cc4)CCC3)cc21
CHEMBL1095510,WQOMZYPBVOXQJY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,14450,46888854,CCOCCN1C2=CC=CC=C2N=C1C3CCCN(C3)C4CCOCC4,CCOCCn1c(C2CCCN(C3CCOCC3)C2)nc2ccccc21
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,5.568636235841013,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,5.5376020021010435,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,5.2839966563652006,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,5700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,5.2441251443275085,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,5.154901959985743,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,5.096910013008056,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,8300.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,5.080921907623926,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,9200.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,5.036212172654444,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.698970004336019,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.6777807052660805,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.657577319177793,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.6020599913279625,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.585026652029182,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,,Drug Metab. Dispos.,PUBLICATION,,4.568636235841013,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL397983,WQTKNBPCJKRYPA-OAQYLSRUSA-N,AMG-487,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22517972.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,14453,24957182,CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F,CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1
CHEMBL1271991,WQUXILRTVPBVCS-HNYUPJOQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,14456,52946733,CCNC(=O)N1C2CCC1CN(C2)C(=O)OC3(CC3)C4COCC(N4S(=O)(=O)C5=CC=C(C=C5)Cl)CC6CC6,CCNC(=O)N1C2CCC1CN(C(=O)OC1(C3COCC(CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2
CHEMBL151449,WQYJPEHBLXPHHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,14457,11160258,CCCCOC1=CC=CC(=C1)C2=CC=NO2,CCCCOc1cccc(-c2ccno2)c1
CHEMBL2386558,WRBFPGYDKJBYBI-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14461,46909057,CN1C=NC(=C1SC2=NC=C(C=C2)Cl)C3=CC=C(C=C3)C4CC4C(=O)N(C)C,CN(C)C(=O)C1CC1c1ccc(-c2ncn(C)c2Sc2ccc(Cl)cn2)cc1
CHEMBL1951348,WRCCQNZGVMRARX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,14462,57395302,CC(C)NC(=O)C1=CC(=CC=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CNC4=NC=N3)Cl,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(Cl)c34)cc2)c1
CHEMBL576138,WRRGABWWSIAMMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19902954.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.,J. Med. Chem.,PUBLICATION,,5.899998417198648,14470,44605617,CC1=C(C=C(C=C1)N(C)C(=O)C2=C(ON=C2C3=CC=CC=C3Cl)C)Cl,Cc1ccc(N(C)C(=O)c2c(-c3ccccc3Cl)noc2C)cc1Cl
CHEMBL3259868,WRXRPPQRURPMPT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,81000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0915149811213505,14475,90656807,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C3=CC=CS3)(C4=NNN=C4)O,CC(C)C(O)(c1ccc2cc(-c3cccs3)ccc2c1)c1cn[nH]n1
CHEMBL401960,WRYKATOCEQATEA-UEVCKROQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18032036.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of GSK221149A: a potent and selective oxytocin antagonist.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,14477,11421025,CC(C)CC1C(=O)NC(C(=O)N1C(C2=CC=C(O2)C(F)(F)F)C(=O)NC(C)C)C3CC4=CC=CC=C4C3,CC(C)CC1C(=O)NC(C2Cc3ccccc3C2)C(=O)N1C(C(=O)NC(C)C)c1ccc(C(F)(F)F)o1
CHEMBL1269681,WSBCYTMHZZVDOP-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,14480,12001786,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNCC(F)F)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL1269681,WSBCYTMHZZVDOP-IZLXSDGUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,14480,12001786,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CNCC(F)F)Cl)C5CC5)Cl,Cc1cc(Cl)c(OCCOc2ccc(C3CCNCC3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1
CHEMBL3319549,WSCXEOSPTMGMGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25001129.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket.,J. Med. Chem.,PUBLICATION,,4.568636235841013,14483,73332001,C1CN(CCN1C2=C(C=C(C=N2)C(C(F)(F)F)(C(F)(F)F)O)C3=CN=CC=C3)S(=O)(=O)C4=CN=C(C=C4)N,Nc1ccc(S(=O)(=O)N2CCN(c3ncc(C(O)(C(F)(F)F)C(F)(F)F)cc3-c3cccnc3)CC2)cn1
CHEMBL502335,WSFARKDYYPRFAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,3110.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.507239610973163,14486,44589825,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC4=CC=CC=C4C=C3,COc1ccc2nc(SCc3ccc4ccccc4c3)[nH]c2c1
CHEMBL2336412,WSIDSJAOLGDFPK-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,14488,11354531,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL2336412,WSIDSJAOLGDFPK-GDLZYMKVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,14488,11354531,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3Br)NC(=O)O4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,O=C(NC(Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
CHEMBL168471,WSJWUIDLGZAXID-ZBFHGGJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12593666.0,IC50,=,81000.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 as BFC substrate,Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.,J. Med. Chem.,PUBLICATION,,4.0915149811213505,14492,10861643,CC(C)CC(C=O)NC(=O)C(C(C)C)NS(=O)(=O)C1=CC=C(C=C1)F,CC(C)CC(C=O)NC(=O)C(NS(=O)(=O)c1ccc(F)cc1)C(C)C
CHEMBL168471,WSJWUIDLGZAXID-ZBFHGGJFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12593666.0,IC50,=,531000.0,NM,,,,,,,,,,,,,,,Inhibition of Cytochrome P450 3A4 as BQ substrate,Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.,J. Med. Chem.,PUBLICATION,,3.274905478918531,14492,10861643,CC(C)CC(C=O)NC(=O)C(C(C)C)NS(=O)(=O)C1=CC=C(C=C1)F,CC(C)CC(C=O)NC(=O)C(NS(=O)(=O)c1ccc(F)cc1)C(C)C
CHEMBL2070148,WSLDJBIBBVFJHZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.251811972993799,14495,70682528,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=C(C=C3)F)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3ccc(F)c(-c4ccccc4)c3)[nH]c2c1
CHEMBL1923117,WSNYMUSQZWXVNZ-YKSBVNFPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,14497,57396096,CC1=C(C=CC=C1C(F)(F)F)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,Cc1c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)cccc1C(F)(F)F
CHEMBL2070151,WSRNACDNBXDTGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,14500,70695120,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=C(C=C3)Cl)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3ccc(Cl)c(-c4ccccc4)c3)[nH]c2c1
CHEMBL209244,WSTSJUHYFOKDQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16503138.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 3A4,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,14503,11464169,C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=C(C=CN=C3)C4=CC(=CC=C4)C(=O)O,O=C(O)c1cccc(-c2ccncc2-c2cc(Cl)ccc2OCc2ccccc2)c1
CHEMBL1934810,WTAIERVWPQNXDM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.619788758288394,14507,56834936,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=CC(=C4)Br)Cl,O=c1[nH]c2cc(Br)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL1089202,WTCGMGACKXOKHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,14508,46884865,C1CC2(C(CC1=O)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,O=C1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1
CHEMBL225465,WTDJZXIANMNOOX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,4.0,14511,16719649,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)F,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2F)nc1C(F)(F)F
CHEMBL1837041,WTDORPHQLSCAEW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21885275.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14512,10456892,CS(=O)(=O)N1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1,CS(=O)(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1
CHEMBL3702774,WTHIVYAJBCYSSM-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.995678626217358,14517,89718359,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)OCCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCN(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL178681,WTPRWIIKNCIYOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,77500.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.110698297493689,14526,44388657,C1=CC(=CN=C1)C2=CC=C(S2)CN.C1=CC(=CN=C1)C2=CC=C(S2)C=N.C1=CC(=CN=C1)C2=CC=C(S2)C=N,NCc1ccc(-c2cccnc2)s1
CHEMBL468672,WTQDFMWCMKSXGH-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,28000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.552841968657781,14527,135875710,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5CCN(CC5)CCCF,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL411118,WTRWFOXPPRLKFP-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.585026652029182,14528,9983904,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,COc1ccc(N2C(=O)C(Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)C2C(=O)O)cc1
CHEMBL411118,WTRWFOXPPRLKFP-BDYUSTAISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,14528,9983904,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(N(C4=O)C5=CC=C(C=C5)OC)C(=O)O,COc1ccc(N2C(=O)C(Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)C2C(=O)O)cc1
CHEMBL1089525,WTXUIYHQKGABGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20236824.0,IC50,=,9100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 30 mins,Design and synthesis of tricyclic sulfones as gamma-secretase inhibitors with greatly reduced Notch toxicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040958607678906,14531,46884866,C1CC2(C(CC1O)COC3=C(C=CC(=C32)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl,O=S(=O)(c1ccc(Cl)cc1)C12CCC(O)CC1COc1c(F)ccc(F)c12
CHEMBL429743,WUBFAXNVDMCVIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,4.301029995663981,14539,24757938,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=C(C=C5)Cl,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3)c2cc1OC
CHEMBL2418948,WUEXEUOEWYMTKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23820386.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,14544,59251852,CC(=O)NC1=NC2=C(S1)C=C(C=C2)C3=CC(=C(N=C3)N)C(F)(F)F,CC(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1
CHEMBL2178253,WUGATYAZBCNSNU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.142667503568732,14545,66851197,C1=CC(=CC(=C1)Cl)C2=C(C=NN2)NC(=O)C3=C4N=CC=CN4N=C3,O=C(Nc1cn[nH]c1-c1cccc(Cl)c1)c1cnn2cccnc12
CHEMBL1808624,WUGRYAJUCLYESW-VQHVLOKHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21742496.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14547,56673467,C1C2=C(CN1C(=O)CC3=CC=CC=C3)C=C(C=C2)C=CC(=O)NO,O=C(C=Cc1ccc2c(c1)CN(C(=O)Cc1ccccc1)C2)NO
CHEMBL334379,WUIIVYZPUDLMGE-OTTPZFKLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14592500.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,In vitro inhibition of Cytochrome P450 3A4,Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,14548,15954476,C1CN(C(CN1CC2=CN(C=C2)C3=C(C(=C(C=C3)F)F)F)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(Cc2ccn(-c3ccc(F)c(F)c3F)c2)CC1C(=O)NCC(F)(F)F
CHEMBL3699334,WUQQGTBJNNXQJA-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3410.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.467245621007502,14553,89718418,CC(C)(C)NNC(=O)C1=CC=C(C=C1)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NNC(C)(C)C)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL520897,WURBVZBTWMNKQT-UHFFFAOYSA-N,TRIADIMEFON,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,9289.66,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.032000180820781,14555,39385,CC(C)(C)C(=O)C(N1C=NC=N1)OC2=CC=C(C=C2)Cl,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1cncn1
CHEMBL229176,WUSUIPCZTUWOIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17500511.0,IC50,>,22000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.,J. Med. Chem.,PUBLICATION,,4.657577319177793,14557,16747701,CCC(C)COC1=CC=C(C=C1)C(CC(=O)O)C2=CC=CC=C2,CCC(C)COc1ccc(C(CC(=O)O)c2ccccc2)cc1
CHEMBL2441842,WVAJNEZWLOLVEH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,14561,15950461,CC1=C(C(=C2C(=N1)CNC2=O)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)NC2
CHEMBL376722,WVBVFBWFVVPNPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15566305.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.",J. Med. Chem.,PUBLICATION,,4.0,14562,5329336,CC1=C(C=CN=C1NC2=NC=C(S2)C#N)CN3CCN(CC3)C(=O)NC,CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2C)CC1
CHEMBL3673939,WVCIKWIWVGCIOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320650,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,14564,67200672,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1
CHEMBL3673939,WVCIKWIWVGCIOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320694,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,14564,67200672,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=CC(=NC=C4)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1
CHEMBL271202,WVDKULPCDHAQIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18307292.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents.,J. Med. Chem.,PUBLICATION,,4.886056647693163,14566,24768413,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CN3CCN(CC3)C)C4=NC=CS4)C,Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1
CHEMBL271202,WVDKULPCDHAQIA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24164628.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Adenosine A2A receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,4.886056647693163,14566,24768413,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CN3CCN(CC3)C)C4=NC=CS4)C,Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1
CHEMBL2251445,WVQBLGZPHOPPFO-LBPRGKRZSA-N,S-METOLACHLOR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,14574,11140605,CCC1=CC=CC(=C1N(C(C)COC)C(=O)CCl)C,CCc1cccc(C)c1N(C(=O)CCl)C(C)COC
CHEMBL2177831,WVQVQQXBOHNXQR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22533986.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins,"Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,14576,58345029,C1=CC=C(C=C1)C(=O)NCC2=CC=C(C=C2)N3C4=C(C=C(C=N4)C5=CN=CC=C5)N=C3C6=C(N=CC=C6)N,Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1
CHEMBL3215850,WVTAOBVWAHTAMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21823597.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 by luceferin-based assay,Design and synthesis of novel Arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,PUBLICATION,,4.698970004336019,14579,90664452,CC1=C(C=CC=C1Cl)N2CCN(CC2)CCCNC(=O)C3=C(N(C(=N3)C4=CC=CC=C4)C5=CC=CC=C5)CN6C=NC=N6.Cl.Cl.Cl,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1
CHEMBL1915563,WVWJNRQKNPFRGF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21924610.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminothiazoles as ��-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,14585,57397434,COC1=C(C=C(C=C1)Br)C2=CSC(=N2)NC3=CC=C(C=C3)N4C=CN=C4,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)cc2)n1
CHEMBL596583,WVXVZSIOYIMDMF-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.200659450546418,14588,46226417,CC1=C2C(=NN1)N=CC(=N2)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=C(OC=C6)C,Cc1occc1-c1ncc(OCC(N)Cc2c[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
CHEMBL505033,WWIQHIRTDVHNNM-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18667310.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.086186147616283,14601,11262242,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)N)C4=C(C(=CC=C4)OCCCCCC(=O)O)F,Cc1c(-c2cccc(OCCCCCC(=O)O)c2F)c(=O)n(CC(N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F
CHEMBL3604717,WWQZYHBACWHPRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,5.40000018605658,14603,122185958,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C(=CC=C3)Cl)Cl,Cc1cc(NCc2cccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1
CHEMBL3628591,WWSWXUCLNZWXKO-IZCXSWDTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,14604,122193588,CC(C)C(C)(C1=CN(N=N1)C(CCS(=O)(=O)C)C(=O)COC2=C(C(=CC(=C2F)F)F)F)NCC3=CC4=C(C=C3)N=CC=C4,CC(C)C(C)(NCc1ccc2ncccc2c1)c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1
CHEMBL478902,WWYOUXCBBIIJAP-AQTBWJFISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,4.0,14609,42629368,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(C(=CC(=O)O)C4=CC=CC=C43)(F)F)Cl,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)C(=CC(=O)O)c4ccccc43)c(Cl)c2)n1
CHEMBL2036208,WXCYUCDZYGCZKX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,14614,49872771,CCC(=O)N(CC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC(=C2)C3=NNN=N3,CCC(=O)N(Cc1cccc(C(F)(F)F)c1)c1cccc(-c2nn[nH]n2)c1
CHEMBL488400,WXFIODYGMHZQAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,720.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,6.142667503568732,14618,44589824,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC(=CC(=C3)OC)OC,COc1cc(CSc2nc3ccc(OC)cc3[nH]2)cc(OC)c1
CHEMBL2163838,WXGCKASPTGCGFN-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,1530.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,5.815308569182402,14619,57522131,CN(C)CCN(C)C(=O)C(CC1=C(C=C(C=C1)Cl)Cl)NC(=O)C2(CC2)C3=C(C=C(C=C3)Cl)Cl,CN(C)CCN(C)C(=O)C(Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1
CHEMBL3702749,WXJJFQFWJXJCNS-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.107905397309519,14622,89718472,CN1CCN(CC1)CCN(C)C(=O)C2=CN(C3=C(C=CC=C23)CN4CC5N(C(C4=O)CC6=CC=C(C=C6)O)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCN(C)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL450471,WXJLFSUTNCMCGA-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,15848.93,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.800000052738446,14623,11467552,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=CC=C4Cl)NCCCC(=O)O,O=C(O)CCCNC(Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL450471,WXJLFSUTNCMCGA-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,14623,11467552,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=CC=C4Cl)NCCCC(=O)O,O=C(O)CCCNC(Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL2436623,WXNHTAGZWUGZCQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24035485.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14626,44622338,C1CC2=CC=CC=C2CN(C1)C3CCN(CC3)C(=O)C4(CCN(CC4)CC5=CC(=NC=C5)N)F,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCCc5ccccc5C4)CC3)CC2)ccn1
CHEMBL3422005,WXTKQYNUESPTFK-SNVBAGLBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,63000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.200659450546418,14633,86274362,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=CSC(=N4)C,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3C)cs1
CHEMBL1258517,WXUUCRLKXQMWRY-UHFFFAOYSA-N,PKI-179,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20797855.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14637,46947264,C1CC2COCC1N2C3=NC(=NC(=N3)N4CCOCC4)C5=CC=C(C=C5)NC(=O)NC6=CC=NC=C6,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1
CHEMBL371613,WXUZGCQTOVWUDO-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,14638,44400261,CS(=O)(=O)C1=CC=CC(=C1CN2C=C(C(=O)N(C2=O)CC(C3=CC=CC=C3)N)C4=CC=CC=C4Cl)F,CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(CC(N)c2ccccc2)c1=O
CHEMBL3104534,WXWZTJHZVPXAHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.7447274948966935,14640,76335564,CC1=CC=CC=C1CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3104534,WXWZTJHZVPXAHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,18000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.7447274948966935,14640,76335564,CC1=CC=CC=C1CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3104534,WXWZTJHZVPXAHK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,14640,76335564,CC1=CC=CC=C1CN2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL3702806,WYJMFZPMALWDGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2370.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.6252516539898965,14653,89718289,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCC(CC8)N9CCCCC9,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1911194,WYJRHMPICZARGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21958544.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Indolin-2-one p38a inhibitors III: Bioisosteric amide replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14654,57397383,CC1=C(C=C(C=C1)C2=NNC(=N2)C)C3=CC4=C(C=C3)C5(CCOCC5)C(=O)N4,Cc1nc(-c2ccc(C)c(-c3ccc4c(c3)NC(=O)C43CCOCC3)c2)n[nH]1
CHEMBL2170630,WYKRFGYHTDMMFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.657577319177793,14655,58269609,C1CN(CCC1C2=C(C=C(C=C2)C(=O)N=C(N)N)C(F)(F)F)C(=O)C3=CC=CC(=C3)C#N,N#Cc1cccc(C(=O)N2CCC(c3ccc(C(=O)N=C(N)N)cc3C(F)(F)F)CC2)c1
CHEMBL2070157,WYLTXXROXQGYPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.060480747381382,14656,70697155,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=NC=C3)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3ccnc(-c4ccccc4)c3)[nH]c2c1
CHEMBL150614,WYMUHCAWPDYRJQ-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,14658,10415353,CCN1C2=C(C=C(C=C2)NC(=O)CN3CCN(CC3)CC(COC4=CC5=C(C=C4)SC(=N5)C)O)C6=CC=CC=C61,CCn1c2ccccc2c2cc(NC(=O)CN3CCN(CC(O)COc4ccc5sc(C)nc5c4)CC3)ccc21
CHEMBL2048204,WYTXJLWGOIYXTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,14663,11670392,COC1=C(C=C(C=C1)C(=O)N2CCC3=CC=CC=C32)CSC4=NC5=C(N4CC(=O)O)C=CC(=C5)F,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
CHEMBL2048204,WYTXJLWGOIYXTG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,14663,11670392,COC1=C(C=C(C=C1)C(=O)N2CCC3=CC=CC=C32)CSC4=NC5=C(N4CC(=O)O)C=CC(=C5)F,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
CHEMBL2036210,WZEGCAWKLRVSGX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,14672,49843520,CCC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
CHEMBL3422016,WZHKQWSHHGMARO-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.958607314841775,14676,71549637,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=NC(=CS5)C,Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1
CHEMBL2336421,WZSCJOMKGFGYAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.346787486224656,14681,10416713,CCC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL2336421,WZSCJOMKGFGYAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23402880.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14681,10416713,CCC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=CC=CC=C7NC6=O,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12
CHEMBL3137452,XAACDTNCWKPUDH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1700.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.769551078621726,14687,76311344,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=CS4,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1
CHEMBL597127,XAAZBMINIBYRPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,14690,25057408,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCCNC3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC
CHEMBL597127,XAAZBMINIBYRPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.522878745280337,14690,25057408,COC1=C(C=C(C=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NCCC3CCCNC3)OC,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC
CHEMBL3393483,XACWBNSEGIFUIV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25369539.0,IC50,=,80.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,"SAR156497, an exquisitely selective inhibitor of aurora kinases.",J. Med. Chem.,PUBLICATION,,7.096910013008056,14693,118725522,CCOC(=O)C1=C2C(=CN1)C(C3=C(N2)CCCC3=O)C4=CC=C(O4)SC5=NC6=C(C=CC=C6N5)N,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(N)cccc3[nH]2)o1
CHEMBL1208960,XAEATFZFGRMBDN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,14694,49862092,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCOCC6)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL1208960,XAEATFZFGRMBDN-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,14694,49862092,CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=CC(=C4)C5=CC(=NC=C5)N6CCOCC6)C(=O)N,CC(Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F
CHEMBL2152525,XAMJZICIEQIVJK-FGZHOGPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,4.900000142057633,14701,71453071,C1CCN(C1)C(C2=CC=CC=C2)C(C3=CC=CC=C3)N4CCCC4,c1ccc(C(C(c2ccccc2)N2CCCC2)N2CCCC2)cc1
CHEMBL2152524,XAMJZICIEQIVJK-VXKWHMMOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12589.25,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli,,ACS Med. Chem. Lett.,PUBLICATION,,4.900000142057633,14702,71419478,C1CCN(C1)C(C2=CC=CC=C2)C(C3=CC=CC=C3)N4CCCC4,c1ccc(C(C(c2ccccc2)N2CCCC2)N2CCCC2)cc1
CHEMBL3125395,XAMUUSXIEMJRLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14703,76325446,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC=C2Br,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
CHEMBL3125395,XAMUUSXIEMJRLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,14703,76325446,CC1CC2=C(N1C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N)C=CC=C2Br,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O
CHEMBL1257567,XAPFGEPPWZRGFN-UHFFFAOYSA-N,DIETHOXYFLOURESCEIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20839775.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,6.0,14705,161373,CCOC1=CC2=C(C=C1)C3(C4=C(O2)C=C(C=C4)OCC)C5=CC=CC=C5C(=O)O3,CCOc1ccc2c(c1)Oc1cc(OCC)ccc1C21OC(=O)c2ccccc21
CHEMBL1907089,XAPVAKKLQGLNOY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23445448.0,IC50,=,17600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells.",J. Med. Chem.,PUBLICATION,,4.7544873321858505,14707,53393916,C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC(=C(C=C4)F)F,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1
CHEMBL1615150,XAVJTYOBWCSWFJ-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14709,49837867,CC1=C(C=CC(=C1)C(=O)O)NC(=O)C(C2CCCCC2)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,Cc1cc(C(=O)O)ccc1NC(=O)C(C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
CHEMBL1784357,XAXGZPUPBCYAIE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21536437.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14712,20725561,C1COCCC1(CS(=O)(=O)N2CCN(CC2)C3=CC=C(C=C3)F)N(C=O)O,O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCOCC1
CHEMBL2069840,XAXKWKHCLDUGSC-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22850208.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Dipeptidyl peptidase-4 inhibitor with ��-amino amide scaffold: synthesis, SAR and biological evaluation.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14713,70684569,C1CN(CCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N)C(=O)C3=CC=C(C=C3)O,NC(CC(=O)N1CCN(C(=O)c2ccc(O)cc2)CC1)Cc1cc(F)c(F)cc1F
CHEMBL404621,XBAKWGXDYRBWJH-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14716,44447281,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1Cl)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL3664685,XBFPHNXOOORGNO-YYONYHEJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,14721,46865844,CC(CN1C=CC(=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4)COC,COCC(C)Cn1ccc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
CHEMBL1079229,XBOFJPSCQGVLPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,14726,46883197,CC(C)(C)CN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CC(C)(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1079230,XBOFJPSCQGVLPB-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,14727,46883198,CC(C)(C)CN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CC(C)(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL1923642,XBPLNMSLGBYKCW-UFKXBGGNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106937.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.,J. Med. Chem.,PUBLICATION,,5.920818753952375,14731,11526745,CC1C(=O)NC(C(=O)NCCCC2=C(C=C(C=C2)F)OCCNC(C(=O)N1C)C3CC3)CC4=CC=C(C=C4)F,CC1C(=O)NC(Cc2ccc(F)cc2)C(=O)NCCCc2ccc(F)cc2OCCNC(C2CC2)C(=O)N1C
CHEMBL592646,XBQOGPRXCCTYMI-AKWYTYQQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585026652029182,14733,42641819,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)C(C)(C3CCCC3)NCC4=CC5=C(C=C4)N=CC=C5,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(C(C)(NCc2ccc3ncccc3c2)C2CCCC2)nn1
CHEMBL498471,XBVDRLSPKAFNGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,4.698970004336019,14737,25034656,C1CC(C2=C1C=C(C=C2)C3=CC=C(C=C3)F)(C4=CN=CC=C4)O,OC1(c2cccnc2)CCc2cc(-c3ccc(F)cc3)ccc21
CHEMBL1911823,XBXQAGKJALZGRX-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21974949.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,Discovery of a new class of glucosylceramide synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,14742,46869566,CC(C)(C)COCC(C(=O)N1CCN(CC1)C)NC(=O)C2=C(N=CC=C2)OC3=C(C=C(C=C3)C(F)(F)F)Cl,CN1CCN(C(=O)C(COCC(C)(C)C)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1
CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.698970004336019,14748,148123,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C
CHEMBL211204,XCFCFGDFIJDQNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,=,19200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.716698771296451,14749,11199490,CCOC1(C2=NOC(=O)N2C(=CS1)C)C3=CC=C(C=C3)Br,CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O
CHEMBL211204,XCFCFGDFIJDQNG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,4.698970004336019,14749,11199490,CCOC1(C2=NOC(=O)N2C(=CS1)C)C3=CC=C(C=C3)Br,CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O
CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.0,14752,8223,CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C,CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)CC21
CHEMBL3401127,XCJBWBMTIYUPEB-GHMZBOCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25655721.0,IC50,=,485000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3�� inhibitors for Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.3142582613977365,14757,57869889,CC1C(OCCN1C2=NC(=CC(=O)N2C)C3=C(C=NC=C3)F)C,CC1OCCN(c2nc(-c3ccncc3F)cc(=O)n2C)C1C
CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24047900.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,,,,,,4.698970004336019,14758,71720883,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24304150.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,14758,71720883,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.221848749616356,14758,71720883,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,12100.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.91721462968355,14758,71720883,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,14758,71720883,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3104375,XCJMUIWIEQFAQX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,100000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.0,14758,71720883,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1
CHEMBL3702803,XCMBYAPIZRSJSM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.1487416512809245,14762,89718372,CC1(CC(CC(N1C)(C)C)NC2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NC6CC(C)(C)N(C)C(C)(C)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3355480,XCOKOJKTXOLUTM-LLVKDONJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25589928.0,IC50,>,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.619788758288394,14763,118720891,CC1COCCN1C2=C3C(=CC(=N2)C4=C5C=CNC5=CN=N4)N(C=N3)C,CC1COCCN1c1nc(-c2nncc3[nH]ccc23)cc2c1ncn2C
CHEMBL3236640,XCRGKBIGLYHHMI-HEBVPBOISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,4.568636235841013,14767,90655373,CC1(CC(C(N(C1=O)C(CS(=O)(=O)C(C)(C)C)C2CC2)C3=CC=C(C=C3)Cl)C4=CC(=CC=C4)Cl)CC5=NC(=CS5)CC(=O)O,CC1(Cc2nc(CC(=O)O)cs2)CC(c2cccc(Cl)c2)C(c2ccc(Cl)cc2)N(C(CS(=O)(=O)C(C)(C)C)C2CC2)C1=O
CHEMBL1819090,XCTNLNITUUOHNO-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21865048.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.",Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,14769,44123747,CC1(CCCN(C1)C2=CC3=C(N2CC4=C(C=CC(=C4)F)C#N)C(=O)N(C(=O)N3C)C)N,Cn1c(=O)c2c(cc(N3CCCC(C)(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O
CHEMBL1270269,XCVJGPONRKMMGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843687.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.455931955649724,14771,11710873,CC(C)(C(=O)N)NCCCC1=CC(=NC(=N1)C#N)C2=CC(=CC=C2)C(F)(F)F,CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O
CHEMBL2347992,XCYCRDIMKXBEOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,14772,71279507,CC(C)(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)F)CCCS(=O)(=O)C,CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12
CHEMBL271121,XCYJXGREMGRASS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,71.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,7.1487416512809245,14773,4193543,CC1=CN=C(N=C1)CNC2=NC(=NC(=C2)C3=CC=CC=C3)C4=CC=NC=C4,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccncc3)n2)nc1
CHEMBL3261485,XDJFTOOYWJXAAZ-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14776,66898172,COC1=CC2=C3C(=C1)C(=O)N(CCN3N=C2)C4CN5CCC4CC5,COc1cc2c3c(cnn3CCN(C3CN4CCC3CC4)C2=O)c1
CHEMBL3358951,XDLANRATEHYNAI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,14777,44544094,CC(C)S(=O)(=O)C1=NC=C2C(=C1)C=C(N2)CC(CC(C)(C)C3=C(C=C(C=C3)F)C(=O)N)(C(F)(F)F)O,CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1
CHEMBL1515648,XDOXZFXJIASILF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,14781,16016502,COC(=O)C1=CC=C(C=C1)CSC2=NC(=O)C3=C(N2)CCC3,COC(=O)c1ccc(CSc2nc(=O)c3c([nH]2)CCC3)cc1
CHEMBL1515648,XDOXZFXJIASILF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25330343.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,PUBLICATION,,4.698970004336019,14781,16016502,COC(=O)C1=CC=C(C=C1)CSC2=NC(=O)C3=C(N2)CCC3,COC(=O)c1ccc(CSc2nc(=O)c3c([nH]2)CCC3)cc1
CHEMBL220407,XDVGYCLZBOMGDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16908150.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14787,16049886,CC(C)N1CCN(CC1)C(=O)N2CCC(CC2)NC(=O)C3CCCC3,CC(C)N1CCN(C(=O)N2CCC(NC(=O)C3CCCC3)CC2)CC1
CHEMBL1760200,XDXNXAQKAHUCSV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21376585.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,14790,8867347,COC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC(=NN3)C4=CC=CC=C4,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccccc3)n[nH]2)CC1
CHEMBL516551,XDZZEIOBAUKKMP-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,14793,44570452,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=NO4)C,Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3CC(C)NC(C)C3)cc2)on1
CHEMBL516551,XDZZEIOBAUKKMP-OYRHEFFESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,14793,44570452,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)CC4=CC(=NO4)C,Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3CC(C)NC(C)C3)cc2)on1
CHEMBL2178742,XEDMJQGYEUEUJR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,5.552841968657781,14798,71451887,CN1CCC(CC1)NC2=C(C=CC(=C2)S(=O)(=O)N3CCOC4=C3C=C(C=C4)Cl)OC,COc1ccc(S(=O)(=O)N2CCOc3ccc(Cl)cc32)cc1NC1CCN(C)CC1
CHEMBL172,XEEQGYMUWCZPDN-DOMZBBRYSA-N,"(S,R)-MEFLOQUINE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,=,667.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,6.175874166083451,14800,40692,C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1
CHEMBL422858,XEKAEMQSBUSNIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,14804,11253245,CCCCOC1=CC=C(C=C1)C2=CC(=NO2)C,CCCCOc1ccc(-c2cc(C)no2)cc1
CHEMBL3112611,XEKWGMXLJBVYET-FQEVSTJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,1670.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.777283528852417,14807,76328655,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC2CCN(CC2)C(=O)OCC3=CN=CS3,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1
CHEMBL1779013,XEKZQVZQOZRWEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,14808,54587759,COC1=C(C=CC(=C1)F)C2=CN=CC(=C2)CNC(=O)C3=CC=CC=N3,COc1cc(F)ccc1-c1cncc(CNC(=O)c2ccccn2)c1
CHEMBL551813,XEOSTBFUCNZKGS-UHFFFAOYSA-N,ACTIMIS,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19608418.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14814,45270144,CN(C)C1=C(C(=NC(=N1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(F)(F)F)N(C)C)CC(=O)O,CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O
CHEMBL240572,XEPRNTQLEBCAFA-HLADLETHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.167491087293763,14815,23635109,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=C(C=C(C=C3)Cl)C)C(C(C)C)NC(=O)CCN(C)C,Cc1ccc(N2CCN(C(=O)C(C)Cc3ccc(Cl)cc3C)CC2)c(C(NC(=O)CCN(C)C)C(C)C)c1
CHEMBL397581,XEURJRGOGLBXPG-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,5400.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.267606240177032,14819,44433296,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCN,CC(C)CC(NC(=O)CCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL229008,XEVJUIZOZCFECP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17585753.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419).",J. Med. Chem.,PUBLICATION,,4.886056647693163,14820,9913339,CCN1CCN(CC1)C2=NC=C(C=C2)C(C)(C)NC(=O)C3=C(C=C4C(=C3)NC5=CC=CC=C5C4=O)F,CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1
CHEMBL1921975,XEYZCKZMDNQROP-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.107905397309519,14825,57402969,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3)O,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL1682893,XEYZCKZMDNQROP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.443697499232713,14826,9927224,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3)O,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL1682893,XEYZCKZMDNQROP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.443697499232713,14826,9927224,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC)(C3=CN=CN3)O,CNC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL3114886,XEYZWQDXEHTOKO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412066.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14827,57965039,CC(C)CC(=O)N1CCC(CC1)N2C3=C(C=N2)C(=NC=N3)OC4=CC=C(C=C4)S(=O)(=O)C,CC(C)CC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1
CHEMBL1761519,XFJSBMXXKPHIIX-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,14832,54580283,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCOC)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1
CHEMBL1761519,XFJSBMXXKPHIIX-NOCHOARKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,=,21600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.665546248849069,14832,54580283,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCOC)C5CC5)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1
CHEMBL1935442,XFQZALCRWJDNNK-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,14842,57402315,C1COC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1
CHEMBL2347328,XFVVLCBORWIGHO-GOTSBHOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23466233.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,14845,71580912,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C(F)(F)F)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)[nH]1)C(C)C
CHEMBL453329,XFWGEKHPBVFSFW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14846,44561276,CN(C(CN1CCOCC1)C2=CC=C(C=C2)C3=CC(=CC=C3)OC)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl,COc1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(Cl)c(Cl)cc43)cc2)c1
CHEMBL1825089,XFWNXRYYGPIPLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,14847,53388319,CS(=O)(=O)N(CCN1CCOCC1)C2=CC=C(C=C2)NC3=NC=C4C=NN(C4=N3)C5CCCCCC5,CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1
CHEMBL1825089,XFWNXRYYGPIPLI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21798738.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,14847,53388319,CS(=O)(=O)N(CCN1CCOCC1)C2=CC=C(C=C2)NC3=NC=C4C=NN(C4=N3)C5CCCCCC5,CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1
CHEMBL1821735,XFXOOLLVYYZWQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21859094.0,IC50,=,14600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,4.835647144215563,14848,54577896,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NN4C(=CC=C4C5=CC=CC=C5N(C)S(=O)(=O)C)C=N3,CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1
CHEMBL529220,XFZDFYYRUDDKBS-HZPDHXFCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18462007.0,IC50,>,65000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.,J. Nat. Prod.,PUBLICATION,,4.187086643357144,14849,24796588,CCCCCC1C(C2=C(C=CC(=C2)OC)C(=O)O1)OC(=O)C,CCCCCC1OC(=O)c2ccc(OC)cc2C1OC(C)=O
CHEMBL263004,XGDYFBGSSSIIDK-WDEPAJCISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14854,44380537,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4C5CCC4CC5)C(C)CNCCC6=CC7=C(C=C6)N=CO7)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2C(C)CNCCc2ccc3ncoc3c2)c1
CHEMBL487569,XGFRRYAZOMJDQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,380.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,6.42021640338319,14855,25138077,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CC(=C3)OC)OC)C,COc1cc(OC)cc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
CHEMBL1672054,XGGTZCKQRWXCHW-WMTVXVAQSA-N,CASOPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,9720.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,5.012333735073725,14856,9917021,CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C,CC(=O)N1CCN(C2CCN(C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL1672054,XGGTZCKQRWXCHW-WMTVXVAQSA-N,CASOPITANT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21149541.0,IC50,=,9860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method,Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.,Drug Metab. Dispos.,PUBLICATION,,5.006123085058789,14856,9917021,CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C,CC(=O)N1CCN(C2CCN(C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C(c3ccc(F)cc3C)C2)CC1
CHEMBL255462,XGRAVLAUZKWSQZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14860,44448876,C1CCN(C1)CC2C(CCCN2C(=O)CN3C4=C(C=CC(=C4)Cl)SC3=O)C5=CC=CC=C5,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1
CHEMBL1076461,XGUNBNDCDWFBAF-SETSBSEESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19853442.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,New classes of potent and bioavailable human renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,14862,46880062,CC1=C(C=CC=C1OC)CN(C2CC2)C(=O)C3=C(CC4COCC3N4)C5=CC=C(C=C5)CCCOC6=C(C=CC(=C6Cl)F)F,COc1cccc(CN(C(=O)C2=C(c3ccc(CCCOc4c(F)ccc(F)c4Cl)cc3)CC3COCC2N3)C2CC2)c1C
CHEMBL1289313,XGYYVDZJWSDWDE-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21036042.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,14867,11647548,CN(C(=O)C1=NC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)F)CN4CCCC4C(=O)N)O,CN(O)C(=O)c1cc2c(CN3CCCC3C(N)=O)cn(Cc3ccc(F)cc3)c2cn1
CHEMBL240780,XHASNPJPTJYEPD-DFHRPNOPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17918824.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,PUBLICATION,,5.221848749616356,14868,23635236,CC1=CC(=C(C=C1)N2CCN(CC2)C(=O)C(C)CC3=CC=C(C=C3)Cl)C(C(C)C)NC(=O)CCNC,CNCCC(=O)NC(c1cc(C)ccc1N1CCN(C(=O)C(C)Cc2ccc(Cl)cc2)CC1)C(C)C
CHEMBL254080,XHAUDRHLRBFHDL-FCHUYYIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,14869,44447033,C1CCN(C1)CC2=NOC(=N2)CC3(CC3)C4CCCC(N4S(=O)(=O)C5=CC=C(C=C5)Cl)C6CC6,O=S(=O)(c1ccc(Cl)cc1)N1C(C2CC2)CCCC1C1(Cc2nc(CN3CCCC3)no2)CC1
CHEMBL2086760,XHCPCYVQXFHJAU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765894.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14871,67161540,CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=C(C=C4)Cl)C5=NC=CN5,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(Cl)cc2)c2ncc[nH]2)C(=O)N3)CC1
CHEMBL394016,XHILZVTVIKVPKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,22000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.657577319177793,14876,23647882,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCNC(=O)C)(C)C(F)(F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C(F)(F)F)O2
CHEMBL2441565,XHJPFLSAHTYUNW-ONEGZZNKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,14879,71585566,CN(C)CC=CC(=O)N1CCOC2=C1C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)F)Cl,CN(C)CC=CC(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21
CHEMBL2448716,XHNSUZALLCTOAT-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,14882,73349664,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
CHEMBL565360,XHQRQWJOOLSDNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,14888,45484893,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3SC4=CC=CC=C4CO,CC1(CC(=O)NCc2ccccc2Sc2ccccc2CO)CC2(CCCCC2)OO1
CHEMBL2420685,XHTUSXVMRHUIGE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23859149.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases.,J. Med. Chem.,PUBLICATION,,5.0,14889,71818233,COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CN=C3,COc1ccc2ccc(-c3cncnc3)c(Cl)c2c1
CHEMBL498114,XHVSEFQNZWHSNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14893,44583679,CC1=C(C(=CC=C1)C)CCC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL498114,XHVSEFQNZWHSNK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.508638306165727,14893,44583679,CC1=C(C(=CC=C1)C)CCC2=CC(=CN3C2=NC(=C3C)C)N4C=CC=CC4=O,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12
CHEMBL389908,XHWIJMYLOJKSST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17477516.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,PUBLICATION,,5.301029995663981,14894,10025406,C1=CC(=CC(=C1)Cl)NC2=NC=C(C(=N2)C(F)(F)F)C(=O)NCC3=CC=C(C=C3)F,O=C(NCc1ccc(F)cc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F
CHEMBL1079957,XIHFOOAKDQNZGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,14899,46879596,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCNC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12
CHEMBL1079957,XIHFOOAKDQNZGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,14899,46879596,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCNC4=O)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12
CHEMBL151354,XIJNLZJHRREJKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,22900.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,4.640164517660112,14904,11424804,CCCCOC1=CC=C(C=C1)C2=CC=NS2,CCCCOc1ccc(-c2ccns2)cc1
CHEMBL330354,XIKMSNPORKHQQQ-FJQKOURKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15139756.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.301029995663981,14906,11308052,CCCCC1=CC(=CC=C1)C2(C3=CC=CC=C3N(C(=O)CN2)CC4=C(C=C(C=C4F)F)F)C(C(=O)O)OC5=NC(=CC(=N5)C)C,CCCCc1cccc(C2(C(Oc3nc(C)cc(C)n3)C(=O)O)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1
CHEMBL1229205,XIPYFDKZPWWWGS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22059882.0,IC50,=,8.8,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,PUBLICATION,,8.05551732784983,14913,46235580,CC1=CN=C(C=C1)COC2=CC3=C(C=C2)N(C(=C3SC(C)(C)C)CC(C)(C)C(=O)O)CC4=CC=C(C=C4)C5=NC=C(C=N5)OC,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1
CHEMBL1923125,XITVKUPYTCBIOT-RLWLMLJZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,14916,57390809,C1CC1N(CC2=CC=CC3=C2N=CC=C3)C(=O)C4CNCCC45C6=CC(=C(C=C6CO5)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1cccc2cccnc12)C1CC1
CHEMBL3125391,XITZHALCAXQXME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24560540.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K�� inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,14917,57411256,C1CN(C2=C1C=C(C=C2)F)C(=O)CC3=C(SC(=N3)N4CCOCC4)C(=O)N,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21
CHEMBL3121800,XIYFVTRDXPGMEW-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24266880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,PUBLICATION,,5.0,14919,66731186,CCC1=CC2=C(C=C1F)C(=C(N2C3=CC=CC=N3)C4=NC=C(C=C4)S(=O)(=O)NC(C)C(F)(F)F)C#N,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)NC(C)C(F)(F)F)cn1)n2-c1ccccn1
CHEMBL523563,XIZBFDTZSLSHTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,14920,44583614,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=CC4=O,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12
CHEMBL523563,XIZBFDTZSLSHTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,14920,44583614,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=CC4=O,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12
CHEMBL2441954,XIZQTPHCQYNKEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.638272163982407,14921,15950831,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N3CCCC3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCC1)C2
CHEMBL1095511,XJANDYKKEVAKFU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,14922,46888855,CC1=CSC(=N1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCCCC5,Cc1csc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)n1
CHEMBL3702689,XJCPULIHXFIZOP-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.4089353929735005,14926,89718294,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCOCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCOCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2058664,XJCYZAUSMGGIRP-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.619788758288394,14927,62707113,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)C5=CC=NC=C5,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccncc3)oc2c1
CHEMBL2441950,XJDKGHMEFQVYDZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23964740.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,"Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).",J. Med. Chem.,PUBLICATION,,4.3979400086720375,14928,57641212,CC1=C(C(=C2C(=N1)CN(C2=O)CC(=O)N)C3=C(C=C(C=C3)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(N)=O)C2
CHEMBL483402,XJEJCCXXTNIOJF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,5.366531544420414,14930,11663187,CC1=C(C(N=C(N1)C2=CC(=NC=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)ccn1
CHEMBL419396,XJPWYIFOSHVNSZ-RMERSUQASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12951118.0,IC50,=,310.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165727,14942,10305705,C1CN(C(CN1CC2=CC3C=CSC3S2)C(=O)NCC(F)(F)F)CC(CC(CC4=CN=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,O=C(NC1c2ccccc2OCC1O)C(Cc1cccnc1)CC(O)CN1CCN(CC2=CC3C=CSC3S2)CC1C(=O)NCC(F)(F)F
CHEMBL3115166,XJTLAMHFTBREAR-KAYWLYCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,14948,76314237,CN(CC1=CN=CS1)C(=O)NCCC(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CN(Cc1cncs1)C(=O)NCCC(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL3264606,XJVOQAFXKZKDRC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,14950,90656806,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OCC(F)(F)F)OCC(F)(F)F)(C3=NNN=C3)O,CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)c(OCC(F)(F)F)cc2c1)c1cn[nH]n1
CHEMBL3680983,XJXWVRYXVARTIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,253316,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",Metalloenzyme inhibitor compounds,,PATENT,,5.853871964321762,14953,53497497,C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)F,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1
CHEMBL3237561,XJZVCDVZCRLIKN-QWHCGFSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24520947.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,PUBLICATION,,4.301029995663981,14955,71626896,CC1=C(N=C(C=C1)NC2=CC(=NN=C2C(=O)N)NC3CCCCC3N)C,Cc1ccc(Nc2cc(NC3CCCCC3N)nnc2C(N)=O)nc1C
CHEMBL3702810,XKDFAVCCGODROP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21520.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.667157733005649,14959,89718291,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCN(CC8)CC9=CC=C(C=C9)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(Cc7ccc(OC)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL594523,XKNDLPMAXNMALL-IBGZPJMESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.200659450546418,14964,46226096,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=COC=C4)C)OCC(CC5=CNC6=CC=CC=C65)N,Cc1nc(-c2ccoc2)c(-c2cnc3n[nH]c(C)c3n2)cc1OCC(N)Cc1c[nH]c2ccccc12
CHEMBL1829768,XKUYBHWZCQUCGO-QYBDOPJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,4.6777807052660805,14969,53473233,CC(C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CCC(OC3=O)(CCO)C4=CC=C(C=C4)F,CC(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CCO)(c2ccc(F)cc2)OC1=O
CHEMBL478283,XKZZIPLEGIRBDK-HKWRFOASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19321349.0,IC50,=,47000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,PUBLICATION,,4.327902142064283,14971,42629369,CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CCC(C(=CC(=O)NCCO)C4=CC=CC=C43)(F)F)Cl,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)C(=CC(=O)NCCO)c4ccccc43)c(Cl)c2)n1
CHEMBL2019026,XLAHUVMRXXMPOW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,520.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,6.2839966563652006,14973,13957609,C1=CC=NC(=C1)CSC2=NC3=C(N2)C=C(C=C3)N,Nc1ccc2nc(SCc3ccccn3)[nH]c2c1
CHEMBL2064330,XLESLWHDVUIEMT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,wild_type,,22524426.0,IC50,>,40000.0,NM,,inhibition,biochemical,,,,,,,,,,,,Inhibition of human recombinant CPY3A4,Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K�� Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,FURTHER INFORMATION ABOUT THE ASSAY IS NOT GIVEN IN THE  ARTICLE,4.3979400086720375,14977,49853823,CN1C2=CC=CC=C2N=C1CC3=NC(=O)C=C(N3)N4CCOCC4,Cn1c(Cc2nc(=O)cc(N3CCOCC3)[nH]2)nc2ccccc21
CHEMBL566683,XLJQUFRVZDFEAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14981,25064072,COC1=CC2=NC=CC(=C2C=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL566683,XLJQUFRVZDFEAF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19819693.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,14981,25064072,COC1=CC2=NC=CC(=C2C=C1)NCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5,COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
CHEMBL465244,XLNMHVBRWVMJDC-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,14984,44570364,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=CC=C4,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)CC(C)N1
CHEMBL465244,XLNMHVBRWVMJDC-ZRZAMGCNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,14984,44570364,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3CN(C)C(=O)COC4=CC=CC=C4,CC1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)CC(C)N1
CHEMBL2070143,XLSXASRFKWCYKL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,14990,70688845,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC(=CC=C3)OC(F)(F)F,CCCS(=O)(=O)c1ccc2nc(-c3cccc(OC(F)(F)F)c3)[nH]c2c1
CHEMBL3112690,XLUFPHQRHPTDJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24387221.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4,Discovery and Optimization of Pyrimidone Indoline Amide PI3K�� Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,14992,49853818,C1CN(C2=CC=CC=C21)C(=O)CC3=NC(=O)C=C(N3)N4CCOCC4,O=C(Cc1nc(=O)cc(N2CCOCC2)[nH]1)N1CCc2ccccc21
CHEMBL328863,XMAYWYJOQHXEEK-BVAGGSTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,897.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,6.047207556955908,15000,12854713,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL319160,XMAYWYJOQHXEEK-JYFHCDHNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,570.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,6.2441251443275085,15001,638701,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,=,12.0,NM,,,,binding,,,,,,,,,,,,,,,,7.920818753952375,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27789139.0,IC50,=,133.0,NM,,inhibition,,,,,,,,,,,,,,,,,,6.876148359032914,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,<,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,7.0,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23355637.0,IC50,=,9.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 activity in human liver microsomes assessed as dibenzo fluuorescene oxidation up to 40 uM,,Drug Metab. Dispos.,PUBLICATION,,8.008773924307505,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26204510.0,IC50,=,180.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.",Eur. J. Med. Chem.,PUBLICATION,,6.7447274948966935,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26900658.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 by luminescence -based microplate reader assay,"Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation.",Eur. J. Med. Chem.,PUBLICATION,,6.853871964321762,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,9.0,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26962886.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,PUBLICATION,,8.397940008672037,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27105029.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate incubated for 30 mins by fluorimetry,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",Eur. J. Med. Chem.,PUBLICATION,,6.552841968657781,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL75,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27145071.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay,2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.,J. Med. Chem.,PUBLICATION,,6.619788758288394,15002,456201,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL157101,XMAYWYJOQHXEEK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,150.0,NM,291613,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",Metalloenzyme inhibitor compounds,,PATENT,,6.823908740944319,15003,3823,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,27789139.0,IC50,=,146.0,NM,,inhibition,,,,,,,,,,,,,,,,,,6.835647144215563,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,786.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,6.104577453960592,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,1495014.0,IC50,=,1260.0,NM,,,,,,,,,,,,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Stereoisomers of ketoconazole: preparation and biological activity.,J. Med. Chem.,PUBLICATION,,5.8996294548824375,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,7.301029995663981,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,7.886056647693163,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,7.795880017344075,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,7.769551078621726,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12930139.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,PUBLICATION,,7.657577319177793,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15270556.0,IC50,=,245.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by radiometric assay,Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities.,J. Nat. Prod.,PUBLICATION,,6.610833915635467,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,720.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,6.142667503568732,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16220979.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against human hepatic cytochrome P450 3A4 enzyme,Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.,J. Med. Chem.,PUBLICATION,,7.301029995663981,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16570918.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.,J. Med. Chem.,PUBLICATION,,7.301029995663981,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,6.6777807052660805,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324762.0,IC50,=,54.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.",J. Med. Chem.,PUBLICATION,,7.267606240177032,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18583127.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,"Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.698970004336019,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672861.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,PUBLICATION,,7.2441251443275085,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,72.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,7.142667503568732,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763754.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,PUBLICATION,,7.2441251443275085,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,4.2441251443275085,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,199.99,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,6.698991719603,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19211174.0,IC50,=,72.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.",Eur. J. Med. Chem.,PUBLICATION,,7.142667503568732,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19239254.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Rational modification of a candidate cancer drug for use against Chagas disease.,J. Med. Chem.,PUBLICATION,,7.3979400086720375,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679475.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,7.958607314841775,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,7.2441251443275085,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21138310.0,IC50,=,7.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.,J. Nat. Prod.,PUBLICATION,,8.10790539730952,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17��-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,7.301029995663981,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21384875.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in baculovirus-infected insect microsomes,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,PUBLICATION,,7.2441251443275085,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497764.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in liver microsomes,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985743,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24328103.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Discovery of a non-estrogenic irreversible inhibitor of 17��-hydroxysteroid dehydrogenase type 1 from 3-substituted-16��-(m-carbamoylbenzyl)-estradiol derivatives.,J. Med. Chem.,PUBLICATION,,7.619788758288394,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24793360.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,"Investigation of a Novel Series of 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Human Immunodeficiency Virus Type 1 Integrase Inhibitors.",J. Med. Chem.,PUBLICATION,,6.552841968657781,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25082126.0,IC50,<,62.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.2076083105017466,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25300820.0,IC50,=,25.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay,"Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5a-androstane-3a,17��-diol derivatives.",Bioorg. Med. Chem.,PUBLICATION,,7.6020599913279625,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25499431.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25868743.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as effect on conversion of beetle D-luciferin derivative into D-luciferin by firefly luciferase based luminescence assay,"Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.",Bioorg. Med. Chem.,PUBLICATION,,6.853871964321762,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26052884.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as remaining enzyme activity by measuring conversion of luciferin-PPXE into D-luciferin by luminescence CYP3A4 P450-Glo assay relative to untreated control,"Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.",J. Med. Chem.,PUBLICATION,,6.853871964321762,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26355532.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).,Eur. J. Med. Chem.,PUBLICATION,,7.221848749616356,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26360048.0,IC50,=,140.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as conversion of luciferin-PPXE to D-luciferin by luminescence Glo assay,"(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.",Eur. J. Med. Chem.,PUBLICATION,,6.853871964321762,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,16.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,7.795880017344075,15004,47576,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
CHEMBL3087347,XMEWECBJZOPGCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,15007,3844414,C1=CC(=CC=C1C2=CN=CO2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2cnco2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL3353341,XMHCFCMVNKTYOH-ZBVNWKHZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24867403.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3��'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,PUBLICATION,,5.6777807052660805,15012,58486268,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
CHEMBL3353341,XMHCFCMVNKTYOH-ZBVNWKHZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.251811972993799,15012,58486268,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
CHEMBL3353341,XMHCFCMVNKTYOH-ZBVNWKHZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25723005.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5��'-methoxyspiro[cyclopropane-1,3��'-indolin]-2��'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,PUBLICATION,,5.0,15012,58486268,CN1CCN(CC1)C2=NC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O,COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
CHEMBL462093,XMIVJNDWTQQRAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19049427.0,IC50,=,6210.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,PUBLICATION,,5.20690839982342,15015,25180108,C1CC2=C(CC1=O)C=CC(=C2)C3=CN=CC=C3,O=C1CCc2cc(-c3cccnc3)ccc2C1
CHEMBL2164422,XMLJHUDPEAJQOK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22801646.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,inhibition of CYP3A4,"4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15017,24985115,C1CC1C2=CC3=C(C=CN=C3N2)C4=CC=C(C=C4)S(=O)(=O)NCCO,O=S(=O)(NCCO)c1ccc(-c2ccnc3[nH]c(C4CC4)cc23)cc1
CHEMBL469917,XMLWGUKRPGLJGA-CABCVRRESA-N,(-)-THUJAPLICATINTRIMETHYL ETHER,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15679319.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,Potent CYP3A4 inhibitory constituents of Piper cubeba.,J. Nat. Prod.,PUBLICATION,,5.958607314841775,15018,192827,COC1=CC(=CC(=C1O)OC)CC2C(COC2=O)CC3=CC(=C(C=C3)O)OC,COc1cc(CC2COC(=O)C2Cc2cc(OC)c(O)c(OC)c2)ccc1O
CHEMBL593813,XMNABEGDUNNDFW-HNNXBMFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20006500.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,15020,46226136,CC1=C2C(=NN1)N=CC(=N2)C3=CC(=C(N=C3C4=C(OC=C4)C)N)OCC(CC5=C(NC6=CC=CC=C65)Cl)N,Cc1occc1-c1nc(N)c(OCC(N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2n[nH]c(C)c2n1
CHEMBL425483,XMOSOHDOZCRMML-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17441705.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,15021,9799867,C1CC(CN(C1)C2=NC3=C(C=C(C=C3)F)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2ccc(F)cc2c1=O
CHEMBL425483,XMOSOHDOZCRMML-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19217790.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,5.6020599913279625,15021,9799867,C1CC(CN(C1)C2=NC3=C(C=C(C=C3)F)C(=O)N2CC4=CC=CC=C4C#N)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2ccc(F)cc2c1=O
CHEMBL180856,XNPARDFAECDMGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,15033,44390134,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=CC=C3)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccccc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL2059804,XNPPAPISIBTENR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,15034,24862842,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC4=C(C=C3)NN=C4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL262320,XNPVNWIDDNEPTG-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,15035,44433283,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCC(=O)O,CC(C)CC(NCCCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL2031470,XOHLGPHQMURXNY-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22617490.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15043,59651957,CC1CCCN1CCCOC2=CC3=C(C=C2)C4=NN(C(=O)C=C4CC3)C,CC1CCCN1CCCOc1ccc2c(c1)CCc1cc(=O)n(C)nc1-2
CHEMBL2063494,XOHMICFWUQPTNP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106171.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.,Drug Metab. Dispos.,PUBLICATION,,4.823908740944319,15044,739374,C1=CC(=C(C=C1Cl)Cl)C(=O)CN2C=NC=N2,O=C(Cn1cncn1)c1ccc(Cl)cc1Cl
CHEMBL2387600,XOMUBBMQPXUGME-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,15048,71659610,C1=CC=C(C=C1)CC2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=CC=CC=C5Cl,O=c1[nH]c2cc(Cc3ccccc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL593490,XONRTPBYDAFIRW-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,15049,46225540,CC1=C2C=C(C=CC2=NN1)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=COC=C6,Cc1[nH]nc2ccc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12
CHEMBL3092195,XONVFTCAGXZIPY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.958607314841775,15050,24753878,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=CC=C4)NS(=O)(=O)NC)F,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
CHEMBL3092195,XONVFTCAGXZIPY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.585026652029182,15050,24753878,CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=CC=C4)NS(=O)(=O)NC)F,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
CHEMBL2436209,XOTGKSFDRNMNQY-FEINMWSASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,5.920818753952375,15051,72711719,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CN=CC=C5)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3581148,XOVHPPILLSHRPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,7500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.1249387366083,15053,24830569,CS(=O)(=O)NC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)Cl,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1
CHEMBL1921981,XPDAYTAXTQFSDQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21978946.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,PUBLICATION,,5.0,15057,9965885,C1CN2C=NC=C2C1(C3=CC4=C(C=C3)C=C(C=C4)C(=O)N)O,NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1
CHEMBL582806,XPEAOXGBRVOUMK-GAJHUEQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19632830.0,IC50,=,2030.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.692503962086787,15058,45486624,CC(C(CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)NC3=NC=C(C=C3)C(F)(F)F,CC(NC(=O)C(C)(C)Nc1ccc(C(F)(F)F)cn1)C(Cc1ccc(Cl)cc1)c1cccc(C#N)c1
CHEMBL401766,XPPPFLDICCXGSJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,15064,135869565,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12
CHEMBL477386,XPTXBBCZWWFNRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,15068,44579131,COC1=CC(=CC=C1)S(=O)(=O)N2C=CC3=CC4=C(CCNCC4)C=C32,COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1
CHEMBL477386,XPTXBBCZWWFNRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18793848.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,15068,44579131,COC1=CC(=CC=C1)S(=O)(=O)N2C=CC3=CC4=C(CCNCC4)C=C32,COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1
CHEMBL248880,XQDQWKMHQLOKBQ-CTNGQTDRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,15073,44442008,CC(C)C1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCN(CC3)CCO,CC(C)C1CCCC(COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL101180,XQHGYIOMSIVJMT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15078,9815391,CC(C)C1=CC=C(C=C1)N=CNO,CC(C)c1ccc(N=CNO)cc1
CHEMBL2036213,XQIZEBWLPMOVGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,15079,49872868,CCC(=O)N(CC1=CC=C(C=C1)OC(F)(F)F)C2=CC(=CC(=C2)C3=NNN=N3)F,CCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nn[nH]n2)c1
CHEMBL2397196,XQOYOWADRSYAQH-NSHDSACASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15084,59293755,CC(C)(C1=NC=CC(=C1)C2=CN=C(S2)NC(=O)N3CCCC3C(=O)N)C(F)(F)F,CC(C)(c1cc(-c2cnc(NC(=O)N3CCCC3C(N)=O)s2)ccn1)C(F)(F)F
CHEMBL598194,XQPFDQVEBGYLHB-UHFFFAOYSA-N,CCT129524,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20151677.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human microsomal preparation,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,PUBLICATION,,5.0,15085,11675388,C1CN(CCC1(C(=O)NCC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
CHEMBL2059800,XQQODFXEFSPXTA-UUWRZZSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22727645.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,15088,70682194,C1CCN(CC1)C2CCN(CC2)C(=O)C(CC3=CC=C(C=C3)C4=CC=CC=C4)NC(=O)N5CCC(CC5)N6C7=CC=CC=C7NC6=O,O=C(NC(Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL408443,XQSGLDYOIWDBIR-CRAIPNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,95.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,7.022276394711152,15089,44457199,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(CC(C)C)N)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)C(N)CC(C)C)c(C)c34)ccc2[nH]1
CHEMBL408443,XQSGLDYOIWDBIR-CRAIPNDOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18288793.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,PUBLICATION,,6.431798275933005,15089,44457199,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(CC(C)C)N)C,Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)C(N)CC(C)C)c(C)c34)ccc2[nH]1
CHEMBL564109,XQTARQNQIVVBRX-UHFFFAOYSA-N,TAZANOLAST,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,289734.36,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,3.537999998156502,15090,5380,CCCCOC(=O)C(=O)NC1=CC=CC(=C1)C2=NNN=N2,CCCCOC(=O)C(=O)Nc1cccc(-c2nn[nH]n2)c1
CHEMBL1222939,XQUSGRXUDTVJOI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,15091,49865105,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC=CC=C5Cl)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3Cl)c3ccccc32)CC1
CHEMBL3422097,XRBFZYFJBUZBIE-MOMDTQCHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,320.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.494850021680094,15097,118735395,CC(C)CC(C1=CC=CC=N1)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)N5C6CCC5CC(C6)O,CC(C)CC(NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1)c1ccccn1
CHEMBL3422098,XRBFZYFJBUZBIE-NDIVSWGXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25763473.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,J. Med. Chem.,PUBLICATION,,6.537602002101044,15098,118735396,CC(C)CC(C1=CC=CC=N1)NC(=O)C2=CC3=C(C=C2)NN=C3C4=CC=C(C=C4)N5C6CCC5CC(C6)O,CC(C)CC(NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1)c1ccccn1
CHEMBL2179222,XRDVQWJPAZZLKN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,5.0,15101,51002362,CC1=CN(C2=C1C=C(C=N2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1
CHEMBL3403822,XROVVBKXTANRKV-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,15109,71288715,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C(C)C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403822,XROVVBKXTANRKV-CTYWIBQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,15109,71288715,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)C(C)C)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(C(C)C)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL272963,XRVNSFDHOMAYDC-XRKRLSELSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15120,44453941,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)c1
CHEMBL255389,XRVNSFDHOMAYDC-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,15121,10369999,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)c1
CHEMBL255389,XRVNSFDHOMAYDC-YTMVLYRLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18291645.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,15121,10369999,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=CC(=C3)CC4C(N(C4=O)C5=CC=C(C=C5)C(C)(C)C)C(=O)O,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2C(=O)N(c3ccc(C(C)(C)C)cc3)C2C(=O)O)c1
CHEMBL1761848,XRXOWLSSJZUJBB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21439819.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11��-hydroxysteroid-dehydrogenase type 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15124,24896062,C1CC2=CC=CC=C2N(C1)C(=O)N3CCC(CC3)C4=CNN=C4,O=C(N1CCC(c2cn[nH]c2)CC1)N1CCCc2ccccc21
CHEMBL2012958,XRXYHTFKWSMTFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,15125,53494972,CC1=NC2=C(C=CC=C2N1C3=CC=C(S3)C(=O)NC4CC4)C#N,Cc1nc2c(C#N)cccc2n1-c1ccc(C(=O)NC2CC2)s1
CHEMBL2419493,XSAIJRMURHASGT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23899349.0,IC50,>,17000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,PUBLICATION,,4.769551078621726,15130,69224054,CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=C(C=C3)C)C,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)CC2)nc1C
CHEMBL459118,XSBPOCYYAOOLIV-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,19.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,15132,135960732,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)N7CCOCC7,Cc1cc(N2CCC(N3CCN(C(=O)N4CCOCC4)CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3265032,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,ENTOSPLETINIB,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24779514.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.",J. Med. Chem.,PUBLICATION,,5.0,15141,59473233,C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6,c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1
CHEMBL397114,XSNHZCBRIHYDIF-SNVBAGLBSA-N,SR-1360,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15143,16662106,CC(C(=O)N1CCN(CC1)C2=CC3=C(C=C2)NN=C3)N,CC(N)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL496386,XSQBHUDKEMPJMV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,7200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.142667503568732,15145,24889840,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=C(C=CC4=O)C(=O)N,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12
CHEMBL496386,XSQBHUDKEMPJMV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,14000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,15145,24889840,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=C(C=CC4=O)C(=O)N,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12
CHEMBL317798,XTFQDUYGGZGGLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15157,10219789,CCCOC1=CC=C(C=C1)N=CNO,CCCOc1ccc(N=CNO)cc1
CHEMBL3127525,XTJBCFNMRKMFGP-ZYKFHVCXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.6020599913279625,15160,76332826,C1CC2CN(CC1O2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)C4CC4C5=CN=CC=C5,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)C1CC1c1cccnc1
CHEMBL3127525,XTJBCFNMRKMFGP-ZYKFHVCXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.050609993355088,15160,76332826,C1CC2CN(CC1O2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)C4CC4C5=CN=CC=C5,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)C1CC1c1cccnc1
CHEMBL1222863,XTLNKZYASKPMLL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15162,44215838,C1CCN(CC1)CCN2C3=CC=CC=C3N(C2=O)C4CCN(CC4)C(=O)C5CCN(CC5)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1
CHEMBL3627955,XTURHBZXAJOBEO-AXHNFQJDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,=,21400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.669586226650809,15167,58950132,C1COC(C2C1(C3=C(C=CC(=C3OC2)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl)CNS(=O)(=O)C(F)(F)F,O=S(=O)(NCC1OCCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC12)C(F)(F)F
CHEMBL3627955,XTURHBZXAJOBEO-AXHNFQJDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26496070.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,"Discovery of a Novel, Potent Spirocyclic Series of ��-Secretase Inhibitors.",J. Med. Chem.,PUBLICATION,,4.522878745280337,15167,58950132,C1COC(C2C1(C3=C(C=CC(=C3OC2)F)F)S(=O)(=O)C4=CC=C(C=C4)Cl)CNS(=O)(=O)C(F)(F)F,O=S(=O)(NCC1OCCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC12)C(F)(F)F
CHEMBL381076,XTVVJSSQHZOGSY-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,15168,11962165,COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)N3C(CNCC3=O)COC4=CC5=C(C=C4)OCC(=O)N5CC(=O)O,COc1ccccc1COCCCOc1ccc(N2C(=O)CNCC2COc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1
CHEMBL1777861,XTXMTBWPTJUGRV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21514824.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15171,53248846,CC#CC(CC(=O)O)C1=CC=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)OC(F)F,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1
CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256005.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsome,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,15179,60823,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CCC(O)CC(O)CC(=O)O
CHEMBL2205043,XUMDENDMRHWGGR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21486038.0,IC50,=,6800.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,5.167491087293763,15181,53237438,C1CN(CCN1)C2=CC=CC=C2SC3=CC=C(C=C3)Cl.Cl,Clc1ccc(Sc2ccccc2N2CCNCC2)cc1
CHEMBL1951340,XUOFRIRHKXSQDU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,53.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.275724130399211,15182,57404046,C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)Nc2ccccc2)c1
CHEMBL2048047,XUPJXTGHHHIDNH-WVBUVRCRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22380629.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of cyclic sulfone hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid ��-peptides.,J. Med. Chem.,PUBLICATION,,6.522878745280337,15184,57387809,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(C(F)(F)F)C(F)(F)F,CC(C)(C)c1cccc(CNC2CS(=O)(=O)CC(Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)C2O)c1
CHEMBL2436222,XUSGYCMAJIJBII-ULLKZFKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,37000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.431798275933005,15185,72712345,CC1C(C(=O)N(C2=CC=CC=C2N1C(=O)CS(=O)(=O)C)CC3=NN(C4=CC=CC=C43)C5=CC=CC=C5C#N)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL1672627,XUYURJQIMYCWBB-UHFFFAOYSA-N,LAS101057,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15189,16071896,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CN=CC=C3)C4=C(C=NC=C4)F,O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1
CHEMBL192850,XVALFXOLDAVCKM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15801819.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.,J. Med. Chem.,PUBLICATION,,6.096910013008056,15191,11410765,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C3=C(NC=N3)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3nc[nH]c3-c3ccc(F)cc3)cc21
CHEMBL2448747,XVEIEUIURLFUMR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,15194,73357237,CC(C)CC1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN=C(S3)C4=CC=CC=C4,CC(C)Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1
CHEMBL271620,XVESHLWLQJLGGM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,15195,1476707,CS(=O)(=O)CC1=CC(=NC(=N1)C2=CC=CC=C2)N3CCCC3,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccccc2)n1
CHEMBL1098766,XVMSTDBLFRGHSD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15199,46861859,CC(C)N1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CC(C)N1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
CHEMBL397582,XVNQYSVVZUWFTA-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,15200,44433297,CC(C)CC(C1=CC=CC=C1N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CCNC,CNCCC(=O)NC(CC(C)C)c1ccccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL1682896,XVSPNIQMNAPNKK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21316976.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.031517051446065,15202,9906455,CC(C)C(C1=CC2=C(C=C1)C=C(C=C2)C(=O)NC(C)C)(C3=CN=CN3)O,CC(C)NC(=O)c1ccc2cc(C(O)(c3cnc[nH]3)C(C)C)ccc2c1
CHEMBL1077324,XWAXDNIZFDHSSU-RUZDIDTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,15206,136164066,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)NC(=O)OC(C)(C)C,Cc1cc(N2CCC(NC(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL146826,XWBLHPDICBKAEX-UHFFFAOYSA-N,DESETHYL ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.0,15207,11450263,CCNCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
CHEMBL146826,XWBLHPDICBKAEX-UHFFFAOYSA-N,DESETHYL ISOQUINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>=,55000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.259637310505756,15207,11450263,CCNCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
CHEMBL1951446,XWIQRYXCWXJXRA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,15214,57397047,C1=CC(=CC=C1C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5)N,Nc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5nc[nH]c45)cc3)cc2)cc1
CHEMBL239150,XWMMNGXDPDSMBN-UHFFFAOYSA-N,SR-899,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17368019.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,15218,16662096,C1CN(CCN1C2=CC3=C(C=C2)NN=C3)C(=O)C(C4=CC=C(C=C4)Br)O,O=C(C(O)c1ccc(Br)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
CHEMBL2448728,XWOSNQDOEDQYOA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1110.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.954677021213342,15220,73352677,C1CC1C(=O)N(CC2=CN=CC=C2)C3=CC(=CC(=C3)C4=NC5=CC=CC=C5S4)F,O=C(C1CC1)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1
CHEMBL168726,XWSMFYRZZIFQGL-WUXOVTSDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15225,44380681,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)C(C)CNCCC6=CC7=C(C=C6)N=C(N7)C(F)(F)F)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2C(C)CNCCc2ccc3nc(C(F)(F)F)[nH]c3c2)c1
CHEMBL1209018,XWUCTSMJFVUKTR-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,15228,46911173,CCN1CCN(CC1)CCCN2C=C(C=N2)C3=CC4=C(C=C3)N(C=N4)C5=CC(=C(S5)C(=O)N)OC(C)C6=CC=CC=C6Cl,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(OC(C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1
CHEMBL1209018,XWUCTSMJFVUKTR-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20594842.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,15228,46911173,CCN1CCN(CC1)CCCN2C=C(C=N2)C3=CC4=C(C=C3)N(C=N4)C5=CC(=C(S5)C(=O)N)OC(C)C6=CC=CC=C6Cl,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(OC(C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1
CHEMBL505652,XWUXNFBFVBWTFY-MUUNZHRXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,1.8,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.744727494896694,15229,135960731,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C(=O)OCCO,Cc1cc(N2CCC(N3CCN(C(=O)OCCO)CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3115169,XXFQAQQBFPSMAQ-GEBXHLAXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,15238,59721381,CN(CC1=CN=CS1)C(=O)NC(CO)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CN(Cc1cncs1)C(=O)NC(CO)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL1096104,XXGHMIJYQJJVNZ-RBSBEOHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20359891.0,IC50,=,5200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,A prodrug approach towards the development of tricyclic-based FBPase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2839966563652006,15240,46888899,CC1=NC=C(C=C1)C2CCOP(=O)(O2)COC3=C4C(=C(C(=C3)C)C)CC5=C4N=CS5,Cc1ccc(C2CCOP(=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)cn1
CHEMBL512414,XXHBZSGXGMJSEC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19339177.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15241,11848793,C1CC2CC(CC1N2C(C3=CC=CC=C3Cl)C4=CC=CC=C4Cl)(C5=CC=CC=C5)C(=O)N,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL237577,XXHJASVEYUQRFO-LMSSTIIKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,15242,44433273,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCNC,CNCCNC(CC(C)C)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL3402641,XXKSMVQSCWXLCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25701253.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,15243,118729222,CC(CCN1CCOCC1)CC(=O)NC2=CC=C(C=C2)C(=O)NC3=NC=CS3,CC(CCN1CCOCC1)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1
CHEMBL1080982,XXODNTBQCNWAAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,15246,44551848,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3CCO)C)C,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12
CHEMBL1080982,XXODNTBQCNWAAG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,15246,44551848,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)N4CCOCC4=O)C(=C(N3CCO)C)C,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12
CHEMBL2069803,XXTHMVRJMJIERU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22185670.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,PUBLICATION,,4.991399828238082,15251,877119,C1CCC(CC1)C2=NC(=NO2)C3=CC=NC=C3,c1cc(-c2noc(C3CCCCC3)n2)ccn1
CHEMBL237146,XYHMIFWCJKCCQZ-URLMMPGGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,15255,44433266,CCN(CC)C(CC(C)C)C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O,CCN(CC)C(CC(C)C)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL578594,XYJYINJWXKGOJA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15256,45484930,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=C(C=C3)SC,CSc1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1
CHEMBL1829765,XYMFJLWCTXMXHU-UZTOHYMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.221848749616356,15260,53473230,CC(C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CCC(OC3=O)(CCCO)C4=CC=CC=C4F,CC(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CCCO)(c2ccccc2F)OC1=O
CHEMBL3092189,XYPITQNKWLZVKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,5.251811972993799,15264,24753607,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=CC=C3)NS(=O)(=O)NC,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1
CHEMBL3092189,XYPITQNKWLZVKI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,,ACS Med. Chem. Lett.,PUBLICATION,,4.886056647693163,15264,24753607,CC1=C(C(=O)OC2=C1C=CC(=C2)OC(=O)N(C)C)CC3=CC(=CC=C3)NS(=O)(=O)NC,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1
CHEMBL1923130,XYRCXXGEWXZMCD-NEEKEDPPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,15268,57396099,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)Cl)CCCNS(=O)(=O)C,COCCCc1cc(CCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1
CHEMBL494917,XYVMIKBYRGFIJE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,15273,44568927,CC1=C(C2=C(C=C1)C(=NO2)NC)C3=CC4=CN=NC(=C4C=C3)OC(C)C,CNc1noc2c(-c3ccc4c(OC(C)C)nncc4c3)c(C)ccc12
CHEMBL2017106,XYWQJJVDYDCQKB-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15275,46932512,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)C3CNCCC3(C4=CC(=C(C=C4)F)F)O)Cl,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2(O)c2ccc(F)c(F)c2)c1Cl
CHEMBL1641613,XZCPNRFCLBNHOY-BAOGCXAUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21134748.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Stereospecific synthesis and structure-activity relationships of unsymmetrical 4,4-diphenylbut-3-enyl derivatives of nipecotic acid as GAT-1 inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15278,50941729,CC1=CC=CC=C1C(=CCCN2CCCC(C2)C(=O)O)C3=CC=CC=C3F,Cc1ccccc1C(=CCCN1CCCC(C(=O)O)C1)c1ccccc1F
CHEMBL3137458,XZGXLRPOTMAXIV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,6.221848749616356,15281,76318574,CC1=CC(=CN=C1)N2CCC(CC2)N(C3=CC=C(C=C3)C(F)(F)F)C4=CN=CC=C4,Cc1cncc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1
CHEMBL207012,XZIZYTUIRQMBPN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16686533.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,PUBLICATION,,4.522878745280337,15283,359052,C1=CC2=C(N=C1)SC(=C2N)C(=O)N,NC(=O)c1sc2ncccc2c1N
CHEMBL3400435,XZJFCCNTHXFRPO-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,15284,68448803,CC(C)N(CC1CNCC1NCC2=CC3=CC=CC=C3C=C2)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NCc2ccc3ccccc3c2)C(C)C)ccc1OC
CHEMBL3400435,XZJFCCNTHXFRPO-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,15284,68448803,CC(C)N(CC1CNCC1NCC2=CC3=CC=CC=C3C=C2)C(=O)C4=CC(=C(C=C4)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NCc2ccc3ccccc3c2)C(C)C)ccc1OC
CHEMBL2165510,XZQRCJXLCKQEIT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22626259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,J. Med. Chem.,PUBLICATION,,5.0,15289,60165514,CC(C)(C(=O)N)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=CN(C5=CC=C4)C)N6CCOCC6,Cn1ccc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc21
CHEMBL381619,XZSLPXJGQLDVET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,15291,11584004,C1CN(CCC1NC(=O)C2(CCNC2)C3=CC=CC=C3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl,O=C(NC1CCN(Cc2cccc(Oc3ccccc3Cl)c2)CC1)C1(c2ccccc2)CCNC1
CHEMBL558752,YABJJWZLRMPFSI-UHFFFAOYSA-N,CHIR-265,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26396681.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,15301,11656518,CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
CHEMBL3403827,YAEUHXARFVDSAM-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,15304,71288739,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)CCO)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(CCO)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403827,YAEUHXARFVDSAM-GYTYNMETSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,15304,71288739,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)CC8CN(C8)CCO)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(CC6CN(CCO)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL1950081,YAGLFTIBFQFZJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,15308,57391165,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=C(C=C4)OC)OC,COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
CHEMBL1950081,YAGLFTIBFQFZJH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,12900.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.889410289700751,15308,57391165,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C#N)C4=CC=C(C=C4)OC)OC,COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3n[nH]c(C)c23)cc1
CHEMBL249292,YAMNDFFLOPYHJZ-WIYYLYMNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,15319,44442013,CC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)OC(=O)N4CCN(CC4)C(C)(C)CO,CC1CCCC(C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21381763.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,6.522878745280337,15320,17747460,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCCC3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1CC1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
CHEMBL1672622,YAPJZGXRIHUBAY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,,ACS Med. Chem. Lett.,PUBLICATION,,6.0,15322,16070448,C1CC1C(=O)NC2=CN=C(C(=N2)C3=CC=NC=C3)C4=CC=NC=C4,O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1
CHEMBL2059119,YARFTVQMCHDCQY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,53.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.275724130399211,15325,70688512,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N(C)C,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)C)oc2c1
CHEMBL2048497,YBDASUYOOMCJRA-ASDZUOGYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,29000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.5376020021010435,15337,11510297,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)C3(CC(C(C(C3O)O)O)CO)O,CCc1ccc(Cc2cc(C3(O)CC(CO)C(O)C(O)C3O)c(OC)cc2OC)cc1
CHEMBL2048497,YBDASUYOOMCJRA-ASDZUOGYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,15337,11510297,CCC1=CC=C(C=C1)CC2=CC(=C(C=C2OC)OC)C3(CC(C(C(C3O)O)O)CO)O,CCc1ccc(Cc2cc(C3(O)CC(CO)C(O)C(O)C3O)c(OC)cc2OC)cc1
CHEMBL3664657,YBDFPAYNZHIEFN-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,32000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.494850021680094,15338,59635640,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)C#N)C4=CC=CC=C4,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CC(C)(C)C#N)(c2ccccc2)OC1=O
CHEMBL1669422,YBDNLKCSUIZMPU-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,=,4416.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.354970935278858,15340,51039225,CC(C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4,CC(C1=C(CCN(C)Cc2ncc[nH]2)Cc2ccccc21)c1cnccn1
CHEMBL1951341,YBIKJBVQOXSYEV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985743,15342,57398848,C1CCC(C1)NC(=O)C2=CC(=CC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccnc3nc[nH]c23)cc1)Nc1cccc(C(=O)NC2CCCC2)c1
CHEMBL3114733,YBLOSHNBIZTDHF-NQVJXQQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.468521082957745,15344,76314207,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCN(CC3=CC=CC=C3Cl)C(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCN(Cc2ccccc2Cl)C(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3236359,YBMODFWQBWSTTG-FIULFVJVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24601644.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.,J. Med. Chem.,PUBLICATION,,5.920818753952375,15346,90655375,CCC(CS(=O)(=O)C(C)(C)C)N1C(C(CC(C1=O)(C)CC2=NC(=O)ON2)C3=CC(=CC=C3)Cl)C4=CC=C(C=C4)Cl,CCC(CS(=O)(=O)C(C)(C)C)N1C(=O)C(C)(Cc2nc(=O)o[nH]2)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
CHEMBL3115183,YBPGJLVCLREDGV-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,15348,68166092,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCNS(=O)(=O)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(CCNS(C)(=O)=O)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL2010816,YBPKUYHMTYRITD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22306122.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,15349,57328465,C1=CC(=CC=C1NC2=NC(=CN=C2)N)OC3=CC=C(C=C3)OC(F)(F)F,Nc1cncc(Nc2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)n1
CHEMBL496606,YCAMYJGGAXTJHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,6700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.173925197299173,15353,24890872,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
CHEMBL496606,YCAMYJGGAXTJHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,15353,24890872,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC=N4,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12
CHEMBL3393730,YCBGAHFPRWRCEG-VDNLBMKXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25597006.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15354,53497131,CC1CC(N(C1)C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=C(S3)C4=CC=C(S4)C5=CC=C(C=C5)C6=CN=C(N6)C7CC(CN7C(=O)C(C(C)C)NC(=O)OC)C,COC(=O)NC(C(=O)N1CC(C)CC1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c(C6CC(C)CN6C(=O)C(NC(=O)OC)C(C)C)nc5s4)s3)cc2)[nH]1)C(C)C
CHEMBL426851,YCHYUPBHYYIHNM-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15357,24825270,CC(C)CN1C2=C(C(=C(S2)CN3C4=CC=CC=C4N=C3NC)C(=O)N5CCC(C5)O)C(=O)N(C1=O)C,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC(O)C1)c(=O)n(C)c(=O)n2CC(C)C
CHEMBL1641811,YCLHCCNXVIOFPI-RHSMWYFYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21185722.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15361,45112038,CC(C1=CC=C(C=C1)F)C(=O)N(C)C2CCC3=C(C4=C(N3C2)N=CC=C4)CC(=O)O,CC(C(=O)N(C)C1CCc2c(CC(=O)O)c3cccnc3n2C1)c1ccc(F)cc1
CHEMBL3672575,YCLPMWDXYKCXAX-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,200.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.698970004336019,15362,57405865,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CSCC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CSCC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672575,YCLPMWDXYKCXAX-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,300.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.522878745280337,15362,57405865,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CSCC2C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)N2CSCC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL218068,YCMQHZLCRNKFNN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17249648.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,PUBLICATION,,5.292429823902063,15364,10268255,C1CN(CCC1CNC2=NC=NC=C2)C(=O)OCC3=CC=CC=C3,O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1
CHEMBL1085107,YCNCXQNUXCHRRX-ZHPDPMBESA-N,AMG-221,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20465278.0,IC50,>,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).",J. Med. Chem.,PUBLICATION,,4.823908740944319,15365,25207668,CC(C)C1(C(=O)N=C(S1)NC2CC3CCC2C3)C,CC(C)C1(C)SC(NC2CC3CCC2C3)=NC1=O
CHEMBL403999,YCOGAHGFEYEAQE-SJLPKXTDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17988864.0,IC50,<,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,15366,44446997,CCC1CCCC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)C3(CC3)CC4=NC=CO4,CCC1CCCC(C2(Cc3ncco3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL2386285,YCQBLTPGQSYLHD-WCWDXBQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25751283.0,IC50,=,285.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay,Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.,J. Med. Chem.,PUBLICATION,,6.54515513999149,15368,60202715,CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN)C3=CC=CC=C3,CCC(=C(c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1
CHEMBL1834659,YCXMKEVLJQGEKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,15378,56594865,CN(C1=NC=NC(=C1)NC2=CC=C(C=C2)OCCN3CCCC3)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl
CHEMBL1834659,YCXMKEVLJQGEKJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,15378,56594865,CN(C1=NC=NC(=C1)NC2=CC=C(C=C2)OCCN3CCCC3)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl
CHEMBL2425610,YDLJWZHCJHGQOV-MMIABTCFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,15386,72191037,CC(C)(C)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC,COc1cc(CC2C[S+]([O-])CC(NCc3cccc(C(C)(C)C)c3)C2O)cc(F)c1N
CHEMBL3087035,YDNYPKDLLNMZPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,=,16200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.790484985457369,15387,72547284,C1=CN=C(N=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl,O=S(=O)(Nc1ccc(-c2ncccn2)cc1)c1cc(Cl)cc(Cl)c1
CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.221848749616356,15389,134551,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]cc(c56)CC4N(C)C3)(C(C)C)C(=O)N12
CHEMBL3400445,YDPUZUFPFFYPHY-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25782742.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165727,15392,59272024,CC(C)N(CC1CNCC1NC(=O)CCC2=CC=CC=C2)C(=O)C3=CC(=C(C=C3)OC)OCCCOC,COCCCOc1cc(C(=O)N(CC2CNCC2NC(=O)CCc2ccccc2)C(C)C)ccc1OC
CHEMBL1650404,YEBKYXHNDLEMKJ-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21186796.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,PUBLICATION,,5.0,15400,11151568,C1CC(CN(C1)C2=NC=C(C(=O)N2CC3=CC=CC=C3C#N)F)N,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)ncc(F)c1=O
CHEMBL2041171,YEDDTSUKSZDINS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,15404,57384236,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC(=O)NN7,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5cc(=O)[nH][nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL2158299,YEEBLJFZYXYIOQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.7447274948966935,15405,11511719,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CN4CCOCC4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL280981,YEHNDLQWKSUNTD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,9730.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.011887159731648,15409,10029563,C1CCN2C(=C(C3=C2C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)NC6=CN=CC=C6)C1,O=C(Nc1cccnc1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
CHEMBL3422004,YEIDLEQRGTVNQJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.0,15411,71225056,C1CN2C(=NN=C2C3=NC(=CC=C3)C(F)(F)F)CN1C(=O)C4=CC=C(C=C4)F,O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2cccc(C(F)(F)F)n2)C1
CHEMBL2041190,YEMQCJMGXORROI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,15417,49849008,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=NC=CN=C4)C5=CC=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1
CHEMBL3634394,YEPBUHWNLNKZBW-FDVAVYTKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26410074.0,IC50,>=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15420,71768520,CC1=C(C=CC2=C1N=C(C=C2OC3CCN4C(C3)C(=O)NC5(CC5C=CCCCCN(C4=O)C)C(=O)NS(=O)(=O)C6(CC6)C)C7=NC(=CS7)C(F)(F)F)OC,COc1ccc2c(OC3CCN4C(=O)N(C)CCCCC=CC5CC5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)C4C3)cc(-c3nc(C(F)(F)F)cs3)nc2c1C
CHEMBL1923106,YEQCXSBSFLRJJT-DGPALRBDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,15422,57392623,COCCCC1=CC(=CC(=C1)OCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC=CC=C5CO4,COCCCc1cc(CN(C(=O)C2CNCCC23OCc2ccccc23)C2CC2)cc(OCCOC)c1
CHEMBL3127521,YERMBKYNILMCNC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,7.045757490560675,15425,71720911,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)C1CC1c1cccnc1
CHEMBL3127521,YERMBKYNILMCNC-UXHICEINSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,680.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.167491087293763,15425,71720911,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)C1CC1c1cccnc1
CHEMBL3127520,YERMBKYNILMCNC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,6.958607314841775,15426,76311096,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)C1CC1c1cccnc1
CHEMBL3127520,YERMBKYNILMCNC-VQTJNVASSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.920818753952375,15426,76311096,C1C(C1C(=O)NC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3)C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)C1CC1c1cccnc1
CHEMBL3699318,YEYJQOPIRCXAMH-ZAQUEYBZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1760.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.7544873321858505,15432,89718397,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)N8CCSCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCSCC6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3310483,YFFZLXAPKOKACC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,15440,118706537,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)Cl,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl
CHEMBL1909991,YFKUZVBMNGNFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,15444,15950383,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL1909991,YFKUZVBMNGNFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,15444,15950383,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL1909991,YFKUZVBMNGNFRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,15444,15950383,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=CC=C3OC)C4=C(C=C(C=C4)Cl)Cl)CN,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL178516,YFOKBFRTGLSZLU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,139900.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.8541822855081724,15447,3040177,C1=CC(=CN=C1)C2=CN=CN2,c1cncc(-c2cnc[nH]2)c1
CHEMBL3216329,YFUUQKJOCLQHMZ-ISJKLOBTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22695132.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Identification of a dual d OR antagonist/�� OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15449,66550842,CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N.Cl.Cl,COc1ccc(CN(C(=O)C(N)Cc2c(C)cc(C(N)=O)cc2C)C(C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O
CHEMBL248867,YFVOIZOCKPSNFU-GMKZXUHWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,15450,44442000,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4)OC,CCC1CC(OC)CC(COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL248866,YFVOIZOCKPSNFU-JRFVFWCSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15451,44441999,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4)OC,CCC1CC(OC)CC(COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3702795,YFWPXVZAAUNARU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6940.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.158640529545145,15452,89718491,CCCN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CN(C4=C(C=CC=C34)CN5CC6N(C(C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1916559,YGAMOUONCVBLTE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21852130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15455,44547414,C1CN(C2=C1C=C(C=C2)C3=NOC(=N3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(=O)CCC(=O)O,O=C(O)CCC(=O)N1CCc2cc(-c3noc(-c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)ccc21
CHEMBL3353862,YGFQBPYOYXCHSZ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556092.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15459,67953837,CC(C)(C)C1=CC(=NO1)NC(=O)C2CCCN2C3=CC=C(C=C3)C(F)(F)F,CC(C)(C)c1cc(NC(=O)C2CCCN2c2ccc(C(F)(F)F)cc2)no1
CHEMBL496456,YGKYXFALHGAEIL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,5.638272163982407,15461,25033808,C1CC(C2=C(C1)C=C(C=C2)C3=CC(=C(C=C3)F)F)C4=CC=NC=C4.Cl,Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F
CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15469,45272895,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15469,45272895,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153347.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15469,45272895,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
CHEMBL479418,YGTZEUKLDBWBIS-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,15470,44570489,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL479418,YGTZEUKLDBWBIS-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,15470,44570489,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)CC5=CC=C(C=C5)F,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)CC(C)N1
CHEMBL1643780,YGUQHAZHYUGNIM-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21106375.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15471,53319320,CN(C1CCC2=C(C3=C(N2C1)C(=C(C=C3)F)F)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F,CN(C1CCc2c(CC(=O)O)c3ccc(F)c(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1
CHEMBL2207081,YGWURLOZYUXZKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23079519.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,15475,15985912,C1=CC(=C(C=C1S(=O)(=O)NC2=C(C=CC(=C2)Cl)CN3C=CN=N3)Cl)Cl,O=S(=O)(Nc1cc(Cl)ccc1Cn1ccnn1)c1ccc(Cl)c(Cl)c1
CHEMBL436753,YGYLUOKAHBFLCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,15477,11563243,CCN1CCC(CC1)(C2=CC=CC=C2)C(=O)NC3(CCN(CC3)CC4=CC(=CC=C4)OC5=CC=CC=C5Cl)C(=O)O,CCN1CCC(C(=O)NC2(C(=O)O)CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1
CHEMBL1169994,YHEVMXYWTAZKST-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20627722.0,IC50,=,436.52,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.359995853468939,15484,49798462,C1=CC(=C(C=C1S(=O)(=O)NC2=C(N=CC(=C2)Cl)OC3=CC(=CN=C3)Cl)Cl)Cl,O=S(=O)(Nc1cc(Cl)cnc1Oc1cncc(Cl)c1)c1ccc(Cl)c(Cl)c1
CHEMBL2403317,YHNQBDQWYZKMDP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23768906.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,15492,58439416,COC1=C(C(=NC=C1)OC2=CC3=C(C=C2)N(C=NC3=O)CC4=C(C=C(C=C4F)F)F)C(F)(F)F,COc1ccnc(Oc2ccc3c(c2)c(=O)ncn3Cc2c(F)cc(F)cc2F)c1C(F)(F)F
CHEMBL1923128,YHNTXMADPCPYPH-SJHOIFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5800.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,15493,57396098,CCN(CC)CCCC1=C(C(=CC(=C1)CCCOC)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)Cl,CCN(CC)CCCc1cc(CCCOC)cc(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1Cl
CHEMBL240598,YHWFSBOTUBZNFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.795880017344075,15501,23647899,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCC(=O)NC)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)NC)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL1778865,YICPRNFRCVOHKV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21524576.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Iinhibition of CYP3A4,"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15506,54581861,COC1=C(C=CC(=C1)F)C2=NC(=CN=C2)CNCC3CC3,COc1cc(F)ccc1-c1cncc(CNCC2CC2)n1
CHEMBL2041167,YIDRPJAESDFDSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,15509,57388005,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6=CNC(=O)N=C6,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3cnc(=O)[nH]c3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL178781,YIGMADWICHWLTQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,109000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,3.962573502059376,15513,44388612,CC1=CN(C=N1)C2=CN=CC=C2,Cc1cn(-c2cccnc2)cn1
CHEMBL1086754,YIHQDWZWZRGAIH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20149649.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15514,45278805,CC1=C(C=C(N1C)C2=CC=CC=C2)C(=O)NCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C
CHEMBL1076210,YIIXUMVWJVOYNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,15515,46879490,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2NC(=C3C)C,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12
CHEMBL1076210,YIIXUMVWJVOYNW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,9600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.017728766960431,15515,46879490,CC1=C(C(=CC=C1)C)CNC2=NC=CC3=C2NC(=C3C)C,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12
CHEMBL466191,YIJJJJWZXATIQL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19010671.0,IC50,=,58000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.236572006437063,15516,44569927,CC(C)C1=CC(=NC=C1C(=O)NCC2CCOCC2)NC3=C(C=C(C=C3)Cl)Cl,CC(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1
CHEMBL3092130,YIJWSWGNFRVEHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24252546.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15518,59179260,C1=CC=C(C=C1)C2=C(C(=NN2C3=NC(=CS3)C(=O)O)C4=CC=CC=C4)N,Nc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1
CHEMBL534723,YIQFFQJVNKNCNB-FSRHSHDFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16750363.0,IC50,=,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15521,45263449,CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3.Cl,CCOc1ccccc1CC(c1ccccc1)N1CCNCC1
CHEMBL540107,YIQFFQJVNKNCNB-FYZYNONXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16750363.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15522,45265818,CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3.Cl,CCOc1ccccc1CC(c1ccccc1)N1CCNCC1
CHEMBL3260756,YIYAOMUUXPETBC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24182233.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,PUBLICATION,,4.3979400086720375,15529,72793393,CCN1C(=O)N2C(=N1)C(=C(C(=O)N2CC3=CC=C(C=C3)C#N)C4=CN=C(N=C4)N(C)C)C5=CC=C(C=C5)Cl,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(N(C)C)nc3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O
CHEMBL3702764,YIYNUEAQYFZKKF-UWXQCODUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9710.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.012780770091995,15530,89756866,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7CCN(CC7)CCCO,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(CCCO)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3699317,YIZDDSJUVVICBC-WCAWKSPSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,15532,89713903,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CN=C(C=C7)NC(=O)NC8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL489500,YJFULAYRAKPBCY-CXAGYDPISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15535,44564565,CC1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CC3)C(=O)N,CC1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
CHEMBL460962,YJFULAYRAKPBCY-DYVFJYSZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15536,24856362,CC1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CC3)C(=O)N,CC1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
CHEMBL465955,YJFULAYRAKPBCY-FWJOYPJLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19181519.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15537,11442292,CC1CN(CCN1S(=O)(=O)C2=CC=C(C=C2)C(C)(C(F)(F)F)O)CC3(CC3)C(=O)N,CC1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1
CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,600.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.221848749616356,15540,10607,COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O,COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC
CHEMBL2059120,YJLFMPGHIVLBOD-RRPNLBNLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.42021640338319,15542,70688513,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)O)C(=O)C3=CC4=C(C=C3)N=C(O4)N5CCOCC5,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCOCC3)oc2c1
CHEMBL3326585,YJLGMMODESAVMW-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,15543,45380748,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=CC(=C4)OC(F)(F)F)(C)C)C=N1,Cc1cc2c(NC(=O)NC3CC(C)(C)Oc4cc(OC(F)(F)F)ccc43)cccc2cn1
CHEMBL3669001,YJRASZMPGGZLLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320643,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,15547,52936259,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)Cl)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1
CHEMBL3669001,YJRASZMPGGZLLW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320687,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,15547,52936259,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=CN=C(C=C4)Cl)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1
CHEMBL436137,YJSFAHMGDRBZGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17113292.0,IC50,=,42000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.376750709602099,15548,11719421,CC1=C(C(=CC=C1)C)C2=CC3=C(C(=C2)C)N=C(N=N3)NC4=CC=C(C=C4)OCCN5CCCC5,Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1
CHEMBL1923129,YKCXEFNZNYQXHC-ZUKKLESISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,15555,57392624,COCCCC1=CC(=C(C(=C1)CN(C2CC2)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F)Cl)CCCCNS(=O)(=O)C,COCCCc1cc(CCCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)C2CNCCC23OCc2cc(F)c(F)cc23)C2CC2)c1
CHEMBL3237444,YKDDWNDRNJMVDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,5.0,15556,58299601,C1CCC(C1)N2C3=C(C=CN=C3Cl)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6,Clc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12
CHEMBL3601189,YKDGQNXRKZSZOG-ICYYRSKXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15557,117885912,COC1=NC=CC(=C1)NC2=NC=C(C(=N2)NC3CC(C(C3O)O)CO)C4=NC5=CC=CC=C5C=C4,COc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(NC3CC(CO)C(O)C3O)n2)ccn1
CHEMBL1079228,YKGANGZPZGMFOH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.187086643357144,15560,46883196,C1=CC=C(C=C1)CC(CN(CC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC(CC4=CC=CC=C4)NC(=O)OCC5=NC=CS5)NC(=O)OCC6=CN=CS6,O=C(NC(Cc1ccccc1)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
CHEMBL1766186,YKJRYOUVLGHMHB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,15563,54584364,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)C(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(O)c3cnc[nH]3)cc2)c1
CHEMBL26485,YKLMGVJEZXDKGA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998323.0,IC50,=,30150.0,NM,,,,,,,,,,,,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.,J. Med. Chem.,PUBLICATION,,4.52071268352383,15565,9828452,C1CCN2C(=C(C3=C2C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F)C(=O)NCC6=CC=CC=N6)C1,O=C(NCc1ccccn1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2
CHEMBL255590,YKTUSHSSKIWDRY-UHFFFAOYSA-N,JNJ-27390467,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18272363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15578,24180717,C1CN(CCC12COC3=C2C=C(C=C3)CN)C(=O)C4=CC=C(O4)C#CC5=CC=CC=C5,NCc1ccc2c(c1)C1(CCN(C(=O)c3ccc(C#Cc4ccccc4)o3)CC1)CO2
CHEMBL3394736,YKTUZLHYXSJRBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15579,89793496,C1=CC(=NC=C1S(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
CHEMBL3394736,YKTUZLHYXSJRBO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25556090.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15579,89793496,C1=CC(=NC=C1S(=O)C2=CC(=CC(=C2)F)F)CNC(=O)C3=CC4=C(O3)C=NC=C4,O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1
CHEMBL498371,YKVPDUWONPUOHW-ASIDMNOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,77600.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.110138278741812,15581,10647667,CC(C)C1=CC(=CC(=C1O)C(C)C)C=C2CCC(=CC3=CC(=C(C(=C3)C(C)C)O)C(C)C)C2=O,CC(C)c1cc(C=C2CCC(=Cc3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O
CHEMBL498371,YKVPDUWONPUOHW-ASIDMNOUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,77624711.66,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,1.1100000000160524,15581,10647667,CC(C)C1=CC(=CC(=C1O)C(C)C)C=C2CCC(=CC3=CC(=C(C(=C3)C(C)C)O)C(C)C)C2=O,CC(C)c1cc(C=C2CCC(=Cc3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O
CHEMBL3702679,YLAPRUSAFZVMFL-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8520.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.0695604052333,15583,89716376,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)NC(=O)NC8=NC=CC=N8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ncccn6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL467187,YLBKDRAXARKXCP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18625554.0,IC50,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,15584,16225483,CC1C(=O)NN=C(O1)CC2=C(C(=C(C=C2)Cl)OC3=CC(=CC(=C3)C#N)Cl)F,CC1OC(Cc2ccc(Cl)c(Oc3cc(Cl)cc(C#N)c3)c2F)=NNC1=O
CHEMBL2178806,YLBXBHSEZZNJPX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23061660.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,PUBLICATION,,5.337242168318426,15585,70496411,CC1=NN(C(=C1)NC(=O)C2=C3N=CC=CN3N=C2)C4=CC(=CC=C4)Cl,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cccc(Cl)c2)n1
CHEMBL1094851,YLEDBIZRBVHBJQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,15588,46888827,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CCCN(C4)C5CCCCC5,COc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1
CHEMBL2070154,YLESIDOZBVSZQT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,15590,70684602,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=N3)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cccc(-c4ccccc4)n3)[nH]c2c1
CHEMBL208154,YLMRCYCGLCIPMC-IERDGZPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,15599,44410799,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
CHEMBL360771,YLMRCYCGLCIPMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,1488.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.82739706879014,15600,11773824,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
CHEMBL360771,YLMRCYCGLCIPMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,15600,11773824,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
CHEMBL3695713,YLPZTDCVMOWRPZ-CVEARBPZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26602277.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15603,76903477,CN1C=C(C=N1)CNC2=CC(=NC3=CC=NN32)OCC4CC4C5=CC=CC=N5,Cn1cc(CNc2cc(OCC3CC3c3ccccn3)nc3ccnn23)cn1
CHEMBL570867,YLSKCQOVDOZHTQ-VWLOTQADSA-N,BMS-344577,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as a substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4089353929735005,15606,44473100,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)N(C)C)nc3)ccc2o1
CHEMBL570867,YLSKCQOVDOZHTQ-VWLOTQADSA-N,BMS-344577,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BZR as substrate,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,15606,44473100,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)N(C)C)nc3)ccc2o1
CHEMBL570867,YLSKCQOVDOZHTQ-VWLOTQADSA-N,BMS-344577,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19896847.0,IC50,>,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 by HHA assay,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.6989700043360187,15606,44473100,CC1=CC2=C(O1)C=CC(=C2)NC(=NC3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C,Cc1cc2cc(NC(=NC3CCCCN(CC(=O)N4CCCC4)C3=O)NC(=O)c3ccc(C(=O)N(C)C)nc3)ccc2o1
CHEMBL3702780,YLWKSJWNDNVJRD-QARUCVQPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6750.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.170696227168975,15607,89718249,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)NCCN(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3409873,YLZAYQGWWQGQAW-OALUTQOASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25838147.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,15608,89789778,COC1=C(C(=CC=C1)F)C2CC(C(=O)N2CC3=CC4=C(C=C3)OC5=CC=CC=C54)F,COc1cccc(F)c1C1CC(F)C(=O)N1Cc1ccc2oc3ccccc3c2c1
CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1000.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.0,15610,65016,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OC1CCOC1)S(=O)(=O)c1ccc(N)cc1
CHEMBL492661,YMBFUJAHKNUKLJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,15611,44568925,CC1=C(C2=C(C=C1)C(=NO2)NC)C3=CC4=CN=NC(=C4C=C3)C(C)C,CNc1noc2c(-c3ccc4c(C(C)C)nncc4c3)c(C)ccc12
CHEMBL3121951,YMCAVGXTSCNFDE-BBACVFHCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24568313.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,J. Med. Chem.,PUBLICATION,,4.481486060122112,15612,57339460,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CC7(CN6C(=O)C(C(C)C)NC(=O)OC)OCCO7)NC(=O)OC,COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc(-c3ccc(-c4cnc(C5CC6(CN5C(=O)C(NC(=O)OC)C(C)C)OCCO6)[nH]4)cc3)cc2)[nH]1)C(C)C
CHEMBL3417511,YMEFXAYUHCDQHO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25671290.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,PUBLICATION,,4.522878745280337,15613,68075088,CC(C)(CN1C=C(C=N1)C2=NC(=NO2)C3(CCC3)C4=CC=C(C=C4)C5=CN=C(N=C5)N)O,CC(C)(O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CCC3)no2)cn1
CHEMBL496035,YMEJDVRSUORBRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,15614,44583591,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=NC=N4)CO,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12
CHEMBL496035,YMEJDVRSUORBRI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,21000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,15614,44583591,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C(=NC=N4)CO,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12
CHEMBL3234568,YMFDSPVIOOOQTH-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,6.0,15616,90654587,CN1CCN(CC1)C2=CC(=NC(=N2)C(F)(F)F)N3CCCC(C3)C(=O)NCCC4=CC=C(C=C4)C#N,CN1CCN(c2cc(N3CCCC(C(=O)NCCc4ccc(C#N)cc4)C3)nc(C(F)(F)F)n2)CC1
CHEMBL2448721,YMGUXTBLOJPLDX-CVKSISIWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1400.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,5.853871964321762,15619,73355721,CC(=NOC)C1=CC(=C(C=C1)N2C=CN=C2)NC(=O)C3=CN(N=C3)C4=CC=CC=N4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2cnn(-c3ccccn3)c2)c1
CHEMBL2048187,YMSMSUFAXNUPLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15625,11682521,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
CHEMBL2048187,YMSMSUFAXNUPLK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22726929.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,15625,11682521,CC(=O)C1=CC(=C(C=C1)OC)CSC2=NC3=C(N2CC(=O)O)C=CC(=C3)F,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O
CHEMBL2431173,YMYCVXPMSMNWEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050755.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).,J. Med. Chem.,PUBLICATION,,4.522878745280337,15629,53382545,CC1(COC1)NC(=O)C2=NC=C(C=C2)C#CC3=CC(=CC=C3)F,CC1(NC(=O)c2ccc(C#Cc3cccc(F)c3)cn2)COC1
CHEMBL3087038,YMYLYYGGKKEUPE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,15631,72547287,CC1=NC=CC(=C1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL1271763,YNBKEKSKMRNJDI-QUCCMNQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,5.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.259637310505756,15634,52943113,CC1(CC1)C2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)COC(=O)N4CCC(CC4)CO,CC1(C2COCC(COC(=O)N3CCC(CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL1705230,YNDMAMUBWKKHPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21966889.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,PUBLICATION,,4.522878745280337,15639,46869951,C1CCC2(CC1)CC(=O)N(C2=O)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=N4)Cl,O=C(Nc1ccc(N2C(=O)CC3(CCCCC3)C2=O)c(Cl)c1)c1ccccn1
CHEMBL1834184,YNFDIGJKJPNFFD-SJORKVTESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21873051.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15642,51346964,CCC(=O)NC1CCC(C1)C(=O)N(C)C2=CC=C(C=C2)C3=NC4=CC=CC=C4O3,CCC(=O)NC1CCC(C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1
CHEMBL2163834,YNGDZADJXARDMA-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22497444.0,IC50,=,480.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,Discovery and characterization of an inhibitor of glucosylceramide synthase.,J. Med. Chem.,PUBLICATION,,6.318758762624412,15643,46893358,CN1CCN(CC1)C(=O)C(CC2=CC=C(C=C2)Br)NC(=O)C3(CC3)C4=C(C=C(C=C4)Cl)Cl,CN1CCN(C(=O)C(Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1
CHEMBL3234572,YNLLKLRKSASFQV-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24666203.0,IC50,<,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,PUBLICATION,,6.522878745280337,15645,90654591,C1CC(CN(C1)C2=NC(=NC(=C2)N3CCNCC3)C(F)(F)F)C(=O)NCCC4=CN=C(C=C4)C#N,N#Cc1ccc(CCNC(=O)C2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cn1
CHEMBL396884,YNRLVFCAEWMMDT-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,35000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.455931955649724,15649,44433268,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCO,CC(C)CC(NCCO)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL1796298,YNSKBMXZDCLQIV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21669521.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15651,53311230,C1CN2CCC1C(C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=NC=NC=C5)O,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
CHEMBL1796298,YNSKBMXZDCLQIV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21669521.0,IC50,>,50118.72,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.300000029139089,15651,53311230,C1CN2CCC1C(C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=NC=NC=C5)O,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
CHEMBL1796298,YNSKBMXZDCLQIV-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22153941.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15651,53311230,C1CN2CCC1C(C2)(C#CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)NCC5=NC=NC=C5)O,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1
CHEMBL443928,YNSVZSPFLAGJJY-MHZHKKNFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19441819.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.",J. Med. Chem.,PUBLICATION,,5.769551078621726,15652,42633319,CCOC(=O)C(CC1=CC=C(C=C1)NC(=O)C2=C(C=NC=C2Cl)Cl)NC(=O)C3CC(CN3S(=O)(=O)C4=CC=CC(=C4)C#N)NC5CCC5,CCOC(=O)C(Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)C1CC(NC2CCC2)CN1S(=O)(=O)c1cccc(C#N)c1
CHEMBL1668238,YOGIUKKDKOWWHX-VWLOTQADSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21269824.0,IC50,=,7600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.119186407719209,15664,53323639,C1CCC(CC1)C(C(=O)NC2CCCCC2)N3C4=CC(=C(C=C4N=C3C5=CC=C(C=C5)Cl)F)F,O=C(NC1CCCCC1)C(C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21
CHEMBL1222940,YOMZERRKMCWALK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,15669,49865106,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=CC=CC=C4N(C3=O)CC5=CC(=CC=C5)Cl)CC6=CC=NC=C6,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3cccc(Cl)c3)c3ccccc32)CC1
CHEMBL400404,YONIHIOBDIZSOE-DEOSSOPVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17239589.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery and preliminary evaluation of 5-(4-phenylbenzyl)oxazole-4-carboxamides as prostacyclin receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15671,16664733,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)CC3=C(N=CO3)C(=O)NC(CC4=CC=CC=C4)C(=O)O,CC(=O)Nc1cccc(-c2ccc(Cc3ocnc3C(=O)NC(Cc3ccccc3)C(=O)O)cc2)c1
CHEMBL2442750,YOPFAMROKXHVCQ-UHFFFAOYSA-N,QAV680,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24021582.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.",Bioorg. Med. Chem.,PUBLICATION,,4.0,15673,11508736,CC1=C(C2=C(N1CC3=CC=C(C=C3)S(=O)(=O)C)N=CC=C2)CC(=O)O,Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1
CHEMBL2407936,YOTOLLDMPKUKJI-ZNTNEXAZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,15678,136166859,CN(C)C1=CC=C(C=C1)C(CC(=NO)C2=CC=NC=C2)C3=CC=CC=C3,CN(C)c1ccc(C(CC(=NO)c2ccncc2)c2ccccc2)cc1
CHEMBL2387506,YOUUXSOSPBCMRE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,15679,71659755,CC1=CC=C(C=C1)C2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=C(C=CC=C5Cl)F,Cc1ccc(-c2ccc3c(c2)[nH]c(=O)c2[nH]c(-c4c(F)cccc4Cl)nc23)cc1
CHEMBL3318957,YOVGCKBDPOHLAV-CNIHBODFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25050166.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15680,25143506,CCOCC(CC(C)C)NC(=O)C1CNCC(C1O)C(=O)N(C2CC2)C3=NC=C(C=C3)C(C)C,CCOCC(CC(C)C)NC(=O)C1CNCC(C(=O)N(c2ccc(C(C)C)cn2)C2CC2)C1O
CHEMBL1909985,YOVGURDWRKRWGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,15681,15951428,CC1=C(C(=C2CN(C(=O)C2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O
CHEMBL1909985,YOVGURDWRKRWGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,15681,15951428,CC1=C(C(=C2CN(C(=O)C2=N1)CC3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O
CHEMBL362702,YOYYBAFJQXCJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.568636235841013,15684,15778480,CC(=O)C1=CC=C(S1)C2=CN=CC=C2,CC(=O)c1ccc(-c2cccnc2)s1
CHEMBL362702,YOYYBAFJQXCJDK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,26900.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay (Testosterone Hydroxylase). To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,PATENT,,4.570247719997592,15684,15778480,CC(=O)C1=CC=C(S1)C2=CN=CC=C2,CC(=O)c1ccc(-c2cccnc2)s1
CHEMBL1170878,YOZKWQSSNGTVAW-JMAPEOGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21256008.0,IC50,=,24900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.603800652904264,15685,21064282,CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)CC5CCCCC5.Cl,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
CHEMBL498840,YPDJKJWWTFDCSB-UNMCSNQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,62000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.207608310501746,15687,44583663,CC1=C(N2C=C(C=C(C2=N1)NC3C(CC4=CC=CC=C34)O)N5C=CC=CC5=O)C,Cc1nc2c(NC3c4ccccc4CC3O)cc(-n3ccccc3=O)cn2c1C
CHEMBL498840,YPDJKJWWTFDCSB-UNMCSNQZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15687,44583663,CC1=C(N2C=C(C=C(C2=N1)NC3C(CC4=CC=CC=C34)O)N5C=CC=CC5=O)C,Cc1nc2c(NC3c4ccccc4CC3O)cc(-n3ccccc3=O)cn2c1C
CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,700.0,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,6.154901959985743,15688,119584,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
CHEMBL605325,YPQGHFUUPYKNGV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20045645.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15700,46231312,CCCC1=C(OC(=N1)C2=CC=CC=C2)C(=O)NC(C)CN3CCN(CC3)C4=NC=CC=N4,CCCc1nc(-c2ccccc2)oc1C(=O)NC(C)CN1CCN(c2ncccn2)CC1
CHEMBL1935114,YPQYVVMLRSSTFW-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22142542.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15702,56835090,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C(C3)(C)C,CC1CCCN1CCCOc1ccc(C2=NNC(=O)C(C)(C)C2)cc1
CHEMBL567376,YPYOVOMTRUTQLX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,15706,45484915,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC=CC=C3N,CC1(CC(=O)NCc2ccccc2N)CC2(CCCCC2)OO1
CHEMBL456279,YPZFFAQSKANNPU-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.508638306165727,15707,44576677,C1=CC=C(C=C1)C(CN2C(=O)C(=CN(C2=O)CC3=C(C=CC=C3F)C(F)(F)F)C4=CC=C(C=C4)CNCCC(=O)O)N,NC(Cn1c(=O)c(-c2ccc(CNCCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL1684059,YQDMPWIZQSYQGP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21310612.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15710,20111626,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)[NH+](C)C.[Cl-],CC([NH+](C)C)C1(c2ccc3ccccc3c2)CCCCC1
CHEMBL403080,YQRYFSQPEXVGIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18417343.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15722,25066443,CC1=CC(=C(C=N1)CN(C)C)OC2=C(C=C(C=C2)Cl)OC,COc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C
CHEMBL358880,YQZHYXJLJOBTSY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14640550.0,IC50,=,116.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 3A4.,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,PUBLICATION,,6.935542010773082,15731,11368215,CCCCOC1=CC=C(C=C1)N2C=NC=C2C,CCCCOc1ccc(-n2cncc2C)cc1
CHEMBL3092423,YQZRXRDKNNOEBQ-AWEZNQCLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,,ACS Med. Chem. Lett.,PUBLICATION,,4.698970004336019,15732,58239287,C1C(OC(=O)N1C2=CC(=C(C=C2)C3=CC4=NC=NN4C=C3)F)CN5C=CN=N5,O=C1OC(Cn2ccnn2)CN1c1ccc(-c2ccn3ncnc3c2)c(F)c1
CHEMBL2017100,YRFOMLDHCYGMMU-KOSHJBKYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15738,46932138,C1CNCC(C1(C2=CC(=C(C=C2)F)F)O)C3=C(C(=NO3)C4=CC=CC5=CC=CC=C54)Br,OC1(c2ccc(F)c(F)c2)CCNCC1c1onc(-c2cccc3ccccc23)c1Br
CHEMBL3702720,YRIWHMGNXZETGH-ZYBCLOSLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,6020.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.220403508742176,15741,89718208,CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3CCN(CC3)C(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL251672,YROXDMYKXGMKSM-MVKHKFTQSA-N,EPI-12-PALMATOSIDE G,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.0,15746,24762504,CC12CC(OC(=O)C1CCC3(C2CC=CC3=O)COC4C(C(C(C(O4)CO)O)O)O)C5=COC=C5,CC12CC(c3ccoc3)OC(=O)C1CCC1(COC3OC(CO)C(O)C(O)C3O)C(=O)C=CCC12
CHEMBL182438,YRZCYALYRQWTET-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,397.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.401209493236885,15757,44390123,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC(=CC=C3)C(=O)NC)N4C=CN=C4)N(C)C,CNC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1
CHEMBL2041168,YRZWSLXIHSDILJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,15758,49849123,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=NN7,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5ccn[nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL398811,YSDAMWLCNDERLC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,15764,23647900,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CC(=O)NCC)(C)C4=CC(=CC(=C4)F)F,CCNC(=O)CN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21
CHEMBL452101,YSEMBYWAAKOCKW-JOBJLJCHSA-N,"2,5-BIS(4-HYDROXYBENZYLIDENE)CYCLOPENTANONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,5.292429823902063,15768,1712706,C1CC(=CC2=CC=C(C=C2)O)C(=O)C1=CC3=CC=C(C=C3)O,O=C1C(=Cc2ccc(O)cc2)CCC1=Cc1ccc(O)cc1
CHEMBL452101,YSEMBYWAAKOCKW-JOBJLJCHSA-N,"2,5-BIS(4-HYDROXYBENZYLIDENE)CYCLOPENTANONE",,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,5105050.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,2.291999999979078,15768,1712706,C1CC(=CC2=CC=C(C=C2)O)C(=O)C1=CC3=CC=C(C=C3)O,O=C1C(=Cc2ccc(O)cc2)CCC1=Cc1ccc(O)cc1
CHEMBL1277770,YSGLQQUCJIOYSX-TUXUZCGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20942472.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,5.0,15772,49836299,C1CC2(CC1N3CCC(CC3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1
CHEMBL3702750,YSGWJWDNJCCXOX-BCRBLDSWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1100.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.958607314841775,15773,89718334,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCN7CCOCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCOCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702734,YSOJTTZJKQKHPW-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3840.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.4156687756324695,15775,89718434,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NCCCOC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCOC)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1951595,YSWYESAJMAXMOW-NRFANRHFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22177783.0,IC50,<=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,15784,23633350,CN1C2=C(C(=O)N(C1=O)CC(=O)C3=CC(=CC=C3)OC)N(C(=C2C#N)N4CCCC(C4)N)CC5=CC=CC=C5,COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCC(N)C4)n3Cc3ccccc3)n(C)c2=O)c1
CHEMBL3664680,YSYKNPFUILIGKX-UGDMGKLASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,5.0,15788,42605612,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC3CC3)N4CCC(OC4=O)(CC(C)(C)O)C5=CC=CC=C5,CC(c1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2)OC1=O
CHEMBL1615186,YSYXAGMNRKARQB-HJPURHCSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21300546.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,15790,50990920,CC(CC(C)(CS(=O)(=O)N1CCC(CC1)OCC2=C(C=C(C=C2)Cl)Cl)N(C=O)O)C3=NC=C(C=N3)F,CC(CC(C)(CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1
CHEMBL1078565,YTDWKPSJWUXUKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15794,42644088,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCCC(=O)O)C3=CC=CC=C3,O=C(O)CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL254497,YTHVKXJUOMIOFP-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.008773924307505,15799,25008621,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1C(F)(F)F)C(=O)NCC2=NC3=C(N2CC4=CC=CC=C4)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1Cc1ccccc1
CHEMBL3622445,YTLROJLEAFXNIK-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26288685.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,15802,91827654,CC1=NN=C2N1C3=C(CC2)C=C(C=C3)C4=CC(=CN=C4)C(C)(C(F)(F)F)O,Cc1nnc2n1-c1ccc(-c3cncc(C(C)(O)C(F)(F)F)c3)cc1CC2
CHEMBL1269682,YTMFZHXRZWNDFQ-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using midazolam as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288394,15803,12001954,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)C)Cl)C5CC5)Cl,CC(=O)NCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL1269682,YTMFZHXRZWNDFQ-IHLOFXLRSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20843686.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using testosterone as substrate,Design and optimization of new piperidines as renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,15803,12001954,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=C(C=CC(=C4)CCNC(=O)C)Cl)C5CC5)Cl,CC(=O)NCCc1ccc(Cl)c(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL429642,YTQRMQYHTODFGQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17574423.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,15806,23647903,CCC1=C(C(=NC(=N1)N)N)C2=CC3=C(C=C2)OC(C(=O)N3CCCC#N)(C)C4=CC(=CC(=C4)F)F,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC#N)C(=O)C(C)(c1cc(F)cc(F)c1)O2
CHEMBL271087,YTYBFVQRVOHAAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,15810,11562728,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCC(C)(C)N)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCC(C)(C)N)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL3092197,YUAUQYXSYMIINF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.0,15812,25256089,CC(C)(C1CCN(CC1)C(=O)C2=C(C=C(C=C2)S(=O)(=O)C)OC(F)(F)F)S(=O)(=O)C3=CC=CC(=C3)C(F)(F)F,CC(C)(C1CCN(C(=O)c2ccc(S(C)(=O)=O)cc2OC(F)(F)F)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1
CHEMBL1923112,YUCWSJHYTURXJL-JPYJTQIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22071301.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15814,57394339,C1CC1N(CC2=CC=CC=C2Cl)C(=O)C3CNCCC34C5=CC(=C(C=C5CO4)F)F,O=C(C1CNCCC12OCc1cc(F)c(F)cc12)N(Cc1ccccc1Cl)C1CC1
CHEMBL3358962,YUMJYMLVVGYABE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,74000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.130768280269024,15820,71143628,C1=CC(=C(C=C1F)F)C(CN2C=NN=N2)(C(C3=NC=C(C=C3)Cl)(F)F)O,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(Cl)cn1
CHEMBL3407822,YUNJDRCKQFFCDE-KQKCUOLZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,6.522878745280337,15822,118730384,C1C(C1NCCC2=NC(=NC=C2)N3C=CN=C3)CC4=CC(=CC=C4)F.Cl,Fc1cccc(CC2CC2NCCc2ccnc(-n3ccnc3)n2)c1
CHEMBL2021577,YUSAYELUMYRKMP-CIUDSAMLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20170186.0,IC50,>,9000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.045757490560675,15825,70685515,CCOCC1C2C1(CNC2)C,CCOCC1C2CNCC21C
CHEMBL3672584,YUTMPZJGRVRLLE-USIGKAAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,190.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.721246399047171,15826,57406558,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC3=C(CC2C(=O)NC(CCC(CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)CC6=CC=CC=C6)N=CN3,CC(C)c1nc(CN(C)C(=O)N2Cc3[nH]cnc3CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3672584,YUTMPZJGRVRLLE-USIGKAAMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,370.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",Inhibitors of cytochrome P450,,PATENT,,6.431798275933005,15826,57406558,CC(C)C1=NC(=CS1)CN(C)C(=O)N2CC3=C(CC2C(=O)NC(CCC(CC4=CC=CC=C4)NC(=O)OCC5=CN=CS5)CC6=CC=CC=C6)N=CN3,CC(C)c1nc(CN(C)C(=O)N2Cc3[nH]cnc3CC2C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL496227,YUXJYSUSUASGKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,15832,24889679,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC(=N4)CO,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12
CHEMBL496227,YUXJYSUSUASGKW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,15832,24889679,CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)N4C=NC(=N4)CO,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12
CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15840,11702115,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1
CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20800486.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15840,11702115,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1
CHEMBL1835786,YVEZLENKSRCDCK-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15841,56658547,CC1CCCN1CCCOC2=CC=C(C=C2)C3=NN(C(=O)C4=C3CCCC4)C,CC1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCCC3)cc1
CHEMBL1289396,YVHQUIYMYRZMIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,24000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,15844,52941699,CN1CCC2=C(C1)N(C3=C2C=CC(=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5)C,CN1CCc2c(n(C)c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1
CHEMBL2316378,YVITVABZYDPMHU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,=,360.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,6.443697499232713,15847,16738321,COC1=NC(=C(C=C1)NC(=O)C2=CC=C(C3=CC=CC=C32)CN4C=CN=N4)C(=O)NCC5CCOCC5,COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1
CHEMBL2070156,YVJHUNTXORFZSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,=,7800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.107905397309519,15849,70682529,CCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CN=CC(=C3)C4=CC=CC=C4,CCS(=O)(=O)c1ccc2nc(-c3cncc(-c4ccccc4)c3)[nH]c2c1
CHEMBL2436981,YVKIJUOXNIWLHR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24044867.0,IC50,=,4200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,PUBLICATION,,5.376750709602099,15851,46233842,C1=CC2=C(C=CN2)C=C1C3=CNC4=C3C=C(C=N4)C5=CN=C(C=C5)N,Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1
CHEMBL2018571,YVPVVMYVUCYNPA-IBVKSMDESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22214363.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,PUBLICATION,,4.698970004336019,15857,45377018,C1C(CN(C1C(=O)NC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)CN4C=CN=N4)CC5=CC=C(C=C5)F,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)C1CC(Cc2ccc(F)cc2)CN1C(=O)Cn1ccnn1
CHEMBL2347993,YVQSMIMOPKDASQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,4.301029995663981,15860,71280128,CC1=CC2=C(C=C1)C(=NN2CCCN(C)C)C3=CN=C4C(=N3)C(=CN4)C(=O)NC(C)(C)CO,Cc1ccc2c(-c3cnc4[nH]cc(C(=O)NC(C)(C)CO)c4n3)nn(CCCN(C)C)c2c1
CHEMBL2158294,YVQZJJDQRBMAQM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,2300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.638272163982407,15861,11562361,CN1C=C(N=C1)CC(=O)N2CCC(CC2)C3=CC(=C(C=C3)NC(=O)C4=NC=C(N4)C#N)C5=CCCCC5,Cn1cnc(CC(=O)N2CCC(c3ccc(NC(=O)c4ncc(C#N)[nH]4)c(C4=CCCCC4)c3)CC2)c1
CHEMBL3137480,YVSDMZMKZZKBMX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,9000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.045757490560675,15862,76311346,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CN=C3)C4=CN=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1
CHEMBL2180905,YVSHQGAIDXNKCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23098566.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Aminopiperidine Sulfonamide Ca(v)2.2 Channel Inhibitors for the Treatment of Chronic Pain.,J. Med. Chem.,PUBLICATION,,5.292429823902063,15863,23642165,CS(=O)(=O)C1=C(C=C(C=C1)F)C(=O)N2CCC(CC2)N(C3CC3)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F,CS(=O)(=O)c1ccc(F)cc1C(=O)N1CCC(N(C2CC2)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1
CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,9700.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,5.013228265733755,15865,16362,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,15865,16362,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1829477,YVXDOSIKSIZMGR-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21782432.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,15866,53483937,CC1CCCN1CCCOC2=C(C=C(C=C2)C3=NN(C(=O)C=C3)C)F,CC1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)n2)cc1F
CHEMBL1079291,YVZSCJHEMPRIEE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15867,46882950,C1CC(CN(C1)C(=O)NC2=CC=C(C=C2)Cl)(CCCO)C3=CC=CC=C3,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCCO)(c2ccccc2)C1
CHEMBL281284,YWGVRSZHUVTQKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14998324.0,IC50,=,1530.0,NM,,,,,,,,,,,,,,,Inhibitory activity against cytochrome P450 3A4,Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.,J. Med. Chem.,PUBLICATION,,5.815308569182402,15878,11327691,COC1=CC2=C(C=C1)C3=C(N2)C(=NC=N3)N4CCN(CC4)CCC5=CC(=C(C=C5)F)F,COc1ccc2c(c1)[nH]c1c(N3CCN(CCc4ccc(F)c(F)c4)CC3)ncnc12
CHEMBL381751,YWJCZGDVJQLZET-GGHFOJMISA-N,MDL-73811,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19289530.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,PUBLICATION,,5.301029995663981,15880,6436013,CN(CC=CCN)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O,CN(CC=CCN)CC1OC(n2cnc3c(N)ncnc32)C(O)C1O
CHEMBL427844,YWMJHCFRFHOSCO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17098427.0,IC50,>=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,15884,10007859,CC1=CC=C(N1C2=CC(=CC(=C2)NC(=O)C)C(=O)O)C3=C(C=CC(=C3)Br)OCC4=C(C=C(C=C4)F)F,CC(=O)Nc1cc(C(=O)O)cc(-n2c(C)ccc2-c2cc(Br)ccc2OCc2ccc(F)cc2F)c1
CHEMBL1078628,YWSWCOZFNGPLJG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19682899.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15889,46882973,CCN(CC)C(=O)CCC1(CCCN(C1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,CCN(CC)C(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1
CHEMBL103320,YXBJKUHHCYVRFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11714595.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human Cytochrome P450 3A4,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15894,13163256,CC1=CC=C(C=C1)N=CNO,Cc1ccc(N=CNO)cc1
CHEMBL1949937,YXCQTGMZPHHUAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,<,200.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,15895,57403780,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cccnc3)c2c1
CHEMBL1949937,YXCQTGMZPHHUAT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22227212.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Time dependent inhibition of CYP3A4,Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,15895,57403780,CC1=CC(=CC2=C(C3=C(NN=C3N=C12)C)C(C4=CN=CC=C4)O)OC,COc1cc(C)c2nc3n[nH]c(C)c3c(C(O)c3cccnc3)c2c1
CHEMBL1241825,YXCVIEZEXGTOJS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20590088.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,PUBLICATION,,5.3979400086720375,15896,46900778,CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=C5C(=CC=C4)N6C=NC(=C6CO5)C#N,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C#N)ncn4-5)CC3)cccc2n1
CHEMBL1243367,YXEZVHWJNRFKSI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20690643.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.455931955649724,15898,46929554,C1=CC(=CC=C1C(F)(F)F)SCC(C2=CC=NC=C2)C3=CN=CN3,FC(F)(F)c1ccc(SCC(c2ccncc2)c2cnc[nH]2)cc1
CHEMBL600002,YXKHZYNSINIHQT-FZNWDQQTSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26144347.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.42021640338319,15902,24881399,CCCCC(C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=C(N=N2)C(C)(C(C)C)NCC3=CC4=C(C=C3)N=CC=C4,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(C(C)(NCc2ccc3ncccc3c2)C(C)C)nn1
CHEMBL236940,YXPCHDOWVWAKKP-AZGAKELHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,49000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.309803919971486,15909,44433264,CC(C)CC(C1=C(C=CC(=C1)C(F)(F)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)N,CC(C)CC(N)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL271512,YXVBGKJDCKGSED-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,15916,11533783,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCNC)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CNCCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1
CHEMBL325429,YXXLYPOJAQBHAQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698153.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,15919,44341241,CN(C)CCOC1=CC=C(C=C1)N2C=CN=C2,CN(C)CCOc1ccc(-n2ccnc2)cc1
CHEMBL2397193,YYBIDABQEDHOBB-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23726034.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15922,59293715,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=NC(=NC=C3)C(C)C,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)C)n1
CHEMBL3702814,YYESOUKOMYBOTJ-ITSSNUEISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7640.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.11690664142431,15923,89718462,CN1CCC2C1CN(C2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC7CCN(C)C7C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL400345,YYFOFDHQVIODOQ-UHFFFAOYSA-O,COLUMBAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17994701.0,IC50,=,30600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria.,J. Nat. Prod.,PUBLICATION,,4.51427857351842,15924,72310,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)O)OC,COc1cc2c(cc1O)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2
CHEMBL1093286,YYIOQINMOGBBMF-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20206513.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,15928,46883798,CC1=CC(=C(C(=C1)Cl)OCCCC2=CC=C(C=C2)CC(CN)C(=O)N(CC3=C(C=CC(=C3)CCCOC)Cl)C4CC4)Cl,COCCCc1ccc(Cl)c(CN(C(=O)C(CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1
CHEMBL578968,YYQFCQMYJKFEBT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,15936,45484961,CCOC1=CC=CC=C1CNC(=O)CC2(CC3(CCCCC3)OO2)C,CCOc1ccccc1CNC(=O)CC1(C)CC2(CCCCC2)OO1
CHEMBL1093623,YYRVJJWBIQUZNR-CYBMUJFWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20227880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15942,46865978,CC(C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CS3,COc1ccc2c(c1)CC(CCN(C)C)=C2C(C)c1nccs1
CHEMBL2017109,YYTAVUDZQYYPJI-MJGOQNOKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450130.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,"Design and synthesis of potent, isoxazole-containing renin inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,15943,46932514,CC(=O)NCCC1=CC=CC=C1C2=C(C(=NO2)C3CNCCC3C4=CC(=C(C=C4)F)F)Br,CC(=O)NCCc1ccccc1-c1onc(C2CNCCC2c2ccc(F)c(F)c2)c1Br
CHEMBL3702719,YYVFUVDTBBIBHS-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.6020599913279625,15944,89718209,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CCC(CC7)NC(=O)C8=CC=C(C=C8)N(C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL205304,YYYKGWKTHWSOEJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16640325.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).",J. Med. Chem.,PUBLICATION,,5.0,15945,11530171,CCNC(=O)C1CCN(CC1)CC2=CC(=CC=C2)OC3=CC=CC=C3,CCNC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1
CHEMBL3331469,YYZODXXLBSUZSX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.876148359032914,15946,118713757,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4.Cl,c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
CHEMBL421841,YZMDGUHXAPIFCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,15957,515052,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C(C=CN=C41)C,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21
CHEMBL421841,YZMDGUHXAPIFCJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14741280.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,15957,515052,CCN1C2=C(C=C(C=N2)CSC3=CC(=NC(=C3)C)C)C(=O)NC4=C(C=CN=C41)C,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21
CHEMBL551921,YZQWPJWDFKAQSN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19645482.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,PUBLICATION,,5.0,15966,45271618,C1CN(CCC1C2=NC(=NO2)C3=NC4=CC=CC=C4C=C3)C(=O)NC5CC5C6=CC=CC=C6,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1
CHEMBL154751,YZXYDKIBYWKPNU-HXUWFJFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14698201.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,15971,10457343,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC4=C(C=C3)SC(=N4)C)O,Cc1nc2cc(OCC(O)CN3CCN(CC(=O)Nc4c(C)cccc4C)CC3)ccc2s1
CHEMBL486179,ZAALQOFZFANFTF-UHFFFAOYSA-N,PROTOPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16562853.0,IC50,>,80000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,4.096910013008056,15976,185559,CN1CCC2=CC3=C(C=C2C(=O)CC4=CC5=C(C=C4C1)OCO5)OCO3,CN1CCc2cc3c(cc2C(=O)Cc2cc4c(cc2C1)OCO4)OCO3
CHEMBL248879,ZAAVDSHTZRRHIN-MZYLBHOOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17890085.0,IC50,=,24300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.614393726401688,15977,44442006,CCC1CC(CC(N1S(=O)(=O)C2=CC=C(C=C2)Cl)COC(=O)N3CCC(CC3)N4CCCCC4)O,CCC1CC(O)CC(COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1
CHEMBL3664660,ZABDLBFFXBIVLQ-LGGPFLRQSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,15978,59635800,CCN1C=C(C=CC1=O)C2=CC=C(C=C2)C(C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,CCn1cc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O
CHEMBL527199,ZAFTWOVROZMXTK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18524591.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,15983,44561123,CN(CC(=O)N(C)C(CN1CCCC1)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,CN(CC(=O)N(C)C(CN1CCCC1)c1ccccc1)c1ccc(Cl)c(Cl)c1
CHEMBL1951450,ZAHXGOCQYQTQGH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22264486.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Imidazopyridines as selective CYP3A4 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.443697499232713,15986,57395277,C1=CC(=CC=C1C2=CC=NC=C2)NC(=O)NC3=CC=C(C=C3)C4=C5C(=NC=C4)N=CN5,O=C(Nc1ccc(-c2ccncc2)cc1)Nc1ccc(-c2ccnc3nc[nH]c23)cc1
CHEMBL1078891,ZAKBVBOEYCRZJE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,15990,136164063,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCF,Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL1078891,ZAKBVBOEYCRZJE-HSZRJFAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,2200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,15990,136164063,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCF,Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3403818,ZAKFKUPJKWHOLD-VJVWWPDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,15991,71288611,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C7COC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL3403818,ZAKFKUPJKWHOLD-VJVWWPDYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25708617.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,15991,71288611,CCOC(C1CC(C2C(O1)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7CN(CCO7)C8CN(C8)C9COC9)C)C)O)C)C(C)(C)O,CCOC(C1CC(C)C2C(O1)C(O)C1(C)C3CCC4C(C)(C)C(OC5CN(C6CN(C7COC7)C6)CCO5)CCC45CC35CCC21C)C(C)(C)O
CHEMBL1829762,ZASJMILIAPSNCZ-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21786805.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11��-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,PUBLICATION,,5.823908740944319,15994,53473138,CCC(C1=CC=C(C=C1)C2=CC=C(C=C2)F)N3CCC(OC3=O)(CCCO)C4=CC=CC=C4,CCC(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CCCO)(c2ccccc2)OC1=O
CHEMBL3114725,ZATFGROOAKZLGK-RDGATRHJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,630.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.200659450546418,15996,76328654,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCNNC(=O)OCC2=CN=CS2)CC3=CC=CC=C3,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCNNC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1
CHEMBL2425601,ZAUGVKYIEPVOOO-CGBBJANDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23981898.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective ��-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid ��-peptides.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,15999,72191660,CC(C)(CO)C1=CC=CC(=C1)CNC2CS(=O)CC(C2O)CC3=CC(=C(C(=C3)F)N)OC(COC)C(F)(F)F,COCC(Oc1cc(CC2C[S+]([O-])CC(NCc3cccc(C(C)(C)CO)c3)C2O)cc(F)c1N)C(F)(F)F
CHEMBL377531,ZBADYPWHOVIUSC-SSEXGKCCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16480874.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,"Ketopiperazine-based renin inhibitors: optimization of the ""C"" ring.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,16004,11387864,COCCCN1CCCC2=C1C=C(C=C2)OCC3CNCC(=O)N3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC,COCCCN1CCCc2ccc(OCC3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21
CHEMBL1484,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,NICARDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12699389.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Inhibition of human cytochrome P450 3A4,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,J. Med. Chem.,PUBLICATION,,6.376750709602099,16007,4474,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
CHEMBL1484,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,NICARDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,16007,4474,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
CHEMBL1484,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,NICARDIPINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,380.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,6.42021640338319,16007,4474,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
CHEMBL1173326,ZBBONVVBPSZXJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20550118.0,IC50,=,1330.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,J. Med. Chem.,PUBLICATION,,5.876148359032914,16009,46854758,CC(=C(C1=CC=C(C=C1)C2=CC(=CC=C2)N)C3=CC=NC=C3)C,CC(C)=C(c1ccncc1)c1ccc(-c2cccc(N)c2)cc1
CHEMBL2018919,ZBCSNQSIGXWJKU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,4860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,5.313363730737707,16012,741004,COC1=CC2=C(C=C1)N=C(N2)SCC3=CC=C(C=C3)Cl,COc1ccc2nc(SCc3ccc(Cl)cc3)[nH]c2c1
CHEMBL3669003,ZBJOFNRBXVLOMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320645,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,16020,52912228,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCOCC5)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1
CHEMBL3669003,ZBJOFNRBXVLOMA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320689,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,16020,52912228,CC1=CC2=C(NC=C2CC3=CN=C(N=C3)NCC4=NC(=CC=C4)N5CCOCC5)N=C1,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1
CHEMBL3264605,ZBRAJOQFSNYJMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,23000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,16030,69093450,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O,CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cn[nH]n1
CHEMBL3264605,ZBRAJOQFSNYJMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,23000.0,NM,233066,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. ",Metalloenzyme inhibitor compounds,,PATENT,,4.638272163982407,16030,69093450,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O,CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cn[nH]n1
CHEMBL2387591,ZBUKSUSOANBWHJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,16031,71659358,C1=CC=C(C(=C1)C2=NC3=C(N2)C(=O)NC4=C3C=C(C=C4)Br)Cl,O=c1[nH]c2ccc(Br)cc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL2347184,ZBUUPRZMJYAPQF-QSCLJHCWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23586711.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.,J. Med. Chem.,PUBLICATION,,5.468521082957745,16032,57415261,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CO3)CC4=CC=CC=C4,CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cnco2)Cc2ccccc2)C(C)C)cs1
CHEMBL514681,ZBWMUFAKPSHRGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16034,44578914,C1=CC=C(C=C1)CCC(=O)NCC(=O)NC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(CCc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL121550,ZBYUCNDWIVKTRN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,14552748.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16036,44346578,C1=CC=C(C(=C1)C2=NC(C3=CN=CN3C4=C2C=C(C=C4)Cl)O)F,OC1N=C(c2ccccc2F)c2cc(Cl)ccc2-n2cncc21
CHEMBL3264597,ZBZKIRAMMFHRIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24775307.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.2441251443275085,16037,56968076,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NNN=C3)O,COc1cc2ccc(C(O)(c3cn[nH]n3)C(C)C)cc2cc1OC
CHEMBL3264597,ZBZKIRAMMFHRIY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,57000.0,NM,233064,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. ",Metalloenzyme inhibitor compounds,,PATENT,,4.2441251443275085,16037,56968076,CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC)OC)(C3=NNN=C3)O,COc1cc2ccc(C(O)(c3cn[nH]n3)C(C)C)cc2cc1OC
CHEMBL3217198,ZCBRBLDHBXTQSQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21699209.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,16040,90665208,C1CC2=C(C=CC(=C2)N=C(C3=CC=CS3)N)N(C1)C4CCNCC4.Cl.Cl,NC(=Nc1ccc2c(c1)CCCN2C1CCNCC1)c1cccs1
CHEMBL1970317,ZCCJKVBTHCOISJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22465635.0,IC50,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 preincubated for 15 mins,Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,16044,49830359,CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC=C(C=C4)NC(=O)NC5=CC(=CC=C5)F)N,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1
CHEMBL1970317,ZCCJKVBTHCOISJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22465635.0,IC50,=,7900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.102372908709558,16044,49830359,CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC=C(C=C4)NC(=O)NC5=CC(=CC=C5)F)N,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1
CHEMBL410333,ZCDQMYGMUJCSPB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18318469.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.",J. Med. Chem.,PUBLICATION,,5.0,16046,15950271,C1C(=O)N(C(=O)C12C3=C(C=CC(=C3)Cl)N(C2=O)CC(=O)O)CC4=CC=CC=C4,O=C(O)CN1C(=O)C2(CC(=O)N(Cc3ccccc3)C2=O)c2cc(Cl)ccc21
CHEMBL180348,ZCFKCDRXDKIAQV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,16049,11154980,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)CC(=O)O)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(CC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL2095208,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,COBICISTAT,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,16050,25151504,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL3115180,ZCIGNRJZKPOIKD-KIGLDFBWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,16051,59414201,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
CHEMBL208443,ZCIYBFFBVPVYLH-FGZHOGPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,3300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,16052,11315814,CCC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3)N(C)C,CCC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C
CHEMBL564840,ZCNKPALYFZNAFQ-DBKRXAPLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19537798.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of testosterone 6-beta-hydroxylation,"Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.",J. Med. Chem.,PUBLICATION,,4.0,16057,44189732,C1CC2CC1C(C23CC3)CN4CCC(CC4)N5C6=CC=CC=C6N(C5=O)CC(CO)O.Cl,O=c1n(CC(O)CO)c2ccccc2n1C1CCN(CC2C3CCC(C3)C23CC3)CC1
CHEMBL1087367,ZCRCTVHOBQJBNB-QGZVFWFLSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16059,46889257,CN(C)C1CCN(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,COc1ccc(Cn2c(N3CCC(N(C)C)C3)nc3ccccc32)cc1
CHEMBL14189,ZCUJYXPAKHMBAZ-UHFFFAOYSA-N,2-PHENYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,16061,69591,C1=CC=C(C=C1)C2=NC=CN2,c1ccc(-c2ncc[nH]2)cc1
CHEMBL14189,ZCUJYXPAKHMBAZ-UHFFFAOYSA-N,2-PHENYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,16061,69591,C1=CC=C(C=C1)C2=NC=CN2,c1ccc(-c2ncc[nH]2)cc1
CHEMBL14189,ZCUJYXPAKHMBAZ-UHFFFAOYSA-N,2-PHENYLIMIDAZOLE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,500000.0,NM,,,,binding,,,,,,,,,,,,,,,,3.3010299956639813,16061,69591,C1=CC=C(C=C1)C2=NC=CN2,c1ccc(-c2ncc[nH]2)cc1
CHEMBL10663,ZCWOGLIPVLGIOM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,16066,10168216,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)Cl)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2
CHEMBL3582472,ZCWSKWSPXNSPLS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26005536.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16067,56645570,C1CC1N2C3=CC(=C(C=C3N=C2C4=CC(=CN=C4)F)F)F,Fc1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1
CHEMBL3358940,ZDCRSQSGCDAAAC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,6.154901959985743,16074,118723175,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)S(=O)(=O)C,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(C)(=O)=O)c1
CHEMBL1272153,ZDDBSJXDOTZFGP-IFMALSPDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,=,11.3,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.94692155651658,16075,50898445,C1CC1CC2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CCC6(CCN6)CC5,O=C(OC1(C2COCC(CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1
CHEMBL1097079,ZDJZIVFLUPLDLB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20429511.0,IC50,=,1628.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,J. Med. Chem.,PUBLICATION,,5.788345599446817,16078,46237259,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC=C(C=C5)F)C)OC,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(F)cc1)cc(=O)n2C)c1cncn1C
CHEMBL3357635,ZDRUKZASWZMRRR-GXHLCREISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25409491.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method,A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles.,J. Med. Chem.,PUBLICATION,,5.0,16082,71244643,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C(=CCN4CCCCC4)F,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C(F)=CCN1CCCCC1
CHEMBL3358936,ZDRXNMVEXXVGIO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,16083,118723172,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)N3CCOCC3)(C(F)(F)F)O)C4=CC(=CC=C4)O,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(O)c1
CHEMBL1761535,ZDTOKBCZSLOGNR-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16086,25119357,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC5(CCCC5)C(=O)O)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1
CHEMBL1761535,ZDTOKBCZSLOGNR-AARKOHAPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16086,25119357,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCCC5(CCCC5)C(=O)O)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1
CHEMBL3326583,ZDWYNWDEQXOWGK-LJQANCHMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25100568.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",J. Med. Chem.,PUBLICATION,,4.698970004336019,16090,46191499,CC1=CC2=C(C=CC=C2NC(=O)NC3CC(OC4=C3C=C(C=C4F)F)(C)C)C=N1,Cc1cc2c(NC(=O)NC3CC(C)(C)Oc4c(F)cc(F)cc43)cccc2cn1
CHEMBL930,ZDXPYRJPNDTMRX-VKHMYHEASA-N,GLUTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,16092,5961,C(CC(=O)N)C(C(=O)O)N,NC(=O)CCC(N)C(=O)O
CHEMBL930,ZDXPYRJPNDTMRX-VKHMYHEASA-N,GLUTAMINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,16092,5961,C(CC(=O)N)C(C(=O)O)N,NC(=O)CCC(N)C(=O)O
CHEMBL2018909,ZEGLOXZHHNZQFC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.301029995663981,16101,4817293,CC(C)CSC1=NC2=C(N1)C=C(C=C2)OC,COc1ccc2nc(SCC(C)C)[nH]c2c1
CHEMBL3331507,ZEIUBTWYEVLKJP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.301029995663981,16103,118713806,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC(=CC=C4)Cl,Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1
CHEMBL2441208,ZENSLLXCLNJAMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16110,46212588,C1CCN(CC1)C2=NC(=C(O2)C(=O)NC3=CN=C(C=C3)N4CCN(CC4)C(=O)NC5=CC=CC=C5Cl)C(F)(F)F,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F
CHEMBL2441208,ZENSLLXCLNJAMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2D6 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,16110,46212588,C1CCN(CC1)C2=NC(=C(O2)C(=O)NC3=CN=C(C=C3)N4CCN(CC4)C(=O)NC5=CC=CC=C5Cl)C(F)(F)F,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F
CHEMBL2441208,ZENSLLXCLNJAMF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24120540.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) coincubated with substrate,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,16110,46212588,C1CCN(CC1)C2=NC(=C(O2)C(=O)NC3=CN=C(C=C3)N4CCN(CC4)C(=O)NC5=CC=CC=C5Cl)C(F)(F)F,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F
CHEMBL14460,ZETBBVYSBABLHL-UHFFFAOYSA-N,SB-243213,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,10737744.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,PUBLICATION,,4.0,16113,443391,CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2
CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24974340.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,16117,60835,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCCC(Oc1cccc2ccccc12)c1cccs1
CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.356547323513812,16117,60835,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCCC(Oc1cccc2ccccc12)c1cccs1
CHEMBL3237704,ZEWPRVBMQMQROZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24641103.0,IC50,=,9500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.",J. Med. Chem.,PUBLICATION,,5.022276394711152,16119,58299870,CC1(CCC(CC1)N2C3=C(C=CN=C3)C4=CN=C(N=C42)NC5=NC=C(C=C5)N6CCNCC6)C,CC1(C)CCC(n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1
CHEMBL2437433,ZEYMAJZOUSDWDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24050887.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,16121,10075685,C1CN(CCC1C(=O)N2CCC(CC2)N3C4=C(C=C(C=C4)F)N(C3=O)C5=NC=CN=C5)CC6=CC(=NC=C6)N,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cnccn5)c5cc(F)ccc54)CC3)CC2)ccn1
CHEMBL452864,ZEZPDHKACVMMCD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19053768.0,IC50,=,3860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,J. Med. Chem.,PUBLICATION,,5.413412695328245,16122,11176403,C1CCC(CC1)NC(=NC2CCCCC2)SCC3=CSC4=NCCN34,C1=C(CSC(=NC2CCCCC2)NC2CCCCC2)N2CCN=C2S1
CHEMBL3407810,ZFCKGWSPRRORFE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25489882.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,"Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,16124,118730369,C1=CC(=CC(=C1)F)CCCNCCC2=NC(=NC=C2)N3C=CN=C3.Cl,Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1
CHEMBL584886,ZFHIOYANRKWHPJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19699641.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,16127,45484894,CC1(CC2(CCCCC2)OO1)CC(=O)NCC3=CC4=C(CCO4)C=C3,CC1(CC(=O)NCc2ccc3c(c2)OCC3)CC2(CCCCC2)OO1
CHEMBL3702815,ZFJGYPUDHCXOCY-WSQZCZOMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3910.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.407823242604133,16128,89718464,CCN1CCC2(C1)CCN(C2)C3=NC=C(C=C3)NC(=O)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7(CCN(CC)C7)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3702760,ZFNMWMGBWJLLBH-HEVIKAOCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,22290.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.651889931519762,16133,89718228,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NN7CCOCC7,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCOCC5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1909994,ZFPIDBLQXYWDHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,16135,15951431,CC1=C(C(=C2CN(C(=O)C2=N1)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)CN,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(Cl)cc1)C2=O
CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,,binding,,,,,,,,,,,,,,,,5.0,16142,2153,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,-1.0,IC50,>,10000.0,NM,,,tissue,binding,,,,,,,,,,,,,,,,5.0,16142,2153,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
CHEMBL498252,ZGALKRMWGKUOEJ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,16144,44583666,CC1=C(N2C=C(C3=C(C2=N1)NC(CC3)C4=CC=CC=C4)N5C=NC=N5)C,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CCC(c1ccccc1)N3
CHEMBL498252,ZGALKRMWGKUOEJ-KRWDZBQOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19467868.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,16144,44583666,CC1=C(N2C=C(C3=C(C2=N1)NC(CC3)C4=CC=CC=C4)N5C=NC=N5)C,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CCC(c1ccccc1)N3
CHEMBL256937,ZGGCVDLJPIVYGN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18502123.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Development of potent and selective small-molecule human Urotensin-II antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,16152,44449171,COCCN(CC(=O)N1CCCC(C1CN2CCCC2)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1
CHEMBL3699324,ZGSOWIAWZLPMBJ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,8070.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.09312646527793,16161,89718211,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC(=CC=C8)O,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(O)c6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3673941,ZGVRUEHWRJFEDB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,5000.0,NM,320659,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,16163,52933789,CCS(=O)(=O)NC1=CC=CC=C1CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)C)F,CCS(=O)(=O)Nc1ccccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
CHEMBL3699329,ZGYCWFMKMMGTNI-MJPWBCPGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,19500.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.709965388637482,16166,89718410,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=C(C=C8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2057518,ZGYNRHPMXDOXFV-LOSJGSFVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22765892.0,IC50,=,28.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,16167,59603304,CCNC1=NC2=C(O1)C=C(C=C2)C(=O)N(CC(C)C)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCNc1nc2ccc(C(=O)N(CC(C)C)CC(O)C(Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1
CHEMBL179618,ZHBLIWDUZHFSJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15634016.0,IC50,=,57000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration value against human cytochrome P-450 3A4,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,PUBLICATION,,4.2441251443275085,16169,595145,C1=CC(=CN=C1)C2=CC=CS2,c1cncc(-c2cccs2)c1
CHEMBL3358944,ZHDQJPLHDTXEKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25516791.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,16171,58026134,CC(C)(CC(CC1=CC2=CC(=NC=C2N1)S(=O)(=O)C)(C(F)(F)F)O)C3=CC=CC=C3S(=O)(=O)C,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O
CHEMBL3706622,ZHHNHYJWRCZSIY-JJCSDTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12852969.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of human liver microsome Cytochrome P450 3A4,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,16175,122197303,CC(C)(C1=NC=C(O1)C2=C(C=CN=C2)Cl)N3CCN(C(C3)C(=O)NCC(F)(F)F)CC(CC(CC4=CC=CC=C4)C(=O)NC5C(COC6=CC=CC=C56)O)O,CC(C)(c1ncc(-c2cnccc2Cl)o1)N1CCN(CC(O)CC(Cc2ccccc2)C(=O)NC2c3ccccc3OCC2O)C(C(=O)NCC(F)(F)F)C1
CHEMBL3298905,ZHKYFXNJJRCRFO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,=,11540.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,4.937794191180288,16179,68235029,CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCN(CC4)C5=CC=C(C=C5)OC(F)(F)F,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1
CHEMBL3137448,ZHLMDGGVEXYXHM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.0,16180,76329429,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)CC4=CC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1
CHEMBL1077933,ZHOHXFLPKBOXJU-FQLXRVMXSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19679477.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,16182,46883339,CC(C)CCN(CC(CC1=CC=CC=C1)NC(=O)OCC2=CN=CS2)CC(CC3=CC=CC=C3)NC(=O)OCC4=NC=CS4,CC(C)CCN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1
CHEMBL3115171,ZHRJGVGXVBKWCG-PUCLRWMGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,16187,59721278,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(COC)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4,COCC(NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)NC(CCC(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
CHEMBL1222717,ZHXRHBJNZARCMY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20685118.0,IC50,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,16192,49864936,COCCN1C2=CC=CC=C2N(C1=O)C3CCN(CC3)C(=O)C4CCN(CC4)CC5=CC=NC=C5,COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21
CHEMBL604249,ZHYPMHNQQRIWRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20000469.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by LCMS/MS assay,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,PUBLICATION,,4.869666231504994,16193,25054568,CC1=C(C=CC(=C1)C(=O)NCC2=CC(=CC=C2)C(=O)NC3=CC=C(C=C3)CN(C)C)OC,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C
CHEMBL252239,ZIBFWTNGDIVMTK-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18243692.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Imidazopyridines: a novel class of hNav1.7 channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,16198,44447279,CC(C)(C)OC(=O)NC(CC1=CC=CC=C1)C(=O)NCC2=NC3=C(N2C4(CC4)C5=CC=CC=C5)N=CC=C3,CC(C)(C)OC(=O)NC(Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
CHEMBL3422246,ZIBHVERILBHVJF-AAJLLMFJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25781223.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.,J. Med. Chem.,PUBLICATION,,4.522878745280337,16199,86343365,CN1C=C(C=N1)C2CC3C(SC(=NC3(CO2)C4=C(C=C(C=C4)F)F)N)CF,Cn1cc(C2CC3C(CF)SC(N)=NC3(c3ccc(F)cc3F)CO2)cn1
CHEMBL3318423,ZIIOGYPKQIDCAA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16203,118708881,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2C#N)C3=CC=CC=C3,N#Cc1ccccc1SC1=C(O)CC(c2ccccc2)CC1=O
CHEMBL2413882,ZIJAFBZNFLICHW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23896611.0,IC50,=,1450.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis,"Tetrazole-based deoxyamodiaquines: Synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",Bioorg. Med. Chem.,PUBLICATION,,5.838631997765025,16205,71770282,CC(C)(C)N1C(=NN=N1)C(C2=CC(=CC=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)N5CCCC5,CC(C)(C)n1nnnc1C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)N1CCCC1
CHEMBL1649685,ZIPGXLPLMWBESM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21128618.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by fluorescence assay,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,PUBLICATION,,5.0,16210,24951944,CN1CCC2=C(C1)N(N=C2C(F)(F)F)C3=CC=C(C=C3)CN4CCCC4=O,CN1CCc2c(C(F)(F)F)nn(-c3ccc(CN4CCCC4=O)cc3)c2C1
CHEMBL3114734,ZIPRFFCNESKMRB-PPTMTGTBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24411125.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.455931955649724,16212,76321486,CC(C)CN(CCC(CC1=CC=CC=C1)NC(=O)C(CCN2CCOCC2)NC(=O)N(C)CC3=CSC(=N3)C(C)C)C(=O)OCC4=CN=CS4,CC(C)CN(CCC(Cc1ccccc1)NC(=O)C(CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)OCc1cncs1
CHEMBL258324,ZISAHLADKQRRPH-NTCNTBNZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18061443.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16213,44455035,CC(C1=C(C=C(C=N1)C2=C(C(=CC(=C2)Cl)F)C3=NN(N=N3)C)F)NC(=O)C(C)(C(F)(F)F)O,CC(NC(=O)C(C)(O)C(F)(F)F)c1ncc(-c2cc(Cl)cc(F)c2-c2nnn(C)n2)cc1F
CHEMBL116438,ZIUSSTSXXLLKKK-KOBPDPAPSA-N,CURCUMIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249473.0,IC50,=,16300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,PUBLICATION,,4.787812395596042,16215,5281767,COC1=C(C=CC(=C1)C=CC(=CC(=O)C=CC2=CC(=C(C=C2)O)OC)O)O,COc1cc(C=CC(=O)C=C(O)C=Cc2ccc(O)c(OC)c2)ccc1O
CHEMBL3127526,ZJADCXIYQQSUTG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.0,16218,76336447,C1COCCC1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)C1CC1c1cccnc1
CHEMBL3127526,ZJADCXIYQQSUTG-RBUKOAKNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24405419.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT).,J. Med. Chem.,PUBLICATION,,5.0,16218,76336447,C1COCCC1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3CC3C4=CN=CC=C4,O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)C1CC1c1cccnc1
CHEMBL451331,ZJATUHGFXPEBQJ-HHHXNRCGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,2.4,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,16219,135960724,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCC(CC5)N6CCN(CC6)C,Cc1cc(N2CCC(N3CCN(C)CC3)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL382574,ZJCPXNRESMOODE-OAQYLSRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,16221,44411116,CC(C)(COC1=CC2=C(C=C1)C=C(C=C2)C(C(C)(C)N(C)C)N3C=CN=C3)C(=O)O,CN(C)C(C)(C)C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
CHEMBL1952142,ZJDHFPFSTLUYKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22266039.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 by luminescent assay,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,16222,53372790,COC1=CC(=NC2=C1N=NN2C3=CC(=CC=C3)OC(F)(F)F)NCC4CCNCC4,COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1
CHEMBL3310993,ZJDSMAHFPFFPMR-BJOHPYRUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24948565.0,IC50,=,32000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,16224,24802616,CC(C1=NC=NC=C1F)C(CN2C=NN=N2)(C3=C(C=C(C=C3)F)F)O,CC(c1ncncc1F)C(O)(Cn1cnnn1)c1ccc(F)cc1F
CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19128860.0,IC50,=,7447.32,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.",Eur. J. Med. Chem.,PUBLICATION,,5.127999984783137,16226,3478,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
CHEMBL479072,ZJRBVCCQUXNYDM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16239,24649020,COC1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=C(C=C3)F,COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1
CHEMBL1766183,ZKDHBAXMHDLJPU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,16250,18668617,CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)C(C)(C3=CN=CN3)O,CC(=O)Nc1cccc(-c2ccc(C(C)(O)c3cnc[nH]3)cc2)c1
CHEMBL270654,ZKEREZNJKGRMFY-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16253,25110821,CC1=CC(=NN1C2=NC(=NC(=C2)NC(=O)CC3=CC=C(C=C3)S(=O)(=O)C)C4=CC=CC=N4)C,Cc1cc(C)n(-c2cc(NC(=O)Cc3ccc(S(C)(=O)=O)cc3)nc(-c3ccccn3)n2)n1
CHEMBL483574,ZKNOJWWMOBXREH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18842034.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,16258,11641686,CC1=C(C(N=C(N1)C2=CN=C(C=C2)OC)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=CC5=C(C=C4)NN=C5,COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cn1
CHEMBL496262,ZKPQJJRSNGTTFM-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18672868.0,IC50,=,13841.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",J. Med. Chem.,PUBLICATION,,4.858832531353768,16260,25033652,C1CC2=C(C=CC(=C2)C3=CC(=C(C=C3)F)F)C(C1)(C4=CC=NC=C4)O,OC1(c2ccncc2)CCCc2cc(-c3ccc(F)c(F)c3)ccc21
CHEMBL2158291,ZKTXNDLMIQBAIK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,5.721246399047171,16262,11698924,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)C4=C[N+](=CC=C4)[O-])NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)c4ccc[n+]([O-])c4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL3702729,ZKWHQYDCQFSQAF-YDAXCOIMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11800.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.928117992693875,16266,89718433,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)N7CC(C7)N8CCC(CC8)OC,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCC(OC)CC6)C5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL1834660,ZKXNIXASIHIFMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,6.0,16267,56594866,CN(C)CCCC1=CC=C(C=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl
CHEMBL1834660,ZKXNIXASIHIFMC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21936542.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using DBF as substrate,"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase.",J. Med. Chem.,PUBLICATION,,5.0,16267,56594866,CN(C)CCCC1=CC=C(C=C1)NC2=CC(=NC=N2)N(C)C(=O)NC3=C(C(=CC(=C3Cl)OC)OC)Cl,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl
CHEMBL3702789,ZLGADOMKEUBDTC-DWQLLFNGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,21060.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,4.676541633150532,16280,89718376,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C(=O)NC7=CN=C(C=C7)N8CCOCC8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL2181088,ZLRQBYKTDVAMPK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21604762.0,IC50,=,2500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,PUBLICATION,,5.6020599913279625,16292,73321266,CC1=CN=C2NC3=CC(=C(C=C3)OCCN4CCCC4)COCC=CCOCC5=CC(=CC=C5)C1=N2,Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2
CHEMBL1224382,ZLRRLSAVNUFCQT-LBPRGKRZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20724153.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16293,44539967,CC1=NN(N=N1)C(CCNC)C2=CC(=C(C=C2)Cl)Cl,CNCCC(c1ccc(Cl)c(Cl)c1)n1nnc(C)n1
CHEMBL3604722,ZLSZDEARRQRWGO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26267483.0,IC50,=,7943.28,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.",J. Med. Chem.,PUBLICATION,,5.100000128334196,16295,122185963,CC1=CC(=C2C=CC=C(C2=N1)C(=O)N)NCC3=C(C=CC=C3Cl)Cl,Cc1cc(NCc2c(Cl)cccc2Cl)c2cccc(C(N)=O)c2n1
CHEMBL1688243,ZMCJFJZOSKEMOM-DNKZPPIMSA-N,INCB-9471,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,,ACS Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,16306,49871007,CCOC1CC2=C(C1N3CCN(CC3C)C4(CCN(CC4)C(=O)C5=C(N=CN=C5C)C)C)C=CC(=C2)C(F)(F)F,CCOC1Cc2cc(C(F)(F)F)ccc2C1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)CC1C
CHEMBL3699081,ZMHFHDVAVPEGFF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,11000.0,NM,273497,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",Metalloenzyme inhibitor compounds,,PATENT,,4.958607314841775,16310,91669042,C1=CC(=C(C=C1F)F)C(CN2C=NN=C2)(C(C3=NC4=C(C=C3)C=C(C=C4)Br)(F)F)O,OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1ccc2cc(Br)ccc2n1
CHEMBL3608687,ZMIOQWILBZBCHW-SECBINFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.0,16311,86274489,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)Cl)C4=NC(=NS4)C,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)cc2)C3C)n1
CHEMBL1258873,ZMIWBFCFIBJHCH-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20801030.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16312,16679707,CC(C)N1CCC(CC1)OC2=CC3=C(C=C2)N4CCN(C(=O)C4=C3)C,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(C)C2=O)CC1
CHEMBL10600,ZMQFSABOKCOPMT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12643913.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against CYP450 3A4 isozyme,The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944319,16322,10233517,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)SC,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(SC)c(=O)nc1SCc1ccc(F)cc1
CHEMBL2017275,ZMSXXNUUWMPXGF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22386529.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,16324,70681172,CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC(=C3NC4=CC=CC=C4CCN5CCOCC5)C(=O)N)OC,COc1cc2c(Nc3ccccc3CCN3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C
CHEMBL1669417,ZMXXHEQIAQJFTR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16329,51039227,C1CN(CC1F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,FC1CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
CHEMBL3298835,ZNBAXIPHEFMSPS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24870926.0,IC50,=,2070.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,PUBLICATION,,5.684029654543083,16332,71293843,CCC1=C(N2C=CC(=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)F,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1
CHEMBL2436333,ZNEDXNJVZVHOKQ-GYUFFBBGSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,6.0655015487564325,16334,72711254,CC(C(=O)NC1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=CC=C5F)NC.Cl,CNC(C)C(=O)NC1CN(C(=O)c2ccccc2F)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O
CHEMBL3699320,ZNEQYXFNVWWCOJ-MVRBIKRMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7040.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.152427340857888,16335,89718402,CN1CCN(CC1)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C4=CN(C5=C(C=CC=C45)CN6CC7N(C(C6=O)CC8=CC=C(C=C8)O)C(=O)CN(N7C(=O)NCC9=CC=CC=C9)CC=C)C,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C)CC7)cc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL257670,ZNHZMFMDDLFSPW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18249540.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16338,44454834,CC1=CC=C(O1)C2=NC(=CC(=N2)N3C(=CC(=N3)C)C)NC(=O)CC4=CC(=CC(=C4)OC)OC,COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(OC)c1
CHEMBL593763,ZNILTQJFNAYPDD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19810674.0,IC50,=,5000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4,"Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.",J. Med. Chem.,PUBLICATION,,5.301029995663981,16340,23657438,CNCC1=CC(=O)OC2=C1C=CC(=C2)OCC3=CC(=CC=C3)Cl.CS(=O)(=O)O,CNCc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12
CHEMBL429585,ZNNAAXZOLAOTRD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18324761.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.",J. Med. Chem.,PUBLICATION,,4.301029995663981,16347,24824450,COC1=CC2=C(C=CN=C2C=C1OC)OC3=C(C4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=C(C=C5)Cl)F,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3F)c2cc1OC
CHEMBL2316383,ZOHCTKDFWBPLPP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23227781.0,IC50,>,20000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,PUBLICATION,,4.698970004336019,16362,71544707,CS(=O)CC1=CC=C(C2=CC=CC=C12)C(=O)NC3=C(N=CC=C3)C(=O)NCC4CCOCC4,C[S+]([O-])Cc1ccc(C(=O)Nc2cccnc2C(=O)NCC2CCOCC2)c2ccccc12
CHEMBL2407952,ZOISCDMRVZOZGO-YYDJUVGSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23831134.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16363,136166845,CC1=CC=CC=C1C(CC(=NO)C2=CC(=NC=C2)C)C3=CC=C(C=C3)C(=O)O,Cc1cc(C(CC(c2ccc(C(=O)O)cc2)c2ccccc2C)=NO)ccn1
CHEMBL3137456,ZOLYPCMRQHGHCV-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,1800.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.7447274948966935,16367,76322226,C1CN(CCC1N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)C4=NC=CC=N4,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1
CHEMBL85080,ZOLZTTFIWWNGSG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,12182870.0,IC50,>,500.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,16368,23395808,CN1C=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N(CC4=CC=C(C=C4)C5=CC=C(C=C5)Cl)CC(=O)N(C)C,CN(C)C(=O)CN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1
CHEMBL445691,ZOMSEVOHXDVESY-MHZLTWQESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18442910.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693163,16370,44576678,COC(=O)CCCNC(CN1C(=O)C(=CN(C1=O)CC2=C(C=CC=C2F)C(F)(F)F)C3=CC=CC=C3Cl)C4=CC=CC=C4,COC(=O)CCCNC(Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1
CHEMBL3664687,ZORFLCOGTJKNGG-UDNBHOFDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,16375,46865845,CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)CC(C)(C)OC)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4,COC(C)(C)Cn1ccc(-c2ccc(C(C)N3CCC(CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O
CHEMBL1813474,ZOSQXAHBYHMVCA-GXFFZTMASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,=,9170.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.037630664329979,16377,46235733,C1CC2CNCC2(C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CCCC2CNC3)cc1Cl
CHEMBL1813475,ZOSQXAHBYHMVCA-MFKMUULPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21739935.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.301029995663981,16378,46701015,C1CC2CNCC2(C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CCCC2CNC3)cc1Cl
CHEMBL2040854,ZOSVRRQXIOFCKF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,16380,57384751,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CN=C(C=C5)C6=C(C=C(C=C6)C(=O)O)C,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(=O)nc[nH]3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1
CHEMBL521523,ZOZCBLGQKDOWFZ-QHCPKHFHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18798607.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,16387,11504490,CC1CN(CCN1)CC2=CC(=CC=C2)C3=C(C=CC(=C3)CNC(=O)C4=CC=CC(=C4)CC5CCNCC5)F,CC1CN(Cc2cccc(-c3cc(CNC(=O)c4cccc(CC5CCNCC5)c4)ccc3F)c2)CCN1
CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23033255.0,IC50,=,23300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.632644078973981,16390,2726,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
CHEMBL3673938,ZPELTGPUSIGURF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320649,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,16391,52932834,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1
CHEMBL3673938,ZPELTGPUSIGURF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,5000.0,NM,320693,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.301029995663981,16391,52932834,CC1=CC2=C(NC=C2CC3=C(N=C(C=C3)NCC4=C(N=CC=C4)F)F)N=C1,Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1
CHEMBL2036653,ZPGZREGNFRDDSM-GOSISDBHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22450133.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,16393,49856084,CC1CCCN1CCCOC2=CC=C(C=C2)C(=O)CN3CCN(CC3)C(=O)OC,COC(=O)N1CCN(CC(=O)c2ccc(OCCCN3CCCC3C)cc2)CC1
CHEMBL1910111,ZPJLWUGRTVIDEI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21996520.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,16400,15950538,CC1=C(C(=C2CN(C(=O)C2=N1)CC(=O)OC)C3=C(C=C(C=C3)Cl)Cl)CN,COC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O
CHEMBL2338472,ZPKQAKFFLWOJGU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,2600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,5.585026652029182,16401,71525220,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl
CHEMBL458242,ZPOFECDYIXUBJD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18947224.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,"Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,16403,25138078,CC1=CC(=NN1C2=NC(=CC(=N2)NC(=O)C)C3=CC(=CN=C3)OC)C,COc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1
CHEMBL2179217,ZPUAIXYROPYWKA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23006002.0,IC50,=,6460.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,5.189767482004916,16406,71457264,CC1=CN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1
CHEMBL1761530,ZPWZLFQVLHYFSM-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16408,25120419,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC(=O)O)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1
CHEMBL1761530,ZPWZLFQVLHYFSM-GPOMZPHUSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429746.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,The discovery and synthesis of potent zwitterionic inhibitors of renin.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16408,25120419,CC1=CC(=C(C(=C1)Cl)OCCOC2=CC=C(C=C2)C3CCNCC3C(=O)N(CC4=CC(=CC(=C4)CCCOC)OCC5(CC5)CC(=O)O)C6CC6)Cl,COCCCc1cc(CN(C(=O)C2CNCCC2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1
CHEMBL1092495,ZQADELCMZHYIPT-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20188547.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16412,11493620,CC(C1=NC=C(C=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccc(F)cn1)c1c(CCN(C)C)sc2ccccc12
CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23009245.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,16414,46182736,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl
CHEMBL479419,ZQBXYQUUWVYTEK-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,16415,44570491,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=CC=C5,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)CC(C)N1
CHEMBL479419,ZQBXYQUUWVYTEK-PSWAGMNNSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19006669.0,IC50,=,17000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769551078621726,16415,44570491,CC1CN(CC(N1)C)CC2=CC=C(C=C2)C3=CC=CC=C3C(=O)N4CCC(CC4)NC5=CC=CC=C5,CC1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)CC(C)N1
CHEMBL1095439,ZQLGJARKBUVURE-XMMPIXPASA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,16418,136086710,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCN(CC5)CCCO,Cc1cc(N2CCN(CCCO)CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL3289806,ZQMUEFCLRDQIPA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24914738.0,IC50,=,14100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,PUBLICATION,,4.85078088734462,16420,90644773,CN1CCN(CC1)C2=NC3=C(C=C2)N=C(N3CC(C4=C(C=C(C=C4)C(F)(F)F)Cl)O)N,CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1
CHEMBL3137464,ZQRDCRBEVYHLGZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.0,16426,76314944,CCC(C(=O)C)N1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3,CCC(C(C)=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2070138,ZQSONULFAWDAJO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22853998.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,16430,70695116,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC=C3,CCCS(=O)(=O)c1ccc2nc(-c3ccccc3)[nH]c2c1
CHEMBL514209,ZQSUXBCZQKUSDE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16431,44579190,C1CCC(C1)C(=O)NCC(=O)NC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(CNC(=O)C1CCCC1)NC(c1ccccc1)c1ccc(Cl)cc1
CHEMBL556449,ZQXPNWSXFWKXRZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19553115.0,IC50,=,72000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.142667503568732,16433,45272894,C1CN(CCC1N2C=CN=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1
CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22650177.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent ��-Secretase Modulators.,J. Med. Chem.,PUBLICATION,,5.5376020021010435,16435,46861576,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22650177.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent ��-Secretase Modulators.,J. Med. Chem.,PUBLICATION,,5.060480747381382,16435,46861576,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25454273.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5376020021010435,16435,46861576,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
CHEMBL2151164,ZQYDYFCAHHBFKE-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25454273.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.060480747381382,16435,46861576,CC1=CN(C=N1)C2=C(N=C(C=C2)NC3=C4C(=CC=C3)N(C(=N4)C5=CC=C(C=C5)F)C)OC,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1
CHEMBL3110076,ZRAMOXHZLIIJGI-INIZCTEOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24294923.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase.,J. Med. Chem.,PUBLICATION,,4.6020599913279625,16436,72737641,CCOC1=CC(=C(C=C1)N2CCN(C(C2)C)C3=NOC(=N3)C4(CCC4)NC(=O)C)C,CCOc1ccc(N2CCN(c3noc(C4(NC(C)=O)CCC4)n3)C(C)C2)c(C)c1
CHEMBL1078595,ZRAVHLYAOHIXOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,16437,45102708,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CN=C(C=C3)N4CCOCC4)CC5=CC=NN5,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(N2CCOCC2)nc1
CHEMBL1078595,ZRAVHLYAOHIXOD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19804969.0,IC50,>,8000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008056,16437,45102708,C1CN(CCC2=C1C=CC(=C2)NS(=O)(=O)C3=CN=C(C=C3)N4CCOCC4)CC5=CC=NN5,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1ccn[nH]1)CC2)c1ccc(N2CCOCC2)nc1
CHEMBL478229,ZRBPKVXRBNGQTN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18805008.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16438,44578958,CCC(C1=CC=CC=C1)NC(=O)CNC(=O)C2=CC=C(C=C2)F,CCC(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1
CHEMBL2448729,ZRBUGCYDIVWFQV-JFLMPSFJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,1000.0,NM,,,,,,,,,,,,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,DATASET,,6.0,16439,73354179,CC1=C(SC(=N1)C2=CC=CC=C2)C(=O)NC3=C(C=CC(=C3)C(=NOC)C)N4C=CN=C4,CON=C(C)c1ccc(-n2ccnc2)c(NC(=O)c2sc(-c3ccccc3)nc2C)c1
CHEMBL2043327,ZREIKOVBKPAVMW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,16442,57387029,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=O)N=CN4)C5=CC=C(C=C5)C6CCCCC6,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(=O)nc[nH]1
CHEMBL3331508,ZRNXFPVASWCYKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25221656.0,IC50,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.920818753952375,16450,118713807,C1C(CN1)CN(CC2=CC=CC=C2Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Clc1ccccc1CN(CC1CNC1)c1ccccc1
CHEMBL3699325,ZRSYWCIWUUCJFJ-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,7630.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.117475462045119,16456,89718392,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC=C(C=C7)C(=O)NC8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccccc6)cc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL3318472,ZRTNLOXFIFZGMK-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16457,118708929,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=C(C=CC=C3Cl)C(F)(F)F,O=C1CC(c2c(Cl)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl
CHEMBL376359,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,ALOGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21186796.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,PUBLICATION,,5.0,16469,11450633,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O
CHEMBL376359,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,ALOGLIPTIN,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23994324.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A (unknown origin),Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.,Eur. J. Med. Chem.,PUBLICATION,,4.522878745280337,16469,11450633,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O
CHEMBL270902,ZSEJKLXYMYILHA-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,7.221848749616356,16473,24768399,C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OC3=C(C=C(C=C3)Cl)Cl,Clc1ccc(OC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL2387601,ZSFXNHSRMWAYAN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23623673.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,PUBLICATION,,4.522878745280337,16474,71659611,C1=CC=C(C=C1)CCC2=CC3=C(C=C2)C4=C(C(=O)N3)NC(=N4)C5=CC=CC=C5Cl,O=c1[nH]c2cc(CCc3ccccc3)ccc2c2nc(-c3ccccc3Cl)[nH]c12
CHEMBL3422009,ZSIQAOCNFRWDNJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25738882.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,4.721246399047171,16477,53472113,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C6=C(C=C(C=C6)F)F,CC1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1
CHEMBL3422009,ZSIQAOCNFRWDNJ-OAHLLOKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26191358.0,IC50,=,19000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.721246399047171,16477,53472113,CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)C4=CC=CS4)C5=CSC(=N5)C6=C(C=C(C=C6)F)F,CC1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1
CHEMBL1270835,ZSIZOKHLIKKQIV-JOCHJYFZSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20880704.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Design and synthesis of aminohydantoins as potent and selective human ��-secretase (BACE1) inhibitors with enhanced brain permeability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.045757490560675,16478,52948140,CN1C(=O)C(N=C1N)(C2=CC=C(C=C2)OC(F)F)C3=CC(=C(C=C3)F)C#CCCCF,CN1C(=O)C(c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CCCCF)c2)N=C1N
CHEMBL2181890,ZSKDOJWDZUSTHX-GMQQYTKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22468684.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,"Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived ��-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.",J. Med. Chem.,PUBLICATION,,7.0,16483,67270974,CC(C)(C)CC1=CC2=C(N=C1)OC3(CCC3)CC2NCC(C(CC4=CC(=CC=C4)C5=NC=CO5)NC(=O)COC)O,COCC(=O)NC(Cc1cccc(-c2ncco2)c1)C(O)CNC1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21
CHEMBL2087639,ZSUZJBBHPTXKIV-SFHVURJKSA-N,ARMENIASPIROLE A,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22921279.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Armeniaspiroles, a new class of antibacterials: antibacterial activities and total synthesis of 5-chloro-Armeniaspirole A.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16494,58534983,CCCCCCC1=C(C=CC2=C1OC3(C2=O)C(=C(C(=O)N3C)Cl)Cl)O,CCCCCCc1c(O)ccc2c1OC1(C2=O)C(Cl)=C(Cl)C(=O)N1C
CHEMBL2158297,ZSVFWIDDNJEWEB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22039836.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,PUBLICATION,,6.0,16495,11627368,C1CCC(=CC1)C2=C(C=CC(=C2)C3CCN(CC3)C(=O)CC4=CC=NC=C4)NC(=O)C5=NC=C(N5)C#N,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)[nH]1
CHEMBL2338473,ZTGVHNBZFLSODQ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23294830.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Discovery of INT131: a selective PPAR�� modulator that enhances insulin sensitivity.,Bioorg. Med. Chem.,PUBLICATION,,5.0,16502,71525221,C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)F,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(F)c1)c1ccc(Cl)cc1Cl
CHEMBL2348856,ZTKGGBYPPJDSRP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23350847.0,IC50,>,7000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,PUBLICATION,,5.154901959985743,16504,71288456,CC(C)(CO)NC(=O)C1=CNC2=NC=C(N=C12)C3=NN(C4=C3C=CC(=C4)Cl)C,Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)CO)c3n2)c2ccc(Cl)cc21
CHEMBL1631859,ZTMGYWMZJBHXBD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,16506,11281280,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC(=NC=C4)C,Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)ccn1
CHEMBL3645217,ZTMKPXUZAMIYCW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,221.0,NM,221145,,,,,,,,,,,,,,BindingDB_Patents: Inhibition Assay. Inhibition assay using P450 CYP enzymes.,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,PATENT,,6.655607726314889,16507,25069443,C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C4=CC=C(C=C4)NC(=O)CCC(=O)O,O=C(O)CCC(=O)Nc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cc1
CHEMBL2204469,ZTPOWDSDKMQVBU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22651823.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Diazine Indole Acetic Acids as Potent, Selective, and Orally Bioavailable Antagonists of Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2) for the Treatment of Allergic Inflammatory Diseases.",J. Med. Chem.,PUBLICATION,,4.795880017344075,16509,52920263,CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NN(C(=O)C=C3)CC4=C(C=C(C=C4)F)F,Cc1c(Cc2ccc(=O)n(Cc3ccc(F)cc3F)n2)c2cc(F)ccc2n1CC(=O)O
CHEMBL231620,ZTSJUQOBFLZJMJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17398093.0,IC50,=,360.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in microsomes,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.443697499232713,16513,135681834,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)C5=NC=C(N5)C,Cc1cnc(-c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)[nH]1
CHEMBL1272208,ZTSMFALKIKFNQE-TZIWHRDSSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20933414.0,IC50,>,30.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 30 mins,"Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ��-secretase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,16514,11555639,C1CC1CC2COCC(N2S(=O)(=O)C3=CC=C(C=C3)Cl)C4(CC4)OC(=O)N5CCC6(CC5)CC(=O)N6,O=C1CC2(CCN(C(=O)OC3(C4COCC(CC5CC5)N4S(=O)(=O)c4ccc(Cl)cc4)CC3)CC2)N1
CHEMBL3126842,ZTTKEBYSXUCBSE-VSBZUFFNSA-N,BECLABUVIR,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24397558.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,16515,49773361,CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8,COc1ccc2c(c1)C1CC1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21
CHEMBL3581146,ZTXPZKBYVPEULR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26039570.0,IC50,=,3800.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,PUBLICATION,,5.42021640338319,16517,24830567,COC1=CC=CC(=C1)CC(=O)NC2=CC(=CS2)C3=CC(=NC=C3)F,COc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1
CHEMBL1080473,ZTYNKXLNXRQPMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,16518,46879550,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC=C4)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12
CHEMBL1080473,ZTYNKXLNXRQPMB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,7700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827518,16518,46879550,CC1=C(C(=CC=C1)C)CNC2=C3C(=CC(=N2)C4=CC=CC=C4)C(=C(N3)C)C,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12
CHEMBL376487,ZUDPNSAXFSEWCD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19945870.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human liver CYP3A4,Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,16521,491206,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)NC(CC4=CNC5=C4C=C(C=C5)O)C6=CSC=N6)N=C2C7=COC=C7,O=C(NC(Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
CHEMBL376487,ZUDPNSAXFSEWCD-SANMLTNESA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20185309.0,IC50,=,440.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,16521,491206,C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)NC(CC4=CNC5=C4C=C(C=C5)O)C6=CSC=N6)N=C2C7=COC=C7,O=C(NC(Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
CHEMBL3699322,ZUEWAKQVCILIJO-COCZKOEFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2130.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",Compound of a reverse-turn mimetic and a production method and use therefor,,PATENT,,5.671620396561262,16523,89718290,CN1C=C(C2=CC=CC(=C21)CN3CC4N(C(C3=O)CC5=CC=C(C=C5)O)C(=O)CN(N4C(=O)NCC6=CC=CC=C6)CC=C)C7=CC(=CC=C7)C(=O)NC8=CC=CC=C8,C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccccc6)c5)cn(C)c34)CC2N1C(=O)NCc1ccccc1
CHEMBL603197,ZUFPYCGWUXYDBH-SFHVURJKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20005102.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693163,16524,46225574,CC1=C2C(=NN1)C=NC(=N2)C3=C(N=CC(=C3)OCC(CC4=CNC5=CC=CC=C54)N)C6=COC=C6,Cc1[nH]nc2cnc(-c3cc(OCC(N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12
CHEMBL2436224,ZULRMJWNHUYYOE-DYRPNGKOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24093940.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,PUBLICATION,,4.301029995663981,16526,72712571,CC1C(C(=O)N(C2=C(N1C(=O)CS(=O)(=O)C)C=C(C=C2)C#N)CC3=C(C=CC4=CC=CC=C43)C)NC(=O)C(C)NC.Cl,CNC(C)C(=O)NC1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)C1C
CHEMBL2440626,ZUOJEWXMTBAQSP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24074843.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,16528,69936726,CC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)Cl)OC3=CN=CN=C3,Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1
CHEMBL168538,ZURGVSINFPSAAI-WPCLDFDBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,16530,44380625,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)C(C)CNCCC6=CC7=C(C=C6)N=CN7)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2C(C)CNCCc2ccc3nc[nH]c3c2)c1
CHEMBL3318415,ZUUIXGIFVWOUQU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25037916.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16532,118708873,C1C(CC(=O)C(=C1O)SC2=CC=CC=C2Cl)C3=CC=CC=C3,O=C1CC(c2ccccc2)CC(O)=C1Sc1ccccc1Cl
CHEMBL204772,ZUXHCWNSICPUJO-MRXNPFEDSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16455256.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16536,24825271,CC1=NC2=CC=CC=C2N1CC3=C(C4=C(S3)N(C(=O)N(C4=O)C)CC(C)C)C(=O)N5CCC(C5)O,Cc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC(O)C1)c(=O)n(C)c(=O)n2CC(C)C
CHEMBL3219283,ZUZXFEFLTIBJAB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,<,200000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),,MedChemComm,PUBLICATION,,3.6989700043360187,16538,67072266,CN(C)CC1=CC2=C(S1)NC(=O)C3=C2C(=CC=C3)O.Br,CN(C)Cc1cc2c([nH]c(=O)c3cccc(O)c32)s1
CHEMBL2013052,ZVASRANJKNGBRB-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22365751.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,16539,57345660,CC(C)C(=O)N1CCC(CC1)OC2=CC3=C(C=C2)OC4(CC3)CCN(CC4)C5CCC5,CC(C)C(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
CHEMBL2041164,ZVCMQZNPBWGCEG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22364528.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,PUBLICATION,,4.301029995663981,16541,57387283,CC1=C(N=CC=C1)CN2CCC3(CC2)C(=O)N(C(=O)N3C4=CC(=NC=N4)OC)C5=CC=C(C=C5)C6=CSC(=C6)C(=O)O,COc1cc(N2C(=O)N(c3ccc(-c4csc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1
CHEMBL270272,ZVJJJFLRYHVRLN-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18311908.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,PUBLICATION,,5.823908740944319,16543,7017202,COC(=O)C(CC1=CN=CN1)NCC2=CC=CC=C2,COC(=O)C(Cc1cnc[nH]1)NCc1ccccc1
CHEMBL147806,ZVMMVSSEAMUNGI-UHFFFAOYSA-N,GSK369796,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19222165.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,PUBLICATION,,4.0,16546,10316203,CC(C)(C)NCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O
CHEMBL524054,ZVSBBBUKPZBFMP-ZDUSSCGKSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,16551,44568805,CC1COCCN1C2=C3C=CC(=CC3=CN=N2)C4=C(C=CC5=C4SN=C5N)C,Cc1ccc2c(N)nsc2c1-c1ccc2c(N3CCOCC3C)nncc2c1
CHEMBL441136,ZVXDTQBHPOHGTP-XTEPFMGCSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,16553,44433286,CC(C)CC(C1=C(C=CC(=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NC(=O)CNC,CNCC(=O)NC(CC(C)C)c1cc(F)ccc1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL270193,ZWBUEQUTXFJDFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,16559,11713409,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL270193,ZWBUEQUTXFJDFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,25000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,16559,11713409,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL270193,ZWBUEQUTXFJDFT-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18221875.0,IC50,=,27000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,16559,11713409,CC(C)C1=C2C(=NC=NN2C=C1C3=NN=C(O3)NCCCCN)NC4=C(C=C(C(=C4)C(=O)NC5CC5)F)F,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12
CHEMBL2018910,ZWFGREILWFKZPZ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22239545.0,IC50,=,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,PUBLICATION,,4.301029995663981,16562,56953771,CC(C)(C)CSC1=NC2=C(N1)C=C(C=C2)OC,COc1ccc2nc(SCC(C)(C)C)[nH]c2c1
CHEMBL585498,ZWGZFELFBFJIHY-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,=,9300.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,5.031517051446065,16564,507751,CC1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=NC=C3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12
CHEMBL585498,ZWGZFELFBFJIHY-CQSZACIVSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19769332.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,PUBLICATION,,4.7447274948966935,16564,507751,CC1CN(CCN1C(=O)C(=O)C2=CNC3=C2C=NC=C3)C(=O)C4=CC=CC=C4,CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12
CHEMBL1923502,ZWIXEQBDJMFCMN-DHHNQDMHSA-N,ULIMORELIN HYDROCHLORIDE,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22106937.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.,J. Med. Chem.,PUBLICATION,,5.619788758288394,16567,56841653,CC1CNC(C(=O)N(C(C(=O)NC(C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4.O.Cl,CC1CNC(C2CC2)C(=O)N(C)C(C)C(=O)NC(Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1
CHEMBL549595,ZWLGQCPYBKFAIX-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19500982.0,IC50,=,2020.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.694648630553377,16570,11635332,CC1=NC=CN1CC(C2=CC=CC=C2)NC(=O)NC3CCN(CC3)CC4=CN(C=C4)C5=CC=C(C=C5)C(F)(F)F,Cc1nccn1CC(NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccccc1
CHEMBL494305,ZWPJNBTUVZEJGC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18817364.0,IC50,>,25000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes,"3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,PUBLICATION,,4.6020599913279625,16573,44568941,CC1=C(C2=C(C=C1)C(=NO2)NC)C3=CC4=CN=NC(=C4C=C3)NC(C)C,CNc1noc2c(-c3ccc4c(NC(C)C)nncc4c3)c(C)ccc12
CHEMBL1784172,ZWQSPUPMQMBACD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19772287.0,IC50,>,63095.73,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,PUBLICATION,,4.200000030616179,16577,21914667,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC4CC4,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1
CHEMBL1082158,ZWVCUFJZBBAOFI-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20138761.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,16580,44631836,C1CC1NC(=O)C2=CC(=C(C=C2)Cl)NC3=C4C=NN(C4=CN=N3)C5=C(C=CC=C5F)F,O=C(NC1CC1)c1ccc(Cl)c(Nc2nncc3c2cnn3-c2c(F)cccc2F)c1
CHEMBL1835785,ZWVLHXRFHSCJTO-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21906941.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,16581,56658546,CN1C(=O)C2CCCC2C(=N1)C3=CC=C(C=C3)OCCCN4CCCCC4,CN1N=C(c2ccc(OCCCN3CCCCC3)cc2)C2CCCC2C1=O
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,6.301029995663981,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16134929.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,PUBLICATION,,5.275724130399211,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18572407.0,IC50,=,0.5,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.301029995663981,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,50.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,7.301029995663981,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,18763755.0,IC50,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BzRes as a substrate,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,PUBLICATION,,5.275724130399211,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20153189.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL401930,ZWVZORIKUNOTCS-OAQYLSRUSA-N,BMS-536924,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20399649.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,16582,135440466,CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21232954.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,16583,11265950,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
CHEMBL1289395,ZXGHIZDLSIWWGJ-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20952195.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,16585,50908737,CN1C2=C(CCNC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5,Cn1c2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc31)CCNC2
CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,3633.7,NM,,,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,5.439650931106894,16588,11057,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
CHEMBL1766172,ZXKRGWHSNSRDIS-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21429754.0,IC50,=,3700.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4 after 30 mins,"17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.431798275933005,16590,12043372,CC(C)C(C1=CC=C(C=C1)C2=CC=CC=C2)(C3=CN=CN3)O,CC(C)C(O)(c1ccc(-c2ccccc2)cc1)c1cnc[nH]1
CHEMBL352806,ZXKTYOLDPJDWSF-DCWSAZFOSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,11859012.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of cytochrome P450 3A4 enzyme,2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,16591,9894997,CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)C(C)CNCCC6=CC7=C(N=C6)N=CN7)C,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2C(C)CNCCc2cnc3nc[nH]c3c2)c1
CHEMBL3137481,ZXMMFXLTPVVJOU-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,20000.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,4.698970004336019,16593,76336705,CC(C)C(CN1CCC(CC1)N(C2=CC=C(C=C2)C(F)(F)F)C3=CN=CC=C3)O,CC(C)C(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1
CHEMBL2048487,ZXMWWEOFNKCIIA-LILXYRQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.481486060122112,16594,11566856,C1CC1C2=CC=C(C=C2)CC3=CC(=CC=C3)C4CC(C(C(C4O)O)O)CO,OCC1CC(c2cccc(Cc3ccc(C4CC4)cc3)c2)C(O)C(O)C1O
CHEMBL2048487,ZXMWWEOFNKCIIA-LILXYRQWSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22652255.0,IC50,=,76000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,C-Aryl 5a-carba-��-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,Bioorg. Med. Chem.,PUBLICATION,,4.119186407719209,16594,11566856,C1CC1C2=CC=C(C=C2)CC3=CC(=CC=C3)C4CC(C(C(C4O)O)O)CO,OCC1CC(c2cccc(Cc3ccc(C4CC4)cc3)c2)C(O)C(O)C1O
CHEMBL3137466,ZXNRMVMIMUJMGG-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,=,2600.0,NM,,,,,,,,,,,,,,,DNDI: CYP Inhibition,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,DATASET,,5.585026652029182,16596,76329431,CS(=O)(=O)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C3=CN=CC=C3,CS(=O)(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1
CHEMBL393788,ZXOJJZQNCXSKSG-WUFINQPMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,17822895.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of microsomal CYP3A4,Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,16597,24180593,CC(C)CC(C1=C(C(=CC=C1)F)N2CCN(CC2)C(=O)C(CC3=C(C=C(C=C3)Cl)Cl)N4CCCC4=O)NCCCN,CC(C)CC(NCCCN)c1cccc(F)c1N1CCN(C(=O)C(Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1
CHEMBL210780,ZXPSJDOWBKNEAW-VGSWGCGISA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,16504501.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.769551078621726,16600,44410861,CCN(C)C(C)C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C(=O)O)N3C=CN=C3,CCN(C)C(C)C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1
CHEMBL1094509,ZXUHVJGJAIGPRR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20347297.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,16603,46888785,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,COc1ccc(Cn2c(C3CCCN(C)C3)nc3ccccc32)cc1
CHEMBL2170617,ZXZKBUDCPJISJW-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22803959.0,IC50,=,26000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,PUBLICATION,,4.585026652029182,16610,58269668,CN1C=CN=C1C(=O)N2CCC(CC2)C3=C(C=C(C=C3)C(=O)N=C(N)N)C(F)(F)F,Cn1ccnc1C(=O)N1CCC(c2ccc(C(=O)N=C(N)N)cc2C(F)(F)F)CC1
CHEMBL181385,ZYAKTISGGAZUDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,16612,11590652,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OC(C)(C)C)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL181385,ZYAKTISGGAZUDF-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,580.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.236572006437063,16612,11590652,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=C(C=C3)OC(C)(C)C)N4C=CN=C4)N(C)C,CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C
CHEMBL1631858,ZYGZDPKEZBLAHD-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,20971004.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,16619,11474913,CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC=NC=C4,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3ccncc3)c1)=N2
CHEMBL469227,ZYOIQICRHUXCRL-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,21189020.0,IC50,=,2770.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17��-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,PUBLICATION,,5.557520230935552,16628,24894072,C1=CC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O,Oc1cccc(-c2ccc3c(-c4ccccc4)c(O)ccc3c2)c1
CHEMBL2348780,ZYTXTXAMMDTYDQ-DGEXFFLYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,23498916.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),"VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.",Bioorg. Med. Chem.,PUBLICATION,,4.301029995663981,16635,3035000,CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1(C(=O)CO)O)C)C,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC2(C)C1(O)C(=O)CO
CHEMBL3673978,ZYUJERAVFWUVMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320656,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,16637,52933057,COC1=C(C=C(C=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F)F,COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F
CHEMBL3673978,ZYUJERAVFWUVMN-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,10000.0,NM,320700,,,,,,,,,,,,,,"BindingDB_Patents: Inhibition Enzyme Assay. CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.","Compounds and methods for kinase modulation, and indications therefor",,PATENT,,5.0,16637,52933057,COC1=C(C=C(C=N1)CNC2=NC(=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)F)F,COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F
CHEMBL3664706,ZYZZURDCHBXQIE-VKGTZQKMSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,,IC50,>,50000.0,NM,,,,,,,,,,,,,,,BindingDB_Patents: Biological Assay Example 6. The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37�� C with human recombinant cytochrome P450 3A4.,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,PATENT,,4.301029995663981,16639,59635764,CC(C1=CC=C(C=C1)C2=CN(C(=O)C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4F,CC(c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CCC(CC(C)(C)O)(c2ccccc2F)OC1=O
CHEMBL3601185,ZZAHNCINSQBRFG-TYFWRSTJSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,26115573.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin),Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,16640,118462026,CC1=CC(=CC(=N1)C)NC2=NC=C(C(=N2)NC3CC(C(C3O)O)CO)C4=NC(=CS4)C5=CC=CC=C5,Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(NC3CC(CO)C(O)C3O)n2)cc(C)n1
CHEMBL2070937,ZZFJAPGUVYMXSJ-IAGOWNOFSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22858142.0,IC50,>,31622.78,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.499999953328896,16645,25129042,C1CCC(C(C1)C(=O)NC2(CC2)C#N)C(=O)N3CCN(CC3)C4=NC5=CC=CC=C5S4,N#CC1(NC(=O)C2CCCCC2C(=O)N2CCN(c3nc4ccccc4s3)CC2)CC1
CHEMBL3577447,ZZFWSQSQNZHVSP-TWPACSSBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25990761.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins by LC-MS/MS method,Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.,J. Med. Chem.,PUBLICATION,,5.187086643357144,16646,122177744,CC1(C2CCC1(CC2NC(=O)C(CC3CCCCC3)NC(=O)NC(CCCCN)C(=O)O)C)C.Cl,CC12CCC(C(NC(=O)C(CC3CCCCC3)NC(=O)NC(CCCCN)C(=O)O)C1)C2(C)C
CHEMBL3577447,ZZFWSQSQNZHVSP-TWPACSSBSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,25990761.0,IC50,=,15000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate incubated for 30 mins by LC-MS/MS method,Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.,J. Med. Chem.,PUBLICATION,,4.823908740944319,16646,122177744,CC1(C2CCC1(CC2NC(=O)C(CC3CCCCC3)NC(=O)NC(CCCCN)C(=O)O)C)C.Cl,CC12CCC(C(NC(=O)C(CC3CCCCC3)NC(=O)NC(CCCCN)C(=O)O)C1)C2(C)C
CHEMBL3115161,ZZGMOZUZSAJAML-MCQSSSDPSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24412072.0,IC50,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,16647,59721296,CC(C)C1=NC(=CS1)CN(C2CC2)C(=O)NC(C(C)C)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,CC(C)c1nc(CN(C(=O)NC(C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)C2CC2)cs1
CHEMBL180805,ZZGVWUSRXVYCSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,16648,11501485,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C
CHEMBL180805,ZZGVWUSRXVYCSC-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,15745819.0,IC50,=,700.0,NM,,,,,,,,,,,,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985743,16648,11501485,CC(C(C1=CC2=C(C=C1)C=C(C=C2)OCC(C)(C)C)N3C=CN=C3)N(C)C,CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C
CHEMBL1076536,ZZHNYWHADLVCEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,5500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,16650,21717336,CC1=C(C(=CC=C1)C)COC2=CC=CN3C2=NC(=C3C)C,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12
CHEMBL1076536,ZZHNYWHADLVCEP-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,19846298.0,IC50,=,18000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7447274948966935,16650,21717336,CC1=C(C(=CC=C1)C)COC2=CC=CN3C2=NC(=C3C)C,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12
CHEMBL3087341,ZZNSTCGBKYJVKR-UHFFFAOYSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,24139583.0,IC50,>,27000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Discovery of 2-methylpyridine-based biaryl amides as ��-secretase modulators for the treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841013,16657,42640092,CC1=NC=CC(=C1)C2=CC=C(C=C2)NC(=O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,Cc1cc(-c2ccc(NC(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1
CHEMBL2181641,ZZYHXFCSTOMZNZ-LICLKQGHSA-N,,,P08684,CYTOCHROME P450 3A4,CYP3A4,,,22849725.0,IC50,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of CYP3A4,Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).,J. Med. Chem.,PUBLICATION,,5.823908740944319,16669,71455676,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C(=O)NC4=CC=C(C=C4)C=CC(=O)O)C(=C1C5=CN=C(C=C5)OC)C6CCCC6,COc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(C=CC(=O)O)cc5)CCC4)cc3n2C)cn1
